BioWorld® - Medical Device Daily

BioWorld ® 

INDUSTRIAL 

BIOTECHNOLGY 

STATREPORT 

IMMEDIATE AND COMPREHENSIVE 

INDUSTRY INFORMATION

BioWorld ® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information 

Michael Harris, Senior Managing Editor 

Amanda Lyle, Senior Editor 

Copyright © 2007 

AHC Media LLC ® 

BioWorld Today 

3525 Piedmont Road, N.E. 

Building Six, Suite 400 

Atlanta, GA 30305 U.S.A. 

All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act 

of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database 

or retrieval system, without the prior written permission of the publisher. 

Product code: SO7429 

ISBN-10: 1-933040-67-X 

ISBN-13: 978-1-933040-67-7 

BioWorld ® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information is published by AHC Media 

LLC ® , 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those of the 

publication. Mention of products or services does not constitute endorsement. (GST Registration Number R128870672) 

Senior Managing Editor: Michael Harris Senior Editor: Amanda Lyle 

Marketing Manager: Chris Walker Account Representatives: Steve Roberts, Bob Sobel, Chris Wiley 

Vice President/Group Publisher: Donald R. Johnston 

Customer Service: (800) 879-8790 or (404) 262-5526 

Please visit our web site: www.bioworld.com 

Please note: 

BioWorld has made every effort to ensure that the information in this report is accurate and up-to-date, but cannot be 

responsible for errors, inaccuracies or changes in the data. If the reader identifies any information that is incorrect or has 

changed, please notify BioWorld so that it can be corrected for future editions. 

Notice: 

This report is an information tool, and the user should make business decisions based on an independent investigation, 

verification and evaluation of this as well as other information relevant to the user’s business interest. BioWorld has 

gathered information for this work from many different sources and quotes information which has been gathered by other 

sources. Although BioWorld has taken reasonable steps to ensure the accuracy of this report, due to the tremendous 

amount of information, and the third-party control of some information, BioWorld cannot verify the accuracy of all 

information that it gathers and reports and thus does not warrant that the information is error-free. AS A RESULT, 

BIOWORLD DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR 

PURPOSE.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information 

ABOUT BIOWORLD ® 

BioWorld Today, the newspaper of record for the biotechnology industry, is read by 

biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today 

is delivered by e-mail and fax every business morning, and is also found exclusively online at 

www.bioworld.com. The BioWorld Online website has been internationally recognized as the most 

comprehensive resource for strategic biotechnology news and information available today. In 

addition to original daily news reporting, BioWorld offers an extensive searchable database with 

more than 15 years of biotechnology archives. This site is not only a great source for insightful, upto-the-minute 

news coverage, but a veritable library of information on the developments of the 

industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of 

biotechnology market intelligence from every biotech hotspot around the globe. 

BioWorld does not post press releases, but rather uses information that is researched and written 

by the top business and science reporters in the industry. With nearly 20 writers spread throughout 

eight countries, BioWorld covers news on public companies and hard-to-find information on private 

companies. Our seasoned reporters get the inside scoop on what’s happening within the corporate 

walls, on regulatory issues in Washington and elsewhere, and on scientific breakthroughs 

worldwide. This news coverage of the biotechnology industry is 100 percent original and available 

only at BioWorld. 

All of the BioWorld resources are available for easy online searching, including: 

� BioWorld Today – The daily biotechnology newspaper. 

� BioWorld International – The weekly monitor of global biotechnology developments. 

� BioWorld Financial Watch – The weekly report on all market data and business trends in 

biotechnology. 

� BioScan: The Worldwide Biotech Industry Reporting Service – The most comprehensive 

directory of biotechnology companies available. 

� The BioWorld Biotechnology State of the Industry Report – A must-have annual report 

reviewing financial trends in the biotechnology industry. 

� The BioWorld Executive Compensation Report – An annual report revealing executive 

compensation data at biotechnology companies in the U.S. 

� The BioWorld RNA/DNA Therapeutics & Technologies Report 2006 – An in-depth look at 

major market opportunities in RNAi, pharmacogenomics and forensics.


� The BioWorld Phase III Report – A quarterly compilation of biotechnology products in 

late-stage clinical trials. 

� BioWorld Snapshots – An exclusive online product updated daily with market data, such 

as collaborations, mergers, acquisitions, financings, market cap rankings and more. 

� BioWorld StatReports – Industry-specific reports including contact information and 

names, R&D focus, products on the market and in development, agreements and 

financial information. 

� Medical Device Daily – The daily medical technology newspaper. Available every 

business morning via fax or online at www.medicaldevicedaily.com. 

For more information on BioWorld ® , please contact: 

Donald R. Johnston, VP/Group Publisher 

AHC Media LLC 

3525 Piedmont Road 

Building Six, Suite 400 

Atlanta, GA 30305 USA 

Phone: 404-262-5439 

Fax: 404-262-5510 

E-mail: don.johnston@ahcmedia.com 

or customerservice@ahcmedia.com 

Website: www.bioworld.com


TABLE OF CONTENTS 

How to Use BioWorld StatReports…………………………………………………………………6 

List of Companies……………………………………………………………………………………9 

Company Profiles…………………………………………………………………………………..13 

Subject Index………………………………………………………………………………………397 

Copyright ©2006 AHC Media ® 5


BioWorld ® 

INDUSTRIAL 

BIOTECHNOLOGY 

STATREPORT 

HOW TO USE 

BIOWORLD STATREPORTS 



HOW TO USE BIOWORLD STATREPORTS 

BioWorld StatReports are fully searchable through Adobe Acrobat Reader by using its search feature (Ctrl. + 

Shift + F). 

Companies may also be located using the list of company names at the beginning of the report. This useful 

feature provides a quick reference guide to coverage. It is an alphabetical listing of all companies in the 

directory and allows the reader to summarily determine if a specific company is represented in the directory. 

The Main Entry section is arranged alphabetically by company name. 

FIELDS AND THEIR DESCRIPTIONS 

Company records include only those fields for which information has been obtained. Where possible, dates 

are included to reflect the approximate occurrence of events. 

Company Name and Address 

Gives the main address, telephone number(s), fax, web site address, and e-mail address, if known. Second 

addresses are given for major research facilities, U.S. facilities of non-U.S. companies, and some subsidiaries 

and divisions. 

Management 

Lists management involved in relevant marketing and R&D areas, such as the Chairman of the Board, Chief 

Executive Officer (CEO), President, Chief Operating Officer (COO), Chief Financial Officer (CFO), Executive or 

Senior Vice Presidents, Vice President or Director of R&D, and Vice President or Director of Marketing. May 

also include names of senior scientists/researchers. 

Employees 

Gives the approximate number employees and, when known, the number of Ph.D.s, M.D.s, and D.V.M.s on 

staff. 

History 

Contains information on founding date, name changes, major acquisitions, previous subsidiaries or 

investments and organization memberships. 

Facilities 

Includes facilities involved in biotechnology. Often provides size (in square feet or square meters). 

Stock-Financial History 

Contains information on public-private status; initial funding; stock exchange and ticker symbol; public 

offerings, including date, price of stock at issuance, number of shares offered and dollar value. For public 

companies, information includes financials for most recently completed fiscal year, including revenue, net 

income or loss, earnings or loss per share, average shares outstanding and total assets. These figures are 

compared with the corresponding figures for the previous year. 

Private Placements 

Usually these arrangements are made through investment firms to fund clinical research for products in 

development. Information may include date, dollar value and use of funds. 

Subsidiaries/Divisions 

Includes subsidiaries of biotechnology companies and often the location of the subsidiary. The address, 

management and research interests are listed if readily available. (A company is usually considered a 

subsidiary if 51% or more is owned by the parent company.) Also included are divisions of large companies 

that focus on biotechnology. 

Subsidiary Of 

Lists the parent company and percentage owned when applicable. 



Investments 

Lists investments by biotechnology companies. For nonbiotechnology companies, generally limited to 

investments in the biotechnology industry. Joint ventures are also listed here. 

Principal Investors 

Includes the principal investors in the biotechnology company profiled. 

Financial Information 

General information, which may include R&D budget, nonprofit offshoots or investment arms of the company. 

Business Strategy 

Reflects new or changed directions of the company, or the company’s mission. 

Agreements 

Consists of a brief summary of the research and contents of the agreement and the date agreement 

commenced. Agreements are arranged alphabetically by company/organization. May contain agreements 

outside of the focus area of the StatReport to ensure completeness. 

Research and Development 

Briefly describes general research interests and technologies worked on by the company or its subsidiaries. 

Research done through agreements with other companies is also included. 

Products on the Market 

Includes (1) all products of biotechnology companies and (2) biotechnology products of nonbiotechnology 

(e.g., chemical and pharmaceutical) companies. May contain products outside of the focus area of the 

StatReport to ensure completeness. 

Products in Development 

Column 1 includes the generic, trade names and uses of the product. The status indicated in column 2 refers 

to the standard stages for a U.S. drug or other product in development. Generally, only products in 

development related to the industry of the StatReport are included. 

Subject Index 

Categorizes companies involved in various aspects of biotechnology. 



BioWorld ® 

INDUSTRIAL 

BIOTECHNOLOGY 

STATREPORT 

LIST OF COMPANIES 



LIST OF COMPANIES 

3DM Inc. 

A/F Protein Inc. 

AB Enzymes Oy 

Abbott GmbH & Co. KG 

Abengoa SA 

Acadian Seaplants Ltd. 

ADI Group Inc. 

ADI Systems Inc. 

Advanced Product Enterprises LLC 

Advanta Seeds UK Ltd. 

AEA Technology plc 

AGI Dermatics 

AgResearch Ltd. 

AgriSense-BCS Ltd. 

Agrium Inc. 

Ag-West Bio Inc. 

Ajinomoto Co. Inc. 

Akzo Nobel NV 

Alberta Research Council Inc. 

Alderon Biosciences Inc. 

Alltech Inc. 

Altair Nanotechnologies Inc. 

Altus Pharmaceuticals Inc. 

Aluline Ltd. 

AMDL Inc. 

American Radiolabeled Chemicals Inc. 

Analox Instruments Ltd. 

Analox Instruments U.S.A. 

Applera Corp. 

Applied Biosystems Inc. 

Applikon Biotechnology Inc. 

Arch Chemicals Inc. 

Arch Personal Care Products LP 

Archer Daniels Midland 

Argonne National Laboratory 

Arysta LifeScience Corp. 

Asahi Kasei Corp. 

Associates of Cape Cod Inc. 

Astellas Pharma Inc. 

astre Corp. 

Athenix Corp. 

Atrium Biotechnologies Inc. 

Axxora Life Science Inc. 

BAC BV (Biotechnology Application Centre) 

BACHEM AG 

Bachem California Inc. 

Bangs Laboratories Inc. 

BASF AG 

Bayer Corp. 

Bayer CropScience AG 

Bayou Biolabs 

Be-Long Group 

BioAssay Works LLC 

Biocatalysts Ltd. 

Bioclear BV 

BioForce Nanosciences Inc. 

BioGenes GmbH 

BioGenesis Enterprises Inc. 

Biogenie Inc. 

Bio-Lab Ltd. 

Biolog Inc. 

Biologos Inc. 

BioMed Diagnostics Inc. 

Biomeda Corp. 

Biomedical Technologies Inc. 

BioMerieux INDUSTRY 

BioMerieux SA 

Biomol GmbH 

Bionas GmbH 

Bionov CNP Inc. 

BIOPAC Systems Inc. 

BioPro International Inc. 

Bioriginal Food & Science Corp. 

Bioscience Inc. 

BioScreen Testing Services Inc. 

BioSure Inc. 

Biosynth International Inc. 

Biotal Ltd. 

Bio-Technical Resources 

Biotechnology Research Institute 

Biotecx Laboratories Inc. 

Biotehnos SA 

Biothane Corp. 

BioTime Inc. 

BioVectra dcl 

Bioxel Pharma Inc. 

Biozyme Laboratories Ltd. 

Boojum Research Ltd. 

Boston Life Sciences Inc. 

BRAIN (Biotechnology Research and Information 

Network AG) 

Bunge Ltd. 

CABI 

Calzyme Laboratories Inc. 

Cambio Ltd. 

Cambrex Corp. 

Canadian Forest Service 

Canadian Seed Coaters 

Cantest Ltd. 

Cardinal Health - Middleton 

Cargill Inc. 

Ceapro Inc. 

Celsis International plc 

Centre for Innovative Biology and Environmental 

Technology 

Ceres Inc. 

Chembiotech Ltd. 

Chemeq Ltd. 

ChemGenes Corp. 

Chr. Hansen Inc. 

Chunghwa Chemical Synthesis & Biotech Co. Ltd. 

Codexis Inc. 

Codon Devices 

CombiMatrix Corp. 

Commercial Microbiology Ltd. 

Cornell Institute for Biotechnology and Life Science 

Technologies 

Cosmo Bio Co. Ltd. 

CryoLife Inc. 

CUBIA (University Centre for Algal Biotechnology) 

Cuno Inc. 

Cyanotech Corp. 

Daiichi Pharmaceutical Co. Ltd. 

Dainippon Sumitomo Pharma Co. Ltd. 



Dalton Pharma Services 

Dextra Laboratories Ltd. 

Dextran Products Ltd. 

Diagnostic Chemicals Ltd. 

Digene Corp. 

Diversa Corp. 

DNA Technologies Inc. 

DOE Joint Genome Institute 

Dojindo Laboratories 

Don Whitley Scientific Ltd. 

Dong-A Pharmaceutical Co. Ltd. 

Dow AgroSciences LLC 

Dragon Pharmaceutical Inc. 

Droycon BioConcepts Inc. 

DSM 

DSM Fine Chemicals 

DuPont 

Dyadic International (USA) Inc. 

Dynavax Europe 

EMD Biosciences Inc./Merck Biosciences 

eMembrane Inc. 

Encelle Inc. 

EnSolve Biosystems Inc. 

Enviro-Zyme International LLC 

Enzyme Research Laboratories Ltd 

Epicore Networks (U.S.A.) Inc. 

Epidauros Biotechnologie AG 

Eurogentec SA 

EvoGenix Ltd. 

Evolva SA 

F. Hoffmann-La Roche Ltd. 

FibroGen Inc. 

First Link (UK) Ltd. 

Fraunhofer Institute for Interfacial Engineering 

and Biotechnology 

Galderma SA 

Genencor International Inc. 

General Electric Global Research 

Genesearch Pty. Ltd. 

Geneva Scientific 

Genomatica Inc. 

Gentra Systems Inc. 

Genzyme Corp. 

GL Biochem (Shanghai) Ltd. 

HaloSource Inc. 

Hammen Corp. 

Harvard Bioscience Inc. 

Hawaii Biotech Inc. 

Helmholtz Centre for Infection Research 

Hercules Inc. 

Hidex Oy 

Huntingdon Life Sciences 

Hybrizyme Corp. 

ICPbio 

Idaho National Laboratory 

Idexx Laboratories Inc. 

IGENE Biotechnology Inc. 

Imperial Innovations Ltd. 

Industrial Biotechnology Corp. 

Industrial Technology Research Institute – 

Biomedical Engineering Center 

inGenious Targeting Laboratory Inc. 

Institute for Biological Research and 

Institute for Biological Research and Technology 

Institute of Food Research 

International Flavors & Fragrances Inc. 

Iogen Corp. 

Isolagen Inc. 

Israel Institute for Biological Research (IIBR) 

Itochu Corp. 

J. Craig Venter Institute 

Johnson Matthey Pharma Services 

Kanebo Ltd. 

Kaneka Corp. 

Kikkoman Corp. (Biochemicals Division) 

Kraeber GmbH & Co. 

Kuraray Co. Ltd. 

Kyorin Pharmaceutical Co. Ltd. 

Kyowa Hakko Kogyo Co. Ltd. 

Laboratoires Eurobio 

Lake States 

LANXESS AG 

Lavipharm SA 

Lawrence Berkeley National Laboratory 

LG Chem Ltd. 

LG Life Sciences Ltd. 

LGC (Laboratory of the Government Chemist) 

LifeCell Corp. 

LifeSensors Inc. 

Link Technologies Ltd. 

Lonza Group Ltd. 

Maine Biotechnology Services Inc. 

Mallinckrodt Inc. 

Marcor Development Corp. 

Maruzen Pharmaceuticals Co. Ltd. 

Mascoma Corp. 

Matreya LLC 

Maxxam Analytics Inc. 

MBI International 

MDS Pharma Services 

MedPharm Ltd. 

Megabase Research Products 

Meiji Seika Kaisha Ltd. 

Mercian Corp. 

Merck KgaA 

Metabolix Inc. 

Microbe Inotech Laboratories Inc. 

Microbia Inc. 

Mo Bio Laboratories Inc. 

MoBiTec GmbH 

Molecular Devices Corp. 

Molecular Probes Inc. 

Monsanto Co. 

Morishita Jintan Co. Ltd. 

M-Scan Ltd. 

MSE Technology Applications Inc. 

Nanogen Inc. 

NanoHorizons Inc. 

NanoLogix Inc. 

Nanophase Technologies Corp. 

National Collection of Yeast Cultures (NCYC) 

National Institute of Advanced Industrial Science and 

Technology (AIST) 

National Institutes of Health (NIH) 

National Research Council of Canada 

Nature Plus Inc. 

NatureWorks LLC 

Neogen Corp. 

New Brunswick Scientific Co. Inc. 

New England BioLabs Inc. 



New Horizons Diagnostics Corp. 

New Zealand Pharmaceuticals Ltd. 

Nigu Bioselect 

Nippon Kayaku Co. Ltd. 

Nitto Denko Corp. 

Norac Technologies Inc. 

North Carolina Biotechnology Center 

NOVA Chemicals Corp. 

NovaSep Process 

november AG 

Noven Pharmaceuticals Inc. 

Novozymes A/S 

Novozymes Inc. 

Omex Environmental Ltd. 

OmniChem 

OmniGene Bioproducts Inc. 

Optigenex Inc. 

Optronics 

Organo Corp. 

Pacific Biodiesel Inc. 

Pacific Northwest National Laboratory 

Pall Corp. 

Paprican 

PBR Laboratories Inc. (PBR) 

PCI Membranes 

Pentapharm Ltd. 

PeproTech Inc. 

Peptides International Inc. 

Pfeiffer Vacuum Ltd. 

Pfizer Inc. 

Pharmbiodyn Consulting Group 

Pioneer Hi-Bred International Inc. 

PLANTON GmbH 

Polium Technologies Inc. 

Polydex Pharmaceuticals Ltd. 

Polysciences Inc. 

POS Pilot Plant Corp. 

PrimeSyn Lab Inc. 

Primm S.R.L. 

Procter & Gamble Co. 

Prokaria ehf 

Prometic BioSciences Inc. 

Proteus SA 

Qbiogene 

Quip Laboratories Inc. 

Ramot at Tel Aviv University Ltd. 

Randox Laboratories Ltd. 

Reanal Finechemical Co. 

RECO Biotechnology 

Recordati SpA 

Regis Technologies Inc. 

Renessen LLC 

Renovo Group plc 

Research Organics Inc. 

Research Triangle Park Laboratories Inc. 

Response Biomedical Corp. 

Roal Oy 

RTI International 

SafePath Laboratories LLC 

Sakai Chemical Industry Co. Ltd. 

Sanyo Chemical Industries Ltd. (Sanyo Kasei) 

Scion - Cellwall Biotechnology Centre 

Sensient Technologies Corp. 

Severn Biotech Ltd. 

Showa Denko KK 

SibEnzyme Ltd. 

Solomon Park Research Laboratories 

Spark Holland BV 

Spherix Inc. 

SRI International 

Stewart Agricultural Research Services Inc. 

Stratagene Corp. 

Strategic Diagnostics Inc. 

Sumitomo Chemical Co. Ltd. 

SunOpta Inc. 

Symbio 

Syngenta International AG 

Synthetech Inc. 

Synthetic Genomics Inc. 

Takeda Pharmaceutical Co. Ltd. 

Teledyne Isco 

The Dow Chemical Co. 

The Nitrate Elimination Co. Inc. 

TNO Quality of Life 

Toray Industries Inc. 

Toronto Research Chemicals Inc. 

Union Chemical Laboratories (UCL) 

UniQuest Pty. Ltd. 

University of Nebraska-Lincoln, Center for Biotechnology 

UVP Inc. 

Valeant Pharmaceuticals International Inc. 

Varied Industries Corp. 

VECTOR State Research Centre of 

Virology/Biotechnology 

Virinova GbR 

Vitrolife AB 

Vizon SciTec Inc. 

Wako Chemicals U.S.A. Inc. 

Waste Stream Technology Inc. 

Webs Ltd. 

Wedgewood Analytical Inc. 

Westbridge Research Group 

Weyerhaeuser Co. 

Xethanol Corp. 

Yeda Research and Development Co. Ltd. 

Yissum Research Development Co. 

YMC Co. Ltd. 

Zeltia SA 

Zeon Corp. 

Zuckerforschung Tulln GmbH 



BioWorld ® 

INDUSTRIAL 

BIOTECHNOLOGY 

STATREPORT 

COMPANY PROFILES 


3DM Inc. 


P.O. Box 425025 

Cambridge MA 02142, US 

Phone: (877) 430-9595; Fax: (877) 430-9595 

Toll-free phone: (877) 430-9595 

Web: www.puramatrix.com 

E-mail: contact@puramatrix.com 

KEY PERSONNEL: Shuguang Zhang, Ph.D.; Chairman 

Zen Chu; President 

Lisa Spirio, Ph.D.; Director, R&D 

EMPLOYEES: 8 employees 

HISTORY: Founded in 2001 

Began biotech R&D in 1994 

FACILITIES: 2,000 sq. ft. headquartes and R&D facilities 

Manufacturing is outsourced 

STOCK-FINANCIAL HISTORY: Privately held 

PRIVATE PLACEMENTS: Raised $1.7M in first round of financing (10/04) 

PRINCIPAL INVESTORS: Bain Capital 

Monitor Ventures 

NMJ Japan 

Technology Directors Inc. 

BUSINESS STRATEGY: Establish and maintain a position as the leading synthetic cell culture 

scaffold for bioproduction, life science R&D and stem cell therapies, through 

a worldwide marketing and distribution partnership with Becton Dickinson 

BDBiosciences. 3DM is developing a pipeline of medical devices for 

orthopedic and cardiac therapies with industry-leading companies. 

AGREEMENTS: Name Products Content of Agreement Date 

Becton Dickinson BD PuraMatrix worldwide marketing 

and distribution 

agreement 

2004 

Becton Dickinson PuraMatrix Synthetic worldwide marketing 2004 

Peptide Hydrogel and distribution 

agreement 

RESEARCH & DEVELOPMENT: Orthopedic and reconstructive surgery medical devices 

Cardiac regeneration therapies 

Cancer invasion assays 

High-content screening 

Collagen plug assays 

Stem cell expansion and delivery 

Bioproduction 

Tissue engineering 

PRODUCTS ON MARKET: PuraMatrix 

PuraMatrixCST 

PuraMatrixGMP 

BD PuraMatrix 

PRODUCTS IN DEVELOPMENT: Name Status 

PuraMatrixCST in preclinicals 

PuraMatrixRGD in preclinicals 




935 Main Street 

Waltham MA 02451, US 

Phone: (781) 899-7755; Fax: (781) 899-8482 

Web: www.afprotein.com; E-mail: eentis@afprotein.com 

KEY PERSONNEL: Elliot Entis; Chairman, President and CEO 

Michael Erisman, Ph.D.; Exec. VP, Science and Technology 

Ronald M. Slate; COO 

Choy L. Hew, Ph.D.; Director and Consultant to A/F Protein 

Garth Fletcher, Ph.D.; President, A/F Protein Canada, and VP 

Boris Rubinsky, Ph.D.; Director and Consultant to A/F Protein 


HISTORY: Founded and began biotech R&D in 1992 

Member--Biotechnology Industry Organization 


PRIVATE PLACEMENTS: Raised $1.2M in private placement of Reg D stock (1993, 1994) 

Raised $4.0M in private placement of Reg D stock (1996) 

SUBSIDIARIES/DIVISIONS: A/F Protein Canada 

P.O. Box 13422 

St. John's, NL A1B 4B7 

Canada 

Phone: (709) 738-4638 

Fax: (709) 738-4644 

E-mail: mail@afprotein.com 

BUSINESS STRATEGY: Develop the use of antifreeze proteins for the control of cold-induced 

damage in medical, food and cosmetic products 

Seeking partners to pursue the development of an AFP-based medium for 

hypothermic preservation of human platelets and AFP-based strategies for 

improved methods of cryosurgery 

RESEARCH & DEVELOPMENT: Hypothermic-cryogenic preservation of mammalian cells, tissues and whole 

organs 

Enhanced cryosurgical ablation of tumours 

Food preservation 

Preservation of reproductive materials 

Enhancement of the protective capacity of skin-care products 

PRODUCTS ON MARKET: Antifreeze Protein Type I 

Antifreeze Protein Type III 

Antifreeze Glycoprotein 

AB Enzymes Oy 

P.O. Box 26 

Rajamaki FIN-05207, Finland 

Phone: +358 9 290 22 510; Fax: +358 9 290 22 550 

Web: www.abenzymes.com; E-mail: info@abenzymes.com 

KEY PERSONNEL: Ralf Lundell; President and CEO 


HISTORY: Formed in 1987 

Changed name from Alko Ltd./Biotechnology (1995) 

Changed name from Primalco Ltd. Biotec (9/97) 

Changed name from Rohm Enzyme (10/01) 

Acquired GAMMA CHEMIE GmbH (2002) 




SUBSIDIARIES/DIVISIONS: AB Enzymes GmbH Beijing Representative Office 

Room 320B, B Tower, Grand Pacific Building 

8A Guanghua Road, Chaoyang District 

Beijing 100026 China 

Phone: +86 10 65814225; Fax: +86 10 65814227 

E-mail: mp_guo@public3.bta.net.cn 

SUBSIDIARY OF: Abitec Group 

Main Office of ABF Ingredients Corp. 

Enzyme Division 

214 Rockmont Drive 

Fort Mill, SC 29708-7934 

Phone: (803) 547-7800 or (803) 547-0852 

Fax: (803) 547-0891; Cell phone: (704) 400-8099 

E-mail: ABEnzymes@comporium.net 

AB Enzymes GmbH Guangzhou 

Representative Office 

Room 2715, Bank of America Plaza 

555 Renminzhong Road 

Guangzhou City 510145 China 

Phone: +86 20 81302718 

Fax: +86 20 81302303 

E-mail: fjj138@pub.guangzhou.gd.cn 

AB Enzimas Brasil Comercial Ltda. 

Al. Amazonas, 938 Bloco A, 3. andar 

06454 – 070, Barueri, SP Brazil 

Phone: +55 11 4688 2555; Fax: +55 11 4688 2259 

E-mail: paulo.sandri@abenzimas.com.br 

AB Enzymes Singapore Branch 

3 International Business Park 

# 07-18 Nordic European Centre 

Singapore 609927 

Phone: +65 6890 6831; Fax: +65 6890 6846 

E-mail: trandinh@abenzymes.com.sg 

AB Enzymes Poland Sp. Z.o.o. 

Ul. POW 35 

PL 98-200 Sieradz 

Phone: +48 43 8223094 

Fax: +48 43 8273808 

E-mail: abenzymes@abenzymes.pl 

AB Enzymes GmbH 

Feldbergstrasse 78 

D-64293 Darmstadt 

Germany 

Phone: +49 (0) 61 51-36 80-100 

Fax: +49 (0) 61 51-36 80-120 

PRINCIPAL INVESTORS: Associated British Foods plc 

BUSINESS STRATEGY: Develop and market industrial enzymes for feed, textile, and pulp and paper 

applications 

RESEARCH & DEVELOPMENT: Development of technical enzyme applications 

PRODUCTS ON MARKET: Biotouch enzymes for textile biofinishing 

Econase enzymes for feed and food 

Ecostone enzymes for textile stonewash and finishing 

Ecopulp enzymes for pulp bleaching 




Finase enzymes for feed and food 

Veron enzymes for baking 

Rohapect, Rohament, Rohavin and Corolase enzymes for fruit/vegetable 

processing, cleaning of ultrafiltration membranes and winemaking 

Corolase enzymes for protein modification 

Max-Planck-Ring 2 

Wiesbaden 65205, Germany 

Phone: +49 6122-58-0; Fax: +49-6122-58-1244 

Web: www.abbott.de 

E-mail: info-diagnostik.de@abbott.com 

KEY PERSONNEL: Holger Liepmann; Chairman, Supervisory Board and Sr. VP, International 

Operations 

Jaime Contreras; Managing Director 

Siegfried Brune; Managing Director 

Geert Walther Nygaard; Managing Director 

Rodolfo Viana; Managing Director 

EMPLOYEES: 4,000 employees 

HISTORY: Formed from the merger of Abbott GmbH, Knoll GmbH and Knoll 

Deutschland GmbH (2001) 


BUSINESS STRATEGY: Discover, develop, manufacture and market innovative medicines 

Establish global network of strategic alliances and partnerships with biotech 

companies 

Manufacture and market pharma active ingredients 

Market proprietary oral drug delivery and process technology of melt 

extrusion 

Build European generic business 


Alza Corp. Oros hydromorphone joint development 

and marketing 

agreement for the 

U.S. 

2/97 

Cambridge therapeutic antibodies joint research 8/93 

Antibody 

Technology plc 

agreement 

Center for 

TET system for 

licensing research 5/96 

Molecular Biology, regulating gene 

agreement 

Heidelberg expression 

Eisai Co. Ltd. sibutramine joint development 

and marketing 

agreement for Japan 

1/98 

PharmaNetics Inc. thrombin inhibitors R&D collaboration 1996 

PharmaNetics Inc. stoke therapy R&D collaboration 1997 

Warner-Lambert interleukin-1 converting joint research 5/95 

Co. 

enzyme inhibitors agreement 

PRODUCTS ON MARKET: Pharmaceuticals worldwide: 

Synthroid® (hypothyroidism) 

Isoptin® (coronary heart disease, hypertension, cardiac arrythmia) 

Rytmonorm®/Rythmol® (cardiac arrthmia) 

Reductil®/ Merida® (obesity) 

Vicodin® Vicaprotein (pain) 

Bruten® (pain) 

Iruxol® (wound healing) 

Gopten®/Mavik® (hypertension) 


Abengoa SA 


Dilaudid® (pain) 

Akineton® (parkinson) 

Cerebrdysin (cerebral insuffiency) 

Pharma active ingredients worldwide: 

Ephedrine 

Caffeine 

Ibuprofen 

Theophylline 

Avenida de la Buhaira 2 

Seville 41018, Spain 

Phone: +34 954 937 111; Fax: +34 954 937 020 

Web: www.abengoa.com; E-mail: abengoa@abengoa.com 

KEY PERSONNEL: Felipe Benjumea Llorente; Co-chairman 

Javier Benjumea Llorente; Co-chairman 

Amando Sanchez Falcon, Financial Director 

Juan Carlos Jimenez Lora; Director, Investor Relations 

Santiago Seage Medela; Head, Corp. Strategy and Development 

Javier Salgado Leirado; President and CEO, Abengoa Bioenergia SA, 

Abengoa Bioenergy Corp. and Abengoa Bioenergy R&D 

Ignacio Garcia Alvear; CFO, Abengoa Bioenergia SA 

Francisco A. Morillo Leon; CTO, Abengoa Bioenergia SA 

Gerson Santos-Leon; Director, R&D, Abengoa Bioenergia SA 

Joel Stone; COO, Abengoa Bioenergy Corp. 

Santiago Ortiz Dominguez; GM, Industrial Waste Management 


HISTORY: Acquired Befesa for EUR300M (2000) 

Started the first bioethanol facility in Spain (2000) 

Acquired High Plains Corp. (now Abengoa Bioenergy Corp.) (2002) 

Started the second bioethanol facility in Spain (2002) 

Acquired Metso Corp.’s Network Management Solutions Division (now 

Telvent Canada and Telvent USA) (2003) 

Started construction of the third bioethanol facility in Spain (2003) 

Acquired Miner & Miner Consulting Engineers Inc. (2004) 

Started construction of the fourth bioethanol facility in Nebraska (2004) 

Acquired Almos Systems (2004) 

Acquired Energoprojekt Gliwice (EPG) (7/06) 

STOCK-FINANCIAL HISTORY: Listed on the Madrid and Barcelona stock exchanges 

IPO-1996 

Sales EUR2.024b (YE 05) compared to EUR1.746b (YE 04) 

Earnings per share EUR0.73/share (YE 05) compared to EUR0.58/share 

(YE 04) 

SUBSIDIARIES/DIVISIONS: Five business units: Industrial Engineering and Construction, Information 

Technology, Environmental Services, Solar and Bioenergy 

Six operational fields: Energy, Environment, Transport, Services, Industry 

and Telecommunications 

Bioenergy subsidiaries: 

Ecocarburantes Espanoles SA 

Ecoagricola SA 

Bioetanol Galicia SA 

Biocarburantes de Castilla y Leon SA 

ETBE Huelva SA 

Abengoa Bioenergia SA 

Abengoa Bioenergy Corp. 



Abengoa Bioenergy France 

Abengoa Bioenergy of Hanover 

Abengoa Bioenergy R&D Inc. 

Greencell SA 

BUSINESS STRATEGY: Solar: Design, promote, attain financing for, construct and operate electric 

energy generating plants that utilize the sun as the primary energy source 

Bioenergy: Produce and develop biofuels for transport--bioethanol and 

biodiesel, among others that utilize biomass (cereals, cellulosic biomass and 

oleaginous seeds) as the raw material 

Environmental Services: Provide environmental services for industry and for 

the construction of environmental infrastructures, while conducting 

aluminum waste recycling, zinc recycling, industrial waste management and 

environmental engineering activities 

Information Technology: Provide high value-added solutions in four 

industrial sectors: energy, traffic, 

transport and the environment) 

Industrial Engineering and Construction: Engineer, construct and maintain 

electric, mechanical and instrumentation infrastructures for the energy, 

industry, transport and services sectors; Promote, construct and operate 

industrial and conventional (cogeneration and combined cycle) power plants 

and renewable energy (bioethanol, biodiesel, biomass, wind, solar and 

geothermal) power plants; Turnkey telecommunication networks and 

projects 

RESEARCH & DEVELOPMENT: Abengoa Bioenergy R&D Inc.: 

Improve actual production process yields and coproduct quality at existing 

dry-mills 

Increase ethanol capacity and develop new feed co-products 

Develop and demonstrate cost competitive technologies for new biomass 

facilities 

Develop demonstration programs which permit an increase in the field of 

ethanol utilization (for example, diesel and hydrogen fuel cells) 


30 Brown Avenue 

Dartmouth B3B IX8, Canada 

Phone: (902) 468-2840; Fax: (902) 468-3474 


Web: www.acadianseaplants.com 

E-mail: info@acadian.ca 

KEY PERSONNEL: Louis Deveau; Chairman 

Jean-Paul Deveau; President 

Perry Bevin; CFO 

Scott Myers; VP, Sales, Plant Science Division 

Glen Gabriel; VP, Sales, Animal Science Division 

John Sewuster; VP, Sales, Food and Food Ingredients Divisions 

Dr. Alan Critchley; VP, Research 

Bill Smith; VP, Manufacturing 

EMPLOYEES: 310 employees, 8 Ph.D.s 


FACILITIES: Head office 

Five processing plants 

Research facility 

Cultivation site 




BUSINESS STRATEGY: Research and application of technology to develop unique marine plant 

applications and strains of cultivated, food-grade seaweed 

Manufacture agricultural (feed and fertilizers) and food ingredient products 

from seaweed 


NRC Institute for plant growth regulators, consulting and 1990 

Marine Bioscience seaweed vegetable licensing agreement 

RESEARCH & DEVELOPMENT: Seaweed cultivation and processing 

Chemical extraction/biostimulants from seaweed 

PRODUCTS ON MARKET: Carrageenan-bearing seaweed 

Natural plant growth regulators 

Hana-nori--edible seaweeds 

Ascophyllum nodosum and Chondrus crispus seaweeds--meals, fine-milled 

powders, extracts for feed, food and cosmetic and health ingredients 

Cultivated edible sea vegetables 


1133 Regent Street, Suite 300 

Fredericton E3B 3Z2, Canada 

Phone: (506) 452-9000; Fax: (506) 451-7451 

Web: www.adi.ca 

E-mail: adigroup@adi.ca 

KEY PERSONNEL: Hollis B. Cole; President and CEO 

A.L. Steeves; VP, Administration and Secretary-Treasurer 

Hazen G. Hawker, CFO 

Paul D. Morrison; President and COO, ADI Limited 

Graham J. Brown, President and COO, ADI Systems Inc. 

Brian MacLean, Operations Manager, Geomembrane Technologies Inc. 



Since 1981, ADI has conducted R&D into the use of innovative and costeffective 

processes for wastewater treatment as well as removal of arsenic 

and other contaminants from drinking water. 

FACILITIES: Environmental laboratory 


SUBSIDIARIES/DIVISIONS: ADI Systems Inc. (see separate entry) 

ADI International Inc. 

Geomembrane Technologies Inc. 

FINANCIAL INFORMATION: ADI is 100% employee-owned 

BUSINESS STRATEGY: Promote and apply its anaerobic and aerobic technologies in the treatment 

of high-strength wastewater 

Promote and apply water treatment (arsenic, manganese removal) 

Continue R&D efforts and develop new treatment processes and systems 

Continue to develop innovative monitoring and control systems 

RESEARCH & DEVELOPMENT: Wastewater treatment processes 

Water treatment processes 

Conceptual planning, implementation, supervision, and monitoring of 

mineral exploration programs 

Evaluation of mining properties and assessment of investment properties 



PRODUCTS ON MARKET: Patents are held and pending on several of the following systems: 

ADI-BVF® 

ADI-Hybrid 

ADI-SBR 

Floating and structurally supported insulated membrane covers 

Media G2 arsenic removal 

Sulpha Bind H2S removal 


1133 Regent Street, Suite 300 

Fredericton E3B 3Z2, Canada 

Phone: (506) 452-7307; Fax: (506) 452-7308 


Web: www.adisystems.ca 

E-mail: rcl@adi.ca 

KEY PERSONNEL: Graham Brown; President 




SUBSIDIARIES/DIVISIONS: U.S. office: 

182 Main Street, Unit 6 

Salem, NH 03079 

Phone: (603) 893-2134 

Fax: (603) 898-3991 

ADI Systems Inc. Laboratory 

6 Lewis Street 

Oromocto, NB E2V 2X5 

Canada 

Phone: (506) 357-2470 

Contact: Jonathan Dargavel 

E-mail: jgd@adi.ca 

SUBSIDIARY OF: ADI Group Inc. (see separate entry) 

BUSINESS STRATEGY: Supply and install anaerobic and aerobic systems for industrial wastewater 

treatment 

Seek suitable overseas companies to license ADI wastewater treatment 

technology 

RESEARCH & DEVELOPMENT: Design anaerobic treatment systems, biogas handling and SBR decanters 

PRODUCTS ON MARKET: Proprietary ADI-BVF® low-rate anaerobic system, ADI-Hybrid high-rate 

anaerobic system, ADI-SBR (Sequencing Batch Reactor) technology, ADI- 

AMR (Anaerobic Modular Reactor), ADI-MBR (Membrane Biological 

Reactor), generic and package wastewater treatment systems 

Conducts treatability studies, pilot testing, bench-scale studies, operator 

training and aftercare services 



Advanced Product Enterprises LLC 

5716-F Industry Lane 

Frederick MD 21704, US 

Phone: (888) 496-8333; Fax: (888) 496-8333 


Web: www.ape-bio.com 

E-mail: info@ape-bio.com 

KEY PERSONNEL: Joseph N. Garner, Ph.D.; President and CEO 

Bhavesh Joshi, Ph.D.; CSO 



BUSINESS STRATEGY: Advanced Product Enterprises LLC (or APE) is a Maryland-based 

biotechnology company involved in the identification, testing, development, 

and production of biomolecular and molecular biology products for industrial 

and academic partners. With the provision of services such as antibiotic 

assessment, cell based assay development, endotoxin testing, and 

pharmaceutical assessment we assist pharmaceutical companies with their 

research and development, preclinical testing, and quality control and 

assurance needs. The provision of services which include animal model 

elucidation, recombinant protein, antibody and virus production APE is 

capable of assisting vaccine development companies with all of their 

preclinical needs. As services can be bundled or provided individually, we 

can assist any individual or company with a project of any size. 


Sorbitase in preclinicals 

Varimentix in preclinicals 


Off Southgate 

Sleaford NG34 7HA, UK 

Phone: +44 1529 304511; Fax: +44 1529 303908 

Web: www.advantaseeds.co.uk 

E-mail: info@advantaseeds.co.uk 

KEY PERSONNEL: Dr. Thomas Jolliffe; General Manager 


HISTORY: Founded in January 1997 from the merger of Sharpes International Seeds 

Ltd. and Zeneca Seeds UK Ltd. 

FACILITIES: 2,000 sq. m. headquarters 

1,000 sq. m. R&D facility 

20,000 sq. m. manufacturing facility 


SUBSIDIARY OF: Limagrain Group (France) 

PRINCIPAL INVESTORS: Limagrain Group 

INVESTMENTS: Plant Breeding--major U.K. crops 

BUSINESS STRATEGY: Produce wholesale and multiplication grade seed and conduct plant 

breeding 

RESEARCH & DEVELOPMENT: Plant breeding 

Crop biotechnology 



PRODUCTS ON MARKET: Crop varieties for U.K. agriculture 


Crop varieties in development 


Harwell Business Centre 

Didcot OX11 ORA, UK 

Phone: +44 (0) 870 190 1900; Fax: +44 (0) 870 190 8261 

Web: www.aeat.com; E-mail: jan.lindsay@aeat.co.uk 

KEY PERSONNEL: Bernard Bulkin; Chairman 

Andrew McCree; CEO 

David Lindsay; Group Finance Director 

Keith Russell; Director, Corporate Resources and Company Secretary 

Stuart Hill; Managing Director, Rail 

Robert Bell; Managing Director, Environment 

Ralph Watts; Managing Director, Nuclear Programs 


HISTORY: Evolved from U.K. Atomic Energy Authority, Harwell Laboratory--separated 

in 1994 

Acquired biotech expertise and facilities of Warren Spring Laboratory (1994) 

Acquired the British Rail Research Centre (1996) 

Privatized as AEA Technology plc. (1996) 

Sold AEA Technology Battery Systems Ltd, AEA HK, QSA, nCode, 

Accentus, Engineering, Safety and Risk, Risk Solutions, Safeguard 

International, EASA and Lexware International Ltd. to Coller Capital (10/05) 

STOCK-FINANCIAL HISTORY: Traded on the London Stock Exchange--AAT 

IPO--1996 

Turnover £236.7M (YE 05) compared to £251.6M (YE 04) 

Net loss (YE 05) compared to (YE 04) 

Earnings per share 35.7p/share (YE 05) compared to 3.4p/share (YE 04) 

SUBSIDIARIES/DIVISIONS: Two core businesses: 

Rail 

Environment: Future Energy Solutions (FES), Netcen, Waste and Resource 

Management, National Chemical Emergency Centre (NCEC), Momenta 

Nuclear programmes--One business unit: Waste Management Technology 

PRINCIPAL INVESTORS: M&G Investment Management 

Invesco Perpetual 

Deutsche Asset Management Ltd. 

Newton Investment Management Ltd. 

BUSINESS STRATEGY: Environmental business--Supply energy and environmental services to the 

U.K. government and agencies 


AGI Dermatics 


205 Buffalo Avenue 

Freeport NY 11520, US 

Phone: (516) 868-9026; Fax: (516) 868-9143 

Web: www.agiderm.com 

E-mail: businessdevelopment@agiderm.com 

KEY PERSONNEL: Daniel B. Yarosh, Ph.D.; Chairman and President 

Jonathan D. Klein; VP, Operations 

Adrienne O’Connor; Director, Quality Control and Assurance 

Georgia W. Binns; Director, Production 

Nick Bizios; Director, Process Development 

Frederic Carr; Director, Sales and Marketing 


HISTORY: Founded in May 1985 to focus on DNA repair technology 

Changed name from Applied Genetics Inc. (1998) 

FACILITIES: Liposome manufacturing facility 

Molecular biology, fermentation and enzyme purification 


BUSINESS STRATEGY: Form strategic alliances with cosmetic/dermatology companies for marketing 

RESEARCH & DEVELOPMENT: Bicyclic monoterpene diols 

DNA repair enzyme delivery 

PRODUCTS ON MARKET: Cosmetic ingredients: Photosomes®, Ultrasomes®, Oxysomes®, 

Roxisomes, Thiotaine®, Merospheres®, VitAine®, Evodiox, Pinoxide 

Pharmaceutical products: Dimericine® (T4N5 Liposome Lotion) 


Dimericene for xeroderma pigmentosum completed Phase III 

Dimericene for renal transplant in Phase II clinicals 

Dimericene for at-risk populations to begin Phase II 


5th Floor, Tower Block, Ruakura Research Centre, East Street 

Hamilton 3123, New Zealand 

Phone: +64 7-834-6600; Fax: +64 7-834-6640 

Web: www.agresearch.co.nz; E-mail: webmaster@agresearch.co.nz 

KEY PERSONNEL: Rick Christie; Chairman 

Andrew West, Ph.D.; CEO 

Dr. Stephen Goldson; Chief Science Strategist 

Jimmy Suttie, Ph.D.; GM, Science and Technology, Applied Biotechnologies 

Mark Ward; GM, Sience and Technology, Food and Health 

Peter Benfell; GM, Science and Technology, Agriculture and Environment 

Ian Boddy, Ph.D.; GM, Commercial Services 

Geoff Balme; CFO 

Phillip Lindsay, Ph.D.; CIO 

Allanah James; Corporate Affairs Manager 

EMPLOYEES: 1,000+ employees 

HISTORY: Founded in 1992 in a restructuring of the former Ministry of Agriculture and 

the Department of Scientific and Industrial Research (DSIR) 

Sold AgVax (8/05) 



FACILITIES: Five campuses 

STOCK-FINANCIAL HISTORY: Government-owned company established under the Crown Research 

Institutes Act 

SUBSIDIARIES/DIVISIONS: BioPacificVentures--50% 

EnCoate--50% 

Clone International--25% 

Grasslanz Technology Ltd.--100% 

Farmax--50% 

BUSINESS STRATEGY: Three main objectives: 

To underpin the New Zealand pastoral sector’s sustainability and profitability 

To establish a range of biotechnologies and systems in New Zealand 

To export AgResearch biotechnologies and systems where appropriate 


Pharming Group recombinant human manufacturing 6/05 

NV 

lactoferrin 

agreement 

RESEARCH & DEVELOPMENT: Agriculture and environment 

Applied biotechnologies 

Food and health 

PRODUCTS ON MARKET: Licensing opportunities: 

AGR-0100: Device for Administration of Beneficial Materials to Ruminants 

AGR-0101: Delivery Mechanism 

AGR-0200: A Thermostable Biomatrix 

AGR-0201: Stable Bio-Matrix Composition and Method of Preparation 

AGR-0202: A Granulated Composition 

AGR-0300: A Method of Processing Data from a Spectrophotometer 

AGR-0301: Compound Preparation Method 

AGR-0400: Method and Kitset for Sampling and Storage of Biological 

Samples 

AGR-0401: Improvements in and Relating to a Method of DNA Testing 

AGR 0402: Controlled Release Vitamin B12 Compositions and Methods of 

Using Them 

AGR-0403: Serratia Proteins 

AGR-0404: A Novel Drug Dosing Regimen 

AGR-0405: Mycobacterial Vaccines 

AGR-0406: Hydatids Vaccine 

AGR-0407: An Animal Repellent 

AGR-0408: Process for Production of Immunoglobulin A in Milk 

AGR-0409: Animal Treatment 

AGR-0410: Mammary-Specific Transcription Factor BrEts 

AGR-0411: Nuclear Transfer with Selected Donor Cells 

AGR-0412: Methods and Compositions for Improving the Developmental 

Ability and Quality of Pre-Implantation Embryos 

AGR-0413: Compositions Isolated from Bovine Tissue and Methods for 

Their Use 

AGR-0500: Rapid Method for Measuring Complex Carbohydrates in 

Mammalian Tissue 

AGR-0501: A Homogeniser 

AGR-0502: A Sampling Tool 

AGR-0503: Apparatus for the Removal of Bone 

AGR-0504: Carcass Management 

AGR-0505: Neck Breaker Machine 

AGR-0506: A Method and Means for the Processing of the Head Portion of 

an Animal Carcass 

AGR-0507: A Cutting Machine 

AGR-0508: A Method and Apparatus for Removing Meat 

AGR-0601: Genetically Modified Plants having Modulated Flower 

Development 

AGR-0602: Flowering Locus T (FT) and Genetically Modified Plants having 

Modulated Flower Development 



AgriSense-BCS Ltd. 

Taffs Mead Road, Treforest Industrial Estate 

Pontypridd CF37 5SU, UK 

Phone: +44 (0)1443 841 155; Fax: +44 (0)1443 841 152 

Web: www.agrisense.co.uk 

E-mail: mail@agrisense.co.uk 

KEY PERSONNEL: Owen Jones, Ph.D.; GM and Director, Business Development 

David Judd; Director, Sales and Marketing, Retail 

David Loughlin; Director, Sales and Marketing, PCO 

David Avery; Business Development Manager 

Enzo Casagrande; Director, Technology 

Nap Coverdale; Director, Operations 

Neil Bryan; Director, Finance 


HISTORY: Established in 1984 

Formerly Biological Control Systems Ltd., acquired by AgriSense in 1989 

Acquired by biosys (1993) 

Acquired by Thermo Trilogy (1/97) 

Acquired by Mitsui (5/01) 

Acquired by Suterra (6/06) 

FACILITIES: 20,000 sq. ft. factory with offices, laboratory and production facilities 


SUBSIDIARY OF: wholly-owned subsidiary of Suterra LLC 

BUSINESS STRATEGY: AgriSense is a major developer and manufacturer of bio-rational insect pest 

monitoring and control products for the agricultural, industrial and home and 

garden market sectors 

RESEARCH & DEVELOPMENT: Insect behavior-modifying chemicals (semiochemicals, attractants and 

repellents) 

Controlled-release technology for semiochemicals and other volatile 

compounds 

Insect glue technology 

Trap design 

PRODUCTS ON MARKET: Trappit range of pest trapping systems 

Polycore range of liquid controlled-release pheromone formulations 

Selibate range of hand-applied, controlled-release pheromone 

formulations 

Frustrate range of hand-applied, controlled-release pheromone 

formulations 

Agrium Inc. 

13131 Lake Fraser Drive SE 

Calgary T2J 7E8, Canada 

Phone: (403) 225-7000 

Fax: (403) 225-7609 


Web: www.agrium.com 

E-mail: webmaster@agrium.com 

KEY PERSONNEL: Frank W. Proto; Chairman 

Michael Wilson; President and CEO 

Bruce G. Waterman; Sr. VP, Finance and CFO 

Richard L. Gearheard; Sr. VP and President, Retail 

Ron Wilkinson; Sr. VP and President, Wholesale 




Andrew K. Mittag; Sr. VP, Corporate Development and Strategy 

Kevin Helash; VP, Marketing and Distribution 

Stephen Dyer; VP, Manufacturing 


Acquired AgBiologicals division of Esso/Exxon 

Acquired Microbials Division of Allelix Crop Technologies 

Changed name from Cominco Fertilizers Ltd. AgBiologicals (1995) 

Changed name from Agrium Inc. AgBiologicals (1996) 

Acquired Nu-Gro fertilizer technology and professional products businesses 

from Spectrum Brands Inc. (1/06) 

STOCK-FINANCIAL HISTORY: NYSE--AGU / TSX--AGU 

Net sales $3.294b (YE 05) compared to $2.838b (YE 04) 

Net earnings $283M (YE 05) compared to $266M (YE 04) 

Earnings per share $2.14/share (YE 05) compared to $2.03/share (YE 04) 

Total assets $2.785b (YE 05) compared to $2.661b (YE 04) 

BUSINESS STRATEGY: Develop and commercialize new products and services for agricultural crops 

RESEARCH & DEVELOPMENT: Specialty controlled-release fertilizers 

Microbial inoculants for nutritional, environmental, pest and disease stresses 

PRODUCTS ON MARKET: RhizUp legume inoculant 

Enfix legume inoculant 

AtEze bacterial inoculant 


Controlled-release fertilizers test market 

Biological control agents test market 

High-sulfur fertilizers test market 

Plant growth promoters test market 

Insect pheromone mating disruption test market 


101-111 Research Drive 

Saskatoon S7N 3R2, Canada 

Phone: (306) 975-1939; Fax: (306) 975-1966 

Web: www.agwest.sk.ca 

E-mail: agwest@agwest.sk.ca 

KEY PERSONNEL: Armand Lavoie; Chairman 

Dr. Ashley O'Sullivan; CEO and President 

Ron Kehrig; VP, BioProducts and BioProcesses 

Dr. Lisette Mascarenhas; VP, Health and Nutrition 

Muriel Adams; GM 

Janice Tranburg; Director, Regulatory Affairs 

EMPLOYEES: 10+ employees 

HISTORY: Ag-West Botech Inc. was founded in 1989 as nonprofit company in 

partnership with the government of Saskatchewan to bring new technologies 

to Saskatchewan as well as commercialize technologies developed in the 

province 

Joined forces with Bio-Products Saskatchewan and Saskatchewan 

Nutraceutical Network to create Ag-West Bio Inc. (4/04) 


STOCK-FINANCIAL HISTORY: Nonprofit agency 

FINANCIAL INFORMATION: Funding provided by Saskatchewan Agriculture and Food 



BUSINESS STRATEGY: Ag-West Bio Inc., at the forefront of Saskatchewan's bio-economy, works as 

a catalyst for industry growth through investments, aiding strategic alliances, 

regulatory advice, communications and education. Ag-West's leadership 

goes beyond biotech to support agriculture, food, health and bio-based 

industries to be a complete resource for bioscience information in 

Saskatchewan 

RESEARCH & DEVELOPMENT: Promote and facilitate other companies and organizations in research and 

development in the sectors of agriculture, environment and natural health 

products 


KEY PERSONNEL: 

15-1 Kyobashi, 1-chome, Chuo-ku 

Tokyo 104-8315, Japan 

Phone: +81 (3) 5250-8180; Fax: +81 (3) 3297-8720 

Web: www.ajinomoto.com 

E-mail: info@ajinomoto.co.jp 

Kunio Egashira; Chairman 

Norio Yamaguchi; President and CEO 

Takashi Kurematsu; Exec. Officer, Corporate Planning Dept. 

Toshio Takahashi ; Exec. Officer, Specialty Chemical Dept. 

Takashi Utagawa; Exec. Officer, Fermentation and Biotechnology 

Laboratories 

Keiichi Yokoyama; Exec. Officer, Marketing Division 

Yutaka Kunimoto; Amino Acid Division 

Hirozumi Eto; R&D Management Dept. 

Yasuhiko Koda; Public Relations Dept. 

Kanji Mimoto; Asean Division 

Koichi Maeda; China Division 

Hiroaki Nomura; Europe and Africa Division 

Tomoyasu Toyoda ; Pharmaceutical Dept. 

Kiyoshi Miwa; Exec. Officer, Institute of Life Sciences 

Tomoaki Hisatsuka; Food Research and Development Laboratories 

Keisuke Nagai; Exec. Officer; International Production and Biotechnology 

Center 


HISTORY: Formed in May 1909 

Established in December 1925 

Began biotech research in 1955 

Acquired Amoy Food Group Companies from Groupe Danone (1/06) 

FACILITIES: 102 plants in 16 countries and regions 

STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange 

IPO--5/49 

Net sales ¥1,073b (YE 05) compared to ¥1,040b (YE 04) 

Net income ¥44.817b (YE 05) compared to ¥36.276b (YE 04) 

Earnings per share ¥68.8 (YE 05) compared to ¥55.6/share (YE 04) 

Total assets ¥903.542b (YE 05) compared to ¥871.780b (YE 04) 

SUBSIDIARIES/DIVISIONS: Ajinomoto U.S.A. Inc. 

BUSINESS STRATEGY: Maintain a worldwide leadership position as a global food and amino acid 

products company 


Apex Bioscience hemoglobin to treat collaboration 3/95 

Inc. 

various diseases agreement 

Biotech Research MAbs (against human joint venture to 

Labs, Fujirebio tumor antigens) for 

cancer treatment and as 

antiviral agent 

develop and market 



Orsan lysine and feed 

additives 

Orsan lysine and amino acid 

feed additives 

Sankyo Co. Ltd. development, 

manufacturing and 

marketing of AJD101 

and related compounds 

Scotia Holdings 

plc 

Scotia's SC103 for 

treating diabetes 

complications 

Senomyx Inc. discovery and 

development of novel 

flavor ingredients 

Seragen Inc. IL-2 gene patents for 

fusion toxin 

Tadamitsu 

Kishimoto 

PRODUCTS ON MARKET: Food products 

Amino acids 

Pharmaceuticals 

Akzo Nobel NV 

joint venture called 

Heartland Lysine, 

Inc. 


Eurolysine 

exclusive global 

licensing agreement 

development and 

marketing 

agreement-- 

Ajinomoto gets 

exclusive rights in 

Japan and several 

other Asian 

countries, Scotia 

gets up-front fee and 

milestones 

R&D, 

commercialization 

and licensing 

worldwide licensing 

agreements (12/94), 

restructured to 

reduce and defer 

Seragen's financial 

obligations to 

Ajinomoto (including 

royalties on product 

sales), Seragen's 

partner Eli Lilly has 

signed separate 


with Ajinomoto and 

assumed most of 

Seragen's remaining 

obligations to 

Ajinomoto 

IL-6 joint research 

agreement 

Velperweg 76, P.O. Box 9300 

Arnhem 6824 BM, Netherlands 

Phone: +31 26 366 44 33; Fax: +31 26 3663250 

Web: www.akzonobel.com; E-mail: acc@akzonobel.com 

KEY PERSONNEL: Hans Wijers; Chairman and CEO 

Rob Frohn; CFO 

Keith Nichols; Sr. VP, Finance 


Copyright ©2006 AHC Media ® 29 

8/06 

3/97 

3/06 

6/97 

2/97


HISTORY: Algemeene Kunstzijde Unie N.V. merged with Koninklijke Zwanenberg 

Organon to form Akzo (1969) 

Akzo and Nobel Industries merged to form Akzo Nobel (1994) 

Acquired Courtaulds (1998) 

Intervet subsidiary acquired Hoechst Roussel Vet (1999) 

Technical Services department in Rotterdam, the Netherlands, acquired by 

Stork NV 

Divested its Polymerization Catalysts & Components business in the U.S. to 

Basell Polyolefins (4/06) 

Acquired remaining shares of its Asian Akzo Nobel Chang Cheng Coatings 

joint venture (5/06) 

Divested its Ink and Adhesive Resins business to Hexion Specialty 

Chemicals (6/06) 

STOCK-FINANCIAL HISTORY: NASDAQ--AKZOY / Euronext Amsterdam--AKZ 

Revenue EUR13.0M (YE 05) compared to EUR12.833M (YE 04) 

Net income EUR 961M (YE 05) compared to EUR945M (YE 04) 


(YE 04) 

SUBSIDIARIES/DIVISIONS: 13 business units 

Subsidiaries in more than 80 countries 


Feixiang 

to form a 50/50 joint strategic alliance 8/06 

Chemicals 

(Zhangjiagang) 

Co. Ltd. 

venture 

PRODUCTS ON MARKET: HUMAN HEALTHCARE: Andriol®, Cerazette®, Desogen® (US), 

Esmeron®, Follistim® (US/Japan), Gracial®, Implanon®, Laurina®, Livial®, 

Marvelon®, Mercilon®, Norcuron®, NuvaRing®, OncoTice / Tice BCG, 

Orgalutran®, Ovestin®, Pregnyl®, Puregon®, Remeron SolTab®, 

Remeron®, Riselle®, TOF-watch, Zemuron® (US) 

Animal healthcare products 

Coatings products 

Chemicals products 


NuRx Services, 250 Karl Clark Road 

Edmonton T6N 1E4, Canada 

Phone: (780) 450-5111; Fax: (780) 450-5333 

Web: www.arc.ab.ca/nurx 

E-mail: nurx@arc.ab.ca 

KEY PERSONNEL: Tom Facklam; VP, Life Sciences 

Donna M. Day; Manager, NuRx Services 





Member--Society for Industrial Microbiology 

Established western Canada's first large-scale biologics manufacturing 

facility for development, scale-up and manufacturing 

FACILITIES: 1,400 sq. m. pilot plant housing highly instrumented fermenters (oxygen 

enrichment and process monitoring) ranging in scale from 20 liters to 5,000 

liters 

Biotechnology lab that includes a fermentation suite for small-scale research 

QC lab has Health Canada establishment license for CGMP analysis 



STOCK-FINANCIAL HISTORY: Government agency 

SUBSIDIARIES/DIVISIONS: NuRx Services 

BUSINESS STRATEGY: Provide contract R&D, scale-up and manufacturing services for companies 

using bacterial, yeast (including pichia), algal, fungal, insect cell and rDNA 

fermentation processes 


Biowest Inc. animal vaccine five-year 

manufacturing 

agreement 

12/97 

MicroBio 

Rhizobium manufacturing 1/95 

RhizoGen Corp. 

agreement 

Nuvotech 

collaboration 12/93 

Ventures 

International 

agreement 

Veterinary 

memorandum of 3/98 

Infectious 

understanding to 

Diseases 

develop animal 

Organization 

vaccines 

RESEARCH & DEVELOPMENT: Contract R&D using bacterial, yeast (including Pichia), algal, fungal and 

rDNA processes 

Carbohydrate chemistry, process engineering, fermentation optimization and 

scale-up manufacturing, including biopharmaceuticals, and enzymes 


2810 Meridian Parkway, Suite 152 

Durham NC 27713, US 

Phone: (919) 544-8220; Fax: (919) 544-9808 

Web: www.alderonbiosciences.com 

E-mail: info@alderonbiosciences.com 

KEY PERSONNEL: Robert Henkens, Ph.D.; President and CEO 

John O'Daly; VP and COO 

Marek Wojciechowski; Director, R&D 


HISTORY: Founded in August 2001, building on technology of AndCare (now a division 

of Alderon Biosciences) 


SUBSIDIARIES/DIVISIONS: Beaufort, N.C. location: 


120 Turner Street 

Beaufort, NC 28516 

Phone: (252) 728-2964 

Fax: (252) 728-2109 

BUSINESS STRATEGY: Provide alternative, low-cost, simple to use diagnostic systems for medical, 

environmental, and laboratory research and testing needs 

RESEARCH & DEVELOPMENT: Technologies include unique electrode surfaces modified with colloidal gold 

or biomaterials (such as gene probes, enzymes, antibodies, other proteins, 

etc.) and proprietary electroanalytical techniques 

PRODUCTS ON MARKET: Portable electrochemical instruments 

Disposable electrochemical sensors 

Test kits 

Assay reagents and accessories 

Instrument accessories 


Alltech Inc. 


3031 Catnip Hill Pike 

Nicholasville KY 40356-9769, US 

Phone: (859) 885-9613; Fax: (859) 885-6736 

Web: www.alltech.com 

E-mail: info@alltech.com 

KEY PERSONNEL: Dr. T. P. Lyons; President 

W. J. Cheek; VP, Marketing 

N. Hohman; VP, Finance 

K. A. Jacques, Ph.D.; Director, Nutrition 

Dr. Karl Dawson; Director, Worldwide Research 

Dr. Ronan Power; Director, Research 


HISTORY: Founded in 1980 as a private company 

Conducts research and product development at 25 universities 

Sells products to more than 85 different countries 

Holds annual symposium on biotechnology in feed industry 

FACILITIES: 100,000 sq. ft. biotechnology center; 140 acres of property (over $20M 

invested in property) 

56,000 sq. ft. corporate headquarters (opened in 2004) 

Research farm 

Opened fermentation block with $2M capital investment (3/88), since 

increased capital 

North American Bioscience Center in Nicholasville, KY--50 employees 

European Bioscience Center in Dublin, Ireland--40 employees 

Chinese Bioscience Center Beijing--25 employees 

14 production facilities around the world 


SUBSIDIARIES/DIVISIONS: Subsidiaries in 35 countries 

Animal Nutrition Division, Human Nutrition Division, Agronomic Division, 

Alltech Aquaculture 

BUSINESS STRATEGY: Improve animal health and performance by adding nutritional value to 

animal feed, enhancing the performance of the animal and increasing 

animal production 

RESEARCH & DEVELOPMENT: Yeast-derived products to maximize animal health through nutrition 

PRODUCTS ON MARKET: TOP BRANDS: 

ANIMAL NUTRITION: Bio-Mos®, Bioplex® Mineral Range, MTB-100®, 

Mycosorb®, Sel-Plex®, Sil-All®, Yea-Sacc®1026 

HUMAN NUTRITION: ExlPrime, Preventox, All-BGY, Bio-Mos FG 

AGRONOMIC: Crop-Set, Turf-Set, Stubble-Aid, Grain- Set, Agro- 

Mos, Compost-Aid 

AQUA: Bio-Mos Aqua Grade, Aqua-Mos, NuPro®, De-Odorase, 

Bioplex®, Sel-Plex®, Mycosorb®, Shrimp-Pak 604, Allzyme® SSF 


Lactoferrin in development 

Antisalmonella program in development 

New bioherbicide in development 

New phytase enzyme in development 

Range of immune modulators in development 




204 Edison Way 

Reno NV 89502, US 

Phone: (775) 856-2500; Fax: (775) 856-1619 

Web: www.altairnano.com 

KEY PERSONNEL: Jon Bengston; Chairman 

Alan J. Gotcher, Ph.D.; CEO and President 

Edward H. Dickinson; CFO 

Douglas K. Ellsworth; Sr. VP, Performance Materials 

Roy Graham; Sr. VP, Commercial Development 

Ken Lyon; VP, Business Development 

Bruce Sabacky, Ph.D.; CTO 

Dennis Nagle; VP, Manufacturing 


HISTORY: Changed name from Altair International (8/01) 

STOCK-FINANCIAL HISTORY: NASDAQ--ALTI (Capital Market) 

Revenue $2.807M (YE 05) compared to $1.152M (YE 04) 


Loss per share (YE 05) compared to (YE 04) 

Average shares outstanding 57.767M (YE 05) compared to 48.677M (YE 

04) 

Total assets $33.464M (YE 05) compared to $15.547M (YE 04) 

SUBSIDIARIES/DIVISIONS: Life Sciences division 

Performance Materials division 

INVESTMENTS: Altairnano Bateman Titania, Inc.--joint venture with Bateman Engineering 

BV 


Elanco Animal development of animal research, licensing 5/06 

Health Division health products using and 

(Eli Lilly and Co.) Altairnano's 


nanotechnology-based 

products 

agreement 

Spectrum 

human therapeutic and exclusive worldwide 1/05 

Pharmaceuticals diagnostic applications licensing agreement 

Inc. 

to develop, market and 

sell RenaZorb 

product line 

PRODUCTS ON MARKET: RenaZorb products for phosphate control in patients with Chronic Kidney 

Disease and hyperphosphatemia associated with End Stage Renal Disease 

Renalan products for phosphate control in companion animals suffering from 

Chronic Renal Failure 

Altium TiNano 40 Series nano-sized TiO2 products 

NanoCheck for phosphate control in water treatment 

TiNano Spheres for drug and chemical delivery 

Titanium dioxide and Zirconia based thermal spray grade powders 




125 Sidney Street 

Cambridge MA 02139-4807, US 

Phone: (617) 299-2900; Fax: (617) 299-2999 

Toll-free phone: (888) ALT-CLEC 

Web: www.altus.com; E-mail: info@altus.com 

KEY PERSONNEL: John Richard; Chairman 

Sheldon Berkle; President and CEO 

Jonathan Lieber; VP, CFO and Treasurer 

Alexey L. Margolin, Ph.D.; Sr. VP, Research and Preclinical Development 

and CSO 

Burkhard Blank, M.D.; Sr. VP, Medicine, Regulatory Affairs and Project 

Management 

Renato Fuchs; Sr. VP, Manufacturing and Technical Operations 

Don G. Burstyn, Ph.D.; VP, Regulatory Affairs and Quality Assurance 

Alan Kimura, M.D., Ph.D.; VP, Clinical Development and Medical Affairs 

Robert Gallotto; VP, Commercial Development and Alliance Management 

Lauren Sabella; VP, Commercial Development 

John M. Sorvillo, Ph.D.; VP, Business Development 


HISTORY: Founded in December 1992 

FACILITIES: 3,000 sq. ft. fully equipped facility 

STOCK-FINANCIAL HISTORY: NASDAQ--ALTU 

IPO--7M shares at $15/share, $105M (1/06) 



Loss per share (YE 05) compared to (YE 

04) 

Average shares outstanding 1.719M (YE 05) compared to 1.704M (YE 04) 


PRIVATE PLACEMENTS: Raised $35M in private financing (10/01) 

Raised $15M in second closing of Series B financing (12/01) 

Raised $51M in Series C financing (5/04) 

SUBSIDIARY OF: Vertex Pharmaceuticals Inc. (see separate entry) 

PRINCIPAL INVESTORS: BankInvest 

China Development Industrial Bank (CDIB) 

Clariden Bank 

CMEA Ventures 

Hotung International Co. Ltd. 

Nomura International 

Palladin Group 

U.S. Venture Partners 

Vertex Pharmaceuticals 

Warburg Pincus 

FINANCIAL INFORMATION: Awarded $500K grant to develop catalysts to neutralize nerve agents using 

Cross-Linked Enzyme Crystal technology (1/97) 

Received $51M in Series C financing led by Warburg Pincus and including 

U.S. Venture Partners, Nomura Phase4 Ventures, BankInvest, CMEA 

Ventures and Clariden Bank (5/04) 

BUSINESS STRATEGY: Develop a series of products jointly with potential users while retaining broad 

rights to distribute to entire market 


Dr. Falk Pharma TheraCLEC development and 2/03 

GmbH 


agreement 



GlaxoSmithKline biocatalysts development 

plc 

agreement 

Nagase & Co. biocatalysts joint development 

agreement 

Novartis AG cross-linked enzyme two-year R&D 

crystal brand forms of 

subtilisin for use in 

detergents 

collaboration 

U.S. Department CLEC technology for $100K research 

of Defense high performance 

catalysts to detoxify 

nerve agents 

grant 

RESEARCH & DEVELOPMENT: Develop highly stable forms of enzymes used in chemical synthesis 

PRODUCTS ON MARKET: ChiroCLEC-BL for performing chiral resolutions and regioselective 

reactions in aqueous and organic media 

ChiroCLEC-CR for performing resolutions of chiral chemicals primarily 

esters, alcohols, and acids 

ChiroCLEC-EC for resolving alcohols, amines, and acids 

ChiroCLEC-PC for resolving alcohols, acids, and esters under a variety of 

reaction conditions 

ChiroKit-EH for performing resolutions of alcohols, acids, and esters by 

ester hydrolysis 

ChiroKit-TE for performing resolutions of alcohols and amines by acylation 

reactions 

PeptiCLEC-BL for synthesizing peptides and peptidomimetics 

PeptiCLEC-TR for performing peptide coupling of both protected and 

unprotected peptides 

PeptiKit for performing quick identification of best catalyst for peptide 

coupling chemistry 

SynthaCLEC-PA catalyst for bulk manufacture of semi-synthetic penicillin 

antibiotics 


TheraCLEC (ALTU-135) in Phase II clinicals, orphan 

drug status 

ALTU-238 for growth deficiency in Phase II clinicals 

ALTU-237 for kidney stones/primary 

hyperoxaluria (oral) 

in preclinicals 

ALTU-236 for phenylketonuria (oral) in preclinicals 

Aluline Ltd. 

Harbour House, 1 Aldborough Street 

Blyth NE24 2EU, UK 

Phone: +44 (0) 1670 544 322; Fax: +44 (0) 1670 544 340 

Web: www.aluline.co.uk 

E-mail: enquiry@aluline.co.uk 

KEY PERSONNEL: William G. Clark; President 

Caroline Clark; Exec. VP 

P. Abdo; Purchasing Manager 

Ian Richardson; Scientist 



FACILITIES: 1,200 sq. ft. headquarters 

6,000 sq. ft. manufacturing facility 



7/93 

11/93 

5/96 

1/96


SUBSIDIARIES/DIVISIONS: Aluline LDA--Portugal 

Aluline LLC--Dubai 

BUSINESS STRATEGY: Supply and manufacture products that do not harm microorganisms in 

drainage 

RESEARCH & DEVELOPMENT: Chemicals for industrial use 

PRODUCTS ON MARKET: Alucleanse stain and odor remover 

Aluclean multipurpose detergent 

Aluzyme grease trap and drain treatment 

Aluclear dish cleaner 

Alurinse rinse aid 

Alucare cleaner 

Aluscale scale build-up remover 

Alusoil crystal granules 

Alupro biological urinal tablets 

Freshloo toilet cleaner 

Aquaflush cleaner 

Aluclean degreaser 

Aluwash 

Alubac 

Aluline spray polish 

Aluclean drain cleaner 

Aluglaze 

Aluline beerline cleaner 

Aluextract 

AMDL Inc. 

2492 Walnut Avenue, Suite 100 

Tustin CA 92780-6953, US 

Phone: (714) 505-4460; Fax: (714) 505-4464 

Web: www.amdl.com 

E-mail: info@amdl.com 

KEY PERSONNEL: William M. Thompson III, J.D., M.D.; Chairman 

Gary L. Dreher; President and CEO 

Akio Ariura; CFO 


HISTORY: Founded in June 1987 


To acquire Jiangxi Jade Biochemistry Pharmacy Co. Ltd. and Yangbian 

Yiqiao Biochemistry Pharmacy Co. Ltd. (as of 5/06) 


4,000 sq. ft. R&D and manufacturing facilities 

STOCK-FINANCIAL HISTORY: AMEX--ADL 

Revenue $67.565K (YE 05) compared to $186.182K (YE 04) 



PRIVATE PLACEMENTS: Raised $1.2M from combined Regulation D/Regulation S private offering of 

shares and warrants (12/04) 

Raised $1.07M from combined Regulation D/Regulation S private offering of 

shares and warrants (8/05) 

Raised $1.812M from combined Regulation D/Regulation S private offering 

of shares and warrants (4/06) 

BUSINESS STRATEGY: Supply countries with underserved medical markets with premier diagnostic 

products that are accurate, fast and easy to use 



RESEARCH & DEVELOPMENT: Tumor-marker technology for cancer 

PRODUCTS ON MARKET: DR-70 - tumor-marker detection test 

PyloriProbe - IVD test for antibodies to H. pylori 

More than 300 nonproprietary tests, including CEA for colon cancer, PSA for 

prostate cancer and AFP for liver cancer 


DR-70 tumor marker for lung cancer filed 510K application 


101 ARC Dr. 

St. Louis MO 63146, US 

Phone: (314) 991-4545; Fax: (314) 991-4692 


Web: www.arc-inc.com; E-mail: arcinc@arc-inc.com 

KEY PERSONNEL: Surendra Gupta, Ph.D.; Chairman, President, CEO and Purchasing 

Manager 

Karen Gupta; Exec. VP 

Kamal Das, Ph.D.; Sr. Scientist 

Chan Vora, Ph.D.; Sr. Scientist 

Phil Korb; Scientist 


HISTORY: Founded in September 1983 

Acquired Radiochemicals Business from Tocris Bioscience (7/05) 


2,500 sq. ft. R&D facilities 

4,000 sq. ft. manufacturing facilities 

20,000 sq. ft. office warehouse building 


BUSINESS STRATEGY: Provide high-quality radiolabeled products for biomedical research 

RESEARCH & DEVELOPMENT: Radiolabeled drugs 

PRODUCTS ON MARKET: Catalog of more than 2,500 different radiolabeled products 


8 Goldhawk Industrial Estate, Brackenbury Road 

London W6 0BA, UK 

Phone: +44 (0)20-8749-7635; Fax: +44 (0)20-8740-6608 

Web: www.analox.com 

E-mail: info@analox.com 

KEY PERSONNEL: Dr. David Redstone; President 

Dr. Stuart Price; Director, R&D 




SUBSIDIARIES/DIVISIONS: Analox Instruments U.S.A. (see separate entry) 

P.O. Box 208 

Lunenburg, MA 01462-0208 

Phone: (978) 582-9368; Fax: (978) 582-9588 



BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science 

and industrial applications 

RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques 

PRODUCTS ON MARKET: Clinical analyzers: 

GM9 for the analysis of glucose 

LM5 for the analysis of lactate 

AM1 for the analysis of alcohol in blood 

GL5 for the analysis of glucose, lactate, cholesterol, uric acid and alcohol 

GM7 for the analysis of glucose, lactate, urea, uric acid, cholesterol, alcohol, 

acetoacetate, 3-hydroxybutyrate, creatinine, pyruvate, ammonia, glutamine, 

glycerol and triglycerides. 


Industrial/Biotech analyzers: 

AM2/AM3 for the analysis of ethanol 

AM5 for the analysis of methanol 

LM5 for the analysis of lactate 

GL6 for the analysis of glucose, lactate, methanol, glycerol and ethanol 

GM8 for the analysis of glucose, lactate, methanol, glycerol, urea, ethanol, 

sucrose, lactose, pyruvate, ammonia and glutamine 

P.O. Box 208 

Lunenburg MA 01462-0208, US 

Phone: (978) 582-9368; Fax: (978) 582-9588 

Web: www.analox.com 

E-mail: info@analoxusa.com 

KEY PERSONNEL: Dr. David Redstone; President 

Martin Widdowson; Exec. VP 

Dr. Stuart Price; Director, R&D 




SUBSIDIARY OF: Analox Instruments Ltd. (see separate entry) 

BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science 

and industry 

RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques 

PRODUCTS ON MARKET: Metabolite analyzers 

GM9-glucose 

LM5-lactate 

GM7 microstat (ammonia, ketones, glucose, lactate, cholesterol and 

alcohol) 

AM1-alcohol 

GL5 microstat (glucose, lactate, cholesterol, uric acid and alcohol) 


Applera Corp. 


P. O Box 5435, 301 Merrit 7 

Norwalk CT 06856-5435, US 

Phone: (203) 840-2000; Fax: (203) 762-6000 


Web: www.applera.com 

KEY PERSONNEL: Tony L. White; Chairman, President and CEO 

Dennis Winger; Sr. VP and CFO 

Kathy Ordonez; Sr. VP and President, Celera Genomics Group 

Catherine M. Burzik; Sr. VP and President, Applied Biosystems Group 

Barbara J. Kerr; VP, Human Resources 

William B. Sawch; Sr. VP and General Counsel 

Peter Dworkin, VP, Investor Relations and Corporate Communications 

EMPLOYEES: 5.024 employees 

HISTORY: Member--Biotechnology Industry Organization 

Member--Personalized Medicine Coalition 

Acquired Applied Biosystems Inc. (2/93) 

Acquired Tropix 

Acquired amplified fragment-length polymorphisms (AFLP) technology from 

Keygene NV in takeover of GenScope Inc. (2/97) 

Acquired PerSeptive Biosystems Inc. for $13/share in stock exchange worth 

$360M (1/98) 

Acquired Molecular Informatics Inc. (11/97) 

Formed genomics company with The Institute for Genomic Research (TIGR) 

(5/98) 

Changed name from PE Corp. to Applera Corp. (11/00) 

STOCK-FINANCIAL HISTORY: Applera has two classes of stock: Applera-Applied Biosystems stock and 

Applera-Celera Genomics stock. Applera-Applied Biosystems stock is listed 

on the New York Stock Exchange under the ticker symbol 'ABI' and is 

intended to reflect the relative performance of the Applied Biosystems 

Group. Applera-Celera Genomics stock is listed on the New York Stock 

Exchange under the ticker symbol 'CRA' and is intended to reflect the 

relative performance of the Celera Genomics Group. There is no single 

security that represents the performance of Applera Corp. as a whole 

SUBSIDIARIES/DIVISIONS: Celera Genomics (see separate entry) 

Applied Biosystems Inc. (see separate entry) 

BUSINESS STRATEGY: Improve human health and society by understanding and applying the power 

of biology to develop breakthrough research technologies, diagnostic 

products and drugs 

PRODUCTS ON MARKET: DNA and PCR-related systems 

Applied Biosystems-MDS SCIEX LC/MS systems 

Protein analysis systems 

Custom oligosynthesis service 

Genetic analysis systems for forensic, animal and plant breeding 

Bioinformatics systems for genetic research and genomic drug discovery 

Forensics--human identification 

Functional genomics systems 

Certain infectious disease assays and genetic assays 




850 Lincoln Centre Drive 

Foster City CA 94404, US 

Phone: (650) 638-5800; Fax: (650) 638-5884 


Web: www.appliedbiosystems.com 

KEY PERSONNEL: Tony L. White; Chairman, President and CEO, Applera Corp. 

Catherine M. Burzik; President 

Dennis A. Gilbert, Ph.D.; CSO 

Paul D. Grossman, Ph.D.; VP, Strategiic Planning and Business 

Development 

John Duddy; VP, Global Marketing 

Laura Lauman; Division President, Proteomics and Small Molecule 

Sandeep Nayyar; VP, Finance 

Michael G. Schneider; Division President, Service 

Mark P. Stevenson; Division President, Molecular and Cell Biology 

Leonard Klevan; Division President, Applied Markets 


HISTORY: Founded in 1981 in Foster City, Calif. 

Sold interest in Celera Diagnostics joint venture to Celera Genomics (1/06) 

Acquired the research products division (now called Asuragen Inc.) of 

Ambion Inc. (3/06) 

Acquired Agencourt Personal Genomics Inc. (7/06) 


FACILITIES: US main facilities: 

-Foster City, Calif. (headquarters) 

-Pleasanton, Calif. 

-Bedford, Mass. 

-Framingham, Mass. 

-Austin, Texas 

STOCK-FINANCIAL HISTORY: NYSE--ABI 

IPO--Raised $22M (1983) 

Revenue $1.8b (YE 05) compared to $1.7b (YE 04) 

Net income $236.9M (YE 05) compared to $182.9M (YE 04) 

SUBSIDIARIES/DIVISIONS: Applied Biosystems Inc. is one of two businesses of Applera Corp. 

SUBSIDIARY OF: Applera Corp. (see separate entry) 

PRINCIPAL INVESTORS: Asset Management Co. 

BUSINESS STRATEGY: The Applied Biosystems Group serves the life science industry and research 

community by developing and marketing instrument-based systems, 

consumables, software, and services. Customers use these tools to analyze 

nucleic acids (DNA and RNA), small molecules, and proteins to make 

scientific discoveries and develop new pharmaceuticals. Applied 

Biosystems’ products also serve the needs of some markets outside of life 

science research, which we refer to as 'applied markets,' such as the fields 

of: human identity testing (forensic and paternity testing); biosecurity, which 

refers to products needed in response to the threat of biological terrorism 

and other malicious, accidental, and natural biological dangers; and quality 

and safety testing, for example in food and the environment. Applied 

Biosystems is headquartered in Foster City, Calif., and reported sales of 

nearly $1.8 billion during fiscal 2005. 


Affymetrix Inc. manufacturing, sales nonexclusive, 12/05 

and use of microarrays worldwide licensing 

for gene expression 

analysis 

agreement 



Dionex Corp. (with 

MDS Sciex) 

development of IC- 

MS/MS and LC/MS/MS 

solutions for emerging 

market opportunities 

DuPont Qualicon development of nextgeneration 

DNA 

detection tests and 

systems for food 

testing, targeted food 

quality and safety 

assessment 

Geospiza Inc. integration of genetic 

analysis products 

Hitachi High- 

Technologies 

Corp. 


commercialization of 

capillary 

electrophoresis-based 

DNA analysis 

technologies 

Invitrogen Corp. Deliver advanced 

proteomic solutions for 

biomarker discovery 

National Center 

for Toxicological 

Research of the 

FDA 

National Institute 

of Genomic 

Medicine (Mexico) 

and validation 

investigation of toxicity 

of diabetes drugs 

pharmacogenomic 

therapeutics 

Qiagen NV PCR and PCR-related 

technologies 

VisiGen 

sequencing 

Biotechnologies technologies 

alliance 6/05 

strategic alliance 8/05 

platform 

collaboration 

agreement, 

expanded 8/06 

exclusive 

collaboration 

agreement 


2005 

1/06 



R&D agreement 6/05 

expanded licensing 

agreement 

12/05 

equity investment 10/05 

RESEARCH & DEVELOPMENT: Focused on the following markets: basic research, commercial research 

(pharmaceutical and biotechnology) and standardized testing, including 

forensic human identification, paternity testing and food testing 

Development and marketing of instrument-based systems, consumables, 

software and services to the life science industry and research community 

PRODUCTS ON MARKET: Products for: 

DNA Sequencing 

Gene Expression 

SNP Genotyping 

Gene Expression Array 

Biochromatography 

Cellular Detection Systems 

Human Identification/Forensics 

BioSecurity (infectious disease identification) 

Informatics Software 

Mass Spectrometry 

Molecular Diagnostics 

Molecular Microbiology 

Nucleic Acid Sample Preparation 

PCR 

Peptide Synthesis 

Protein Quantitation 

Protein Sequencing 

Real-Time PCR 

Surface Plasmon Resonance


Services include: 

Custom Services 

Support Plans 

Service Call Center 

Financing Solutions 


1180 Chess Drive 


Phone: (650) 578-1396; Fax: (650) 578-8836 

Web: www.applikon.com 

E-mail: info@applikonbio.com 

KEY PERSONNEL: John Chory; President 

Vickie Sanchez; Purchasing Manager 

Arthur Oudshoorn; Director, Biotechnology Division 

Christine Corsette; Director, Product Development 



FACILITIES: 10,000 sq. ft. facility 


SUBSIDIARY OF: Applikon BV Netherlands 

BUSINESS STRATEGY: Develop, manufacture and supply bioreactor systems for both research and 

production use. Focus on development of innovative technologies and 

products compliant with cGMP regulations 


Finesse LLC TruBio O/S--Bioreactor 

Control Operating 

System 

licensing agreement 9/06 

PRODUCTS ON MARKET: Fermentors, cell culture reactors, single use bioreactors, micro-bioreactors, 

controllers, PLC integration, fieldbus I/O, sensors, software, biomass 

monitor and cell separation 


501 Merritt 7 

Norwalk CT 06856-5204, US 

Phone: (203) 229-2900; Fax: (203) 229-3652 

Web: www.archchemicals.com 

KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President 

Paul J. Craney; Exec. VP 

Louis S. Massimo; Exec. VP 

Hayes Anderson; VP, Human Resources 

Sarah A. O’Connor; VP, General Counsel and Secretary 

W. Paul Bush; VP and Treasurer 

Steven C. Giuliano; Controller 


HISTORY: Founded in August 1998 as a wholly-owned subsidiary of Olin Corp. 

Became a separate, publicly-held company in February 1999 

Acquired remaining 50 percent share of Nordesclor SA joint venture (12/05) 



FACILITIES: Research sites in Cheshire, Conn.; New Castle, Dela.; South Plainfield, N.J.; 

Conley, Ga.; Blackley, U.K.; and Pianoro, Italy 

STOCK-FINANCIAL HISTORY: NYSE--ARJ 

Sales $1.305b (YE 05) compared to $1.121b (YE 04) 





BUSINESS STRATEGY: Provide innovative, chemistry-based solutions to control the growth of 

harmful microbes. Concentration is in water, hair and skin care products, 

pressure-treated wood, paints and building products, and health and 

hygiene applications. 

PRODUCTS ON MARKET: Treatment products: HTH water products (HTH®, Poolife®, Baquacil® and 

Baqua Spa®) 


Personal care and industrial biocides: Omadine®, Omacide®, Triadine®, 

Proxel®, Purista®, Vantocil®, Reputex®, Cosmocil® and Densil® biocides 

Wood protection and industrial coatings: Wolman®, Dricon®, Tanalith®, 

Vacsol® and Resistol® 

Performance products: Urethane intermediate products, hydrazine hydrates 

and derivatives 

70 Tyler Place 

South Plainfield NJ 07080, US 

Phone: (908) 561-5200; Fax: (908) 561-9174 


Web: www.archpersonalcare.com 

E-mail: archpc@archchemicals.com 

KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President, Arch Chemicals 

Paul J. Craney; Exec. VP, Arch Chemicals 

Louis S. Massimo; Exec. VP, Arch Chemicals 



Formerly Brooks Industries Inc. 

Acquired by Arch Chemicals Inc. (2000) 


SUBSIDIARY OF: Arch Chemicals Inc. (see separate entry) 


Ausimont SpA Fomblin sales agreement 1992 

Knoll Microcheck protective enzyme 

system 

sales agreement 1992 

Polymedica Inc. Pu/Meth entrapment 

technology 

joint venture 1991 

Quest ceramides sales agreement 1997 

PRODUCTS ON MARKET: Zinc Omadine® anti-dandruff actives 

Animal, marine, milk, plant and silk proteins 




Biotechnological actives: Acqua-Biomin® Calcium Y3, Acqua-Biomin®, 

βetavera®, Biocell SOD, Biodynes®, Biomin® Acquacinque Liquid, Biomin® 

Marine, Bio-Oil® HBSL, Biophos 35, Bio-Plex NMF, Bio-Plex RNA, Bio- 

Pol®, Hydromide Blend, Kudzu Zymbiozome® Fermentum, Lotus 

Zymbiozome® Fermentum, Musol 20, Peptamide 6, Phytohyaluronate, 

Pseudocollagen, Pseudofilaggrin, Soy Zymbiozome® Fermentum, Vegepol, 

Vitazyme® 

Deliver systems: Brookosome® ACE, Brookosome® ACEBC, Brookosome® 

EPO, Brookosome® P, Brookosome® Retinol, Brookosome® SOD, 

Brookosome® TA, Brookosome® TRF®, Brookosome® V, Brookosome® 

Willowbark, Cationic SMEC, ChronoSphere® Bio-Pol® OE, ChronoSphere® 

Hyaluronic, ChronoSphere® Sal, Emollient SMEC, Liposome Cocoa Extract 

/ Caffeine, SMEC Concentrate #1, SMEC DHA, SMEC Sun, Spiraplex® 

technology 

Functional ingredients: AquaPhos TD, Brookswax D, Brookswax P/P, 

CT-100, Gel Base, Gel Base 2, Gel Base BSM 5, Gel Base BSM PE, Gel 

Base BSM PT, Gel Base BSM VT, Gel Base Product Line, Gel Base SIL, 

KeraCoat, Liquiwax, Liquipure EDG NF, Liquiwax, Quamectant AM- 

50, Relaxer Concentrate Product Line, SilSlip, ViscUp® 160 

Rheology modifiers: β-Gel, ViscUp® EZ 

Natural and Plant Actives: Genti-Fol® SA, Honeyquat 50, Marula Oil, 

Multifruit® BSC, NAB® Arnica Extract, NAB® Asafetida Extract, NAB® 

Clintonia Borealis Extract, NAB® Fennel Seed Extract, NAB® Grape 

Extract, NAB® GrassRoots Extract, NAB® Hawthorn Extract, NAB® 

Jewelweed Extract, NAB® Mushroom Extract, NAB® Pikea Robusta, NAB® 

Queen of the Prairie Extract, NAB® Red Clover Isoflavones, NAB® Rhodiola 

Extract, NAB® Siberian Ginseng Extract, NAB® Spotted Geranium Extract, 

NAB® Willowbark Extract, NAB® Yucca Glauca Extract, Oligoquat M, 

Planell® Oil, ProCircul8, Vital Hair & Scalp Complex 

Preservation systems: Biovert® Enzyme and Substrate, Cosmocil® CQ, 

Mikrokill COS, Mikrokill PCC 

4666 Faries Parkway 

Decatur IL 62526, US 

Phone: (217) 424-5200; Fax: (217) 424-4004 


Web: www.admworld.com; E-mail: info@admworld.com 

KEY PERSONNEL: G. Allen Andreas; Chairman 

Patricia A. Woertz; CEO and President 

David J. Smith; Exec. VP, Secretary and General Counsel 

William H. Camp; Exec. VP, Global Processing 

John D. Rice; Exec. VP, Global Marketing and Risk Management 

Lewis W. Batchelder; Sr. VP, Agricultural Services 

Edward A. Harjehausen; Sr. VP, Food and Feed Ingredients 

Brian F. Peterson; Sr. VP, Corporate Affairs 

Douglas J. Schmalz; Sr. VP and CFO 


HISTORY: Formed from the acquisition of Midland Linseed Products Company by 

Archer-Daniels Linseed Company (1923) 



STOCK-FINANCIAL HISTORY: NYSE--ADM 


Net earnings $1.044b (YE 05) compared to $494.710M (YE 04) 


Average shares outstanding 656.123K (YE 05) compared to 649.810K (YE 

04) 


Metabolix Inc. eco-friendly, high- commercialization 11/04 

performance natural 

plastics 

agreement 

RESEARCH & DEVELOPMENT: Fermentation for alcohol production, ethanol 

High-fructose corn syrup, enzymes, amino acids 

Protein research 

PRODUCTS ON MARKET: Feed-grade amino acids, vitamins/colorants 

Lysine, threonine, astaxanthan 

Food additives: citric acid, lactic acid, xantham gum 

Distilled monoglycerides, sodium stearyl lactate, isoflavones 


9700 South Cass Avenue 

Argonne IL 60439, US 

Phone: (630) 252-2000; Fax: (630) 252-5230 


Web: www.anl.gov; E-mail: partners@anl.gov 

KEY PERSONNEL: Robert Rosner; Laboratory Director 

Donald Joyce; Deputy Laboratory Director 

Adam Cohen; COO 

Stuart A. Rice; Scientific Advisor to the Directorate 

Phillip Finck; Associate Laboratory Director, Applied Science and 

Technology 

J. Murray Gibson; Associate Laboratory Director, Scientific User Facilities 

Alfred P. Sattelberger; Associate Laboratory Director, Physical Sciences 

Rick Stevens; Associate Laboratory Director, Computing and Life Sciences 




FACILITIES: 1,500-acre facilities site owned by DOE and operated by the University of 

Chicago 

STOCK-FINANCIAL HISTORY: Government agency (U.S. Department of Energy) 

SUBSIDIARIES/DIVISIONS: Argonne National Laboratory West (Idaho, U.S.) 

BUSINESS STRATEGY: Engage in multi-disciplinary research that further increases understanding of 

the fundamental mechanisms of life and enables valuable advances in 

health protection, environmental restoration, energy production, industrial 

processing and other applications 

Conduct clinical studies in the areas of bioinformatics, genomics, protein 

engineering, biochips, proteomics, bio-based chemicals, structural biology, 

and environmental technologies, while maintaining a technology transfer 

program that is directed toward enhancing the Laboratory's research and 

development programs, meeting federal, national, and international research 

needs, and increasing the worldwide competitiveness of U.S. industry 




Ongoing 

technology 

transfer 

collaborations for 

drug discovery, 

contract R&D, 

patent licensing, 

etc. 

RESEARCH & DEVELOPMENT: Bio-chemicals 

Nanobiotechnology 

Biomimetic membranes 

Structural biology 

Structural genomics 

RNAi technology 

Biodefense applications 

Environmental biotechnologies 

Biochip technology 

Batteries and fuel cells 

Materials 

Nuclear reactor testing 

multi-disciplinary 

technology transfer 

agreements 

PRODUCTS ON MARKET: Marketable services include technology transfer comprised of: 

Cost-shared research and development 

Reimbursable R&D (Work-for-Others) 

Licensing 

Technical assistance 

Personnel exchange 


38/39th Floor, St. Luke's Tower, 8-1, Akashicho, Chuo-Ku 


Phone: +81 3-3547-4500; Fax: +81 3-3547-4699 

Web: www.arystalifescience.com 

E-mail: altin@arysta-ls.com 

KEY PERSONNEL: John Hagaman; Chairman 

Dr. Christopher Richards; President and CEO 

Rudorf Van Houten; CFO 

Dipak Amin; Global Head, Strategy 

Robert Lence; General Counsel 

Makoto Saji; Global Head, Corporate Affairs 

Tatsumi Ikeda; Global Head, Acquisitions and Licensing 

John Killmer; Global Head, Marketing and Supply Chain 

Itaru Hori; Head, Japan 

Nobumasa Ishiai; Global Head, Life Science 

William Lewis; Head, North America and Australasia 

Eric Barbedette; Head, Europe, Africa and Middle East 

Yukio Arai; Head, South America 

EMPLOYEES: 2,300 employees (including affiliated companies) 

HISTORY: Founded in 2000 through a consolidation of the Tomen and Nichimen Agro 

and LifeSciences businesses 

Acquired Azocyclotin from Bayer CropScience (10/05) 

Acquired Prothiofos from Bayer CropScience (11/05) 

Acquired Omethoate from Bayer CropScience (1/06) 

Acquired major sssets of Micro Flo Co. LLC from BASF Corp. (3/06) 




SUBSIDIARIES/DIVISIONS: Arysta LifeScience North America (www.arystalifescience-na.com) 

Arysta LifeScience Europe, Africa and Middle East (www.arysta-eame.com) 

Arysta LifeScience South America (www.arystalifescience-sa.com) 

PRINCIPAL INVESTORS: Olympus Capital 

BUSINESS STRATEGY: Develop, market and distribute high quality crop protection and lifescience 

products to global markets 


Bayer 

amitraz, marketing of licensing 

4/05 

CropScience fluoxastrobin and comarketing 

of 

deltamethrin 

agreements 

PRODUCTS ON MARKET: Select® 

Captan 

Everest® 

Orthene® 

Elevate® 



1-2 Yurakucho 1-chome, Chiyoda-ku 

Tokyo , Japan 

Phone: +81 3-3507-2060; Fax: +81 3-3507-2495 

Web: www.asahi-kasei.co.jp 

Nobuo Yamaguchi; Chairman 

Shiro Hiruta; President 

Masaki Sakamoto; President, Asahi Kasei Fibers 

Taketsugu Fujiwara; President, Asahi Kasei Chemicals 

Keiji Kamei; President, Asahi Kasei Life & Living 

Yoichi Saji; President, Asahi Kasei Construction Materials 

Shingo Hatano; President, Asahi Kasei Homes 

Makoto Konosu; President, Asahi Kasei EMD 

Kei Ohe; President, Asahi Kasei Pharma 


HISTORY: Founded in May 1931 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka, Sapporo stock exchanges 


Net income ¥59.67b (YE 06) comapred to ¥56.45b> (YE 05) 

Earnings per share ¥42.46/share (YE 06) compared to ¥40.16/share 

(YE 05) 

Total assets ¥1,376b (YE 06) compared to ¥1,270b (YE 05) 

SUBSIDIARIES/DIVISIONS: Group companies: 

Asahi Kasei Fibers 

Asahi Kasei Chemicals 

Asahi Kasei Life & Living 

Asahi Kasei Construction Materials 

Asahi Kasei Homes 

Asahi Kasei EMD 

Asahi Kasei Pharma 


BioStar Inc. POC infectious disease, development 8/97 

instrumented 

agreement 

City of Hope human gene deletion funding basic 

technology 

research 



Dainippon, Tokyo rabbit TNF joint development 

University 

agreement 

Diffchamb SA fish freshness test distribution 

agreement 

3/90 

G. D. Searle & Co. Angiotensin II 

licensing 

1994 

antagonist 

agreement for 

Japan 

GenVec Inc. Asahi's gene therapy licensing 

4/98 

applications of tumor agreement for the 

necrosis factor alpha 

gene 

U.S. 

Kowa Co. Ltd. tPA as an intravenous joint development 1990 

injection for 

thrombolysis 

agreement 

Kyowa Hakko tissue plasminogen joint development 1/86 

Kogyo 

activator (tPA) 

agreement 

Memorial Sloan- TNF technology transfer 

Kettering 

agreement 

Mie University thrombomodulin R&D agreement 

Molecumetics Ltd. oral factor VIIA 

research and 5/97 

inhibitors 

licensing 

agreement 

Purely Proteins methods for purifying R&D agreement 12/04 

Ltd. 

proteins using Purely 

Proteins' ligand 

discovery systems 

Queens University 

(Canada) 

Samuel Lunenfel 

Research 

Foundation 

atrial natriuretic 

polypeptide 

cancer cell 

communication 

patent licensing 

agreement 

two-year research 

agreement 

RESEARCH & DEVELOPMENT: Directed toward the creation of customer value through high-performance 

products based in competitive chemical technology, with emphasis on the 

development of new businesses in the growing fields of electronics, 

medicine, and energy and ecology, for the future development and growth of 

the Asahi Kasei Group 

All R&D is guided by the principles of green and sustainable chemistry 

Main research fields are: material science and polymer science, 

microelectronics, electrochemistry, microbiology, µTAS (micro total 

analysis), medical care, biochemistry, residential materials, membrane 

science and technology, information technology, analysis and simulation 

PRODUCTS ON MARKET: Asahi Kasei Pharma: Elcitonin, Bredinin, Flivas, Toledomin, 

Planova virus removal filters, artificial kidneys, Sepacell, leukocyte 

reduction filters, blood and plasma filters, contact lenses 

Asahi Kasei Chemicals: Suntec polyethylene, Tenac polyacetal, 

Xyron modified polyphenylene ether (mPPE), Leona nylon 66, 

Duranate, Ceolus, APR photosensitive resins, AFP photosensitive 

plates, printing plate making systems, Microza ultrafiltration and 

microfiltration membranes and systems, Hipore fine porous membranes 

Asahi Kasei EMD: Sunfort photosensitive dry film resist (DFR), Pimel 

photosensitive polyimide, Fine pattern coils, Luminous plastic optical fiber 


5/87 

3/96



Falmouth Technology Park, 124 Bernard E. Saint Jean Drive 

East Falmouth MA 02536-4445, US 

Phone: (508) 540-3444; Fax: (508) 540-8680 


Web: www.acciusa.com; E-mail: info@acciusa.com 

KEY PERSONNEL: A.J. Meuse, Ph.D.; President and CEO 

Michelle Knuth; Director, Finance 

Peter Langlais; VP, Business Development and Global Distribution 

Alison Skinner, Ph.D.; Exec. VP 



While a senior scientist at Woods Hole Oceanographic Institute, Dr. Stanley 

Watson, the founder of ACC, developed LAL (limulus amebocyte lysate) for 

enumeration of gram-negative bacteria. Recognizing its use for monitoring 

lipopolysaccharides in pharmaceutical products, he formed his own 

company and was the first licensed by the FDA for sales of LAL 



SUBSIDIARY OF: Seikagaku Corp. 

BUSINESS STRATEGY: Develop innovative products from the marine environment for the health 

care industry 


IBEX 

IBEX's glycobiology distribution 

9/05 

Technologies Inc. enzymes 

agreement 

RESEARCH & DEVELOPMENT: LAL methodology and test instrumentation 

LAL biochemistry 

New products from marine organisms 

Endotoxin detection 

PRODUCTS ON MARKET: Pyrotell® LAL 

LAL-5000 automatic endotoxin detection system 

Pyrosol® LAL reconstitution buffer 

Endotoxin control standard 

LAL reagent water (LRW) 

Depyrogenated reaction tubes 

Pyroplates, pyroblocks 

Pyrochrome® chromogenic LAL test kits 

Pyrotell-T® turbidimetirc lysate 

Fungitell 


3-11 Nihonbashi-Honcho 2-chome, Chuo-ku 


Phone: +81 3-3244-3000; Fax: +81 3-3244-3272 

Web: www.astellas.com 

KEY PERSONNEL: Hatsuo Aoki, Ph.D.; Chairman 

Toichi Takenaka, Ph.D.; President and CEO 

Makoto Nishimura, Ph.D.; Chairman and CEO, Astellas Pharma US, Inc. 

Toshinari Tamura, Ph. D.; Exec. VP 

Masafumi Nogimori; Exec. VP 

Sef Kurstjens, M.D., Ph.D.; Head, R&D, US 




HISTORY: Created from the merger of Fujisawa Pharmaceutical Co. Ltd. and 

Yamanouchi Pharmaceutical Co. Ltd. (4/05) 

To sell all rights to Aczone gel to QLT Inc. (as of 7/05) 

To sell Zepharma Inc. to Daiichi Sankyo Co. (as of 3/06) 

Acquired North Carolina-based research facility of Dynogen 

Pharmaceuticals Inc. (3/06) 

Astellas Pharma U.S. Inc. to acquire Amevive® (alefacept) from Biogen Idec 

Inc. (as of 4/06) 

Yamanouchi Pharmaceutical Co. Ltd.: 

Founded in 1923 

Acquired Shaklee Japan K.K. (1989) 

Acquired Shaklee Corp. (USA) (1989) 

SUBSIDIARIES/DIVISIONS: 

Fujisawa Pharmaceutical Co. Ltd.: 


Astellas US LLC--Ill., U.S. 

Astellas Pharma US Inc.--Ill., U.S. 

Astellas Pharma Manufacturing Inc.--N.Y., U.S. 

Astellas Pharma Technologies Inc.--Okla., U.S. 

Astellas Research Institute of America LLC--Ill., U.S. 

Astellas Pharma Canada Inc.--Ontario, Canada 

Astellas Pharma Europe Ltd.--London, U.K. 

Astellas BV--The Netherlands 

Astellas Pharma Europe BV--The Netherlands 

Astellas Pharma GmbH--Germany 

Astellas Ireland Ltd.--Ireland 

Astellas Pharma SpA--Italy 

Astellas Pharma Korea Inc. 

Astellas Pharma Taiwan Inc. 

Astellas Pharma China Inc. 

Astellas Pharma Hong Kong Ltd. 

Astellas Pharma Philippines Inc. 

Astellas Pharma (Thailand) Co. Ltd. 

P.T. Astellas Pharma Indonesia 

Astellas Pharma Chemicals Co. Ltd. 

BUSINESS STRATEGY: Develop breakthrough products in the areas of immunology, infectious 

disease, dermatology, urology and cardiovascular disease while continuing 

to explore unmet needs in other areas 


Apoxis SA development and licensing 

12/05 

marketing of FIK866 agreement 

AtheroGenics Inc. AGI-1096 as an oral R&D agreement, 1/04 

treatment for the 

prevention of organ 

transplant rejection 

extended 2/06 

Ferring 

developing and 

licensing 

1/06 

Pharmaceuticals marketing of degarelix 

in Japan 

agreement 

FibroGen Inc. FG-2216 in Japan licensing 

agreement 

9/04 

FibroGen Inc. rights to certain 

licensing 

4/06 

hypoxia-inducible factor 

prolyl hydroxylase 

inhibitors for the 

treatment of anemia, 

including FG-2216 and 

FG-4592, in Europe, 

CIS, Middle East and 

South Africa 

agreement 

Ilypsa Inc. ILY101 in Japan licensing 

agreement 

4/06 



MerLion 


Pte. Ltd. 

new drug candidates 

derived from natural 

products chemistry 

Metabolex Inc. validation of novel drug 

targets identified 

through Metabolex's 

discovery program, for 

diabetes and obesity 

discovery and 

development 

agreement 

multi-year research 

collaboration, 

expanded 5/05 


10/05 

3/02 

Nippon Kayaku Gelpart exclusive licensing 

agreement 

2/05 

Portola 

development of a series licensing 

6/05 

Pharmaceuticals of Astelas preclinical agreement 

Inc. 

compounds 

Suntory Ltd. Farom (antibiotic) marketing 

agreement 

6/97 

Theravance Inc. Theravance's telavancin development and 


agreement, 

expanded 7/06 

11/05 

Toyama Chemical marketing. development licensing 

3/06 

Co. Ltd. 

of oral formulations of 

T-3811 in Japan 

agreement 

XenoPort Inc. development and licensing 

12/05 


XP13512 in Japan and 

other Asian countries 

agreement 

RESEARCH & DEVELOPMENT: Diabetes, infectious diseases, gastrointestinal disorders, disorders of the 

central nervous system, urology, inflammatory disorders and immunology 

(transplants) 

PRODUCTS ON MARKET: Adenoscan® 

AmBisome® 

Flomax® 

Prograf® 

Protopic® 

VESIcare® 

astre Corp. 

3801 Mount Vernon Avenue, P.O. Box 25766 

Alexandria VA 22313-5766, US 

Phone: (703) 548-1343; Fax: (703) 783-1340 

Web: www.astrecg.com 

E-mail: info@astrecg.com 

KEY PERSONNEL: R. A. Ackerman; Chairman and Director, R&D 

K. Smith; CEO 





BUSINESS STRATEGY: Provide research, development, consulting and production of biotechnology 

products/process in environmental and medical domains 

PRODUCTS ON MARKET: Process and product design services

Athenix Corp. 


2202 Ellis Road, Suite B 

Durham NC 27703, US 

Phone: (919) 281-0900; Fax: (919) 281-0901 

Web: www.athenixcorp.com 

E-mail: info@athenixcorp.com 

KEY PERSONNEL: Jerry Caulder; Chairman 

Mike Koziel; President and CEO 

Markus Andres; COO 

Nadine Carozzi; VP, Product Development 

Nicholas Duck; VP, Research and Business Development 

Mike Schierbeek; CFO 



FACILITIES: 11,000 sq. ft. of laboratory and office space 


PRIVATE PLACEMENTS: Raised $8M in financing (9/01) 

Raised $12.5M in Series B financing (1/04) 

Raised $13M in Series C financing (1/06) 

SUBSIDIARIES/DIVISIONS: Agriculture 

Industrial 

PRINCIPAL INVESTORS: Boston Millennia Partners 

Eastman Ventures 

Finistere Partners 

Hunt Ventures 

Intersouth Partners 

Polaris Venture Partners 

BUSINESS STRATEGY: Develop novel products, technologies and processes for agricultural and 

chemical applications 


Iowa Corn applying innovative research 

2/05 

Promotion Board technologies to corn cooperation 

RESEARCH & DEVELOPMENT: Athenix is a leading biotechnology company that discovers and develops 

novel products, technologies and processes for the agricultural and 

chemical businesses. Athenix is focused on enhanced plants, microbes, 

enzymes and processes for a variety of industry sectors with emphasis on 

two major market opportunities: 1) the discovery of genes and proteins for 

novel input traits such as insect resistance, nematode resistance and 

herbicide tolerance, and their use to develop transgenic plants for the 

agricultural chemical and seed industries, and 2) the discovery of genes and 

proteins for use in the chemical and animal feed industries. 


Herbicide resistant crops (corn, soybean in greenhouse testing, field 

and cotton) 

testing 

Insect resistant crops (corn, soybean, 

cotton and rice) 

in greenhouse testing 

Nematode resistant crops (soybean) in laboratory testing, plant 

testing 




1405 boul. du Parc-Technologique 

Quebec G1P 4P5, Canada 

Phone: (418) 652-1116; Fax: (418) 652-0151 

Web: www.atrium-bio.com 

E-mail: atrium@atrium-bio.com 

KEY PERSONNEL: Pierre Laurin, Ph.D.; Chairman 

Luc Dupont; President and CEO 

Richard Bordeleau; President, Health and Nutrition 

Charles Boulanger; President, Active Ingredients and Specialty Chemicals 

John Dempsey; VP, Finance and CFO 


HISTORY: Founded in January 2000 


Acquired ADF Chimie S/A (5/02) 

Acquired Siricie SA (11/03) 

Acquired Pure Encapsulations Inc. (3/04) 

Acquired Multichem (1/05) 

Acquired HVL Inc. and Douglas Laboratories (12/05) 

MultiChem subsidiary acquired Amisol Co. Ltd. (5/06) 

Acquired assets of Douglas Laboratories Canada (9/06) 

STOCK-FINANCIAL HISTORY: TSX--ATB 

IPO--6.250M shares at $12/share, $75M (3/05) 





SUBSIDIARIES/DIVISIONS: Atrium Biotech USA--Fairfield, N.J. 

Unipex SA--Ruiel-Malmaison, France 

Pure Encapsulations Inc.--Sudbury, Mass. 

Chimiray--Ruiel-Malmaison, France 

Atrium Biotech Europe--Marly le Roi, France 

Multichem - Quebec--Boucherville, Canada 

SUBSIDIARY OF: Aeterna Zentaris Inc. (see separate entry) 

BUSINESS STRATEGY: Acquisition program: 

-Acquisition of nutritional supplement products or companies 

-Acquisition of companies specializing in the manufacturing of active 

ingredients and specialty products 

-Acquisition of cosmetic active ingredient lines or companies 

Inlicensing program: 

-Prospect for new products and new technologies among established or 

emerging biotech companies and specialized research centres. Atrium 

Biotechnologies can offer its strategic partners rapid access to a network of 

leading customers 

RESEARCH & DEVELOPMENT: New products and new versions of existing products in response to client 

requests 

Atrium has a patented molecular separation technology platform 

PRODUCTS ON MARKET: More than 1,500 active ingredients and specialty chemicals and 400 health 

and nutrition finished products 




6181 Cornerstone Court East, Suite 103 

San Diego CA 92121, US 

Phone: (858) 550-8830; Fax: (858) 550-8825 


Web: www.axxora.com 

E-mail: axxora-usa@axxora.com 

KEY PERSONNEL: Georges Chappuis, Ph.D.; CEO and President 

Tamara Sales; CFO 

Brian Conkle; President, Axxora LLC 

Wilfried Boecher; Managing Director, Axxora Deutschland GmbH and 

Axxora Ltd. 

Silvia Dettwiler; President, Alexis Corp. 

Ravi Kalahasthi; Managing Director, Alexis Laboratories 





SUBSIDIARIES/DIVISIONS: Axxora LLC--U.S. 

Alexis Corp.--Switzerland 

Apotech Corp--Switzerland 

Axxora Deutschland GmbH--Germany 

Axxora Ltd.--U.K. 

Alexis Laboratories--U.S. 

Apotech Laboratories--Switzerland 

PRINCIPAL INVESTORS: Ampersand Ventures 

Ventana Growth Fund 

BUSINESS STRATEGY: Develop, produce, market and sell life science research reagents worldwide 

RESEARCH & DEVELOPMENT: Life science reagents and fine chemical raw materials 

PRODUCTS ON MARKET: Nitric oxide pathway reagents 

Neurochemicals 

Apoptosis 

Signal transduction reagents 

Endothelins 

Human plasma protein and enzymes 

Lipids 

Phospholipids 

Glycolipids 


Huizerstraatweg 28 

Naarden 1411 GP, Netherlands 

Phone: +31 35-69-92595; Fax: +31 35-69-49576 

Web: www.bac.nl, www.captureselect.com 

E-mail: info@bac.nl 

KEY PERSONNEL: Dr. Laurens Sierkstra; CEO 

Dr. Ingeborg van Gemeren; VP, Business Development 


HISTORY: Founded in 1995 as a subsidiary of Unilever 

Spun off from Unilever 



FACILITIES: Production facility comprises a fermentation development laboratory (10L 

fermenters), a dedicated quality control laboratory, and a fully contained 

processing plant (with medium preparation and continuous sterilization, 

fermentation and downstream processing and aseptic packaging) 


PRIVATE PLACEMENTS: Raised EUR3.5M in private financing (2/05) 

SUBSIDIARY OF: Unilever 

BUSINESS STRATEGY: Development and manufacture of ligands for Affinity Separation applications 

RESEARCH & DEVELOPMENT: CaptureSelect® products are based on the company's proprietary single 

domain antibody fragments and efficiently produced in-house using 

Saccharomyces cerevisiae 

Expression systems and fermentation production systems 

Industrial scale 15,000l for production of novel single-chain Llama antibody 

fragments, peptides, fusion proteins 

PRODUCTS ON MARKET: Products: 

CaptureSelect® products possess a combination of unique properties such 

as stability, affinity, and selectivity that provides competitive benefits in 

terms of reduced cost of purification, higher quality product, and increased 

flexibility in the purification process. BAC offers a wide range of 

CaptureSelect® products for different applications: 

-Life science research such as sample preparation and small scale 

purification 

-Biopharma manufacturing including monoclonal antibodies and viruses 

-Healthcare applications such as therapeutic apheresis 

-Custom tailored purification solutions 

BACHEM AG 

Services: 

Custom manufacturing and upscaling of production of biotechnological 

molecules through microbial fermentations 

Plug-in of genes into yeasts, followed by process development and scale up 

Hauptstrasse 144 

Bubendorf CH-4416, Switzerland 

Phone: +41 61 935 2323; Fax: +41 61 935 2325 

Web: www.bachem.com 

E-mail: sales.ch@bachem.com 

KEY PERSONNEL: Dr. Peter Grogg; Chairman 

Rolf Nyfeler, Ph.D.;CEO 

Michael Husler; CFO 

Dr. Daniel Erne; CTO 

Thomas Fruh, Ph.D; Exec. VP and COO, BACHEM AG 

Jose de Chastonay, Ph.D.; President, BACHEM Americas 

Philip Ottiger; President and COO, Bachem California Inc. 

Dr. Mike Pennington; President and COO, Bachem Bioscience Inc. 

Dr. Damir Vidovic; President and COO, Peninsula Laboratories Inc. 

Dr. Stanley Moore; COO, Bachem (UK) Ltd. 

Dr. Jacques-Alain Cotting; COO, Sochinaz SA 



Founded BACHEM Bioscience in Philadelphia, Pa. (1987) 

Founded BACHEM Biochemica in Heidelberg, Germany (1988) 

Founded BACHEM Biochimie in Voisins-le-Bretonneux, France (1993) 

Acquired BACHEM California Inc in Torrance, Calif., and its U.K. subsidiary 

in Saffron Walden (1996) 



Changed name from BACHEM Feinchemikalien AG to BACHEM AG 

Acquired Peninsula Laboratories Inc. and Peninsula Laboratories Ltd. 

(12/99) 

Merger of Peninsula Laboratories Europe Ltd. and Bachem (UK) Ltd. (8/00) 

Acquired Sochinaz SA (2001) 

FACILITIES: 218,000 sq. ft. facility including GMP production facilities in Bubendorf, 

Switzerland, and Torrance, Calif., for large-scale solid phase and solution 

phase peptide synthesis 

STOCK-FINANCIAL HISTORY: SWX--BANB 

Sales CHF153.7M (YE 05) compared to CHF147.8M (YE 04) 

Net income CHF39.2M (YE 05) compared to CHF30.7M (YE 04) 

Earnings per share CHF2.98/share (YE 05) compared to CHF2.33/share 

(YE 04) 

SUBSIDIARIES/DIVISIONS: BACHEM California Inc. (see separate entry) 

3132 Kashiwa Street 

Torrance, CA 90505 

Phone: (310) 539-4171; Toll-free phone: (888) 422-2436 

Fax: (310) 530-1571; E-mail: sales@us.bachem.com 

BACHEM Bioscience Inc. 

3700 Horizon Drive 

King of Prussia, PA 19406 USA 


Fax: (610) 239-0800; E-mail: sales@us.bachem.com 

BACHEM Biochemica GmbH 

Haberstrasse 6 

Heidelberg D-69126 Germany 

Phone: +49 06221 33 05 0; Fax: +49 06221/33 05 99 

E-mail: verkauf.de@bachem.com 

BACHEM Biochimie SARL 

136, ave. Joseph Kessel 

Voisins-le-Bretonneux F-78960 France 

Phone: +33 (0)1 30 12 15 95; Fax: +33 (0)1 30 57 38 82 

E-mail: vente@fr.bachem.com 

BUSINESS STRATEGY: 

BACHEM (U.K.) Ltd. 

69 High Street 

Saffron Walden, Essex CB10 1AA UK 

Phone: +44 (0)1 799 52 64 65; Fax: +44 (0)1 799 52 63 51 

E-mail: sales.uk@bachem.com 

Supply peptides, peptidomimetics, proteins, amino acid derivatives and 

related biologicals to the research market 


AstraZeneca plc Goserelin extended supply 

agreement 

1/03 

Jerini AG Jerini's Icatibant production and 

supply agreement 

3/04 

mondoBiotech Thymopentin production and 4/05 

Holding SA 


mondoBiotech mondoBiotech's production and 7/04 

Holding SA Aviptadil 


mondoBiotech mondoBiotech's production and 4/05 

Holding SA Thymopentin (TP-5) supply agreement 

mondoBiotech new peptide projects for development 3/06 

Holding SA potential therapeutic 

use 

agreement 



RESEARCH & DEVELOPMENT: Growth factors, lymphokines 

Bioactive peptides, enzyme substrates and inhibitors, cytokines, related 

biologicals 

GMP production of peptides and related compounds 

GMP Contract manufacturing 

Peptides and proteins for diagnostics 

PRODUCTS ON MARKET: More than 7,000 products including biologically active peptides, proteins, 

amino acid derivatives, enzyme substrates and inhibitors, neuropeptides, 

cytokines, lymphokines, growth factors, HIV proteins, monoclonal and 

polyclonal antibodies 


3132 Kashiwa Street 

Torrance CA 90505, US 

Phone: (310) 539-4171; Fax: (310) 530-1571 


Web: www.bachem.com 

E-mail: pottiger@bachem.com 

KEY PERSONNEL: Philip Ottiger; President and COO 



Acquired by Bachem in 1996 


RESEARCH & DEVELOPMENT: Synthetic peptides, reagents, bulk pharmaceuticals, synthetic intermediates 

and recombinant growth factors and cytokines 

PRODUCTS ON MARKET: Clinical grade peptides (CRF, GRF, somatostatin, LHRH, ANF, calcitonin, 

parathyroid hormone, peptide T) 

Bioactive peptides 

Synthetic intermediates 

Recombinant growth factors and cytokines 

Large-scale custom synthesis service 


9025 Technology Drive 

Fisher IN 46038-2886, US 

Phone: (317) 570-7020; Fax: (317) 570-7034 


Web: www.bangslabs.com 

E-mail: info@bangslabs.com 

KEY PERSONNEL: Michael H. Ott; Chairman and CEO 

Chad Owen; President 

Kate Edwards; Product Manager 

Sharmi Isaiah; Scientist and Lab Coordinator 

Mary Meza; Technology Manager 

Yun Qiu; Scientist 

Kathy Turner; Technical Service Manager 


HISTORY: Founded in April 1988 

Acquired by Polysciences Inc. (7/03) 




SUBSIDIARY OF: Polysciences Inc. 

PRODUCTS ON MARKET: More than 2,000 varieties of microspheres 

BASF AG 

Carl Bosch Strasse 38 

Ludwigshafen D-67056, Germany 

Phone: +49 (0)621 60-0 

Fax: +49 (0)621 60-42525 

Web: www.basf.de 

E-mail: info.service@basf.de 

KEY PERSONNEL: Dr. Jurgen Hambrecht; Chairman 

Dr. Thorlef Spickschen; Managing Director, Pharmaceuticals 

Dr. Friedrich Vogel; Managing Director, Crop Protection 

Peter Oakley; Chairman, President and CEO, BASF Corp. 

Dr. Stefan Marcinowski; Head, Research 

Prof. Dr. Werner Kusters; Head, Main Laboratory 

Dr. Robert Kamen; President, BASF Bioresearch Corp. 

EMPLOYEES: 94,000 employees worldwide 



Acquired Knoll AG (1982) 

Acquired Blazer® herbicide business from Rohm and Haas (12/87) 

Genzyme Corp. reacquired rights to Protein C (8/88) 

Acquired majority interest in BioResearch, an Italian pharmaceutical group 

(spring 1990) 

International pharmaceutical business combined under BASF Pharma 

(1993) 

Acquired Boots Pharmaceuticals (3/95) 

Acquired Hokuriku Seiyaku (4/96) 

Acquired global electronic chemicals business of Merck KGaA (1/05) 

To acquire Johnson Polymer from JohnsonDiversey Inc. (as of 5/06) 

Acquired Engelhard Corp. (6/06) 

FACILITIES: Commercial-scale biotechnology fermentation facility in Ludwigshafen, 

Germany, and Worcester, Mass. 

Agricultural Research Center in Research Triangle Park, N.C. 

Latin American headquarters located in Mexico, and Asian/Australian 

regional division headquarters located in Singapore 

Nanotechnology research center in Singapore 

STOCK-FINANCIAL HISTORY: NYSE and Frankfurt Stock Exchange--BASF 


Net income EUR3,007b (YE 05) compared to EUR2.004b (YE 04) 


(YE 04) 

SUBSIDIARIES/DIVISIONS: Five business segments: Chemicals, Plastics, Performance Products, 

Agricultural Products and Nutrition, and Oil and Gas 

KNOLL Belgium 

Avenue Hamoir 14 

B-1180 Bruxelles, Belgium 

Phone: +32 2373-1471; Fax: +32 2373-1489 

Knoll France S.A. 

49, Avenue Georges Pompidou 

F-92593, Levallois-Perret, Cedex, France 

Phone: +33 1496-45880; Fax: +33 1496-45919 



Knoll Pharmaceuticals/BASFIN 

St. Nicholas Court, 25-27 Castle Gate 

Nottingham NG1 7AR, Great Britain 

Phone: +44 115-912-4000; Fax: +44 115-912-4816 

Ravizza Farmaceutici spa 

Via Europa 35 

I-20053 Muggio, Italy 

Phone: +39 39-24421; Fax: +39 39-791824 

Knoll Farmaceutici Spa 

Via Europa 35 

I-20053 Muggio, Italy 

Phone: +39 39-24426; Fax: +39 39-79-5014 

Knoll Farmaceutici Spa 

Via Lorenteggio 270A 

I-20152 Milano, Italy 

Phone: +39 24-831-6301; Fax: +39 24-830-1976 

Knoll Zagrel 

Planinska bb, 10000 Zagreb, Croatia 

Phone: +385 1233-3733; Fax: +385 1233-38279 

Knoll Pharma 

Postbus 22622 

NL-1100 DC Amsterdam Z.O., Netherlands 

Phone: +31 2056-40101; Fax: +31 2069-14311 

EBEWE Arzneimittel GmbH 

A-4866 Unterach, Austria 

Phone: +43 7665-81230; Fax: +43 7665-812311 

Przedstawicielstwo Knoll AG 

w Polsce, Aleje Jerozolimskie 154 

02-326 Warsaw, Poland 

Phone: +48 22-822-462123; Fax: +48 22-822-4624 

Knoll Lusitana Lda. 

Rua Alfredo da Silva 3 C e D 2 

P-1300 Lisboa, Portugal 

Phone: +35 1136-15350; Fax: +35 1136-16378 

BASF/Knoll AG 

ul. Malaja Trubezkaja 8 

119881 Moscow, Russia 

Phone: +7 95-234-9666; Fax: +7 95-234-9667 

Knoll-BioResearch S.A. 

Succursale di San Antonino 

CH-6592 San Antonino, Switzerland 

Phone: +41 9185-19191; Fax: +41 9185-19192 

Knoll AG 

Postfach 631 

CH-4410 Liestal, Switzerland 

Phone: +41 6192-50505; Fax: +41 6192-12563 

Knoll Prag 

Frana Krala 35 

81105 Bratislava, Slovak Republic 

Phone: +427 398-837; Fax: +427 398-850 



Laboratoires Knoll S.A. 

Avenida Burgos 91 

E-28050 Madrid 34, Spain 

Phone: +34 91334-3900; Fax: +34 91766-1973 

Knoll Alman Ltd. 

TR-80040 Tophane-Istanbul, Turkey 

Phone: +90 216-492-9400; Fax: +90 216-492-5768 

Knoll spol. Sr. o. 

Kounicka 70 

10000 Prague, Czech Republic 

Phone: +420 27822-539; Fax: +420 27822-595 

BASF Hungaria Kft./Knoll Divizio 

H-1036 Budapest, Galagonya u.5., Hungary 

Phone: +36 1-436-0820; Fax: +36 1-436-0830 

Knoll Pharma Inc. 

100 Allstate Parkway, Suite 600 

Markham, ON L3R 6H3, Canada 

Phone: (905) 475-7070; Fax: (905) 475-3064 

Knoll Pharmaceutical Co. 

3000 Continental Drive N. 

Mount Olive, NJ 07828-1234 USA 

Phone: (973) 428-4000; Fax: (973) 887-8131 

BASF Bioresearch Corp. 

100 Research Drive 

Worcester, MA 01605-4314 USA 

Phone: (508) 849-2500 

INVESTMENTS: BASF-LYNX Bioscience AG--joint venture with Lynx Therapeutics Inc. 

(10/96) 


AgBioChem Inc. Gallex distribution 

agreement 

Ares Sorono human growth hormone manufacturing 8/96 

(hGH) 

agreement 

BioBase GmbH Brenda enzyme 

licensing 

6/04 

database 

agreement 

Bujard University gene regulation for CNS research 

8/92 

of Heidelberg 

Clontech 

Laboratories Inc. 

disorders 

tetracycline-controlled 

gene expression system 

Diversa Corp. Diversa to discover and 

optimize new enzymes, 

BASF responsible for 

product and process 



IBEX 

Technologies Inc. 

Incyte 


Inc. 

agreement 

semi-exclusive 8/96 

licensing 

agreement 

alliance 2/06 

Neutralase production and 


Incyte's LifeSeq research 

genomics database agreement 

Intercardia Inc. Bextra for CHF development and 

marketing 

agreement for 

outside the U.S. 

and Japan 


10/94 

6/96 

12/96


Lynx Therapeutics 

Inc. (now Solexa 

Inc.) 

access to Lynx's cloning 

and sequencing 

technologies 

technology 


services agreement 

research 


10/96 

Mitotix Inc. inhibitors of the cell 

5/96 

cycle enzymes cdc 25 agreement 

Mitsui Toatsu multiple drug resistance cross-licensing 6/94 

Chemicals Inc. suppressors for cancer 

chemotherapy 

agreement 

Norak Biosciences Norak's Transfluor collaboration 8/04 

Inc. 

technology to screen 

GPCR targets 

developed by BASF 

Warner-Lambert ICE inhibitors R&D and marketing 3/95 

Co. 

agreement 

RESEARCH & DEVELOPMENT: Specialty chemicals, agricultural chemicals, including herbicides for rice and 

cereal crops via biotechnology 

Vitamin B2 by fermentation 

MAb of tumor necrosis factor 

PEG-hirudin by recombinant fermentation 

Cardiovascular, central nervous system, oncology, and immunology 

research 

Molecular biology, bioengineering, biophysics, drug design, medicinal 

chemistry, combinatorial chemistry, preclinical and clinical development 

Thyroid hormone replacement 

Drugs for metabolic and immunological diseases 

PRODUCTS ON MARKET: INORGANIC CHEMICALS: Adhesives and impregnating resins, alcoholates, 

alkali metal amides, alkali metal compounds, ammonium salts, boron 

compounds, carbonyl iron powders, catalysts, chlorine compounds, 

developmental products, electronic chemicals, food additives, 

hydroxyacetophenone, hydroxylamine compounds, nitrogen oxide 

derivatives, powder injection molding, sodium carbonate, sodium hydroxide, 

potassium hydroxide, sulfur products 

Bayer Corp. 

PETROCHEMICALS: Alkylen oxide and glycols, cracker products, 

plasticizers and plasticizer raw materials, solvents, technical gases 

AGRICULTURAL PRODUCTS AND NUTRITION: Herbicides, fungicides, 

insecticides, vitamins, pharmaceutical active ingredients and UV absorbers 

ANIMAL NUTRITION PRODUCTS 

COSMETIC INGREDIENTS/AROMA CHEMICALS 

PLASTICS 

COATINGS 

PERFORMANCE CHEMICALS 

FUNCTIONAL POLYMERS 

100 Bayer Road 

Pittsburgh PA 15205-9741, US 

Phone: (412) 777-2000 

Web: www.bayerus.com 

KEY PERSONNEL: Werner Wenning, Ph.D.; Chairman, Management Board, Bayer AG 

Attila Molnar; President and CEO 

George J. Lykos; Chief Legal Officer 

EMPLOYEES: 23,300 employees



Name changed from Miles Inc. (4/95) 

Bayer AG acquired Microbial Developments Ltd. (Malvern, U.K.) (12/95) 

Spun off most of chemicals business and about one-third of polymer 

business (1/05) 


SUBSIDIARIES/DIVISIONS: Business areas: 

Bayer HealthCare 

Bayer MaterialScience 

Bayer CropScience 

Service areas: 

Bayer Business Services 

Bayer Technology Services 

Bayer Site Services 

SUBSIDIARY OF: Bayer Group AG (see separate entry) 

BUSINESS STRATEGY: Improve lives through a broad range of essential products that help 

diagnose and treat diseases, protect crops and advance automobile safety 

and durability 


ALZA Corp. Mycelex antifungal marketing 

agreement 

4/96 

Axys 

tryptase and chymase five-year, $70M 7/97 

Pharmaceutical inhibitors 

R&D agreement 

Inc. 

(12/94), expanded 

to include oral and 

inhaled 

therapeutics 

(10/96), modified-- 

Bayer returned to 

Axys rights to 

tryptase inhibitors 

for psoriasis and 

inflammatory bowel 

disease 

Celltech Group plc anti-TNF MAbs to treat $47.8M 

5/92 

septic shock 


marketing 

agreement 

Chiron Corp. anti-TNF MAbs to treat licensing 

1989 

septic shock 

agreement 

Cortex Biochem 

Inc. 

immunoreagents 1995 

CV Technologies cardiovascular product research 

12/92 

Inc. 

agreement 

Dharmacon Inc. siRNAs for drug 

discovery research 

supply agreement 3/04 

Genetics Institute DiscoverEase program- partnership 

8/97 

-provides Bayer access 

to GI's library of novel 

human secreted 

proteins and related 

database for identifying 

novel human 

therapeutics 

agreement 

GlaxoSmithKline cerivastatin reductase co-promotion 1997 

plc 

inhibiting compound agreement for the 

U.S. 



The Immune 

Response Corp. 

Molecular 

Simulations Inc. 

Myriad Genetics 

Inc. 

Myriad Genetics 

Inc. 

Nabi Biopharmaceuticals 

Onyx 


OSI 


Inc. 

Pharmacia & 

Upjohn (now part 

of Pfizer Inc.) 

Pharmacopeia 

Inc. 

gene therapy for 

hemophilia A 

computer software for 

use in combinatorial 

chemistry 

obesity, osteoporosis, 

and asthma gene 

discovery 

Myriad's ProNet protein 

interaction database 

source plasma and 

certain immune 

plasmas 

RAS proteins to treat 

cancer 

tumor markers and 

protein products of 

oncogenes, tumor 

suppressor genes and 

others in cancer 

diagnostic tests 

exclusive licensing 

agreement 

three-year 

development 

agreement 

research 

collaboration 


7/96 

4/97 

9/95 

five-year, $54M 11/97 

database 

subscription--Bayer 

gets worldwide 

therapeutic rights 

for discoveries in 

dementia and 

depression, Myriad 

retains diagnostic 

rights and keeps all 

rights to 

discoveries outside 

the fields of 

dementia and 

depression 

five-year contract 2/95 

five-year R&D 

agreement 

5/94 


animal health acquisition 

agreement--Bayer 

to acquire selected 

assets of P&U's 

animal health 

biologicals 

business including 

production and 

Pharmacopeia's 

combinatorial chemistry 

and high-throughput 

screening technology 

for new drug discovery 

research facilities 

research 

collaboration and 

library out-licensing 

PharmaNetics Inc. test cards and 

distribution 

analyzers 

agreement 

Serologicals Corp. IVIG five-year supply 

agreement 

Takeda Chemical cerivastatin codevelopment 

Industries, Ltd. 

agreement 

VI Technologies contract fractionation take-or-pay 

processing 

agreement to 

produce 

intermediate 

plasma fractions 

1997 

2/96 

1998 

12/94 

1993 

1995


PRODUCTS ON MARKET: 10,000+ products, including: 

Bayer CropScience AG 

Animal Health: Advantage®, Baytril®, CheckMite+ Bee Hive Pest Control 

Strip, Clout (bromethalin) Rodenticide, Co-Ral® (coumaphos) Fly and Tick 

Spray, Co-Ral® Plus Insecticide Cattle Ear Tag, CyLence® (cyfluthrin) Pour- 

On Insecticide, CyLence® Ultra Insecticide Cattle Ear Tags, Droncit®, 

Drontal®, K9Advantix, Legend®, Lysoff Pour-On Insectide, Marquis®, 

QuickBayt, Spotton® (fenthion) Cattle, Tempo® (cyfluthrin) Insecticide 

Biological products: Gaminmune® N, 10%, Kogenate® FS and Kogenate®, 

Koate®-DVI, Plasbumin®-5, Albumin (human) 5%, USP, Plasbumin®-20, 

Albumin (human) 20%, USP, Plasbumin®-25, Albumin (human) 25%, USP, 

Plasmanate®, Plasma Protein Fraction (human) 5%, USP, Prolastin® 

Consumer care: Aleve®, Bayer® Aspirin, Vanquish®, Aleve® Cold & Sinus, 

Alka-Seltzer Plus®, NaSal, Alka-Mints®, Alka-Seltzer®, Phillips'®, Phillip's 

M-O®, Bactine®, Campho-phenique®, Domeboro®, Flintstones® Vitamins, 

Bugs Bunny Vitamins, One-A-Day® Vitamins, Fergon®, Midol®, 

Mycelex®-7, Mycelex®-3, Femstat® 3 

Diagnostics: ADVIA® systems, Technicon H*® Systems, Bayer Immuno 1® 

Immunoassay Analyzer, ADVIA CentraLink® Networking Solution, 

Rapidlink® Critical Care Information Management System, CLINITEK® 

analyzers, Rapidlab® systems, Multistix® reagent strips, TRUGENE® tests 

and kits, VERSANT® assays, Bayer ® System 340 (bDNA Analyzer), 

OpenGene® DNA Sequencing System, Ascensia® blood glucose 

monitoring systems, diabetes self-care software and lancing devices 

Bayer MaterialScience: Coating, Adhesive and Sealant Raw Materials, 

Inorganic Basic Chemicals, Polycarbonates, Polyurethanes, Thermoplastic 

Polyurethanes (TPU) 

Bayer CropScience: products for lawn, garden and home care and crop 

protection 

Alfred-Nobel-Str. 50 

Monheim am Rhein D-40789, Germany 

Phone: +49 (0) 21 73-38-0 

Web: www.bayercropscience.com 

E-mail: info@bayercropscience.com 

KEY PERSONNEL: Prof. Dr. Friedrich Berschauer; Chairman 

Dr. Rudiger Scheitza; Portfolio Management and Labor Director 

Dr. Dirk Suwelack; Business Planning and Administration 

Dr. Wolfgang Welter; Industrial Operations and Investments 


HISTORY: Formed from a merger of Bayer Crop Protection and Aventis CropScience in 

June 2002 

Acquired assets of Associated Farmers Delinting Inc. (2/05) 

Acquisition of Icon Genetics AG (1/06) 


FACILITIES: R&D centers in Monheim, Frankfurt and Potsdam, Germany; Lyon and 

Sophia Antipolis, France; Gent, Belgium; Yuki, Japan; Haelen, the 

Netherlands; and Stilwell, Kan., USA 

Major sites in Monheim, Germany; Lyon, France; Singapore; Research 

Triangle Park, N.C., USA; and Sao Paulo, Brazil 

STOCK-FINANCIAL HISTORY: Privately held by Bayer AG 



SUBSIDIARIES/DIVISIONS: Crop protection business (Insecticides, Herbicides, Fungicides, Seed 

Treatment) 

BioScience (Green Biotech) 

Environmental Science (non-agricultural pest and weed control products) 

SUBSIDIARY OF: Bayer Group AG (see separate entry) 


Arysta LifeScience amitraz, marketing of licensing 

4/05 

fluoxastrobin and comarketing 

of deltamethrin 

agreements 

Commonwealth RNAi gene-silencing worldwide 

4/04 

Scientific and technology for crops licensing 

Industrial 

Research 

Organisation 

agreement 

Cresset 

BioMolecular 

Discovery Ltd. 

use of Cresset's molecular 

field technology for the 

discovery of 

agrochemicals 

Icon Genetics AG evaluation of expression 

levels and quality of 

selected preclinical 

Large Scale 

Biology Corp. 

pharmaceutical proteins 

investigation of the plantbased 

expression of 

lysosomal acid lipase 

Medicago Inc. feasibility of using 

Medicago technology for 

producing human 

therapeutic protein 

discovery and 

licensing 

agreement 

collaborative 

agreement 


1/06 

1/05 

CRADA 4/05 

research 

agreement 

RESEARCH & DEVELOPMENT: Crop protection (herbicides, fungicides, insecticides), seed treatment, seeds, 

green biotechnology and non-agricultural pest control 

PRODUCTS ON MARKET: Nunhems vegetable seeds (main crops: onions, carrots, melons and leeks), 

FiberMax cottonseed (incorporating LibertyLink, Round Up Ready and 

Bollgard technologies), InVigor canola (with SeedLink hybridization 

technology), hybrid rice seed, pest control and crop protection products 

Bayou Biolabs 

1500 Edwards Avenue, Suite Q 

Harahan LA 70123, US 

Phone: (504) 733-3849; Fax: (504) 734-5106 


Web: www.bayoubiolabs.com 

E-mail: support@bayoubiolabs.com 

KEY PERSONNEL: Edward David Hyman; President 



Changed name from Sybtrel Biotechnology (1995) 

FACILITIES: 1,500 sq. ft. laboratory research facility 


BUSINESS STRATEGY: Offer custom plasmid preparation service, including bulk quantities of all 

types and sizes 

1/05


RESEARCH & DEVELOPMENT: Custom plasmid preparation 

Oligonucleotide synthesis technology 

Manufacture of biochemical reagents 

PRODUCTS ON MARKET: DNA Ladders for conventional electrophoresis 

DNA Ladders for pulsed field gel electrophoresis 

Vectors 

Lederberg Plasmid Collection 

Custom plasmid preparation 

Be-Long Group 

KEY PERSONNEL: Michael Song; President 


P.O. Box 139 Gulou Post Office 

Nanjing 210008, China 

Phone: +86 25 8471 2602; Fax: +86 25 8470 9922 

Web: www.be-longgroup.com 

E-mail: business@be-long.com.cn 


FACILITIES: Headquarters in Nanjing, China 

Branches in Shanghai, Tianjin, Hong Kong, Hebei Langfang and Zhejiang 

Wenzhou 

Produce plant in Shandong 


BUSINESS STRATEGY: Produce and market feed additives, food additives, chemical raw materials, 

pharmaceutical raw materials, pearl pigments and traffic marking materials 

PRODUCTS ON MARKET: Choline chloride 

Zinc bacitracin 

Bacitracin methylene dicalicylate 

Dicalcium phosphate 

Vitamins 

Amino-acids 

Gelatine 

Pearl luster pigments 


10075 Tyler Place, #18 

Ijamsville MD 21754, US 

Phone: (301) 874-8888; Fax: (301) 874-8889 

Web: www.bioassayworks.com 

E-mail: sales@bioassayworks.com 

KEY PERSONNEL: Leslie Kirkegaard, Ph.D.; President 

Glen Ford; VP, Operations 

Stephen Mefferd; VP, Business Development 

Leslie Kirkegaard, Ph.D.; Director, R&D 

Rachael Keesey; Purchasing Manager 

EMPLOYEES: 7 employees, 2 Ph.D.s, 1 M.D. 

HISTORY: Founded in May 2005 

Began biotech R&D in June 2005 




BUSINESS STRATEGY: Patents in process for novel gold particle production and new rapid assay, 

lateral flow technology. BioAssay Works intends to combine the improved 

technologies with assay development experience for contract assay 

development. 


Cefn Coed, Parc Nantgarw 

Wales CF15 7QQ, UK 

Phone: +44 (0)1443 843 712; Fax: +44 (0)1443 846 500 

Web: www.biocatalysts.com 

E-mail: sales@biocats.com 

KEY PERSONNEL: W. Salisbury; Chairman 

Stuart West; Managing Director 

Martin Duff; Sales Manager 

Mike Clay; General Manager 


HISTORY: Originally founded in 1983 as part of Grand Metropolitan plc 

Acquired by Shell Ventures (9/89) 

Regained independence (2/91) 


FACILITIES: Laboratory, production and warehouse facilities 


BUSINESS STRATEGY: Manufacture and supply industrial enzymes to the food, diagnostic and 

pharmaceuticals industries 

RESEARCH & DEVELOPMENT: New enzymes for biotransformations, biosensors, diagnostics, chiral 

separations and environmental applications 

Products include Depol, Lipomod, Promod, Combizyme, food 

processing enzymes, tissue culture enzymes including virus-free trypsin, 

microbial lipases and xylanase 

PRODUCTS ON MARKET: Extensive range of lipases: xylanase, myrosinase, phenylalanine 

dehydrogenase, and secondary alcohol dehydrogenase (chiral synthesis 

catalysts), galactose dehydrogenase 

Bioclear BV 

P.O. Box 2262 

Groningen 9704 CG, Netherlands 

Phone: +31 (0) 50-571 84 55; Fax: +31 (0) 50-571 79 20 

Web: www.bioclear.nl 

E-mail: bio@bioclear.nl 

KEY PERSONNEL: Dr. Sytze Keuning; Managing Director 

Dr. Janneke Krooneman; Project Manager 

Maurice Henssen; Associate Director and Project Manager 






RESEARCH & DEVELOPMENT: Environmental biotechnology 

Microbial identification 

Bioreactor development 

Biological treatment processes 

Microbiological detection and monitoring 


1615 Golden Aspen Drive, Suite 101 

Ames IA 50010, US 

Phone: (515) 233-8333; Fax: (515) 233-8337 

Web: www.bioforcenano.com; E-mail: info@bioforcenano.com 

KEY PERSONNEL: Eric Henderson, Ph.D.; Chairman and CEO 

Kerry Frey; COO 

Curtis Mosher, Ph.D.; VP, R&D 

Asrun Kristmundsdottir; Human Resources Manager 

Mike Lynch; NanoArrayer Product Manager 

Saju Nettikadan, Ph.D.; Director, Applications Development 

Collin Dettmann; Production Manager 




Merged with BioForce Nanoscience Holdings Inc. (formerly Silver River 

Ventures Inc.) (3/06) 

STOCK-FINANCIAL HISTORY: OTC BB--BFNH 


Loss per share $0.00/share (YE 05) compared to $0.00/share (YE 04) 

Average shares outstanding 4M (YE 05) compared to $4M (YE 04) 

PRIVATE PLACEMENTS: Raised $6M in private placement of restricted common shares at 

~$1.50/share (3/06) 

SUBSIDIARY OF: BioForce Nanosciences Holdings Inc. 

PRINCIPAL INVESTORS: Gulfstream Capital Management 

Societe Generale Asset Management 

Iowa First Capital Fund 

FINANCIAL INFORMATION: $4.7M NIH/SBIR; $11M private and institutional investors 

BUSINESS STRATEGY: Develop logical business units with synergistic potential. Provide the 

NanoArrayer System for precise delivery of femtoliter volumes of liquids to 

surfaces to enable the production of ultraminiaturized biomedical devices 

and other ultraminiaturized sensors and constructs. Ultraminiaturized 

biodevices allow biomarker-based disease detection and monitoring with 

high sensitivity and accuracy while reducing sample requirements to a few 

cells and thereby reducing cost and patient impact. 

RESEARCH & DEVELOPMENT: Instrumentation for creating ultraminiaturized diagnostics and devices 

Nanotechnology for drug discovery 

Nanotechnology for direct pathogen sensing 

PRODUCTS ON MARKET: NanoArrayer System (NanoArrayer, Surface Patterning Tools [SPTs] 

and Sindex chips) 

UV TipCleaner 

AFM Solutions (Products and applications for atomic force microscopy) 



BioGenes GmbH 

Kopenicker Strabe 325 

Berlin 12555, Germany 

Phone: +49 (0)30 65762396; Fax: +49 (0)30 65762397 

Web: www.biogenes.de 

E-mail: service@biogenes.de 

KEY PERSONNEL: Dr. Alexander Knoll; CEO 

Dr. Sergej Ovodov; CSO 

Dagmar Schwertner; Marketing Director 

Dr. Sabine Steinbach; Head, Quality Management 


HISTORY: Founded and began biotech R&D in July 1992 

STOCK-FINANCIAL HISTORY: Private foundation 

PRINCIPAL INVESTORS: Essential Management GmbH 

IBB Beteiligungsgesellschaft mbH 

BUSINESS STRATEGY: Outsourcing partner for pharmaceutical companies 

PRODUCTS ON MARKET: Immunological and biochemical services 


610 West Rawson Avenue 

Oak Creek WI 53154, US 

Phone: (414) 571-6230; Fax: (414) 571-6231 

Web: www.biogenesis.com 

E-mail: customerservice@biogenesis.com 

KEY PERSONNEL: Paul N. Temple; Chairman 

Mohsen C. Amiran, Ph.D.; President, CEO and Technical Director 

Charles L. Wilde; COO 

Michael Dubey; Operations Manager 

EMPLOYEES: 9 employees, 1 Ph.D. 




Additional offices in Washington, D.C., and Chicago 


SUBSIDIARIES/DIVISIONS: Washington, D.C. office: 

7420 Alban Station Blvd., B-208 

Springfield, VA 22150 

Phone: (703) 913-9700 

Fax: (703) 913-9704 

BUSINESS STRATEGY: Develop, manufacture and provide products and services for industrial 

cleaning, odor control and soil and sediment remediation 

PRODUCTS ON MARKET: Soil washing, sediment washing, water treatment, filtration, fire 

suppressants, odor control, specialty extractants 


Biogenie Inc. 


350 Franquet Street 

Quebec G1P 4P3, Canada 

Phone: (418) 653-2074; Fax: (418) 653-2675 


Web: www.biogenie-env.com 

E-mail: marketing@biogenie-env.com 

KEY PERSONNEL: Benoit Cyr; President 

Carl Rodzewich; GM, U.S. 

Dominic Belanger; GM, Paris 

Graham Holtom; GM, U.K. 

Richard Corbin; Corporate Director 

Bryan O’Gallagher; Project Director 



FACILITIES: 28,000 sq. ft. facility including engineering and laboratory space for chemical 

analysis, microbiology and process simulation 

Operates mobile units for soil biotreatment studies 


BUSINESS STRATEGY: Develop biological processes for the treatment of soil, water effluents and air 

Seek research contracts, joint ventures and technology transfer 

RESEARCH & DEVELOPMENT: Microorganisms, bioreactors, biological and physical/chemical processes for 

treatment of contaminated soil, water and air 

PRODUCTS ON MARKET: Soil and groundwater decontamination for organic contaminants: 

hydrocarbons, solvents, pentachlorophenol, creosote, polyaromatic 

hydrocarbons (PAH), nitroaromatics and inorganic contaminants such as 

mercury 

Waste gas biofilters and air quality services 

Bio-Lab Ltd. 

P.O. Box 34038 

Jerusalem 91340, Israel 

Phone: +972 2-584 1110; Fax: +972 2-584 1111 

Web: www.bio-lab.co.il; E-mail: bio_lab@netvision.net.il 

KEY PERSONNEL: Dr. Leo Samuel; Managing Director 

Dr. Michel Ehrenfreund; Managing Director 

Dr. Jean Hildesheim; Director, Biotech and R&D 



FACILITIES: 7,000 sq. m. facility in Jerusalem 


BUSINESS STRATEGY: Produce and distribute high purity solvents and chemicals for research, 

routine laboratories and industries 

RESEARCH & DEVELOPMENT: HPLC: Up-grading of current specifications, introduction of new products 

Molecular biology: Up grading of current specifications, introduction of new 

products 

DNA synthesis: Up grading of current specifications, introduction of new 

products, synthesis of new reagents 

Peptide synthesis: Development of formulations, quality up grading of 

reagents, blocked amino-acid 



PRODUCTS ON MARKET: Solvents and chemicals 

Solvents and formulations for HPLC 

Environmental solvents 

Dry solvents 

Chiral solvents 

Molecular biology solvents, chemicals and formulations 

Peptide synthesis solvents and formulations 

DNA synthesis solvents 

Reagents 

Custom synthesis 

Biolog Inc. 

21124 Cabot Blvd. 

Hayward CA 94545, US 

Phone: (510) 785-2564; Fax: (510) 782-4639 

Web: www.biolog.com; E-mail: info@biolog.com 

KEY PERSONNEL: Barry R. Bochner, Ph.D.; President, CEO and CSO 

Douglas E. Rife; VP, Operations 

Edwin Fineman; VP, Finance and CFO 

John D. Groat; VP, Global Sales 



R&D facilities opened in July 1984 


FACILITIES: Offices, laboratory, R&D and manufacturing facilities 


FINANCIAL INFORMATION: Funding from equity, SBIR grants and development contracts 

BUSINESS STRATEGY: Continue growing as the recognized authority in cellular phenotype analysis 

with particular emphasis in functional genomics and drug discovery, 

microbial identification and analysis of microbial ecosystems 


Axiohelix and the E. coli genome-- research 

11/04 

NARA Institute phenotyping and 

determining the function 

of each gene 

agreement 

RESEARCH & DEVELOPMENT: Broad spectrum kits and phenotype MicroArrays based on a patented 

technology for the characterization and identification of microorganisms 

(gram-negative, gram-positive, yeast and anaerobe) at the species and 

subspecies level, as well as custom kits for specific applications or groups of 

microorganisms 

Functional genomics, phenotype testing and contamination identification 

PRODUCTS ON MARKET: GN2 MicroPlate--test panel for identification/characterization of 566 gramnegative 

bacteria 

GP2 MicroPlate--test panel for identification/characterization of 250 grampositive 

bacteria plus 57 lactic acid bacteria 

AN MicroPlate--test panel for identification/characterization of 300 species 

of anaerobic bacteria 

YT MicroPlate--test panel for identification/characterization of 267 yeast 

species 

FF Microplate-- test panel for identification/ characterization of filamentons 

fungi 

MT2 MicroPlate--test panel for catabolic surveys and bioremediation 

studies 

ECO MicroPlate--test panel for microbial community characterization and 

analysis 


Biologos Inc. 


KEY PERSONNEL: Dennis Raine; President 


BUG--universal growth medium for growing a broad range of 


BUA--universal growth medium for anaerobes 

BUY Agar--universal growth medium for yeast 

Rainbow® Agar O157--selective chromogenic culture medium for toxigenic 

strains of E. coli such as O157:H7 

Rainbow® Agar Salmonella--selective chromogenic medium for H2S+ 

Salmonella species 

Rainbow® Agar UTI--non-selective chromogenic medium for enumeration 

and identification of urinary tract pathogens 

MicroLog--manual system for reading and interpreting MicroPlate tests 

MicroStation--automated microbiology workstation for reading and 

interpreting MicroPlate tests 

OmniLog ID System--rapid automated incubation and identification of 

aerobic bacteria 

OmniLog PM System--automated instrument and software for kinetic 

analysis of 2000 cellular phenotypes 

Phenotype MicroArray Panels--MicroPlates for metabolic analysis of 

bacterial, fungal and mammalian cells 

2235 Cornell Avenue 

Montgomery IL 60538-3201, US 

Phone: (800) 246-4088; Fax: (630)-801-4766 


Web: www.biologos.com; E-mail: info@biologos.com 





RESEARCH & DEVELOPMENT: Animal tissue culture 

PRODUCTS ON MARKET: Normal animal sera 

Tissue culture media 

Antibiotic solutions 

Enzyme solutions 

Growth additives 

Miscellaneous biologicals 


1388 Antelope Road 

White City OR 97503-1619, US 

Phone: (541) 830-3000; Fax: (541) 830-3001 


Web: www.biomed1.com 

E-mail: info@biomed1.com 

KEY PERSONNEL: Robert D. Hall; Chairman and Exec. VP 






BUSINESS STRATEGY: Provide test methodologies that can be performed without sophisticated 

equipment or highly skilled personnel 

Utilize company's patented and proprietary packaging concepts to extend 

shelf life and improve performance of various media 


CMS/Fisher InPouch and InTray distribution 

7/98 

Healthcare systems 


U.S. 

PRODUCTS ON MARKET: InPouch and InTray systems for detecting protozoa and fungi 

Custom contract packaging 


Group B strep in field trials 

Biomeda Corp. 

KEY PERSONNEL: Ron Walraven; Chairman 

Pete Derrico; CEO 




1191 Chess Drive, Suite F 


Phone: (650) 341-8787; Fax: (650) 341-7095 


Web: www.biomeda.com; E-mail: customer@biomeda.com 

BUSINESS STRATEGY: Develop, manufacture and sell the highest quality immunochemicals 

RESEARCH & DEVELOPMENT: Immunology, cell biology, cell culture, molecular biology products 

PRODUCTS ON MARKET: Quality Leaders: 

-Primary antibodies 

-Secondary antibodies 

-ELISA 

-Detection systems 

-Mounting media 

-Sera 


378 Page Street 

Stoughton MA 02072, US 

Phone: (781) 344-9942; Fax: (781) 341-1451 

Web: www.btiinc.com; E-mail: info@btiinc.com 

KEY PERSONNEL: Maurice Lamarque; President 



PRODUCTS ON MARKET: Cell growth factors 

Cell culture products 

EIA kits 

RIA kits 




Assay kits and components 

MAbs, polyclonals, and proteins 

Specialty plastic labware 


595 Anglum Road 

Hazelwood MO 63042-2320, US 

Phone: (314) 731-8500; Fax: (314) 731-8678 


Web: www.biomerieux-vitek.com 

E-mail: tim.malloy@na.biomerieux.com 

Alain Merieux; Chairman and CEO, bioMerieux sa 

Tom O'Brien; Director, U.S. Industry Sales 

Karen Mullen; Sr. Market Manager; Pharma 

Mike Bullard; National Business Manager, Pharma 

Lee Doughton; Corporate Account Manager, Pharma 


HISTORY: Began biotech R&D in 1966 


FACILITIES: Headquarters in St. Louis, Mo. 

Manufacturing facilities in St. Louis, Mo., and Rockland, Mass. 

STOCK-FINANCIAL HISTORY: Privately held by parent 

SUBSIDIARIES/DIVISIONS: BioMerieux Inc. 

100 Rodolphe Street 

Durham, NC 27717, USA 

Phone: (919) 620-2000 

SUBSIDIARY OF: BioMerieux SA (see separate entry) 

BUSINESS STRATEGY: Develop and manufacture microbiology and immunoassays 


Affymetrix Inc. DNA probe arrays using development 9/96 

Affymetrix GeneChip agreement for 

technology 

bacteriology testing 

Gen-Probe Inc. probe assays for Vidas development 

agreement 

5/97 

MRL The Surveillance global surveillance 5/97 

Network (TSN) 

partnership 

OraVax Inc. human diagnostic exclusive 

11/96 

products incorporating worldwide licensing 

CagA for H. pylori 

detection 

agreement 

RESEARCH & DEVELOPMENT: Microbiology, immunoassays, pharmacy 

PRODUCTS ON MARKET: Vitek 

Vidas 

mini-Vidas 

API 

Slidex 

Chromogenic media 

TheraTrac 2 

TSN 



BioMerieux SA 

376 Chemin de l'Orme 

Marcy l'Etoile F-69280, France 

Phone: +33 04 78 87 20 00; Fax: +33 04 78 87 20 90 

Web: www.biomerieux.com 

KEY PERSONNEL: Alain Merieux; Chairman 

Benoît Adelus; Exec. VP 

Christophe Merieux; Sr. VP, R&D and Medical Affairs 

Frederic Benoliel; Corp. VP, Asia Pacific 

Thierry Bernard; Corp. VP, Europe, Middle East, Africa 

Xavier Fargetton; Corp. VP, Global Marketing and Strategic Development 

Jocelyne Latour; Corp. VP, Quality Assurance and Regulatory Affairs 

Jean-Francois de Lavison; Corp. VP, Public and International Affairs 

Marc Mackowiak; Corp. VP, R&D 

Pierre Piffeteau; Corp. VP, Industrial Operations and Purchasing 

Alexandre Merieux; Corp. VP, Industrial Microbiology 

Henri Thomasson; Corp. VP, Finance 

Peter Kaspar; Corp. VP and Head, Molecular Biology 




Changed name from Institut Merieux (1974) 

Acquired API System (1987) 

Acquired VITEK Systems (1988) 

Acquired the diagnostics unit of Organon Teknika, a division of Akzo Nobel 

(2001) 

Sold its hemostasis range of products to Trinity Biotech plc (6/06) 

FACILITIES: Corporate headquarters facilities in France with 2,100 employees 

Operations and facilites in over 130 countries, with more than 110 

distributors 

Nine research centers worldwide 

STOCK-FINANCIAL HISTORY: Listed on the Premier Marche of Euronext, Paris (FR0010096479 – BIM) 

Net sales EUR993.6M (YE 05) compared to EUR929.3M (YE 04) 

Net income EUR90.1M (YE 05) compared to EUR79.7M (YE 04) 


(YE 04) 

Total assets EUR906.1M (YE 05) compared EUR838.6M (YE 04) 

SUBSIDIARIES/DIVISIONS: Thirty-three subsidiaries in 130 countries 

Two business areas: 

Clinical diagnostics: Focuses on diagnosing infectious diseases, such as 

hepatitis B, HIV, tuberculosis, respiratory infections and increasingly 

pathologies, such as cardiovascular diseases and cancers 

Industrial diagnostics: Focuses on controlling the microbiological quality of 

an industrial or environmental sample 

BUSINESS STRATEGY: Become a key player in the in vitro diagnostics field of infectious diseases 

and other pathologies, such as cardiovascular diseases or cancers. It has 

implemented the following strategy: 

-Focusing its development on applications with a high potential 

-Launching new products to better satisfy the needs of patients and the 

imperatives of public health in general 

-Reinforcing its worldwide network to seize growth opportunities 

-Continuing with its sustained effort in research and development 

-Investing in new technologies via strategic alliances and targeted 

purchases that guarantee growth and technological independence 

-Pursuing a balanced financial strategy to seize on growth opportunities 




Affymetrix Inc. detection of nucleic 

acids in bacteriology, 

virology and industrial 

microbiological control 

applications 


Apibio molecular biology 

research 


Applied 

biologic test for 

development 12/04 

NeuroSolutions diagnosis of Alzheimer's agreement 

Inc. 

disease 

B·R·A·H·M·S AG Procalcitonin as a non-exclusive 3/05 

diagnostic marker for licensing 

severe bacterial 

infections 

agreement 

Cepheid molecular biology 

platforms 


DiagnoSwiss development, 

exclusive 

7/05 

manufacturing and worldwide licensing 

marketing of 

electrochemical 

microchips 

agreement 

ExonHit 

new blood diagnostics discovery and 2003 

Therapeutics in the area of early development 

cancer detection agreement, 

extended 10/05 

Genome Express Genome Express to licensing 

5/05 

carry out bacterial 

analyses 

agreement 

Gen-Probe Inc. Gen-Probe's ribosomal non-exclusive 10/04 

RNA technologies and licensing 

bioMerieux's genetic 

mutation detection IP 

agreements 

IDI new targets in 

microbiology 

applications 


Primagen Holding coronavirus CoV-NL63 exclusive licensing 2/06 

BV 

agreement 

Proteome 

Proteome's biomarkers licensing 

5/06 

Sciences plc for use in stroke 

diagnostics 

agreement 

Roche 

development, 

non-exclusive 4/05 

Diagnostics manufacturing and licensing 

marketing of 

immunoassays for 

congestive heart failure 

and acute coronary 

syndrome 

agreement 

RESEARCH & DEVELOPMENT: Bacteriology 

Immunoassays 

Molecular biology 

Hemostasis 

Instrumentation 

Software 

Genetics 

Pharmacogenomics 

Proteomics, biocomputing 

Micro-technologies (micro-fluidic, electronic, etc.) 



PRODUCTS ON MARKET: PHARMACEUTICALS, COSMETICS and BIOTECHNOLOGY: 

Identification of micro-organisms 

API® strips 

mini API® 

Vitek® 

Vitek®2 

apiweb® 

Microbiological control for sterile and non sterile products 

Bactometer® 

BacT/Alert® 3D Pharmaceutical, cosmetics and biotechnology 

Culture media - Pharmaceutical, cosmetics and biotech range 

Environmental control 

Culture media 

Culture media - Environmental control range 

Air Monitoring 

air Ideal® 

NucliSens EasyQ® Influenza H5 and N1 - avian flu test (for research) 

FOOD: 

Culture media 

Culture media - Food range 

Identification 

API® strips 

mini API® 

Vitek® 

FoodExpert-ID® 

apiweb® 

Pathogen immunodetection 

Vidas® Environment 

Vidas® Next Day 

Vidas® 2nd Generation 

Vidas® Safety 

Quality indicators 

Bactometer® 

Sterility testing 

BacT/Alert® 3D Food 

Tempo® microbial enumeration system 

BLOOD BANK and TISSUE BANK: 

Culture media 

Culture media - environmental control range 

Quality control testing of apheresis platelets 

BacT/Alert® 3D System 

WATER TESTING: 

Culture media 

Legionella GVPC medium 

Identification 

API® strips 

mini API® 

Vitek® 

apiweb® 


Biomol GmbH 



Waidmannstrasse 35 

Hamburg D-22769, Germany 

Phone: +49 40 85 32 600; Fax: +49 40 85 32 6022 


Web: www.biomol.de 

E-mail: info@biomol.de 

Dr. Eckhard Renken; Managing Director 

Carsten Schulz; Head, Finance 

Dr. Thomas Wiesemann; Head, Marketing 

Dr. Hans-Jurgen Heilmann; Head, Project Management 





Biomol Research signal transduction agency agreement 1989 

Laboratories reagents eicosanoids, for Germany, 

lipids 

Austria, and Eastern 

Europe 

Geneka 

Immunological and agency agreement 1999 

Biotechnology Inc. molecular biology for Germany, Austria 

products for 

transcription factors and 

functional genomics 

and Switzerland 

StressGen Inc. heat shock proteins and agency agreement 1991 

antibodies 

for Germany 

Upstate 

signal transduction sales agreement 1990 

Biotechnology Inc. antibodies 

and agency 

agreement for 

Germany, Hungary, 

Poland, and the 

Czech Republic 

PRODUCTS ON MARKET: Antibodies 

Arrays 

Compound libraries 

EIA kits/plate assays 

Enzymes and proteins 

Lectins 

Plasmid/vectors 

Bionas GmbH 

Friedrich-Barnewitz-Strasse 3 

Rostock 18119, Germany 

Phone: +49 381 5196-241; Fax: +49 381 5196-246 

Web: www.bionas.de 

E-mail: michael.schulze@bionas.de 

KEY PERSONNEL: Dr. Ralf Ehret; CEO 

Dr. Michael Schulze; Head, Sales and Marketing 


HISTORY: Founded 2001 




BUSINESS STRATEGY: Bionas specializes in analyzing systems and services for in-vitro profiling of 

the metabolic activity of cells to understand cellular function. Bionas® 2500 

analyzing system is a bench-top instrument that measures multiple 

metabolic parameters simultaneously like acidification, oxygen consumption 

and adhesion of living cells. 

The label-free and non-invasive live cell-based assay employs sensor chips 

that replace the conventional bottom of culture wells. Various cell types 

including primary cells have been successfully tested. The readout is carried 

out continuously over long periods of time and can be watched online 

revealing a deeper insight in cellular function than possible with endpointbased 

assays. Regeneration and recovery effects can also be monitored. 

Bionas® 2500 analyzing system closely mimics the in vivo situation and 

allows a more precise selection of promising drug candidates for preclinical 

development; reduces needless, expensive and time consuming animal 

studies; and saves money due to reduction of development time (faster 

time-to-market). 

PRODUCTS ON MARKET: Bionas 2500 analyzing system 


4495, boul. Wilfrid-Hamel 

Quebec G1P 2J7, Canada 

Phone: (418) 653-4422; Fax: (418) 653-3583 


Web: www.qbc.clic.net/~bionov 

E-mail: bionov@qbc.clic.net 

KEY PERSONNEL: Yvan Pouliot; President 




SUBSIDIARIES/DIVISIONS: Nutrimer enr. 

BUSINESS STRATEGY: Partnering strategy: 

Bionov is looking for: 

-Animal food wholesalers interested in the distribution of petfood products 

(frozen form in aquarium, seaworld and zoo, and dried form in petshop) 

-Companies in the food flavoring industry searching for new raw material for 

seafood flavoring 

-Food processing plant looking for the development of new products 

RESEARCH & DEVELOPMENT: Aquatic and marine resources: Development of new products, nutritional 

characteristics, upgrading of new resources or by-products, survey of 

natural resource, biomass production (aquaculture) 

PRODUCTS ON MARKET: Fish food (from amphipods) 

Amphipods 

Environment: Ecological management (pollution control, aesthetic, 

biodiversity), control of nuisances (bacteria, algae, weeds), ecological study 

and environmental evaluation (contamination), Nordic environment 




42 Aero Camino 

Goleta CA 93117, US 

Phone: (805) 685-0066; Fax: (805) 685-0067 

Web: www.biopac.com; E-mail: info@biopac.com 

KEY PERSONNEL: Alan Macy; President and CEO 

Marc Wester; CFO 

William McMullen; VP 




3,000 sq. ft. R&D facility 



BUSINESS STRATEGY: Provide products for medical research and educational markets 

RESEARCH & DEVELOPMENT: High-speed data acquisition platform (MP150) 

Computerized student physiology laboratory 

PRODUCTS ON MARKET: MP100 System 

MP 150 System 

Biopac Student Lab 

MP30/35 

AcqKnowledge waveform analysis software 

AcqKnowledge GLP 

Biopac Science Lab 

MP40 


MP200 in development 

Telemetry in development 


P.O. Box 156, 265 Conklin Street 

Farmingdale NY 11735, US 

Phone: (516) 249-0099; Fax: (516) 249-0494 

Web: www.biopro.com; E-mail: info@biopro.com 

KEY PERSONNEL: Rene Lohser; President and CEO 

John Campagnola; Sales and Service Manager 

Marc Lohser; Head, Marketing 

Therese Furger; Treasurer 

Denise Lohser; Head, Administration 




BUSINESS STRATEGY: Market and service processing equipment and instruments used for 

research, development and production of biochemicals, therapeutic drugs, 

enzymes, vaccines, antibodies and other biological products 


Aquasant AG sensors custom sensor 1993 

(Switzerland) 

Bioengineering 

AG (Switzerland) 

design 

fermenter/bioreactors custom equipment 

design 


1993


RESEARCH & DEVELOPMENT: Bioreactors, fermenters, shakers 

Bioxplore (UK) multiple fermenters custom fermenter 

design 

1996 

Dairei (Denmark) Ultra-Low Temperature 

Freezer 

custom design 2005 

Fedegari (Italy) autoclaves custom designed 

autoclaves for labs 

2002 

Graber 

(Switzerland) 

vibrating mixer custom design 1993 

Kuhner AG biological shakers custom shaker 1993 

(Switzerland) 

design 

M. Christ 

Freeze Driers and custom designs for 1999 

(Germany) vacuum concentrators drug discovery 

Prior (Austria) preparative continuous 

annular 

chromatography 

custom design 1999 

Riebesam 

glassware washing custom design 2000 

(Germany) machines 

PRODUCTS ON MARKET: Marketing and service of processing equipment and instruments from global 

sources used for research, development and production of biochemicals, 

therapeutic drugs, enzymes, vaccines, antibodies and other biological 

products 

Processes and designs for chemical engineering and environmental 

technology 


102 Melville St. 

Saskatoon S7J 0R1, Canada 

Phone: (306) 975-1166; Fax: (306) 242-3829 

Web: www.bioriginal.com 

E-mail: business@bioriginal.com 

KEY PERSONNEL: Joe Vidal; President and CEO 

Johan Kamphuis; Exec. VP, Global Marketing and Sales 

Gene Gerspacher; VP, Finance 

Dr. Jim Nugent; Director, Product Development 

Manny Sabares; Director, Marketing 




PRODUCTS ON MARKET: Condition-Specific Products 

Borage Products (oils, softgels, powders) 

EPA/DHA Products (oils, softgels, powders) 

Flax Products (oils, softgels, powders) 

EPO Products (oils, softgels, powders) 




1550 Valley Center Parkway, Suite 140 

Bethlehem PA 18017, US 

Phone: (610) 974-9693; Fax: (610) 691-2170 


Web: www.bioscienceinc.com 

E-mail: bioscience@bioscienceinc.com 

KEY PERSONNEL: Thomas G. Zitrides; CEO 




BUSINESS STRATEGY: Provide innovative products and services for environmentally-sound and 

efficient treatment of wastewater, wastewater sludge, contaminated soils 

and biotreatment for aquaculture and agriculture 

PRODUCTS ON MARKET: Microbial products for bioaugmentation 

Process improvement and stabilization of wastewater plants 

Activated sludge plants 

Plumbing systems 

Soil reclamation/bioremediation 

Aquaculture programs 

Analytical instruments and test kits 

Heater blocks and colorimeters for monitoring wastewater parameters 

Package biotreatment plants, aerators, product feeders and related 

instrumentation 

Laboratory biodegradation and biotreatability testing 

Engineering scale-up for bioremedial projects and in-house technical 

services 

Environmentally-friendly degreasers and oily water treatment and 

management programs 


3892 Del Amo Boulevard 

Torrance CA 90503, US 

Phone: (310) 214-0043; Fax: (310) 370-3642 

Web: www.bioscreen.com 

E-mail: info@bioscreen.com 

KEY PERSONNEL: Bradford L. Rope; President and CEO 

Dr. Richard Sullivan; Director, R&D 

Dr. Lawrence Rheins; VP, Clinical Services 



FACILITIES: Facilities in Phoenix, Ariz., and Shawnee Mission, Kan. 


SUBSIDIARIES/DIVISIONS: Pharmaceutical and Biotechnology Services 

Medical Device 

Cosmetic, Household & Industrial Products 

Midwest Clinical Trials (Human Clinical and Claim Substantiations) 



RESEARCH & DEVELOPMENT: Microbiology, chemistry and toxicology testing 

Medical devices 


Water testing 

BioSure Inc. 

KEY PERSONNEL: J. R. Riese; CEO 


12301 Loma Rica Drive, Suite G 

Grass Valley CA 95945-9355, US 

Phone: (530) 273-5095; Fax: (530) 273-5097 


Web: www.biosure.com; E-mail: richardr@biosure.com 

HISTORY: Founded and began biotech research in 1986 





BUSINESS STRATEGY: Provide unique products and expert technical assistance to research, 

industry, clinical laboratories, hospitals and medical/dental facilities 

worldwide 

The company focuses on biological safety, biological controls and standards 

and regulatory conformance in the manufacturing of biomedical devices and 

reagents 

RESEARCH & DEVELOPMENT: Biological controls and reagents for flow cytometry, immunocytometry and 

DNA analysis 

PRODUCTS ON MARKET: BioSure® steam sterilization integrators for verification of autoclave cycles 

and sterility 

BioSure® flow cytometry biological controls, DNA controls, reagents and 

buffers 

Consulting services, custom products and packaging 


1665 West Quincy Avenue, Suite 155 

Naperville IL 60540, US 

Phone: (630) 305-8400; Fax: (630) 305-8420 


Web: www.biosynth.com 

E-mail: welcome@biosynth.com 

KEY PERSONNEL: Urs Spitz, Ph.D.; Chairman and CEO 



FACILITIES: Worldwide headquarters: 

Biosynth AG 

Rietlistr. 4 

Postfach 125 

9422 Staad, Switzerland 

Phone: +41 (0)71 858 20 20 

Fax: +41 (0)71 858 20 30 




BUSINESS STRATEGY: Innovate, develop and produce reagents and biochemicals for the life 

science and pharmaceutical industries 

RESEARCH & DEVELOPMENT: Manufacture of substances for the detection of enzyme activity indicative of 

health conditions in clinical samples 

Identification of bacterial infections in clinical, food and environmental 

samples or products for hygiene monitoring 

Rare biochemicals such as culture media additives, biological detergents, 

plant growth hormones, and biochemical reagents used in standard assays 

Synthesis of indole derivatives 

PRODUCTS ON MARKET: Biochemicals: Biological detergents, plant growth regulators and 

biochemical reagents, including diagnostic reagents, cosmetic ingredients, 

pharmaceutical ingredients, biochemical substances 

Biotal Ltd. 

KEY PERSONNEL: Stuart Patterson; Director 




Carbohydrates and inositols: Monosaccharides, disaccharides, 

oligosaccharides, polysaccharides and inositols 

Culture media additives: Carbohydrates, growth inhibitors, C-390, bile acids, 

keto acids, L-amino acids and SPS 

Dyes, stains, labels and indicators: Colorimetric and fluorometric reagents, 

dyes and stains, indicators and labels 

Enzyme substrates: Glycosidases, peptidases, esterases, phosphatases, 

peroxidases, sulfatases, phospholipases, luciferases and enzyme reagents 

Fine chemicals: Alcohols, aldehydes, ketones; amines, amides, guanidines, 

ureas; amino acid derivatives; carboxylic and inorganic acids and 

derivatives; phenols, quinones, coumarines and other aromatics; 

heterocycles and alkaloids; steroids and bile acids 

Indole derivatives: Mono-substituted indoles, di-substituted indoles, trisubstituted 

indoles, higher substituted indoles, tryptamines, serotonins, 

tryptophans, tryptophols, gramines, harmines and harmanes, fluoroindoles, 

azaindoles and indolines 

Lipids and Phospholipids: Propanol-based lipids, glycol-based lipids, 

glycerol-based lipids, other lipids, propanol-based phospholipids, glycolbased 

phospholipids, glycerol-based phospholipids, other phospholipids 

Life science reagents: Biochemistry tools, cell biology tools, molecular 

biology tools, receptor agonists and antagonists and reducing agents 

Collivaud House, Ocean Way 

Cardiff CF24 5PD, UK 

Phone: +44 (0)29 2047 5550; Fax: +44 (0)29 2047 5598 

Web: www.biotal.co.uk 

SUBSIDIARIES/DIVISIONS: Agricultural business 

Equine business 

Garden products business 

Industrial products business 



BUSINESS STRATEGY: Develop products based on microbial and enzyme technology 

RESEARCH & DEVELOPMENT: Agricultural business: Focus is on the research, development, manufacture 

and supply of forage additives using naturally occurring micro-organisms 

and enzyme formulations 

PRODUCTS ON MARKET: BioCrimp 

Biograin 

Biostraw 

Wholecrop 

Wholecrop Legume 

Axcool 

Solo 

Axphast 

Supersile 

SoloMaize 

MaizeCool 

Top-Treat 

SC yeast range 

Equine Gold 

Garden cleaners 

Compost Maker 

Water Clear 

Fountain Clear 

Refresh and Refresh Plus 

Soil Restore 

Biotal GD 

Biological urinal/toilet cleaner 


1035 South 7th Street 

Manitowoc WI 54220, US 

Phone: (920) 684-5518; Fax: (920) 684-5519 

Web: www.biotechresources.com 

E-mail: info@biotechresources.com 

KEY PERSONNEL: Tom Jerrell; President 

Reinhardt A. Rosson, Ph.D.; VP and Director, R&D 

Michele T. Schmidt; VP, Operations 

Julia Maurina-Brunker; Director, Business Development 

Dr. Linsheng Song; Sr. Research Scientist 

EMPLOYEES: 30 employees, 22 scientists and engineers 


FACILITIES: 15,000 sq. ft. facility with extensive analytical equipment, fully equipped 

molecular biology laboratory, isotope rooms and fermenters (1 to 250 liters) 


SUBSIDIARY OF: Arkion Life Sciences LLC 

PRINCIPAL INVESTORS: Arkion Life Sciences LLC 

BUSINESS STRATEGY: Develop process technologies based on microbial fermentation and 

biocatalysis 

Provide laboratory and consulting services--including recombinant and 

classical strain improvement, industrial expression systems, fermentation 

and downstream process development and scale-up, metabolic engineering 

and microbial screening--on a contract basis 



RESEARCH & DEVELOPMENT: Microbial screening 

Strain improvement, classical and recombinant 

Fermentation development, recovery and scale-up 

Metabolic engineering 


Biocatalysis, enzyme and whole cell 

Expression systems 


6100 Royalmount Avenue 

Montreal H4P 2R2, Canada 

Phone: (514) 496-5329; Fax: (514) 496-5007 

Web: www.irb-bri.cnrc-nrc.gc.ca 

E-mail: bri-info@cnrc-nrc.gc.ca 

KEY PERSONNEL: Dr. Michel Desrochers; Director General 

Dr. Andrew Storer; Director, Health Sector 

Dr. Bernard Massie; Director, Bioprocess Platform 

Adrien Pilon; Director, Environmental Sector 

Eileen Raymond; Director, Industrial Affairs Sector 

EMPLOYEES: 812 employees (277 NRC employees, 304 employees from private 

companies, 210 students and guest researchers) 

HISTORY: Established by National Research Council of Canada in 1984 to conduct 

state-of-the-art research in molecular biology and biochemical engineering 

with specific applications to the pharmaceutical and environment and 

resource industries 

FACILITIES: 315,000 sq. ft. of laboratories, offices, pilot plants and spaces leased to 

industry 


PRINCIPAL INVESTORS: National Research Council of Canada 

BUSINESS STRATEGY: Make a significant contribution to the wealth-generating capability in Canada 

and represent a source of expertise for both industry and the scientific 

community 

Work with companies through collaboration research, contract and licensing 

agreements 

RESEARCH & DEVELOPMENT: Molecular design strategies for the development of peptidyl and nonpeptidyl 

blockers as potential therapeutic agents (cancer, cardiovascular, and 

degenerative and inflammatory diseases) 

Development of biotechnology products, development of new bioprocesses, 

improvement of existing bioprocesses, scale-up of bioprocesses to industrial 

levels using microorganisms, animal cells or enzymes as catalysts 

Bioremediation of contaminated soils, air, groundwater and sediments 

Biological monitoring, biosensors and biopesticides 




6023 South Loop East 

Houston TX 77033, US 

Phone: (713) 643-0606; Fax: (713) 643-3143 


Web: www.biotecx.com 

E-mail: biotecx@aol.com 

KEY PERSONNEL: Dr. Mohan Mehra; President 








BUSINESS STRATEGY: Develop products for molecular biology and clinical diagnostics 

Find partners for OEM distribution and direct selling 

RESEARCH & DEVELOPMENT: ELISA products for infectious disease 

Hormone assays 

PRODUCTS ON MARKET: Ultraspec RNA 

RNA Tack 

DNA Multriprep 

BioPlaz 

Ezout 

Expresep 

Ontrack 

Prokay 

OptiCoat ELISA kits for TORCH, thyroids, fertility hormones 

Biotehnos SA 

18, Dumbrava Rosie Street, District 2 

Bucharest 020464, Romania 

Phone: +40 21 210 20 15; Fax: +40 21 210 97 05 

Web: www.bth.ro 

E-mail: office@biotehnos.com 

KEY PERSONNEL: Prof. Dr. Ioan Manzatu; President and CEO 

Liliana Manzatu; Deputy Director General 

Iuliana Zaharia; Financial Director 

Stefan Badusi; Commercial Director 

Alexandru Stoica; Marketing Director 

Laura Olariu; Director, R&D 

Mariana Ghica; Production Director 

Viorica Dinga; QA Director; Quality Control 

Ruxandra Elisa Dobos; Head, QC Department 

Ludmila Turcanu; Scientific Director 


HISTORY: Began biotech R&D in 1983 



PRINCIPAL INVESTORS: Tehman Ltd.--20% 



INVESTMENTS: National Institute of Biotechnologies--$30K 

Biotehnos and Tehman Association--$5M 

BUSINESS STRATEGY: Develop, market and export biopharmaceuticals and biocosmetics 


Artur-K pharmaceuticals distribution 

Biotechman 

GmbH 

pharmaceuticals and 

cosmetics 

agreement 

Commercialization 

of yeast extracts, 

marketing, 

tehnology transfer, 

new products 

registration, GMP 

rules implementation 

CMS GmbH biotechnology joint venture for 

R&D, production 

Falbi pharmaceuticals 

and marketing 

distribution 

agreement 

Farmotehnos SA pharmaceuticals and Joint venture for 

cosmetics 

products 

registration, 

distribution, 

promotion of new 

technologies and 

production 

Guangzhou pharmaceuticals and distribution 

Economic and 

Technological 

Development 

District (China) 

cosmetics 

agreement 

Interfarma pharmaceuticals distribution 

agreement 

Lenniichimmash- pharmaceuticals distribution 

Centrofarm 

agreement 

Masung Co. Ltd. pharmaceuticals sales agreement for 

(Seoul) 

the Far East 

North 

pharmaceuticals distribution 

Pharmaceutical 

Network 

agreement 

Planeta pharmaceuticals distribution 

agreement 

Protec pharmaceuticals distribution 

agreement 

Rompharm Co. pharmaceuticals distribution 

agreement 

Travel Medinsure pharmaceuticals distribution 

agreement 

PRODUCTS ON MARKET: Biopharmaceuticals: Alflutop®/Alflutop® gel, Armon®, Gelisept®, Alflutop® 

vet, Salvapoderm®, Salvaderm®, Rhinogel® vet, Cervisalva® vet 

Biocosmetics: Biounda skin care products and body care products, 

Solarmon sunbathing products 

Plant extracts 

Structured water 


1997 

1997 

1996



2500 Broadway, Drawer 5 

Camden NJ 08104, US 

Phone: (856) 541-3500; Fax: (856) 541-3366 

Web: www.biothane.com 

E-mail: sales@biothane.com 

KEY PERSONNEL: Robert I. Sax, Ph.D.; President 

Jay Murphy; Exec. VP 

Jelte Lanting; Technology Manager 

Jill Jordan; Technical Services Manager 







SUBSIDIARIES/DIVISIONS: Biothane Systems International 

Tanthofdreef 21 

P.O. Box 5068 

2600 GB Delft, The Netherlands 

Phone: +31 15 270 0111 

Fax: +31 15 256 0927 

E-mail: sales.europe@biothane.com 

Biothane Asia Pacific 

Ventura Building, 9th floor Suite 903 

Jl. R.A. Kartini no 26 

Jakarta 12430, Indonesia 

Phone: +62 (0)21 750 4707 

Fax: +62 (0)21 750 4708 

E-mail: sales.asia@biothane.com 

Biothane Systems Ltd. 

446 Houldsworth Mill Business Centre 

Houldsworth Street 

Reddish, Stockport SK5 6DA, UK 

Phone: +44 (0) 161 975 6052 / 6051 

Fax: +44 (0) 161 975 6053 

E-mail: sales.europe@biothane.com 

SUBSIDIARY OF: Joseph Oat Holding Inc. 

PRODUCTS ON MARKET: Biothane high rate anaerobic wastewater treatment process 

Biobed high rate anaerobic wastewater treatment process 

Biopuric Hydrogen Sulfide biogas scrubber 

SEAD- Shear Enhanced Anaerobic Digestion process 


BioTime Inc. 



6121 Hollis Street 

Emeryville CA 94608, US 

Phone: (510) 350-2940; Fax: (510) 350-2948 

Web: www.biotimeinc.com; E-mail: contacts@biotimemail.com 

Judith Segall; VP, Technology and member of office of president 

Hal Sternberg, Ph.D.; VP, R&D and member of office of president 

Harold Waitz, Ph.D.; VP, Regulatory and member of office of president 

Jeffrey B. Nickel, Ph.D.; VP, Business Development and Marketing 

Stephen Seinberg; CFO 


HISTORY: Founded in November 1990 


FACILITIES: 5,244 sq. ft. of leased space in Emeryville, Calif. 

STOCK-FINANCIAL HISTORY: OTC BB--BTIM 

Subscription rights offering--283K shares at $20/share (2/97) 

3:1 stock split (10/97) 

Revenue $903.200K (YE 05) compared to $688.377K (YE 04) 




04) 


PRIVATE PLACEMENTS: Raised $1.8M in rights offer of stock and warrants (12/05) 

BUSINESS STRATEGY: Develop blood plasma volume expanders, blood replacement solutions for 

hypothermic surgery, organ preservation solutions and technology for use in 

surgery, emergency trauma treatment and other applications 


Abbott 

Hextend plasma- $40M licensing 4/97 

Laboratories expanding product agreement--Abbott 

paid $1.4M 

licensing fee (7/97) 

Barrow 

blood substitute for low- research 

1993 

Neurological 

Institute of St. 

Joseph's Hospital 

temperature surgery agreement 

Baylor College of Hextend artificial blood research 

12/95 

Medicine 

(Houston, TX) 

plasma solution 

agreement 

Bronx Veterans blood replacement research 

1993 

Affairs Medical 

Center 

solutions 

agreement 

Davies Medical freeze-protecting research 

1993 

Center--Buncke solutions to preserve full agreement 

Clinic 

thickness skin grafts 

McGaw Inc. Hextend production 

agreement 

12/94 

Metropolitan blood replacement research 

1993 

Hospital 

solution 

agreement 

Mt. Sinai Medical blood replacement research 

1993 

Center 

solution 

agreement 

Summit 

Hextend and PentaLyte development 12/05 


International Corp. 

for the Japanese market agreeement 

RESEARCH & DEVELOPMENT: Synthetic solutions that can be used as blood plasma volume expanders, 

blood replacement solutions during hypothermic surgery, and organ 

preservation solutions 



PRODUCTS ON MARKET: Hextend® blood substitute solution for low-temperature surgical procedures 


Pentalyte in Phase II clinicals 

Hetacool in discovery 

Hetafreeze in discovery 

BioVectra dcl 

16 McCarville Street 

Charlottetown PE--C0A 1H0, Canada 

Phone: (902) 566-9116; Fax: (902) 628-2045 


Web: www.biovectra.com 

E-mail: info@biovectra.com 

KEY PERSONNEL: Dr. Rejis Duffy; Chairman 

Ron Keefe; President 

Dale Zajicek; COO 

Gordon Rogers; CFO 

Dr. Gary R. Reid; VP, R&D 

Dr. Tibor Breining; Director, R&D 

Dr. Richard Bethell; Sr. Scientist 

Patrick Duffy; Purchasing Manager 

EMPLOYEES: 200+ employees, 7 Ph.D.s 



SUBSIDIARIES/DIVISIONS: Diagnostic Chemicals Limited 

BUSINESS STRATEGY: Custom manufacturing 

Provide bioprocessing reagents and services 


3075 Chemin des Quatre-Bourgeois, Suite 440 

Sainte-Foy G1W 4Y5, Canada 

Phone: (418) 654-9666; Fax: (418) 654-9655 

Web: www.bioxelpharma.com 

E-mail: bioxelpharma@bioxelpharma.com 

KEY PERSONNEL: Andre P. Boulet, Ph.D.; Chairman 

Pascal Delmas; CEO and President 

Louis McGuire; VP, Finance and CFO 

Paul Metz; Exec. VP, Commercial Operations 

Andre Lalonde; VP, Biomass 

Louis Estaque, Ph.D.; VP, Production 



STOCK-FINANCIAL HISTORY: TSX--BIP 

Public offering--13.571M common shares at $0.70/share, $9.5M (3/03) 





04) 




PRIVATE PLACEMENTS: Raised $4.5M in private placement of 6.429M common shares at 

$0.70/share (8/03) 

Raised $3.3M in private placement of 8.041M units at a $0.41/unit (9/04) 

Raised $4.7M in private placement of 13.817M common shares at 

$0.34/share (2/06) 

Raised $2.7M from 7.980M common shares at $0.34/share, received upon 

the exercise of an equivalent number of warrants (4/06) 

SUBSIDIARIES/DIVISIONS: U.S. office: 

2429 Ginny Way 

Lafayette, CO 80026 

Phone: (303) 926-9878 

Fax: (303) 926-9877 

BUSINESS STRATEGY: Manufacture and distribute taxane pharmaceutical ingredients, including 

paclitaxel, docetaxel, 9-DHB and 10-DAB 

RESEARCH & DEVELOPMENT: Portfolio of new products that include docetaxel, paclitaxel via a semisynthetic 

route of production and innovative taxane-based drugs 

PRODUCTS ON MARKET: natural paclitaxel 

9-DHB 

10-DAB 


Unit 6, Gilchrist Thomas Estate, Blaenavon 

Torfaen NP4 9RL, UK 

Phone: +44 1495-790678; Fax: +44 1495-791780 

Web: www.biozyme.com 

E-mail: info@biozyme.co.uk 

KEY PERSONNEL: John Chesham; Managing Director 

Ken Murray; Sales and Marketing Manager 

Jane Howells; Sales and Marketing Coordinator 

John O'Shea; Quality Manager 


HISTORY: Established in December 1971 at Bourne End, Buckinghamshire, as 

manufacturer of enzymes for diagnostic reagents 

FACILITIES: Two manufacturing facilities in the U.K. 

Sales and marketing office in San diego, Calif. 

Worldwide network of distributors 


SUBSIDIARIES/DIVISIONS: Biozyme Laboratories International Ltd. 

9939 Hibert Street, Suite 101 

San Diego, CA 92131-1029 


Fax: (858) 549-0138 

E-mail: bioinfo@biozyme.com 

SUBSIDIARY OF: Theratase plc 

BUSINESS STRATEGY: Develop and manufacture high purity enzymes and proteins 

RESEARCH & DEVELOPMENT: Enzymes as active pharmaceutical ingredients, for example, high activity 

hyaluronidase for applications other than opthalmology 

Protein purification specializing in extraction from plant and animal tissues 

using chromatography and other methods 

Product assay 



PRODUCTS ON MARKET: Highly purified enzymes and related biochemicals for clinical diagnostics, 

immunodiagnostics, biosensors, diagnostic probe and research applications 

(includes alkaline phosphatase, peroxidase, glucose oxidase, urease, 

catalase, aldehyde dehydrogenase, hexokinase, phospho-enolpyruvate 

carboxylase, glycerol-3-phosphate dehydrogenase, ascorbate oxidase, 

cholesterol esterase, xanthine oxidase, alpha-glucosidase, elastase, 

enterokinase, deoxyribonuclease and ribonuclease) 


KEY PERSONNEL: Margarete Kalin; President 

139 Amelia Street 

Toronto M4X 1E6, Canada 

Phone: (416) 861-1086; Fax: (416) 861-0634 

Web: www.boojumresearch.com; E-mail: margarete.kalin@utoronto.ca 

EMPLOYEES: 2 employees, 4 specialty contractors 


FACILITIES: 850 sq. ft. headquarters 


BUSINESS STRATEGY: Seek marketing, investment and joint venture opportunities 

RESEARCH & DEVELOPMENT: Wetland microbiology and ecosystem recovery 

Bioremediation of mining sites 

Environmental mining 

PRODUCTS ON MARKET: Chara process 

Microbiological AMD treatment 

Biological polishing 

Ecological engineering 

ARUM (acid reduction using microbiology) process 

Project management for clean-up of mine sites 



Hopkinton MA 01748, US 

Phone: (508) 497-2360; Fax: (508) 497-9964 

Web: www.bostonlifesciences.com 

E-mail: ir@bostonlifesciences.com 

KEY PERSONNEL: Peter G. Savas; Chairman and CEO 

Mark J. Pykett, Ph.D.; President and COO 

Kenneth L. Rice Jr.; Exec. VP, Finance and CFO 

Mark R. Hurtt, M.D.; CMO 

Irene Gonzalez, Ph.D.; Sr. VP, Protein Development 

Noel J. Cusack, Ph.D.; Sr. VP, Preclinical Development 

Richard Thorn, Ph.D.; Sr. VP, Program Operations 

Sharon Correia; Director, Corporate Communications and Investor Relations 


HISTORY: Founded in 1992 by the Castle Group and Dr. Marc Lanser 

Completed reverse merger with Greenwich Pharmaceuticals Inc. to become 

a public company (6/95) 


Member--Massachusetts Biotechnology Council 



FACILITIES: 5,900 sq. ft. office facility in Hopkinton, Mass. 

3,300 sq. ft. laboratory facility in Baltimore, Md. 

2,500 sq. ft. office facility in Woburn, Mass. 

STOCK-FINANCIAL HISTORY: NASDAQ--BLSI 

One-for-five reverse stock split (2/05) 




Total assets $10.515M (YE05) compared to $2.545M (YE 04) 

PRIVATE PLACEMENTS: Raised $2.2M through issuance of 7% senior bridge notes (6/95) (notes 

converted into 157K shares of common stock in 1st quarter 1996) 

Raised $1.8M in private placement of 320K shares (11/95) 

Raised $24M in private placement of 240K shares of Series A preferred 

stock and warrants to purchase 600K shares at $6.70/share (1/96) 

Raised $5M in private placement of 500K shares (7/96) 

Raised $8M in private placement of convertible preferred stock and warrants 

(12/03) 

Raised $5M in private placement of 2M shares of common stock at 

$2.50/share (3/05) 

Raised $12.8M in private placement of 6M shares of common stock at 

$2.13/share (8/05) 

BUSINESS STRATEGY: Research and clinical development of diagnostic and therapeutic products 

for central nervous system (CNS) disorders such as Parkinson’s disease, 

essential tremor, ADHD, stroke, traumatic brain injury, spinal cord injury and 

ocular indications 


Children’s 

key factors that inhbit exclusive, 

5/06 

Hospital Boston the inhibitors of axon worldwide licensing 

regeneration 

and sponsored 

research 

agreements 

Children’s 

key factors that promote exclusive, 

12/98 

Hospital Boston axon regeneration worldwide licensing 

and sponsored 

research 

agreements, 

amended 5/06 

Harvard University Altropane molecular exclusive, 

3/00 

imaging agent for worldwide 

ADHD 

licensing, amended 

5/04 

Harvard University Altropane molecular exclusive, 

12/93 

imaging agent for PD worldwide licensing 

agreement, 

amended 5/04 

Harvard University BCLx-gamma gene that licensing 

3/98 

controls apoptosis agreement 

Zeneca 

small molecule 

exclusive R&D 6/95 

Pharmaceuticals inhibitors of MHC Class 

II gene transcription 

factors to treat 

autoimmune diseases 

agreement 

RESEARCH & DEVELOPMENT: 1) Molecular imaging program focused on molecular imaging agents used 

as an aid in diagnosing Parkinson's disease and ADHD with SPECT, PET 

and MRI 

2) Dopamine transport blocker program as a therapeutic and in potential 

disease modification for Parkinson's disease 

3) Axon regeneration program focused on treatments for stroke, TBI, SCI 

and ocular diseases 



BRAIN (Biotechnology Research and 

Information Network AG) 


Darmstadter Strasse 34-36 

Zwingenberg 64673, Germany 

Phone: +49 (0) 62 51 / 9331-0 

Fax: +49 (0) 62 51 / 9331-11 

Web: public@brain-biotech.de 

E-mail: public@brain-biotech.de 

Dr. Holger Zinke; Chairman and CEO 

Dr. Jurgen Eck; CSO 

Dr. U. Dechert; Sr. Scientist 

Dr. M. Krohn; Unit Head 

Dr. M. Langer; Corporate Development 

Dr. P. Lorenz; Unit Head 

Dr. G. Meurer; Unit Head 




Spun off VISCUM AG (2000) 


537 sq. ft. R&D facilities 


BUSINESS STRATEGY: Discover and develop novel bioactives, biocatalysts and enzymes 


BASF AG new oxidoreductases R&D cooperation 2005 

Ciba AG microorganisms for 

production of speciality 

chemicals 

R&D cooperation 2005 

Degussa AG new ADH for production 

of chiral alkohols 


Genencor 

BRAIN's metagenome R&D agreement 2004 

International to develop enzyme 

platform 

Henkel KGaA new detergent enzymes R&D cooperation 2005 

Nutrinova GmbH nutraceuticals development 

agreement 

2004 

Sandoz GmbH enzymes for biotech 

prod of ß-lactam 

antibiotics 

RESEARCH & DEVELOPMENT: Expression systems 

Secondary metabolites 

Microbial strain optimisation 

Bioactive compounds 

Industrial enzymes 

Technical enzymes and biocatalysts 

Cellular based assays 

R&D agreement 2004 

Schering AG design of microorganisms 

for 

production of steroid 

drugs 


Sudzucker AG functional carbohyrates R&D cooperation 2005 


Bunge Ltd. 



White Plains NY 10606, US 

Phone: (914) 684-2800 

KEY PERSONNEL: Alberto Weisser; Chairman and CEO 

Andrew J. Burke; Managing Director, New Business, Bunge Ltd. 

Archibald Gwathmey; Managing Director, Agribusiness Division, Bunge Ltd., 

and CEO, Bunge Global Markets Inc. 

Joao Fernando Kfouri; Managing Director, Food Products Division, Bunge 

Ltd. 

Flavio Sa Carvalho; Chief Personnel Officer 

William M. Wells; CFO 

Mario A. Barbosa Neto; CEO, Bunge Fertilizantes SA 

Jean Louis Gourbin; CEO, Bunge Europe 

Carl L. Hausmann; CEO, Bunge North America Inc. 

Raul Padilla; Bunge Argentina SA 

Sergio Roberto Waldrich; Bunge Alimentos SA 


HISTORY: Founded in 1818 as a grain trading company in Amsterdam, the 

Netherlands 

In the second half of the 1800s, expanded grain operations in Europe and 

entered the South American agricultural commodities market 

Entered the South American food products industry (1888) 

Started U.S. operations (1923) 

Entered the fertilizer industry in Brazil (1938) 

FACILITIES: More than 500 facilities in 32 countries: 

Agribusiness: 275 grain storage facilities, approximately 50 oilseed 

processing plants and approximately 25 international marketing offices 

Fertilizer: Four phosphate mines in Brazil, 35 processing plants in Brazil 

Food products operations: Approximately 50 refining and bottling facilities 

and 20 other facilities 

STOCK-FINANCIAL HISTORY: NYSE--BG 

IPO--17.6M shares at $16/share (8/01) 

Net sales $24.275M (YE 05) compared to $25.168M (YE 04) 

Net income $530M (YE 05) compared to $469M (YE 04) 


Average shares outstanding 112,132b (YE 05) compared to 106,016b (YE 

04) 


SUBSIDIARIES/DIVISIONS: Three divisions: Agribusiness, fertilizer and food products, which include 

four reporting segments: Agribusiness, fertilizer, edible oil products and 

milling products 

Subsidiaries: 

U.S.A.: AGRI-Bunge LLC, Bunge North America (East) LLC, Bunge North 

America Foundation, Sabina Bunge LLC, Bunge North America Inc., Bunge 

Milling Inc., The Crete Mills Inc., Lauhoff Finance Corp., Bunge Oils Inc., 

Bunge North America (OPD West) Inc., Bunge Mexico Holdings Inc., Bunge 

North America Capital Inc., Bunge Mextrade LLC, Delphos Terminal Co. 

Inc., CSY Holdings Inc., CSY Agri-Finance Inc., Universal Financial Services 

LP, Batavia Leasing Co., Bunge Chicago Inc., International Produce Inc., 

Bunge NA Holdings Inc., Bunge Global Markets Inc., Bunge Finance North 

America Inc., Bunge Management Services Inc., Bunge Funding Inc., Bunge 

Asset Funding Corp., Bunge Ltd. Finance Corp., Solae Holdings LLC, 

Bunge Canada Investments Inc., DDO Processing LLC 

Canada: Bunge of Canada Ltd., Bunge Canada, Bunge Canada Holdings I 

ULC, Bunge Canada Holdings II ULC, CF Oils Investments Inc., Leblanc & 

Lafrance Inc., Neptune Bulk Terminals (Canada) Ltd. 



Mexico: Controladora Bunge SA de CV, Agroproductos Bunge SA de CV, 

Harinera La Espiga SA de CV, Inmobiliaria A Gil SA, Inmobiliaria Gilsa SA, 

Servicios Bunge SA de CV, Molinos Bunge SA de CV, Bunge Comercial SA 

de CV 

Bermuda: Ceval Holdings Ltd., Brunello Ltd., Greenleaf Ltd., Bunge Finance 

Ltd., Serrana Holdings Ltd., Bunge Global Markets Ltd., Fertimport 

International Ltd. 

Barbados: Bunge Export Sales (Barbados) Corp. 

Cayman Islands: Bunge Fertilizantes International Ltd., Santista 

International Ltd., Santista Export Ltd., Ceval Export Securitization Ltd., 

Ceval International Ltd., Bunge Trade Ltd. 

Argentina: Terminal Bahia Blanca SA, Bunge Argentina SA, Terminal 6 SA, 

Terminal 6 Industrial SA 

Guide SA, Fertimport SA, Bunge Inversiones SA 

Brazil: Fosbrasil SA, Serrana Logistica Ltda., Amoniasul Servicos de 

Refrigeracao Industrial Ltda., Bunge Alimentos SA, Bunge Fertilizantes SA, 

Fertilizantes Ouro Verde Ltda., Fertilizantes Fosfatados SA, Ultrafertil SA, 

Fertifos Administracao e Participacoes SA, Macra Administracao e Servicos 

Ltda., Agrisat Solucos Integradas Ltda., IFC Industria de Fertilizantes de 

Cubatao SA, Bunge Armazens Gerais Ltda., Ceval Centro Oeste SA, 

Terminal de Graneis do Guaruja SA, Terminal Maritimo do Guaruja SA 

(TERMAG), IFC - Industria de Fosfatados Catarinense Ltda., Cereol do 

Brasil Ltda., MBB Comercio e Servicos Ltda., Serra do Lopo 

Empreendimentos e Participacoes SA, Fertimport SA, Moinho Jauense 

Industria e Comercio de Alimentos Ltda., Eco Invest Carbon PP Ltda. 

Uruguay: Bunge Uruguay SA, Dinelsur Corp. SA, Agritrade SA 

Paraguay: Bunge Paraguay SA 

Peru: Bunge Peru SAC 

Venezuela: Almacen Terminal Santana CA 

Dominican Republic: Bunge Caribe SA 

Australia: Bunge Global Markets Australia Pty. Ltd. 

Southeast Asia: Bunge Agribusiness Singapore Pte. Ltd., PT. Bunge 

Agribusiness Indonesia, Bunge Agribusiness (M) Sdn. Bhd., Bunge 

(Thailand) Ltd., Bunge Agribusiness Philippines Inc., Grains and Industrial 

Products Trading Pte. Ltd. 

China: Bunge International Trading (Shanghai) Co. Ltd. 

Mauritius: Bunge Mauritius Ltd. Bunge Mauritius Holdings Ltd., International 

Produce Ltd. 

India: Bunge India Pvt. Ltd. 

U.K.: Bunge Corp. Ltd., Bunge UK Ltd. 

Spain: Bunge Iberica SA, Estacion de Descarga y Carga SA (Esdecasa), 

Ergransa SA, Bunge Iberica Investment SRL, Moyresa Girasol SL, Biodiesel 

Bilbao SL 

France: Bunge France SAS, Bunge Holdings France SAS, Bunge SAS, 

Novaol France SAS, Saipol SAS, Diester Industries International SAS 



Holland: Koninklijke Bunge BV, Bunge Cooperatief UA, Bunge Europe 

Finance BV, Bunge Brasil Holdings BV, Bunge Finance Europe BV, Bunge 

Alimentos Holding BV 

Switzerland: Bunge SA, Oleina SA, Ecoinvest Carbon SA 

Germany: Bunge Deutschland GmbH, Bunge Handelsgesellshaft mbH 

Italy: Bunge Italia SpA, Escercizio Raccordi Ferroviari SpA 

Turkey: Bunge Gida Ticaret AS 

Cyprus: Bunge Cyprus Ltd., Eastern Agro Investment Ltd., Brea 

Commodities Ltd. 

Hungary: Bunge ZRT, Cereol Befektetesi Kft. 

Portugal: Bunge Iberica Portugal SA, Gardone-Consultoria e Servico, 

Sociedade Unipessoal Lda. 

Luxembourg: Bunge Europe SA 

Austria: Bunge Austria GmbH 

Latvia: Dan Store LSEZ SIA 

Ukraine: Suntrade SE, Fisakiyske Khp, DOEP, CJSC Dolynsky Elevator, 

LLC Oleina Distributors, LLC Lan Elevator, Black Sea Industries Ltd. 

Romania: SC Unirea SA, Muntenia SA, Interoil SA, Bunge Romania Srl 

Poland: ZT Kruszwica SA, EWICO S.p.z.o.o., Polska Trade Services 

S.p.z.o.o., ZPT W Warszawie SA, Olvit Pro S.p.z.o.o. 

Belgium: Afrique Initiatives 

Russia: LLC Bunge CIS, LLC Prichalny Complex, Rostov Grain Terminal 

LLC, LLC Elevatorniy Complex, LLC Elevator, LLC Grain CO Dara, OJS 

Kholmsky 

Bulgaria: Kaliakra AD 

INVESTMENTS: The Solae Co.--joint venture with DuPont 

Saipol SAS--joint venture with Sofiproteol 

Joint venture with Aceitera General Deheza SA for the operation of the 

Terminal 6 port facility in Argentina and adjacent crushing facility 

AGRI-Bunge LLC--joint venture with AGRI Industries 

Fosbrasil SA--joint venture with Astaris Brasil Ltda. and Societe Chimique 

Prayon Rupel SA 

EWICO S.p.z.o.o.--joint venture in Poland 

Harinera La Espiga SA de CV--joint venture with Grupo Neva SA de CV and 

Cerrollera SA de CV 

Terminal de Graneis do Guaruja SA--joint venture with Ferronorte SA 

Diester Industries International SAS--joint venture with Diester Industrie 

BUSINESS STRATEGY: Agribusiness division: Purchase, process, store and sell grains and oilseeds 

Fertilizer: Involved in every stage of the fertilizer business, from mining raw 

materials to the selling fertilizer products 

Food products: Two business segments--edible oil products and milling 

products. Businesses in these segments produce and sell food products 

such as edible oils, shortenings, margarine, mayonnaise and milled products 

such as wheat flours and corn products 


CABI 



DuPont joint venture for the alliance and 1/03 

global production and 

distribution of specialty 

food ingredients 

(starting with soy 

proteins and lecithins), 

joint development and 


soybeans with improved 

quality traits, and 

development of a 

broader offering of 

services and products 

to farmers 

agreement 

Procter & Gamble production and 

alliance 11/04 

and Peter Cremer marketing of 

North America cholesterol-reducing 

phytosterol ingredients 

for pharmaceuticals and 

foods 

KEY PERSONNEL: Dr. Trevor Nicholls; CEO 

Bakeham Lane 

Egham TW20 9TY, UK 

Phone: +44 (0)1491-829-080; Fax: +44 (0)1491-829-100 

Web: www.cabi.org 

E-mail: information@cabi.org 

EMPLOYEES: 350 employees (220 in the U.K.) 

HISTORY: CABI was founded in 1920 

Formerly the Commonwealth Mycological Institute, International Mycological 

Institute (IMI), International Institutes of Entomology (IIE), Parasitology (IIP) 

and Biological Control (IIBC) 

FACILITIES: 4,200 sq. m. in six buildings in the U.K. 

STOCK-FINANCIAL HISTORY: Intergovernmental nonprofit enterprise 

FINANCIAL INFORMATION: Nonprofit. Financed through sales of services and consultancies to 

governments, foundations and the corporate sector 

BUSINESS STRATEGY: CABI is a leading provider of authoritative and unbiased scientific 

information in agriculture and the environment. It conducts research into 

agricultural and environmental issues, aiming to improve peoples’ lives in 

direct and indirect ways. The organization also publish books, journals and 

scientific research aiming to further science and its application to real life. 


Academia Sinica mycological services, collaborative 2/88 

Institute of publications and agreement-- 

Microbiology, cultures 

research, training 

Systematic 

courses, exchange 

Mycology & 

of specimens and 

Lichenology 

cultures, and 

Laboratory 

production and sale 

(Beijing, China) 

of books 



Biosystematics 

Research Centre 

Agriculture 

Canada (Ottawa, 

Canada) 

Fundaçao Tropical 

de Pesquisas e 

Tecnologia 

(FTPT) 

(Campinas, Brazil) 

Institute of 

Genetics, 

Uzbekistan 

N. G. Kholodny 

Institute of Botany, 

Ukrainian 

Academy of 

Sciences 

ODNRI (Overseas 

Development & 

Natural Resources 

Institute) 

M. S. 

Swaminathan 

Research 

Foundation India 

University of Al- 

Azhar (Egypt) 

Universidade 

Federal do Rio 

Grande do Sul 

(UFRGS) Brasil 

mycological services, 

publications and 

cultures 

mycological services, 

publications, cultures 

and training on 

databases 

collaborative 

agreement-identification 

of 

fungi, research, 

consultancy and 

project work in 

biosystematics 

collaborative 

agreement-exchange 

of 

specimens and 

cultures, training 

courses and staff 

exchanges 

research and cultures collaborative 

agreement 

mycological specimens 

and cultures, 

publications, 

geographical data and 

training 

consulting and advisory 

services in plant 

pathology 

research and training, 

especially in 

bioindicators and 

biomonitors 

RESEARCH & DEVELOPMENT: Systematic and applied bioscience 

PRODUCTS ON MARKET: Identification services 

Information services 

Contract research 

Consultancy 

Publications 

Fungal and bacterial cultures 

Training courses 


5/86 

8/90 

12/96 

collaborative 11/91 

agreementexchange 

of 

specimens and 

cultures, scientific 

data, training 

courses and staff 

exchanges 

staff support at IMI 1990 

collaborative 

agreementecosystem 

research, training 

courses in applied 

mycology and 

exchange of 

scientific data 

research and training collaborative 

agreement 

research and training collaborative 

agreement 

11/91 

3/93 

5/94



3443 Miguelito Court 

San Luis Obispo CA 93401, US 

Phone: (805) 541-5754; Fax: (805) 541-8301 


Web: www.calzyme.com; E-mail: iqbal@calzyme.com 

KEY PERSONNEL: Dr. Muzaffar Iqbal; Chairman, President and CEO 

Umer Iqbal; Director, R&D 

Usman Iqbal; Purchasing Manager 



FACILITIES: Production and research facility on more than 300 acres in Tulelake, Calif. 

European sales and research office in Croydon, England 


SUBSIDIARIES/DIVISIONS: Calzyme Laboratories Ltd. 

102-104 Park Lane 

Croydon, Surrey 

CRO 1JB, UK 

BUSINESS STRATEGY: Custom manufacture enzymes and related biochemicals 

PRODUCTS ON MARKET: Enzymes 

Proteins 

Coenzymes 

Substrates 

Related biochemicals 

Cambio Ltd. 

The Irwin Centre, Scotland Road, Dry Drayton 

Cambridge CB3 8AR, UK 

Phone: +44 (0)1954-210 200 

Fax: +44 (0)1954-210 300 

Web: www.cambio.co.uk; E-mail: support@cambio.co.uk 

KEY PERSONNEL: Peter Dean; Managing Director 

Bethy Booth.; Development Manager 

Shani Jamieson; Export Manager 

Margaret Fox; Office Manager 

Paula Cooper; Support 

Ian Rushton; Financial Manager 


HISTORY: Founded in 1986 as a division of Cambridge Life Sciences 

Acquired by management buyout in 1987 

IS09002 accreditation (1995) 

FACILITIES: Access to R&D laboratories and several production facilities 



Biontex entire range of products distribution 

agreement 

Biotech Support entire range of products distribution 

2001 

Group 

agreement 

BioVentures entire range of products distribution 

agreement 


1992


Epicentre 

Technologies 

Corp. (now 

Epicentre 

Biotechnologies 

Corp.) 

entire range of products distribution 

agreement 

Gene Bridges entire range of products distribution 

agreement 

Glen Research entire range of products distribution 

Corp. 

agreement 

Minerva entire range of products distribution 

agreement 

MoBio entire range of products distribution 

agreement 

Open Biosystems entire range of products distribution 

agreement 

Princeton 

entire range of products distribution 

Separations 

agreement 

University of STAR*FISH 

distribution 

Cambridge chromosome paints agreement 

RESEARCH & DEVELOPMENT: Developing novel DNA amplification and processing systems 

Contract antibody production 

PRODUCTS ON MARKET: Contract RNA and DNA production and technology transfer 

Products for DNA, RNA synthesis 

More than 3,000 antibodies 

Most restriction enzymes 

Most modification enzymes 

Most polymerases (DNA and RNA) 

Wide range of Chromosome Painting kits and DNA probes for various 

species 

Superior nucleic acid purification kits from MoBio 

Mycoplasma detection and elimination 

Extract protein by precipitation leaving DNA and RNA unaffected 

High quality tools required to unlock the functions of human genes and 

proteins and their relationships to disease development 

Gene regulation enzymes 

Plasmid extraction kits 

Cambrex Corp. 

One Meadowlands Plaza 

East Rutherford NJ 07073, US 

Phone: (201) 804-3000; Fax: (201) 804-9852 

Web: www.cambrex.com 

KEY PERSONNEL: James A. Mack; Chairman, CEO and President 

Luke M. Beshar; Exec. VP and CFO 

Paulo Russolo; President, Cambrex Profarmaco 

Shawn Cavanagh; Sr. VP and GM, Bioproducts 

Thomas N. Bird; VP, Business Development 

Dan Marshak, Ph.D.; VP and CTO, Biotechnology 

Ron D. Carroll, Ph.D.; VP and CTO, Pharmaceutical Technology 




Acquired BioWhittaker Inc. (1997) 

Acquired Bioproducts Division of FMC (1999) 

Acquired LumiTech (2000) 

Acquired Cambrex Biosciences (2001) 


1990 

2004 

1989 

2002 

1997 

2003 

2003 

1992


Cambrex France SARL acquired Genolife SA (10/04) 

Cambrex Bio Science Walkersville Inc. to acquire Cutanogen Corp. (as of 

2/06) 

STOCK-FINANCIAL HISTORY: NYSE--CBM 



Loss per share $0.49/share (YE 05) compared to $0.77/share (YE 04) 


04) 

SUBSIDIARIES/DIVISIONS: Cambrex Karlskoga AB 

Cambrex Charles City Inc. 

Cambrex North Brunswick Inc. 

Cambrex Landen NV 

Cambrex Cork Ltd. 

Cambrex Milan S.r.l. 

Cambrex France SARL 

Cambrex BioScience Baltimore Inc. 

Cambrex BioScience Hopkinton Inc. 

Cambrex BioScience Verviers s.p.r.l. 

Cambrex BioScience Walkersville Inc. 

Cambrex BioScience Wolkingham Ltd. 

Cambrex BioScience Nottingham Ltd. 

Cambrex BioScience Rockland Inc. 

Cambrex BioScience Copenhagen AB 

INVESTMENTS: Osiris--$5M 

Synthon Chiragenics--$3M 

BUSINESS STRATEGY: Maintain a position as a global, diversified life sciences company dedicated 

to essential products and services to accelerate drug discovery and 

commercialization for our pharmaceutical, biopharmaceutical, biotechnology 

and research customers 


Ortec International Orcel marketing and 10/04 

Inc. 

distribution 

agreement 

PRODUCTS ON MARKET: ApoGlow 

BioWhittaker® endotoxin detection products (LAL) 

BioWhittaker cell culture media, sera, buffers, reagents and antibiotics 

Clonetics® human cells and media 

Poietics human stem cells and media 

GelBond® film 

GelStar® nucleic acid gel stain 

I.D.NA® agarose 

InCert® agarose 

IsoGel® IEF plates 

Latitude® precast agarose gels 

Long Ranger®--DNA sequencing 

MetaPhor® agarose--DNA separation 

MDE gel solutions--mutation detection 

NuSieve® agarose--PCR separation 

PAGEr precast acrylamide gels 

ProSieve® protein separation 

Reliant® precast agarose gels 

SeaPlaque® agarose--DNA separation 

SeaKem® agarose--DNA separation 

SeaPrep® agarose 

SYBR® gel stains--nucleic acid detection 

SYPRO® gel stain--protein separation 

ViaLight 

Contract development and manufacturing services for small molecule APIs, 

biologics and cell therapies 




Natural Resources Canada, 580 Booth Street 

Ottawa KIA OE4, Canada 

Phone: (613) 947-7341; Fax: (613) 947-7397 

Web: www.nrcan.gc.ca/cfs-scf 

E-mail: info@nrcan.gc.ca/cfs-scf 

KEY PERSONNEL: Brian Emmett; Assistant Deputy Minister 

Geoff Munro; Director, General Sciences 




FACILITIES: Research centers in Victoria, BC; Edmonton, Alberta; Sault Ste. Marie, 

Ontario; Sainte-Foy, Quebec; and Fredericton, New Brunswick 


SUBSIDIARY OF: Natural Resources Canada 

BUSINESS STRATEGY: Mission: 

To promote the sustainable development of Canada's forests and 

competitiveness of the Canadian forest sector for the well-being of present 

and future generations of Canadians 

RESEARCH & DEVELOPMENT: Tree biotechnology and advanced genetics 

Pest management methods 

Environmental safety research 

PRODUCTS ON MARKET: Biopesticides 

Tissue cultures 

Diagnostic kits 


Biopesticides in development 

Gene isolation in development 

Genetic markers in development 

Tissue cultures and tissue culture protocols in development 

Diagnostic tools in development 


P.O. Box 1748 

North Battleford , Canada 

Phone: (306) 445-1077; Fax: (306) 446-0664 

Web: www.seedcoaters.com 

E-mail: kelly.ray@canadianseedcoaters.com 

KEY PERSONNEL: Kelly Ray; General Manager 

Lance Tokle; Assistant Manager 

EMPLOYEES: 35 employees (10 full-time/25 seasonal) 


FACILITIES: 50,000 sq. ft. building 


SUBSIDIARY OF: SeedVentures Inc. 

BUSINESS STRATEGY: Provide first-class coating technology and superior service 



PRODUCTS ON MARKET: Coatings: 

Chemseal® (talc based coating for canola) 

Chemgard (seed treatment with precise chemical application and 

dispersion) 

Rhizoseal® and Rhizoseal® Premium (talc based coatings for alfalfa and 

other legumes) 

Prill-On® (lime/phosphate coat for legumes and turf grasses) 

Nutriprill® (lime/phosphate coat for forage and native grasses) 


Chemseal Plus in field trials 

Cantest Ltd. 

Burnaby Life Sciences Centre, 4606 Canada Way 

Burnaby V5G 1K5, Canada 

Phone: (604) 734-7276; Fax: (604) 731-2386 


Web: www.cantest.com; E-mail: cantest@cantest.com 

KEY PERSONNEL: Donald B. Rix, M.D.; Chairman 

Don Enns; CEO and President 

Barbara Morrissey; Director, Forensic Equine Drug Testing Services 

Simon Mortimer-Lamb; Director, Finance 

Adrien Musuku, Ph.D.; Director, Research 

Steve Timuss; Director, Business Development 

David Gray, Ph.D.; Director, BioPharma Services 



Member of the CANAM Laboratories Group 

Acquired JB Laboratories Ltd. (6/04) 

Acquired SOILCON Laboratories Ltd. (4/04) 

Acquired Elemental Research Inc. (4/06) 

Acquired Vizon SciTec Inc. (8/06) 


SUBSIDIARIES/DIVISIONS: Offices in British Columbia, Manitoba and Ontario, and affiliates in Canada, 

the U.S. and southeast Asia 

BUSINESS STRATEGY: Operates as a full service laboratory that provides professional analysis and 

consultation for companies, governments and individuals in environmental, 

biotechnology, pharmaceutical, food safety and industrial hygiene related 

fields 


Cantest Ltd. has 

partnerships with 

Entech, Consolab 

and Prime Trials 

RESEARCH & DEVELOPMENT: Analytical services 

PRODUCTS ON MARKET: BioPharma services: 

GLP bioanalysis (including clinical bioanalysis and toxicokinetic bioanalysis) 

Drug discovery support 

Method development and validation 

Pharmacokinetic and bioequivalence studies 

Environmental services: 

Soil and water contamination 

Drinking water analysis 




Mobile/Field services 

Mold speciation and identification 

Food safety services: 

Nutrition labeling 

Food microbiology 

Pestices residues and hormones 

Nutraceuticals 

Industrial hygiene services: 

Air quality testing 

Bulk insulation identification 

Compressed breathing air testing 

Medical gas inspection and certification 

Mold speciation and identification 

Equipment rentals 

Forensic equine drug testing services: 

Racetrack drug testing 

Horseshow drug testing 

Pre-purchase screening 

Research and development 

8137 Forsythia Street, PO Box 620160 

Middleton WI 53562, US 

Phone: (608) 824-9920; Fax: (608) 824-9930 

Web: www.gala.com 

E-mail: galainfo@cardinal.com 

KEY PERSONNEL: Paul Weiss, Ph.D.; President and CEO 

Boh Branflick; CFO 

Mike Jenkins; Director, Commercial Operations 

EMPLOYEES: 40+ employees, 16 Ph.D.s 

HISTORY: Founded and began biotech R&D in May 1996 

Changed name from Gala Biotech 



SUBSIDIARY OF: Cardinal Health 

PRINCIPAL INVESTORS: Cardinal Health 

BUSINESS STRATEGY: To partner with clients with protein expression needs 


Cambridge 

cell line engineering 5/05 

Antibody 

Technology 

collaboration 

RESEARCH & DEVELOPMENT: Post-genomic protein expression 

Novel gene product expression 

High-throughtput gene product screening 

Manufacture scale-in mammalian cells 

Mammalian cell line production and cGMP manufacture 


Several development-stage products various stages 


Cargill Inc. 


P.O. Box 9300 

Minneapolis MN 55440-9300, US 

Phone: (952) 742-7575 

Web: www.cargill.com; E-mail: public_relations@cargill.com 

KEY PERSONNEL: Warren R. Staley; Chairman and CEO 

Gregory R. Page; President and COO 

Robert L. Lumpkins; Vice Chairman 

Guillaume Bastiaens; Vice Chairman 

William Veazey; Sr. VP, CFO 

David M. Larson; Exec. VP 

Robbin S. Johnson; Sr. VP, Director of Corporate Affairs 

David W. Rogers; Sr. VP 

Ronald L. Christenson; Corp. VP and CTO 


HISTORY: Founded in 1865 as a single grain elevator. Now operates more than 1,000 

facilities in 61 countries. 

Acquired ingredients operations operations of Degussa AG (2005) 



Net earnings $2.103b (YE 05) compared to $1.331b (YE 04) 


SUBSIDIARIES/DIVISIONS: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada, 

Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed & 

Processing (joint venture) 

Food ingredients and applications: Food Ingredients North America (Cargill 

Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry 

Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils, 

Cargill Sweeteners North America, Horizon Milling (joint venture with CHS 

Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food 

Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global 

Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill 

Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia, 

Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food 

Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur, 

Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America, 

Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food 

System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food 

& Pharma Specialties North America, Cargill Health & Food Technologies 

(HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef 

Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor 

Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill 

Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley 

Europe, Sun Valley Foods Canada, Sun Valley Thailand) 

Industrial: Agricultural Feedstocks (Cargill Dow (joint venture), Cargill 

Industrial Oils & Lubricants), Steel, Fertilizer (Cargill Fertilizantes Brazil, 

Cargill Phosphate Production, Saskferco (joint venture)), Salt (Cargill Salt, 

Cargill Deicing Technology) 

Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply 

Chain, Cargill Sugar 

Risk Management and Financial: Black River Asset Management LLC, 

Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum, 

Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade & 

Structured Finance, Cargill Value Investment, Cargill Ventures 



INVESTMENTS: Joint venture with Monsanto Co. to use biotechnology to improve feed for 

pigs, cattle, poultry and fish (5/98) 

BUSINESS STRATEGY: Provide food, agricultural and risk management products and services 


Bayer Crop 

alliance to produce 1/05 

Science 

high stability 

specialty canola 

Kansas Polymer soy-based polyols for joint research 8/03 

Research Center 

(Pittsburg State 

University, KS) 

the urethane industry agreement 

Metamorphix exclusive 

agreement with 

Caprock Cattle 

Feeders and Excel 

Corp., both part of 

Cargill, to develop 

genomic selection 

tools for 

consistency and 

tenderness 

11/02 

Monsanto Co. Vistive low-linolenic participating 10/05 

soybeans and marketer processor of 

of Vistive oil 

VISTIVE 

soybeans and 

marketer of 

VISTIVE oil 

Mycogen Corp. NatureGard hybrid seed distribution 

9/95 

(now Mycogen corn with Bt-based agreement under 

Seeds) 

insect resistance Mycogen brand 

Zeneca Mogen fungal resistant canola licensing 

3/96 

and sunflower varieties, 

Binary Vector System 

for genetic 

transformation of crop 

plants 

agreements 

RESEARCH & DEVELOPMENT: Fermentation systems and enzyme applications 

Biobased urethane polyols 

PRODUCTS ON MARKET: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada, 

Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed & 

Processing (joint venture) 

Food ingredients and applications: Food Ingredients North America (Cargill 

Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry 

Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils, 

Cargill Sweeteners North America, Horizon Milling (joint venture with CHS 

Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food 

Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global 

Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill 

Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia, 

Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food 

Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur, 

Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America, 

Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food 

System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food 

& Pharma Specialties North America, Cargill Health & Food Technologies 

(HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef 

Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor 

Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill 

Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley 

Europe, Sun Valley Foods Canada, Sun Valley Thailand) 


Ceapro Inc. 


Industrial: Agricultural Feedstocks, NaturedWorks, LLC, Cargill Industrial 

Oils & Lubricants (Cargill Industrial Bioproducts), Steel, Fertilizer (Cargill 

Fertilizantes Brazil, Cargill Phosphate Production, Saskferco (joint venture), 

Salt (Cargill Salt, Cargill Deicing Technology) 

Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply 

Chain, Cargill Sugar 

Risk Management and Financial: Black River Asset Management LLC, 

Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum, 

Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade & 

Structured Finance, Cargill Value Investment, Cargill Ventures 

Suite# 1008 RTF, University of Alberta, 8308 - 114 Street 

Edmonton T6G 2E1, Canada 

Phone: (780) 421-4555; Fax: (780) 421-1320 

Web: www.ceapro.com 

E-mail: info@ceapro.com 

KEY PERSONNEL: Edward Taylor; Chairman 

Dr. Mark Redmond; President and CEO 

Laurie Lanuke; Manager, Customer Service and Logistics 

Diana Shaw, Ph.D.; Manager, Business Development 

Sarah Lord; Ph.D.; Manager, Clinical Affairs 

Shawn McMillan; VP, Finance and CFO 

David Fielder; VP, Scientific Affairs 



Acquired Minera Animal Health (1996) 

Amalgamated Vexco Healthcare (12/96) 



STOCK-FINANCIAL HISTORY: TSX Venture Stock Exchange--CZO 

IPO--C$10M (1/97) 


Net income (YE 05) compared to (YE 04) 

Earnings per share /share (YE 05) compared to 

(YE 04) 

PRIVATE PLACEMENTS: Raised $16M in private placement (9/96) 

Raised $4M in private placement (1/97) 

Raised $2.1M in private placement (10/98) 


Raised $204.8K from private placement of 683K units at $0.30/unit (3/05) 

Raised $1.3M in financing (12/05) 

BUSINESS STRATEGY: Extract natural ingredients from cereal crops and formulate into products for 

cosmetics and human or veterinary pharmaceutical industries 

Use strategic alliances for distribution and marketing 


Alberta Wheat oats strategic alliance-- 2/97 

Pool 

Ceapro has 

exclusive 10-year 


with AWP, AWP to 

make $4M equity 

investment with 

option to invest 

$2M in next year 



Aventix Veterinary dermal for veterinary 

(Canada) 

applications 

Canderm Pharma Lipsorex exclusive licensing 

Inc. 

agreement--Ceapro 

to get royalties on 

sales 

Daisen Sangyo dermal for veterinary marketing 

Ltd. (Japan) applications 

agreement 

McCarthy & Sons dermal for veterinary marketing 

(Canada) 

applications 

agreement 

Nutrinova oat extracts for food letter of intent 

industry 

regarding 

marketing 

agreement 

Pharmavet (UK) dermal for veterinary 

applications 

Veterinary dermal for veterinary marketing 

Marketing 

Network 

(Australia/New 

Zealand) 

applications 

agreement 

RESEARCH & DEVELOPMENT: Functional foods and nutraceutidals 

Dermal and wound care 

Diabetes tests and medical foods 

Immune system stimulants 

Therapeutic shampoos 

CeaProve® kit for pets 

PRODUCTS ON MARKET: ACTIVE INGREDIENTS: Beta glucan, colloidal oat extract, oat oil 

VETERINARY THERAPEUTICS: Oat Shampoo, ear cleanser, dermal 

complex 

AccuScreen - tool for identification of type II diabetes and pre-diabetes 


Immune stimulant (veterinary) in preclinicals 

Topical non-steroidal anti-inflammatory in preclinicals 

Hot spot treatment in Phase I clinicals (veterinary) 


Suite 15, Lyndon House, Kings Court 

Newmarket CB8 7SG, UK 

Phone: +44 (0) 1638 600 151; Fax: +44 (0) 1638 600 160 

Web: www.celsis.com; E-mail: info@celsis.co.uk 

KEY PERSONNEL: Jack Rowell; Chairman 

Jay Lecoque; CEO 

Christian Madrolle; Finance Director and Company Secretary (U.K.) 



Celsis floated on LSE in June 1993 

Celsis acquired Lumac in September 1996 

Acquired SAI (contract testing laboratory in St. Louis, MO) for £4.4M (10/97) 

Acquired In Vitro Technologies Inc. (IVT) (8/06) 

STOCK-FINANCIAL HISTORY: London Stock Exchange (LSE)--CEL 

IPO--£90M (9/96) 

Turnover $30.4M (YE 05) compared to $27.595M (YE 04) 

Profit $5.75M (YE 05) compared to $4.83M (YE 04) 

Earnings per share 6.83cents/share (YE 05) compared 6.04cents/share (YE 

04) 

Net assets $33.468M (YE 05) compared to $27.209M (YE 04) 


8/04 

6/98 

9/96 

12/99 

12/99 

10/05 

12/99


PRINCIPAL INVESTORS: Barclays Global Investors 

Barclays Personal Investment Management 

Cavendish Asset Management 

Comdirect 

Fidelity Investments 

Gartmore Investment Management 

Insight Investment Management 

M&G Investment Management 

SG Asset Management 

BUSINESS STRATEGY: Research, develop and manufacture diagnostic kits and instrumentation for 

the rapid detection of microorganisms and provide laboratory testing 

services 


U.K. 

Adenylate Kinase Assay technology license 1/98 

Government's 

Defense 

Evaluation and 

Research Agency 

Technology 

agreement 

RESEARCH & DEVELOPMENT: Rapid microbiology methods for enumeration, identification and toxicity 

measurements 

PRODUCTS ON MARKET: Pharmaceutical, personal care and beverage test kits 

Advance, Advance coupe and CellScan Innovate luminometers 

Centre for Innovative Biology and 

Environmental Technology 

Chelammotil Building, National Highway 47, Ambattukavu 

Aluva-6, Kerala, Kochi 683106, India 

Phone: +91 484-2631135; Fax: +91 484-2682557 

Web: www.cibet.org; E-mail: info@cibet.org 

KEY PERSONNEL: P. Sunil Kumar; CEO 

Sabu Abdulhameed, Ph.D.; President 

G. Nagendra Prabhu, Ph.D.; Exec. VP and Director, R&D 

Jayachandran K., Ph.D.; Exec. VP 

Rajeev K. Sukumaran, Ph.D.; Sr. Scientist 

Swapna TS, Ph.D.; Sr. Scientist 



Began biotech R&D in October 2005 


BUSINESS STRATEGY: Transfer scientific know-how in to viable eco-friendly technologies 


Ceres Inc. 


1535 Rancho Conejo Blvd. 

Thousand Oaks CA 91320, US 

Phone: (805) 376-6500 

Web: www.ceres.net 

E-mail: info@ceresbiotechnology.com 

KEY PERSONNEL: Walter De Logi; Chairman 

Dr. Richard Hamilton; CEO 

Dr. Patrick McCroskey; CFO 

Dr. Richard Flavell; CSO 

Dr. Anne-Marie Bouckaert; Sr. VP, Technology Planning, Protection and 

Acquisition 

Ms. Wilfriede van Assche; Sr. VP, General Counsel and Secretary 

Dr. Kenneth Feldmann; VP, Agricultural Genomics/Trait Development 

Dr. Peter Mascia; VP, Product Development 

Dr. Steven Bobzin; Director, Natural Products Chemistry 

Dr. Roger Pennell; Director, Trait Development 

Anna Rath; Director, Business Development 

Dr. Steven Thomas; Director, Bioproducts 




PRINCIPAL INVESTORS: Ambergate Trust 

Artal Luxembourg SA 

GIMV NV 

Hambrecht & Quist Capital 

KBC Bank & Insurance Group 

Monsanto Co. 

Oppenheimer International Growth Fund 

Oxford Bioscience Partners 

QuestMark Partners LP 

Soros Private Equity Partners 

BUSINESS STRATEGY: Develop energy crops such as switchgrass, miscanthus and poplar for 

cellulosic ethanol 

Leverage its technologies into established markets through strategic 

partnerships 


Agricultural improvement of 

CRADA 2/06 

Research Service switchgrass genetics 

(ARS) at the 

United States 

Department of 

Agriculture 

through biotechnology 

Aurora 

Aurora's fluorescent licensing 

10/00 

Biosciences Corp. protein technology for 

use in agricultural 

applications 

agreement 

Genset agricultural genetics alliance 1/98 

Monsanto Co. application of genomics discovery and 4/02 

technologies to provide development 

improvements in certain 

agricultural crops 

collaboration 

Oregon State use of genomics to collaboration 9/05 

University 

enhance biomassmediated 

carbon 

sequestration 

agreement 



The Institute for 

Genomic 

Research (TIGR) 

The Samuel 

Roberts Noble 

Foundation Inc. 

University Of 

California 

identification of the 

structure of genes and 

their encoded proteins 

in the chromosomes of 

the plant species 

Arabidopsis thaliana 



new, advanced biomass 

crops for fuel ethanol 

production 

collaboration 

agreement 

long-term 

collaboration 

Plant Genetics 

Partnership 

RESEARCH & DEVELOPMENT: Technology platforms: 

-Sequencing and cDNAs: Generation and sequencing of full-length cDNA 

-Computational biology: EST/cDNA/protein clustering, Ockham gene 

prediction, high-throughput functional annotation and expression data 

analysis 

-Promoters: Computational programs and a transcription profiling database 

to identify and analyze novel plant promoters or promoter elements in DNA 

sequences for trait development, enhancer-trap system for finding useful 

promoters 

-Functional genomics: Sequencing of full-length cDNAs; assessment of the 

concentrations of mRNAs in extracts from plant tissues; evaluation of plants 

with known genes silenced by insertions within them; studies on plants with 

new, defined genes inserted into them; screens to find plants with improved 

phenotypes; characterization of promoters to determine where and when 

they program gene expression and systems to epigenetically change gene 

structure and activity; and computational biology analyses of genes 

-Metabolites: Metabolic profiling platform to provide plants with optimized 

levels and kinds of metabolites for functional foods, pharmaceutical 

discovery, feed quality and extractable sources for use in other products 

-Genetic confinement: Technology for genetically confining a crop by 

eliminating viable seeds and/or pollen 


Trait development platform 

Switchgrass (Panicum virgatum) genomics program for enhancing biomass 

yield, completed analysis of more than 12,000 switchgrass genes and 

characterized the genetic variation associated with them (7/06) 

Institute of Research and Development 

Birmingham Research Park, Vincent Drive, Birmingham 

Edgbaston B15 2SQ, UK 

Phone: +44 (0)121 414 7029 

Web: www.chembiotech.co.uk 

E-mail: enquiries@chembiotech.co.uk 

KEY PERSONNEL: Prof. John F. Kennedy, Ph.D.; Director 

C. J. Knill, Ph.D.; CSO 


HISTORY: Founded in 1977 to provide R&D and consultant services and product 

development in chemistry, biotechnology, biochemistry and medical devices 

FACILITIES: Laboratories and offices in the University of Birmingham Research Park 



12/00 

6/06 

4/00


BUSINESS STRATEGY: Deliver world-class contract research and development, and technical and 

consultancy services that provide effective and cost-efficient solutions to all 

our clients in the areas of, biotechnology, chemistry and biochemistry of 

carbohdyrates, proteins and medicine 

RESEARCH & DEVELOPMENT: Cellulose and starch 

Characterization/modification and design/synthesis of biologically active 

derivatives 

Enzyme immobilization and glycoprotein characterization 

Avoidance methods for river/sea water pollution by carbohydrates 

Use of by-products from milk and seaweed industries 

Waste water treatment 

Downstream processing 

Novel developments in starch and paper industries 

Wound management compounds 

Slow release pharmaceuticals 

Chromatography--HPLC, GPC, GC, GC-MS 

Starch chemistry and biotechnology 

Drug contamination detection 

Food components--evaluation analysis 

On-site assessments, trouble shooting, surveys and verificaiton 


Hylauronan-based products in development 

Wound management materials in development 

Chemeq Ltd. 

3 Brodie Hall Drive, Technology Park 

Bentley WA 6102, Australia 

Phone: +61 8 9362 0100; Fax: +61 8 9355 0199 

Web: www.chemeq.com.au 

E-mail: info@chemeq.com.au 

KEY PERSONNEL: John Hopkins; Chairman 

David Williams; CEO 

Brian Mangano; CFO 



FACILITIES: Pharmaceutical production facility in Rockingham, Australia 

STOCK-FINANCIAL HISTORY: Austalian Stock Exchange--CMQ 

IPO--$3.5M (8/99) 

Revenue $1.1M (YE 05) compared to $905.177K (YE 04) 


Loss per share (YE 05) compared to 

(YE 04) 


BUSINESS STRATEGY: Focus on its core competencies and pursue further commercialization of its 

intellectual property and products through strategic partnerships 

PRODUCTS ON MARKET: Chemeq® polymeric antimicrobial (for pigs) 

Chemeq® polymeric antimicrobial (for poultry) 




33 Industrial Way 

Wilmington MA 01887, US 

Phone: (978) 694-4503; Fax: (978) 694-4502 


Web: www.chemgenes.com; E-mail: enquiries@chemgenes.com 

KEY PERSONNEL: Suresh Srivastava, Ph.D.; President 




FACILITIES: Combined R&D and manufacturing facilities 


BUSINESS STRATEGY: Form strategic alliances to develop key DNA-based diagnostics for various 

diseases and DNA-based antisense therapeutics 

RESEARCH & DEVELOPMENT: Antisense DNA-based therapeutics for AIDS 

PRODUCTS ON MARKET: DNA and RNA phosphoramidites 

Antisense phosphoramidites 

Modified base phosphoramidites 

Chromophores and ligands 

Nucleosides 

Reagents for oligosynthesis 

Ancillary reagents 

Solid supports and prepacked columns for DNA/RNA synthesis 


9015 West Maple Street 

Milwaukee WI 53214, US 

Phone: (414) 607-5700; Fax: (414) 607-5959 


Web: www.chr-hansen.com 

E-mail: chr-hansen@info-chr-hansen.com 

KEY PERSONNEL: David R. Carpenter; President and CEO 

Don Cox; Sr. VP, Sales 

Dr. Jeff Kondo; Sr. VP of R&D 



STOCK-FINANCIAL HISTORY: Parent company listed on Danish Stock Exchange 

SUBSIDIARY OF: Chr. Hansen A/S 

BUSINESS STRATEGY: To improve the quality of food and health for people all over the world 


Integrated 

Integrated Genomics' licensing 

12/04 

Genomics Inc. ERGO database and 

genomic discovery 

system 

agreement 

RESEARCH & DEVELOPMENT: Ingredients for dairy, food and beverage, meat and prepared foods, and 

products for food safety, human health and nutrition and animal health and 

nutrition 



PRODUCTS ON MARKET: Dairy, probiotic, meat and wine cultures 

Cheese coagulants 

Colors 

Flavors 

Seasonings 

Sweeteners 

Natural food safety products 

Pharmaceutical coatings and excipients 

Silage inoculants 

Direct fed microbials 

Chunghwa Chemical Synthesis & 

Biotech Co. Ltd. 

1 Tung-Hsing St., Shu-Lin 238, Hsien 

Taipei, Taiwan 

Phone: 886-2-8684-3318; Fax: 886-2-8684-3202 

Web: www.ccsb.com.tw; E-mail: ccsb@ccsb.com.tw 

KEY PERSONNEL: Derek Wang; Chairman 

Dr. Steve Chang; President 



Founded Pharmaports LLC (1999) 

FACILITIES: 8.7 acre manufacturing site 

Pilot lab equipped with 100 liter and 250 liter glass reactors, a 75 liter 

stainless reactor, 5 liter and 100 liter glass-lined reactor fors scale-up 

activities and process validation 

Pilot lab equipped with three 20 litre and a 600 litre fermentor for scale-up 

study and process validation 


SUBSIDIARIES/DIVISIONS: U.S. sales office: 

Pharmaports LLC 

160 Summit Ave. 

Montvale, NJ 07645 

Phone: (201) 391-3336 


Fax: (201) 391-8811 

E-mail: info@pharmaports.com 

SUBSIDIARY OF: China Chemical Pharmaceutical Group 

BUSINESS STRATEGY: Bulk manufacture of pharmaceuticals Taiwan 

RESEARCH & DEVELOPMENT: Products in pipeline: Tacrolimus, Rosuvastatin, Fluvastatin, Lansoprazole, 

Perindopril, Terbinafine and Trandolapril 

Key technologies: Friedel crafts acetylations, alkylations, chiral resolutions, 

hantzsch pyridine synthesis, dehydration, reduction/oxidation, 

addition/substitution, ammonolysis, decarboxylation, genetic engineering, 

strain improvement, microbial fermentation, cell culture, protein purification, 

enzyme immobilization, bio-conversion and impurity analysis 

Activities include: Development of innovative and cost-effective 

manufacturing processes, custom manufacturing for pharmaceutical 

intermediates and bulk pharmaceuticals, collaborating with major 

universities and research institutes for technical supports, analysis of 

impurity profiles for DMFs, development of innovative and cost-effective 



manufacturing processes for high value metabolites, recombinant proteins 

and enzymes, contract research and custom manufacturing for bio-products 

and pharmaceutical intermediates, quality/regulatory testing and release all 

raw materials, packaging materials, and final products, provision of 

manufacturing operations support across operating units and product lines, 

technology transfer and scale-up activities 

PRODUCTS ON MARKET: Pharmaceutical bulk products: 

ANALGESIC/NSAIDS: Acetaminophen, Bucetin, Oxaprozin 

ANTI-ANXIETY AGENTS: Alprazolam, Fluoxetine 

ANTIHYPERGLYCEMICS: Glipizide, Glibenclamide, Moclobemide 

LAXATIVE: Calcium Polycarbophil 

ANTIFUNGAL: Fluconazolel 

ANTIHISTAMINE: Dexbrompheniramine Maleate 

ANTISEPTIC: Benzalkonium Chloride 50% 

CARDIOVASCULAR: Nifedipine 

EXPECTORANT: Guaifenesin 

ANTILIPEMIC AGENT: Pravastatin Sodium 

MUSCULOSKELETAL RELAXANTS: Methocarbamol, Carisoprodol 

EXCIPIENT: Sodium Starch Glycolate 

IMMUNOSUPPERSSIVE AGENTS: Mycophenolate Mofetil, Rapamycin 

Codexis Inc. 

200 Penobscot Drive 

Redwood City CA 94063, US 

Phone: (650) 980-5600; Fax: (650) 298-5449 

Web: www.codexis.com; E-mail: tassos.gianakakos@codexis.com 

KEY PERSONNEL: Tom Baruch; Chairman 

Alan Shaw, Ph.D.; President and CEO 

Robert S. Breuil; Sr. VP, Finance and CFO 

John Grate, Ph.D.; Sr. VP, R&D and CTO 

Tassos Gianakakos; Sr. VP and Head, BU Pharmaceuticals 

David Walshaw; VP, Operations 

Peter Seufer-Wasserthal, Ph.D.; VP and GM, Codexis Enzymes & 

Intermediates 

Gregory Rocklin; VP and Head, BU Generics 


HISTORY: Started as the chemicals business unit of Maxygen (since 1997) 

Founded in February 2002 

Private spin-out from Maxygen (2004) 

Acquired Julich Fine Chemicals GmbH (2/05) 

Acquired assets and IP from Enzis BV (4/06) 



PRIVATE PLACEMENTS: Raised $25M in private financing (10/02) 

Raised $37M in Series D financing (8/06) 

SUBSIDIARIES/DIVISIONS: Julich Chiral Solutions GmbH--independent, wholly-owned subsidiary 

SUBSIDIARY OF: Maxygen Inc. (see separate entry) 

PRINCIPAL INVESTORS: Bio*One Capital Pte Ltd. 

ChevronTexaco Technology Ventures 

CMEA Ventures 

Maxygen Inc. 

Pequot Ventures 

BUSINESS STRATEGY: Develop innovative bio-based solutions for pharmaceutical chemical process 

development and manufacturing 




Arch Pharmalabs use of 


Ltd. 

MolecularBreeding manufacturing 

technology in 

manufacturing 

compound 

agreement 

Bristol-Myers pharmaceutical process research 

5/05 

Squibb Co. research 

agreement, 

extended 1/06 

Cargill Dow LLC novel synthesis for development 2002 

Cargill Dow's 

NatureWorks PLA 

(polylactide) 

agreement 

Chevron 

novel bioprocesses for three-year 

10/02 

Research and specific petrochemical development 

Technology Co. products 

agreement 

Eli Lilly & Co. improved fermentations development 12/02 

for Lilly’s natural 

product drugs 

agreement 

Gist-brocades NV development of novel three-year research 3/99 

(subsidiary of enzymes for the and licensing 

DSM NV) 

manufacture of penicillin 

antibiotics 

agreement 

Matrix 

API for a high-value development and 6/05 

Laboratories Ltd. pharmaceutical product commercialization 

agreement 

Novozymes development and bulk five-year strategic 9/97 

production of specific 

industrial enzymes in 

fields of laundry 

detergents, leather 

processing and pulp 

and paper 

manufacturing, among 

others 

collaboration 

Pfizer Inc. biochemical 

extension of 5/98 9/00 

manufacturing of 

undislcosed 

pharmaceutical product 

agreement 

Pfizer Inc. pharmaceutical life 

cycle management 


Sandoz process for the 

production of a key 

fermented active 

pharmaceutical 

Schering-Plough 

Corp. 

Shasun 

Chemicals and 

Drugs Limited 

Teva 


Industries Ltd. 

compound of Sandoz 

development of a 

synthetic process for 

Schering-Plough 


intermediate for a 

generic drug 

improved processes for 

manufacturing of an 

undisclosed 

pharmaceutical product 

using Codexis' 

MolecularBreeding 

directed evolution 

platform 

development 

agreement 

research 

agreement 



research 

collaboration 

agreement 


10/03 

3/06 

5/05 

12/04


RESEARCH & DEVELOPMENT: Codexis' technology platforms can rapidly generate biocatalysts with desired 

commercial properties. The biocatalysts usually fall into two categories: 

enzymes and fermentation strains. The technology platforms used to 

develop the biocatalysts include MolecularBreeding directed evolution and 

WGShuffling strain development. The technologies can be used to: 

-Develop low-cost, efficient catalysts with improved performance for the 

synthesis of complex molecules 

-Develop improved chemical production organisms in less than the typical 

process development time 

-Develop proprietary syntheses of high-value chemicals by integrating 

chemistry and biology in new ways 

-Develop alternative synthesis technologies and intellectual property for use 

by pharmaceutical and generic companies in life cycle management, can be 

used to create new patents 

-Demonstrate the validity of the technology for multiple applications at 

relevant commercial scale 

PRODUCTS ON MARKET: ThoroughBred biocatalysts 

ThoroughBred cell lines 

Active pharmaceutical ingredients 


More than 15 products and processes in 

the pipeline, with two products in advanced 

development 


One Kendall Square, Building 300, Third Floor 


Phone: (617) 995-7999; Fax: (617) 995-7970 

Web: www.codondevices.com 

E-mail: info@codondevices.com 

KEY PERSONNEL: Noubar Afeyan; Chairman 

John Danner; CEO and President 

Brian Baynes; CSO 

Craig D. Muir; Sr. VP, Technical Operations 

Jennifer Camacho; VP, Intellectual Property and Chief Patent Counsel 

Michael J. Fitzpatrick; VP, Sales 




PRINCIPAL INVESTORS: Flagship Ventures 

Alloy Ventures 

Kleiner Perkins 

Vinod Khosla 

BUSINESS STRATEGY: Provide engineered devices for molecular biology research, improve cell 

engineering for the production of high value chemicals and engineer 

biotherapeutics 

RESEARCH & DEVELOPMENT: Molecular biology: Construction of comprehensive sets of genetic reagents 

for basic research and development and in the area of structural/functional 

genomics, the construction of codon optimized, expression-ready clones 

and designed variants for protein studies 

Pharmaceutical: Improved therapeutic protein development, such as 

engineering therapeutic proteins to improve properties such as stability, 

potency, binding affinity and immunogenicity; natural and engineered 

therapeutic production, such as rapidly developing cell lines to explore 

biosynthetic pathways for improved performance and cost; rapid response 

vaccines, such as rapidly obtaining putative antigen genes, optionally 



coupled to adjuvants, for pandemic and seasonal vaccine development 

Industrial biotech and bioenergy: Focus is on the development of enzymes 

with improved properties, including stability, specificity and catalytic 

efficiency, as well as engineering cell lines to produce large amounts of 

specialty and commodity chemicals from renewable feed stocks 

Agriculture: Precision trait engineering, the enhancement of plant genetic 

traits by engineering at the kilobase- to megabase-scale - more efficiently 

than traditional breeding 

PRODUCTS ON MARKET: Constructed clones and custom vectors 

Constructed variant libraries 

Constructed operons and operon variant libraries 

Genomic engineering 

CombiMatrix Corp. 

6500 Harbour Heights Parkway, Suite 301 

Mukilteo WA 98275, US 

Phone: (425) 493-2000 

Fax: (425) 493-2010 

Toll-free phone: (800) 985-CBMX 

Web: www.combimatrix.com 

E-mail: info@combimatrix.com 

KEY PERSONNEL: Amit Kumar, Ph.D.; President and CEO 

Brooke Anderson, Ph.D.; COO 

John Besser; CFO 

Jeffrey Oster, Ph.D.; Sr. VP, Intellectual Property 

Scott Burell; VP, Finance 

H. Sho Fuji; VP, Engineering and Production 

Andy McShea, Ph. D.; VP, Biology and Chemistry 


HISTORY: Incorporated in 1999 

FACILITIES: Headquarters and R&D facilities in Mukilteo, Wash. 

STOCK-FINANCIAL HISTORY: Privately held by parent (NASDAQ--CBMX) 

SUBSIDIARIES/DIVISIONS: Acacia Technologies Group 

CombiMatrix Molecular Diagnostics Inc. 

SUBSIDIARY OF: Acacia Research Corp. 

BUSINESS STRATEGY: Leverage strengths in technology, innovation and product development by 

establishing partnerships for commercialization. CombiMatrix seeks 

partnerships with organizations that have well-developed infrastructure for 

manufacturing, sales and distribution. By combining the strengths of our 

technologies with the distribution and manufacturing capabilities of partners, 

CombiMatrix seeks to successfully develop and introduce industry-leading 

products into the life science research, industrial and biothreat markets 


Benitec Ltd. Benitec IP related to cross-licensing and 2/05 

pools of siRNAs as collaboration 

therapeutic agents for 

viral diseases, 

CombiMatrix sequences 

targeting HIV 

agreement 

BioDesign peptide array 


Institute at Arizona 

State University 

synthesizer 

agreement 



Case Western 

Reserve 

University 

novel diagnostic for 

Alzheimer's disease 

Cell Sciences Ltd. CombiMatrix products 

and services in 

Singapore 


nonexclusive 

distribution 

agreement 


12/05 

Cyrano Sciences chemical sensors R&D agreement 1/04 

InBio CombiMatrix’s 

distribution 

1/05 

CustomArray 

microarray products in 

Australian and New 

Zealand 

agreement 

Inter Medical CustomArrays products non-exclusive 5/05 

in Japan 

distribution 

agreement 

J.K. International CustomArray 

distribution 

7/05 

Inc. 

microarray products in 

Japan 

agreement 

Novavax technique for in-process development 11/05 

monitoring of vaccine 

production 

agreement 

Oklahoma State influenza virus 


University 

therapeutics 

Prisma Biotech CombiMatrix products in distribution and 4/06 

Corp. 

Taiwan, China and manufacturing 

other countries 

agreement 

Seattle Biomedical 

Research Institute 

St. Jude 

Children's 

Research Hospital 

STMicroelectro- 

RNAi compounds for 

gene regulation 

research 

Influenze A virus 

therapeutics 

nics 

point-of-care diagnostic 

products 

Toppan Corp. electrochemical 

detection microarrays 

and products 

U.S. Army Medical environmental and 

Research Institute medical detection of 

of Infectious 

Diseases 

biothreat agents 

U.S. Department custom microarrays for 

of Defense biothreats 

VWR International CustomArrays and 

Inc. 

CatalogArrays 

Washington chemical synthesis of 

University 

non-nucleic acid 

molecules 

RESEARCH & DEVELOPMENT: RNAi introduction 

Systems biology for drug discovery research 



co-development 

agreement 

6/05 




global distribution 

agreement 

9/05 


PRODUCTS ON MARKET: CombiMatrix CustomArray chip 

RNAi Express Track program 

Nanotechnology/Materials Development Product Service 

Biothreat Detection Technology 


Ongoing custom array programs various stages of progress



Kettock Lodge, Campus 2, Aberdeen Science Park, Bridge of Don 

Aberdeen AB22 8GU, UK 

Phone: +44 (0) 1224-706-062; Fax: +44 (0) 1224-706-012 

Web: www.microbio-centre.co.uk 

E-mail: info@commercialmicrobiology.com 

KEY PERSONNEL: Dr. Stephen Maxwell; Managing Director 

Iain Spark; Consultant 

Lisa Graham; Financial Controller 

Lucille Harries; Chemist 




SUBSIDIARIES/DIVISIONS: Commercial Microbiology Inc. 

1764 West Sam Houston Pkwy. N. 

Houston, TX 77043 

Phone: (713) 974-1211 

Fax: (713) 974-3636 

Email: infousa@commercialmicrobiology.com 

BUSINESS STRATEGY: Offer analytical solutions to problems and processes involving 

microbiological growth 

RESEARCH & DEVELOPMENT: Bacteria in hostile environments 

PCR applications in environmental testing 

Optimization of bacterial growth media 

PRODUCTS ON MARKET: Food and hygiene testing and services, hygiene test kits, sampling 

consumables, equipment for hire, energy/oilfield testing and services, 

bacterial growth media / test kits, dipslides, Sidestream®, environmental 

testing and services 

Cornell Institute for Biotechnology and 

Life Science Technologies 

KEY PERSONNEL: Kelvin Lee; Director 


Cornell University, 130 Biotechnology Building 

Ithaca NY 14853-2703, US 

Phone: (607) 255-2300; Fax: (607) 255-6249 

Web: www.biotech.cornell.edu; E-mail: nyscat@cornell.edu 


New York State Office of Science, Technology and Advanced Research 

(NYSTAR) designated Center for Advanced Technology ; Cornell Center for 

Life Science Enterprise 

FACILITIES: Service laboratories-- plant tissue culture and transformation; fermentation; 

computing and computational biology; confocal microscopy, imaging, and 

fluorimetry; DNA sequencing and genotyping; mouse transgenics; 

microarray; proteomics and mass spectrometry; flow cytometry; protein 

production and characterization 

STOCK-FINANCIAL HISTORY: Partnership of Cornell University, government and industry 



BUSINESS STRATEGY: The Institute emphasizes technology, people, and research involved in the 

life sciences. The Center marries the diversity, discovery, and knowledge 

base of Cornell University with the jobs, innovation, and impact of NewYork 

State businesses. The result is a diverse portfolio of projects and expertise 

that positively impacts human and animal health, agriculture, and the 

environment, and leads to economic growth and job creation in New York. 

RESEARCH & DEVELOPMENT: Agricultural and environmental biotechnology 

Biochemistry and biophysics 

Computational biology 

Diagnostics and detection technologies 

Genomics and proteomics 

Health care and biomedical engineering 

Nanobiotechnology 

Science education and public policy 


Toyo-Ekimae Bldg., 2-20, Toyo 2-Chome, Koto-ku 


Phone: +81 3-5632-9617; Fax: +81 3-5632-9618 

Web: www.cosmobio.co.jp 

E-mail: export@cosmobio.co.jp 

KEY PERSONNEL: Tamostu Nakamura; President 

Jihei Suwa; Sr. Exec. Managing Director 

Takashi Yokomizo; Managing Director, Research Reagent Development 

Department 

Yasushi Kuriya; Purchasing Manager 


HISTORY: Established in March 1978 as technical development department of 

Maruzen Oil Co. Ltd. 

Biochemical department established in 1982 

Established Maruzen Oil Biochemical Co. Ltd. in 1983 

Changed name to Cosmo Bio Co. Ltd. in 1986 


SUBSIDIARIES/DIVISIONS: Cosmo Bio USA 

PRINCIPAL INVESTORS: Cosmo Oil Co. Ltd. 

BUSINESS STRATEGY: Export, import and sell research reagents, instruments and software, and 

diagnostics 


Biopool AB hemostasis and blood exclusive distribution 1996 

group serology 

agreement 

Cappel Lab MAbs, polyclonal exclusive distribution 

antibodies 

agreement 

EY Lab lectin exclusive distribution 

agreement 

Genzyme Corp. lymphokine, cytokine nonexclusive 

distribution 

agreement 

VMRD Inc. biotech products Cosmo to distribute 

VMRD's products in 

Japan 

1989 

PRODUCTS ON MARKET: Research Reagents for Gene Engineering: Restriction enzymes, 

modification enzymes, nucleic acids, reagents for detecting genes, PCRrelated 

reagents and equipment 


CryoLife Inc. 


Research Reagents for Tissue Culture: Animal serums, media, culture 

systems/apparatus and antibiotics 

Miscellaneous Research Reagents for Biochemistry: Sugars, lipids, lectins, 

hormones, peptides, amino acids, chemical substances, virus, bacteria, 

enzymes and enzyme substrates 

Apparatus for Biochemical Research: Electrophoresis apparatus, cell-gene 

operation equipment, analysis software, isolation-refining equipment, culture 

apparatus, measuring instruments, gel photograph devices and related 

products, disposable products, biohazard safety appliances and auxiliary 

equipment for experiments such as cold insulation 

Reagents for Clinical Diagnostics: Reagents for transfusions, blood and 

serum, bacteria tests and pathological tests 

1655 Roberts Boulevard NW 

Kennesaw GA 30144, US 

Phone: (770) 419-3355; Fax: (770) 426-0031 


Web: www.cryolife.com 

E-mail: info@cryolife.com 

KEY PERSONNEL: Steven G. Anderson; Chairman, President and CEO 

David M. Fronk; VP, Regulatory Affairs and Quality Assurance 

Albert E. Heacox, Ph.D.; Sr. VP, R&D 

D. Ashley Lee; Exec. VP, COO and CFO 

Gerald B. Seery; Sr. VP, Sales and Marketing 




11,000 sq. ft. pilot production facility for bioadhesives 

18,000 bioprosthesis lab 

STOCK-FINANCIAL HISTORY: NYSE--CRY 

IPO--(2/93) 





04) 


PRIVATE PLACEMENTS: Raised $20M private placement (1/04) 

BUSINESS STRATEGY: The company cryopreserves and distributes donated living human tissues 

for use in reconstructive cardiac, vascular, and orthopaedic surgeries. The 

company’s BioGlue® Surgical Adhesive, is FDA approved as an adjunct to 

sutures and staples for use in adult patients in open surgical repair of large 

vessels and is CE marked in Europe and approved in Cananda for use in 

soft tissue repair and approved in Australia for use in vascular and 

pulmonary sealing and repair. 


Clearant Inc. Inactivates 

microorganisms in 

human tissues 



The Magdi 

Yacoub Institute at 

Imperial College 

U.S. Department 

of Defense 

methods to improve the 

utilization of unfixed 

xenografts for human 

transplantation 

BioFoam for use in deep 

wound injuries that occur 

on the battlefield 

three-year research 

collaboration 

development 

agreement 

RESEARCH & DEVELOPMENT: Bioadhesives, xenograft/allograft implantable heart valves, vascular and 

orthopaedic tissues 

PRODUCTS ON MARKET: CryoValve® human allograft aortic and pulmonary heart valves 

CryoVein® human saphenous veins and superficial femoral veins and 

arteries 

CryoArtery® aortoiliac artery 

CryoGraft Tendon – semitendonosus/gracillis and tibialis tendons, 

quadriceps, achilles and patellar tendons 

CryoGraft Menisci 

Osteoarticular (OA) allografts 

BioGlue® Surgical Adhesive 

CryoLife-O’Brien porcine heart valves 

SG Model #100 bovine ureter for arteriovenous (AV) access 


BioFoam in development 

BioLastic in development 

BioDisc in development 

CUBIA (University Centre for Algal 

Biotechnology) 

University of Liege B22, Sart-Tilman 

Liege 4000, Belgium 

Phone: +32 4-366-3807; Fax: +32 4-366-2926 

Web: No Web site 

E-mail: m.brouers@ulg.ac.be 

KEY PERSONNEL: M. Brouers; President and CSO 


HISTORY: Founded and began biotech R&D in December 1996 

FACILITIES: 250 sq. m. offices and laboratory 

STOCK-FINANCIAL HISTORY: Nonprofit university research center 

RESEARCH & DEVELOPMENT: Edible microalgae 

Extraction of byproducts for food, feed, cosmetic, dietetic and parapharmacy 

Feasibility studies for construction of industrial microalgae production plant 

PRODUCTS ON MARKET: Spirulina algae and byproducts 

Colorings 

Wound healing 

Dietetic complements 


Algaplan fertilizer in research phase 


6/05

Cuno Inc. 


400 Research Parkway 

Meriden CT 06450, US 

Phone: (203) 237-5541; Fax: (203) 238-8977 


Web: www.cuno.com 

KEY PERSONNEL: Mark G. Kachur; CEO and President 

Frederick C. Flynn Jr.; Sr. VP, Finance and Administration and CFO 

Thomas J. Hamlin; Sr. VP, R&D 

Anton McElevey; VP and GM, Europe 

Geoff Wilcox; Director, Biopharmaceutical Group 


HISTORY: CUNO Inc. founded in 1912 

Acquired Polymerics Inc. (6/04) 

Acquired WTC Industries Inc. (8/04) 

Acquired by 3M (8/05) 


Formerly listed on NASDAQ--CUNO 

IPO--(9/96) 

Net sales $$351.611M (YE 04) compared to $288.231M (YE 03) 




03) 

Total assets $434.558M (YE 04) compared to $288.008 (YE 03) 

SUBSIDIARIES/DIVISIONS: Cuno Ltd.--U.K. 

Cuno Pacific Pty. Ltd.--Australia 

Cuno Europe SA--France 

Cuno SA--France 

Cuno Belux--Belgium 

Cuno Srl--Italy 

Cuno Filtration Asia Pte. Ltd.--Singapore 

Cuno Latina Ltda.--Brazil 

Cuno Latina Surcusal Argentina 

Cuno GmbH--Germany 

Cuno KK--Japan 

SUBSIDIARY OF: 3M 

BUSINESS STRATEGY: Create enhanced methods of purification and unique separation matrices for 

use in the biotechnology and bioprocessing industries 

RESEARCH & DEVELOPMENT: Filtration/separations for biopharmaceutical process development and 

manufacturing 

Chromatography column protection 

PRODUCTS ON MARKET: Zeta Plus® virus reduction filters 

Zeta Plus® disposable prefilter cartridges 

Zetapor® nylon membrane filter cartridges 

Microfluor II® sterile air filters 

SterAssure nylon membrane prefilters 

Microcheck automated integrity test instrument 

Sanitary design cartridge filter housings 

PolyPro® XL pleated high area depth filters 

PolyNet PB polypropylene depth filters 




73-4460 Queen Kaahamanu Hwy., Suite 102 

Kailua-Kona HI 96740, US 

Phone: (808) 329-4677; Fax: (808) 329-4533 


Web: www.cyanotech.com 

E-mail: info@cyanotech.com 

KEY PERSONNEL: Gerald R. Cysewski; Chairman, President and CEO 

William R. Maris; VP, Finance and CFO 

Glenn Jenson; VP, Operations 

Robert J. Capelli; VP, Sales 


HISTORY: Founded in 1983 by Gerald Cysewski (5% equity interest, 6/96) 

Originally formed from merger of Altex Technology and White Mountain Inc. 

FACILITIES: Algae production facility on 90-acre site in Kailua-Kona, Hawaii 

STOCK-FINANCIAL HISTORY: NASDAQ--CYAN (Capital Market) 

Follow-on public offering--1.5M shares at $7/share, $11.445M (3/96) 





05) 


PRIVATE PLACEMENTS: Spirulina Research Partners--RDLP for spirulina research--$635K (10/84) 

$150K, 600K shares (11/83) 

$276K, 920K shares (6/84) 

$250K, 625K preferred shares (6/85) 

$1.5M (7/86) 

$2.35M, 235K shares (1/94) 

$1.55M, convertible subordinated debentures and common stock (11/02) 

PRINCIPAL INVESTORS: Continental Corp.--$500K, 1.25M preferred shares (1985); 292,430 shares 

of common stock at $1/share (1986), $1.97M, 79shares of preferred stock 

(2/90) 

Cosmo Ventures--$1M, 750K shares (1985, 1986) 

BUSINESS STRATEGY: Develop high-value products from microalgae 

Establish retail marketing subsidiary 


Scripps Research Scripps' Aldolase licensing agreement 4/98 

Institute 

Catalytic Antibody 38C2 

in microalgae 

University of microalgae that is toxic licensing agreement 7/95 

Memphis 

to mosquito larvae 

RESEARCH & DEVELOPMENT: Algal drying technique permitting dormancy 

Pigments for cosmetics, fragrances, food coloring 

Astaxanthin for aquaculture feeds 

PRODUCTS ON MARKET: BioAstin® natural astaxanthin 

Phycobiliproteins as fluorescent dyes for labeling MAbs in cell sorters and 

assays 

Spirulina Pacifica® protein supplement as food supplement 

NatuRose® natural astaxanthin product 

Genetic engineering of microalgae to produce transgenic protein 




14-10, Nihonbashi, 3-chome, Chuo-ku 


Phone: +81 3-3272-0611; Fax: +81 3-3272-7348 

Web: www.daiichipharm.co.jp 

E-mail: andokb5o@daiichipharm.co.jp 

KEY PERSONNEL: Kiyoshi Morita; President and CEO 

Tsutomu Une, Ph.D.; Sr. Managing Director 

Tadao Suzuki, Ph.D.; Sr. Manging Director 

Hidetoshi Imaizumi; Managing Director 

Ryuzo Takada; Managing Director 

Hiroshi Sugiyama; Managing Director 

Toru Kuroda; Managing Director 

Akira Nagano; Managing Director 


HISTORY: Established in January 1918 

Founded as Arsemin Shokai in October 1915 

Established Daiichi Sankyo Co. Ltd. with Sankyo Co. Ltd., and became its 

subsidiary (2005) 

FACILITIES: Factories in Osaka, Shizuoka and Akita 

Research and development center in Tokyo 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges 

Net sales ¥328.534b (YE 05) compared to ¥322.767b (YE 04) 


Earnings per share ¥137.95/share (YE 05) compared to ¥97.25/share (YE 

04) 


SUBSIDIARIES/DIVISIONS: Daiichi Sankyo Co. Ltd.----Tokyo 

Daiichi Sankyo Healthcare Co. Ltd.--Tokyo 

Daiichi Pure Chemicals Co. Ltd.--Tokyo 

Daiichi Radioisotope Laboratories Ltd.--Tokyo 

Daiichi Pharmatech Co. Ltd.--Tokyo 

Daiichi Fine Chemical Co. Ltd. (DFK)--Tokyo 

Saitama Daiichi Pharmaceutical Co. Ltd.--Saitama 

Daiichi Asubio Pharma Co. Ltd. (ASB)--Tokyo 

Tokyo Iyaku Shiki Co. Ltd.--Saitama 

Nishimura Shiki Co. Ltd.--Osaka 

Daiichi Estate Co. Ltd.--Tokyo 

Daiichi Butsuryu Co. Ltd.--Tokyo 

D.P.C.Medical Co. Ltd.--Tokyo 

Kanto Daiichi Service Co. Ltd.--Tokyo 

Daiichi Sankyo Inc.--N.J., U.S. 

Daiichi Pharmaceuticals UK Ltd.--London 

Daiichi Pharmaceutical (Beijing) Co. Ltd.--China 

Daiichi Pharmaceutical Asia Ltd.--Hong Kong 

Daiichi Pharmaceutical Taiwan Ltd.--Taiwan 

Daiichi Pharmaceutical Korea Co. Ltd.--Korea 

Daiichi Pharmaceutical (Thailand) Ltd. 

Laboratoires Daiichi Sanofi-Aventis--Paris 

Daiichi Fine Chemicals Inc.--N.Y., U.S. 

Daiichi Fine Chemical Europe GmbH--Germany 

Daiichi Asubio Pharmaceuticals Inc.--N.J., U.S. 

Daiichi Asubio Holdings Inc.--U.S. 

Daiichi Asubio Medical Research Laboratories LLC (Daiamed)--Cambridge, 

Mass., U.S. 

SUBSIDIARY OF: Daiichi Sankyo Co. Ltd. 




GE Healthcare research and 


development of nonnuclear 

contrast media 

agreement 

CIMYM 

development and licensing agreement 7/06 

BioSciences Inc. marketing rights for 

nimotuzumab in Japan 

Ingenuity Systems Ingenuity's Pathways expanded licensing 4/06 

Analysis 

agreement 

YM Biosciences development and licensing agreement 7/06 

Inc. 

marketing rights to 

TheraCIM 

(nimotuzumab) in Japan 

PRODUCTS ON MARKET: OTC pharmaceuticals, quasi-pharmaceuticals, pharmaceuticals, cosmetics, 

medical equipment, food products, beverages, diagnostic reagents, 

radiopharmaceuticals, radioisotope products, fine chemicals, packaging 

materials for pharmaceuticals and logistics services 


2-6-8 Doshomachi, Chuo-ku 

Osaka 541-0045, Japan 

Phone: +81 06-6203-5321; Fax: +81 06-6233-2288 

Web: www.ds-pharma.co.jp 

KEY PERSONNEL: Yasuo Okamoto; Chairman 

Kenjiro Miyatake; President 


HISTORY: Created from the merger of Dainippon Pharmaceutical Co. Ltd. and 

Sumitomo Pharmaceuticals Co. Ltd. (10/05) 

Sumitomo Pharmaceuticals: 

Founded in February 1984 as a joint venture through merger of respective 

pharmaceutical divisions of Sumitomo Chemical Co. Ltd. and Inabata & Co. 

Dainippon Pharmaceutical: 

Founded in May 1897 

STOCK-FINANCIAL HISTORY: Sumitomo Pharmaceuticals: 




SUBSIDIARIES/DIVISIONS: Pharmaceuticals 

Animal science 

Food science 

Fine chemicals 

Laboratory products 

Dainippon Pharmaceutical: 



Earnings per share ¥48.05/share (YE 04) compared to ¥88.02/share (YE 03) 


BUSINESS STRATEGY: Manufacture, sell/purchase and import/export pharmaceuticals, diagnostics, 

medical devices, veterinary products, food additives, industrial chemicals 

and other chemical products 




Chelsea 

rights to L-Threo DOPS licensing agreement 5/06 

Therapeutics (Droxidopa) outside 

International Ltd. Asia 

Conforma 

Amrubicin HCl 


Therapeutics (Amrubicin) 

Eisai Co. Ltd. development, 


marketing of Gasmotin 

in 10 Asian countries 


PRODUCTS ON MARKET: PHARMACEUTICALS UNIT: Amlodin (used in the treatment of hypertension 

and angina), Gasmotin (used to improve digestive tract function), Prorenal 

(a peripheral circulation stimulant), and Meropen (a carbapenem antiobiotic 

preparation) 


ANIMAL SCIENCE UNIT: disease prevention and treatment products for 

pet, livestock, and marine use 

349 Wildcat Road 

Toronto M3J 2S3, Canada 

Phone: (416) 661-2102; Fax: (416) 661-2108 

Toll-free phone: (800) 567-5060 (Canada only) 

Web: www.dalton.com 

E-mail: chemist@dalton.com 

KEY PERSONNEL: Peter Pekos; President 

Natalie Lazarowych; Director, R&D 



Changed name from Dalton Chemical Laboratories Inc. (4/05) 





BUSINESS STRATEGY: Maintain a position on the forefront of technology in drug discovery, drug 

synthesis and analysis through provision of chemistry expertise to generate 

new drugs, optimize the synthesis of potential therapeutic candidates, and 

provide chemistry expertise to partners in the biotech and pharma fields 

Continue to focus on small molecule chemistry, developing novel routes and 

molecules as well as providing focused and directed chemistry for our 

partners to enhance their own in-house programs and expertise 


As a contract 

services company, 

majority of 

agreements are 

confidential 

RESEARCH & DEVELOPMENT: All research and development under contract of clients 

PRODUCTS ON MARKET: Fine chemicals, custom peptides, custom chemical synthesis 

cGMP manufacturing of active pharmaceutical ingredients and sterile filling 

of clinical trail drug products 




Science and Technology Centre, Earley Gate, Whiteknights Road 

Reading RG6 6BZ, UK 

Phone: +44 (0)118 935 7000; Fax: +44 (0)118 926 7917 

Web: www.dextra-labs.co.uk 

E-mail: dextra@dextra-labs.co.uk 

KEY PERSONNEL: Dr. Andrew Hacking; CEO 

Dr. C. J. Lawson; CEO 

Dr. Alex Weymouth-Wilson; Head, Chemistry 


HISTORY: Founded in October 1989 

FACILITIES: 2,500 sq. ft. of laboratories and offices, small pilot chemical equipment and 

analytical equipment (HPLC, GC, GC/MS, NMR, DIONEX, DSC, UV, IR) 


PRINCIPAL INVESTORS: 3i Group plc--25% 

BUSINESS STRATEGY: Exploit emerging technologies related to carbohydrates in medical advances 


Cambrex AB, carbohydrate and chiral manufacturing, sales 

Karlskoga, intermediates and 

Sweden 

building blocks 

and marketing 

agreement 

10/03 

RESEARCH & DEVELOPMENT: Oligosaccharides involved in communication between mammalian cells, cell 

adhesion molecules, chiral synthons and intermediates 

Drug discovery, carbohydrates, custom synthesis, analytical services, 

oligosaccharides, glycoproteins, chiral compounds 

PRODUCTS ON MARKET: More than 400 biologically significant oligosaccharides and glycoconjugates 

including N-linked, O-linked, fucosylated, sialylated, sulphated sugars, 

monosaccharides and lactones derived by synthesis and extraction from 

plant and animal tissues 


421 Comstock Road 

Toronto M1L 2H5, Canada 

Phone: (416) 755-2231; Fax: (416) 755-0334 

Web: www.polydex.com 

E-mail: swardlaw@polydex.com 

KEY PERSONNEL: George G. Usher; Chairman 

Sharon Wardlaw; President 


HISTORY: Founded in 1936 by Thomas Usher, moved from U.K. to present location in 

1966 

FACILITIES: 30,000 sq. ft. factory 

STOCK-FINANCIAL HISTORY: Owned by parent 

SUBSIDIARY OF: Polydex Pharmaceuticals Ltd. (see separate entry) 

BUSINESS STRATEGY: Develop and sell specialty chemicals 




Canadian 

regulation of 

research agreement 4/94 

Bacterial Diseases macrophage 

Network 

antibacterial activity 

RESEARCH & DEVELOPMENT: Developing human drugs for AIDS, arteriosclerosis and cystic fibrosis 

PRODUCTS ON MARKET: Dextran derivatives 


Dextran for lung infections in cystic fibrosis 

patients 

preparing IND application 

Ushercell (contraceptive application) in Phase II clinicals 

Ushercell (HIV indication) in Phase III clinicals 


West Royalty Industrial Park 

Charlottetown C1E 2A6, Canada 

Phone: (902) 566-1396; Fax: (902) 628-6504 


Web: www.dclchem.com 

E-mail: sales@dclchem.com 

KEY PERSONNEL: J. Regis Duffy, Ph.D.; Chairman 

Ronald J. Keefe, LL.B, MBA, CA; President and Chief Executive Officer 

Rob Binns; Chief Operating Officer 

Gordon Rogers, C.A.; VP, Finance and Corporate Systems and CFO 

Julien Gaudin, Ph.D.; Director, Diagnostic Manufacturing Operations 

Marlene Walker, M.Sc.; Director of Quality Systems 

Bob Fredrickson, Ph.D.; Director, Research and New Technology 

Development 

Lee Lipski; VP, Sales 


HISTORY: Founded in 1970 as a manufacturer of fine chemicals, today its major 

products are clinical chemistry reagents, fine chemicals and biochemicals 


SUBSIDIARIES/DIVISIONS: Biochemical division 

Diagnostic division 

Diagnostic Chemicals Ltd. (U.S.) 

Diagnostic Chemicals Ltd. (Mexico) 

BUSINESS STRATEGY: Build on our leadership in clinical chemsitry to develop new and innovative 

technology for the in vitro diagnostic industry. Develop new biochemicals, 

pharmaceutical intermediates and new immunodiagnostic procedures. 

RESEARCH & DEVELOPMENT: New In vitro-diagnostic products and technologies guided by the specific 

needs of our OEM partners. New enzymes utilizing immunochemistry and 

other proteins as well as enzyme substrates for use in biotechnology. 

Chemical process development and production of high purity chemical 

intermediates. Individualized contract manufacturing solutions. 

PRODUCTS ON MARKET: Clinical chemistry reagents 

Calibrators and controls 

ImmunoDip® 


Digene Corp. 


1201 Clopper Road 

Gaithersburg MD 20878, US 

Phone: (301) 944-7000; Fax: (240) 632-7121 

Toll-free phone: (800) DIGENE 

Web: www.digene.com; E-mail: inforeq@digene.com 

KEY PERSONNEL: Attila T. Lorincz; Sr. VP, R&D and CSO 

Joseph Slattery; CFO 

Belinda O. Patrick; Sr. VP, Manufacturing Operations 

Robert McG. Lilley; Sr. VP, Global Sales and Marketing 

Donna Marie Seyfried; VP, Business Development 



Acquired the molecular diagnostics division of Life Technologies Inc. (12/90) 

Name changed from Digene Diagnostics Inc. (1996) 

FACILITIES: 110,000 sq. ft. R&D and manufacturing facility 

STOCK-FINANCIAL HISTORY: NASDAQ--DIGE 

IPO--$35M (5/96) 

Public offering--2.25M shares of common stock at $10/share, $22.5M 

(10/97) 

Public offering--2M shares of common stock at $28/share, $56M (11/05) 


Net income $8.439M (YE 06) compared to (YE 05) 

Earnings per share $0.39/share (YE 06) compared to 

(YE 05) 


05) 


SUBSIDIARIES/DIVISIONS: Digene Europe - London, England 

BUSINESS STRATEGY: Develop DNA diagnostic and biomedical supply company through internal 

developments, strategic partnerships and acquisitions 


Asuragen Inc. Asuragen's cystic worldwide marketing 4/06 

fibrosis screening and distribution 

products 

agreement 

Cytyc Corp. Digene's DNA probe development 10/96 

tests and Cytyc's 

specimen collection 

and preparation 

technology 

agreement 

International 

five-year exclusive 2/97 

Murex 

agency agreement 

Technologies 

for distribution in 

Corp. 

Europe 

International Digene's tests for HIV distribution 

9/97 

Murex 

RNA, hepatitis B and agreement for 

Technologies cytomegalovirus Europe, the U.K., 

Corp. 

Africa, the Middle 

East and Singapore 

(1993), extended 

International infectious disease worldwide 

4/98 

Murex 

DNA probe diagnostics development and 

Technologies 

distribution 

Corp. 

agreement, 

expanded to include 

STD products (6/94) 

Mitsubishi 

DNA diagnostic probes distribution 

10/98 

Petrochemical Co. for disease detection agreement for Japan 



National Institute 

of Allergy and 

Infectious 

Diseases 

herpes simplex virus 

tests using Hybrid II 

technology 

NCI diagnostic assays for 

HPV 

Toray Industries DNA diagnostic probes 

for disease detection 

$750K Phase II 

SBIR contract 

RESEARCH & DEVELOPMENT: DNA amplification 

Enzymes linked to nucleic acid as diagnostic probes 

Diagnostic probes for HPV, infectious disease and cancer 

$600K research 

contract 

distribution 

agreement for Japan 

PRODUCTS ON MARKET: DNA probe kits for HBV, CMV, mycobacteria, HIV and HPV 

Hybrid Capture System Human Papillomavirus DNA Assay 


Diversa Corp. 

Hybrid Capture II CT and GC DNA tests for 

Chlamydia trachomatis and Neisseria 

gonorrhea for collection out of liquid 

cytology 

4955 Directors Place 

San Diego CA 92121-1609, US 

Phone: (858) 526-5000; Fax: (858) 526-5551 

Web: www.diversa.com 

E-mail: information@diversa.com 

KEY PERSONNEL: James H. Cavanaugh, Ph.D.; Chairman 

Edward T. Shonsey; CEO 

Anthony E. Altig; Sr. VP, Finance and CFO 

William H. Baum; Exec. VP, Bioscience Products 

Patrick Simms; Sr. VP, Operations 


HISTORY: Founded and began biotech R&D in May 1994 

Name changed from Recombinant BioCatalysis Inc. (8/97) 


FACILITIES: 75,000 sq. ft. headquarters and R&D facilities 


6/98 

11/92 

12/00 

filed three 510(k)s--one for 

each test individually and one 

for simultaneous testing 

STOCK-FINANCIAL HISTORY: NASDAQ--DVSA 

IPO--8.34M shares at $24/share, $200.1M (2/00) 

47.1M shares outstanding (6/1/06) 





04) 


PRIVATE PLACEMENTS: Raised $21M in oversubscribed round of venture capital financing (10/97) 

SUBSIDIARIES/DIVISIONS: Innovase LLC 

PRINCIPAL INVESTORS: HealthCare Ventures 

Syngenta AG 

T. Rowe Price 

Rho Management


BUSINESS STRATEGY: Diversa delivers unparalleled enzyme performance for alternative fuels, 

industrial, and health/nutrition processes. Diversa’s patented gene mining 

and DirectEvolution technologies have yielded the world’s largest bank of 

biodiverse enzymes. These enzymes enable manufacturers to make 

products more efficiently and inexpensively while protecting the 

environment. Diversa’s goal is to be the leadiing provider of industrial 

enzymes and biologically active compounds for use in unique, economically 

attractive applications. 

The key elements of Diversa’s strategy are to: 

Further enhance their technology leadership position 

Continue strong focus on alternative fuel markets 

Expand their existing DNA libraries through access to novel genetic material 

and utilize our proprietary technologies to discover new genes and gene 

pathways 

Deploy their technologies across diverse markets in order to maximize their 

return on investment 

Pursue additional strategic alliances with market leaders to access funding 

and industry-specific expertise 

Independently develop and commercialize products in specific markets to 

capture their full economic value 

Discover, modify and commercialize protein-based enzyme catalysts for 

chemical synthesis and industrial processes 

Discover new lead drug compounds from bioactive pathways in 

microorganisms and transgenic application of enzymes to plants for insect 

and disease control 


BASF AG Diversa to discover and 

optimize new enzymes, 

BASF responsible for 

product and process 



alliance 2/06 

Cargill Health and enzymes for the cost- discovery and 4/05 

Food 

effective production of a development 

Technologies proprietary product agreement 

Merck & Co. Inc. therapeutic antibodies development 1/05 

using Diversa's MedEv agreement, 

platform 

expanded 6/05 

RESEARCH & DEVELOPMENT: Alternative energy 

Specialized industrial processes 

Health and nutrition 

PRODUCTS ON MARKET: Valley Ultra-Thin improves ethanol production 

Luminase enzyme 

Phyzyme XP enzyme (for pigs and chickens) 

Quantum Phytase (for pigs and chickens) 

Pyrolase 160 enzyme 

ThermalAce DNA Polymerase 

Bayovac® SRS (vaccine for farmed salmon, available in Chile) 


Sordarins antifungal in preclinicals 

Purifine (converts biomass to biofuel) in development 

Amylase-T in regulatory review (U.S.) 

Enzyme cocktail for cellulosic ethanol 

production (unnamed) 

in development 

Phytase-T in development 

Various antibodies, anti-SARs, anti-anthrax 

and anti-plague antibodies 





201 Perry Parkway, Suite 1 

Gaithersburg MD 20877, US 

Phone: (301) 956-1065; Fax: (301) 963-2156 

Web: www.dnati.com; E-mail: info@dnati.com 

KEY PERSONNEL: Dr. Javed Siddiqi; Chairman, President and CEO 




FACILITIES: 3,000 sq. ft. R&D facility 



BUSINESS STRATEGY: Market kits for DNA research 

Market contract research for molecular biology 

RESEARCH & DEVELOPMENT: Molecular biology research 

PRODUCTS ON MARKET: Cloning and screening kits 

Gene expression kits 

Premade Western blots 


2800 Mitchell Drive 

Walnut Creek CA 94598, US 

Phone: (925) 296-5670 

Web: www.jgi.doe.gov 

E-mail: gilbert21@llnl.gov 

KEY PERSONNEL: Dr. Edward M. Rubin; JGI Director 

Dr. Steven Chu; Director, Lawrence Berkeley National Laboratory 


HISTORY: Founded in 1997, JGI is a collaboration of Lawrence Livermore, Lawrence 

Berkeley, and Los Alamos National Laboratories funded by the Department 

of Energy's Office of Biological and Environmental Research 

FACILITIES: 56,600 sq. ft. Production Genomics Facility (PGF) in Walnut Creek, Calif. 


SUBSIDIARIES/DIVISIONS: JGI partner institutions include Oak Ridge National Laboratory (genome 

annotation), Pacific Northwest National Laboratory (proteomics) and 

Stanford Genome Center (finishing) 

SUBSIDIARY OF: U.S. Department of Energy (DOE) 

FINANCIAL INFORMATION: Funding for JGI is predominantly from the Office of Biological and 

Environmental Research in DOE’s Office of Science, with additional support 

from NIH, NSF, USDA and NASA 

BUSINESS STRATEGY: Develop and exploit new sequencing and other high-throughput, genomescale 

and computational technologies as a means for discovering and 

characterizing the basic principles and relationships underlying the 

organization, function and evolution of living systems 

Leverage the unique capabilities of the Department of Energy National 

Laboratory system to achieve these goals, and to use the resulting 

understanding to address key DOE missions related to energy, the 

environment and human susceptibilities 



RESEARCH & DEVELOPMENT: PROGRAMS: 

Computational Genomics 

Evolutionary Genomics 

Production Sequecing 

Vertebrate Biology 

Microbial Genome Analysis 

Microbial Ecology 

Technology Development 

Community Sequencing Program (CSP): www.jgi.doe.gov/CSP 


GENOMES: 

Human Chromosomes 5, 16, 19, Poplar, Xenopus tropicalis, Fugu rubripes, 

Ciona intestinalis, over 200 microbes and microbial communities. 

COMPUTATIONAL/BIOINFORMATIC TOOLS: 

Integrated Microbial Genome (IMG) analysis data management system: 

http://img.jgi.doe.gov/v1.1/main.cgi 

2025-5 Tabaru, Mashiki-machi, Kamimashiki-gun 

Kumamoto 861-2202, Japan 

Phone: +81-96-286-1515 

Fax: +81-96-286-1525 

Web: www.dojindo.co.jp, www.dojindo.com 

E-mail: info@dojindo.co.jp, info@dojindo.com 

KEY PERSONNEL: Eiji Noda; President 

Mutsuo Yoshida; Marketing Director, Japan 

Yasuo Okumura; Marketing Director, USA 

Kenichi Mitsuda; Marketing Director, China 




SUBSIDIARIES/DIVISIONS: Dojin Glocal Corp. 

Dojin East 

Dojindo Molecular Technologies Inc. 

Dojindo China Republic (Shanghai) 

RESEARCH & DEVELOPMENT: Labeling reagents for protein analysis 

Cell viability and cytotoxicity assay 

Oxidative stress detection 

Nitric oxide research 

Spin trap compounds 

Intracellular fluorescent probes 

New water-soluble tetrazolium salts 

Reagents for self-assembled monolayers 

Detergents for life science research and industry 

PRODUCTS ON MARKET: Reagents for life science research, Miscellaneous biochemical reagents, 

Organic analytical reagents, Quick test kits, Specialty organic materials, 

Reagents for peptide synthesis, Bifunctional cross-linking reagentsm, 

Reagents for cell biology, Tetrazolium salts, Calcium chelators 

Ionophores 

Colloid titration kits 

Reagents for research into NO pathway 




14 Otley Road 

Shipley BD17 7SE, UK 

Phone: +44 (0)1274-595-728; Fax: +44 (0)1274-531-197 

Web: www.dwscientific.co.uk; E-mail: info@dwscientific.co.uk 

KEY PERSONNEL: Don Whitley; Chairman 

Paul Walton; Managing Director 

Dr. Peter Silley; Research Director 

Nyk Kosmirak; Director, Finance 

Andrew Pridmore; Head, Microbiology 

Sally Shelton; Export Manager 





BUSINESS STRATEGY: Develop, manufacture and sell innovative scientific instruments and 

associated products for microbiological applications worldwide, ranging from 

simple reagents through automated instrumentation for the detection and 

enumeration of micro-organisms to specialised workstations 


AES Laboratoire dilumat 3 media exclusive distribution 7/95 

preparation 


U.K. 

Synoptics Ltd. protocol (image 

exclusive distribution 2/92 

analysis) 


U.K. 

Warnex inc. Genevision pcr for food exclusive 

distributorship in the 

U.K. 

9/04 

RESEARCH & DEVELOPMENT: Focus is on the enhancement of existing technologies and the development 

of novel microbiological products and services 

PRODUCTS ON MARKET: Modular Atmosphere Controlled Systems (MACS) 

Whitley Automatic Spiral Plater (WASP) 

Rapid Automated Bacterial Impedance Technique (RABIT) 

Contract microbiological services (GLP compliant laboratory) 

Autoclaves (65 to 150 liters) 


252 Yongdu-Dong, Dongdaemun-Gu 

Seoul, Korea 

Phone: +82 2 920 8220; Fax: +82 2 925 4026 

Web: www.donga.co.kr 

E-mail: export@donga.co.kr 

KEY PERSONNEL: Kang Shin-Ho; Chairman 

Yu Chung-Sik; Vice Chairman 

Kim Won-Bea; President 



Incorporated in 1949 

STOCK-FINANCIAL HISTORY: KSE--000640.KS 

Sales W533.625b (YE 05) compared to W541.214b (YE 04) 

Net income W25.413b (YE 05) compared to W26.575b (YE 04) 



Earnings per share W2.886K/share (YE 05) compared to W3.239K/share 

(YE 04) 

Total assets W576.726b (YE 05) compared to W556.434b (YE 04) 

SUBSIDIARIES/DIVISIONS: Dong-A America Corp. 

5348 Lindbergh Lane 

Bell, CA 90201 

Phone: (323) 261-9400 

Fax: (323) 261-9500 


Toyama Chemical quinolone antibacterial licensing agreement 2/04 

Co. Ltd. 

eye drops TN-3262a 

(tosufloxacin tosilate) 

PRODUCTS ON MARKET: Biologicals: Eporon, Growtropin II, Leucostim, Stifol and Viteron 

Ethical drugs: Alofia, Caltonin, Cholesnone, Closerinn, Diflex, Gabapentin, 

Gemcit, Glimel, Melanon, Melocox, Orodipine, Pantoline, Riopedone, Stillen, 

Vasotrol, Zydena 

OTC: Bacchus, Bacchus Sugar Free, Bacchus-D, Baccus-X, Korean 

Ginseng Royal Jelly, Korean Ginseng Ginkgo, Panpyrin® F Liquid, 

Panpyrin® F capsule, Champ Cold®, Amcilon® Tablet, Garglin Mint® Mouth 

Wash, Garglin Dent® Mouth Wash, Garglin toothpaste, Tempo®, Circulan 

capsule, Kyean, Pompolic Liquid 

APIs: Cycloserine, epirubicin hydrochloride, formoterol fumarate, 

gemcitabine hydrochloride, terizidone, topiramate, voglibose 

Cosmetics 


DA-3801 for infertility in Phase III clinicals 

DA-6034 for ulcerative colitis and Crohn's 

disease 

in Phase II clinicals 

VMDA-3601 for ischemic disease in Phase II clinicals 

GX-12 for AIDS in Phase I clinicals 

DA-9102 for atopic dermatitis in Phase II clinicals 


9330 Zionsville Road 

Indianapolis IN 46268, US 

Phone: (317) 337-3000; Fax: (317) 337-4096 


Web: www.dowagro.com 

E-mail: info@dowagro.com 

KEY PERSONNEL: Jerome Peribere; President and CEO 

Rogelio Lara; VP, Finance 


HISTORY: DowElanco joint venture founded (1989) 

Acquired majority ownership in Mycogen Seeds (1996) 

Acquired by The Dow Chemical Co.; name changed to Dow AgroSciences 

(1997) 



SUBSIDIARIES/DIVISIONS: Agricultural and Specialty Chemicals 

Plant Genetics and Biotechnology 



SUBSIDIARY OF: The Dow Chemical Co. (see separate entry) 

BUSINESS STRATEGY: Provide pest management and biotechnology products to improve the 

quality of the earth's food supply and contribute to the health and quality of 

life of the world's population 


Chlorogen Inc. use of Chlorogen's research 

9/05 

chloroplast technology 

to produce animal 

health products in plant 

cell cultures 

agreements 

Monsanto Co. new technology options global business 1/06 

and more choice in 

products for farmers 

agreement 

MTI GmbH exclusive rights to MTI's licensing 

4/06 

U.S. corn product 

development pipeline 

agreement 

Sangamo 

ZFP TFs and ZFNs for research and 10/05 

BioSciences Inc. plant agriculture commercial 

licensing 

agreement 

University of development of plant- research 

12/05 

Melbourne made production 

systems for an avian 

Influenza vaccine 

collaboration 

RESEARCH & DEVELOPMENT: Plant-cell-produced vaccines and antibodies for animals 

Improvement of crop production and delivery of improved agricultural 

outputs for a multitude of food and feed uses 

Improvement of plant components 

Use of conventional breeding techniques and biotechnology to produce oils 

low in saturated fat and trans fat free 

PRODUCTS ON MARKET: Herbicides 

Insecticides 

Fumigants 

Fungicides 

Agronomic seeds and traits 

Healthy oils 


Concert Plant-Cell-Produced System approved 


KEY PERSONNEL: Yanlin Han; CEO 

Zhanguo Weng; VP, China 

Garry Wong; CFO 

Maggie Deng; COO 


650 West Georgia Street, Suite 310 

Vancouver V6B 4N9, Canada 

Phone: (604) 669-8817; Fax: (604) 669-4243 

Toll-free phone: (877) 388-DRUG (3784) 

Web: www.dragonbiotech.com; E-mail: info@dragonbiotech.com 


Acquired Oriental Wave Holding Ltd. (1/05) 

To sell part of its formulation business to C&Y Pharmaceutical Investment 

Holdings Ltd. (as of 7/06) 



FACILITIES: 258,300 sq. ft. manufacturing facility (for Pharma Division) in the Datong 

Economic and Technology Development Zone in Datong City, Shanxi 

Province, China 

947,200 sq. ft. Chemical and Biotech Division facilities in Datong City 

STOCK-FINANCIAL HISTORY: OTC BB--DRUG / TSX--DDD / BBSE--DRP 


Net income $182.6K (YE 05) compared to $6.362M (YE 04) 



04) 


SUBSIDIARIES/DIVISIONS: Chemical division--bulk pharmaceutical chemical 

Biotech division--recombinant drugs (EPO and G-CSF) 

Pharma division--prescription and over-the-counter drugs 


Suzhou Zhongkai commercialization of licensing agreement 2004 

Bio- 

rhG-CSF worldwide, 


Co. Ltd. 

excluding China 

PRODUCTS ON MARKET: Prescription and over-the-counter generic drugs 

Bulk pharmaceutical chemicals 

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) 


315 Dewdney Avenue 

Regina S4N 0E7, Canada 

Phone: (306) 585-1762; Fax: (306) 585-3000 

Web: www.dbi.sk.ca 

E-mail: webman@dbi.ca 

KEY PERSONNEL: Dr. D. R. Cullimore; President and CEO 

Natalie Ostryznuik; Exec. VP 

Vincent Ostryzniuk; Operations Manager 




BUSINESS STRATEGY: Specialize in applied microbial technology used in environmental diagnostics 

and bioremediation 

Focus on marketing of products and services 

RESEARCH & DEVELOPMENT: Microbial technology as applied to biodetection and bioremediation in soil 

and waste water 

PRODUCTS ON MARKET: BART biodetector systems--portable devices for measuring water filtration 

and other properties of soil 

BART-READ--computer assisted BART measurement 


DSM 


P.O. Box 6500 

Heerlen 6401 JH, Netherlands 

Phone: +31 45 578 81 11; Fax: +31 45 571 97 53 

Web: www.dsm.com 

E-mail: info@dsm.com 

KEY PERSONNEL: Peter Elverding; Chairman 

Arnold Gratama Van Andel; acting CFO 

Paul Fuchs; Corporate Secretary 

Rob van Leen; Chief Innovation Officer 

Bernard van Schaik; Communications 



Aquired Chemie Linz and Deretil (1996) 

Aquired Gist-brocades (1998) 

Aquired Catalytica Pharmaceuticals (2000) 

Aquired Roche's Vitamins and Fine Chemicals Division (10/03) 

Acquired NeoResins (2/05) 

FACILITIES: More than 250 offices and production sites in more than 40 countries 

STOCK-FINANCIAL HISTORY: EURONEXT--DSMN 

Net sales EUR8.195b (YE 05) compared to EUR7.832b (YE 04) 

Net profit EUR527M (YE 05) compared to EUR293M (YE 04) 


(YE 04) 

Total assets EUR10.025b (YE 05) compared to EUR9.626b (YE 04) 

SUBSIDIARIES/DIVISIONS: Nutrition--DSM Nutritional Products (Human nutrition and health, Animal 

nutrition and health), DSM Food Specialties 

Pharma--DSM Pharmaceutical Products, DSM Anti-Infectives 

Performance Materials--DSM Elastomers, DSM Engineering Plastics, DSM 

Resins and DSM Dyneema 

Industrial Chemicals--DSM Fibre Intermediates, DSM Melamine, DSM Agro 

and DSM Energy 

DSM Venturing and Business Development 

BUSINESS STRATEGY: Create innovative products and services that help improve the quality of life 

in the areas of human and animal nutrition and health, cosmetics, 

pharmaceuticals, automotive and transport, coatings, housing and electrics 

and electronics 


Genomatica Inc. Genomatica's 

and licensing 4/05 

SimPheny 

agreement 

Genomatica Inc. implementation of expanded multi-year 6/06 

Genomatica's metabolic collaboration and 

modeling and simulation 


capabilities to help DSM 

develop improved 

biological processes for 

product production 


PRODUCTS ON MARKET: Products for the pharmaceutical, food and feed and agrochemical industries 

High-quality materials such as UV-coatings for optical fibers, elastomers, 

engineering plastics and resins for dry and wet paints and for the production 

of pipes, tanks and containers 

Production of fiber feedstock, melamine and fertilizers 

Production of HPPE fiber for life protection, leisure, marine and medical 

applications 




P.O. Box 43 

Sittard 6130 AA, Netherlands 

Phone: +31 (46) 4773487; Fax: +31 (46) 4773172 

Web: www.dsm.com 

E-mail: info@dsm.com 

KEY PERSONNEL: Jan Wolters; Business Group Director, DSM Fine Chemicals 

Andrea Pollak; Business Unit Director, DSM ACTIS 

Frank Teeuwisse; Business Unit, Director DSM Minera 

Jan Vriens; Business Unit Director, Special Products 


HISTORY: Acquired BMS Regensburg (fine chemicals activities) 

Acquired 70% of Chemie Linz (Austria) (1/96) 

Acquired Deretil (9/96) 

FACILITIES: Plant in Holland to produce aspartame 

Multipurpose plants for fine chemical intermediates produced by enzyme 

technology 

Biotech R&D facility 


SUBSIDIARIES/DIVISIONS: Three business units: 

DSM ACTIS 

DSM Minera 

DSM Special Products 

SUBSIDIARY OF: DSM (see separate entry) 

INVESTMENTS: Holland Sweetener Co.--joint venture with TOSOH Corp. for aspartame 

Chemferm--joint venture with Gist-brocades for semi-synthetic 

cephalosporines 

Bio-Intermediair International Holding BV--7% 


To become the partner of choice for innovative life science companies 

based upon: 

-A superior technology toolbox 

-Optimal production facilities 

-Service throughout the product life cycle 

To ensure our customers benefit from our global leadership and extensive 

expertise in: 

-The manufacturing of standard and advanced intermediates 

-The manufacturing of active ingredients 

-Upscaling from kg- to ton-scale 

-New process development 

-Exclusive synthesis and custom development 

RESEARCH & DEVELOPMENT: Aspartame 

L- and D-amino acids via enzymatic resolutions, as well as other optically 

active compounds 

PRODUCTS ON MARKET: REGULAR PRODUCTS: Acetaldehyde oxime, Acetonyl succinic acid 

diethylester, 2-Acetylnicotinic Acid, Allantoin, 2-Amino-4,6dimethoxypyrimidine, 

D,L-Aspartic acid, L-Aspartic acid, Benzaldehyde, 

Benzoic acid, Benzylalcohol, N-Bromosuccinimide, N-tert.-Butylacrylamide, 

N-Butyl levulinate, Carbethoxypyrazolone, N-Chlorosuccinimide, Cinnamic 

alcohol, Cinnamic aldehyde, Copper iodide, 1,3-Cyclohexanedione, 1,4- 

Cyclohexanedione, Cyclohexanone oxime, Diacetone acrylamide, 1,4- 

Diaminobutane, N,N’-Dibenzylethylenediamine diacetate, N,N- 

Dibenzylamine, 1,3 Dibromo-5,5-dimethylhydantion, 2,2 

Dichlorophenylacetic acid ethylester, Diethyl maleate, Diethyl succinate, 


DuPont 


Diethylacetal succinate, Diisopropyl succinate, Dimethyl maleate, Dimethyl 

succinate, Dimethyl succinylo succinate, Dimethylacetyl succinate, 2,3- 

Dimethylpyridine (2,3-Lutidine), Di-n-butyl fumarate, Di-n-butyl maleate, 

Dioctylfumarate, Dioctylmaleate, Fumaric acid, Glyoxylic acid 50%, Glyoxylic 

acid methylester methylhemiacetal, sec.-Guanidine phosphate, Iodine, 

Levulinic acid, Maleic acid, Maleic anhydride, Methyl iodide, Monosodium 

fumarate, D,L-Phenylalanine, 3-Phenylpropanol-1, o-Phthalaldehyde, 

Potassium benzoate, Potassium iodate, Potassium iodide, Potassium iodide 

with Ca-Stearate, Potassium iodide with tixosil, 2,3-Pyridine dicarboxylic 

acid, Pyrrolidine, Pyruvic acid ethylester (ethyl pyruvate), Pyruvic acid 

methylester (methyl pyruvate), Sodium benzoate, Sodium iodide, Sodium 

metaperiodate, Succinic acid, Succinic anhydride, Succinimide, 1,2,4- 

Triazole, 1,2,4-Triazole, sodium salt (sodium triazole), Trimethylsulfoxonium 

iodide 

DEVELOPMENT PRODUCTS: Adipic acid dihydrazide, (R)-2-Chloromandelic 

acid, Diethoxyethyl acetate, Diethyl succinylo succinate, 2,5- 

Dimethoxytetrahydrofuran, Diphenyl acetic acid, Glyoxylic acid ethylester 

ethylhemiacetal, Glyoxylic acid methylester, Glyoxylic acid monohydrate, 2- 

Hydroxymethylpyrimidine, 1,8-Octanedialtetramethylacetal, 1,8-Octanediol, 

N-tert.-Octyl-acrylamide, 4-Oxobutanoic acid methylester, Phthalazine, 2- 

Picolinic acid, Pyridine-2-aldehyde 

Chestnut Run Plaza 728/1307 

Wilmington DE 19880, US 

Phone: (866) 476-7662 Toll-free phone: (866) 476-7662 

Web: www.sorona.dupont.com 

KEY PERSONNEL: Charles O. Holliday Jr.; Chairman and CEO 

Richard R. Goodmanson; Exec. VP and COO 

Jeffrey L. Keefer; Exec. VP and CFO 

James C. Borel; Sr. VP, Human Resources 

Terry Caloghiris; Group VP, Coatings & Color Technologies 

Uma Chowdhry; Sr. VP, CSO and CTO 

Thomas M. Connelly; Exec. VP and Chief Innovation Officer 

J. Erik Fyrwald; Group VP, Agriculture & Nutrition 

Diane H. Gulyas; Group VP, Performance Materials 

John C. Hodgson; Sr. VP and Chief Marketing and Sales Officer 

W. Donald Johnson; Chairman and Representative Director, DuPont KK 

Ellen J. Kullman; Exec. VP, Safety & Protection, Coatings & Color 

Technologies, Marketing & Sales and Safety & Sustainability 

Stacey J. Mobley; Sr. VP and Chief Administrative Officer and General 

Counsel 

Craig G. Naylor; Group VP, Electronic & Communication Technologies 

Gary M. Pfeiffer; Sr. VP 

Mark P. Vergnano; Group VP, Safety & Protection 

Mathieu Vrijsen; Sr. VP, Operations & Engineering 



FACILITIES: Operates in more than 70 countries 

More than 40 R&D and customer service labs in the U.S., and more than 35 

labs in 11 other countries 

STOCK-FINANCIAL HISTORY: NASDAQ--DD 


Net income $2.053b (YE 05) compared to $1.780b (YE 04) 




SUBSIDIARIES/DIVISIONS: Agriculture and Nutrition 

Coatings and Color Technologies 

Electronic and Communication Technologies 

Performance Materials 


Safety and Protection 

Subsidiaries: 

Agar Cross SA--Argentina 

Antec International Ltd.--U.K. 

Building Media Inc.--Delaware 

ChemFirst Inc.--Mississippi 

Christiana Insurance Ltd.--Bermuda 

Destination Realty Inc.--Delaware 

DPC (Luxembourg) SARL 

DPC S/A Brazil 

DPC South America--Brazil 

DSRB Ltda. Brazil 

DuPont Kansai Automotive Coatings Co.--Delaware 

DuPont (Australia) Ltd. 

DuPont (Korea) Inc. 

DuPont (New Zealand) Ltd. 

DuPont (South America) Holdings LLC--Delaware 

DuPont (Thailand) Co. Ltd. 

DuPont (U.K.) Investments 

DuPont (U.K.) Ltd. 

DuPont Agricultural Caribe Industries Ltd.--Bermuda 

DuPont Agricultural Chemicals Ltd.--China 

DuPont Agro Hellas SA--Greece 

DuPont Argentina SA--Argentina 

DuPont Asia Pacific Ltd.--Delaware 

DuPont Beteiligungs GmbH--Austria 

DuPont BVco BV--Netherlands 

DuPont Capital Management Corp.--Delaware 

DuPont Chemical and Energy Operations Inc.--Delaware 

DuPont China Holding Co. Ltd. 

DuPont China Ltd.--Hong Kong 

DuPont China Ltd. (U.S.)--Delaware 

DuPont Coatings SAS France 

DuPont Company (Singapore) Pte. Ltd. 

DuPont Conid SpA Delaware 

DuPont Coordination Center NV--Belgium 

DuPont CZ sro--Czech Republic 

DuPont DACI Beteiligungs GmbH--Austria 

DuPont Danmark ApS--Denmark 

DuPont de Colombia SA 

DuPont de Nemours (Belgium) BVBA 

DuPont de Nemours (Deutschland) GmbH--Germany 

DuPont de Nemours (Flandre) SA--France 

DuPont de Nemours (France) SAS 

DuPont de Nemours (Luxembourg) SARL 

DuPont de Nemours (Nederland) BV 

DuPont de Nemours Development SA--Switzerland 

DuPont de Nemours Groupe SARL--France 

DuPont de Nemours International SA--Switzerland 

DuPont de Nemours International SA--South Africa 

DuPont de Nemours Italiana Srl 

DuPont Deutschland Holding GmbH & Co. KG--Germany 

DuPont Diagnostics Inc.--Delaware 

DuPont Display Enhancements Inc.--California 

DuPont Displays Inc.--California 

DuPont do Brasil SA 

DuPont Performance Elastomers LLC--Delaware 

DuPont Eastern Europe BV--The Netherlands 

DuPont Elastomers Inc.--Delaware 



DuPont Electronic Materials Inc.--Delaware 

DuPont Electronics Microcircuits Industries Ltd.--Bermuda 

DuPont Energy Co. LLC--Delaware 

DuPont Engineering Products SARL--Luxembourg 

DuPont Environmental Remediation Services Inc.--Delaware 

DuPont Far East Inc.--Delaware 

Dupont Far Eastern Petrochemicals Ltd.--China 

DuPont Feedstocks Co.--Delaware 

DuPont Flandre Finance--France 

DuPont Foreign Sales Corp.--Virgin Islands 

DuPont Global Operations Inc.--Delaware 

DuPont Herberts Automotive Systems Services BVBA--Belgium 

DuPont Holdco Spain I SL--Spain 

DuPont Holdco Spain II SL--Spain 

DuPont Holographics Inc.--New York 

DuPont Iberica SL--Spain 

DuPont India Ltd.--Delaware 

DuPont International (Luxembourg) SCA 

DuPont International Trading Inc.--Delaware 

DuPont Kabushiki Kaisha--Japan 

DuPont KGA BV--The Netherlands 

DuPont Khimprom--Russia 

DuPont Medical Products Inc.--New York 

DuPont Mexico SA de CV 

DuPont North America Inc.--Delaware 

DuPont NLco BV--The Netherlands 

DuPont Operations (Luxembourg) SARL 

DuPont Operations Inc.--Delaware 

DuPont Operations Worldwide Inc.--Delaware 

DuPont Orient Operations Ltd.--Delaware 

DuPont Performance Coatings France SAS 

DuPont Performance Coating Nederland BV 

DuPont Performance Coatings (Thailand) Ltd. 

DuPont Performance Coatings (U.K.) Ltd. 

DuPont Performance Coatings Austria GmbH 

DuPont Performance Coatings GmbH & Co KG--Germany 

DuPont Performance Coatings Iberica SL--Spain 

DuPont Performance Coatings Polska Spolka zoo--Poland 

DuPont Performance Coatings Pty. Ltd.--Australia 

DuPont Performance Coatings Scandinavia AB--Sweden 

DuPont Performance Coatings Inc.--Delaware 

DuPont Performance Coatings Tintas e Vernizes SA--Portugal 

DuPont Pharma Inc.--Delaware 

DuPont Poland BV--The Netherlands 

DuPont Poland Sp zoo--Poland 

DuPont Polimeros Ltda.--Brazil 

DuPont Polyester Europe Aps--Denmark 

DuPont Polymer Powder SARL--Switzerland 

DuPont Powder Coatings (Malaysia) Sdb. 

DuPont Powder Coatings Andina SA--Colombia 

DuPont Powder Coating Belgium NV 

DuPont Powder Coatings France SAS--France 

DuPont Powder Coatings Iberica SL--Spain 

DuPont Powder Coatings Saudia Co. Ltd.--Saudi Arabia 

DuPont Powder Coatings Scandinavia AB--Sweden 

DuPont Powder Coatings U.K. Ltd. 

DuPont Powder Coatings USA Inc.--Delaware 

DuPont Protective Apparel Marketing Co.--Delaware 

DuPont Pulverlack Deutschland GmbH & Co. KG--Germany 

DuPont Quimica de Venezuela CA 

DuPont SA de CV--Mexico 

DuPont Scandinavia GmbH--Germany 

DuPont Services BV--The Netherlands 

DuPont Specialty Grains (dba Optimum Quality Grains LLC)--Delaware 

DuPont Taiwan Ltd. 



DuPont Textile Fibers SA--China 

DuPont Textiles & Interiors (South America) Holdings LLC--Delaware 

DuPont Textiles & Interiors Holdings Inc.--Delaware 

DuPont Trading (Shanghai) Co. Ltd.--China 

DuPont Treasury Ltd.--U.K. 

DuPont Vespel Parts and Shapes Inc.--Pennsylvania 

DuPont Wirex Ltd.--Taiwan 

E.I. du Pont Canada Co. 

E. I. DuPont India Private Ltd. India 

EID Singapore Inc.--Delaware 

Electronic Materials DuPont Dongguan Ltd.--China 

Entek Corp.--Delaware 

Entek Europe Inc.--Delaware 

Granirex--California 

Griffin Brasil Ltda. 

Griffin Colombia SA 

Griffin LLC--Delaware 

Helmstedter Lack-und Chemische Fabrick GmbH & Co. KG--Germany 

Herberts America Inc.--Delaware 

Herberts Mexico SA de CV 

Herberts Plascon Pty. Ltd.--Delaware 

Hickory Holdings Inc.--Delaware 

Holding DP SA de CV--Mexico 

Huajia Chemical Co.--China 

IDAC Belgium – EP Branch BVBA 

Initiatives de Mexico SA de CV 

International Dioxcide Inc.--Delaware 

Liqui-Box Corp.--Ohio 

Permatex Italia Srl 

Pioneer Hi-Bred International Inc.--Iowa 

Pitt-Consol Chemical Co.--New Jersey 

PT DuPont Agricultural Products--Indonesia 

PT DuPont Powder Coatings--Indonesia 

Renner DuPont SA Brazil 

Sentinel Transportation LLC--Delaware 

Solae Holdings LLC--Delaware 

Solae LLC (dba The Solae Co.)--Missouri 

Spies-Hecker GmbH--Switzerland 

Sporting Goods Properties Inc.--Delaware 

Teodur BV--The Netherlands 

UNIAX Corp.--California 

Verdia Inc.--Delaware 

Verniplast SA--Switzerland 

INVESTMENTS: Joint venture with Tate & Lyle plc--formed to produce 1,3-propanediol (PDO) 

BUSINESS STRATEGY: Offer a wide range of products and services for markets including 

agriculture, nutrition, electronics, communications, safety and protection, 

home and construction, transportation and apparel 


Affinergy Inc. R&D of new line of biobased 

products for 

DuPont's BioSurfaces 

business 


BP development, 


marketing of a next 

generation of biofuels 

partnership 6/06 

RESEARCH & DEVELOPMENT: Core Research Competencies of DuPont R&D: 

Chemical science and catalysis: Chemical synthesis, all fields of chemistry, 

catalysis, combinatorial chemistry, discovery chemistry, fine particle 

synthesis 



Leveraged technologies: Analytical science, information science, image 

processing, computer science, modeling and simulation, properties 

modeling 

Biology: Agronomy, Ag environmental chemistry, Ag formulation science, 

biochemistry, biochemical engineering, bioinformatics, cell culture, 

ecosphere modeling, genetics, genomics, microbiology, molecular biology, 

plant science 

Material science and engineering: Polymerization fundamentals, polymer 

modifications, multi-component polymer systems, interfacial science, 

polymer recycling, polymer characterization, polymer process development, 

polymer fabrication, fiber science and engineering, fibrous/fibrid systems 

engineering, composite structures, coatings, photosensitive coatings and 

materials, color science, interfacial science, polymer synthesis, solidification, 

image substrate materials 

Process science and engineering: Digital imaging systems; environmental 

engineering; hazards evaluation and control; materials engineering; 

operations optimization; particle technology; process development/scale-up; 

process measurement and control; process modeling and simulation; 

process synthesis; reaction engineering; thermodynamics, kinetics, 

mechanisms; transport phenomena; unit operations; experimental design 

and empirical modeling 

PRODUCTS ON MARKET: Autograph® non-stick coating for cookware 

DuPont Air Filters 

DuPont Biodegradable Stakes 

DuPont Bird Netting 

DuPont Deer Netting 

Corian® solid surface 

DuPont Carbon Monoxide Alarms 

DuPont Car Care Products 

DuPont FlameResist Blanket 

DuPont Frost Blanket 

DuPont Garden Products 

Granite Certified by DuPont 

GreenVista garden products 

Kevlar® ballistic protection 

DuPont Pool Care System 

DuPont Self-Charging Smoke Alarms 

DuPont Spa Care System 

DuPont Seed Bed Cover 

DuPont Seed Germination Blanket 

Kevlar® StormRoom residential in-home storm shelter 

SentryGlas® safety glass interlayer 

Simplicity solid surfaces 

Solae® soy protein 

Stain Protectors 

Teflon® surface coatings 

Tyvek® envelopes 

Tyvek® fibers 

Tyvek® HomeWrap® 

Tyvek® StuccoWrap® 

Tyvek® tape 

Tyvek® ThermaWrap 

DuPont Vinyl Flooring 

DuPont Garden Products Weed Control Fabric 

Water Filtration 

Zodiaq® solid surface 



Dyadic International (USA) Inc. 

140 Intracoastal Pointe Drive, Suite 404 

Jupiter FL 33477-5094, US 

Phone: (561) 743-8333; Fax: (561) 743-8343 

Web: www.dyadic-group.com; E-mail: information@dyadic-group.com 

KEY PERSONNEL: Mark Emalfarb; Chairman, President and CEO 

Wayne Moor; CFO 

Dr. Glenn Nedwin; CSO 

Kent Sproat; Exec VP, Enzymes 

Ray Chandra; Sr. VP, Marketing, Biotech Systems 

Alexander (Sasha) Bondar; VP, Corporate Development 

Charles W. (Bill) Kling IV; VP, Sales and Marketing, Enzymes 

Dan Michalopoulos, Ph.D.; VP, Pulp and Paper 

Richard Burlingame, Ph.D.; Exec. Director, R&D 



STOCK-FINANCIAL HISTORY: AMEX--DIL 




PRIVATE PLACEMENTS: Raised $2.1M in warrants and options exercise (5/06) 

SUBSIDIARIES/DIVISIONS: Enzyme Business 

Biosciences Business 

BUSINESS STRATEGY: Leverage its technology platform to discover novel genes and biological 

products for use by its strategic partners, and to further the company’s own 

R&D efforts 

Seek strategic alliances with leaders in the agricultural, biological, industrial, 

chemical and biopharmaceutical industries that have in-house genomic 

capabilities. Collaborate with companies whose genomic capabilities are 

limited in order to discover and express biological materials for these 

strategic partners 

Commercialize enzymes for use in targeted markets including the animal 

nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and 

textile industries 

RESEARCH & DEVELOPMENT: Discover, develop and manufacture novel products derived from the DNA of 

complex living organisms (including humans) 

Development of biological products such as proteins, enzymes, polypeptides 

and small molecules for applications in large segments of the agricultural, 

industrial, chemical and biopharmaceutical industries 

Discovery and expression of eukaryotic genes and manufacturing for 

commercial application 


Eichsfelder Strasse 11 

Dusseldorf 40595, Germany 

Phone: +49 (0)211 7 58 45 0; Fax: +49 (0)211 7 58 45 130 

Web: www.rheinbiotech.de 

E-mail: info@rheinbiotech.de 

KEY PERSONNEL: Zbigniew Janowicz, Ph.D.; CEO, Dynavax Europe 

Petra Zimmer; CFO 

Oliver Bartelsen, Ph.D.; Director, Business Development 





Acquired by Berna Biotech AG (2002) 

Acquired by Dynavax Technologies Corp. (4/06) 

Changed name from Rhein Biotech GmbH (4/06) 


SUBSIDIARY OF: Dynavax Technologies Corp. (see separate entry) 

BUSINESS STRATEGY: Develop proprietary biopharmaceutical products and establish strategic 

alliances designed to leverage and add value to the company's core 

capabilities in the areas of process, analytical and preclinical development, 

quality control, quality assurance, manufacturing and technology transfer 

Through marketing and sales of recombinant antigens on the diagnostic 

market, leverage the value of the established vaccine production 

technologies 


10394 Pacific Center Court 


Phone: (858) 45005500; Fax: (858) 453-3552 

Web: www.emdbiosciences.com 

KEY PERSONNEL: Douglas S. Brown; President and CEO 

Hans Ahl; GM, European Sales and Marketing 


HISTORY: Established in 1952 as a manufacturer of research biochemicals 

Sold to Hoechst Corp. in 1977 

Sold to Biodor in 1988 

Sold to Warburg, Pincus and Alex Brown in 1992 

Acquired Oncogene Science Research Products division (8/95) 

Changed name from Calbiochem-Novabiochem International (7/96) 

Acquired Novagen (12/97) 

Acquired by Merek KGaA, Dormstadt, Germany (12/98) 

Changed name from CN Biosciences Inc. (2/03) 

The company, an affiliate of Merck KGaA, is known as EMD Biosciences in 

North America and as Merck Biosciences in all other countries 

FACILITIES: Manufacturing facilities in San Diego, Calif.; Cambridge, Mass.; Madison, 

Wis.; and Switzerland 


SUBSIDIARY OF: Merck KGaA (see separate entry) 


Chromagen Inc. Chromagen's Direct multiyear marketing 3/98 

Read RNA and DNA and distribution 

assays and other agreement--CN 

products in life sciences Biosciences' 

research market subsidiary 

Calbiochem- 

Novabiochem 

Corp. gains 

exclusive access to 

certain research 

uses of products 

and technology that 

Chromagen has 

developed for other 

markets 



Epitome 

Biosystems 

German Resource 

Center for 

Genome 

Research 

products based on 

Epitome's EpiTag 

technology 

licensing and 

development 

agreement 

genome research cooperative 

agreement 

RESEARCH & DEVELOPMENT: Molecular biology kits and reagents 

Cellular reagents, including caged compounds, antibodies, intracellular 

probes, inhibitors, signal transduction tools, apoptosis tools, proteins, amino 

acid derivatives, peptides, buffers, detergents, combinatorial chemistry 

linkers and resins 

Development of custom products on contractual basis 

PRODUCTS ON MARKET: More than 15,000 products on the market, including signal transduction 

reagents, molecular biology kits and reagents, apoptosis reagents, cancer 

study reagents, combinatorial chemistry, Buffers, Zwittergent® detergents, 

Ultrol® grade detergents and buffers, Pronase® protease, Pansorbin® cells, 

reagents for peptide synthesis, peptides, inhibitors, enzymes, proteins, 

antibodies, immunochemicals, antibodies to signaling proteins, calcium 

modulators, neurochemicals and neurotoxins 


4 Richmond Square, Suite 500 

Providence RI 02906, US 

Phone: (401) 861-9770; Fax: (401) 861-9777 

Web: www.emembrane.com 

E-mail: info@emembrane.com 

KEY PERSONNEL: William Lee, Ph.D.; President and CEO 




PRIVATE PLACEMENTS: Raised $370K in three rounds of financing 

PRINCIPAL INVESTORS: Slater Technology Fund 

--Angels 

BUSINESS STRATEGY: Vision: 

Be the world leader in research, development and commercialization of 

Multifunctional Polymeric Materials and Membranes for chemical and 

biological applications 

Mission: 

To enable chemical and biotech companies to create innovative and costeffective 

solutions to problems of separating and handling chemical and 

biological materials by using proprietary technology to functionalize 

polymeric materials and membranes used in systems and devices 

RESEARCH & DEVELOPMENT: Nano-grafting of combinatorial functionalized polymer brushes 


9/05 

11/04



3209 Gresham Lake Road, Suite 147 

Raleigh NC 27615, US 

Phone: (919) 954-6196; Fax: (919) 954-6197 

Web: www.ensolve.com 

E-mail: info@ensolve.com 

KEY PERSONNEL: Dr. Jason Caplan; Chairman, President and CEO 




BUSINESS STRATEGY: Develop biospecialty products that eliminate pollutants from air, water and 

soil using biotechnology 


Bath Iron Works Petroliminator, Oily marketing 

8/01 

Water Separator agreement for U.S. 

Navy projects 

Burlington 

specialty chemicals-- sales and 

1/97 

Chemical 

EnSolve's GreaseFeast distribution 

biocleanser 

agreement 

PRODUCTS ON MARKET: PetroLiminator® bilge water treatment system 

GF 2010 multi-purpose liquid detergent 

EnCell bioreactor 

EnFlow Air Filter 

GreaseFeast® biocleanser 

Oxi-Blast non-polluting cleaner 

EnSorb, granular formulation of EnSolve's oil degrading microbes 


2885 Bartells Drive 

Beloit WI 53511, US 

Phone: (800) 882-9904; Fax: (608) 361-9883 


Web: www.envirozyme.com 

E-mail: info@envirozyme.com 

KEY PERSONNEL: Jay Silverstein; Chairman and President 

Karen Silverstein; VP 


HISTORY: Founded in March 1989 

FACILITIES: 20,000 sq. ft. headquarters and manufacturing facility in Beloit, Wis. 


BUSINESS STRATEGY: Manufacture products that are all biodegradable, non-toxic, non-corrosive 

and non-volatile 

PRODUCTS ON MARKET: Degradation of hydrocarbons in wastewater treatment facilities, septic 

systems, and grease traps in kitchens and bioremediation of oil, aliphatic, 

aromatic chemical pollutants, and composting 

BR--Bioremediation of aliphatic and aromatic pollutants 

C--degradation of cellulose 

COMP--for composting mulch and sludge 

DIN--for nitrification and denitrification (liquid) 




DOC--biological odor control 

EZ--sludge reduction and odor control 

GT--degradation of grease, oils and fats in kitchen grease traps 

L--degradation of animal fats, oils and greases 

LGD--liquid for kitchen grease traps 

N--to control foaming, bulking or rising sludge caused by filamentors 

bacteria 

O--wintergreen fragrance and sludge reduction and odor control 

P--for phosphorus reduction 

Pouch--for lift stations, wet wells and pump stations 

R--for septic systems 

T--for hydrogen sulfide reduction 

XC--degradation of grease oils and fats in kitchen grease 

15 Sketty Road 

Swansea SA2 OEU, UK 

Phone: +44 (0)1792 466166; Fax: +44 (0)1792 466366 

Web: www.enzymeresearch.co.uk 

E-mail: info@enzymeresearch.co.uk 

KEY PERSONNEL: Nils von Sicard, Ph.D.; Managing Director 

Michael Morris; Exec. VP 

Hazel Pannett; Office Manager 

EMPLOYEES: 5 employees; 2 Ph.D.s 




SUBSIDIARIES/DIVISIONS: Enzyme Research Laboratories Inc. 

412 S. Lafayette 

South Bend, IN 46601 USA 

Phone: (574) 288-2268 

Fax: (574) 288-2272 

PRINCIPAL INVESTORS: Private LTD Co. 

BUSINESS STRATEGY: A drug discovery company 

R&D targets new anticoagulant products for the treatment of blood clots, 

heart attacks and stroke 

RESEARCH & DEVELOPMENT: Anticoagulants from blood sucking animals 

PRODUCTS ON MARKET: ERL provides a number of high quality coagulation reagents to scientist 

involved in haemostasis and thrombosis research. Products include 

coagulation factors, polyclonal and monoclonal antibodies to coagulation 

factors, ELISA kits, haematological diagnostic kits and factor deficient 

plasmas 


TEPI (anticoagulant) in preclinicals 




4 Lina Lane 

Eastampton NJ 08060, US 

Phone: (609) 267-9118; Fax: (609) 267-9336 


Web: www.epicorebionet.com 

E-mail: epicore@gbsias.com 

KEY PERSONNEL: Hugh C. Hart; Chairman 

William P. Long; CEO 

Paul Massam; Director, Business Development 

Nancy Robinson; Scientist 

William Castner; Purchasing Manager 


HISTORY: Founded and began biotech R&D in March 1994 



STOCK-FINANCIAL HISTORY: Parent company: TSX--EBN 

SUBSIDIARIES/DIVISIONS: Epicore Ecuador SA 

Attn: Lorena Vanoni 

9 de Octubre 2305 y Tungurahua 

Primer Piso- Dept. #1 

Guayaquil, Ecuador 

Phone: 5939 783 5875 

Fax: 5934 237 4167 

E-mail: lvaepi@telconet.net 

SUBSIDIARY OF: Epicore BioNetworks Inc. 

BUSINESS STRATEGY: Grow through biological product sales 

RESEARCH & DEVELOPMENT: Aquaculture environment treatments 

Animal waste digestion 

Aquaculture feeds 

PRODUCTS ON MARKET: Aquaculture: 

Epicin hatchery and pond treatment 

Epifeed LHF 1&2&3 liquid feed for hatcheries 

Epibal 150, 300 & 500 granular feed for hatcheries 

Epifeed MBF maturation feed 

Epizym VMC vitamin mineral concentrate 

Epizym BGM growth medium for Epicin 

Epizym AGP algae growth promoter 

Agriculture and Horticulture: 

Epizym AW animal waste liquifier and deodorizer 

Photozym liquid foliar spray and seed treatment 

Epithatch biological thatch digestor 

Bioremediation: 

Epizym HC microbial ecosystem for hydrocarbon digestion 

Nutripak companion product for Epizym HC 

Emulsifier companion product for Epizym HC 

Waste Water Management: 

Epizym 100 microbial ecosystem for municipal and industrial wastewater 

treatment 

Epizym 200 microbial ecosystem for biodegradation of hydrocarbons in 

wastewater 




Cleaning and Sanitation: 

Epizym ST septic and RV tank treatment 

Epizym CU carpet and upholstery shampoo 

Epizym DT drain and grease trap cleaner 

Epizym DG aqueous cleaner and degreaser 

Epizym HS hard suface cleaner 

Epizym SR scale remover 

Am Neuland 1 

Bernried 82347, Germany 

Phone: +49 (0)8158-9985 - 0; Fax: +49 (0)8158-9985 - 48 

Web: www.epidauros.com 

E-mail: contact@epidauros.com 

KEY PERSONNEL: Falk Nuber; Chairman 

Dr. Michael Lutz; CEO 

Hubert Wechner; VP, Human Resources, IT, and Finances 

Dr. Karl Kleine; VP, Quality Management 

Hans Peter Arnold, Ph.D.; Sr. Director, Business Development, Sales and 

Marketing 

Dr. Katrin Granderath; Director Genotyping Services 

Dr. Elke Roschmann; Sr. Manager, Business Development and Marketing 

Vera Sturma; Sr. Manager, Business Development and Marketing 

Dr. Stephan Reschauer; Director, Patents and Licensing 





PRINCIPAL INVESTORS: DEWB 

BUSINESS STRATEGY: Make drug development and therapy safer, more focused, and more cost 

efficient through pharmacogenetic research and application that investigates 

the genetic factors that influence a person's response to a drug 

Investigate and characterize variations of genes (polymorphisms) that 

encode drug transporter proteins and drug metabolizing enzymes, as well as 

investigate genes encoding drug targets to which drugs bind 

Offer pharmaceutical and biotechnology companies a comprehensive 

package of proprietary pharmacogenetic assays and services which will 

significantly improve the results of clinical studies and drug treatment 


Focuc Clinical 

Drug 

Developemnt 

GmbH 

Parexel 

International 

R&D and co-marketing 

agreement 

R&D and co-marketing 

agreement 

Pharmacia Corp. R&D and co-marketing 

agreement 

Tm Bioscience Epidauros' patents on co-exclusive 

Corp. 

a biomarker related to commercial licensing 

the P450-CYP2D6 

gene 

agreement 


3/06


PRODUCTS ON MARKET: Genotyping services 

Pharmacogenetic contract research 

Consulting 

Eurogentec SA 

LIEGE Science Park, Rue Bois Saint Jean 5 

Seraing B-4102, Belgium 

Phone: +32 4 372 74 00; Fax: +32 4 372 75 00 

Web: www.eurogentec.com 

E-mail: info@eurogentec.com 

KEY PERSONNEL: Joseph Martial, Ph.D.; Chairman 

Jean-Pierre Delwart; CEO 

Gottfried Proess; Production Manager 

Veronique Distexhe; CFO 

Daniel Radoux; Sales and Marketing Manager 

Philippe Cronet; Biologics Business Unit Director 


HISTORY: Founded in 1985 as a spin-off of the University of Liege 


Established Nippon EGT joint venture in Japan (8/03) 


PRIVATE PLACEMENTS: EUR5M private placement (2001) 

SUBSIDIARIES/DIVISIONS: Subsidiaries: 

Eurogentec France s.a.s.u. 

Eurogentec Deutschland GmbH 

Eurogentec Nederland b.v. 

Eurogentec s.a., succursale de Genève 

Nippon EGT Co., Ltd. 

RB EGT (Singapore) 

Eurogentec North America, Inc. 

Eurogentec Ltd. 

Biotech-related divisions: 

Genomics 

Proteomics 

Biologics 

BUSINESS STRATEGY: Design and deliver reliable and innovative services and products for the life 

science community 

Act as a leading supplier for genomic and proteomic research, in offering the 

company's customers integrated solutions, whether they use DNA, 

antibodies, peptides or proteins as research tools 

Offer research and development services for the biopharmaceutical industry 


Alnylam 

research products and nonexclusive 7/05 

Pharmaceuticals services in RNAi under 

Alnylam's Kreutzer- 

Limmer patent family 



EvoGenix Ltd. 



2/37 Bligh Street 

Sydney NSW 2000, Australia 

Phone: +61 2 8257 3393 

Fax: +61 2 8257 3399 

Web: www.evogenix.com 

E-mail: m.sleigh@evogenix.com.au 

Christopher Harris; Chairman 

Merilyn Sleigh, Ph.D.; CEO 

Steffen Nock, Ph.D.; President, Evogenix Inc. and Exec. Director 

Robert Crombie, Ph.D.; COO and VP, Business Development 

David Wilson, Ph.D.; VP, Antibody Products 

George Kopsidas, Ph.D.; Director, Protein Technologies 


HISTORY: Founded and began biotech R&D in August 2001 

Acquired Absalus Inc. (4/05) 

FACILITIES: Headquarters: Head office in the Sydney CBD 

Corporate and R&D facilities in Parkville, Melbourne 

EvoGenix Inc.: Leased facilities in Mountain View, Calif. 

Manufacturing: access to medium scale fermentation for protein production 

STOCK-FINANCIAL HISTORY: Australian Stock Exchange--EGX 

IPO--36M shares at A$0.25/share, A$9M (7/05) 

PRINCIPAL INVESTORS: Startup Australia Ventures Pty. Ltd.--33% 

BioFusion Capital Pty. Ltd.--6% 

CRC for Diagnostics--9% 

BUSINESS STRATEGY: Utilise technology platform for protein optimisation by molecular evolution to 

build improved and novel therapeutic products for partners and internal 

pipeline. Through acquisition of US-based Absalus Inc., now Evogenix Inc., 

provide access to integrated humanization and optimisation for developing 

novel antibody products. Technology is also available for licensing. 


Absalus Inc. combine technology strategic alliance 5/04 

BresaGen Ltd. protein production 

protocols 


Cooperative protein discovery and licensing 

7/01 

Research Centre optimization technology agreement 

for Diagnostics patents 

CSL Ltd. EvoGenix to apply its technology 

5/06 

technologies to CSL 

antibody products, in 

order to generate 

superior antibodies 

collaboration 

DiNonA Inc. antibody for treatment worldwide licensing 9/05 

of leukemia 

agreement 

Domantis Ltd. affinity improve single 

domain antibodies 


Genesis R&D select receptor-specific R&D agreement 5/03 

Corp. 

proteins 

GlaxoSmithKline application of 


plc 

EvoGenix’s EvoGene collaboration 

technology to the 

optimisation of GSK 

compounds 

agreement 



University of 

Massachusetts 

Medical School 

Viventia Biotech 

Inc. 

anticancer antibody licensing 

agreement 

affinity improve antibody 

products 


4/06 


RESEARCH & DEVELOPMENT: Antibody optimization projects on behalf of partner companies (4) 

commencing April 2003 

Internal project for improvement in specificity of a therapeutic growth factor 

for large unmet market need 

Several antibodies for large markets under development 

Continuing strategies for development of technology to improve its efficiency 

and scope 

Development of Evibody framework for display of peptide libraries for drug 

discovery and imaging applications 

PRODUCTS ON MARKET: EvoGene technology for finetuning of the properties of proteins via a 

random mutagenesis and selection approach; antibody 

humanization/optimization through acquisition of US-based Absalus Inc. 


Evibody technology - novel human protein 

framework for display of binding peptides 

in research 

as a tool in drug discovery, diagnostics and 

therapeutics 

EGX010 - engineered growth factor for 

treatment of bone cancer 

in preclinicals 

EGX020 - humanized monoclonal antibody 

for treatment of infectious diease 

in research 

EGX030 - humanised monoclonal antibody 

for treatment of primary liver cancer 

in research 

EGX040 - humanized monoclonal for 

treatment of leukaemia 

in research 

EGX050 - humanized monoclonal for 

treatment of melanoma/lung cancer 

in research 

Evolva SA 

Hagmattstrasse 6 

Allschwil CH-412, Switzerland 

Phone: +41 61 485 2000; Fax: +41 61 485 2001 

Web: www.evolvabio.com 

E-mail: info@evolvabio.com 

KEY PERSONNEL: Jean-Philippe Tripet; Chairman 

Neil Goldsmith; CEO 

Alexandra Santana Sorensen; VP, R&D 

Pascal Longchamp; VP, Business Development 

Melya Hughes Crameri; VP, Alliances and IP 

Michael Naesby; Head, Library Creation 



Acquired certain assets of Poalis A/S (9/05) 


PRIVATE PLACEMENTS: Raised EUR12M in Series A financing (8/04) 

SUBSIDIARIES/DIVISIONS: Evolva A/S 

Bulowsveg 25 

1870 Fredericksberg C 

Denmark 

Phone: +45 3536 4429 

Fax: +45 3528 3885


Evolva India Pvt. Ltd. 

IICT, Uppal Rd. 

Hyderabad 500 007 

India 

Phone: +91 93 4673 8534 

PRINCIPAL INVESTORS: APIDC-VC 

Aravis 

Astellas Venture Capital LLC 

Danish Growth Fund 

Danish Innovation Investment (Dansk Innovationsinvestering) 

Novartis Venture Fund 

Symbion Capital 

BUSINESS STRATEGY: Fundamentally improve the logistics and success rates of small molecule 

therapeutic discovery, development and manufacturing through the 

application of advanced evolutionary technologies, while sharing in the value 

generated by these improvements, and the molecules that result, through 

selective partnering, as well as the development of the Company's own 

compound pipeline 


AnalytiCon generation and 

research alliance 7/05 

Discovery GmbH optimization of nuclear 

receptor agonists and 

related compounds 

RESEARCH & DEVELOPMENT: Compounds for the treatment of cancer and diabetes, as well as antiinfectives 

Watchmaker® technology platform 


Grenzacherstrasse 124 

Basel CH-4070, Switzerland 

Phone: +41 61-688-1111; Fax: +41 61-691-9391 

Web: www.roche.com 

E-mail: info@roche.com 

KEY PERSONNEL: Dr. Franz B. Humer; Chairman and CEO 

Dr. Erich Hunziker; CFO 

Prof. Dr. Jonathan K.C. Knowles; Head, Research 

William M. Burns; CEO, Pharmaceuticals Division 

Dr Severin Schwan; CEO, Diagnostics Division 


HISTORY: Founded F. Hoffmann-La Roche & Co. in 1896 (Ltd. Since 1919) 

Roche Holdings Inc. incorporated in Delaware in 1987 

Scientists at Basel Institute for Immunology (Roche-sponsored) awarded 

Nobel Prizes in 1984 and 1987 

Founded Roche Holding Ltd. In 1989 

Sold Medi-Physics in 1990 

Acquired 60% equity in Genentech for $2.1b, with an option to acquire the 

remaining interest until June 1999 (9/90) 

Sold plant-protection business to Ciba-Geigy Ltd. (9/90) 

Acquired worldwide PCR rights (1991) 

Roche Biomedical Laboratories merged with National Health Laboratories to 

become the Laboratory Corporation of America (1994) 

Acquired Syntex Corp. for $5.3b (10/94) and renamed it Roche Bioscience 

(see separate entry) 

Sold the Syntex animal health products business to American Home 

Products Corp. (7/95) 



Acquired flavors producer Tastemaker (2/97) 

Acquired Corange group (Boehringer Mannheim and DePuy) (3/98), 

received approval from U.S. FTC to acquire Corange on condition that 

Roche not acquire dominant position in the thrombolytics market, Roche 

also agreed to sell rights to Retevase to Centocor Inc. (2/98) 

Sold DePuy to Johnson & Johnson (7/98) 

Changed name from F. Hoffmann-La Roche to Roche Holding Ltd. (8/00) 

Roche alliance with Chugai (Japan), majority shareholders--50.1% (10/02) 

Acquired Disetronic and Igen (2003) 

Acquired GlycoArt Biotechnology AG (7/05) 


FACILITIES: Facilities in Switzerland and more than 50 countries worldwide 

Expanding research and production facilities 

STOCK-FINANCIAL HISTORY: Shares and nonvoting equity securities are listed on the Basel, Zurich and 

Geneva stock exchanges 

Sales CHF35.511b (YE 05) compared to CHF29.522b (YE 04) 

Net income CHF6.730b (YE 05) compared to CHF7.063b (YE 04) 


(YE 04) 

SUBSIDIARIES/DIVISIONS: American subsidiaries include: 

Hoffmann-La Roche Inc.--Nutley, N.J. 

American Roche International Inc.--Clifton, N.J. 

Genentech Inc. 

Roche Holdings Inc.--Dover, Del. 

Roche Diagnostic Systems Inc.--Indianapolis, Ind. 

Roche Molecular Systems Inc.--Pleasanton, Calif. 

Roche Professional Service Centers Inc.--Paramus, N.J. 

Roche Bioscience 

Divisions: pharmaceuticals, diagnostics 

INVESTMENTS: Laboratory Corp. of America 

Genentech--about 66% 

Foundations: 

Roche Research Foundation, Basel (1996) 

Roche Organ Transplant Research Foundation--$16.5M (7/98) 

BUSINESS STRATEGY: Focus on health care, especially innovative drugs, biotech products, and 

molecular diagnostics 

Invest in own research and form strong relationships with biotech companies 

and universities 

Use synergies between diagnostics and drug development to offer 

integrated health care solutions 


454 Life Sciences development, 

exclusive five-year 5/05 

promotion, sale and worldwide 

distribution of 454's 

Genome Sequencing 

Systems 

agreement 

Actelion Ltd. development and 


Actelion's selective 

S1P1 receptor agonist 

Affymetrix Inc. Genechip technology 

for research in 

genomics 

exclusive 

worldwide 

collaboration 

research 

agreement--joint 

development 

agreement through 

Roche Molecular 

Systems 


7/06 

12/95 

Alanex Corp. screening libraries 4/97 

Ambit Biosciences Ambit's kinase- 

licensing 

8/04 

Corp. 

screening platform agreement


Ambrx Inc. next generation proteins 

and peptides 


licensing 

agreement 

alliance and option 

agreement 


12/05 

Amira 

two clinical-stage 

1/06 

Pharmaceuticals compounds from Roche 

ArQule Inc. combinatorial chemistry 9/96 

BioCryst 

development and exclusive licensing 11/05 

Pharmaceuticals commercialization of agreement 

Inc. 

BioCryst's BCX-4208 

BioFocus (service BioFocus to supply three-year 

4/06 

division of 

Roche with chemical collaboration 

Galapagos NV) compoound libraries 

Borean Pharma 

A/S 

Trimeric Apo A-I Roche to acquire 5/06 

Caliper ultra high-throughput 

screening (UHTS) 

10/96 

Cardinal Health Tamiflu manufacturing and 

packaging 

agreement 

7/06 

Cell Therapeutics Roche's bisplatinum worldwide licensing 12/04 

compounds 

agreement 

CombiChem Inc. combinatorial chemistry 12/96 

Crucell NV Crucell's PER.C6 licensing 

agreement 

2/05 

deCODE genetics phosphodiesterase 4 development and 11/04 

Inc. 

(PDE4) inhibitors commercialization 

agreement 

deCODE genetics disease genes based five-year genomics 2/98 

Inc. 

on studies of Iceland's collaboration-relatively 

isolated Roche to make 

populations 

equity investment, 

provide research 

funding and make 

milestone 

payments, 

Entelos Inc. metabolic disease two-year 

5/06 

research 

collaboration 

Epitomics Inc. Epitomics' rabbit licensing 

10/05 

monoclonal antibody 

technology (RabMab 

technology) 

agreement 

Evotec AG two compounds for exclusive 

1/06 

Alzheimer's disease worldwide licensing 

agreement 

Evotec AG compounds against a discovery and 6/06 

target for CNS diseases development 

and other indications agreement 

Exonhit 

identification of bovine research 

7/02 

Therapeutics SA spongiform 

encephalopathy (BSE), 

or mad cow disease 

agreement 

Gene Logic Inc. Roche drug candidates drug repositioning 12/05 

that did not pass Phase and development 

II or III 

agreement 

Genedata AG Genedata Screener multiyear 

12/05 

technology to estimate expansion of 

the biological potency of existing 

compounds 

collaboration 

Genentech Inc. Herceptin (trastuzumab) exclusive marketing 7/98 

for metastatic breast agreement outside 

cancer 

the U.S.--Roche to 

pay up-front fee 

plus milestones


Genentech Inc. IL-8 and LFA/ICAM 

antagonists 

Genentech Inc. platelet GPIIb/IIIa 

antagonists 

Genentech Inc. DNase to treat cystic 

fibrosis and chronic 

Glycart 

Biotechnology AG 

Hitachi High- 

Technologies 

Corp. 

Memory 


Corp. 

Millennium 


Inc. 

bronchitis 

research 

collaboration 

agreement 

research 

collaboration 

agreement 

joint development 

and joint marketing 

agreement 

therapeutic antibodies development and 

marketing 

laboratory automation 

solutions in 

immunochemistry 

market 

agreement 

collaboration 

agreement 

PDE4 inhibitors research 

agreement, 

extended 7/04, 

obesity and Type II 

diabetes 

MorphoSys AG therapeutic antibodies 

against Alzheimer's 

disease 

Pharmasset Inc. Pharmasset's hepatitis 

Praecis 


Inc. 

Progenics 


Inc. 

Protein Design 

Labs Inc. 

C drug program 

PPI-149 hormone 

antagonist 

T cell chemokine 

receptor assays for HIV 

amended 8/05 


worldwide licensing 

agreement, Roche 

has identified lead 

obesity gene, 

triggering an 

undisclosed 

milestone to 

Millennium (4/98) 

R&D agreement, 

expanded 3/06 


drugs 

1994 

1994 

1992 

9/04 

5/04 

2002 

3/94 

9/00 

licensing and R&D 10/04 

agreement 

development and 6/98 

marketing 

agreement 

research contract 12/97 

Zenapax (daclizumab) development and 


agreement, 

Sanofi-Aventis shikimic acid by 

fermentation for 

Roche's Tamiflu supply 

chain 

expanded 11/05 

production 

agreement 

RESEARCH & DEVELOPMENT: Basic research: 

Immunology, molecular biology, cell biology, gene regulation, 

neurosciences, molecular oncology, virology and genome research 

Pharmaceutical research: 

Infectious diseases: antibacterials (Basel) 

CNS disorders and chronic degeneration: antidepressants, antiparkinsonian, 

drugs for the treatment of Alzheimer's disease; hypnotics, anesthetics 

(Basel) 

Cardiovascular diseases: antihypertensives, antithrombotics, chronic heart 

failure and arteriosclerosis (Basel) 

Metabolic diseases: obesity, NIDDM, osteoporosis (Nutley, NJ) 

Peripheral nervous system disorders, inflammation/autoimmune diseases 

(Palo Alto, CA) 

Antifungal drugs (Kamakura, Japan) 

Oncology (Penzberg, Bavaria) 

9/04 

3/06


Nonclinical development (Basel, Nutley, NJ) 

Diagnostics: 

Clinical chemistry, immunology, hematology, molecular diagnostics (PCR), 

diagnostic equipment 

PRODUCTS ON MARKET: Pharmaceutical specialties: 

Antibacterials (Bactrim, Rocephin, Globocef) 

Anticancer drugs (Roferon-A, Furtulon, Xeloda, Vesanoid, Mabthera) 

Antidepressants (Aurorix) 

Antiepileptic (Rivotril) 

Antifungals (Loceryl) 

Antimalarials (Fansidar, Lariam, Fansimef) 

Antiparkinsonian (Madopar, Tasmar) 

Antirheumatic, pain (Tilcotil, Naprosyn/Aneprox, Toradol) 

Antivirals (Roferon-A, Hivid, Invirase/Fotovase, Viracept, 

Cymevene/Cytovene) 

Anxiolytics (Valium Roche, Lexotan, Nobrium, Librium) 

Hypnotics and anesthetics (Dormicum/Versed, Rohypnol, 

Dalmadorm/Dalmane) 

Benzodiazepine antagonist (Anexate, Romazicon) 

Cardiovascular (Inhibace, Ticlid, Cardene, Coreg, Dilatrend, Reteplase) 

Dermatologicals (Accutane/Roaccutane, Tigason, Neotigason) 

Hematological drugs (Neupogen, Recormon) 

Immunosuppressant (Cellcept, Zenapax) 

Metabolic drugs (Xenical, Rocaltrol, Euglucon, Cedur) 

Others (Pulmozyme) 

OTC drugs: vitamins, analgesics, antacids 

FibroGen Inc. 

225 Gateway Boulevard 

South San Francisco CA 94080, US 

Phone: (650) 866-7200; Fax: (650) 866-7201 

Web: www.fibrogen.com; E-mail: info@fibrogen.com 

KEY PERSONNEL: Thomas B. Neff; Chairman and CEO 

Russell H. Ellison; VP, Clinical Development 

William Hodder; VP, Business Development 

Wilbert Lee; VP, CFO and Treasurer 

David Y. Liu, Ph.D.; VP, Research 

Claire J. Lockey; VP, Regulatory Affairs 

Tim C. Opler; VP, Strategy 

James W. Polarek, Ph.D.; VP, Collagen and Gelatin Development 

Leanne C. Price; VP, Intellectual Property 

David A. Yeowell, Ph.D.; VP, Product Development 


HISTORY: Incorporated in September 1993 

Began R&D operations in 1994 

FACILITIES: FibroGen Inc.--South San Francisco, Calif. (Headquarters, R&D) 

FibroGen Europe Corp.--Helsinki, Finland (R&D) 


PRIVATE PLACEMENTS: 5 offerings totalling $94.1M (through 9/00) 

Raised $100M from placement of convertible preferred stock (2/05) 

FibroGen Europe Ltd.--2 offerings totalling $13.5M 

SUBSIDIARIES/DIVISIONS: FibroGen Europe Corp. 

Tukholmankatu 8 B (Biomedicum II) 

FIN-00290 Helsinki Finland 

Phone: +358 9 56 373 220 

Fax: +358 9 56 373 224 



PRINCIPAL INVESTORS: Adage Capital Management 

Apothecary Capital 

American Express 


Brookside Capital 

BankInvest Biomedical Development 

Bio Fund Ventures II Oy 

Blue Anchor Holdings Corp. 

Corriente Biotechnology Partners 

Credit Suisse London Nominees 

Duquesne Capital Management 

Franklin Fairview 

Franklin Templeton 

Goldman Sachs 

Janus Capital 

Merlin BioMed Group 

Och-Ziff Capital Management 

The Parthenon Group 

Pictet Bank 

Privat Kredit Bank 

The Rosewood Corp. 

Sedgefield Investments 

Sigma Capital Management 

SITRA 

SMBC Capital 

Taisho Pharmaceutical Co. Ltd. 

Three Arch Bay Health Science Fund I LP 

T. Rowe Price 

Wagner & Brown 

BUSINESS STRATEGY: Discovery, development and commercialization of novel biomaterials and 

therapeutics utilizing expertise in extracelluar matrix biology 


Astellas Pharma rights to certain 

licensing 

4/06 

Inc. 

hypoxia-inducible factor 

prolyl hydroxylase 

inhibitors for the 

treatment of anemia, 

including FG-2216 and 

FG-4592, in Europe, 

CIS, Middle East and 

South Africa 

agreement 

Astellas Pharma FG-2216 in Japan licensing 

9/04 

Inc. 

agreement 

Medarex Inc. human monoclonal development 1998 

antibodies 

agreement 

PPL Therapeutics recombinant collagen agreement for PPL 6/97 

produced in transgenic to produce 

animals 

recombinantcollage 

n using transgenic 

animals 

TEKES recombinant collagen funding for 

development of 

recombinant 

human collagen 

technology for use 

in medical and 

commercial 

applications 

5/97 

Thomas Jefferson 

University 

collagen biosynthesis license agreement 11/95 

University of CTGF research and 11/95 

Miami 

development 

agreement 



University of Oulu, 

Finland 

University of 

South Florida 

University of 

Wisconsin 

Zeneca 

LifeScience 

Molecules (now 

AstraZeneca) 

RESEARCH & DEVELOPMENT: Recombinant collagens and gelatin 

Anti-fibrotic therapeutics 

Wound repair/tissue engineering 

recombinant collagen research and 

license agreement 

4/94 

CTGF license agreement 6/95 

collagen biosynthesis research and 


recombinant human process 

collagen 

development/ 

scale-up 


FG-3019 (patients with diabetic 

nephropathy) 

in Phase Ib clinicals 

FG-3019 (patients with idiopathic 

pulmonary fibrosis) 

completed Phase I 

FG-3019 (patients with pancreatic cancer) IND filed 

FG-2216 for anemia in Phase II clinicals 

FG-4592 for iron processing deficiency in Phase I clinicals 

FG-5017 - cosmetic dermal filler to begin pivotal efficacy and 

safety trial in 2006 

FG-4539 for ischemic disease in preclinicals 

FG-5016 completed safety study 

FG-5009 completed safety study 


1, Valepits Road, Garretts Green 

Birmingham B33 0TD, UK 

Phone: +44 121 783 8139; Fax: +44 121 786 2747 

E-mail: info.firstlink@virgin.net 

KEY PERSONNEL: Mick Terry; Director 

Dr. Yvette Goward; Director and Company Secretary 


HISTORY: Formed by original management of Advanced Protein Products Ltd. (1995) 





BUSINESS STRATEGY: Research, develop, manufacture, and supply in field of biological chemicals, 

especially contract manufacturing 

RESEARCH & DEVELOPMENT: Large-scale media for mammalian cell culture 

Contract process development 

Develop culture media for transplantation of natural and artificial organs 

PRODUCTS ON MARKET: High-purity bovine serum albumin and porcine serum albumin 

Density gradient media for cell separation 

Native and recombinant growth factors 

Sera and proteins for cell culture and research 


4/96 

3/99


Fraunhofer Institute for Interfacial 

Engineering and Biotechnology 

Nobelstrasse 12 

Stuttgart 70569, Germany 

Phone: +49 (0) 7 11/9 70-40 01; Fax: +49 (0) 7 11/9 70-42 00 

Web: www.igb.fraunhofer.de 

E-mail: info@igb.fraunhofer.de 

KEY PERSONNEL: Prof. Dr. Herwig Brunner; Managing Director 

Dr. Steffen Rupp; Head, Department Molecular Biotechnology 

Prof. Dr. Walter Troesch; Head, Department Environmental Biotechnology 

and Bioprocess Engineering 

Prof. Dr. Heike Mertsching; Head, Department Cell and Tissue Engineering 

Dr. Christian Oehr; Head, Department Interfacial Technology and Material 

Science 

Dr. Gunter Tovar; Head, Department Biomimetic Interfaces 

Dr. Thomas Schiestel; Head, Department Inorganic Interfaces and 

Membranes 




SUBSIDIARY OF: Fraunhofer-Gesellschaft 

BUSINESS STRATEGY: New technologies for health, the environment and industry 

RESEARCH & DEVELOPMENT: Molecular biotechnology for diagnostic, pharma, and fine chemistry: 

Research in infectious diseases and drug screening, assay development, 

biochip technologies (genomics and proteomics), protein expression, 

fermentation and downstream processing. 

Tissue Engineering for medical technology, diagnostics, drug development, 

and individual therapy: 

Three-dimensional organoid human test systems, biocompatibility testing, 3- 

D autologous transplants, cell sorting and cell therapy, GMP-compliant 

manufacturing of tissue engineering products. 

Functional interfaces for technology and medicine: 

Molecularly defined and smart surfaces, ultra-thin layers, biomimetic and 

biofunctional surfaces, nanobiotechnology, nanoparticles, carbon 

nanotubes, membranes. 

Sustainable bioprocess engineering for industry, urban infrastructure and 

the environment: 

Reprocessing and conversion of organic raw and waste materials, 

generation of biogas, wastewater purification and urban water management, 

production of natural substances (vitamins, neutraceuticals) and energy by 

microalgae. 

PRODUCTS ON MARKET: Two-stage high performance plant for digestion of organic waste 

In-Vitro whole skin model as test system 

Cartilage transplant 


Galderma SA 


Tour Europlaza - La Defense 4, 20 avenue Andre Prothin 

Levallois-Perret 92927, France 

Phone: +33 1 58 86 45 45; Fax: +33 1 58 86 45 00 

Web: www.galderma.com 

E-mail: contactus@galderma.com 

KEY PERSONNEL: Humberto C. Antunes; CEO 


HISTORY: Founded in 1981 as a joint venture between Nestle and L’Oreal 

FACILITIES: Headquarters in Switzerland 

Three R&D centers (in France, the U.S. and Japan) 

Three manufacturing sites (in France, Canada and Brazil) 


SUBSIDIARIES/DIVISIONS: 32 affiliates 


As the global leading company in dermatology, Galderma will contribute to 

the treatment of dermatological diseases and conditions by developing and 

marketing products to meet the needs of dermatologists and patients 

RESEARCH & DEVELOPMENT: Acne, rosacea, psoriasis, seborrheic dermatitis, fungal nail infections, 

melasma, non-melanoma skin cancer 

PRODUCTS ON MARKET: Arcolan® (ketoconazole), Benzac® (benzoyl peroxide), Calmurid® (urea), 

Capex® (fluocinolone acetonide), Cetaphil®, Clindagel® (clindamycin), 

Clobex® (clobetasol), Desowen® (desonide), Differin® (adapalene), 

Efficort® (hydrocortisone aceponate), Ell Cranell®/Avixis® (alphaoestradiol), 

Eryacne® (erythromycine), Loceryl® lacquer (amorolfine), 

Metvix® (methylaminolevulinate), Nutracort® (hydrocortisone), Nutraderm®, 

Nutraplus® (urea), Rozex®/Metro® (metronidazole), Silkis® (calcitriol), 

Tetralysal® (oral lymecycline), Tri-Luma® 

(hydroquinone/tretinoin/fluocinolone/acetonide) 


925 Page Mill Road 

Palo Alto CA 94304, US 

Phone: (650) 846-7500; Fax: (650) 845-6507 

Web: www.genencor.com 

KEY PERSONNEL: Robert Mayer; Chairman and CEO 

Thomas J. Pekich; President 

Michael V. Arbige, Ph.D.; Sr. VP, Technology 

Carole Beth Cobb; Sr. VP, Global Supply 


HISTORY: Founded in 1990 as a joint venture between Eastman Chemical Co. and 

Cultor Ltd. 

Member--Enzyme Technology Association 

Member--Soap and Detergent Association 


Sold dairy and dietary enzyme business to Gist-brocades International BV 

(7/97) 

Acquired by Danisco A/S (4/05) 



FACILITIES: European headquarters in Leiden 

R&D Facilities in Palo Alto, Calif.; Leiden; Netherlands 

Manufacturing facilities in Rochester, N.Y.; Wuxi, China; Arroyito, Argentina; 

Hanko and Jamsankoski, Finland; Bruges, Belgium; and Beloit, Wis. 


Formerly listed on NASDAQ--GCOR: 





03) 


SUBSIDIARY OF: Danisco A/S 

BUSINESS STRATEGY: Develop, manufacture and market products for healthcare, agriculture, 

industrial, and consumer markets using molecular biology and protein 

chemistry 


Ablynx Ablynx's Nanobody drug discovery 9/04 

platform against tumor 

targets specified by 

Genencor 

collaboration 

BioMarin 

Genencor to perform contract research 4/06 

Pharmaceutical research services for agreement 

Inc. 

BioMarin 

CAMR sterilization process for 

medical instruments, 

rendered animal 

material and human 

blood supply 


Cargill biocatalysts for wet corn exclusive supply 1/01 

milling facilities 

agreement 

Gyros microfluidics technology 

collaboration 

5/01 

Integrated 

Genomics 

microbial genome 

sequencing 

technologies 

Mayo Clinic transgenic mouse for 

celiac disease 

Protein Polymer Genencor biomaterials 

Technologies and technology and 

personal care product 

applications 

licensing 

agreement 

cooperative R&D 

agreement 

licensing and 

development 

agreement, 

expanded 3/05 

RESEARCH & DEVELOPMENT: Industrial enzymes for use in cleaning, textile, starch, animal feed, food and 

biochemical industries 

Protein chemistry and genetic engineering 

High-expression fungal and bacterial technology 

Fine and specialty chemicals based on novel biocatalysts and diols 

technology 

Biosynthetic peptides 

Human Immunology platform 

Conversion of biomass to ethanol to reduce the USA's dependence on 

foreign oil 

PRODUCTS ON MARKET: Through utilization of our i-biotech solution, more than 250 biotechnology 

products, including: 

IndiAge® and Primafast® (textile processing) 

Laminex® (brewing enzymes) 

Spezyme® (grain processing enzymes) 

Multifect® (food enzymes) 

Euro® (textile cellulases) 


9/01 

1/01 

12/00


Xylanase enzyme for pulp and paper processing 

Aromatic amino acids 

L-sugars (food and pharmaceutical) 

Purafect® (detergent enzymes) 

Fermgen (acid fungal protease enzyme product) 

Glucose oxidase and catalase for industrial and food use 


Bioingredients in development 

Biomaterials in development 

Therapeutics in development 



1 Research Circle 

Niskayuna NY 12309, US 

Phone: (518) 387-7914; Fax: (518) 387-7911 

Web: www.crd.ge.com 

E-mail: info@ge.com 

Michael Idelchik; VP and Acting Director, GE Global Research 

EMPLOYEES: 2,500 employees, 835+ Ph.D.s 

HISTORY: Founded in 1900 as GE and the U.S.'s first industrial research laboratory 

FACILITIES: 525-acre Global Research Center Headquarters campus in Niskayuna, N.Y. 

STOCK-FINANCIAL HISTORY: NYSE--GE (parent) 

SUBSIDIARIES/DIVISIONS: China Technology Center - Shanghai, China 

John F. Welch Technology Centre - Bangalore, India 

GE Global Research - Europe - Munich, Germany 

Technicare--acquired from Johnson & Johnson (7/86) 

SUBSIDIARY OF: General Electric Co. 

INVESTMENTS: Progene Partners--joint venture with Proteus International and Genelabs 

Technologies to design and develop DNA-binding drugs for viral infections 

and cancer 

BUSINESS STRATEGY: Develop innovative technology that ensures that the customer is always its 

first beneficiary and use it to accelerate growth 


U.S. Department TCE biodegradation joint research 9/98 

of Defense 

agreement 

U.S. Department PCB biodegradation joint research 7/99 

of Energy 

agreement 

U.S. 

TCE biodegradation joint research 9/94 

Environmental 

Protection Agency 

agreement 

U.S. 

PCB biodegradation joint research 12/99 

Environmental 

Protection Agency 

agreement 

U.S. Department TCE biodegradation joint research 9/97 

of Energy 

agreement 

RESEARCH & DEVELOPMENT: Core technology areas: 

Biosciences: Research in applied biology and biomedicine, with an 

emphasis in diagnostic imaging, pharmaceutical discovery technologies and 

protein separations 

Ceramic and Physical Metallurgy Technologies: Development of advanced 

ceramic, composite, electronic, and metallic materials; material life and 



reliability research; coating composition and process development; joining, 

repair and refurbishment studies; and the utilization of novel processes 

including high temperature, high pressure and thermal-mechanical, to 

achieve the desired material responses for a broad range of products 

Computing and Decisioning Sciences: Next generation solutions to take 

health care to the next level of personalized medicine and to identify novel 

biomedical applications for all GE industries 

Electronics and Energy Conversion: Alternative energy and energy systems, 

including wind, solar, solar desalination, renewable energy grids; electrical 

power distribution and control technologies; mobile electric power systems; 

electrical machines; communication systems: controls, diagnostics and 

embedded controls and systems; sensor, security and lighting electronics 

systems; optoelectronic devices and systems; electrophysics, 

electrophysiology, plasma systems, high voltage and vacuum electronics 

Energy and Propulsion Technologies: Developing low-emissions combustion 

for gas turbines, aircraft engines, and locomotives; fuel Cells, micro turbines, 

and other advanced distributed power generation systems; computational 

and experimental fluid dynamics for turbo machinery and other components 

of aircraft engines and power plants; cooling and sealing technologies for 

propulsion, power generation and other industrial and consumer products; 

propulsion technology beyond conventional turbine engines and diesels; 

technology for remote monitoring and prognostics of high-value assets 

towards condition-based maintenance; technologies for hydrogen production 

from coal, natural gas and water; coal gasification and integrated 

gasification combined cycle; and methods of liquid fuel purification and 

conversion 

Imaging Technologies: New applications for imaging in both the security and 

industrial non-destructive testing spaces, molecular imaging 

Material Analysis and Chemical Sciences: Analysis of materials to 

understand their chemical composition, surface and bulk structure and 

physical properties; development of chemical and biological sensors, 

especially the sampling technology and detection chemistry; high-throughput 

experimentation to accelerate materials discovery as accomplished via 

creation of materials in miniaturized arrays using automation, followed by 

rapid testing for desirable properties; application of chemistry and chemical 

engineering to environmental issues, such as pollution prevention, 

remediation, environmental monitoring and water treatment; and toxicology, 

especially as applied to environmental and health issues 

Material Systems Technologies: Development of high-performance material 

systems to deliver new product breakthroughs and applications for GE 

businesses and customers 

Micro and Nano Structures Technologies 

Polymer and Specialty Chemical Technologies: Development of new and 

specialized materials for GE’s Industrial Business, water technologies 

(membranes and coatings) and in support of alternate energy activities 

(wind turbines, fuel cells and photovoltaics); identification of emerging 

technologies (such as nanotechnology, photonics and organic light emitting 

diodes) 

In addition, GE has an increased focus on six advanced technology 

programs: 

Molecular imaging and diagnostics 

Nanotechnology 

Pulse detonation propulsion 

Sustainable energy 

Energy conversion 




Gold Coast Technology Park, 14 Technology Drive 

Arundel 4214, Australia 

Phone: +61 7-5594-0299; Fax: +61 7-5594-0562 

Web: www.genesearch.com.au 

E-mail: info@genesearch.com.au 

KEY PERSONNEL: Dr. John L. Reichelt; CEO 

Dr. Robin Craig; Director, R&D 

Dr. Bonni Y. Reichelt; Director, R&D 

Sarah Reichelt; Scientist 

Keith Pyle; Scientist 

Joy Pyle; Scientist 

Tim Reichelt; Administration 







SUBSIDIARIES/DIVISIONS: Ecosearch (waste treatment) 

BUSINESS STRATEGY: Conduct in-house R&D to develop products internally, as well as contract 

research in microbial genetics and fermentation 

RESEARCH & DEVELOPMENT: R&D is focused on: 

Enzymes for molecular biology 

Microalgal products 

Bioplastics 

Bioinsecticides 

Waste treatment products and processes 

Probiotics 

Silage inoculants 

Microbial genetics and fermentation 

The company performs in-house R&D to develop its own products, and 

conducts contract research in microbial genetics and fermentation, 

including: Industrial and feed chemicals from bacteria (e.g. amino acids), 

biodegradable plastics from bacteria grown on sugar, and biopesticides 

PRODUCTS ON MARKET: Restriction enzymes 

Ecobac powdered bacterial product for waste treatment 

Waste treatment processes for food wastes 

Si-Lac silage inoculant 




P.O. Box 408 

Fontana WI 53125, US 

Phone: (262) 245-1500; Fax: (262) 245-6678 

Web: www.geneva-scientific.com 

E-mail: john@geneva-scientific.com 

KEY PERSONNEL: John Urlakis; President 



PRODUCTS ON MARKET: Laboratory equipment 

Caseworks 

Fume hoods 

Autoclaves 

Sterilizers 

Bio safety cabinets 

Glassware washers 

Rack washers 

Tunnel washers 

Refractometers 

Environmental rooms 

Refrigerators and freezers 

Scraping stations 

Downdraft tables 

Backdraft stations 

Hydraulic tables 

Vacuum waste management and disposal systems 

Automated dump stations 

Bulk bag bedding vacuum transfer systems 

Automated bedding dispensers 

Necropsy tables 


5405 Morehouse Drive, Suite 210 


Phone: (858) 824-1771; Fax: (858) 824-1772 

Web: www.genomatica.com 

E-mail: info@genomatica.com 

KEY PERSONNEL: Christophe Schilling, Ph.D.; President and CSO 

Thomas Reed; VP, Finance and Corporate Development 




FINANCIAL INFORMATION: Received a $750K Phase II Small Business Innovation Research Grant from 

the U.S. Department of Energy (9/04) 

BUSINESS STRATEGY: As a leader in computational systems biology, use validated technology to 

deliver industry-leading solutions for the modeling and simulation of 

metabolis. These solutions drive a powerful new paradigm wherein 

computer models are used to accelerate biological research and discovery 

across the life sciences. To advance to frontiers of biological discovery and 

the development of innovative products in medical and industrial 

biotechnology while streamlining existing product development and 

enhancing the overall business efficiency of our clients 




DSM Genomatica's 

SimPheny 


DSM implementation of expanded multi-year 6/06 

Genomatica's metabolic collaboration and 



capabilities to help DSM 

develop improved 

biological processes for 

product production 


Kyowa Hakko Genomatica's modeling licensing agreement 1/05 

Kogyo Co. Ltd. and simulation platform 

Unilever expansion of projects multi-year 

8/06 

started in 2005--use of collaboration and 

Genomatica's metabolic 


technologies to develop 

ingredients to improve 

Unilever products 


RESEARCH & DEVELOPMENT: Computational systems biology 

Medical and industrial biotechnology 

PRODUCTS ON MARKET: SimPheny modeling platform 


13355 10th Avenue N, Suite 120 

Minneapolis MN 55441, US 

Phone: (763) 543-0678; Fax: (763) 543-0699 


Web: www.gentra.com 

E-mail: info@gentra.com 

KEY PERSONNEL: Ruth M. Shuman, Ph.D.; CEO and President 

Dennis Thalhuber; CFO 

Robert Kwiatkowski, Ph.D.; VP, R&D 



Acquired by Qiagen NV (5/06) 


BUSINESS STRATEGY: Develop and market manual and automated nucleic acid purification 

products that address the need for high quality nucleic acid, ease of use and 

increased throughput for clinical and clinical research laboratories 

RESEARCH & DEVELOPMENT: Nucleic acids purification 

PRODUCTS ON MARKET: DNA and RNA purification products including: 

Puregene® DNA Purification Kit 

Generation® 

Purescript® 

Autopure ls® DNA Purification Instrument 

Versagene RNA 

Versagene RNA purification Kit 

Clotspin® De-clotting Tubes 

Autotech Automated Nucleic Acid Purification Instrument 



Genzyme Corp. 

500 Kendall Street 


Phone: (617) 252-7500; Fax: (617) 252-7600 

Web: www.genzyme.com; E-mail: info@genzyme.com 

KEY PERSONNEL: Henri A. Termeer; Chairman, President and CEO 

Mara G. Aspinall; President, Genetics 

Mark R. Bamforth; Sr. VP, Corporate Operations and Pharmaceuticals 

John Butler; President, Genzyme Renal 

Earl M. Collier Jr.; Exec. VP, Cardiovascular and Oncology 

Thomas J. DesRosier; Sr. VP, General Counsel and Chief Patent Counsel 

Richard H. Douglas, Ph.D.; Sr. VP, Corporate Development 

David D. Fleming; Group Sr. VP 

Georges Gemayel; Exec. VP, Therapeutics, Transplant and Renal 

James A. Geraghty; Sr. VP 

Elliott D. Hillback Jr.; Sr. VP, Corporate Affairs 

Alison Lawton; Sr. VP, Regulatory Affairs and Corporate Quality Systems 

Evan M. Lebson; VP and Treasurer 

Roger W. Louis; VP, Healthcare and Regulatory Counsel and Chief 

Compliance Officer 

Mary McGrane; VP, Government Relations 

John M. McPherson, Ph.D.; Sr. VP, Cell and Protein R&D 

David Meeker, M.D.; President, Lysosomal Storage Disorder Therapeutics 

Ann Merrifield; President, Genzyme Biosurgery 

Richard A. Moscicki, M.D.; Sr. VP, Medical, Clinical and Regulatory Affairs 

and CMO 

Donald E. Pogorzelski; President, Genzyme Diagnostics 

Alan E. Smith, Ph.D.; Sr. VP, Research and CSO 

Sandford D. Smith; President, International Group 

Peter T. Traynor; VP and Corporate Controller 

Peter Wirth; Exec. VP, Legal, Corporate Development and Drug Discovery, 

Chief Legal Officer and Secretary 

Michael S. Wyzga; Exec. VP, Finance, CFO and CAO 


HISTORY: Founded in June 1981 by Henry Blair and Sherry Snyder 

Began operations by acquiring Whatman Biochemicals Ltd., U.K. 


Founded 16 labs (1990) 

Formed Neozyme Corp. to fund development of programs (10/90) 

Formed Neozyme II to fund the research, development, and clinical testing 

of biotherapeutic products for the treatment of cystic fibrosis (4/92) 

Subsidiary IG Laboratories Inc. purchased Genetic Design Inc., a privately 

held genetic testing company (6/92) 

Acquired phospholipid business of Enzymatix Ltd. (6/92) 

Acquired Medix Biotech Inc. (6/92) 

Acquired Vivigen Inc., in exchange for stock valued at $40M (11/92) 

Neozyme I buyback of four programs, $49M (12/92) 

Established Genzyme Transgenics (now GTC Biotherapeutics) for 

producing human biotherapeutic products in the milk of transgenic animals 

(2/93) 

Acquired diagnostic business Virotech System-Diagnostika GmbH (4/93) 

Acquired diagnostic business Omnia Res srl (5/93) 

Neozyme I buyback of two programs, $49M (12/93) 

Acquired Swiss pharmaceutical manufacturer, Sygena Ltd. (7/94) 

Subsidiary Genzyme Transgenics purchased TSI, a publicly held clinical 

testing and production company (10/94) 

Created Genzyme Tissue Repair by acquiring BioSurface Technology Inc. 

and combining with several of Genzyme Corp.'s tissue repair programs 

(12/94) 

Acquired all shares of IG Laboratories Inc. (9/95) 



Formed Aristogen GmbH with Symbiomed (Germany) to offer genetic 

diagnostic services in Germany (3/96) 

Acquired Genetrix Inc. (4/96) 

Acquired Deknatel Snowden Pencer Inc., $250M (7/96) 

Neozyme II Corp. buyback, $109M (9/96) 

Formed Genzyme Molecular Oncology Division after acquisition of 

PharmaGenics Inc. (6/97) 

Acquired ABIOMED Inc. for $15M (7/97) 

Sold research products business to Techne Corp. for $65.5M (6/98) 

Acquired GelTex Pharmaceuticals Inc. (12/00) 

Acquired Novazyme Pharmaceuticals (9/01) 

Ceased trading of Genzyme Biosurgery and Genzyme Molecular Oncology 

stock (7/03) 

Acquired Sangstat Medical Corp. (12/03) 

Acquired ILEX Oncology Inc. (12/04) 

Acquired Verigen AG (2/05) 

Acquired Bone Care International (7/05) 

Acquired AAV gene therapy assets from Avigen Inc. (12/05) 

FACILITIES: 75 locations in 32 countries, including 15 manufacturing facilities and 9 

genetic testing laboratories 

STOCK-FINANCIAL HISTORY: NASDAQ--GENZ 

IPO--2.9M common shares at $10/share (6/86) 

Public offering--2.9M common shares at $13.125/share (12/89) 

Public offering--4.025M shares of common stock at $35.50/share (3/91) 

Authorized shares of Genzyme Corp. common stock redesignated as 

General Division Common Stock (GENZ); second class of common stock, 

Tissue Repair Division common stock (GENZL), authorized to effect 

acquisition of BioSurface Technologies (12/94) 


Two-for-one stock split (7/96) 






04) 


PRIVATE PLACEMENTS: $10M RDLP to fund clinicals and manufacturing of GCR for Gaucher's 

disease (closed 9/87) 

Formed $36.75M limited partnership to fund development of surgical 

products (11/89) 

$100M of 6.75% convertible subordinated notes due Oct. 2001 (10/91) 

Sold $250M in 5.25% convertible subordinated notes due 2005 (5/98) 

SUBSIDIARIES/DIVISIONS: Genzyme General Division 

Genzyme Biosurgery Division 

Genzyme Molecular Oncology Division 

Genzyme de Argentina SA 

Genzyme do Brasil Ltda. 

Genzyme Chile Ltda. 

Genzyme Colombia SA 

Genzyme Mexico S. de RL de CV 

Genzyme Middle East FZ LLC 

Genzyme Turkey Ltd. 

Genzyme Israel Ltd. 

Genzyme Austria G.m.b.H 

Genzyme Flanders BVBA/SPRL--Belgium 

Genzyme Belgium NV/SA 

Genzyme Europe BV--Czech Republic 

Genzyme A/S--Denmark 

Genzyme SAS--France 

Genzyme Polyclonals SAS--France 

Genzyme GmbH--Germany 

Genzyme CEE GmbH--Germany 



Genzyme Virotech GmbH--Germany 

Genzyme Hellas LLC--Greece 

Genzyme Europe BV Kepviselet--Hungary 

Genzyme Ireland Ltd. 

Genzyme Italy 

Genzyme Polska Sp. z o.o.--Poland 

Genzyme Portugal 

Genzyme Barcelona 

Genzyme Madrid 

Genzyme GmbH--Switzerland 

Genzyme Sygena--Switzerland 

Genzyme Cambridge--U.K. 

Genzyme Ltd.--U.K. 

Genzyme Oxford--U.K. 

Verigen Australia Pty. Ltd.--Australia 

Genzyme China 

Genzyme Asia Ltd. 

Genzyme Tokyo 

Genzyme Korea 

Genzyme Singapore Pte. Ltd. 

Genzyme GmbH Russia 

Genzyme Taiwan 

INVESTMENTS: Genzyme Clinical Partners LP--reacquired the assets for 1.4M shares of 

Genzyme common stock (2/90) 

RenaGel LLC--joint venture with GelTex Pharmaceuticals, Inc. to handle 

development and commercialization of GelTex's RenaGel non-absorbed 

phosphate binder 

Abiomed Inc.--14% 

50/50 joint venture with Genzyme Transgenics Corp.--$33M (7/97) 

Joint venture with BioMarin Pharmaceutical Inc. 

Joint venture with Pharming Group NV (7/98) 


Acadia 

Acadia's cell-based collaborative 10/97 

Pharmaceuticals screening technology screening 

Inc. 

and Genzyme's library 

of more than 1M 

compounds 

agreement 

Alcon Labs ophthalmic products supply agreement 12/86 

(Nestle) 

using hyaluronic acid 

such as Surgicoat 

Angiotech 

identification, 

strategic 

5/06 

Pharmaceuticals development and collaboration 

Inc. 


therapies for cancer 

patients undergoing 

surgical removal of 

tumors 

agreement 

Aronex 

Atragen development and 3/97 


marketing 

Inc. 

agreement (9/93), 

amended-- 

Genzyme has 

option to 

commercialize 

ArQule Inc. drug candidates for 

identifying cancer, 

infectious diseases and 

autoimmune/inflammato 

ry diseases 

development 

agreement--ArQule 

to provide 

Genzyme with 

access to Mapping 

Array program for 

identifying new lead 

compounds against 

Genzyme's targets 


4/97


Bayer AG Genzyme's small 

molecule library 

licensing 

agreement-- 

Genzyme will 

receive up-front 

and service fees 

and milestones 


12/97 

Behringwerke AG amylase substrate licensing 

agreement 

11/91 

Biogen Idec Inc. Avonex (interferon beta- commercialization 9/98 

1a) for MS 

and exclusive 

distribution 

agreement for 

Japan 

Celtrix 

TGF-B2 for tissue product 

6/94 

Pharmaceuticals repair, treatment of MS, development, 

Inc. 

and other systemic licensing, and 

applications 

marketing 


Genzyme Tissue 

Repair 

Crucell NV production of 

nonexclusive STAR 12/05 

monoclonal antibodies research licensing 

agreement 

Cubist 


drug discovery 3/97 

Pharmaceuticals compounds targeting alliance--Cubist will 

Inc. 

bacterial and fungal screen Genzyme's 

infections 

compound library, 

once potential 

therapeutic 

compounds are 

discovered, Cubist 

and Genzyme will 

negotiate 

development terms 

Cyclacel Group Licensing of two of option agreement 9/05 

plc 

Cyclacel's Cyclin- 

Dependent Kinase 

inhibitors 

Daiichi Pure HDL cholesterol blood distribution 

1/96 

Chemicals Co. 

Ltd. 

test 

agreement 

De Novo 

De Novo to apply its drug discovery 1/06 

Pharmaceuticals molecular structure collaboration 

Ltd. 

generating technology 

to focus on a disease 

target that is of interest 

to Genzyme 

agreement 

DiagnoCure Inc. 40 genes for potential licensing 

11/05 

use in detecting lung 

cancer 

agreement 

Dyax Corp. Dyax's phage display non-exclusive 1996 

patents 

patent licensing 

agreement, 

including signing 

fees, milestone 

payments and 

royalties, Dyax gets 

access to related 

patented 

technology owned 

by licensee 

Dyax Corp. Dyax's human plasma letter of intent for 12/98 

Kallikrein inhibitor (EPI- development 

KAL-2) 

agreement


Dyax Corp. antibody phage-display 

libraries for the 

discovery of human 

GelTex 


Inc. 

Imperial Cancer 

Research Fund 

(ICRF) 

antibodies 

RenaGel phosphate 

binder 

gene therapies for 

cancer 

Institut Merieux glucocerebrosidase 

(GCR) products to treat 

IntroGene BV 

(Netherlands) 

Johns Hopkins 

University School 

of Medicine 

Kaken 


Co. Ltd. 

Gaucher's disease 

gene therapy for 

Gaucher's disease 

cardiovascular gene 

therapy 

Seprafilm and 

Sepracoat for 

prevention of post- 

operative adhesions 

LeukoSite Inc. drug candidates for 

treating autoimmune 

and inflammatory 

diseases 

Macrozyme Corp. exploration of 

applications of 

Macrozyme's small 

Mass General 

Hospital 

molecule library 

gene therapy 

treatments for chronic 

hepatitis B and liver 

cancer 

license and 

research 

agreement 



agreement-- 

Genzyme to pay 

GelTex up to 

$27.5M upon FDA 

approval of product 

development 

agreement 

technology license 

and supply 

agreement 

licensing 

agreement-- 

Genzyme to make 

equity investment 

and provide 

research, 

milestone, and 

royalty payments 

devleopment 

collaboration 

marketing 

agreement for 

Japan 

screening 

agreement-- 

LeukoSite will have 

access to more 

than 800K 

compounds in 

Genzyme's library 

and will screen 

against its 

biological targets 

related to cell 

adhesion and 

inflammatory bowel 

disease; after 

screening is 

complete, 

companies will 

negotiate research 

collaboration 

covering 



of compounds 

discovered in 

screening 

exclusive 

collaboration 

development 

collaboration 


6/04 

6/97 

1/96 

9/89 

10/94 

5/98 

2/97 

6/97 

11/05 

6/97


Medtronic Inc. treatments for 

joint venture named 6/04 

cardiovascular disease MG Biotherapeutics 

Molecular 

MI's BioMerge software licensing 

7/97 

Informatics Inc. to integrate and analyze 

genomics information 

agreement 

National Cancer gene therapy for three-year 

10/96 

Institute 

metastatic melanoma collaborative R&D 

agreement 

Partners 

research in oncology, non-exclusive basic 9/97 

HealthCare orthopedics, tissue and clinical 

System 

repair, genetic 

research alliance-metabolic 

diseases, Genzyme to 

cardiovascular disease, provide research 

surgical research, tools, probes and 

genetics, gene therapy reagents, Genzyme 

and neurology 

to provide $300K 

grant to fund 

exchange program 

RenaMed 

development and strategic 

9/05 

Biologics Inc. commercialization of 

RenaMed's Bio- 

Replacement 

Therapy 

collaboration 

St. Elizabeth's cardiovascular gene development 5/98 

Medical Center therapy 

collaboration 

Tm Bioscience undisclosed development and 11/04 

Corp. 


University of gene mutations 

licensing 

10/05 

California at Los believed to be 

agreement 

Angeles (UCLA) associated with drug 

Jonsson Cancer 

Center 

resistance to Gleevec® 

University of gene therapy for research 

11/94 

Pittsburgh 

Gaucher's disease collaboration 

agreement 

Valentis Inc. Valentis' GeneSwitch expanded licesing 9/04 

technology, Genzyme's 

static mixer intellectual 

property 

agreement 

ViaCell Inc. diabetes R&D agreement 3/05 

Vical Inc. nonviral vector gene multiyear R&D 10/90 

therapies for treating agreementcystic 

fibrosis using includes option for 

Vical's cytofectins Genzyme to 

exclusively license 

Vical's cytofectins 

for CF therapy in 

exchange for 

licensing fee, as 

well as research, 

milestone, and 

royalty payments 

(10/93), Genzyme 

paid $1M in 

exercise of option 

for exclusive 

license 

Wyeth 

Synvisc Genzyme to buy 11/04 


back rights in USA 

and five European 

countries 

RESEARCH & DEVELOPMENT: Chronic kidney disease, cancer treatments, transplantation medicine, 

autoimmune disease, orthopaedics, adhesion prevention, cardiovascular 

disease, diagnostic products and services 



PRODUCTS ON MARKET: Lysosomal Storage Disorders 

Cerezyme® (imiglucerase for injection) for Type 1 Gaucher disease 

Fabrazyme® (agalsidase beta) for Fabry disease 

Aldurazyme® (laronidase) for Mucopolysaccharidosis I 

Myozyme® (alglucosidase alfa) for Pompe disease 


Renal Disease 

Renagel® (sevelamer hydrochloride) 

Hectorol® (doxercalciferol) 

Orthopaedics 

Synvisc® (hylan G-F 20) 

Carticel® (autologous cultured chondrocytes) 

MACI®, (Matrix-induced Autologous Chondrocyte Implantation) 

Transplant and Immune Diseases 

Thymoglobulin® (anti-thymocyte globulin, rabbit) 

Oncology 

Campath® (alemtuzumab for injection) for the treatment of B-cell chronic 

lymphocytic leukemia 

Clolar® (clofarabine for intravenous infusion) 

Thyrogen® (thyrotropin alfa for injection) 

351 Guo Shoujing Road 

Shanghai 201203, China 

Phone: +86 21-54925326; Fax: +86 21-64189186 

Web: www.glschina.com; E-mail: glsync@online.sh.cn, glsync@hotmail.com 

KEY PERSONNEL: Hongyan Xu, Ph.D.; President 

Zhou Min; General Manager 



FACILITIES: 17,000 sq. m. manufacturing facility 


BUSINESS STRATEGY: Research, develop, manufacture and market diverse biochemicals and fine 

chemicals, especially peptide, peptide reagents and related products 

PRODUCTS ON MARKET: Coupling reagents 

Labeling reagents 

Linkers for solid phase synthesis 

N-protecting reagents 

Unusual amino acids 

Amino acids derivatives 

Boc-amino acids 

Fmoc-amino acids 

Z-amino acids 

Amino alcohols 

N-methyl amino acids 

Fmoc-amino acids attached to wang resin 

Amino acids attached to 2-chlorotrityl-chloride-resin 

Resins 

Generic and custom peptides 

Specialty chemicals 

Custom peptide synthesis 

Custom antibody services 

Custom organic synthesis 




14716 NE 87th Street 

Redmond WA 98052, US 

Phone: (425) 881-6464; Fax: (425) 882-2476 

Web: www.halosource.com 

E-mail: info@halosource.com 

KEY PERSONNEL: John Kaestle; President and CEO 

Jeffrey F. Williams, Ph.D.; Sr. VP and CTO 

James Thompson; VP and CFO 

Everett J. Nichols, Ph.D.;VP, R&D 

Eric B. Robinson; VP, Operations 



Merged with HaloSource Corp. (5/02) 

Changed name from Vanson Inc. 

Changed name from Vanson HaloSource Inc. (2/06) 





PRIVATE PLACEMENTS: Raised $5M in financing (3/05) 

PRINCIPAL INVESTORS: Mars Inc. 

Alexander Hutton Venture Partners LP 

Buerk Dale Victor LLC 

BUSINESS STRATEGY: Provide reliable, tested and proven solutions in the product categories of 

safe water, infection control and healing enhancement 

RESEARCH & DEVELOPMENT: Antimicrobial and disease prevention solutions that reliably and effectively 

kill germs 

PRODUCTS ON MARKET: HaloPure®--Drinking water purification solutions 

SeaKlear®--Water treatment solutions for the pool and spa industry 

StormKlear® and Klarify®--Waste and storm water treatment solutions 

HaloPure FT--Industrial fluid treatment solutions 

HaloShield®--Coating solutions that harness the antimicrobial power of 

chlorine 

Biomedical--Hemostasis and wound-healing solutions 

Hammen Corp. 

4200 Fox Farm Road 

Missoula MT 59802, US 

Phone: (406) 728-5897; Fax: (406) 728-5924 

KEY PERSONNEL: Richard F. Hammen, Ph.D.; President 

Mary Gordon; Manager, Marketing 



FACILITIES: Headquarters, executive offices, and laboratories located in Missoula, Mont. 


PRINCIPAL INVESTORS: Montana Science & Technology Alliance (MSTA) 



BUSINESS STRATEGY: Seek partners to develop technology for removal of toxic metals from water 

and to develop drug master files for biotechnology products 

PRODUCTS ON MARKET: HiPAC® affinity chromatography columns 


84 October Hill Road 

Holliston MA 01746, US 

Phone: (508) 893-8066; Fax: (508) 429-5732 


Web: www.harvardbioscience.com 

E-mail: info@harvardbioscience.com 

KEY PERSONNEL: Chane Graziano; CEO 

David Green; President 

Susan Luscinski; COO 

Bryce Chicoyne; CFO 

Mark Norige; COO, Harvard Apparatus 

David Strack; President, Genomic Solutions and Union Biometrica 

David Parr; Managing Director, Biochrom 


HISTORY: Founded in March 1996, when it acquired a portion of the assets of Harvard 

Apparatus (founded in 1901) 

Changed name from Harvard Apparatus Inc. (12/00) 

Asys Hitech GmbH acquired select assets of the microplate reader and 

washer product lines from Anthos Labtec Instruments GmbH (6/06) 

FACILITIES: 43,750 sq. ft. leased facility in Holliston, Mass. (corporate headquarters) 

28,000 sq. ft. leased facility in Cambridge, U.K. 

22,600 sq. ft. leased facility in San Francisco, Calif. 

18,000 sq. ft. leased facility in Warwickshire, U.K. 

15,500 sq. ft. owned facility in Edenbridge, U.K. 

9,000 sq. ft. leased facility in March-Hugstetten, Germany 

7,500 sq. ft. leased facility in Hamden, Conn. 

4,700 sq. ft. leased facility in Eugendorf, Austria 

Additional leased facilities for sales and administrative support in Geel, 

Belgium; Les Ulix, France; and Montreal, Canada 

STOCK-FINANCIAL HISTORY: NASDAQ--HBIO 

IPO--7.4M shares, $58.9M (12/00) 


Net income (YE 05) compared to $2.329M (YE 04) 

Earnings per share (YE 05) compared to $0.08/share (YE 

04) 


04) 


SUBSIDIARIES/DIVISIONS: HBIO Securities Corp.--U.S. 

Harvard Apparatus FSC Inc.--U.S. Virgin Islands 

Warner Instruments LLC--U.S. 

Union Biometrica Inc.--U.S. 

Harvard Apparatus Ltd.--U.K. 

Harvard Apparatus SARL--France 

Biochrom Ltd.--U.K. 

Scie-Plas Ltd.--U.K. 

Asys Hitech GmbH--Austria 

Hugo Sachs Elektronik Harvard Apparatus GmbH--Germany 

Union Biometrica GmbH--Germany 

Maia Scientific NV--Belgium 

Ealing Scientific Ltd. Canada (dba Harvard Apparatus, Canada) 

Genomic Solutions Inc.--U.S. 



Cartesian Technology Inc.--U.S. 

Genomic Solutions Ltd.--U.K. 

Genomic Solutions Canada Inc.--U.S. 

Genomic Solutions Inc.--Canada 

Hoefer Inc.--U.S. 

KDS Inc.--U.S. 

BUSINESS STRATEGY: Have a broad range of specialized products that hold strong positions in 

niche markets focused on the bottlenecks in drug discovery research in 

order to reduce the risk of being dependent on a single technology, to 

reduce head-to-head competition; and to position ourselves to achieve 

above-average revenue growth and above-average margins 

RESEARCH & DEVELOPMENT: Focus is on the development of products that address bottlenecks within the 

drug discovery process, in particular, for application in the areas of ADMET 

screening, molecular biology, genomics, proteomics and highthroughput/high-content 

screening 

PRODUCTS ON MARKET: ADMET screening products, including absorption diffusion chambers, 96 

well equilibrium dialysis plate for serum protein binding assays, organ 

testing systems, precision infusion pumps, cell injection systems, ventilators, 

electroporation products 

Molecular biology products, including spectrophotometers; 

DNA/RNA/Protein calculators; multi-well plate readers; amino acid analysis 

systems; low volume, high-throughput liquid dispensers; gel electrophoresis 

systems 


99-193 Aiea Heights Drive, Suite 200 

Aiea HI 96701, US 

Phone: (808) 486-5333; Fax: (808) 792-1343 

Web: www.hibiotech.com 

E-mail: info@hibiotech.com 

KEY PERSONNEL: Nicholas Mitsakos; Chairman 

David G. Watumull; President and CEO 

Samuel F. Lockwood, M.D.; Medical Director 

Carolyn Weeks-Levy, Ph.D.; VP, Research, Preclinical Development and 

Regulatory Affairs 

Richard L. Sherman; Sr. VP, Business Development and General Counsel 




Merged vaccine business with Avantogen Ltd.'s vaccine business (5/06) 


FACILITIES: 9,000 sq. ft. headquarters and R&D facility 


PRIVATE PLACEMENTS: Raised $8.5M in Series A financing 

Raised $4M in federal funding (2003) 

Raised $8M (2004) 

Raised $7.8M in Series C financing (1/06) 

INVESTMENTS: PanThera Biopharma Inc. 

FINANCIAL INFORMATION: Received $15.5M through three awards from the NIH for West Nile Virus 

and dengue vaccine development (12/04) 




Avantogen Ltd. evaluation of 

worlwide, 

10/05 

Avantogen's GPI-0100 nonexclusive 

licensing 

agreement 

Cobra 

material for clinical trials manufacturing and 3/05 

Biomanufacturing of vaccines against supply agreement 

plc 

dengue fever and West 

Nile disease 

RESEARCH & DEVELOPMENT: rDNA, cell tissue culture, purification (lab-scale), hybridoma/cell fusion 

Dengue vaccine 

Immunoassays for marine natural products 

Taxol immunoassays 

Prodrugs 

Enteric pathogens 

PRODUCTS ON MARKET: Immunoassay kits for Taxol and Taxanes 

Marine toxins for palytoxins and derivatives lyngbyatoxin A 

Antitoxin moonoclonal antibodies for mAG 73D3, neutralizing anti-palytoxin; 

mAGT20G110, neotralizing antitetrodotoxin 


Mascheroder Weg 1 

Braunschweig D-38124, Germany 

Phone: +49 (0) 531-6181-0; Fax: +49 (0) 531-6181-515 

Web: www.helmholtz-hzi.de 

E-mail: info@helmholtz-hzi.de 

KEY PERSONNEL: Dr. Peter Lange; Chairman, Supervisory Board 

Prof. Rudi Balling; Scientific Director 

Dr. Georg Frischmann; Administrative Director 


HISTORY: Founded by Stiftung Volkswagenwerk in 1965 

State-owned research institute since 1976 

Changed name from Gesellschaft fur Biotechnologische Forschung mbH 

(German Research Centre for Biotechnology) (7/06) 


Member--Hermann von Helmholtz-Gemeinschaft Deutscher 

Forschungszentren (HGF) 

Partner--BioRegioN 

STOCK-FINANCIAL HISTORY: Private government agency 

PRINCIPAL INVESTORS: German Federal Government (BMBF)--90% 

State of Lower Saxony--10% 

BUSINESS STRATEGY: Establish collaborative agreements with industrial partners and universities 

Contract manufacturing and research for clients from universities and 

industry 

Non-profit organization (governmental research centre) 

Research and development, technology transfer via patents, licensing 

National and international cooperation with universities, institutes and 

companies 

RESEARCH & DEVELOPMENT: Cell and immune biology 

Microbiology 

Molecular biotechnology 

Structural biology 

Biochemical engineering 


Hercules Inc. 


Hercules Plaza, 1313 North Market Street 

Wilmington DE 19894-0001, US 

Phone: (302) 594-5000; Fax: (302) 594-5400 

Web: www.herc.com 

E-mail: info@herc.com 

KEY PERSONNEL: Craig A. Rogerson; President and CEO 

Edward V. Carrington; VP, Human Resources 

Richard G. Dahlen; Chief Legal Officer 

Israel J. Floyd; Corp. Secretary and General Counsel 

John E. Panichella; VP and President, Aqualon 

Paul C. Raymond III; VP and President, Paper Technologies and Ventures 

Group 

Allen A. Spizzo; VP and CFO 



Sold Aerospace division for $439M to Alliant Techsystems (3/95) 

Acquired Quantum Hi-Tech Co. Ltd. (12/03) 

Agreed to purchase the guar and guar derivative manufacturing business of 

Benchmark Polymer Products LP (subsidiary of Benchmark Performance 

Group Inc.) (1/06) 

STOCK-FINANCIAL HISTORY: NYSE--HPC 

Three-for-one stock split (1/95) 


Net income (YE 05) compared to $28.1M (YE 04) 

Earnings per share (YE 05) compared to $0.26/share (YE 

04) 



SUBSIDIARIES/DIVISIONS: Two major operating segments: 

Aqualon Group: 

Aqualon--Leader in products that modify the physical properties of waterbased 

systems 

Pinova--Leader in pine chemistry since 1920, the world's only pale wood 

rosin derivatives producer 

Paper Technologies and Ventures Group 

BUSINESS STRATEGY: Continuously improve to better serve our customers and extend our 

competitive advantage 

Maximize cash flow, reduce financial leverage and return to investment 

grade credit rating 

Grow profitably and increase ROIC 

Mitigate and reduce legacy liabilities 


Barbara Ann 

Karmanos Cancer 

Institute (Wayne 

State University), 

University of 

Michigan 

citrus pectin for cancer R&D agreement 12/95 

Uniqema 

synthetic lubricants extended 

7/06 

(business of ICI 

manufacturing 

Americas) 

agreement 

RESEARCH & DEVELOPMENT: In-house program in functional foods 

Biochemical production of natural food ingredients via fermentation and 

enzyme processing, pharmaceutical coatings, excipients, nutraceuticals 



PRODUCTS ON MARKET: Aqualon--thickeners used in water-based products such as latex paint 

FiberVisions--staple fiber used in hygienic products and automotive textiles 

Pinova--adhesives, flavor and beverage, construction, fragrance, household 

and industrial 

Pulp and Paper--solutions for pulp and paper manufacturing needs 

Industrial Specialities--thickeners used in water-based products such as 

latex paint 

Hidex Oy 

Mustionkatu 2 

Turku 20750, Finland 

Phone: +358 2 275 0557; Fax: +358 2 241 0075 

Web: www.hidex.com 

E-mail: info@hidex.com 

KEY PERSONNEL: Haaslahti Jukka; CEO 

Ville Haaslahti; Product Specialist 

Risto Juvonen; Product Manager 





PRINCIPAL INVESTORS: Sitra 

PRODUCTS ON MARKET: Plate Chameleon multi technology plate reader, Triathler portable 

multitechnology vial reader, Consumables and reagents for our readers, 

Radiowater Generator for Positron Emission Tomography (PET) studies. 


Micro-Plate Automation / Screening 

Systems 


Woolley Road, Alconbury 

Huntingdon PE28 4HS, UK 

Phone: +44 (0) 1480 892 000; Fax: +44 (0) 1480 890 693 

Web: www.huntingdon.com 

E-mail: sales@ukorg.huntingdon.com 

KEY PERSONNEL: Andrew Baker; Chairman 

Brian Cass; Managing Director 

Dr. M.J. Butler; Pharmaceutical Services Director 

Dr. D.R. Hawkins; Agrochemical and Food Services Director 

Dr. P.C. Brooker; Industrial Chemical Services Director 




SUBSIDIARY OF: Life Sciences Research 

BUSINESS STRATEGY: Provide biological and chemical contract safety evaluation services to 

pharmaceutical, biotechnology, agrochemical and industrial chemical 

markets 




2801 Blue Ridge Road, Suite G-70 

Raleigh NC 27607, US 

Phone: (919) 783-9595; Fax: (443) 494-0005 

Web: www.hybrizyme.com 

E-mail: hybrizyme@aol.com 

KEY PERSONNEL: Randy Allen, Ph.D.; CEO 




BUSINESS STRATEGY: Develop proprietary testing methods that incorporate the latest innovations 

in molecular and cellular toxicology either as a replacement for existing 

protocols or as new tests for compounds that cannot be accurately 

measured using current technology 

RESEARCH & DEVELOPMENT: Diagnostic tests for environmental toxins and other compounds 

PRODUCTS ON MARKET: Wallac Victor2 (with PerkinElmer Life Sciences) 

Delfia reagents 

AhRC PCR assay 


Dioxin and Furan assay in development 

ICPbio 

P. O. Box 1607, 26 Waipareia Avenue 

Auckland , New Zealand 

Phone: +64 9-838-4205; Fax: +64 9-838-4209 

Web: www.icpbio.com 

E-mail: dglen@icpbio.com 

KEY PERSONNEL: Dr. Earl Stevens; Managing Director 

Kelvin Hunter; CFO 

Annette Nickless; Financial Controller 

Dr Jerome Demmer; Manager, R&D 

Ben Perrin; Marketing Manager 

Alan Cocks; Sales Manager 

Greg Shewfelt; Manager, Business Development 

Karen Munro; Production Manager 

Praveena Rawls; QA and QC Manager 




BUSINESS STRATEGY: Commercialize research to provide innovative technical and commercial 

solutions to the animal health and pharmaceutical industries 

RESEARCH & DEVELOPMENT: Laboratory and process scale protein purification to levels suitable for 

animal trials. Protein purification process development. Analytical protein 

chemistry. Development of enzyme immunoassays. Development of embryo 

handling products. Bulk formulation of sterile solutions. Sterile lyophilisation. 

Clean room facilities. 



PRODUCTS ON MARKET: Confirm, animal pregnancy test using milk or faeces sample 

Emcare, new media for freezing/thawing/culturing animal embryos 

(phosphate-free) 

Ovagen, an FSH product for superovulation of livestock 

Bovine serum albumin for cell culture and laboratory use 


P.O. Box 1625 

Idaho Falls ID 83415, US 

Phone: (208) 526-0111 

Web: www.inl.gov 

KEY PERSONNEL: John J. Grossenbacher; Laboratory Director 

Art Clark; Deputy Laboratory Director, Operations 

Dr. David Hill; Deputy Laboratory Director, Science and Technology 

Juan Alvarez; Deputy Laboratory Director, Management Systems 

Dr. James Lake; Associate Laboratory Director, Nuclear Programs 

Dr. KP Ananth; Associate Laboratory Director, National and Homeland 

Security 

Dr. J.W. (Bill) Rogers Jr.; Associate Laboratory Director, Science and 

Technology and Chief Research Officer 

David L. Kudsin; Associate Laboratory Director, Specific Manufacturing 

Capability 

David Richardson; Associate Laboratory Director, Nuclear Operations 

Fran B. Williams; Director, Environment, Safety, Health and Quality 

Dr. Brian Sack; Director, Business Management and CFO 

Dwayne Coburn; Director, Facilities and Site Services 

John Lindsay; Director, Communications 

Dr. Ralph Bennett; Director, Science and Technology Strategic Planning 

Dr. Susan B. Arnold; Director, Human Resources and Diversity Programs 

Carol Johnson; Director, Infrastructure, Optimization, Integration and 

Planning 

John J. (Jack) Lance; Director, Technology Partnerships 

Mark D. Olsen; General Counsel 

Dr. Andrew C. Klein; Director, Education, Training, and Research 

Partnerships 

Dr. Leonard J. Bond; Director, Center for Advanced Energy Studies 


HISTORY: Founded in 1949 as the National Reactor Testing Station 

FACILITIES: 890-square-mile area in southeastern Idaho 

Materials and Fuels Complex (formerly Argonne National Laboratory-West) 

Reactor Technology Complex (formerly Test Reactor Area) 

Science and Technology Campus 


SUBSIDIARIES/DIVISIONS: Divisions and departments: 

Physical Science: Physics, Material Sciences, Chemical Sciences, 

Analytical Chemistry & Instrumentation, Advanced Modeling & Simulation, 

Prototype Engineering 

Life & Earth Science: Biological Sciences, Ecological Sciences, 

Geosciences, Modeling & Measurement 

Engineering Technology: Environmental Engineering, Process Engineering, 

Nuclear Materials Disposal & Engineering, Applied Mechanics & Sustainable 

Design, Systems Engineering 

Energy & Technology Systems: Fossil Energy, Renewable Energy, 

Transportation Technology, Industrial Technology, Robotics & Human 

Systems 



RESEARCH & DEVELOPMENT: Science and Technology: Developing America's hydrogen economy and 

alternative fuels and energy systems. Supports the development of 

advanced energy storage and transportation systems, critical energy 

infrastructure and water resources. Manages the environmental 

consequences of energy development and use. Research on compressed 

and liquefied natural gas, high powered batteries and ultra capacitors, 

integrated fuel processors and fuel cell systems, renewable energy systems, 

carbon capture and sequestration, hazardous waste management 

treatment, advanced offgas treatment systems, advanced welding systems, 

surface and subsurface monitoring systems, sustainable building design, 

and autonomous unmanned aerial and ground vehicles. 


National and Homeland Security: Global security, homeland security, 

national defense, energy security and special programs 

Nuclear programs: Nuclear safety analysis, irradiation services, nuclear 

operations, management of spent nuclear fuel, biocorrosion of fuels 

One IDEXX Drive 

Westbrook ME 04092, US 

Phone: (207) 856-0300; Fax: (207) 856-0346 


Web: www.idexx.com 

E-mail: businesscommunications@idexx.com 

KEY PERSONNEL: Jonathan W. Ayers; Chairman, President and CEO 

William C. Wallen, Ph.D.; Sr. VP and CSO 

Merilee Raines; VP and CFO 

Conan R. Deady; VP, General Counsel and Secretary 

Sam Fratoni, Ph.D.; VP and CIO 

Robert Hulsy; VP, Laboratory Services 

Jennifer Joiner; VP, North American Commercial Operations 

Laurel LaBauve; VP, Worldwide Operations 

Quentin Tonelli, Ph.D.; VP, Rapid Assay and Production Animal Services 



Purchased certain assets of Baxter Diagnostics (2/91) 

Purchased diagnostics business of Fermenta Animal Health Co. (10/91) 

Purchased assets of VetTest, a manufacturer of biochemical monitoring 

tests for animal health care, acquisition completed (1/92) 

Acquired Environetics Inc., a manufacturer and marketer of environmental 

diagnostics (2/93) 

Acquired Amis, a commercial veterinary laboratory in Japan (9/94) 

Acquired Cardiopet Inc., which provides veterinary, cardiology, internal 

medicine, and other consulting services (5/95) 

Acquired VetLab Inc., veterinary laboratory (3/96) 

Acquired Grange Laboratories, veterinary laboratory (4/96) 

Acquired Veterinary Services Inc., veterinary laboratory (5/96) 

Acquired Idetek Inc. (1996) 

Acquired Blue Ridge Pharmaceuticals (10/98) 

Acquired veterinary laboratory business of Sonora Quest Laboratories (3/99) 

Acquired veterinary laboratory business of Tufts University School (12/99) 

Acquired Sierra Veterinary Laboratory (3/00) 

Acquired Veterinary Pathology Services Pty Ltd. (7/00) 

Acquired Genera Technologies Ltd. (9/01) 

Acquired Syracuse Bioanalytical Inc. (8/04) 

Acquired Bommeli Diagnostics (12/04) 

Acquired Vet Med Lab (11/04) 



FACILITIES: 329,000 sq. ft. of leased office and manufacturing space in Westbrook, 

Maine 

97,500 sq. ft. of leased industrial space in Memphis, Tenn. 

40,000 sq. ft. of leased office and manufacturing space in Eau Claire, Wis. 

48,000 sq. ft. of leased warehouse and office space in the Netherlands 

STOCK-FINANCIAL HISTORY: NASDAQ--IDXX 

IPO--1.6M shares at $15/share (6/91) 


Two-for-one common stock split (10/93) 

Two-for-one common stock split (6/95) 

Public offering--4.6M shares of common stock at $35/share (9/95) 





04) 


SUBSIDIARIES/DIVISIONS: Three business segments: Companion Animal Group (CAG), Water testing 

business and Food Diagnostics Group 

BUSINESS STRATEGY: Manufacture, develop and market rapid test kits for food safety, quality 

control, environmental testing and veterinary testing 


Alteon Inc. pimagedine as oral licensing 

6/97 

therapeutic for diabetes 

and aging in companion 

animals 

agreement 

Banfield, The Pet Idexx to provide Idexx five-year 

5/05 

Hospital® 

VetLab laboratory 

system and rapid assay 

products to Banfield 

hospitals 

agreement 

Beckman 

Icon immunoassay worldwide licensing 6/86 

Instruments Inc. technology for 

veterinary diagnostics 

and agricultural 

applications 

agreement 

Becton Dickinson BD's hematology development and 10/93 

and Co. 

products and 

marketing 

technology for 

veterinary markets 

agreement 

RESEARCH & DEVELOPMENT: Molecular biology, cellular biology, MAbs, immunoassays, membrane filter 

delivery systems 

Expansion of current EIA test system and micro fabrication technology 

Immuno-based optical biosensors 

Bacterial Ice Nucleation Diagnostic (BIND) pathogen test kits 

Antibody development for antibiotics, toxins, microbial pathogens, pesticides 

and environmental contaminants 

New immunoassay formats for multi-analyte, one-step testing 

PRODUCTS ON MARKET: More than 100 products, including over 50 immunoassays for infectious 

diseases in swine, cattle, poultry, horses, cats and dogs 

Tests for contaminants on food production surfaces and in milk or grain 

Clinical chemistry, hematology, and electrolyte systems and reagents 

Tests for environmental monitoring--E. coli, coliforms, and enterococci 

ELISA test for B. abortus 

LacTek residue screening test kits for milk 

LacTek antibiotic residue test system 

Sultamethazine serum/plasma test kit 

Phytodetek plant growth regulator 

Quantix workstation for petroleum/hydrocarbon contamination measurement 

in soil and water 




Quantix labstation test kits for pesticides, petroleum and TNT contaminants 

BIND® salmonella one-day pathogen test 

SNAP® Heartworm Antigen test 

NAVIGATOR® (32% nitazoxanide) Antiprotozoal oral paste treatment for 

equine protozoal myeloencephalitis 

9110 Red Branch Road 

Columbia MD 21045-2024, US 

Phone: (410) 997-2599; Fax: (410) 730-0540 

Web: www.igene.com 

E-mail: igene@igene.com 

KEY PERSONNEL: Michael G. Kimelman; Chairman 

Stephen F. Hiu, Ph.D.; President, CTO and Director, R&D 

Edward J. Weisberger; CFO 

Patrick F. Monahan; VP and Director, Manufacturing 

Per A. Benjaminsen; Director, Sales and Marketing 


HISTORY: Founded in October 1981 by Robert Milch and William Hall 

Formerly called Genetic Research Corp. and IGI Biotechnology Inc. 

Formed a wholly-owned subsidiary, Igene Chile Comercial Ltda. (2000) 

Acquired ProBio Nutraceuticals AS (2001) 

Sold ProBio Nutraceuticals AS (2/03) 

FACILITIES: Leases approximately 8,500 sq. ft. of space in the Oakland Ridge Industrial 

Park located in Columbia, Md.--2,000 sq. ft. of the space is used for 

executive and administrative offices; 2,500 sq. ft. for R&D activities; and 

4,000 sq. ft. for the company's intermediate-stage or scale-up pilot plant 

facility 

Leased manufacturing facilities at Fermic SA de CV in Mexico City 

Leased warehouse space for product storage in Mexico City 

220 sq. ft. of leased office space in Chile 

STOCK-FINANCIAL HISTORY: OTC BB 

IPO--800K shares at $6/share, $4.8M (7/86) 




PRIVATE PLACEMENTS: Private placement 796K share/warrant units (12/83) 

Subscription offering of 50K shares (3/85) 

Subscription offering of 375K share/note units (2/86) 

Private placement 625K shares (9/87) 


Private placement 4.596M shares (3/91) 


Private placement 1.2M shares (8/95) 

SUBSIDIARIES/DIVISIONS: Igene Chile Comercial Ltda. 

INVESTMENTS: Formed 50:50 joint venture to produce AstaXin® for the aquaculture industry 

with Tate & Lyle plc (3/03) 

BUSINESS STRATEGY: Developing, market and manufacture specialty ingredients for human and 

animal nutrition 


Fermic SA de CV AstaXin renewed 

manufacturing 

agreement 

5/00 



RESEARCH & DEVELOPMENT: Development of proprietary processes to convert selected agricultural raw 

materials or feedstocks into commercially useful and cost effective products 

for the food, feed, flavor and agrochemical industries 

PRODUCTS ON MARKET: AstaXin® yeast with high level of astaxanthin pigment 


Electrical and Electronic Engineering Building 

Imperial College London, South Kensington 

London SW7 2AZ, UK 

Phone: +44 020-7581-4949 

Fax: +44 020-7589-3553 

Web: www.imperialinnovations.co.uk 

E-mail: innovations@imperial.ac.uk 

KEY PERSONNEL: Martin Knight; Chairman 

Susan Searle; CEO 

Julian Smith; CFO and COO 

Jon Page; Head, New Ventures 

Naiem Hussain; Head, Asset and Investment Management 

Tony Hickson; Head, Biosciences Team 

Brian Graves; Head, Engineering and Technology Team 


HISTORY: Name changed from RPMS Technology Ltd. (1998) 

Created more than 60 spin-out companies 

STOCK-FINANCIAL HISTORY: University-funded research center 

PRIVATE PLACEMENTS: Raised US$37.9M in private placement (5/05) 

SUBSIDIARY OF: Imperial College London 

BUSINESS STRATEGY: Conduct technology transfer from research program of Imperial College 


2033 Main Street, Suite 400 

Sarasota FL 34237, US 

Phone: (941) 925-2500; Fax: (941) 925-2503 

Web: www.industrialbiotechnology.com 

E-mail: jhensley@industrialbiotechnology.com 

KEY PERSONNEL: Andy Badolato; CEO 

David L. West; CFO 

Mark Truei, Ph.D.; VP, Manufacturing 

Gary Howell, Ph.D.; VP, Business Development 

Gurinder Shahi, M.D., Ph.D.; Chief Technologist 

J. Ron Doran; Director, Sales and Marketing 

Tom Hentschell; VP, Operations and Marketing 

Jack Hensley; VP, Investor and Public Relations 

Dr. Eric I. Tsao; Chief Scientist 


HISTORY: Acquired Bio-Repellant Technologies Inc. (BRT) from UTEK Corp. (5/06) 

Acquired assets of Bio-Flavorance Technologies and Research Inc. (1/06) 

Acquired Advanced Pheromone Technologies Inc. (9/06) 

STOCK-FINANCIAL HISTORY: Pink Sheets--IBTY 



BUSINESS STRATEGY: Commercializes technologies and intellectual property in the field of 

biologically produced chemicals 

Through licensing, partnerships and direct sales, IBC will bring to market 

new and established chemicals for use in flavors and fragrances, fine 

chemicals, pharmaceutical, agricultural, environmental and bio-energy 

applications 


Isis Innovation Cytochrome P-450 expanded licensing 7/06 

Ltd. (technology technology and two agreement 

transfer company 

of Oxford 

University) 

patented technologies 

UTEK Corp. UTEK to assist in the strategic alliance 1/06 

identification of IP 

acquisitions 

agreement 

RESEARCH & DEVELOPMENT: Two platform technologies: 

The Oxford Cytochrome P450 Designer Enzyme Technology Platform 

The Rice FPP Biosynthesis Technology Platform 

PRODUCTS ON MARKET: ALCHEMx Production Platforms--Processes for the design, development, 

scale-up and optimization of specific chemical compounds 

Industrial Technology Research Institute – 

Biomedical Engineering Center 

Room 607, Building 51, Sec. 4, 195 Chunghsing Rd. 

Hsin Chu 31040, Taiwan 

Phone: +886 3-591-2686; Fax: +886 3-582-0464 

Web: www.itri.org.tw; E-mail: lhsieh@itri.org.tw 

KEY PERSONNEL: Hsin-I Lin; Chairman 

Dr. Johnsee Lee; President 

Dr. Jyuo-Min Shyu; Exec. VP 

Dr. Hsin-Sen Chu; Exec. VP 

Dr. Yeou-Gong Hsu; VP 

Dr. Shing-Yuan (Bill) Tsai; VP 


HISTORY: Founded in 1973 by the Ministry of Economic Affairs (MOEA) to attend to 

the technological needs of Taiwan's industrial development 

Spun off United Microelectronices Corp. (UMC) (1979) 

Spun off Taiwan Semiconductor Manufacturing Company Ltd. (TSMC) 

(1987) 

Spun off Taiwan Mask Corp. (TMC) (1988) 

Spun off Mirle Automation Corp. (1989) 

Spun off Vanguard International Semiconductor Corporation (VIS) (1994) 

FACILITIES: Seven laboratories and four centers 


SUBSIDIARY OF: Industrial Technology Research Institute 


-Engage in applied research and technical services to accelerate the 

industrial development of Taiwan 

-Develop key, compatible, forward-looking technologies to meet industrial 

needs and strengthen industrial competitiveness 

-Disseminate research results to the industrial sector in a timely and 

appropriate manner, in accordance with the principles of fairness and 

openness 



-Foster the technology development of small and medium-sized businesses, 

and cultivating industrial technology human resources for the benefit of the 

nation 

RESEARCH & DEVELOPMENT: Research projects in the following areas: 

Communications and Optoelectronics 

Precision Machinery and MEMS 

Materials and Chemical Engineering 

Sustainable Development 

Biotechnology and Medicine 

Nanotechnology 


LIHTI Building, Suite 106, 25 Health Sciences Drive 

Stony Brook NY 11790-3350, US 

Phone: (631) 444-6640; Fax: (631) 444-6645 

Web: www.genetargeting.com 

E-mail: info@genetargeting.com 

KEY PERSONNEL: Wel Weng; President and CEO 

Paul Sheiffele; Exec. VP 

Ellen Chen; Exec. VP 


HISTORY: Founded in Febuary 1998 

Began biotech R&D in November 2000 

FACILITIES: 8,500 sq. ft. headquarters located in Stony Brook, N.Y. 

2,000 sq. ft. animal facility located in Stony Brook, N.Y. 

3,000 sq. ft. warehouse located in Islip, N.Y. 


SUBSIDIARIES/DIVISIONS: mouse-knockout technology 

BUSINESS STRATEGY: Improve the R&D conditions and business results for scientists and 

companies by offering effective and well defined knockout animals 

RESEARCH & DEVELOPMENT: Improve technology for mouse knockout production; search for novel animal 

models for drug discovery 

Institute for Biological Research and Technology 

University of South Carolina 

Coker Life Sciences Building, Room 403 

Columbia SC 29208, US 

Phone: (803) 777-2468; Fax: (803) 777-4002 

Web: www.cosm.sc.edu/biotech 

E-mail: austin@biol.sc.edu 

KEY PERSONNEL: Austin L. Hughes; Director 

Travis Glenn; Associate Director 

Robert P. Lawther, Director, DNA Synthesis and Licor Sequencing Facility 

Loren Knapp; Director, Monoclonal Antibody Facility 

Bert Ely; Director, Biotechnology Training Laboratory 

Lewis Bowman; Director, Bioinformatics Resources 

Laszlo Marton; Director, Plant Genetic Engineering Facility 

Michael Dewey; Director, Transgenic Mouse Facility 

Thomas Borg; Director, Integrated Microscopic Analysis Facility 




HISTORY: Founded in 1988 by scientists at the University of South Carolina who had 

worked together to acquire the equipment needed to facilitate the use of 

biotechnological innovations in their research programs 

STOCK-FINANCIAL HISTORY: University research center 

BUSINESS STRATEGY: Promote the use of biotechnology and make facilities available to scientists, 

industry and other institutions throughout the region 

RESEARCH & DEVELOPMENT: Basic research in genetics, molecular biology, biochemistry and 

environmental biotechnology 


Norwich Research Park, Colney 

Norwich NR4 7UA, UK 

Phone: +44 1603 255000; Fax: +44 1603 507723 

Web: www.ifr.ac.uk; E-mail: ifr.communications@bbsrc.ac.uk 

KEY PERSONNEL: Prof. David White; Director 

Dr. Roger Fenwick; International Coordinator 

Mrs. Catherine Reynolds; Head of Communications 

Prof. Sue Southon; Head of Enterprise 


HISTORY: Formerly AFRC Institute of Food Research 

A company limited by guarantee, grant-aided by the Biotechnology and 

Biological Science Research Council 

FACILITIES: Laboratory in Norwich 


SUBSIDIARIES/DIVISIONS: IFR Enterprises Ltd. 

Food and Health Network (FHN) 

National Collection of Yeast Cultures (NCYC) (see separate entry) 

BUSINESS STRATEGY: Fundamental research applicable to the marketplace 

Innovation via patenting, joint ventures, and confidential development 

RESEARCH & DEVELOPMENT: Protein and enzyme science for biotransformations of food functional 

molecules 


Microbial genetics 

Natural preservation 

Metabolic engineering 

Novel polysaccharides 

Personalized nutrition 


521 West 57th Street 

New York NY 10019, US 

Phone: (212) 765-5500; Fax: (212) 708-7132 

Web: www.iff.com 

E-mail: iff.information@iff.com 

KEY PERSONNEL: Robert M. Amen; Chairman and CEO 

Jim Dunsdon; COO 

Dennis M. Meany; Sr. VP, General Counsel and Secretary 




Douglas J. Wetmore; Sr. VP and CFO 

Clint D. Brooks, Ph.D.; Sr. VP, R&D 

Steven J. Heaslip; Sr. VP, Human Resources 

Joe Faranda; VP and Chief Marketing Officer 

Nicolas Mirzayantz; Sr. VP, Fine Fragrances and Beauty Care and Regional 

Manager, North America 


Purchased Auro Tech, a Wisconsin biotechnology company specializing in a 

broad range of natural dairy flavors, dairy and meat cultures, natural cheese 

and other flavor products (1992) 

Acquired Bush, Boake Allen Inc. (2000) 

FACILITIES: 62 facilities in 30 countries 

30 manufacturing facilities 

STOCK-FINANCIAL HISTORY: NYSE--IFF 

Repurchase of up to 15M shares of common stock authorized (9/92, 9/96) 






04) 


BUSINESS STRATEGY: Create and manufacture flavor and fragrance products used by other 

manufacturers to impart or improve flavor or fragrance in a wide variety of 

consumer products 


Johns Hopkins odor binding protein collaborative 1988 

Medical School 

neuroscience 

research agreement 

Xinanjiang fragrance ingredients joint venture 

1993 

Perfumery Factory using Chinese raw 

materials 

agreement 

RESEARCH & DEVELOPMENT: Enzymology and fermentation to improve ingredients and develop natural 

flavor molecules 

Large-scale commercial manufacturing 

Olfactory biochemistry 


Head space analysis techniques for capture and synthesis of 

fragrance/flavor molecules from flowers and fruits 

Recombinant DNA for production of natural flavoring materials and food 

ingredients 

Microemulsion preparation for clear beverages 

Fragrances with organoleptic properties to provide natural insect and 

mosquito repellancy 

PRODUCTS ON MARKET: Flavors and fragrances for beverages, dairy products, fabric care, fine 

fragrances, home care, ingredients, oral and pharmaceuticals, toiletries, 

foods 


Iogen Corp. 


310 Hunt Club Rd. East 

Ottawa K1V 1C1, Canada 

Phone: (613) 733-9830; Fax: (613) 733-0781 

Web: www.iogen.ca 

E-mail: info@iogen.ca 

KEY PERSONNEL: Patrick Foody, Sr.; Chairman 

Brian Foody; President and CEO 

Patrick Foody Jr.; COO 

Grant Blanchard; CFO 

Jeff Passmore; Exec. VP 

Ray Barnes; Exec. VP and General Manager, Iogen Bio-Products 

Nancy Clark; VP, Human Resources 

Ron Paradis; VP, Ethanol and Co-Product Marketing 




FACILITIES: Enzyme manufacturing plant--Produces food-grade and industrial-grade 

enzymes for use in the pulp and paper, textile and animal feed industries 

Cellulose ethanol demonstration facility--Designed to process about 40 

tonnes per day of feedstock, and to produce 3 to 4 million litres of ethanol 

per year 


PRINCIPAL INVESTORS: Goldman Sachs 

Royal Dutch/Shell Group 

Petro-Canada 

Government of Canada 

BUSINESS STRATEGY: Specializes in cellulose ethanol 

Develop, manufacture and market enzymes used to modify and improve the 

processing of natural fibres within the textile, animal feed, and pulp and 

paper industries 


DSM (formerly exclusive manufacturing supply agreement 1991 

Roche Vitamins) and distribution of 

Roxazyme G2 animal 

feed enzymes 

National Research enzymes for the pulp development 1994 

Coucil of Canada and paper industry agreement 

Petro-Canada develop cellulose 

ethanol technology 

partnership 1997 

Royal Dutch/Shell commercialization of development 2002 

Group 

biofuels 

agreement 

Technology 

Partnerships 

Canada (TPC) 


Volkswagen and assess the economic joint study 1/06 

Shell 

feasibility of producing 

cellulose ethanol in 

Germany 

RESEARCH & DEVELOPMENT: Enzymes for fiber modification in pulp and paper, textile and animal feed 

industries 

Cellulase and xylanase enzymes 

Ethanol from biomass 

PRODUCTS ON MARKET: Fiber modifying enzymes able to enhance yield or reduce viscosity 


Isolagen Inc. 


405 Eagleview Boulevard 

Exton PA 19341, US 

Phone: (484) 713-6000; Fax: (484) 713-6001 

Web: www.isolagen.com; E-mail: info@isolagen.com 

KEY PERSONNEL: Nicholas J. Teti; Chairman and CEO 

Susan Ciallella; President 

Declan Daly; CFO and Exec. VP 

Steven Trider; Sr. VP, Global Business and Market Development 

Dr. Marie Lindner; Sr. VP, Medical and Business Affairs 



Acquired a 57% interest in Agera Laboratories Inc. for $2.655M (8/06) 

FACILITIES: 86,500 sq. ft. leased facility for manufacturing and product development 

STOCK-FINANCIAL HISTORY: AMEX--ILE 

IPO--12/02 

Public offering--7M shares of common stock at $8.50/share, $61.2M (6/04) 





04) 


PRIVATE PLACEMENTS: Raised $10.1M from sale of 2.895M shares of Series A Convertible 

Preferred Stock at $3.50/share (7/02) 

Raised $4.4M from sale of 155.750K shares of Series B Convertible 

Preferred Stock at $28/share (5/03) 


SUBSIDIARIES/DIVISIONS: UK office: 

Isolagen Europe Ltd. 

59/61 Park Royal Road 

London NW10 7JJ England 

Phone: +44 (0) 20 8834 1080 

Fax: +44 (0) 20 8834 1165 

Email: infouk@isolagen.com 

Australia Office 

2 Lincoln Street 

Lane Cove 

NSW 2066 

Australia 

Tel: 1300 303 906 

Fax: 02 9808 4442 

Email: info@isolagen.com.au 

Web: www.isolagen.com.au 

PRINCIPAL INVESTORS: Heartland Advisors 

U.S. Bancorp Asset Management 

Perceptive Life Sciences 

Stark Investments 

INVESTMENTS: Agera Laboratories Inc. 

BUSINESS STRATEGY: Establish and formalize strategic partnering relationships on a global scale 

Accelerate current research efforts in ACS technology 

Expand cellular production capacity of laboratory facilities 

Expand business development, sales, production and distribution resources 

Supplement and leverage existing advisory relationships 

Facilitating the company's marketing strategies to supplement and leverage 

existing physician and corporate relationships 



RESEARCH & DEVELOPMENT: Autologous cellular system (ACS) technology, with applications in cosmetic 

dermatology, cosmetic surgery, periodontal disease, and reconstructive 

dentistry, among other therapies 


treatment for dermal defects in Phase III clinicals 

treatment of facial wrinkles in Phase III clinicals 

autologous fibroblasts for gingival disease in Phase I clinicals 


P.O. Box 19 

Ness-Ziona 74100, Israel 

Phone: (972) 8-9381656; Fax: (972) 8-9401404 

Web: www.iibr.gov.il 

E-mail: mambi@iibr.gov.il 

KEY PERSONNEL: Avigdor Shafferman, Ph.D.; General Director 

Arie Ordentlich, Ph.D.; Head, Biological Sciences 

Zvi Teitelbaum, Ph.D.; Head, Medicinal Chemistry 

Avraham Lacser, Ph.D.; Head, Environmental Sciences 

Baruch Velan, Ph.D.; Coordinator, Biotechnological Projects 

Natan Rosenbaum; Head, Personnel 

Ariella Raz; Head, Marketing 

EMPLOYEES: 350 employees, 150 scientists 


FACILITIES: Research facility 

Biotechnological and chemical pilot plants 

Pharmacological screening facilities including animal housing and 

behavioral laboratory 

STOCK-FINANCIAL HISTORY: Government applied research institute 

SUBSIDIARIES/DIVISIONS: Life Science Research Israel (LSRI)--commercial arm of IIBR to promote 

and commercialize IIBR-generated intelligence and applied research 

projects (established in 1978) 

Three scientific divisions--Biology, Medicinal Chemistry and Environmental 

Sciences 

BUSINESS STRATEGY: Establish R&D agreements with other companies that could lead to joint 

ventures with equity investments 


Snow Brand Milk novel treatment for research contract 5/84 

Products Co. Ltd. senile dementias of the 

Alzheimer's type 

with rights 

RESEARCH & DEVELOPMENT: Biology: Diagnosis of infectious diseases; development of rapid, sensitive 

and specific diagnostic methods (and reagents) for pathogen detection and 

identification; viral and bacterial pathogenesis mechanisms in order to 

design strategies for vaccine and drug development, for the evaluation of 

novel modes of therapy and for diagnostic purposes; functional genomics 

and proteomics, including microbial genomes, gene selection from various 

pathogens; vaccine development and evaluation; engineering of proteins 

and enzymes, including molecular design, engineering of novel proteins, 

protein and peptide chemistry, chemical modification of engineered proteins, 

manipulation of post-translation processing and customized protein 

derivatives; generation of human or mammalian cell clones; evaluation of 

recombinant producer cells; development of efficient cultivation systems of 

mammalian anchorage-dependent cells in surface propagators; fixed-bed 

reactors and stirred microcarrier cultures; development of batch, fed batch 


Itochu Corp. 


and perfusion cultures of suspended cells; development of monoclonal 

antibodies and antigens from cell culture; development of recombinant 

enzymes from animal cells, development of bacterial and viral veterinary 

vaccines, subunit vaccines, and human and veterinary recombinant 

lymphokines; fuel and environmental biotechnology R&D projects in 

petroleum microbiology, biodeterioration, biohydrometallurgy and 

bioremediation 

Medicinal Chemistry: Therapeutics for Alzheimer's disease; pharmacological 

and neuroscience projects include the treatment and therapy of the effects 

caused by toxic compounds used in agriculture and industry, prevention, 

treatment and therapy of the effects caused by chemical and thermal burns, 

ocular studies of chemical and physical injuries to the cornea and retina, and 

their prevention and treatment; physiological studies of seizure activity and 

prevention of the resulting irreversible brain damage; stress mechanisms 

and preventive therapeutic means against aging and stress-induced 

neuronal damage; investigation of inflammatory modulators using ex-vivo 

and tissue-culture methods; pharmacokinetic studies and investigation of 

drug delivery systems, and drug-receptor interactions and physiological 

responses mediated by distinct neurotransmitter receptor sub-types; design 

and synthesis of biologically active molecules 

Environmental Sciences: Air pollution meteorology and risk assessment, 

including air pollution measurements on site, occupational air quality 

measurements, environmental surveys, meteorological measurements, 

granulometric, aerodynamic and image analyses, risk assessment, air 

pollution modelling; real time chemical and granulometric analyses--portable 

GC, FTIR, MIRAN, Spraytech, Aerosizer, Knollenberg; optics in the 

atmosphere; physical protection group; and detectors and biosensors 

5-1, Kita-aoyama, 2-chome, Minato-ku 


Phone: +81 3-3497-7300; Fax: +81 3-3497-7389 

Web: www.itochu.co.jp; E-mail: info@itochu.co.jp 

KEY PERSONNEL: Uichiro Niwa; Chairman 

Eizo Kobayashi; President and CEO 

Akira Yokota; Exec. VP 

Kouhei Watanabe; Exec. VP 

Toshihito Tamba; CFO 

Shigeki Nishiyama; President, Aerospace, Electronics & Multimedia 

Masahiro Okafuji; President, Textile Company 

Yosuke Minamitani; President, Chemicals, Forest Products & General 

Merchandise Company 

Shigeharu Tanaka; President, Food Company 

Takanobu Furuta; President, Machinery Company 

Yoichi Kobayashi; President, Energy, Metals & Minerals Company 

Takao Shiomi; President, Finance, Realty, Insurance & Logistics Services 

Company 

Yoshio Akamatsu; President and CEO, Itochu International Inc. 

Yoshihisa Suzuki; President, Itochu Canada Ltd. 

Toyoshige Yamada; General Manager, Strategic Business Development 

Department 

Takeyoshi Ide; General Manager, European Operations 

Yuji Fukuda; COO, Chemicals Division 



Incorporated in December 1949 

Formerly named C. Itoh & Co. Ltd., changed name (10/92) 



FACILITIES: 18 offices in Japan and 135 offices overseas 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock 

exchanges 



05) 


SUBSIDIARIES/DIVISIONS: Energy, Metals and Minerals: 

Itochu Non-Ferrous Materials Co. Ltd.--Japan 

Marubeni-Itochu Steel Inc.--Japan 

Itochu Enex Co. Ltd.--Japan 

Itochu Petroleum Japan Ltd. 

Itochu Energy Marketing Co. Ltd.--Japan 

Itochu Oil Exploration Co. Ltd.--Japan 

Itochu Minerals & Energy of Australia Pty. Ltd. 

Itochu Petroleum Co. (Singapore) Pte. Ltd. 

Chemoil Corp.--U.S. 

Galaxy Energy Group Ltd. 

IPC (USA) Inc. 

Chemicals, Forest Products & General Merchandise: 

Dailite Co. Ltd.--Japan 

Itochu Plastics Inc.--Japan 

Itochu Techno-Chemical Inc.--Japan 

Chemical Logitec Co. Ltd.--Japan 

The Japan Cee-Bee Chemical Co. Ltd. 

CI Kasei Co. Ltd.--Japan 

Takiron Co. Ltd.--Japan 

VCJ Corp.--Japan 

Illums Japan Co. Ltd. 

Sankyu Pharmaceutical Co. Ltd.--Japan 

Itochu Forestry Corp.--Japan 

Itochu Kenzai Corp.--Japan 

Itochu Pulp & Paper Corp.--Japan 

Itochu Ceratech Corp.--Japan 

PPG-CI Co. Ltd.--Japan 

Itochu Windows Co. Ltd.--Japan 

Beaver Tozan Corp.--Japan 

Hexa Color (Thailand) Ltd. 

Itochu Plastics Pte. Ltd.--Singapore 

Tetra Chemicals (Singapore) Pte. Ltd. 

Bonset America Corp.--U.S. 

Itochu Tekstil Kimya Ltd. Sti.--Turkey 

Shanghai Jinchang Engineering Plastics Co. Ltd.--China 

Shanghai Baoling Plastics Co. Ltd.--China 

Thaitech Rubber Corp. Ltd.--Thailand 

CIPA Lumber Co. Ltd.--Canada 

Albany Plantation Forest Co. of Australia Pty. Ltd. 

Food: 

Fuji Oil Co. Ltd.--Japan 

Itochu Sugar Co. Ltd.--Japan 

Itochu Feed Mills Co. Ltd.--Japan 

Japan Foods Co. Ltd. 

Shibushi Silo Co. Ltd.--Japan 

Cholburi Sugar & Trading Corp. Ltd.--Thailand 

Palmaju Edible Oil Sdn. Bhd.--Malaysia 

CGB Enterprise Inc.--U.S. 

PT Aneka Tuna Indonesia 

Winner Food Products Ltd.--Hong Kong 



BUSINESS STRATEGY: Aim to become a high-profit corporate group earning over ¥100b in 

consolidated net income in a steady and sustainable manner by: 

Taking on the challenge of expanding earnings 

Creating new businesses 

Enhancing solid management 


Baxter 

Hemoglobin 

Therapeutics Inc. 

DNA probe licensing agreement 1989 

Bioreactor bioreactor marketing 

6/86 

Technology 

agreement 

British Technology 

Group 

chemiluminescence licensing agreement 1991 

Innogenetics NV cytokinin growth factor, 

hepatitis C virus kit 

import agreement 1991 

Repligen Corp. rProtein A import agreement 1986 

PRODUCTS ON MARKET: Chemicals, Forest Products & General Merchandise: Logs, lumber, wooden 

building materials, wood chips, wood pulp, recycled paper, cotton linter, 

paper, paperboard, paper products, natural rubber, tyres, footwear, furniture, 

glass, cement, slag, landscape materials, refractory materials and products, 

natural gypsum, chemical feedstock, olefin, aromatics, raw materials for 

synthetic resins, tar chemicals, raw materials for synthetic fibers, organic 

chemicals, methanol, ethanol, solvents, speciality chemicals, inorganic 

chemicals, chemical fertilizers, vinyl chloride, polyolefin, synthetic rubbers, 

carbon black, thermoplastic and thermosetting resins, resin additives and 

glass fibers 


Energy, Metals & Minerals: Iron ore, direct reduced iron, coking coal, 

thermal coal, ferro alloy and its materials, steel scrap, pig iron, metal 

powder, electrodes, activated carbon, steel plates, hot and cold rolled 

sheets, galvanised steel, steel for machinery, stainless steel, high tensile 

steel, various specialty steel materials, construction materials, welded steel 

pipes, seamless steel pipes, steel wires, marine steel structures, bridges, 

prefabricated steel for buildings, rails, non-ferrous metals, non-ferrous/light 

metal products, rare metals, aluminum, alumina, aluminum rolled products, 

aluminum extrusion products, electric wires, optical fiber cables, electronic 

materials and products, crude oil, natural gas liquid (NGL), gasoline, 

naphtha, kerosene, jet fuel, gas oil, fuel oil, bunker oil, lubricant, asphalt, 

liquefied petroleum gas (LPG), liquefied natural gas (LNG), dimethyl ether 

(DME) and nuclear fuel 

Food: Wheat, barley, wheat flour, rice, starches, soybeans, sunflower oil, 

olive oil, palm oil, coconut oil, corn, soybean meal, rapeseed meal, fish 

meal, alfalfa pellets, raw sugar, sweeteners, high-fructose corn syrup, dairy 

products, nuts, coffee, cocoa, fruit juice, liquor, soft drinks, beef, pork, 

chicken, fruits and vegetables, processed foods, frozen foods, canned 

foods, pet foods and consulting services for food business 

9704 Medical Center Drive 

Rockville MD 20850, US 

Phone: (240) 268-2605; Fax: (240) 268-4000 

Web: www.venterinstitute.org 

E-mail: press@venterinstitute.org 

KEY PERSONNEL: J. Craig Venter, Ph.D.; President, and Group Leader, Environmental 

Genomics 

Robert L. Strausberg, Ph.D.; Group Leader, Human Genomic Medicine 

Hamilton O. Smith, M.D.; Group Leader, Synthetic Biology and Biological 

Energy 




HISTORY: Formed from the consolidation of The Center for the Advancement of 

Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA) 

and the J. Craig Venter Science Foundation Joint Technology Center (JTC) 

(9/04) 


FACILITIES: Joint Technology Center--60,000 sq. ft. 

5 Research Place 

Rockville, MD 20850 

Phone: (240) 243-1500 

Fax: (240) 243-0600 

STOCK-FINANCIAL HISTORY: Nonprofit research institute 

BUSINESS STRATEGY: The J. Craig Venter Institute is dedicated to the advancement of the science 

of genomics, understanding its implications for society, and communicating 

those results to the scientific community, public and policymakers. 

RESEARCH & DEVELOPMENT: Genomic medicine with an emphasis on cancer genomics and human 

genome resequencing and analysis 

Environmental genomic analysis with an emphasis on microbial biodiversity, 

ecology and evolution 

Use of molecular and genomic methods to develop biological sources of 

clean energy 

Synthetic genome development 

Policy research on the ethical, legal and economic issues associated with 

genomic science and technology 


35 Patton Road 

Devins MA 01434, US 

Phone: (978) 784-5000; Fax: (978) 784-5000 

Web: www.jmpharmaservices.com 

E-mail: etetreau@jmusa.com 

KEY PERSONNEL: Roger Kilburn; Exec. VP and GM 

Lee Piver; Sr. Director, Industry Relations 

Mike McKinley; Director, Finance and Materials Management 

Harwood Stiles; Director, Quality 

Paula J. Lorence; Director, Sales and Marketing 

Daniel J. Coughlin, Ph.D.; Director, Medicinal Chemistry 

Heather Taft, Ph.D.; Director, Chemical Development 

Tony Chong, Ph.D.; Director, Chemical Development and Pilot Plant 




Acquired by Johnson Matthey (2001) 

Changed name from Pharm-Eco (12/04) 

FACILITIES: 50,000 sq. ft. headquarters and R&D facilities 


STOCK-FINANCIAL HISTORY: Privately held--Parent company Johnson Matthey is a public company 

SUBSIDIARY OF: Johnson Matthey 

BUSINESS STRATEGY: Provide API chemistry services to clients throughout the drug development 

process, from early stage discovery services to commercial manufacturing. 



RESEARCH & DEVELOPMENT: Services provided for small molecule drugs; broad range of therapeutic 

areas including, but not limited to: oncologics, Alzheimer's disease, AIDS, 

infectious diseases, Parkinson's disease, memory enhancement and 

schizophrenia 

PRODUCTS ON MARKET: Services: medicinal chemistry, chemical development, process research, 

process development, process optimization, process scale-up, process 

validation, production of intermediates, high potency compounds and 

production of APIs, commercial manufacturing, separation technologies, 

catalytic services, analytical and regulatory services 

Kanebo Ltd. 

20-20 Kaigan, 3-chome, Minato-ku 


Phone: +81 3-5446-3002; Fax: +81 3-5446-3027 

Web: www.kanebo.co.jp 

E-mail: webmaster@kanebo.co.jp 

KEY PERSONNEL: Akiyoshi Nakajima; Chairman 

Tetsuo Komori; President 


HISTORY: Established in May 1887 as Tokyo Cotton Trading Co. 

Renamed Kanegafuchi Spinning Co. (Kanegafuchi Boseki KK) (1893) 

EstablishedKanebo Service Co. (1931) 

Established Kanegafuchi Industrial Co. (1938) 

Established Kanebo Haris Inc. (1964) 

Absorbed Tachibana Confectionery Co. (1964) 

Entered pharmaceutical industry by takeover of Yamashiro Pharmaceutical 

Co. (1966) 

Established Kanebo Cosmetics Sales Co. (1967) 

Began biotech research in the 1970s 

Established Kanebo Soap Sales Co. (later Kanebo Home Products) (1971) 

Established Kanebo Soap Manufacturing Co. (1971) 

Absorbed Izumi Confectionery Inc. (1971) 

Established Kanebo Synthetic Chemicals Co. (1971) 

Established Kanebo-Stevens Co. (1971) 

Established Kanebo Engineering Co. (1971) 

Established Kanebo Pharmaceuticals Co. (1972) 

Absorbed Watanabe Confectionery Co. (1972) 

Established the Laboratory for Herbal Medicine (1976) 

Established Japan Synthetic Textile Co. with Asahi Kasei (1978) 

Established Kanebo Fashion Research Ltd. (1979) 

Established Kanebo Cosmetics (Europe) Ltd. (1980) 

Opened the Kanebo Museum of Textiles (1986) 

Changed name to Kanebo Ltd. (2000) 

Established the Kanebo Beauty Care Laboratory (2004) 

Sold Synthetic Fiber Division (2005) 

Established Kanebo Trinity Horldings Ltd. (2006) 

FACILITIES: Plants: 

Tsushima (Toiletries) 

Second Takatsuki, Takaoka (Pharmaceuticals) 

First Takatsuki, Shinmachi, Fukuchiyama (Foods) 

STOCK-FINANCIAL HISTORY: Formerly listed on the Tokyo and Osaka stock exchanges; delisted in 2005 

SUBSIDIARIES/DIVISIONS: Toiletries, pharmaceuticals and foods divisions 




Ontogen Corp. compounds to treat skin development 6/96 

diseases 

agreement 

Protein Design Smart HUM195 


Labs Inc. (now antibody for acute licensing agreement 

PDL BioPharma 

Inc.) 

myelogenous leukemia 

PRODUCTS ON MARKET: Toiletries division: Skin care products, body soaps, shampoos, hair 

conditioners, hair rinse, hair styling, and bath products 

Pharmaceuticals division: Prescription and OTC products 

Foods division: chewing gum, confectionaries, powdered drinks and frozen 

desserts 


KB-195 to treat acute myelogenous 

leukemia 

in Phase I clinicals 

Kaneka Corp. 

3-2-4, Nakanoshima, Kita-ku 


Phone: +81-6-6226-5050; Fax: +81-6-6226-5037 

Web: www.kaneka.co.jp; E-mail: info@kaneka.co.jp 

KEY PERSONNEL: Masatoshi Takeda; Chairman 

Masami Onishi; President 

Uichiro Shimomi; Exec. VP 

Hideo Yasui; Exec. Officer 

Kimikazu Sugawara; Exec. Officer 

Yoichi Shima; Exec. Officer 

Satomi Takahashi; Exec. Officer 

Kiyomi Imou; Exec. Officer 

Masatoshi Hatori; Exec. Officer 

Toshiji Kanou; Exec. Officer 

Toshihiro Suzuki; Exec. Officer 



FACILITIES: Plants in Takasago, Osaka, Shiga and Kashima 

Research institutes: 

Life Science R&D Center 

Advanced Polymer Materials R&D Center 

Polymer Designing & Processing Product Development Center 

Electronics R&D Center 

Production Technology R&D Center 

Foods R&D Center 

High Performance Materials Research Laboratories 

Additional locations in the U.S. Belgium, Singapore, Malaysia, Australia and 

China 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and Nagoya stock exchanges 




Total assets ¥453.159b (YE 06) compared to ¥224.143 (YE 05) 

SUBSIDIARIES/DIVISIONS: Kaneka Singapore Co. (Pte.) Ltd.--Singapore (sales and manufacture of 

pharmaceutical intermediates) 

Kaneka Consulting (Shanghai) Co. Ltd.--China (technical consulting for 

Kaneka products) 



Kaneka Technical Service Co. Ltd.--China (technical service of functional 

plastics) 

Kaneka Eperan (Suzhou) Co. Ltd.--China (manufacture of expandable 

plastics and products) 

Hifua Fiber Co. Ltd.--China (manufacture of synthetic fibers) 

Kaneka (Malaysia) Sdn. Bhd.--Malaysia (sales and manufacture of 

functional plastics) 

Kaneka Electec Sdn. Bhd.--Malaysia (sales and manufacture of electronic 

products) 

Kaneka Eperan Sdn. Bhd.--Malaysia (sales and manufacture of expandable 

plastics and products) 

Kaneka Paste Polymers Sdn. Bhd.--Malaysia (sales and manufacture of 

specialty PVC resins) 

TGA Pastry Company Pty Ltd.--Australia (sales and manufacture of 

foodstuffs products) 

Kaneka Texas Corp. (sales and manufacture of functional plastics and 

expandable plastics and products) 

Kaneka Nutrients LP--U.S. (sales and manufacture of functional foodstuffs) 

Kaneka America LLC--U.S. (marketing and technical consulting for Kaneka 

products) 

Kaneka Pharma America LLC--U.S. (sale of medical devices) 

Kaneka Belgium NV (sales and manufacture of functional plastics and 

expandable plastics and products) 

Kaneka Pharma Europe NV--Belgium (sale of functional foodstuffs and 

medical devices) 

BUSINESS STRATEGY: Manufacture and sell chemicals, functional plastics, expandable plastics and 

products, foodstuffs products, life science products, electronic products and 

synthetic fibers 

RESEARCH & DEVELOPMENT: Life Science R&D Center: Controlling R&D activities related to fine 

chemicals, medical devices and foodstuffs based on the company's bio and 

synthesis technologies 

Performance Materials R&D Center: R&D for the synthetic resinsmodifiers, 

functional (performance) polymers and synthetic fibers based on Kaneka's 

macromolecular technology 

Electronics R&D Center: Controlling R&D related to information, 

communication and clean energy businesses based on high-polymer 

material designing, high-polymer fabrication, functional thin-film fabrication 

and systematizing technologies 

Foods R&D Center: Controlling R&D related to a foodstuff field based on 

biotechnologies in cooperation with the Life Science R&D Center 

Polymer Designing & Processing Product Development Center: 

Development of products related to formed plastics based on the 

technologies of high-polymer material designing and forming, mold 

designing and plastics fabrication 

Production Technology R&D Center: Development of production 

technologies ranging from facility-intensive processes to plastisc fabrication 

based on reaction analysis, simulation and process designing technologies 

in cooperation with each R&D center related to product development 

PRODUCTS ON MARKET: Chemicals: Polyvinyl chloride (PVC), caustic soda, hydrochloric acid, flexible 

PVC compounds, rigid PVC compounds, paste PVC and chlorinated PVC 

Functional Plastics: Modifier resins, heat-resistant ABS resins, selfextinguishing 

ABS resins, modified silicone polymer (MS polymer) and Allyl 

(Silyl) terminated polyisobuthylenes (Epion®) 



Expandable Plastics and Products: Extruded polystyrene foam boards, 

insulating PVC sash windows, polystyrene foam sheets, polyolefin foam 

(beads and moldings) and expandable polystyrene 

Foodstuffs: Margarine and shortening, confectionary fats, bakery yeast 

Life Science Products: Ubidecarenone (Coenzyme Q10), anti-hypertensive 

drug intermediates, intermediates for antibiotics, liposorber system (LDLcholesterol 

adsorption system) and Lixelle® (Adsorption column for dialysisrelated 

amyloidosis) 


2-1-1 , Nishi-Shinbashi, Minato-ku 


Phone: +81 3-5521-5490; Fax: +81 3-5521-5498 

Web: www.kikkoman.co.jp/bio 

E-mail: biochem@mail.kikkoman.co.jp 

KEY PERSONNEL: Yuzaburo Mogi; Chairman and CEO, Kikkoman Corp. 

Takashi Ushiku; President and COO, Kikkoman Corp. 

Shigetaka Ishii; Sr. Corp. Officer, R&D and Biochemicals 



STOCK-FINANCIAL HISTORY: Kikkoman Corp. is listed on the Tokyo and Osaka stock exchanges: 





SUBSIDIARIES/DIVISIONS: Kikkoman Corp.: 

R&D Division 

Biochemicals Division 

RESEARCH & DEVELOPMENT: Fermentation processes, rDNA, pharmaceuticals, research reagents 

(enzymes), luciferase 

Protease 

PRODUCTS ON MARKET: Nutritional supplements 

Pharmaceutical raw materials 

Reagents for clinical diagnostics 

Checklite 250 Plus luciferase kit to detect microorganisms via 

bioluminescence 

LuciPac device for hygiene monitoring 

ZeptoLite ABC kit for enzyme immunoassay via bioluminescence 

InteLite AB kit for enzyme immunoassay via bioluminescence 

Cyclic AMP 

Ellagic acid dihydrate 

Proanthocyanidins 

Maltooligosaccharides 

Tannase 

Protease (acid-stable) 

B-glucosidase 

Glucoamylase 

Sarcosine oxidase 

Creatine amidinohydrolase 

Uricase 

Sucrose phosphorylase 

Maltase phosphorylase 

B-phosphoglucomutase 




Diagnostic enzymes in development 

High sensitive bioluminescent enzyme 

immunoassay methods 



Waldhofstr 14 

Ellerbek 25474, Germany 

Phone: +49 4101 3053 0; Fax: +49 4101 3053 90 

Web: www.kraeber.de 

E-mail: kraeber@t-online.de 

KEY PERSONNEL: Jens-Uwe Kraeber; President 

Birgit Petroschka; Director, R&D 

Gabriele Weiss; Head, Pharmaceutical Chemicals division 




Acquired Biospa, Wedel (1992) 


SUBSIDIARIES/DIVISIONS: Six divisions: 

1. Pharmaceutical Chemicals: Active pharmaceutical ingredients, excipients 

and intermediates supplied to the pharmaceutical and cosmetic industry as 

well as refined materials in bulk for sale to the laboratory chemical sector. 

2. Biopharmaceuticals: Active biopharmaceutical ingredients and excipients, 

cosmeceuticals and nutraceuticals are supplied to the human and veterinary 

pharmaceutical, cosmetic, health food and pet food industries. 

3. Animal Blood Fractions: Manufacturer of animal blood fractions presently 

reared from 18 spezies for supply to the biotechnology, diagnostic, 

pharmaceutical and cosmetic industries. 

4. Production: Extraction and separation from other tissues. 

5.Distribution Seagarden AS and Maripro AS. 

6. Kraeber UK Ltd. 

16 The Street 

Saxon Street 

nr. Newmarket CB8 9RU, UK 

Phone: +44 1638-731297 

Fax: +44 1638-731291 

E-mail: dja@kraeber.com 

INVESTMENTS: Kraeber U.K. Ltd. 

BUSINESS STRATEGY: Produce animal blood fractions in Europe for biotechnology, pharmacy and 

cosmetics 

PRODUCTS ON MARKET: Animal blood fractions in various qualities 

Pharmaceutical raw materials 

Biopharmaceutical raw materials 



Kuraray Co. Ltd. 

Shin-Hankyu Building, 1-12-39, Umeda, Kita-ku 


Phone: +81 6-348-2111; Fax: +81 6-6348-2165 

Web: www.kuraray.co.jp 

E-mail: koho@kuraray.co.jp 

KEY PERSONNEL: Hiroto Matsuo; Chairman 

Yasuaki Wakui; President 

Junsuke Tanaka; Sr. Managing Director 

Seiji Wajiki; Managing Director 

Osamu Asaba; Managing Director 

Nobuo Iwawaki; Managing Director 

Yoichi Ninagawa; Managing Director 

Fumio Ito; Managing Director 




FACILITIES: Headquarters in Tokyo and Osaka, Japan 






SUBSIDIARIES/DIVISIONS: Specialty Resins and Films: Poval Resin Co., Poval Film Co., EVAL Co. 

Fibers and Textiles: Fibers and Industrial Materials Co., Clarino Co., Kuraray 

Fastening Co. Ltd., Kuraray Kuraflex Co. Ltd. 

Chemicals: Methacrylate Division, Chemicals Division, Elastomer Division, 

Genestar Division 

Affiliated companies: Kuraray Trading Co. Ltd., Kuraray America Inc., 

Kuraray Europe GmbH, Kuraray Specialities Europe, Kuraray Plastics Co. 

Ltd., Kuraray Medical Inc., Kuraray Chemical Co. Ltd., Kuraray Engineering 

Co. Ltd., Kuraray Interior Co. Ltd., Kuraray Family Products Co. Ltd., 

Kuraray Techno Co. Ltd., Techno Soft Co. Ltd. 

PRODUCTS ON MARKET: Chemicals and resins, fibers and textiles, high performance material, 

medical products 


5, Kanda Surugadai 2-chome, Chiyoda-ku 


Phone: +81 03-3293-3411 

Fax: +81 03-3293-3470 

Web: www.kyorin-pharm.co.jp 

KEY PERSONNEL: Hiroshi Uchida; Chairman 

Ikuo Ogihara; President and CEO 

Yoshizumi Amano; Exec. Director 

Keiji Hirai; Exec. Director 

Masahiro Yamashita; Exec. Director 

Minoru Hogawa; Exec. Director 

Shinichi Saito; Exec. Director 

Akihiro Tanaka; Exec. Director 

Takayoshi Ishizaki; Exec. Director 





Established in 1940 

Acquired ActivX Biosciences Inc. (2/05) 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange 

SUBSIDIARIES/DIVISIONS: Kyobundo Co. Ltd. 

Bistner Co. Ltd. 

Toyo Pharmar Co. Ltd. 

Dr. Program Co. Ltd. 

ActivX Biosciences Inc. 

Kyorin USA. Inc. 

Kyorin Europe GmbH 

Nisshin Kyorin Pharmaceutical Co. Ltd. 

Nippon Rika Co. Ltd. 

SUBSIDIARY OF: Kyorin Co. Ltd. 

BUSINESS STRATEGY: Manufacture and sell prescription medicines and quasi-drugs, diagnostics 

and industrial chemicals 

Build alliances that will capitalize on external resources, allowing the 

company to further contribute to better the health of people throughout the 

world 

Invest management resources in specific therapeutic fields for drug 

discovery and marketing 


MediciNova Inc. development and 


MN-001 (except Japan, 

China Taiwan and 

South Korea) 


Novartis AG KRP-203 global development 

and 



2/06 

RESEARCH & DEVELOPMENT: Drug discovery operations are centered on three therapeutic fields: 

Infectious diseases, immunological/allergic and metabolic diseases 

PRODUCTS ON MARKET: Gatiflo® tablets 

Kipres® tablets 

Mucodyne® 

Ketas® capsules 

Baccidal® tablets 

Aplace® 

Pentasa® tablets 

Rocaltrol® capsules 

Bestron® for ear and nose 


1-6-1 Otemachi, Chiyoda-ku 

Tokyo 100, Japan 

Phone: +81 3-3282-0007; Fax: +81 3-3284-1968 

Web: www.kyowa.co.jp/eng; E-mail: info@kyowa.co.jp 

KEY PERSONNEL: Dr. Yuzuru Matsuda; President and CEO 

Yoshito Imai; Sr. Exec. Managing Officer and President, Pharmaceuticals 

Business Unit 

Yukinobu Kotani; Sr. Exec. Managing Officer and President, Bio-Chemicals 

Business Unit 




HISTORY: Founded in July 1949 

Established Kyowa Hakko Kogyo Co. Ltd. as a secondary company of 

Kyowa Sangyo Co. Ltd. (1949) 

Bought out Sanyo Kagaku Co. Ltd. (1954) 

Established Daikyowa Sekiyu Kagaku Co. Ltd. through joint investment with 

Daikyo Sekiyu Co. Ltd. (1961) 

Began the pharmaceutical business (1963) 

Established Kyowa Yuka Co. Ltd., as a separate company from Daikyowa 

Sekiyu Kagaku Co. Ltd. (1966) 

Established Kyowa Hakko USA Inc. (1969) 

Established Kyowa Hakko Europe GmbH (1973) 

Established Kyowa Miles, a merger company with United States Miles Inc. 

(1973) 

Established Kyowa FD Foods Co. Ltd. to produce freeze-dried foods (1973) 

Established Ohland Foods Co. Ltd. to start producing and selling frozen 

dough for bread and cake mix (1974) 

Established Fermex for the production of feed-grade L-Lysine (1977) 

Established Janssen-Kyowa Co. Ltd. (1978) 

Established the Bio Business Division (1981) 

Established Kyowa Medex Co. Ltd. to develop, produce and sell diagnostic 

reagents (1981) 

Established Biokyowa Inc. in the U.S. for the production of amino acids 

(1984) 

Established Kyowa Hakko (Thailand) Ltd. (1985) 

Established Agroferm Hungarian-Japanese Fermentation Industry Ltd., a 

consolidated company in Hungary (1987) 

Established Japan Oxocol Co. Ltd. to strengthen the plasticizers business 

(1988) 

Acquired all stock of Shinwa Pharmaceutical Co. Ltd. (1989) 

Established Nutri-Quest Inc., a company for research and development in 

the U.S. (1989) 

Established Kyowa Iryo Kaihatsu Co. Ltd. (1989) 

Established Kyowa Hakko (HK) Co. Ltd. (1989) 

Merger of Kyowa Yuka Co. Ltd. and Japan Oxocol Co. Ltd. (1991) 

Established Kyowa Pharmaceutical Inc. in the U.S. (1992) 

Established Dinavec Research Inc. (1995) 

Established Shanghai Guan Sheng Yuan Kyowa Amino Acid Co. Ltd. (1998) 

Established Kyowa America Inc., a holding company in the U.S. (1999) 

Established J Plus Co. Ltd., a joint venture for the plasticizers business 

(2000) 

Established Kyowa Foods (H.K) Co. Ltd. (2000). 

Transferred alcoholic beverage business (excluding raw alcohol) to Asahi 

Breweries (9/02) 

Established Yantai Kyowa Foods Co. Ltd. in China (2002) 

Established Japan Ethyl Acetate Co. Ltd., a joint venture with Showa Denko 

KK for the production of ethyl acetate (2003) 

Established BioWa Inc. in the U.S. to promote Kyowa Hakko’s 

biopharmaceutical business (2003) 

Spun off Kyowa Hakko Food Specialties Co. Ltd. (2005) 

FACILITIES: 27,000 sq. m. pharmaceutical research facilities 

STOCK-FINANCIAL HISTORY: Net sales ¥353.440 (YE 06) compared to ¥358.963b (YE 05) 




SUBSIDIARIES/DIVISIONS: The company consists of two business units--Pharmaceuticals Business 

Unit and Bio-Chemicals Business Unit 

Overseas network: 

Kyowa America Inc. 

767 Third Avenue, 19th Floor 

New York, NY 10017 USA 

Phone: (212) 319-5353 



Biokyowa Inc. 

5469 Nash Road, P.O.Box 1550 

Cape Girardeau, MO 63702-1550 USA 

Phone: (573) 335-4849 

Kyowa Hakko USA Inc. 

767 Third Avenue, 19th Floor 

New York,NY 10017 USA 

Phone: (212) 319-5353 

Web site: www.kyowa-usa.com 

Kyowa Hakko USA Inc. 

West Coast Office 

85 Enterprise, Suite 430 

Aliso Viejo,CA 92656 USA 

Phone: (949) 425-0707 

Select Supplements Inc. 

5800 Newton Drive 

Carlsbad, CA 92008 USA 

Phone: (760) 431-7509 

Kyowa Pharmaceutical Inc. 

212 Carnegie Center, Suite 101 

Princeton, NJ 08540 

Phone: (609) 919-1100 

Web site: www.kyowa-kpi.com 

BioWa Inc. 

212 Carnegie Center, Suite 101 

Princeton, NJ 08540 USA 

Phone: (609) 580-7500 

Web site: www.biowa.com 

Kyowa Hakko Europe GmbH 

Immermannstrasse-3 

D-40210, Dusseldorf, Germany 

Phone: +49 211-17-728-0 

Web site: http://www.kyowa.de 

Kyowa Hakko U.K. Ltd. 

258 Bath Road, Slough 

Berkshire SL1 4DX, UK 

Phone: +44 1753-566000 

Kyowa Italiana Farmaceutici SRL 

Viale Fulvio Testi 280 

20126, Milan, Italy 

Phone: +39 02-644-704-1 

Web site: kyowa@kyowa.it 

Kyowa Hakko Industry (S) Pte. Ltd. 

260 Orchard Road, #12-04 

The Heeren, Singapore 238855 

Phone: +65 6733-4948 

Kyowa Hakko (Malaysia) Sdn. Bhd. 

20, Jalan SS 19/5, 47500 Subang Jaya 

Selangor, Darul Ehsan, Malaysia 

Phone: +60 3-5634-0669 




Beijing Representative Office 

Room 701, Beijing Fortune Bldg. 

5 Dong San Huan Bei-Lu 

Chao Yang District, Beijing 100004, China 

Phone: +86 10-6590-8515 

Web site: http://www.kyowa.bj.cn 


Shanghai Representative Office 

Room 1712, Rui Jin Bldg. 

205 Maoming Nan Lu, Shanghai 200020 

China 

Phone: +86 21-6466-1222 


Guangzhou Representative Office 

Room 701, Yi An Plaza No.33 

Jianshe 6 Ma Lu, Guangzou 510060, China 

Phone: +86 20-8364-4123 

Kyowa Hakko (H.K.) Co., Ltd. 

Room 2103, Hang Lung Centre, 

2-20 Paterson Street,Causeway Bay 

Hong Kong, China 

Phone: +852 2895-6795 

Kyowa Hakko (HK) Co. Ltd. 

Guangzhou Representative Office 

Room 411, China Hotel Office Tower 

Liu Hua Road, Guangzhou 510015 

China 

Phone: +86 20-8667-5381 

Kyowa Pharmaceuticals (HK) Co. Ltd. 

Room 2103, Hang Lung Centre 

2-20 Paterson Street, Causeway Bay, Hong Kong 

China 

Phone: 852-2895-6795 

Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd. 

No.115 QingQju Street, Suzhou Industrial Park 

Jiangsu 215021, China 

Phone: +86 512-6283-1082 

Shanghai Kyowa Amino Acid Co. Ltd. 

No.158 Xintuan Road 

Qingpu Industrial Zone, Shanghai, 201700 

China 

Phone: +86 21-5970-1998 

Wuxi Kyowa Food Co. Ltd. 

No.158 Xu Xiang Lane Li Yuan 

Wuxi 214072, China 

Phone: +86 510-8512-9781 

Yantai Kyowa Foods Co. Ltd. 

Zhao Wang Zhuang Town, 

Laiyang City, Shandong 265225 

China 

Phone: +86 535-761-5778 




BioWa Inc. anti IL-5 receptor 


antibody 


agreement 

BioWa Inc. development and 


Anti-Fibroblast Growth 

Factor 8 (FGF8) 

monoclonal antibody 

worldwide, except Asia 


Bunge Australia activated gluten licensing agreement 10/85 

Cephalon Inc. Myotrophin (mecasermin development and 7/93 

[recombinant DNA marketing 

origin]) injection 

agreement 

Cephalon Inc. small neurotrophic 

molecules for treating 

head and spinal injuries 

and other 

neurodegenerative 

disorders 


COR 


three-year 

12/95 

Therapeutics Inc. pharmaceuticals for development 

treating restenosis agreement (12/92), 

following angioplasty extended for an 

additional two years 

Eli Lilly and Co. combinatorial chemistry research 

collaboration--Lilly 

to provide 

technology transfer 

and to receive upfront 

fees, 

milestone payments 

and royalties on first 

two products to 

reach market 

3/97 

Ethical Holdings morphine product distribution 

10/95 

plc 

agreement for 

Singapore and 

Malaysia 

European 

Organization of 

Research and 

Treatment for 

Cancer (EORTC) 

EO9 anticancer agent R&D agreement 

Genomatica Inc. Ganomatica's modeling 

and simulation platform 


Geron Corp. Geron's assay for 

detection of telomerase 

activity in tumors 


Geron Corp. small molecule drugs R&D agreement 5/95 

Government of genetically engineered joint venture called 1991 

Hungary 

lysine 

Agroferm 

Hungarian- 

Japanese 

Fermentation 

Industry Ltd., 

Kyowa is supplying 

the bacterial host 

and the 

manufacturing 

technology 



LeukoSite Inc. CCRI and CXCR3 collaborative R&D 

and licensing 



developing 

treatments for 

inflammatory and 

autoimmune 

diseases (11/97), 

Murex 

Diagnostics Inc. 

Scotia 


Ltd. 

MAb-based AIDS 

diagnostics 

Scotia's Foscan 

photosensitizing drug for 

cancer 

extended 

development, 

manufacturing, and 

marketing 


Kyowa Medex Co., 


Ltd. 

licensing 

agreement-- 

Boehringer 

Ingelheim gets 

exclusive rights to 


in North and South 

America and 

Europe, Kyowa 

Hakko gets 

exclusive rights in 

Japan, Scotia 

retains rights in 

other territories-- 

Scotia gets $54M in 

up-front and 


and will 

manufacture 

product for both 

partners 

RESEARCH & DEVELOPMENT: Therapeutics (modified G-CSF), Mab-based cancer diagnostics and 

fermentation strain improvement (enzymes, amino acids, and nucleic acids) 

Cell fusion technology 

Plant cell culture 

Aquaculture rDNA salmon growth hormone 

Industrial-scale process for cell cultivation, immobilized enzymes 

Diagnostics to detect HTLV-I 

PRODUCTS ON MARKET: PHARMACEUTICALS: Coniel®, Allelock®, Celtect®, Itrizole®, Durotep 

Patch®, Depakene®, Neu-up®, Inovan®, Mitomycin, 5-FU, Leunase®, 

diagnostic reagents 

BIO-CHEMICALS: amino acids, nucleic acids, malic acid, enzymes, 

citicoline, minocycline, ubidecarenone (CoQ10), agrochemicals, animal 

health products, feeds, feeds additives, health foods, raw material alcohol 

CHEMICALS: solvents, plasticizers and their raw materials, organic acids, 

diols 

FOOD: seasonings, bakery products and ingredients, freeze-dried foods 

4/98 

6/87 

9/97




7 avenue de Scandinavie 

Les Ulis 91953, France 

Phone: +33 (0) 1 69-07-94-77; Fax: +33 (0) 1 69-07-95-34 

Web: www.eurobio.fr 

E-mail: adv@eurobio.fr 

Stephane Reveilleau; President 



FACILITIES: 2,000 sq. m. of state-of-the-art clean rooms and GMP biological production 

capacity 

STOCK-FINANCIAL HISTORY: Privately held--Wholly-owned by the Reveilleau family 

SUBSIDIARIES/DIVISIONS: Human Diagnosis division: Immuno-hematology and viral and bacterial 

diagnosis 

Life Science division: molecular biology and cellular culture 

BUSINESS STRATEGY: Develop, produce and market reagents intended for research and the 

biomedical diagnosis 


Hemagen MRL diagnostic kits distribution 

agreement 

1987 

Institut Merieux HLA typing antisera exclusive worldwide 2/88 

(now Sanofi 

distribution 

Pasteur) 

agreement 

MRL distribution 

agreement 

1990 

Roche PCR license 1996 

PRODUCTS ON MARKET: Bovine serum 

Horse serum 

Other sera 

Cell culture media 

Insect cell culture media 

Powdered and liquid salt solutions 

Separation media 

Antibiotics 

Cell culture buffers 

Cytogenetics and dissociating reagents 

Dyes 

RNA extraction kits 

RNA/DNA purification 

Other reagents for nucleic isolation 

Enzymes for reverse transcription 

Enzymes for in vitro amplification 

dNTP's 

Oligonucleotides 

Agaroses 

Acrylamide 

Electrophoresis buffers/dyes 

Biochemical products 


Lake States 


515 West Davenport Street 

Rhinelander WI 54501, US 

Phone: (715) 369-4397; Fax: (715) 369-4034 

Web: www.wplakestates.com 

E-mail: lgary@wausaupaper.com 

KEY PERSONNEL: Linda Fox; Manager 

Linda Gary; Marketing 







STOCK-FINANCIAL HISTORY: Privately owned by parent 

SUBSIDIARY OF: Wausau Paper Corp. 

BUSINESS STRATEGY: Develop value-added yeast products for the food, biotech, health food, HBA, 

feed, and pet food markets 

RESEARCH & DEVELOPMENT: Yeast related research 

PRODUCTS ON MARKET: Inactive torula yeast 

Autolyzed yeasts 

Smoked yeasts 

Yeast extracts 

LANXESS AG 

Building K 10 

Leverkusen 51369, Germany 

Phone: +49 (0)214 / 30-33333 

Web: www.lanxess.com 

E-mail: lanxess-info@lanxess.com 

KEY PERSONNEL: Dr. Axel Claus Heitmann; Chairman 

Matthias Zachert; CFO 

Dr. Martin Wienkenhover; Director, Industrial Relations 


HISTORY: Byer Ag founded in 1863 

Bayer's chemical activities and one-third of polymer activities combined to 

form LANXESS Deutschland GmbH (2004) 

Divested fine chemicals business, which now operates as Saltigo (4/06) 

FACILITIES: 50 locations in 18 countries 

STOCK-FINANCIAL HISTORY: Listed on the Frankfurt Stock Exchange 




(YE 04) 

Total assets EUR4.341b (YE 05) compared to EUR4.577b (YE 04) 

SUBSIDIARIES/DIVISIONS: Business units: 

Performance Rubber: Butyl Rubber, Polybutadiene Rubber, Technical 

Rubber Parts 



Engineering Plastics: Styrenic Resins, Semi-Crystalline Products 

Chemical Intermediates: Basic Chemicals, Inorganic Pigments 

Performance Chemicals: Material Production Products, Functional 

Chemicals, Leather, Textile Processing Chemicals, Paper, Rubber 

Chemicals, Ion Exhcnage Resins 

LANXESS Deutschland GmbH--Germany 

LANXESS Corp.--Pittsburgh, Pa. 

LANXESS Elastomeres SAS--France 

LANXESS Inc.--Sarnia, Ontario 

LANXESS International SA--Switzerland 

LANXESS NV--Belgium 

LANXESS Rubber NV--Belgium 

RheinChemie--Germany 

BUSINESS STRATEGY: Develop, produce and market high-quality chemicals, rubber and plastics 

Lavipharm SA 

Agias Marinas Str. 

Peania NJ 190 02, Greece 

Phone: +30 210 6691 000; Fax: +30 210 6645 386 

Web: www.lavipharm.gr 

E-mail: information@lavipharm.com 

KEY PERSONNEL: Dr. Athanase Lavidas; Chairman and CEO 

Tania Vranopoulos; COO 

Spyridon Fotinos; Exec. VP, Corporate Research and Innovation 



Established Laboratoires Lavipharm (1989) 

Started Synthelabo-Lavipharm, a joint venture with Synthelabo-France 

(1992) 

Started Lavicosmetica, a joint venture with L’Oreal CosmetiqueActive (1992) 

Lavipharm S.A. listed on the Athens Stock Exchange (1995) 

Acquired Separex (2000) 

Acquired Phasex (2000) 

FACILITIES: 109,000 sq. m. total area (4,600 sq. m. of facilities) in Princeton, N.J. 

STOCK-FINANCIAL HISTORY: Athens Stock Exchange--LAVI 


Operating profit EUR14.642 (YE 05) compared to EUR18.537M (YE 04) 


(YE 04) 

Total assets EUR194.701M (YE 05) compared to EUR217.571M (YE 04) 

SUBSIDIARIES/DIVISIONS: Lavipharm Hellas SA--Rx and OTC 

Castalia Laboratoires Dermatologiques SA--Dermocosmetics 

LAS SA--Pharmaceutical wholesaler 

Pharma Logistics SA--Logistics service provider 

Pharma Plus SA--Integrated services to pharmacies 

Lavipharm Pharmaceutical Services Ltd.--joint venture with businessman 

Efthyvoulos Paraskevaides 

Lavipharm Distribution Ltd.--Subsidiary of Lavipharm Pharmaceutical 

Services Ltd. 

Lavipharm Cyprus Ltd.--Subsidiary of Lavipharm Pharmaceutical Services 

Ltd. 

Lavipharm Corp.--Affiliated holding company in the pharmaceutical 

technology sector 

Lavipharm Laboratories Inc.--R&D center in the U.S. 

Phasex SA--Affiliated company specializing in supercritical fluids (SCF) 

technology 



Separex SA--Affiliated French pharmaceutical company pioneering SCF 

technology 

Hitex SA--Affiliated company that has SCF extraction and contract 

manufacturing departments 

Laboratoires Lavipharm SA--Affiliated company responsible for international 

promotion of dermocosmetic products 

BUSINESS STRATEGY: Develop, manufacture, market and distribute pharmaceutical, cosmetic and 

consumer health products in Greece and internationally 


GlaxoSmithKline Lavipharm's SCF three-year research 4/03 

plc 

technology 

collaboration and 

licenaing agreement 

Intervet Pharma Intervet compound for development 5/02 

R&D SA (through veterinary 

agreement 

Lavipharm Corp.) pharmaceutical 

products 

Senetek PLC Lavipharm to launch 

line of Kinetin-based 

skin care products 

under its Castalia brand 


RESEARCH & DEVELOPMENT: Focus is on pioneer technologies of particle design, drug delivery systems, 

cosmetic delivery systems, and the development of natural products 

Development of pharmaceutical products containing new drugs that might 

otherwise have been abandoned because of solubility or other drug delivery 

problems 

Modification of existing drugs in order to improve their pharmacokineticpharmacodynamic 

profiles, extend their patent coverage duration and 

increase their competitive position, thus extending the drug's life cycle 

PRODUCTS ON MARKET: Lavipharm Hellas: Algon (pain reliever), Addditiva (vitamins), Ivaliten (antilice), 

Laxemel (laxative), Prot Algon-Antipyretic 'enfants,' Breath Right, 

RFSU, Lactal 

Otccastalia Laboratoires Dermatologiques: Laviderm 


1 Cyclotron Road 

Berkeley CA 94720, US 

Phone: (510) 486-6467; Fax: (510) 486-6457 

Web: www.lbl.gov; E-mail: ttd@lbl.gov 

KEY PERSONNEL: Steven Chu; Laboratory Director 

Jeff Fernandez; CFO 

EMPLOYEES: 4,000 employees, 1,200 Ph.D.s 




SUBSIDIARIES/DIVISIONS: Includes 15 divisions organized within the areas of Computing Sciences, 

Energy Sciences, Biosciences, General Sciences, and Resources and 

Operations 

BUSINESS STRATEGY: Berkeley Lab conducts unclassified research across a wide range of 

scientific disciplines with key efforts in fundamental studies of the universe; 

quantitative biology; nanoscience; new energy systems and environmental 

solutions; and the use of integrated computing as a tool for discovery. It is 

organized into 17 scientific divisions and hosts four DOE national user 

facilities. 




undisclosed 

RESEARCH & DEVELOPMENT: Materials 

Energy efficiency 

Energy and environment 

Earth science 

High energy physics 

Accelerator and fusion 

Life science 

Nanoscience 

Physical bioscience 

Genomics 

Computing science 

LG Chem Ltd. 

LG Twin Towers, 20, Yeouido-doing, Yeongdeungpo-gu 

Seoul 150-721, Korea 

Phone: +82 2-3773-0617, 0618; Fax: +82 2-785-0324 

Web: www.lgchem.com 

E-mail: info@lgchem.com 

KEY PERSONNEL: Bahn-Suk Kim; President and CEO 

Yu-Sig Kang; CEO and Vice Chairman 

Suk-Jeh Cho; Exec. VP and CFO 

Kyusok Park; Exec. VP, Industrial Materials 

Sangjin Hong; VP, LG Chem, China 

Jin-Nyoung; Exec. VP, LG Chem Research Park 



Established its central research institute in 1979 

Started R&D in genetic engineering field in 1981 

Acquired Anjin Pharma Corp., Pharmaceutical Division (1989) 

Name changed from Lucky Ltd. (1995) 

Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and 

LG Household & Healthcare (4/01) 

STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange 

Sales W71.274b (YE 04) compared to W56.725b (YE 03) 

Net income W5.364b (YE 04) compared to W3.621b (YE 03) 

SUBSIDIARIES/DIVISIONS: Three main businesses: Chemicals and polymers, industrial materials, and 

information and electronic materials 

Subsidiaries: 

LG Petrochemical Ltd. 

LG Dow Polycarbonate Ltd. 

Tianjin LG Dagu Chemical Co. Ltd. 

Ningbo LG Yongxing Chemical Co. Ltd. 

Tianjin LG New Building Materials Co. Ltd. 

Tianjin LG Window & Doors Co. Ltd. 

LG Chemical (Guangzhou) Engineering Plastics Co. Ltd. 

LG Chem (Nanjing) Information & Electronica Materials 

LG Chemical India Private Ltd. 

LG Chemical America Inc. 

LG Chemical Hong Kong Ltd. 

Compact Power Inc. 

LG Chem Industrial Materials 

LG VINA Chemcial 

LG Chem (China) Investment Co. Ltd. 

LG Chem (Tianjin) Engineering Plastics Co. Ltd. 



Tianjin LG Bohai Chemical Co. Ltd. 

LG Chem Poland Sp. zoo 

LG Chem Brasil Ltd. 

LG Chem Europe GmbH 

BUSINESS STRATEGY: Petrochemical and industrial materials business: Consolidate its foothold 

and position itself as a major player in main growing markets such as China 

and the U.S. by raising its product quality and cost competitiveness through 

enhanced R&D and marketing abilities. 

Information and electronic materials business: Focus on rapid developments 

of new high-tech products and increasing capacities for its main products 

such as rechargeable batteries and display materials. 

PRODUCTS ON MARKET: Industrial materials: housing and space materials, living materials, 

automobile components, interior decoration materials 


Chemicals and polymers: PVC and plasticizers, acrylates and e-chemicals, 

polyolefin, AVS/PS, engineering plastics, specialty polymers 

LG Twin Tower, East Tower, 20, Yoido-dong, Youngdungpo-gu 

Seoul, Korea 

Phone: +82 2-3773-1114; Fax: +82 2-3773-7012 

Web: www.lgls.co.kr; E-mail: hycho@lgls.co.kr 

KEY PERSONNEL: Heung-Joon Yang; CEO and Chairman 

Han-Yong Yang; VP and CFO 



Established its central research institute in 1979 

Started R&D in genetic engineering field in 1981 

Acquired Anjin Pharma Corp., Pharmaceutical Division (1989) 

Name changed from Lucky, Ltd. (1995) 

Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and 

LG Household & Healthcare (2001) 

Spun off from LGCI and name changed to LG Life Sciences (2002) 

Factive quinolone antibiotics approved by US FDA (2003) 

FACILITIES: Two manufacturing facilities and R&D Park located in South Korea 

Pharmaceutical division has two GMP main factories in Iksan and in 

Daejeon 

STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange 

Sales W213,636 (YE 04) compared to W179,037M (YE 03) 

Net income W10,073 (YE 04) compared to W3,225M (YE 03) 

SUBSIDIARIES/DIVISIONS: Pharmaceutical Division 

Agricultural Division 

LG Life Sciences India Pvt. Ltd. 

LG Life Sciences Poland Sp. Z.o.o 


Beijing representative office 

INVESTMENTS: Elitra Pharmaceuticals 

BUSINESS STRATEGY: Enhancement of Efficiency in R&D: 

-Focus all-out efforts on candidate materials for developments that have 

passed pre-clinical trials 

-More systematic promotion of R&D projects 

-Solidify alliances with world-class business enterprises 



Advance into Markets for Generic Bio Drugs in Industrialized Countries 

-Advance into markets in industrialized countries through marketing 

alliances 

-Establish local corporations in strategically important areas 

Firm Up our Position as a Market Leader in the Domestic Market 

-Continue development of advanced marketing techniques 

-Focus on the development of products meeting our customers’ specific 

needs 

-Strengthen our licensing activities 


Aeterna anti-cancer drug in-licensing 

agreement 

2003 

Anadys 

hepatitis B treatment out-licensing and 2004 



Inc. 

agreement 

Biogen Idec Inc. psoriasis treatment in-licensing 

agreement 

2004 

BioPartners sustained-release out-licensing and 2001 

human growth hormone joint development 

agreement 

BioPartners genetically-engineered joint development 1997 

products 

and marketing 

agreement 

DepoMed diabetes treatment in-licensing 

agreement 

2004 

Eximias liver cancer treatment in-licensing 

agreement 

2002 

GlaxoSmithKline 

plc 

new quinolone antibiotic licensing agreement 1997 

KYORIN 

development, 

licensing agreement 2005 

Pharmaceutical manufacturing and 

Co. Ltd. 

sales of KRP-197 in 

Korea 

Oscient 

quinolone antibiotics out-licensing 2002 


agreement 

Sinovac Biotech hepatitis B vaccine in distribution 

3/06 

Ltd. 

China 

agreement 

Sinovac Biotech hepatitis A vaccine, letter of intent 5/05 

Ltd. 

hepatitis B vaccine, 

combined hep A and 

hep B vaccine, avian flu 

vaccine 

Yamanouchi (now treatments for obesity, R&D collaboration 2001 

Astellas Pharma 

Inc.) 

hyperlipidaemia 

RESEARCH & DEVELOPMENT: Anti-cancers 

Anti-infectives 

QOL (Quality of Life) 

PRODUCTS ON MARKET: Factive (Quinolone antibiotics) 

Intermax gamma (Gamma-IFN) 

Intermax alpha (Alpha-IFN) 

LG HCD (hepatitis C diagnostic) 

LG HBs Ag Elisa (hepatitis B diagnostic) 

LG Anti-HBs Elisa (hepatitis B diagnostic) 

LG HCD confirm (hepatitis C diagnostic) 

Euvax B (hepatitis B vaccine) 

Eutropin (hGH) 

Leucogen (GM-CSF) 

IFN-a 

Hyruan (Hyaluronic acid) 

HCD 



HBD 

EPO 

BGH 

Ivermectin 

Ceftiofur 


NEW CHEMICAL ENTITIES: 

LB 80380 for hepatitis B in Phase II clinicals 

LB 84451 for HCV, NASH in Phase I clinicals 

LB 53280 for obesity in preclinicals 

LC15-0133 for Type II diabetes in preclinicals 

Thrombin Inh - DVT, AF in preclinicals 

HCV inhibitor for hepatitis C completed discovery 


Queens Road 

Teddington TW11 0LY, UK 

Phone: +44 (0) 20 8943 7000; Fax: +44 (0)20 8943 2767 

Web: www.lgc.co.uk 

E-mail: info@lgc.co.uk 

KEY PERSONNEL: Ian Kent; Chairman 

Dr. Nigel Law; CEO 

Dr. Paul Debenham; Director, Life Sciences 

Dr. Angela Gallop; Director, LGC Forensics 



LGC (Holdings) Ltd. is formed (2/93) 

LGC (Holdings) Ltd. acquired Laboratory of the Government Chemist (4/96) 

Acquired Pipeline Developments Ltd. (1997) 

Acquired University Diagnostics Ltd. (1997) 

Acquired ICI's Runcorn analytical unit (1998) 

Formed GeneSolve, a joint venture with Dundee University (1999) 

Acquired the Promochem Group of Companies (2001) 

Sold Pipeline Developments Ltd. (2002) 

Acquired Forensic Alliance Ltd. (9/05) 

Acquired Agowa (1/06) 

FACILITIES: Locations in France, Germany, Spain, Sweden, the U.K., Italy and Poland 

Distribution office in India 


BUSINESS STRATEGY: Vision: 

Be an international business, recognised for setting standards in analytical 

science and providing best value products, services and solutions 

To meet its vision, the company will: increase turnover by 15 percent year 

on year with profit at or above 10 percent of sales, and achieve 25% of its 

turnover from outside the U.K. 


King’s College pharmacogenetic exclusive licensing 11/05 

London 

screening service that 

will predict if a patient 

with schizophrenia will 

respond positively to 

clozapine 

agreement 



Gentris Corp. Gentris can create, use 

and sale of diagnostic 

products and services 

which include testing for 

the CYP2D6*4 

polymorphism in the 

U.S. 

non-exclusive 


RESEARCH & DEVELOPMENT: Bioanalytical and genetic diagnostics and detection methodologies 

DNA analytical technologies 

Reference standards 

PRODUCTS ON MARKET: Analytical services/consultancy 

Paternity testing 

Forensics 

Livestock genotyping 

GMOs 

DNA databasing/analysis 

BSE testing 

Reference standards 


One Millennium Way 

Branchburg NJ 08876-3876, US 

Phone: (908) 947-1100; Fax: (908) 947-1089 


Web: www.lifecell.com 

E-mail: corporatecommunications@lifecell.com 

KEY PERSONNEL: Paul G. Thomas; Chairman, President and CEO 

Steven T. Sobieski; VP, Finance and Administration and CFO 

Lisa N. Colleran; Sr. VP, Commercial Operations 

Dr. Bruce Lamb; Sr. VP, Development, Regulatory Affairs and Quality 

Young C. McGuinn; VP, Manufacturing Operations 


HISTORY: Formed in 1986 by a technology transfer from the University of Texas Health 

Science Center in Houston to commercialize patented biopreservation 

technology 


FACILITIES: 90,000 sq. ft. of leased office, laboratory, production and warehouse space 

STOCK-FINANCIAL HISTORY: NASDAQ--LIFC 

IPO--800K units, each unit consisting of one share of common stock and 

one warrant to purchase 1/2 share of common stock, at $7.75/unit (2/92) 

Public offering--4M shares at $4.50/share, $18M (11/97) 





04) 


PRIVATE PLACEMENTS: $5.3M in an offering of 265K units at $20/unit (11/94) 


Raised $15.7M in private placement of 3.7M shares of common stock at 

$4.25/share (2003) 


6/06


PRINCIPAL INVESTORS: Medtronic Inc. 

Essex Woodlands 

Vector Later-Stage Equity Fund 

CIBC Wood Gundy 

BUSINESS STRATEGY: Develop technology for processing other universally transplantable tissue 

grafts and extended preservation of transfusable blood products 


LifeCore 

AlloDerm for periodontal exclusive distribution 6/97 

Biomedical Inc. procedures 


U.S. 

Medtronic Inc. porcine-tissue heart 

valves 


US Army Institute AlloDerm grafts for use development 1/97 

of Surgical in neurological, 

agreement--LifeCell 

Research 

dermatological and to receive $1.07M 

cardiovascular surgery over two years in 

product 

development 

funding and will use 

tissue preservation 

technology to 

develop vascular 

grafts for bypass 

surgery 

US Navy ThromboSol platelet $600K development 8/98 

storage solution funding 

RESEARCH & DEVELOPMENT: Universal Tissue Grafts, including skin, vascular conduits and heart valves 

Products for extending the shelf life of transfusable blood cells including red 

blood cells and platelets 

PRODUCTS ON MARKET: AlloDerm® - processed tissue products for grafting of third degree burns, 

grafting and guided tissue regeneration in periodontal surgery and tissue 

repair in plastic reconstructive surgery 

Cymetra® - version of AlloDerm in particulate form for the correction of soft 

tissue defects 

Repliform® - acellular tissue matrix for urologic and gynecologic procedures 

Graft Jacket® - accelular tissue matrix for orthopedic applications 

AlloCraftDBM - for bone grafting procedures 


271 Great Valley Parkway, Suite 100 

Malvern PA 19355, US 

Phone: (610) 644-8845; Fax: (610) 644-8616 

Web: www.lifesensors.com 

E-mail: info@lifesensors.com 

KEY PERSONNEL: Tauseef R. Butt, Ph.D.; President and CEO 

Michael R. Mattern, Ph.D.; VP, Research 

John Hall; VP, Business Development 

Bob Griess; Director, Finance 



Began biotech R&D December 1996 



SUBSIDIARY OF: Gene Transcription Technology 



PRINCIPAL INVESTORS: Ben Franklin Technology Partners 

BUSINESS STRATEGY: Discover, develops, manufacture and market important protein expression 

technologies based on advances in cellular and molecular biology 

Market to academic and government research institutions, and 

pharmaceutical and biotechnology companies worldwide in efforts to 

improve the quality of human life 


Embrex Inc. development of a three-year 

1/00 

sensor for the poultry 

gender sorting market 

agreement 

Rohm & Haas Co. development of insect research 

12/96 

receptor based 

screening technology 

collabration 

RESEARCH & DEVELOPMENT: Protein expression and biosensors utilizing the benefits of SUMO 

PRODUCTS ON MARKET: SUMOpro Expression System 

Split SUMOpro Expression System 

Fusion controls 

Proteases 

Expression vectors 

Prokaryotic, yeast and insect expression kits 


Estrogen detection biosensor development stage 

2nd Generation SUMO Expression 

Systems 

development stage 


3 Mallard Way, Strathclyde Business Park 

Bellshill ML4 3BF, UK 

Phone: +44 (0) 1698-849911; Fax: +44 (0) 1698-849922 

Web: www.linktech.co.uk 

E-mail: enquiries@linktech.co.uk 

KEY PERSONNEL: Jim Fisher; Chairman 

Dr. Michael Gray; Managing Director 

Dr. Douglas Picken; Director, R&D 

Dr. John Bremner; Director, Business Development 



Began biotech R&D in May 1989 

FACILITIES: 7,000 sq. ft. laboratory, office and warehouse facility 


RESEARCH & DEVELOPMENT: Nonradioactive labeling of oligonucleotides 

Antisense DNA reagents 

Base-modified nucleotides 

Biomolecule conjugation 

PRODUCTS ON MARKET: Range of reagents for DNA synthesis 

Supported reagents for large-scale synthesis 




Muenchensteinerstrasse 38 


Phone: +41 61-316-8111; Fax: +41 61-316-9111 

Web: www.lonza.com 

E-mail: contact@lonza.com 

KEY PERSONNEL: Rolf Soiron, Ph.D.; Chairman 

Stefan Borgas; CEO 

Toralf Haag, Ph.D.; CFO 

Lukas Utiger, Ph.D.; Head, Organic Fine & Performance Chemicals 

Stephan Kutzer, Ph.D.; Head, Biopharmaceuticals 

Rosario Valido; Head, Polymer Intermediates 



Acquired biologics contract manufacturing business of UCB (1/06) 


FACILITIES: Headquarters in Basel, Switzerland 

R&D facilities in Visp, Switzerland; Slough, U.K.; Portsmouth, N.H.; and 

Guangzhou, China 

Manufacturing facilities in Visp, Switzerland; Kourim, Czech Republic; 

Slough, U.K.; Portsmouth, N.H.; and Conshohocken, Pa. 

STOCK-FINANCIAL HISTORY: Financial data for the Lonza Group: 

Sales CHF2.521b (YE 05) compared to CHF2.182b (YE 04) 

Net income CHF188M (YE 05) compared to CHF138M (YE 04) 


(YE 04) 

Total assets CHF4.331b (YE 05) compared to CHF3.341b (YE 04) 

SUBSIDIARIES/DIVISIONS: Exclusive Synthesis & Biopharmaceuticals 

Organic Fine & Performance Chemicals 

Polymer Intermediates 

BUSINESS STRATEGY: Lonza develops products and processes for fine chemicals and active 

pharmaceutical ingredients in R&D centres and manufacturing plants in the 

U.S., Europe and Asia 

Lonza offers custom manufacturing services in the fields of monoclonal 

antibodies, therapeutic proteins, biotransformations and fermentation 

RESEARCH & DEVELOPMENT: Organic intermediates and APIs 

Biotransformation projects 

Fermentation processes (microbial and mammalian technologies) 

PRODUCTS ON MARKET: Lonza offers a wide range of organic intermediates and active substances 


1037R Forest Avenue 

Portland ME 04103, US 

Phone: (207) 797-5454; Fax: (207) 797-5595 


Web: www.mainebiotechnology.com 

E-mail: info@mainebiotechnology.com 

KEY PERSONNEL: Joseph P. Chandler, Ph.D.; President 

Carrie Cloutier; Sales Director, Custom Services 

Michael Sullivans; Production Manager 






4,200 sq. ft. R&D and manufacturing facilities 


BUSINESS STRATEGY: Provide MAb development and production services and immunodiagnostic 

reagents to commercial and academic laboratories 


675 McDonnell Boulevard 

Hazelwood MO 63042, US 

Phone: (314) 654-2000 

Web: www.mallinckrodt.com 

E-mail: info@mallinckrodt.com 

KEY PERSONNEL: Richard J. Meelia; CEO, Tyco Healthcare 

Michael J. Collins; President, Pharmaceuticals Division 

Douglas A. McKinney; VP, Finance and CFO 

Steven Hanley; President, Imaging Division 

Scott Drake; President, Respiratory 

Lisa Britt; VP, Human Resources 


HISTORY: Divested fertilizer business (now IMC Global Inc.) 

Bought Mallinckrodt, Inc. from Avon 

Bought Coopers Animal Health from ICI/Wellcome 

Changed name from IMCERA Group Inc. (3/94) 

Name changed from Mallinckrodt Group Inc. (10/96) 

Acquired Nellcor Puritan Bennett Inc. for $1.9b (7/97) 


Veterinary Division: 

Acquired by International Minerals & Chemical Corp. from Johnson & 

Johnson (3/87) 

Business is a combination of International Minerals & Chemical Corp.'s feed 

ingredient division, veterinary products division, Sterwin Poultry Health 

Division, Coopers Animal Health and Glaxo AH 

Formerly named Pitman-Moore, Inc., changed name (3/94) 

Acquired Syntro Corp. (11/95) 

Acquired poultry and companion animal business from CBM Laboratories, 

Campinas, Sao Paulo, Brazil, (11/95) 

Sold animal feeds ingredients business to IMC-Agrico (11/95) 

Sold sensor systems business (9/96) 

Divested interest in Tastemaker flavors business (1/97) 

Agreement reached to sell Mallinckrodt Veterinary to Schering-Plough 

Acquired by Tyco International Ltd. (10/00) 

SUBSIDIARIES/DIVISIONS: Pharmaceuticals, Respiratory and Imaging 

SUBSIDIARY OF: Mallinckrodt is a business unit of Tyco Healthcare 

BUSINESS STRATEGY: Create value for shareholders through growth in sales and profitability driven 

by innovation and productivity in human healthcare and specialty chemical 

businesses 


Advanced 

MRI contrast agent manufacturing and 1990 

Magnetics Inc. 

distribution 

agreement in the 

U.S. and Canada 



Advanced 

Warming Systems 

Inc. 

WarmTouch worldwide 


distribution 

agreement 

Centocor Inc. Myoscint exclusive marketing 

agreement for 

Europe, the Middle 

Iradimed Corp. Mridium MRI IV pump in 

the U.S., Canada and 

Mexico 


1992 

9/93 

East, and Africa 

sales agreement 5/06 

Medi-Physics radiopharmaceuticals rights for Medi- 

Physics proprietary 

product line to be 

distributed through 

Mallinckrodt's 35 

Metasyn Inc. MS-325 and other MRI 

vascular agents 

Molecular 

Biosystems Inc. 

Netherlands 

Energy Research 

Foundation 

MBI's Albunex second 

generation product, 

FS069 ultrasound 

imaging agents 

radiopharmacies 

worldwide 


marketing 

agreement (except 

Japan) 

distribution 

agreement 

Molybdenum-99 construction of 

Moly-99 plant 

OPTIMEDx optical imaging agents exclusive worldwide 

licensing rights to 

develop optical 

imaging agents for 

mammography and 

nonexclusive 

license to develop 

agents for use in 

other types of 

Palatin 


Schering AG 

(Germany) 

University Hospital 

Dijkzigt and 

Sandoz Pharma 

Ltd. 

cancer 

Palatin's NeutroSpec marketing 

agreement, 

extended 6/05 

MRI contrast agent enables both 

parties to sell select 

MRI products under 

radiopharmaceuticals 

for cancer imaging 

PRODUCTS ON MARKET: Contrast media and delivery systems 

Radiopharmaceuticals 

Urology imaging systems 

Active pharmaceutical ingredients 

Addiction treatment products 

Restoril®7.5mg and 22.5mg (temazepam capsules USP) 

Tofranil®-PM (imipramine pamoate capsules) 

Generic pharmaceuticals 

each others' patents 

development, 

production, and 

marketing 

agreement 

1995 

10/96 

4/96 

1992 

1994 

1993 

1991



341 Michele Place 

Carlstadt NJ 07072-2304, US 

Phone: (201) 935-2111; Fax: (201) 935-5223 

Web: www.marcordev.com 

E-mail: sales@marcordev.com 

KEY PERSONNEL: Charles J. Garbarini; President 

Sar Dorman; Sales Specialist, Biologicals 

Michael J. Malavasic, Ph.D.; Eastern Sales Manager, Biologicals 

Patty Powers-Feigel; International Manager 




RESEARCH & DEVELOPMENT: Reagents, enzymes 

PRODUCTS ON MARKET: Research reagents, enzymes, fermentation nutrients, peptones, yeast 

extracts 


14703-10 Mukaihigashi, Onomichi 

Hiroshima 722-0062, Japan 

Phone: +81 848-44-2217; Fax: +81 848-44-6851 

Web: www.maruzenpcy.co.jp 

KEY PERSONNEL: Heishiro Higurashi; Chairman 

Akifumi Higurashi; President 

Takao Ikeda; Managing Director 




SUBSIDIARIES/DIVISIONS: Longev Co. Ltd. 

Rooprun Pty. Ltd. 

BUSINESS STRATEGY: Manufacture and distribute pharmaceuticals, quasi-drugs, cosmetics, 

agricultural industrial products, health food, and food. Manufacture and 

distribute veterinary pharmaceuticals, livestock feed and fertilizers for crops. 

RESEARCH & DEVELOPMENT: Antityrosinase agents and radical scavengers for cosmetics 

Anti-inflammatory agents for cosmetics 

Health foods, designer foods 

Seasonings, low-calorie sweetener 

PRODUCTS ON MARKET: Licorice products for foods: Glycymin®, Glycymin® Cool 

Stevia products for foods: Marumilon Pure, alpha-G Sweet H, alpha-G 

Sweet PX, MARUMILON RICH A 

Licorice products for cosmetics: Dipotassium Glycyrrhizinate, Stearyl 

Glycyrrhetinate, Polyol Soluble Licorice Extract P-T (40) 

Quillaja saponin preparation 

Various plant extracts for cosmetics and toiletries 

Health food ingredients 



Mascoma Corp. 

161 First Street, Second Floor East 


Phone: (617) 234-0099; Fax: (617) 868-0408 

Web: www.mascoma.com 

E-mail: info@mascoma.com 

KEY PERSONNEL: Vinod Khosla; Chairman 

Colin South, Ph.D.; President 

Lee R. Lynd, Ph.D.; CSO 

Dr. Andrew Richard; CTO 

Dr. David Hogsett; VP, R&D 

Herve I. Garant, Ph.D.; Director, Bioprocess Engineering/Operations 

Siva Subramanian, Ph.D.; Director, Bioprocess Engineering/Design 




PRIVATE PLACEMENTS: Secured $4M in Series A financing (7/06) 

PRINCIPAL INVESTORS: Khosla Ventures 

Flagship Ventures 

BUSINESS STRATEGY: Develop unique bio and process technology for cost-effective conversion of 

cellulosic biomass (grass, wood, agricultural and forestry wastes) 

Two-pronged strategy of technology development and deployment, including 

patenting technologies for cellulosic production and forming partnerships to 

commercialize new cellulosic ethanol technologies and processes 


Dartmouth Mascoma to research exclusive worldwide 8/06 

College 

and produce ethanol 

from cellulosic biomass 

based on several 

patents from Dartmouth 


Integrated 

analysis of the genome contract 8/06 

Genomics Inc. of a microbe important 

to breaking down 

cellulosic biomass for 

conversion into ethanol 

RESEARCH & DEVELOPMENT: Cellulosic biomass-to-ethanol development and production, based on work 

developed in Prof. Lee R. Lynd’s labs at Dartmouth College 

Matreya LLC 

168 Tressler Street 

Pleasant Gap PA 16823, US 

Phone: (814) 359-5060; Fax: (814) 359-5062 


Web: www.matreya.com 

E-mail: customerservice@matreya.com 

KEY PERSONNEL: Gary C. Walker; VP, Manufacturing 

Amy Houtz; Office Manager/Purchasing Manager 





Successor to Matreya Inc., founded in 1988 





BUSINESS STRATEGY: Isolate, purify and synthesize bioactive lipids 

RESEARCH & DEVELOPMENT: Synthesize sphingolipids 

PRODUCTS ON MARKET: 240 lipids and mixtures 


6740 Campobello Road 

Mississauga L5N 2L8, Canada 

Phone: (905) 817-5700; Fax: (905) 890-0370 


Web: www.maxxam.ca; E-mail: info@maxxamanalytics.com 

KEY PERSONNEL: John Martin; Chairman 

Patricia Nielsen; CEO 

Pierre Beaumier; President 

Dean Taylor; CFO 

Andrew Masters; VP, Eastern Operations 

Bernie Brassard; VP, Western Operations 



Name changed from Mann Testing Laboratories Ltd. (1994) 

Merged with Chemex Labs Alberta (1996) 

Name changed from NOVAMANN (Ontario) Inc. (1997) 

Merged with PSC Analytical Services (PSC) (10/04) 

FACILITIES: 150,000 sq. ft. laboratory facility 


SUBSIDIARY OF: Maxxam Analytics International Corp. 


Provide scientific solutions through innovation and expertise 

RESEARCH & DEVELOPMENT: Application of PCR and DNA testing to animal genetics, parentage testing 

and microbial testing 

Agricultural consulting/testing services, residue registration studies 

Equine drug testing services and research 

PRODUCTS ON MARKET: Services include: drug detection, water quality testing, soil and water 

analysis, toxicity evaluation, air monitoring and analysis, ultra trace 

contaminant analysis by High Resolution Mass Spectrometry (HRMS), 

petroleum testing services, field sampling services, laboratory design and 

set-up, food chemistry and nutrition labeling, paternity tests and animal, 

plant and food genetics 





3900 Collins Road 

Lansing MI 48910, US 

Phone: (517) 337-3181; Fax: (517) 337-2122 

Web: www.mbi.org 

E-mail: info@mbi.org 

Dr. Mark Stowers; President and CEO 

Kellena D. Daigle; VP and CFO 

Robert A. DeVries, Ph.D.; Sr. Scientist 




Acquired CPC, International Corn Products Co. Technology Portfolio 

Package--in-licensing of technologies from several major universities and 

corporations 

Changed name from Michigan Biotechnology Institute (1995) 


SUBSIDIARIES/DIVISIONS: Bio-Business Incubator of Michigan (BBIM)--non-profit subsidiary 


Auxein Corp. plant growth technology new company 1994 

products 

formation to 

commercialize 

products 

BioPlastics Inc. biocompostable plastic new company 1995 

resins 

formation 

EFX Systems Inc. fluid-bed reactor for new company 1995 

environmental cleanup 

applications 

formation 

Enzyme Design enzymes for industrial, new company 1996 

Inc. 

consumer and scientific 

applications 

formation 

EverCorn Inc. biodegradable plastic 

resins 

joint venture 1993 

Lions Adhesives environmentally friendly new company 1996 

packaging and wood 

adhesives 

formation 

Natura Inc. food ingredients and new company 1994 

derivatives 

formation 

Plexis Biosciences expression systems new company 1997 

Inc. 

formation 

Synthon Corp. chiral intermediates new company 

formation 

1993 

RESEARCH & DEVELOPMENT: Biomass processing: MBI has licensed the ammonia fiber explosion (AFEX) 

process, a leading technology to pretreat biomass; Researching the use of 

the AFEX process in ethanol plants to recover sugars from corn fiber waste, 

to produce specialty chemicals in addition to ethanol via fermentation, to 

produce valued compounds from hemicellulose, in the development of high 

protein animal feeds, to facilitate the recovery of other valuable compounds 

locked within corn fiber, to expand the use of agricultural biomass as low 

cost feedstocks for chemical production and in fiber reinforced composites 

Succinic acid production: Isolation of several succinic acid producing 

microorganisms and development of a succinic acid producing bacterium, 

Actinobacillus succinogenes, and hyperproducing mutants 

Polyamide amine polymers: A new class of polymers 



Biorefinery development: Development of various biochemical and 

thermochemical routes to fuels, chemicals and materials and perfecting the 

dry mill biorefinery process 

Cellulose nanofibers: Production of microcrystalline cellulose nanowhiskers 

through the utilization of the low-cost AFEX process with surface, interfacial 

and mechanical properties in order to make them suitable as reinforcements 

and fillers in polymers 

PRODUCTS ON MARKET: Contract Services and Pilot-scale Manufacturing: Production of fragrances, 

high cell density Escherichia coli fermentation for protein reagents and 

protein biologicals, and the scale up of a specialty chemical produced via 

fermentation 


Bio-Business Incubator of Michigan: Offers assistance with the regulatory 

approval process, interim CEOs, business planning, business plan 

development, grant writing, finance and accounting, human resources, 

corporate filings, secretarial support, laboratory and technical support, and 

access to equipment and offices/laboratory space 

The Triad, 2200 Renaissance Blvd., Suite 400 

King of Prussia PA 19406-2755, US 

Phone: (610) 239-7900; Fax: (610) 239-7111 

Web: www.mdsps.com 

E-mail: info@mdsps.com 

KEY PERSONNEL: David Spaight; President and CEO 

Riaz Bandali; VP and GM, Global Early Clinical Research 

Robert Beland; VP, Discovery and Preclinical 

Robert Butz, Ph.D.; Interim VP and GM, Global Clinical Development 

Scott Neilson; VP and GM, Central Laboratories 

John Robson; VP and GM, Global Bioanalytical Services 

Peter Abram; Sr. VP, Finance 

Cam Hicks; Sr. VP, Human Resources and Organizational Development 

Jim McClurg, Ph.D.; Sr. VP and CSO 

Robert Castellucci; VP, Quality 


HISTORY: MDS Pharma Services was formed in 1999 from the merging of eight legacy 

companies: MDS Harris, MDS Panlabs, MDS Glarif, MDS Analytical 

Solutions, MDS Clinical Trial Laboratires, MDS Neo-Pharm, MDS Tricon and 

Phoenix International Life Sciences 

Sold its Fermentation Technologies business to Panlabs Biologics of Taiwan 

(12/05) 

FACILITIES: Locations in Johannesburg, South Africa; Beijing, China; Yokohama, Japan; 

Malaysia; Singapore; Taipei, Taiwan; Pyrmont, Australia; Mississauga, 

Blainville and Saint-Laurent, Canada; Mexico; Phoenix, Ariz.; Irvine, Calif.; 

Lincoln, Neb.; Neptune and North Brunswick, N.J.; King of Prussia, Penn.; 

Bothell, Wash.; New Orleans, La.; Buenos Aries, Argentina; Santiago, Chile; 

Lima, Peru; Brussels, Belgium; Czech Republic; France; Germany; 

Hungary, Italy; Poland; Romania; Madrid, Spain; Lund, Sweden; 

Switzerland; Kiev, Ukraine; and the U.K. 


SUBSIDIARY OF: MDS International Inc. (see separate entry) 

BUSINESS STRATEGY: To be the premier provider of innovative drug discovery and development 

solutions by offering our expertise in the areas of lead optimization, pre-IND 

research, pharmaceutical and biopharmaceutical development, early clinical 

research (bioequivalence, phases I-IIa), bioanalysis, global clinical 

development (phases IIb-IV) and central lab 



MedPharm Ltd. 

Business Centre, Sheep Street, Oxfordshire 

Charlbury OX7 3RR, UK 

Phone: +44 160 881 9267; Fax: +44 160 881 9268 

Web: www.medpharm.co.uk 

E-mail: busdev@medpharm.co.uk 

KEY PERSONNEL: Dr. Geoffrey Vernon; Chairman 

Dr. Andrew Muddle; CEO 

Dr. Mark Brown; CSO 

Dr. Petra Beck; Director, Pharmaceutical Development 

Carole Delauney; Head, Development Manager 

EMPLOYEES: 35 employees, 30 scientists 






BUSINESS STRATEGY: MedPharm is a specialist pharmaceutical development company of 

international reputation, focusing in particular on topical (skin, nail, lung and 

other mucous membranes) drug delivery systems. Projects range from 

simple feasibility tests, dosage design and optimization through to 

preparation of GMP clinical supplies for Phase I/II trials with guaranteed 

smooth technology transfer to manufacturing sites. Developments are 

performed at MedPharm’s GLP accredited laboratories located in London 

and at the GMP facility based closed to London. 

MedPharm develops formulations designed to meet the requirements of its 

clients while maximizing the chance of clinical success. MedPharm relies on 

its high level of scientific expertise to develop pharmaceuticals with all types 

of active pharmaceutical ingredients (APIs) including those difficult to 

formulate such as small organics with extreme physicochemical properties, 

DNA, proteins, peptides and plant-derived active substances. 

As of August 2005, MedPharm has been directly involved in the 

development of four products currently on the market in the EU and/or U.S. 

With more than 60 customers worldwide, MedPharm is recognized 

internationally for its unique and highly specialized service in pharmaceutical 

contract research and development together with expert project 

management, all at an extremely competitive price. 

In parallel to its services, MedPharm invests in its own IP in novel drug 

delivery technologies which can be licensed to clients. 

RESEARCH & DEVELOPMENT: Contract pharmaceutical R&D 

Dermal and transdermal patents 


2726 N. 48th Street 

Lincoln NE 68504, US 

Phone: (402) 467-6499; Fax: (402) 467-6495 

Web: www.pcrjet.com; E-mail: info@pcrjet.com 

KEY PERSONNEL: Michael Nelson; President 

Dr. Nisha Padhye; Sr. Scientist 

Dr. Osvaldo Lopez; Sr. Scientist 

Robyn Hassebrook; Scientist 





FACILITIES: Microbiology and biochemistry lab 


BUSINESS STRATEGY: Seek partners to manufacture and bring patened technologies to market 


Biologix Research technology for the licensing agreement 

Corp. 

detection of Thiopurine 

Methyl Transferase 

(TPMT) from blood 

Roche Molecular development of a fast, R&D contract 

Diagnostics experimental PCRJet 

for evaluation by Roche 

Molecular Diagnostics 

Toyobo Co. Ltd. development of PCRJet R&D contract and 

contract to enter 


University of advanced engineering research 

ongo 

Nebraska (Dr. of PCRJet 

collaborations ing 

Hendrik Viljoen, 

Department of 

Chemical 

Engineering) 

Thermocyclers 

University of rapid diagnostic DNA research 

ongo 

Nebraska Medical 

Center (Dr. Cathy 

Gebhart, 

Molecular 

Diagnostics 

Laboratory) 

tests 

collaborations ing 

RESEARCH & DEVELOPMENT: PCRJet®--pressurized gas thermocycler for the high-speed amplification of 

DNA 


4-16, Kyobashi 2-chome, Chuo-ku 


Phone: +81 3-3272-6511; Fax: +81 3-3271-3528 

Web: www.meiji.co.jp 

KEY PERSONNEL: Ichiro Kitasato; Chairman 

Naotada Sato; President 

Akio Takahashi; Sr. Exec. VP 

Akinobu Otsubo; Exec. VP 

Masaki Nagasaki; Exec. VP 

Masahiko Matsuo; Sr. VP 

Harunobo Tsukanishi; Sr. VP 

Masayuki Matsunaga; Sr. VP 

Hirobumi Mori; Sr. VP 

Hiromichi Kitahara; Sr. VP 

Tadao Shibasaki; Sr. VP 

Osamu Makabe; Sr. VP 

Hideki Takahashi; Sr. VP 

Yoshihiko Mizoguchi; Sr. VP 







Net income (YE 05) compared to ¥348M (YE 04) 

Earnings per share (YE 05) compared to 

¥0.79/share (YE 04) 



SUBSIDIARIES/DIVISIONS: Meiji Food Materia Co. Ltd. 

Donan Shokuhin Co. Ltd. 

Zao Shokuhin Kaisha Ltd. 

Ronde Corp. 

Meiji Sangyo Co. Ltd. 

Meiji Chewing Gum Co. Ltd. 

Azteca Co. Ltd. 

Okayamaken Shokuhin Co. Ltd. 

Shikoku Meiji Co. Ltd. 

Taiyo Shokuhin Co. Ltd. 

Fuji-Amide Chemical Co. Ltd. 

Kitasato Pharmaceutical Industry Co. Ltd. 

Meiji Sports Plaza Ltd. 

Meiji Seika (Singapore) Pte. Ltd. 

D.F. Stauffer Biscuit Co. Inc.--York, Pa., U.S. 

Laguna Cookie Co. Inc.--Santa Ana, Calif., U.S. 

P.T. Meiji Indonesian Pharmaceutical Industries 

Thai Meiji Pharmaceutical Co. Ltd.--Bangkok 

Tedec-Meiji Farma SA--Madrid, Spain 

Mabo Farma SA--Madrid, Spain 

Meiji Seika Europe BV--The Netherlands 

Mecor Inc.--Golden, Colo., U.S. 

Comercio e Industria Uniquimica Ltda.--Sao Paulo, Brazil 

Beghin Meiji--France 

P.T. Ceres Meiji Indotama--Indonesia 

Guangzhou Meiji Confectionery Co. Ltd.--China 

Shantou Meiji Pharmaceuticals Co. Ltd.--China 

Meiji Lukang Pharmaceutical Co. Ltd.--China 

Meiji Seika (Shanghai) Co. Ltd. 

PRINCIPAL INVESTORS: Mizuho Bank Ltd. 

The Master Trust Bank of Japan Ltd. 

The Dai-ichi Mutual Life Insurance Co. 

Nippon Life Insurance Co. 

Japan Trustee Services Bank Ltd. 

Fukoku Mutual Life Insurance Co. 

The Bank of Tokyo-Mitsubishi Ltd. 

The Tokio Marine and Fire Insurance Co. Ltd. 

Asahi Mutual Life Insurance Co. 

The Mitsubishi Trust and Banking Corp. 

INVESTMENTS: M. D. Research--joint venture with Daicel Chemical and Japan Key 

Technology Center 


Allergen-Free 

Technology 

Laboratories Inc. 

allergen-free grains R&D agreement 3/92 

Beghin Say SA fructo-oligosaccharide joint venture to 


Daicel Chemical, technology for 

joint R&D venture 3/86 

Japan Key producing active called M. D. 

Technology peptides via rDNA and Research 

Center 

synthetic processes 

MECOR fructo-oligosaccharide joint venture to 11/88 

with applications in market in the U.S., 

animal feed, ingredients Canada, and the 

and health food 

Caribbean 

NeuroSearch A/S GABA modulators R&D agreement 10/93 



Nippon Roche KK, 

Eisai Co. Ltd., 

Kissei 


SIBIA 

Neurosciences 

Inc. 

cloning of Werner 

syndrome gene 

SIB-1508Y as first-oftype 

treatment for 

Parkinson's disease 

Tokyo University diagnostics of 

pancreatic diseases 


AGENE 



agreement--SIBIA 

will receive 

licensing fee, 


and royalties on 

future sales, and 

will supply product 

to Meiji for clinical 

use, SIBIA to retain 

manufacturing 


rights 

collaborative 


PRODUCTS ON MARKET: Anti-infectives: Meiact, Fosmicin, Habekacin, Omegacin, Sword, Ciproxan 

Central nervous system drugs: Meilax, Depromel, Ebastel 

Agricultural chemicals: Oryzemate, Herbie 

Veterinary drugs: Meirich, Meipole, Astop 

Animal feed supplements: Colistin, Cellulaze 

Healthfood products: Savas, Karadanavi, Lola, Amino Collagen, Prefect 

Plus, Protein Diet 

Over-the-counter drugs: Isodine, Bayer Aspirin 

Food products: Chocolate, chewing gum, snacks, biscuits, candy 

Mercian Corp. 

1-5-8 Kyobashi Chuo-Ku 


Phone: +81 3 3231 3927; Fax: +81 3 3276 0151 

Web: www.mercian.co.jp 

E-mail: chem@mercian.co.jp 

KEY PERSONNEL: Yuji Okabe; President and CEO 

Yasuteru Sakamoto; Sr. VP and President, Pharmaceuticals and Chemicals 

Company 

Yukimichi Tamura; Sr. VP, Finance 

Masahide Takai; Sr. VP and President, Liquor Company 

Masaaki Oshitani; Sr. VP and President, Processing Liquors Company 

Shuji Tsuchimoto; Sr. VP, Sales Dept. 


HISTORY: Founded in 1934 as a liquor manufacturer Showa Brewery Co. Ltd. 

Merged with Nisshin Brewery Co. Ltd. (1961) 

Merged with Ocean Co. Ltd. and changed name to Sanraku Ocean Co. Ltd. 

(1962) 

Changed name to Sanraku Co. Ltd. (1985) 

Acquired Napa, Calif.-based Markham Vineyards (10/87) 

Changed name to Mercian Corp. (9/90) 

FACILITIES: Five branch offices, eight factories and two research facilities in Japan 

One representative office and five production facilities overseas 

3/93 

3/97 

4/90




Net income ¥1.409 (YE 05) compared to ¥2.372b (YE 04) 



SUBSIDIARIES/DIVISIONS: Liquor Company 

Processing Liquors Company 

Pharmaceuticals & Chemicals Company 

Feedstuffs Company 

BUSINESS STRATEGY: Maintain position as a leading producer of alcholic beverages, and 

manufactuer of feedstuffs, chemical products and pharmaceuticals 


ILEX Oncolgy NM-3 license agreement 

RESEARCH & DEVELOPMENT: Screening new anticancer drugs and other chemical compounds produced 

using microorganisms 

Development of manufacturing processes for chiral compounds utilizing 

bioconversion 

Analysis of fermentation characteristics and aroma and taste 

Breeding of new yeast genes 

Study of liquor fermentation mechanisms 

Examination of the health benefits of wine 

Merck KGaA 

Frankfurter Str. 250 

Darmstadt D-64293, Germany 

Phone: +49 6151-72-0; Fax: +49 6151-72-2000 

Web: www.merck.de 

E-mail: service@merck.de 

KEY PERSONNEL: Dr. Michael Romer; Chairman 

Karl-Ludwig Kley; Deputy Chairman 



FACILITIES: Production and/or sales operations in 54 countries 

STOCK-FINANCIAL HISTORY: Reuters--MRCG / Bloomberg--MRK GY / FSE--ISIN: DE 00065 99905 - 

WKN: 659 990 

IPO--(1995) 



(YE 04) 

SUBSIDIARIES/DIVISIONS: Pharmaceuticals Business Sector--divisions include Ethical 

Pharmaceuticals, Generics, OTC 

Chemicals Business Sector--divisions include Liquid Crystals, Performance 

& Life Science 

INVESTMENTS: Agribiotics Holdings Inc. in 3/06 

Survac ApS in 11/05 

Lumitec OLED R&D project of Schott AG in 2/05 

OLED materials (Covion Organic Semiconductors GmbH) and polymer 

electronics businesses fron Avecia in 4/05 

BUSINESS STRATEGY: Focus on business segments in which the company achieves competitive 

advantages through excellent quality of products, services and systems by 

concentrating on innovations and research in the pharmaceuticals business 

and on higher grade products in the chemicals business 




Biomira Inc. Stimuvax (BLP25) global development 1/06 

cancer vaccine 

and promotion 

agreement 

ChemGenex preclinical support for three-year alliance 1/06 

Pharmaceuticals diabetes, insulin 

resistance and 

complications 

agreement 

Dyax Corp. Dyax's phage display non-exclusive 8/05 

libraries 


Eli Lilly and Co. Merck’s Ph. I insomnia 

treatment EMD281014, 

a 5-HT2a antagonist 


Genaissance development and exclusive worldwide 9/04 

Pharmaceuticals commercialization of licensing agreement 

Inc. 

vilazodone 

Organon NV EMM 310066, a novel granted worldwide 5/05 

combination oral development and 

contraceptive 

marketing rights 

Takeda 

Matuzumab co-development 9/05 


and co- 

Co. Ltd. 


agreement 

Tioga 

Asimadoline, for granted 

6/05 

Pharmaceuticals treatment of Irritable 

Bowel Syndrome 

development rights 

RESEARCH & DEVELOPMENT: See annual report or visit our Web site, www.merck.de 

PRODUCTS ON MARKET: PHARMA: Glucophage®, Concor®, Euthyrox®, Jodthyrox®, Praxilene®, 

Neurobion®, Cebion®, Erbitux® 


angiogenesis inhibitor cilengitide in glioma in Phase II clinicals 

humanized monoclonal antibody 

Matuzumab (EMD 72000) in EGFRexpressing 

tumors 

in Phase II clinicals 

Liposomal cancer vaccine Stimuvax (L- 

BLP25) in MUC1-expressing tumors: e.g. 

non-small cell lung cancer 

in Phase II/III clinicals 

Metabolix Inc. 

21 Erie Street 

Cambridge MA 02139-4260, US 

Phone: (617) 492-0505; Fax: (617) 492-1996 

Web: www.metabolix.com 

E-mail: info@metabolix.com 

KEY PERSONNEL: Jim Barber; President and CEO 

Dr. Oliver Peoples; CSO 

Thomas Auchincloss; CFO and VP, Finance and Corporate Development 

Johan van Walsem; VP, Manufacturing, Development and Operations 

Dr. Robert Whitehouse; Director, Applications Development 

Robert Findlen; VP, Sales and Marketing 

Dan Gilliland; Director, Business Development 

Ben Locke; Director, Government Programs 



Acquired Monsanto's Biopol assets (5/01) 

Strategic agreement with ADM (11/04) 

Presidential Green Chemistry Award (2005) 




STOCK-FINANCIAL HISTORY: Filed for IPO, NASDAQ--MBLX proposed (7/06) 

BUSINESS STRATEGY: Create a compelling, sustainable alternative to petrochemical materials and 

establish a technology platform that will enable the widespread adoption of 

PHA bioplastics in the marketplace 


Archer Daniels commercialization of a strategic alliance 11/04 

Midland Co. new generation of highperformanceecofriendly 

natural plastics 


7259 Lansdowne Avenue, Suite 200 

St. Louis MO 63119-3421, US 

Phone: (314) 645-2177; Fax: (314) 645-2544 


Web: www.microbeinotech.com; E-mail: info@microbeinotech.com 

KEY PERSONNEL: Bruce C. Hemming, Ph.D.; President and CEO 

Barry L. Haymore, Ph.D.; Director, Technology 

Laurence E. Hallas, Ph.D.; Director, Field Services 

John Kent Morgan; Laboratory Manager 



Member--Biotech Industry Organization 

FACILITIES: Pharmaceutical, environmental and food microbiology laboratories 


BUSINESS STRATEGY: Provide microbiological characterization and identification services for 

environmental, food and pharmaceutical industries (GC-Fame, Biolog, 

Ribotyping, 16SrRNA DNA pair sequence, Custom Microarrays) 

RESEARCH & DEVELOPMENT: Rapid microbiological diagnostics, environmental mycobacteria detection 

Bio-control technologies, bioremediation assays 

PRODUCTS ON MARKET: Rapid Gluten Home Test Kit 

CombiMatrix Catalog Microarrays and Custom Arrays 

Microbia Inc. 

As a full-service microbiology lab, provides testing services for the 

environmental, food, biotechnological and industrial communities 

320 Bent Street 


Phone: (617) 621-7722; Fax: (617) 494-0908 

Web: www.microbia.com 

E-mail: info@microbia.com 

KEY PERSONNEL: Joseph C. Cook Jr.; Chairman 

Peter M. Hecht, Ph.D.; CEO 

Richard Bailey, Ph.D.; VP and GM, Precision Engineering 

Brian M. Cali, Ph.D.; VP, Program Management 

Mark G. Currie, Ph.D.; VP, R&D 

Michael J. Higgins; Sr. VP, Finance and Strategic Planning and CFO 

Jeffrey M. Johnston, M.D.; VP, Clinical Development and CMO 




G. Todd Nilne, Ph.D.; VP, Biology 

James O'Mara; VP, Business Development 

John J. Talley, Ph.D.; VP, Drug Discovery 




PRIVATE PLACEMENTS: Raised $9.8M in Series A financing (2/99) 

Raised $23M in Series B financing (8/00) 

Raised $40M in Series D financing (5/04) 

Raised $75M in Series E financing (2/06) 

PRINCIPAL INVESTORS: Aberdare Ventures 

Alton Ltd. 

BancBoston Ventures 

Bio*One Capital 

Essex Investment Management Co. 

Fidelity Biosciences Group 

Invus LP 

Jennison Associates 

Linkagene LP 

Maverick Capital 

Paperboy Ventures 

Polaris Venture Partners 

Sigma Capital Management 

Venrock Associates 

BUSINESS STRATEGY: Utilize revenues from yield improvement service business to fund internal 

development of novel anti-infectives 


DuPont Central biomanufacturing CRADA with 2/06 

Research & process for a chemical Microbia's Precision 

Development currently manufactured Engineering® 

from petrochemicalbased 

raw materials 

business unit 

Ranbaxy 

biomanufacturing technology 

2/03 

Laboratories Ltd. processes using development 

Microbia’s Precision 

Engineering 

agreement 

Ranbaxy 

to lower the cost of a research 

11/05 

Laboratories Ltd. Ranbaxy 

biomanufacturing 

process 

collaboration 

Teva 

biomanufacturing development 3/04 

Pharmaceutical processes using agreement, 

Industries 

Microbia’s Precision 

Engineering technology 

expanded 

RESEARCH & DEVELOPMENT: Precision Engineering platform: Applies molecular genetics and proprietary 

profiling methods to rationally design microbes for the efficient production of 

commercially valuable metabolites. Applications include the pharmaceutical, 

food and feed ingredients, specialty chemical industries and industrial 

biotechnology 




2746 Loker Ave. West 

Carlsbad CA 92010, US 

Phone: (760) 929-9911; Fax: (760) 929-0109 


Web: www.mobio.com 

E-mail: info@mobio.com 

KEY PERSONNEL: Mark N. Brolaski; CEO and President 

Liz Brolaski; Exec. VP 

Ravi Venugopal, Ph.D.; Director, R&D 

Melissa Stolow, Ph.D.; Sr. Scientist 

David Stolow, Ph.D.; Sr. Scientist 

Getachew Sequar, Ph.D.; Scientist 



FACILITIES: 11,000 sq. ft. headquarters in Carlsbad, Calif. 


SUBSIDIARIES/DIVISIONS: Molecular Biology Manufacturing 

Contract Testing Services 

BUSINESS STRATEGY: Continue with strength in molecular and microbiology product development 

RESEARCH & DEVELOPMENT: Molecular, micro and protein biology kit development; kits for DNA, RNA and 

protein isolation 

PRODUCTS ON MARKET: DNA and RNA isolation kits used by molecular and microbiologists in fields 

of forensics, anti-biowarfare, environmental microbial analysis, basic 

research and biopharmaceuticals: 

DNA Clean-up and Gel Extraction: PowerClean DNA Clean-Up Kit, 

UltraClean 15 DNA Purification Kit, UltraClean GelSpin Kit, 

UltraClean PCR Clean-up Kit, UltraClean-htp 96 Well PCR Cleanup 

Kit, UltraClean 15 Kit Components, UltraClean GelSpin Kit 

Components, UltraClean PCR Clean-up Kit Components 

Plasmid DNA Isolation: UltraClean 6 Minute Mini Plasmid Prep Kit, 

UltraClean-htp 96 Well Plasmid Prep Kit, UltraClean Standard Mini 

Plasmid Prep Kit, UltraClean Midi Plasmid Prep Kit, UltraClean Maxi 

Plasmid Prep Kit, UltraClean Endotoxin-Free Mini Plasmid Prep Kit, 

UltraClean Endotoxin-Free Midi Plasmid Prep Kit, UltraClean 

Endotoxin-Free Maxi Plasmid Prep Kit, UltraClean Endotoxin Removal Kit, 

UltraClean Endotoxin-Free Precipitation Kit, UltraClean 6 Minute Mini 

Prep Kit Components, UltraClean Midi Plasmid Prep Kit Components, 

UltraClean Maxi Plasmid Prep Kit Components, UltraClean Endotoxin- 

Free Mini Kit Components, UltraClean Endotoxin-Free Midi Kit 

Components, UltraClean Endotoxin-Free Maxi Kit Components, 

Endotoxin-Free Reagents and Supplies 

Soil DNA Isolation: PowerSoil - htp 96 Well Soil DNA Isolation Kit, 

PowerClean DNA Clean-Up Kit, PowerMax Soil DNA Isolation Kit, 

PowerSoil DNA Isolation Kit, UltraClean Soil DNA Kit, UltraClean 

Mega Soil DNA Kit, UltraClean-htp 96 Well Soil DNA Kit, UltraClean 

Fecal DNA Kit, PowerMax Soil DNA Isolation Kit Components, 

PowerSoil DNA Isolation Kit Components, UltraClean Soil DNA Kit 

Components, UltraClean Mega Soil DNA Kit Components, UltraClean 

Fecal DNA Kit Components 

Microbial DNA Isolation: PowerMicrobial Midi DNA Isolation Kit, 

PowerMicrobial Maxi DNA Isolation Kit, UltraClean Microbial DNA Kit, 

UltraClean-htp 96 Well Microbial DNA Kit, UltraClean Microbial DNA Kit 



Components, PowerMicrobial Midi DNA Isolation Kit Components, 

PowerMicrobial Maxi DNA Isolation Kit Components 

Blood DNA Isolation: UltraClean BloodSpin Kit, UltraClean Mega 

BloodSpin Kit, UltraClean Blood DNA Kit (Non-Spin), UltraClean-htp 

96 Well BloodSpin DNA Kit, UltraClean BloodSpin Kit Components, 

UltraClean Mega BloodSpin Kit Components, UltraClean Blood DNA 

Kit (Non-Spin) Components 

Tissue DNA Isolation: UltraClean Tissue DNA Kit, UltraClean-htp 96 

Well Tissue DNA Kit, UltraClean Tissue DNA Kit Components 

Plant DNA Isolation: PowerPlant DNA Isolation Kit, UltraClean Plant 

DNA Kit, UltraClean-htp 96 Well Plant DNA Isolation Kit, PowerPlant 

DNA Isolation Kit Components, UltraClean Plant DNA Kit Components 

Water DNA Isolation: UltraClean Water DNA Kit (0.45 um), UltraClean 

Water DNA Kit (0.22 um), UltraClean Water DNA Kit (No filters), Water 

Filters, UltraClean Water DNA Kit Components 

Forensic DNA Isolation: UltraClean Forensic DNA Kit 

RNA Isolation: RNA PowerSoil Total RNA Isolation Kit, UltraClean 

Tissue RNA Kit, UltraClean Plant RNA Kit, UltraClean Microbial RNA 

Kit, RNA PowerSoil Total RNA Isolation Kit Components, UltraClean 

Tissue RNA Kit Components, UltraClean Plant RNA Kit Components, 

UltraClean Microbial RNA Kit Components 

Nuclease Detection: RNase Detection Kit, DNase Detection Kit 

Lab Supplies: Electrophoresis Equipment (Mini Horizontal Gel System; Mini 

Horizontal Gel Caster; Mini Horizontal Gel Tray; Comb, Polycarbonate; 

Comb, Teflon; Dual Comb, Polycarbonate; Dual Comb, Teflon; Power 

Supplies), Electrophoresis Reagents (TAE Buffer, 50X (Tris-acetate-EDTA); 

TBE Buffer, 10X (Tris-borate-EDTA); UltraClean Agarose; UltraClean 

Low Melt Agarose; UltraClean Low Melt Sieve Agarose; UltraClean MS- 

8 Agarose; UltraClean Forensic Agarose; DNA Molecular Weight Markers; 

Ethidium Bromide Solution; Ethidium Bromide Destaining Tea Bags; Gel 

Loading Buffer, Bromophenol Blue; Gel Loading Buffer, Bromophenol 

Blue/Xylene Cyanol), Water (PCR Water, Molecular Biology Grade Water, 

DEPC Treated Water, Endotoxin-Free Water), Growth Media (TB DRY 

Powder Growth Media; LB Broth Powder Growth Media; LB Agar Powder 

Growth Media; LB Broth (Lennox) Powder Growth Media; LB Agar (Lennox) 

Powder Growth Media; Soybean-Casein Digest Medium (TSB), USP; 

Soybean-Casein Digest Agar Medium (TSA), USP; Yeast Extract; Tryptone; 

Agar), Vortexes and Adapters (Vortex-Genie® 2; Labnet VX100 Vortex; 

Vortex Adapters for Vortex-Genie® 2; Vortex Adapters for Labnet VX100 

Vortex), Lab Accessories (RNase-Free Gloves, UltraClean Lab Cleaner), 

96 Well Kit Equipment (96 Well Plate, Shaker, Plate Adapter Set, Tube 

Adapter Set, UltraVac Manifold, Vacuum Pump) and Homogenization 

Equipment (Precellys® 24 Homogenizer) 

Samples: MO BIO SAMPLES - No Sales Calls & No Interruptions, 

UltraClean 6 Minute Mini Plasmid Prep Sample Kit, UltraClean PCR 

Clean-up Sample Kit, UltraClean GelSpin Kit Sample, PowerMax 

Soil DNA Isolation Kit Sample, RNA PowerSoil Total RNA Isolation Kit 

Sample, UltraClean Forensic DNA Sample Kit, UltraClean 15 DNA 

Purification Kit Sample, UltraClean Standard Mini Plasmid Prep Sample 

Kit, UltraClean Midi Plasmid Prep Sample Kit, UltraClean Maxi Plasmid 

Prep Sample Kit, UltraClean Endotoxin-Free Mini Plasmid Sample Kit, 

PowerSoil DNA Isolation Kit Sample, UltraClean Soil DNA Sample Kit, 

UltraClean Fecal DNA Sample Kit, UltraClean Microbial DNA Sample 

Kit, UltraClean Microbial RNA Sample Kit, UltraClean BloodSpin 

Sample Kit, UltraClean Blood DNA Sample Kit (Non-Spin), UltraClean 

Tissue DNA Sample Kit, PowerPlant DNA Isolation Sample Kit, 

UltraClean Tissue RNA Sample Kit, UltraClean Plant RNA Sample Kit, 



MoBiTec GmbH 

TB DRY Powder Growth Media Sample, LB Broth Powder Growth Media 

Sample, LB Agar Powder Growth Media Sample, LB Agar (Lennox) Powder 

Growth Media Sample, LB Broth (Lennox) Powder Growth Media Sample 

Yeast Extract Sample, Tryptone Sample, Agar Sample 

Lotzestrasse 22a 

Goettingen 37083, Germany 

Phone: +49 551-707-220; Fax: +49 551-707-2222 

Web: www.mobitec.com; E-mail: info@mobitec.com 

KEY PERSONNEL: Jorg Ronnenberg; Chairman 




BUSINESS STRATEGY: Provide an extraordinary wide range of innovative tools for molecular and 

cell biology to make daily lab research faster, easier and more efficient 

Enzyme technology in research, food technology, pharmaceuticals and 

environment 

RESEARCH & DEVELOPMENT: Pharmaceutical diagnostics 

Environmental purification 

Water purification 

PRODUCTS ON MARKET: Cloning vectors 

Expression systems for E.coli, yeast, B.megaterium, B.subtilis 

Two- and One-Hybrid Systems 

Phagemid technology 

Genomic libraries 

Antibodies 

Cytokines and growth hormones 

Tools for proteomics and genomics 

Fluorescence technology 

Affinity chromatography 

Lab suplies 


1311 Orleans Drive 

Sunnyvale CA 94089-1136, US 

Phone: (408) 747-1700; Fax: (408) 747-3601 


Web: www.moleculardevices.com 

E-mail: info@moldev.com 

KEY PERSONNEL: Joe Keegan; President and CEO 

Timothy Harkness; Sr. VP, Finance and CFO 

Gillian M.K. Humphries, Ph.D.; VP, Strategic Affairs 

Robert Murray; VP, Operations 

J. Richard Sportsman, Ph.D.; VP, Assay and Reagent R&D 

Robert Wicke; VP, Engineering 

Jan Hughes; VP, Marketing 

Tom Olenic; VP, Sales 

Pat Sharp; VP, Human Resources 




HISTORY: Founded in 1983 by Dr. Harden McConnell 

Reincorporated in Delaware in 1995 

Acquired the Laser Capture Microdissection business of Arcturus Bioscience 

for $10M (4/06) 

FACILITIES: 150,000 sq. ft. facility in Sunnyvale, Calif. (headquarters) 

Offices in Union City, Calif.; Great Britain; Korea; China; Japan; 

Downingtown, Pa.; Germany; and Brazil 

STOCK-FINANCIAL HISTORY: NASDAQ--MDCC 

IPO--$11/share (12/95) 





04) 


BUSINESS STRATEGY: Develop innovative bioanalytical systems for life science research and drug 

discovery 

RESEARCH & DEVELOPMENT: Microplate readers and spectrophotometers, multi-mode benchtop readers, 

electrophysiology instruments, imaging systems, microarray scanning 

equipment, amplifiers, software and HTS systems 

PRODUCTS ON MARKET: Emax Precision Microplate Reader for endpoint analysis 

VersaMax, SpectraMax Plus 384, SpectraMax 190, Gemini XPS 

FLIPR Tetra Flourometric Imaging Plate Reader 

SoftMax Pro® data analysis software 

SpectraMax 340PC 384 Microplate Spectrophotometer for UV and visible 

analysis of biomolecules 

SpectraMax Plus High Throughput Spectrophotometer 

SpectraMax® M5 five-mode multi-detection microplate reader system 

Threshold® biosensor assay system for rapid sensitive detection of 

contaminants in biopharmaceuticals 

Threshold® Total DNA assay kit for quantitation of DNA in protein solutions 

Threshold® Immuno-Ligand assay kit for immunoassay and other binding 

assays in protein solutions 

Vmax® Kinetic Microplate Reader using vertical beam photometry 

Lmax II Luminomter 

IonWorks HT Electrophysiology system 

PatchXpress Electrophysiology system 

OpusXpress Electrophysiology system 

GenePix 4200AL Microarray Scanner 

MetaMorp Imaging Software 

MetaFluor Imaging Software 

Discovery-1 Imaging System 

Axoporator Amplifier 

ImageXpress Imaging System 

Analyst HT Multi-Mode System 

AquaMax DW4 Dispenser/Washer 

QBT Fatty Acid Uptake Assay Kit 




P.O. Box 22010, 29851 Willow Creek Road 

Eugene OR 97402-0469, US 

Phone: (541) 465-8300; Fax: (541) 335-0504 

Toll-free phone: (800) 438-2209 (orders only) 

Web: www.probes.invitrogen.com 

E-mail: tech@probes.com 

KEY PERSONNEL: August Sick; General Manager 



Acquired by Invitrogen Corp. (8/03) 


SUBSIDIARIES/DIVISIONS: Molecular Probes Europe BV--wholly owned subsidiary located in the 

Netherlands 

SUBSIDIARY OF: Invitrogen Corp. (see separate entry) 

BUSINESS STRATEGY: Be the leading provider of fluorescence-based detection solutions to 

advance scientific and biomedical research 

PRODUCTS ON MARKET: Over 3,000 fluorescent probes for bioscience research listed in the 

'Handbook of Fluorescent Probes and Research Chemicals' including 

Calcium Green, Live/Dead® viability/cytotoxicity kits, SYBR® Green 

nucleic acid gel stain, SYPRO® Protein gel stain, FluoSpheres®, Cascade 

Blue®, Toto®-1, Yoyo®-1 and Bodipy® 

Monsanto Co. 

800 North Lindbergh Boulevard 

St. Louis MO 63167, US 

Phone: (314) 694-1000; Fax: (314) 694-4228 

Web: www.monsanto.com 

E-mail: info@monsanto.com 

KEY PERSONNEL: Hugh Grant; Chairman, President and CEO 

Terrell K. Crews; Exec. VP and CFO 

Dr. Robert T. Fraley; Exec. VP and CTO 

Charles W. Burson; Exec. VP, Secretary and General Counsel 

Carl M. Casale; Exec. VP, North America Commercial 

Brett D. Begemann; Exec. VP, International Commercial 

Robert A. Paley; VP and Treasurer 

Mark J. Leidy; Exec. VP, Manufacturing 

Gerald A. Steiner; Exec. VP, Commercial Acceptance 

Steven C. Mizell; Sr. VP, Human Resources 

Cheryl Morley; Sr. VP, Corporate Strategy 

Richard B. Clark; VP and Controller 

Janet M. Holloway; VP and Chief of Staff 

Scarlett Lee Foster; VP, Investor Relations 



Agricultural division established (1960) 


Acquired the Jacob Hartz Seed Co. (1982) 

Acquired 49% of Calgene Inc. (3/96) 

Acquired Agracetus (7/96) 

Increased ownership of Calgene Inc. to 54.6% through purchase of 6.25M 

shares (8/96) 



Acquired Asgrow agronomics seed business (1997) 

Acquired Holden's Foundation Seeds Inc., Corn States Hybrid Service Inc. 

and Corn States International Sarl for up to $1b (1/97) 

Acquired remaining shares of Calgene for $8/share, $240M (7/97) 

Monsanto split into two companies--Monsanto Co. (life sciences, agriculture, 

health and food products) and Solutia Inc. (chemicals and fibers) (9/97) 

Announced plans to acquire remaining shares of Dekalb Genetics Corp. for 

$2.5b and Delta & Pine Land Co. for an undisclosed amount (5/98) 

American Home Products Corp. (now Wyeth) and Monsanto Co. announced 

plans to merge for $33b in stock and to create new company (6/98) 

Announced plans to acquire Cargill's international seed operations in Central 

and Latin America, Europe, Asia and Africa for $1.4b (6/98) 

Merged with Pharmacia & Upjohn to form Pharmacia Corp. Monsanto is the 

acknowledged agricultural subsidiary and will retain its name, while 

Pharmacia owns 85% of Monsanto. The business became a separate legal 

entity with a stand-alone board of directors and its own publicly traded stock. 

(4/00) 

Divested by Pharmacia Corp. in lieu of Pharmacia's merger into Pfizer Inc. 

(4/03) 

Formed American Seeds Inc. (ASI) (2004) 

ASI acquired Channel Bio Corp. (including three seed brands: Crows Hybrid 

Corn, Midwest Seed Genetics and Wilson Seeds) (2004) 

Acquired North American canola seed assets of Advanta Seeds from 

Advanta BV (9/04) 

Acquired the Stoneville cotton business (including its NexGen brand) (2005) 

ASI subsidiary acquired NC+ Hybrids Inc. (2005) 

ASI acquired Fontanelle Hybrids, Stewart Seeds, Trelay Seeds and Stone 

Seeds (2005) 

ASI acquired Specialty Hybrids (2005) 

Acquired agricultural genomics assets of Icoria Inc. (3/05) 

Acquired Seminis Inc. (3/05) 

Acquired Emergent Genetics Inc. (4/05) 

Sold Monsanto Enviro-Chem Systems Inc. (8/05) 

ASI acquired the seed marketing and sales businesses of Diener Seeds and 

and Sieben Hybrids (6/06) 

ASI to acquire Kruger Seed Co. Trisler Seed Farms and the seed marketing 

and sales business of Campbell Seed (as of 6/06) 

To acquire Delta and Pine Land Co. for $1.5b (as of 8/06) 


FACILITIES: Manufacturing facilities, laboratories, seed production and other agricultural 

facilities, office space, warehouses and other land parcels in North America, 

South America, Europe, Asia, Australia and Africa 

Seed conditioning plants at Bellary, India; Constantine, Mich.; Eluru, India; 

Grinnell, Iowa; Kearney, Neb.; Oxnard, Calif.; Peyehorade, France; 

Phitsanoluk, Thailand; Trebes, France; Uberlandia, Brazil; and Villagran, 

Mexico 

Chemicals manufacturing facilities at Alvin, Texas; Antwerp, Belgium; 

Augusta, Ga.; Camacari, Brazil; Luling, La.; Muscatine, Iowa; Sao Jose dos 

Campos, Brazil; Soda Springs, Idaho; and Zarate, Argentina 

STOCK-FINANCIAL HISTORY: NYSE--MON 





SUBSIDIARIES/DIVISIONS: Two business segments: 

Seeds and Genomics (global seeds and traits businesses and genetic 

technology platforms) 

Agricultural Productivity (crop protection products, animal agriculture 

businesses and lawn-and-garden herbicide products) 

INVESTMENTS: The Liposome Co. 

Target Therapeutics 

HybriTech Seed Europe-SNC--joint venture with CACBA 

Calgene Inc.--100% 



Joint venture with Cargill to use biotechnology to improve feed for pigs, 

cattle, poultry and fish (5/98) 

Formed American Seeds Inc. (ASI), a holding company to support regional 

seed businesses (11/04) 

BUSINESS STRATEGY: Produce leading seed brands and develop biotechnology traits that assist 

farmers in controlling insects and weeds 

Provide other seed companies with genetic material and biotechnology traits 

for their seed brands 

Provide lawn-and-garden herbicide products for the residential market 

Provide animal agricultural products focused on improving dairy cow 

productivity and swine genetics 


Genaissance to map single nucleotide research agreement 3/05 

Pharmaceuticals polymorphism (SNP) 

Inc. and the DNA markers in 

Agricultural 

Research Service 

(part of USDA) 

soybeans 

Agracetus Inc. transgenic cotton purchased all plant 4/96 

technology 

biotech assets from 

W.R. Grace & Co 

Arcadia 

development and licensing agreement 9/05 

Biosciences Inc. commercialization of 

Arcadia's nitrogen use 

efficiency technology in 

canola 

ArQule Inc. agrochemicals development 

agreement 

12/96 

Calgene Inc. fresh produce and plant 

oils 


Calgene Inc. oilseed research cross-licensing 5/96 

programs 

agreement-- 

Calgene will receive 

royalty-free license 

to current and 

future Monsanto 

agronomic 

technology in 

combination with 

Calgene's oils 

modification genes. 

Monsanto will pay 

Calgene royalties 

and $17M and will 

receive portion of 

profits of Calgene's 

specialty oils 

business 

Calgene Inc. patented technologies cross-licensing 

agreements-- 

Monsanto received 

licenses to 

Calgene's patents 

and patents 

pending in the 

areas of plant 

transformation, 

certain genetically 

engineered plants, 

and antisense RNA 

technology. 

Calgene received 

licenses to 

4/93 



Calgene Inc. Russet Burbank 

potatoes genetically 

modified to resist potato 

viruses X and Y 

California Institute 

of Technology 

Columbia 

patented rDNA 

Monsanto's patents 

and patents 

pending in the 

areas of plant 

transformation 

technologies, 

selectable markers, 

and the right to 

obtain certain 

licenses to 

Monsanto's Bt 

insect resistance 

technology for use 

in cotton 

development 

agreement 

instrument design development 

agreement 

nonexclusive 

University 

extraction process licensing agreement 

Dekalb Genetics field crops, seeds, R&D collaboration 2/96 

Corp. 

produce 

and cross-licensing 

agreement 

Delta and Pine Bollard gene for marketing 

11/95 

Land Co. 

selected varieties of 

cotton 

agreement 

Divergence Inc. nematode-resistant development and 9/04 

soybeans 


Dow 

new technology options global business 1/06 

AgroSciences LLC and more choice in 

products for farmers 

agreement 

Dyax Corp. Dyax's phage display non-exclusive 5/97 

technology 

licensing 

agreement, 

including signing 

fees, milestone 

payments and 

royalties, Dyax gets 

access to related 

patented 

technology owned 

by licensee 

Ecogen Inc. Bt technology for in- development 1/96 

plant applications agreement 

Finnfeeds feed microingredients joint venture for for 


marketing of feed 

microingredients in 

plants 

4/98 

GeneTrace Inc. plant and animal $17M technology 4/98 

genomics 

collaboration-- 

Monsanto gets 

exclusive license to 

GeneTrace's 

technology for plant 

and animal 

genomics, including 

gene-expression 

analysis and 

genotyping 



Incyte 


Inc. 

Incyte 


Inc. 

Incyte's gene 

expression microarray 


functional genomics 

applications in plant, 

animal and human 

genomes 

Incyte's LifeTools 

software and plant 

sequences 

3-year, large-scale, 

genome-wide 

agreement-- 

Monsanto gets 

access to up to 50K 

DNA microarrays 

for use across its 

life science 

programs, Incyte 

will provide data 

from custom and 

prefabricated DNA 

microarrays, 

software to manage 

and analyze data 

and consulting 

services 

broad-based 

genomics and 

software licensing 



LifeSeq®, LifeSeq 

FL®, LifeSeq 

Atlas, LifeSeq 

GeneAlbum 

cDNA, PathoSeq 

and ZooSeq 


5/98 

10/97 

Japan Tobacco high-yield rice joint development 12/95 

Inc. 

agreement 

Mendel 

Monsanto to 

partnership, 1997 

Biotechnology Inc. commercialize 

expanded and 

technologies developed extended through 

by Mendel, both 

companies will develop 

an integrated framework 

for predictive control of 

plant gene expression 

2011 (7/06) 

Mexican Ministry genetically engineered R&D agreement 7/93 

of Agriculture and potato to resist viral 

Water Resources diseases 

Millennium Millennium's genomics 5-year, $218M 10/97 

Pharmaceuticals technology platform to agreement-- 

Inc. 

develop agricultural Monsanto to pay 

products 

$118M in licensing 

and technology 

transfer fees ($38M 

up-front, $16M per 

year for five years), 

Monsanto could pay 

an additional 

$20M/year in 


based on research 

objectives, 

Monsanto to form 

subsidiary in 

Cambridge, MA 

with 100 scientists, 

Millennium retains 

right to use 

technologies 

developed by the 

subsidiary for non-


Mitsubishi Kasei 

Corp. 

Modular Genetics 

Inc. 

Molecular 

Informatics Inc. 

North Carolina 

State University 

exclusive use 

outside of plant and 

agricultural areas 

rDNA and MAbs joint R&D venture in 

advancement of 

Monsanto's protein 

optimization platform 

BioMerge software for 

analysis of genomic 

Japan 

three-year 

collaboration 


data 

genetically engineered 

nematicides 

three-year licensing 

agreement 

licensing 

agreement-- 

Monsanto to 

develop the 

technology in major 

agricultural crops in 

developed countries 

3/05 

1/97 

4/93 

Pioneer Hi-Bred YieldGard insect- licensing agreement 12/95 

International Inc. protected Bt corn 

Sandia National alignment of Sandia's three-year research 8/06 

Laboratories capabilities in 

bioanalytical imaging 

and analysis with 

Monsanto's research in 

the development of 

seed-based products, 

including corn products 

that may be able to 

produce more ethanol 

per bushel 

collaboration 

Sandoz Seeds insect-protected Bt corn nonexclusive 8/95 

Ltd. 

worldwide license to 

Monsanto patents 

Strategic 

GeneCheck R&D and 

Diagnostics Inc. 

manufacturing 

agreement 

Synteni Inc. gene expression in development 6/96 

plants and organisms agreement 

Targeted Growth development and licensing agreement 9/05 

Inc. (TGI) 

commercialization of a 

TGI-developed yield 

enhancement gene 

The Solae Co. soy proteins development and 

marketing 

agreement 

10/05 

RESEARCH & DEVELOPMENT: Insect-protected corn and cotton 

Soybeans, canola, cotton, and corn genetically modified to tolerate 

Roundup® herbicide 

Virus- and insect-protected potatoes 

Delayed ripening tomatoes 

Cholesterol oxidase gene to protect cotton, corn, and potato plants from 

weevils, worms, and beetles 

PRODUCTS ON MARKET: Seeds and Genomics: 

Roundup Ready traits in soybeans, corn, canola and cotton 

Bollgard and Bollgard II traits in cotton 

YieldGard Corn Borer and YieldGard Rootworm traits in corn 

Agroceres, Asgrow, Dekald, Stoneville and Vistive branded seeds 

Holden’s Foundation Seeds 

Monsoy foundation seed 

American Seeds Inc. branded seed 

Seminis, Royal Sluis, Asgrow and Petoseed branded seeds



Agricultural Productivity: 

Roundup and other glyphosate-based herbicides 

Harness, Degree, Lasso, Machete and other acetanilide-based herbicides 

Other selective herbicides, such as Maverick, Certainty, Outrider, Leader 

and Monitor sulfosulfuron herbicides 

Lawn-and-garden herbicides 

Posilac bovine somatotropin 

Monsanto Choice Genetics genetics lines 

1-30, Tamatsukuri 1-chome, Chuo-ku 

Osaka, Japan 

Phone: +81 6-6761-1131; Fax: +81 6-6768-1661 

Web: www.jintanworld.com 

E-mail: info@jintanworld.com 

KEY PERSONNEL: Yukihisa Aibara; President and CEO 


HISTORY: Founded in February 1893 


SUBSIDIARIES/DIVISIONS: Branches in Shizuoka, Kagawa, Toyama and Shiga Pref. 

BUSINESS STRATEGY: Develop and sell health foods, medical supplies, unregulated drugs and 

cosmetics based on Chinese medicines and encapsulation technology for 

seamless capsules 

PRODUCTS ON MARKET: Pharmaceuticals: Bifina Constipation, Solmiran 

Health foods and dietary supplements 

M-Scan Ltd. 

3 Millars Business Centre, Fishponds Close 

Wokingham RG41 2TZ, UK 

Phone: +44 (0)118 989 6940; Fax: +44 (0)118 989 6941 

Web: www.m-scan.com 

E-mail: services.ltd@m-scan.com 

KEY PERSONNEL: Prof. H. R. Morris; Chairman 

Dr. Fiona M. Greer; Director 

Dr. Andrew Reason; Director 

Dr. C. Harbach; Sr. Scientist 

Dr. David Chapman; Business Manager 



FACILITIES: Four analytical laboratories--located in: Wokingham, UK; Geneva, 

Switzerland; and West Chester, Pa. 

Marketing offices in Manchester, U.K.; Freiburg, Bonn and Munich, 

Germany; and South Korea 




SUBSIDIARIES/DIVISIONS: M-Scan SA 

12, Chemin des Aulx 

1228 Plan-les-Ouates 

Geneva, Switzerland 

Phone: + 41 (0)22 794 83 74 

Fax: + 41 (0)22 794 83 55 

E-mail: services.sa@m-scan.com 

M-Scan Inc. 

Dr. Mark Rogers 

606 Brandywine Parkway 

West Chester, PA 19380 

Phone: (610) 696-8210 

Fax: (610) 696-8370 

E-mail: services.inc@m-scan.com 

RESEARCH & DEVELOPMENT: Use of mass spectrometry for the structure and sequence analysis of 

recombinant protein products and analysis of posttranslational modifications 


P.O. Box 4078, 200 Technology Way 

Butte MT 59701, US 

Phone: (406) 494-7100; Fax: (406) 494-7230 

Web: www.mse-ta.com 

E-mail: contact@mse-ta.com 

KEY PERSONNEL: Donald R. Peoples; President 

Jeff Ruffner; Exec. VP and General Manager 

Neal Egan; Head, Business Development 



FACILITIES: Butte, Mont.--Corporate office, 53-acre Mike Mansfield Advanced 

Technology Center, Montana Information Technology Enterprise Center, 

welding and fabrication center 


SUBSIDIARY OF: Montana Economic Revitalization and Development Institute 

BUSINESS STRATEGY: MSE Technology Applications Inc. is a diversified research and engineering 

firm. We are a small business headquartered in Butte, Montana, with offices 

in Washington, Idaho, North Carolina, South Carolina, Washington, D.C., 

and West Virginia. MSE scientists and engineers are internationally 

recognized as the very best in their fields--developing and deploying some 

of the nation’s most sophisticated cutting-edge technology. 

Business Areas: 

Remediation Services--MSE provides services to private commercial entities 

and government agencies for municipal and industrial water treatment, 

biotechnologies, biological barriers, biological remediation, enhanced oil 

recovery, and counter chemical and biological terrorism. 

Site Cleanup and Closure Support--MSE develops, tests, evaluates and 

deploys innovative technology to address the environmental issues 

surrounding site closures across the United States. We also identify and 

develop promising technologies to address the Department of Energy's site 

waste problems (such as transuranic mixed waste problems). More than 80 

projects, at 26 facilities in 21 states, have been completed or are underway, 

resulting in significant operational cost savings. 



Waste Treatment Technology--The Waste Treatment Technology area 

provides a full range of treatment services to customers including plasma 

services, facilities and products. We develop and deploy technologies to 

resolve Department of Energy and Department of Defense waste problems. 

Facility Modernization and Sustainability--MSE supports infrastructure 

modernization at troop-based facilities by providing engineering solutions to 

plant processes. Specifically, modernizing and increasing the efficiency of 

outdated processes at various ammunition and troop installations around the 

Army complex. This group’s real strength is providing process modifications 

through instrumentation and control system modernization as well as 

chemical and materials handling improvements. 

Advanced Energy and Aerospace Programs--MSE is conducting cutting 

edge research for advanced energy and aerospace technology 

development. Projects have the potential for breakthroughs in aerospace 

technology and could reduce the cost of commercial and military space 

operations. MSE is developing an ultrahigh-pressure test system to provide 

ground testing for aerospace technologies that are crucial to development of 

the world’s first hypersonic wind tunnel. 

Plasma Services--MSE is a world leader in the field of plasma technology for 

waste material treatment and is currently deploying two systems for the U.S. 

Army in Nevada and West Virginia. 

Mine Waste Technology Program--MSE demonstrates innovative 

groundwater remediation technologies in Montana, South Dakota, Nevada, 

California, Minnesota, Missouri, Utah and Colorado to advance the 

development of engineering solutions to national environmental issues 

resulting from mining. 

Information Technology Services--MSE’s Montana Information Technology 

Enterprise Center is a complete data center, provides a strategically isolated 

location, redundant power and fire protection, OCx capacity, triple levels of 

security and environmental controls. MSE provides contingency planning 

and implementation, disaster recovery, online data storage/ warehousing/ 

vaulting, parallel computing, telecommunications, project management, and 

web services and development. 

RESEARCH & DEVELOPMENT: Heavy metals in soils and water 

Thermal spray technology 

Lightweight materials technology 

Plasma arc treatment technology 

Biological remediation 

Counter chemical and biological terrorism 

Aerospace technology 

Nanogen Inc. 

10398 Pacific Center Court 


Phone: (858) 410-4600; Fax: (858) 410-4952 


Web: www.nanogen.com 

E-mail: dludvigson@nanogen.com 

KEY PERSONNEL: Howard C. Birndorf; Chairman and CEO 

David Ludvigson; President and COO 

Robert Saltmarsh; CFO 

Graham Lidgard, Ph.D.; Sr. VP, R&D 

Walt Mahoney; VP, R&D 

Merl F. Hoekstra; VP, Business Development 





Acquired SynX Pharma Inc. (4/04) 

Merged with Epoch Biosciences Inc. (12/04) 

To acquire Spectral Diagnostic Inc.’s rapid cardiac immunoassay test 

business (as of 12/05) 

To acquire the diagnostics division of Amplimedical SpA (as of 4/06) 

FACILITIES: 51,000 sq. ft. in San Diego, Calif. 

30,000 sq. ft. in Bothell, Wash. 

50,000 sq. ft. in Toronto, Canada 

2,600 sq. ft. in Helmond, Netherlands 

STOCK-FINANCIAL HISTORY: NASDAQ--NGEN 

IPO--3.9M shares at $11/share, $42.9M (4/98) 

Secondary offering--$80M (11/00) 





04) 


PRIVATE PLACEMENTS: Raised $26.2M through private placement of Series C preferred stock (3/97) 

Raised $20M through private placement of 6.8M shares and 1M warrants 

(9/05) 

SUBSIDIARIES/DIVISIONS: Molecular Research Products division: 

21720 23rd Drive S.E., No. 150 

Bothell, WA 98021 

Phone: (800) 562-5544 

Fax: (425) 482-5550 

E-mail: molecularresearch@nanogen.com 

Point of Care Diagnostics division: 

1 Marmac Drive 

Toronto , Ontario 

M9W 1E7 Canada 

Phone: (877) 246-7593 

Fax: (416) 798-3447 

E-mail: nanogenpoc@nanogen.com 

Nanogen Europe BV: 

Steenovenweg 3 

5708 HN Helmond 

Netherlands 

Phone: +31 (0)492-507-160 

Fax: +31 (0)492-507-179 

PRINCIPAL INVESTORS: Birndorf Biotechnology Development 

Enterprise Partners 

InterWest Partners 

Kleiner, Perkins, Caufield and Byers 

New Leaf Venture Partners 

INVESTMENTS: Jurilab Ltd. 

FINANCIAL INFORMATION: Completed $3.5M round of venture capital financing (2/94) 

Completed $9.5M round of venture capital financing (10/95) 

Received $2M two-year grant from U.S. Department of Commerce (7/95) 

Received $500K grant from Bude Technology Group (4/96) 

Received $250K grant from the State of California Defense Conversion 

Matching Grant (6/96) 




Become a leading supplier of molecular diagnostic tests by developing 

commercial applications for our proprietary platform technology and by 

promoting our technology as the standard for molecular identification and 

analysis. Key elements of our strategy include: 

-Developing commercial applications 

-Developing research and genomics applications 

-Establishing strategic collaborations 

-Developing advanced technologies and point-of-care applications 


Becton Dickinson test systems to 

worldwide, multi- 5/97 

and Co. 

diagnose infectious year collaborative 

diseases (based on 

Nanogen's DNA 

microchip and Becton 

Dickinson's system for 

DNA amplification) 

agreement 

Bode Technology forensics one-year 

1996 

Group 

development 

agreement 

deCode Genetics new genomics assay supply and licensing 4/05 

using Nanogen 

products for single 

nucleotide 

polymorphism (SNP) 

discovery, validation 

and screening 

agreement 

Department of integrated 

two-year, $2M 1995 

Commerce microelectronic DNA 

diagnostic system 

development grant 

Department of portable genetic $2M development 3/97 

Commerce analysis device for 

forensic investigations, 

trauma victim 

identification, medical 

diagnostics and 

environmental 

monitoring 

grant 

Fisher Scientific molecular diagnostics expanded Fisher's 8/06 

International Inc. 

equity investment in 

Nanogen (3/06) to 

include R&D 

collaboration 

Jurilab Ltd. development of 

diagnostics based on 

genes and markers 

discovered by Jurilab 


Jurilab Ltd. identification and research 

5/06 

validatation of 

prognostic markers for 

Type II diabetes 

collaboration 

Pathway 

Nanogen to develop nonexclusive, 3/05 

Diagnostics diagnostic products that worldwide licensing 

detect genetic variations 

associated with 

responses to 

antidepressant and 

antipsychotic 

therapeutics 

agreement 



Prolinx Inc. enhanced sensitivity 

detection system for 

use with Nanogen's 

proprietary 

electronically 

addressable microchip 

U.S. Justice 

Department 

(National Institue 

of Justice) 

array technologies 

portable microchip 

array-based genetic 

detector for rapid 

genetic testing and 

identification at the point 

of evidence collection 

sponsored research 

agreement 

$710K research 

grant 

RESEARCH & DEVELOPMENT: Integrated system for rapid analysis of charged macromolecules using 

microelectronics and molecular biology 

Nanogen APEX (Automated Programmable Electronic Matrix) to move, 

concentrate, bind, wash and separate charged molecules in electronic field 

PRODUCTS ON MARKET: NanoChip Molecular Biology Workstation 

NanoChip cartridges 

Analyte specific reagents (ASRs) 


Technology Center, Suite 208, 200 Innovation Blvd. 

State College PA 16803, US 

Phone: (814) 861-9909; Fax: (814) 861-9903 

Web: www.nanohorizons.com 

E-mail: info@nanohorizons.com 

KEY PERSONNEL: Stephen Fonash, Ph.D.; Chairman and CTO 

Robert F. Burlinson; President and CEO 

Joseph D. Cuiffi, Ph.D.; Head, R&D and Production 

Daniel J. Hayes, Ph.D.; Head, Operations 

Dennis I. Schneider; Head, Marketing 




PRINCIPAL INVESTORS: Ben Franklin Technology Partners 

Life Sciences Greenhouse of Central Pennsylvania 

Pulsar Ventures 


Develop and produce state-of-the-art nanotechnology products and 

processes for near term biotechnology, pharmaceutical, chemical and 

microelectronic applications 


Arrow 

opportunities to apply research 

3/04 

International Inc. nanotechnology to 

emerging cost and 

performance issues in 

biomedical technology 

collaboration 

pSiMedica opportunities to utilize materials transfer 2/04 

NanoHorizon's 

nanostructured silicon 

films in areas such as 

tissue engineering and 

diagnostics 

agreement 


4/97 

9/97


Solarity NanoHorizons' solar cell 

technology 


agreement 

RESEARCH & DEVELOPMENT: Technologies: Photovoltaics and organic LEDs, sensors and flexible 

electronics 

PRODUCTS ON MARKET: Noble Metal Embedded Nanoparticles - Low-cost line of polymer-compatible 

anti-odor nanoparticles 

QuickMass - Mass spectrometry targets for high-speed analysis of small 

molecules for pharmaceutical product development and medical research 

Humidity Sensors for Respiratory Monitoring - Rapid-response, highsensitivity 



87 Stambaugh Avenue, Suite 2 

Sharon PA 16146, US 

Phone: (724) 346-1302; Fax: (724) 346-9596 

Web: www.nanologix.net 

E-mail: ir@nanologix.net 

Mitchell S. Felder, M.D.; CEO 

David McClelland; President 

Thomas A Kelly, Ph.D.; Sr. Scientist 



Changed name from Infectech Inc. (4/05) 



STOCK-FINANCIAL HISTORY: Pink Sheets--NNLX 

SUBSIDIARIES/DIVISIONS: MD-Diagnostics.com Inc. 

SUBSIDIARY OF: Nutra Pharma Corp. 

BUSINESS STRATEGY: NanoLogix is an R&D company which partners with multi-national 

corporations for product development 


Brigham & 

Women's Hospital 

Pseudomonas vaccine option agreement 1998 

BioRemedial bioremediation investment and 1998 

Technologies 


RESEARCH & DEVELOPMENT: Technologies for the production of bacteria and disease testing kits, 

alternative sources of fuel, cancer therapy and remediation of toxic materials 

PRODUCTS ON MARKET: M. tuberculosis 

M. avium (experimental use) 


M. tuberculosis field testing 

M. avium field testing 

Pseudomonus vaccine clinical stage 

Apoptosis (cancer tx) development stage 


8/06



1319 Marquette Drive 

Romeoville IL 60446, US 

Phone: (630) 771-6700; Fax: (630) 771-0825 

Web: www.nanophase.com 

E-mail: investor-relations@nanophase.com 

KEY PERSONNEL: Donald S. Perkins; Chairman 

Joseph Cross; CEO and President 

Jess Jankowski; CFO 

Richard W. Brotzman; VP, R&D 

Robert Haines; VP, Operations 

Daniel S. Bilicki; VP, Sales and Marketing 

Edward G. Ludwig; VP, Business Development 


HISTORY: Founded in 1989 as a spinoff of Argonne National Labs 

STOCK-FINANCIAL HISTORY: NASDAQ--NANX 

IPO--$8/share (11/97) 





04) 


BUSINESS STRATEGY: Provide nanoengineered solutions for multiple industrial product applications 

such as commercial quantity and quality nanoparticles, coated nanoparticles 

and nanoparticle dispersions in a variety of media. Sell intermediate 

products enabling high-value add customer applications. The company has 

major partnerships (including BASF, Rohm & Haas and BYK Chemie) 

exploiting broad applications expertise and global distribution channels. 


Alfa Aesar nanomaterials for distribution 

10/05 

(research 

research and 

agreement 

chemicals unit of development 

Johnson Matthey) applications 

Competitive CT to identify 

option, evaluation, 10/05 

Technologies nanotechnologies that licensing and 

may be synergistic with commercialization 

Nanophase’s 

technologies 

agreement 

Roche 

nanoparticles for a supply agreement 3/06 

Diagnostics medical diagnostics 

application through 

2014 

PRODUCTS ON MARKET: Metal oxides 

Coated metal oxides 

Nanoparticle dispersions 

Custom synthesis 



National Collection of Yeast Cultures (NCYC) 

Institute of Food Research, Norwich Research Park, Colney 

Norwich NR4 7UA, UK 

Phone: (+44) 1603-255000; Fax: (+44) 1603-458414 

Web: www.ncyc.co.uk; E-mail: ncyc@bbsrc.ac.uk 

KEY PERSONNEL: Ian N. Roberts, Ph.D.; Curator 

Chris J. Bond; Deputy Curator 

Stephen A. James, Ph.D.; Molecular Biologist 

Georgina A. Pope, Ph.D.; Molecular Biologist 

Robert Davey, Ph.D.; Bioinformaticist 


HISTORY: Collection of more than 4,000 yeast cultures used in brewing, winemaking, 

biotechnology, and the food industry 


SUBSIDIARY OF: IFR Enterprises, Ltd., the technology interaction company of the Institute of 

Food Research (see separate entry), a company limited by guarantee, 

grant-aided by the Biotechnology and Biological Sciences Research Council 

BUSINESS STRATEGY: Supply the academic and industrial community with yeast cultures and yeast 

microbiological services 

RESEARCH & DEVELOPMENT: Yeast genetics 

Identification methods 

Yeast biotechnological information databases 

PRODUCTS ON MARKET: Catalog of cultures (yeast cultures) 

Safe deposit service 

Patent deposit service 

Online database 

Identification service 

National Institute of Advanced Industrial 

Science and Technology (AIST) 

1-1-1 Umezono, Tsukuba 

Ibaraki 305-8568, Japan 

Phone: +81 29 861 2298; Fax: +81 29 862 6148 

Web: www.aist.go.jp; E-mail: maoriya-t@aist.go.jp 

KEY PERSONNEL: Dr. Hiroyuki Yoshikawa; President 

Kisaburo Kodama; Sr. VP 


HISTORY: Formed from the amalgamation of 15 research institutes in April 2001 

STOCK-FINANCIAL HISTORY: Publicly funded institution 

BUSINESS STRATEGY: Pursue advanced research by exploring broad spectra of research fields and 

integrating multidisciplinary subjects to promote innovation in versatile fields 

that strengthen the competitiveness of Japanese industries in the world 

market and create new industries 

Pursue interdisciplinary and cross-disciplinary research that enables 

planning long-range governmental policies by exploiting the current and 

future needs of society 

Pursue basic research that maintains and strengthens competitiveness of 

national science and technology by developing and maintaining high 

standards of scientific and engineering research under the sole 

responsibility of AIST 



RESEARCH & DEVELOPMENT: Life science and technology: Development of new technologies for drugs 

and diagnostic agents based on post-genome research; promotion of 

neuroscience, human-technology and biomedical engineering for health 

maintenance/improvement; and research for new biofunctions/biomaterials 

and development of efficient biomaterial production technology 


Information technology: Research and development of ultra-high density 

optical storage technology; development of grid middleware; development of 

ultrafast optical switching technology using intersubband transition; practical 

application of model checking method to embedded software verification; 

success in fastest optical fiber quantum crypto transmission; development of 

porous silica low permittivity (low-k) insulator film; development of filmfabrication 

technologyfor high permittivity (high-k) gate insulatorfilm; 

development of miniaturization technology for ultrasonic 3-D tag for 

measurement of daily human activities; development of the first 4-terminal 

drive type XMOS-FET; development of technology for therapeutic 

application of Mental Commitment Robot 'PARO'; development of 

CONSORTS multiagent computing architecture; and development of 

application system using grid technology 

Nanotechnology, materials and manufacturing: Synthesis technology for 

single-walled carbon nanotubes; on-demand processing using microplasma; 

manufacture of active-targeting DDS nanoparticles; development of 

analysis method using microreactor; development of highest resolution 

magnetic force microscope; development of analytical electron microscope 

with the highest sensitivity; development of synthesis technology for large 

diamond single crystals; control of interface magnetism of stronglycorrelated 

electron oxides; discovery of the Hall effect of light; elucidation of 

chemical reaction in supercritical water by computational science; 

development of room temperature coating technology for ceramic materials; 

ceramic sintering technology using centrifugal force; development of 

technology for large magnesium alloy components 

Environment and energy: Development of new decomposition/detoxification 

reaction processes for harmful substances, development of in-plant 

separation/concentration processes and environment-friendly alternative 

substances; development of distributed energy, including renewable energy, 

and energy networks, development of clean coal technology and biomass 

fuels and related application technologies; establishment of methods for 

estimating resources/energy utilization rates and hazardous substance risk, 

development of evaluation methods for global warming countermeasures 

and their social acceptability 

Geological survey and applied geoscience: Research on volcanoes and 

development of methods for survey/evaluation/control of soil contamination 

Metrology and measurement technology: Development and supply of 

measurement standards, including calibration of measurement instruments, 

as well as scientific research in metrology 

Building 1, 1 Center Drive 

Bethesda MD 20892, US 

Phone: (301) 496-4000 

Web: www.nih.gov 

E-mail: info@nih.gov 

KEY PERSONNEL: Elias A. Zerhouni, M.D.; Director 

Raynard S. Kington, M.D., Ph.D.; Deputy Director 

Norka Ruiz Bravo, Ph.D.; Deputy Director, Extramural Research 





Michael Gottesman, M.D.; Deputy Director, Intramural Research 

Colleen Barros; Deputy Director, Management and CFO 

FACILITIES: NIH scientists conduct their research in laboratories located on the main 

campus in Bethesda, and in several field units across the country and 

abroad. The 870,000 sq. ft. Mark O. Hatfield Clinical Research Center 

opened in September 2004. The NIH also has facilities in the Rockville, Md., 

area and the NCI Frederick Cancer Research and Development Center 

(FCRDC) at Fort Detrick in Frederick, Md. The National Institute of 

Environmental Health Sciences' main facility is located in Research Triangle 

Park, N.C.. 


FY 2004 Budget: $27.9b 

Other laboratory facilities include the NIH Animal Center in Poolesville, Md.; 

the National Institute on Aging's Gerontology Research Center in Baltimore, 

Md.; the Division of Intramural Research of the National Institute on Drug 

Abuse, also in Baltimore; the National Institute of Allergy and Infectious 

Diseases' Rocky Mountain Laboratories in Hamilton, Mt., and several 

smaller field stations. 

SUBSIDIARIES/DIVISIONS: Office of the Director (OD)--The Office of the Director is the central office at 

NIH for its 27 Institutes and Centers. The OD is responsible for setting policy 

for NIH and for planning, managing, and coordinating the programs and 

activities of all the NIH components. OD's program offices include the Office 

of AIDS Research and the Office of Research on Women's Health, among 

others. 

National Cancer Institute (NCI)--Established in 1937, the NCI leads a 

national effort to reduce the burden of cancer morbidity and mortality. Its 

goal is to stimulate and support scientific discovery and its application to 

achieve a future when all cancers are uncommon and easily treated. 

Through basic and clinical biomedical research and training, NCI conducts 

and supports programs to understand the causes of cancer; prevent, detect, 

diagnose, treat, and control cancer; and disseminate information to the 

practitioner, patient, and public. 

National Eye Institute (NEI)--Established in 1968, the NEI conducts and 

supports research that helps prevent and treat eye diseases and other 

disorders of vision. This research leads to sight-saving treatments, reduces 

visual impairment and blindness, and improves the quality of life for people 

of all ages. NEI-supported research has advanced our knowledge of how 

the eye functions in health and disease. 

National Heart, Lung, and Blood Institute (NHLBI)--Established in 1948, the 

NHLBI provides leadership for a national program in diseases of the heart, 

blood vessels, lung, and blood; blood resources; and sleep disorders. Since 

October 1997, the NHLBI has also had administrative responsibility for the 

NIH. 

Woman's Health Initiative--The Institute plans, conducts, fosters, and 

supports an integrated and coordinated program of basic research, clinical 

investigations and trials, observational studies, and demonstration and 

education projects. 

National Human Genome Research Institute (NHGRI)--Established in 1989, 

the NHGRI supports the NIH component of the Human Genome Project, a 

worldwide research effort designed to analyze the structure of human DNA 

and determine the location of the estimated 30,000 to 40,000 human genes. 

The NHGRI Intramural Research Program develops and implements 

technology for understanding, diagnosing, and treating genetic diseases. 



National Institute on Aging (NIA)--Established in 1974, the NIA leads a 

national program of research on the biomedical, social, and behavioral 

aspects of the aging process; the prevention of age-related diseases and 

disabilities; and the promotion of a better quality of life for all older 

Americans. 

National Institute on Alcohol Abuse and Alcoholism (NIAAA)--Established in 

1970, the NIAAA conducts research focused on improving the treatment and 

prevention of alcoholism and alcohol-related problems to reduce the 

enormous health, social, and economic consequences of this disease. 

National Institute of Allergy and Infectious Diseases (NIAID)--Established in 

1948, the NIAID research strives to understand, treat, and ultimately prevent 

the myriad infectious, immunologic, and allergic diseases that threaten 

millions of human lives. 

National Institute of Arthritis and Musculoskeletal and Skin Diseases 

(NIAMS)--Established in 1986, the NIAMS supports research into the 

causes, treatment, and prevention of arthritis and musculoskeletal and skin 

diseases, the training of basic and clinical scientists to carry out this 

research, and the dissemination of information on research progress in 

these diseases. 

National Institute of Biomedical Imaging and Bioengineering (NIBIB)-- 

Established in 2000, the NIBIB improves health by promoting fundamental 

discoveries, design and development, and translation and assessment of 

technological capabilities in biomedical imaging and bioengineering, enabled 

by relevant areas of information science, physics, chemistry, mathematics, 

materials science, and computer sciences. 

National Institute on Deafness and Other Communication Disorders 

(NIDCD)--Established in 1988, the NIDCD conducts and supports 

biomedical research and research training on normal mechanisms as well 

as diseases and disorders of hearing, balance, smell, taste, voice, speech, 

and language that affect 46 million Americans. 

National Institute of Dental and Craniofacial Research (NIDCR)--Established 

in 1948, the NIDCR provides leadership for a national research program 

designed to understand, treat, and ultimately prevent the infectious and 

inherited craniofacial-oral-dental diseases and disorders that compromise 

millions of human lives. 

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-- 

Established in 1948, the NIDDK conducts and supports basic and applied 

research and provides leadership for a national program in diabetes, 

endocrinology, and metabolic diseases; digestive diseases and nutrition; 

and kidney, urologic, and hematologic diseases. Several of these diseases 

are among the leading causes of disability and death; all seriously affect the 

quality of life of those who have them. 

National Institute on Drug Abuse (NIDA)--Established in 1973, the NIDA 

leads the nation in bringing the power of science to bear on drug abuse and 

addiction through support and conduct of research across a broad range of 

disciplines and rapid and effective dissemination of results of that research 

to improve drug abuse and addiction prevention, treatment, and policy. 

National Institute of Environmental Health Sciences (NIEHS)--Established in 

1969, the NIEHS reduces the burden of human illness and dysfunction from 

environmental causes by, defining how environmental exposures, genetic 

susceptibility, and age interact to affect an individual's health. 

National Institute of General Medical Sciences (NIGMS)--Established in 

1962, the NIGMS supports basic biomedical research that is not targeted to 

specific diseases. NIGMS funds studies on genes, proteins, and cells, as 

well as on fundamental processes like communication within and between 



cells, how our bodies use energy, and how we respond to medicines. The 

results of this research increase our understanding of life and lay the 

foundation for advances in disease diagnosis, treatment, and prevention. 

NIGMS also supports research training programs that produce the next 

generation of biomedical scientists, and it has special programs to 

encourage underrepresented minorities to pursue biomedical research 

careers. 

National Institute of Mental Health (NIMH)--Established in 1949, the NIMH 

provides national leadership dedicated to understanding, treating, and 

preventing mental illnesses through basic research on the brain and 

behavior, and through clinical, epidemiological, and services research. 

National Institute of Neurological Disorders and Stroke (NINDS)-- 

Established in 1950, the mission of the NINDS is to reduce the burden of 

neurological diseases--a burden borne by every age group, every segment 

of society, and people all over the world. To accomplish this goal the NINDS 

supports and conducts research, both basic and clinical, on the normal and 

diseased nervous system, fosters the training of investigators in the basic 

and clinical neurosciences, and seeks better understanding, diagnosis, 

treatment, and prevention of neurological disorders. 

National Institute of Nursing Research (NINR)--Established in 1986, the 

NINR supports clinical and basic research to establish a scientific basis for 

the care of individuals across the life span--from the management of 

patients during illness and recovery to the reduction of risks for disease and 

disability; the promotion of healthy lifestyles; the promotion of quality of life 

in those with chronic illness; and the care for individuals at the end of life. 

This research may also include families within a community context, and it 

also focuses on the special needs of at-risk and under-served populations, 

with an emphasis on health disparities. 

National Library of Medicine (NLM)--Established in 1956, the NLM collects, 

organizes, and makes available biomedical science information to 

investigators, educators, and practitioners and carries out programs 

designed to strengthen medical library services in the United States. Its 

electronic data bases, including MEDLINE and MEDLINEplus are used 

extensively throughout the world by both health professionals and the public. 

Center for Information Technology (CIT formerly DCRT, OIRM, TCB)-- 

Established in 1964, the CIT incorporates the power of modern computers 

into the biomedical programs and administrative procedures of the NIH by 

focusing on three primary activities: conducting-computational biosciences 

research, developing computer systems, and providing computer facilities. 

Center for Scientific Review (CSR)--Established in 1946, the CSR is the 

focal point at NIH for the conduct of initial peer review, the foundation of the 

NIH grant and award process. The Center carries out peer review of the 

majority of research and research training applications submitted to the NIH. 

In addition, the Center serves as the central receipt point for all such Public 

Health Service (PHS) applications and makes referrals to scientific review 

groups for scientific and technical merit review of applications and to funding 

components for potential award. To this end, the Center develops and 

implements innovative, flexible ways to conduct referral and review for all 

aspects of science. 

John E. Fogarty International Center (FIC)--Established in 1968, the FIC 

promotes and supports scientific research and training internationally to 

reduce disparities in global health. 

National Center for Complementary and Alternative Medicine (NCCAM)-- 

Established in 1992, the NCCAM is dedicated to exploring complementary 

and alternative medical (CAM) practices in the context of rigorous science; 

training CAM researchers and disseminating authoritative information. 



National Center on Minority Health and Health Disparities (NCMHD)-- 

Established in 1993, the mission of NCMHD is to promote minority health 

and to lead, coordinate, support, and assess the NIH effort to reduce and 

ultimately eliminate health disparities. In this effort NCMHD will conduct and 

support basic, clinical, social, and behavioral research, promote research 

infrastructure and training, foster emerging programs, disseminate 

information, and reach out to minority and other health disparity 

communities. 

National Center for Research Resources (NCRR)--Established in 1962, the 

NCRR advances biomedical research and improves human health through 

research projects and shared resources that create, develop, and provide a 

comprehensive range of human, animal, technological, and other resources. 

NCRR's support is concentrated in four areas: biomedical technology, 

clinical research, comparative medicine, and research infrastructure. 

Warren Grant Magnuson Clinical Center (CC)--Established in 1953, the CC 

is the clinical research facility of the National Institutes of Health. As a 

national resource, it provides the patient care, services, and environment 

needed to initiate and support the highest quality conduct of and training in 

clinical research. 

SUBSIDIARY OF: NIH is an agency of the U.S. Department of Health and Human Services 

BUSINESS STRATEGY: Provide leadership and direction to programs designed to improve the health 

of the nation by conducting and supporting research: in the causes, 

diagnosis, prevention, and cure of human diseases; in the processes of 

human growth and development; in the biological effects of environmental 

contaminants; in the understanding of mental, addictive and physical 

disorders; in directing programs for the collection, dissemination, and 

exchange of information in medicine and health, including the development 

and support of medical libraries and the training of medical librarians and 

other health information specialists 

NIH is the steward of medical and behavioral research for the nation. Its 

mission is science in pursuit of fundamental knowledge about the nature and 

behavior of living systems and the application of that knowledge to extend 

healthy life and reduce the burdens of illness and disability. The goals of the 

agency are as follows: 1) foster fundamental creative discoveries, innovative 

research strategies, and their applications as a basis to advance 

significantly the nation's capacity to protect and improve health; 2) develop, 

maintain, and renew scientific human and physical resources that will assure 

the nation's capability to prevent disease; 3) expand the knowledge base in 

medical and associated sciences in order to enhance the nation's economic 

well-being and ensure a continued high return on the public investment in 

research; and 4) exemplify and promote the highest level of scientific 

integrity, public accountability, and social responsibility in the conduct of 

science. 


Numerous NIH 

programs relating 

to grants, 

contracts, 

licensing, and 

collaborations 

varied NIH sponsors 

various projects that 

support the 

extramural research 

community of more 

than 50,000 non- 

Federal scientists 

located at more than 

1,700 universities, 

research institutions, 

and medical centers 

across the United 

States and abroad 



RESEARCH & DEVELOPMENT: NIH is involved in hundreds of research projects, including: 

GENOMICS 

Human Genome Project 

Human Sequence Databases 

Human Genetic Variation 

Cancer Diagnosis 

Genes and Aging 

Genes and Environment 

Gene Hunting for Schizophrenia and Manic-Depressive Illness 

Birth Defects and Inherited and Developmental Disorders 

Genes for Diabetes 

Genetics of Addiction 

Mouse Genome 

Mouse Mutants 

Genomes of Bacteria, Viruses, and Parasites 

ADVANCED TECHNOLOGIES 

Structural Genomics 

Toxic Chemicals 

New Organs and Tissues 

Repair and Replacement of Tissues of the Face and Head 

Drugs for Neurological Disorders 

Drug Addiction 

Understanding Alcohol Addiction 

Chemical Libraries 

Assistive Devices for the Visually Impaired 

DISEASE PREVENTION, DIAGNOSIS and TREATMENT 

Early Cancer Detection 

Alternative Cancer Therapies 

Treating Diabetes 

Blocking the Effects of Alzheimer's Disease 

Preventing and Treating Parkinson's 

Autism Centers of Excellence 

Treating Mental Illness in Children 

Ear Infections in Children 

Heart, Lung, and Blood Diseases 

Acute Stroke Centers 

AIDS Prevention and Treatment 

HIV Transmission to Infants 

Musculoskeletal Medicine 

Overcoming Salivary Gland Problems 

Drug Abuse Treatment 

Nicotine Addiction 

INTERDISCIPLINARY TRAINING AND COLLABORATIVE RESEARCH 

Computer Analysis of Biological Data 

Virtual Cell Research 

Women's Health 

Sex and Gender Differences in the Immune System 

Alcohol and the Brain 

HEALTH DISPARITIES 

Cancer Centers for Population Health 

Reducing Preterm Births. 

Reducing Sudden Infant Death 

Geographic and Racial Differences in Stroke 

Hepatitis C in Minority Populations 

Programs to Train Minority Scientists 

Clinical Research Training at Institutions That Serve Minorities 

Specialized Neuroscience Research Programs (SNRPs) at Minority 

Institutions 

Ensuring Access to Information Services 

Diabetes in Minority Populations 



PRODUCTS ON MARKET: NIH research has contributed to numerous therapies, drugs, programs, 

innovations and diagnostics that address myriad health issues and 

conditions 


NIH research has contributed to the 

progress of many products and 

technologies that advance through the 

clinical development stages 


1200 Montreal Road, Bldg. M-58 

Ottawa K1A 0R6, Canada 

Phone: (613) 993-9101; Fax: (613) 952-9907 

Toll-free phone: (877) NRC-CNRC (672-2672) 

Web: www.nrc-cnrc.gc.ca 

E-mail: info@nrc-cnrc.gc.ca 

KEY PERSONNEL: Dr. Pierre Coulombe; President 

Dr. Sherif Barakat; VP, Engineering 

Don T. Di Salle; VP, Corporate Services 

Patricia Mortimer; Acting VP, Technology and Industry Support 

Dr. Richard Normandin; VP, Physical Sciences 

Dr. Roman Szumski; VP, Life Sciences 

Marielle Piche; Acting Secretary General 


HISTORY: Created by the Canadian government in 1916, NRC fulfills three main 

responsibilities: as a partner with industry in R&D; as a source of basic 

scientific and engineering strength for the national interest; and as a 

contributor to the development of the national science and technology 

infrastructure 



SUBSIDIARIES/DIVISIONS: NRC Plant Biotechnology Institute (NRC-PBI), Saskatoon, SK--plant cell 

biotechnology 

NRC Institute for Biological Sciences (NRC-IBS), Ottawa, ON--cell biology of 

neurodegenerative diseases; immunochemistry of vaccines; diagnostics; 

immunotherapeutics for human and veterinary applications 

NRC Biotechnology Research Institute (NRC-BRI), Montreal, PQ--seeks to 

exploit biotechnological processes in collaboration with Canadian industries 

NRC Institute for Marine Biosciences (NRC-IMB), Halifax, NS--marine plant 

biology and biochemistry 

NRC Institute for Biodiagnostics (NRC-IBD), Winnipeg, MB--research in 

developing more sophisticated diagnostic techniques 

NRC Institute for Nutrisciences and Health (NRC-INH), Charlottetown, PE-- 

naturally-occurring compounds to benefit human and animal health—impact 

of nutraceuticals and bioactives on neurologic, obesity-related disorders; 

and infection and immunity 

Fourteen other nonbiotech institutes nationwide 

Industrial Research Assistance Program Office--supports research in a 

number of Canadian industries, including biotechnology 

Canada Institute for Scientific and Technical Information (CISTI) 

SUBSIDIARY OF: Government of Canada 

INVESTMENTS: NRC's Biotechnology Program is a founding member of Genome Canada 

and contributes to Canadian innovation in genomics through the NRC 

Genome and Health Initiative (GHI), which was launched in 1999 

BUSINESS STRATEGY: Enter into agreements with Canadian industries to facilitate creation of 

products 



RESEARCH & DEVELOPMENT: All areas of science and technology, including biotechnology, plant 

biotechnology, marine biosciences, molecular sciences, and microstructural 

sciences, either as active participants or as consultant/advisors 

Research areas include: Bioinformatics, environmental and sustainable 

development technologies, fuel cells, genomics, nanotechnology, photonics, 

nutraceuticals, proteomics 


555 Lordship Boulevard 

Stratford CT 06115, US 

Phone: (203) 380-0316; Fax: (203) 380-0358 

Web: www.nature-plus.com 

E-mail: info@nature-plus.com 

KEY PERSONNEL: Dr. Sheldon R. Murphy; President and CEO 




BUSINESS STRATEGY: Expand current products into international sales 

RESEARCH & DEVELOPMENT: Ingredients, concentrates 

PRODUCTS ON MARKET: TerraZyme® soil stabilizer 

EcoCare® odor eliminator products 

NaturCare® cleaning and odor control products 

SAFE home products 

Pool and medical products 


P.O. Box 5830 

Minnetonka MN 55440-5830, US 

Phone: (989) 633-1746 Toll-free phone: (877) 423-7659 

Web: www.natureworksllc.com 

KEY PERSONNEL: Dennis McGrew; President and CEO 

Lisa Owen; Global Business Leader, Rigid Packaging 


HISTORY: Founded in 1997 as Cargill Dow LLC, a 50:50 joint venture between Cargill 

and The Dow Chemical Co. 

Acquired completed by Cargill (1/05) 

FACILITIES: Plant in Blair, Neb. 


SUBSIDIARY OF: Cargill 

BUSINESS STRATEGY: Produce and sell renewable-resource-based resin derived from the sugar 

found in common field corn 

PRODUCTS ON MARKET: NatureWorks® PLA--bottles packaging, packaging for consumer goods, 

food and serviceware 

Ingeo® fibers (www.ingeofibers.com) 


Neogen Corp. 


620 Lesher Place 

Lansing MI 48912-1595, US 

Phone: (517) 372-9200; Fax: (517) 372-2006 


Web: www.neogen.com 

E-mail: inform@neogen.com 

KEY PERSONNEL: James Herbert; Chairman and CEO 

Lon M. Bohannon; President and COO 

Richard R. Current; VP and CFO 

Edward L. Bradley; VP, Food Safety Sales and Marketing 

Kenneth Kodilla; VP, Manufacturing 

Joseph M. Madden, Ph.D.; VP, Scientific Affairs 

Anthony E. Maltese; VP, Corporate Development 

Terri A. Morrical; VP, Animal Safety Sales and Marketing 

Mark A. Mozola, Ph.D.; VP, R&D 

Paul S. Satoh, Ph.D.; VP, Basic and Exploratory Research 




Purchased WTT Inc. (now ELISA Technologies), a developer of 

immunoassay diagnostics for the equine and dog racing industries and 

research markets (9/92) 

Acquired plant diagnostics product lines of Quantix Systems (3/93) 

Purchased assets of Enzytec of Kansas City, MO (10/93) 

Acquired AMPCOR Diagnostics Inc. of Camden, NJ (8/94) 

Acquired International Diagnostic Systems' animal diagnostics product line 

(6/95) 

Acquired Triple Crown Veterinary Pharmaceuticals (7/97) 

Acquired assets of Vetoquinol U.S.A. (ImmunoVet products) (1/98) 

Acquired Acumedia (2000) 

Acquired Adgen Ltd. (3/03) 

Acquired Hacco Inc. and Hess & Clark (11/03) 

Acquired distribution business of BiologischeAnalysensysteme GmbH (BAG) 

(10/04) 

Acquired UCB's dairy antibiotic testing business (12/05) 

Acquired Centrus International Inc. (2/06) 

FACILITIES: Headquarters in Lansing, Mich. 

25,000 sq. ft. food safety diagnostic manufacturing facility near Lansing, 

Mich. 

30,000 sq. ft facility for veterinary instruement operations in Lansing, Mich. 

80,000 sq. ft. Animal Safety Division facility in Lexington, Ky. 

STOCK-FINANCIAL HISTORY: NASDAQ--NEOG 

IPO--1.2M shares, $7.2M (10/89) 

Five-for-four stock split (12/03) 

Public offering--800K shares (6/06) 





SUBSIDIARIES/DIVISIONS: Food Safety Division 

Animal Safety Division 

Life Sciences Division 

Acumedia 

Neogen Europe Ltd. 

BUSINESS STRATEGY: Become dominant company in the development and marketing of solutions 

for food and animal safety 




CPI International Colitag water test distribution 

6/04 

system 

agreement 

RESEARCH & DEVELOPMENT: Food and animal safety--all animals: mycotoxin diagnostics; Food Allergens; 

veterinary delivery instrument, microbiological tests and drug detection diay. 

PRODUCTS ON MARKET: More than 200 diagnostic test kits, including: 

Agri-Screen® aflatoxin B1 diagnostic kit 

Agri-Screen® Ticket pesticide detection kit 

Agri-Screen® vomitoxin diagnostic kit 

Agri-Screen® nitrate diagnostic kit 

Agri-Screen® pH diagnostic kit 

Agri-Screen® triazine herbicide resistance test in weeds 

Agri-Screen® fumonisins diagnostic test 

Agri-Screen® ochratoxin diagnostic test 

Alert® for histamine 

Alert® for sulfites 

Ideal® line of veterinary instruments 

Bot Tox-B Clostridium botulinum type B vaccine 

Alert® disease detection kit 

ELISA Technologies® racing kits for detection of drugs of abuse in horses 

and dogs 

ELISA Technologies® research kits 

K-Blue Substrate® 

K-Gold Substrate 

Veratox® vomitoxin diagnostic kit 

Veratox® T-2 toxin diagnostic kit 

Veratox® aflatoxin quantitative diagnostic kit 

Veratox® zearalenone diagnostic kit 

Veratox®-AST aflatoxin single diagnostic test kit 

Veratox® for fumonisin quantitative diagnostic kit 

Ticket pesticide detector 

Reveal® for E. coli 0157:H7 

Reveal® for Salmonella 

Reveal® BioPlate for E. coli 

Reveal® for listeria 

REVIVE media 

EqStim® 

ImmunoRegulin® 

MycAseptic 

MycAseptic E 


44 Talmadge Road 

Edison NJ 08817, US 

Phone: (732) 287-1200; Fax: (732) 287-4222 


Web: www.nbsc.com 

E-mail: bioinfo@nbsc.com 

KEY PERSONNEL: David Freedman; Chairman and CEO 

Jim T. Orcutt; President and COO 

Thomas E. Bocchino; VP, Finance and CFO 

Dr. Lee Eppstein; VP, Technology 


HISTORY: Founded in 1946 by David and Sigmund Freedman 

Acquired RS Biotech Laboratory Equipment Ltd. (11/03) 




STOCK-FINANCIAL HISTORY: NASDAQ--NBSC 

Second stock offering (1983) 



Earnings per share (YE 05) compared to 

(YE 04) 



SUBSIDIARIES/DIVISIONS: New Brunswick Scientific (U.K.) Ltd. (see separate entry) 

New Brunswick Scientific NV 

Kerkenbos 1101 

6546 BC Nijmegen, The Netherlands 

Phone: +31 (0)24 3717 600; Fax: +31 (0)24 3717 640 

E-mail: sales@nbsbv.nl; Web site: www.nbsc.com/bv 

New Brunswick Scientific GmbH 

In der Au 14 

D-72622 Nurtingen, Germany 

Phone: +49 (0)7022-932490 

Fax: +49 (0)7022-32486 

E-mail: sales@nbsgmbh.de 

Web site: www.nbsgmbh.de 

New Brunswick Scientific NV-SA 

Stationsstraat 180/4 

B-3110 Rotselaar 

Belgie/Belgique 

Phone: +32 (0) 16 562 831 

Fax: +32 (0) 16 572 753 

E-mail: sales@nbsnv-sa.be 

New Brunswick Scientific SarL 

12-14, Rond Point des Champs Elysees 

75008 Paris, France 

Phone: +33 (0)1 53 53 15 11 

Fax: +33 (0)1 53 53 15 57 

E-mail: sales@nbssarl.fr 

New Brunswick Scientific Sales Office 

A903, 904 Yin Hai Building 

No. 250, Cao Xi Road 

Shanghai, 200235, China 

Phone: +86-21-64845955, +86-21-64845966 

Fax: +86-21-64845933 

E-mail: nbschc@online.sh.cn 

BUSINESS STRATEGY: Design, manufacture and market advanced systems for growth, detection 

and storage of cultures. Products include the world’s largest line of biological 

shakers and a full line of bench-to-production-scale fermentors and 

bioreactors used to produce therapeutic drugs, enzymes, biochemicals, 

antibiotics, vaccines and more. NBS also manufactures ultra-low 

temperature freezers, CO2 incubators, air samplers, automated media 

preparation equipment and roller drums. 

PRODUCTS ON MARKET: Biological shakers (Innova® and Excella) 

Fermentation systems, bench-to- production-scale (BioFlo®) 

Spinners, Mammalian cell culture bioreactors, bench-to-production-scale 

(FibraStage Disposable Cell Culture System, Spinner Basket, CelliGen 

Plus®, BioFlo®) 

Bioprocessing software (BioCommand®) 

Roller drums 

Air samplers (STA) 

Media sterilization and dispensing equipment (AgarMatic and PourMatic) 




240 County Road 

Ipswich MA 01938-2723, US 

Phone: (978) 927-5054; Fax: (978) 921-1350 

Toll-free phone: Ordering: (800) 632-5227; 

Technical Service: (800) 632-7799 

Web: www.neb.com; E-mail: info@neb.com 

KEY PERSONNEL: James V. Ellard; CEO 

Richard J. Roberts, Ph.D.; CSO 

Elisabeth Raleigh, Ph.D.; Director, R&D 



FACILITIES: State-of-the-art 140,000 sq. ft. research and production laboratory 


SUBSIDIARIES/DIVISIONS: Organic synthesis division 

German, Canadian and U.K. subsidiaries 

RESEARCH & DEVELOPMENT: Restriction and modification of DNA 

Protein analysis and modifications 

Parasitic diseases 

PRODUCTS ON MARKET: Restriction enzymes for DNA research, oligonucleotides, DNA synthesis kits 

Kits for molecular biology 

Protein modification/analysis reagents 


9110 Red Branch Road 

Columbia MD 21045, US 

Phone: (410) 992-9357; Fax: (410) 992-0328 

Web: www.nhdiag.com 

E-mail: nhdiag@aol.com 

KEY PERSONNEL: Lawrence Loomis; President 

David Trudil; VP and General Manager 



FACILITIES: 14,000 sq. ft. facility in Columbia, Md. 



Power3 Medical antibody-based 


Products Inc. diagnostics for 

neurogenerative 

diseases 

agreement 

RESEARCH & DEVELOPMENT: Direct Salmonella and E. coli tests 

Infectious disease diagnostics for the hospital lab and physician's office 

Bioluminescent probes technology for food, environment, biowarfare, water, 

and bioluminescence test for urinary infections 

Membrane strip technology for direct diagnostic tests, especially for antigen 

detection 

Develop tests for NASA and U.S. military 

Develop tests for detection of food- and water-borne pathogens 



PRODUCTS ON MARKET: Gonogen II (N. gonorrhoeae) diagnostic test reagents using Mab 

Bioluminescence test for human, food, environmental, biowarfare 

Trust--Syphilis detection test 

Smart II--diagnostic kit for E. coli and Salmonella 

STD tests: GonoGen II and TRUST 

Cholera test kits 

Environmental testing 

Profile-1 bioluminescence test for detection of food, water, environment and 

human-borne pathogens 

Biowarfare detection kits 


P. O. Box 1869, 68 Weld Street 

Palmerston North 4440, New Zealand 

Phone: +64 6-952-3800; Fax: +64 6-952-3801 

Web: www.nzp.co.nz 

E-mail: market@nzp.co.nz 

KEY PERSONNEL: Dr. Richard Garland; Managing Director 

Andrew Lewis; General Manager 

Barry Old; Marketing and Technical Director 

Selwyn Yorke; Market Development Manager 

Michael Callagher; Commercial Manager 



FACILITIES: Two pilot plants with a total area of 188 sq. m., one of which has explosion 

protected operations. Three factory and one more under construtcion. 


INVESTMENTS: Just the Berries Ltd.--joint venture between NZP Holdings Ltd. and Just the 

Berries Holdings Ltd. (2/03) 

BUSINESS STRATEGY: Manufacture plant and animal extracts for biotechnology, pharmaceutical 

and health food and cosmetics industries. Chemical synthesis of specialty 

carbohydrates and related compounds. 

PRODUCTS ON MARKET: Peptones, cholic acid, deoxycholic acid, dehydrocholic acid, taurocholate, 

glycocholate taurodeoxycholate, methyl cholate, bile salts, heparin, chiroinositol, 

chondroitin sulphate, ferritin, pinitol, galactasomine, and 

acetylmannosamine, mannosamine, sialic acid, actinidin, evening primrose 

polyphenolic antioxidants, actinidin, cartilage products. 


Carbohydrates in pilot plant 

Blackcurrant extracts in pilot plant 


Beuthener Strasse 2 

Waldkraiburg D-84478, Germany 

Phone: +49 86 38-962-0; Fax: +49 86 38-962-287 

Web: www.nigu.de 

E-mail: info@nigu.de 

KEY PERSONNEL: Dr. Klaus Engel; Chairman, Degussa 

Joachim Semel, Ph.D.; Managing Director, Nigu Chemie 




HISTORY: Chemische Werke LOWI founded in 1947 

Spun off NIGU Chemie (1964) 

NIGU Chemie acquired by SKW Trostberg AG (from 1987 to 1991) 

Became a subsidiary of Degussa AG when SKW Trostberg AG merged with 

Degussa-Huls AG 

FACILITIES: State-of-the-art, GMP-conform production facilities for ultrapure guanidine 

salts and a worldwide unique recycling plant for guanidine-containing 

process waste 


SUBSIDIARIES/DIVISIONS: Nigu Bioselect is a business area of Nigu Chemie GmbH 

SUBSIDIARY OF: Degussa AG 

BUSINESS STRATEGY: Develop, produce and distribute fine and biochemicals for the 

pharmaceutical, diagnostic and life science industry 

PRODUCTS ON MARKET: Ultrapure guanidine hydrochloride 

Ultrapure guanidine thiocyanate 

Guanidine und derivatives 

Recycling of guanidine containing process waste 

Nippon Kayaku Co. Ltd. 

Tokyo Fujimi Bldg., 11-2, Fujimi 1 chome, Chiyoda-ku 


Phone: +81 3-3237-5046; Fax: +81 3-3237-5081 

Web: www.nipponkayaku.co.jp 

E-mail: kouho@nipponkayaku.co.jp 

KEY PERSONNEL: Koichiro Shimada; President 

Masao Komaki; Director, Functional Chemicals Group 

Akira Mandai; Director, Pharmaceuticals Group 

Yoshiyuki Ikeda; General Manager, Safety Systems Division 

Yoshiaki Fukushima; Director, Fine Chemicals Group 

Hidetoshi Kitazawa; Director, Strategic Corporate Planning Group and 

Director, R&D Group 

Koichi Chiba; Director, Administration Group 

Koichi Takase; President, Polatechno Co. Ltd. 


HISTORY: Established in June 1916 


Formed Kayaku Asta Medica, joint venture with Asta Medica AG, to develop 

the anticancer drugs Cetrorelix and D21266 (6/95) 

FACILITIES: Plants located in Tokyo, Takasaki, Kasima, Fukuyama, Asa, and Himeji; 

plus four laboratories 

Biotech production facility located at Takasaki plant 





SUBSIDIARIES/DIVISIONS: Organizaton: 

Strategic Corporate Planning Group 

Administration Group 

Technical Operations Group 

Research & Development Group: Research & Development Planning 

Division, Intellectual Property Division, Functional Chemicals R&D 

Laboratories, Pharmaceuticals Laboratories, Safety Systems Development 

Laboratories, Agrochemicals Laboratories 



Functional Chemicals Group: Functional Materials Division, Electronic 

Materials Division, Catalysts Division 

Pharmaceuticals Group: Pharmaceuticals Marketing Division, Specialty 

Chemicals & Diagnostics Division, Regulatory Affairs Division, 

Pharmaceuticals Technical Operations Division, Pharmaceuticals 

Development Division, Licensing Division 

Fine Chemicals Group: Agrochemicals Division, Color Chemicals Division, 

Explosives Division 

Group companies: 

Functional Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon Kayaku 

Tokyo Co. Ltd., Nippon Kayaku Fukuyama Co. Ltd., Tomusu Co. Ltd., 

Naigai Nikka Co. Ltd., Nippon Kayaku (Taiwan) Co. Ltd., Kayaku Chemical 

(Wuxi) Co. Ltd., Itabashi Chemical Ind. Co. Ltd., Polatechno Co. Ltd., 

Nippon Kayaku America Inc., Kayafloc Co. Ltd., Wuxi Polatechno Optics Co. 

Ltd., Moxtek Inc., Polatechno (Hong Kong) Co. Ltd., Kayaku MicroChem 

Corp., Dejima Tech BV, Dejima Optical Films BV, Minoshima Sangyo Co. 

Ltd. 

Fine Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon KayakuTokyo Co. 

Ltd., Nippon Kayaku Fukuyama Co. Ltd., Naigai Nikka Co. Ltd., N.S. Color 

Techno Co. Ltd., Shinwa Sangyo Co. Ltd., Sanko Kagaku Kogyo Co. Ltd., 

Dalian Advanced Chemical Co. Ltd., Hokuyou Kayaku Co. Ltd., Zhaoyuan 

Advanced Chemical Co. Ltd., Wuxi Advanced Kayaku Chemical Co. Ltd., 

Kayatech Co. Ltd., Techno Green Co. Ltd., P.T. Petrokimia Kayaku, Shikoku 

ANFO Inc. 

Pharmaceuticals Group: Nac Co. Ltd., Gunnan Sangyo Co. Ltd., Euro 

Nippon Kayaku GmbH, Nippon Kayaku (Taiwan) Co. Ltd., Nippon Kayaku 

America Inc., JHMS Corp., Nanotherapy Co. Ltd., Kayaku Zentaris Co. Ltd., 

Nippon Kayaku Food Techno Co. Ltd., Nippon Kayaku MedicalCare Co. 

Ltd., Nippon Kayaku Medinet Co. Ltd., Naigai Nikka Co. Ltd. 

Safety Systems Division: Toyotomi Kogyo Co. Ltd., Indet Safety Systems 

AS, LifeSparc Inc., NKNM Ltd. 

Other Businesses: Wako Toshi Kaihatsu Co. Ltd., Tocos Co. Ltd., Okiura 

Golf Center Co. Ltd., Nikos Co. Ltd., Kayaku Akzo Corp. 

BUSINESS STRATEGY: Maintain a strong focus on markets and customers, and rapidly execute 

business strategy for targeting niche markets by utilizing a fusion of 

technologies within and beyond the company. Based on this basic strategy, 

Nippon Kayakyu has identified three growth fields: 

information/communications, health care, and safety systems 


Astellas Pharma Gelpart exclusive licensing 2/05 

Inc. 

agreement 

Axiom 

Biotechnologies 

Inc./Zaiya Inc. 

National Cancer 

Center (Japan) 

Pasteur Merieux 

Connaught 

Canada (now 

Sanofi Pasteur) 

small-molecule cancer 

drugs 

MAbs for stomach 

cancer diagnostics 

BCG vaccine for 

bladder cancer 

research 

agreement--Axiom 

to receive research 

funding for three 

years, license fees, 

milestones and 

royalties, Nippon 

Kayaku gains Asian 

marketing and 

manufacturing 

rights and options 

for other territories 

outside North 

America 

collaborative 

agreement 


agreement 


11/97 

9/95


Research 

Development 

Corp. of Japan 

(JRDC) 

Signal 


Inc. 

Silenus 

Laboratories 

anticancer drug-carrier 

complex for missile 

therapy 

small molecule NGF 

mimetics for neuropathy 

hemoglobin-specific 

MAb for GI cancer 

diagnosis 

SunPharm Corp. diethylnorspermine for 

cancer 

¥1b 


agreement 


11/90 


licensing and 


exclusive 


marketing rights in 

Japan 

RESEARCH & DEVELOPMENT: Development of cancer-related products 

Fusing technologies from within and beyond the company to accelerate the 

development of a broad range of anti-cancer drug products 

Development of a drug delivery system in which an anti-cancer drug is 

contained inside nano-size polymer 

micelles 

Development of anti-cancer drugs that are effective against hormonedependent 

cancer 

Development of heat immunotherapy, in which heat is used to treat cancer 

PRODUCTS ON MARKET: Epoxy resins (EOCN-1020, EPPN-500, NC-3000, BREN) 

Hardeners for epoxy resins (Kayahard) 

Photo-curing resins (Kayarad, Kayamer, Kayacure) 

Polyamide/polyimide resins 

Polymer flocculants (Kayafloc) acrylic acids, methacrylic acids and other 

catalysts used in manufacturing 


Anti-cancer and cancer-related drugs: Calsed, Epirubicin, IA Call, Oncovin, 

Exal, Carbomerck, Immucyst, Hycamtin®, MS-Twicelon, Coforin, Fareston, 

Odyne, Starasid, Pinorubin, Lastet, Bestatin, Randa, Pepleo, Bleo 

Immunosuppressants: Spanidin 

Cardiovascular Drugs: Millisrol, Adehl, Millistape, Nitropen Tablets, 

Nitroglycerine Tablets 

Neurological Drugs: Saligren, Muscalm 

Other Drugs: Astric Dry Syrup 

Diagnostic Agents: Lana Mammo Card CEA, Lana TP Auto, Lana 1.5AG 

Auto Liquid, Lanazyme BFP Plate, Lanazyme ST-439 Plate 

Active pharmaceutical ingredients and intermediates 

Agrochemicals: Diazinon, Matric, Safrotin, Evisect, Cyclosal, MCPB, 

Chloropicrin, Cucumeris, Ratden, Simetryn, Chlorpic-Flow 

Color chemicals: Kayalon Polyester, Kayacryl-ED, Kayacelon React, 

Kayarus, Kayacion, Kayaaffect, Kayaphor Liquid, Kayaset 

Explosives: Dynamite, slurried explosives, ammonium nitrate fuel oil 

explosive (ANFO explosive), black powder, electric detonators 

2-5-25, Umeda, Kita-ku 


Phone: +81 726-22-2981; Fax: +81 726-26-1505 

Web: www.nitto.com; E-mail: sales@nitto.com 

KEY PERSONNEL: Masamichi Takemoto; CEO and COO 

Yukio Nagira; Deputy COO 

Yasuo Ninomiya; CTO 

1988 

3/94


Tatsunosuke Fujiwara; CFO 

Wataru Kitao; CSO 


HISTORY: Founded in October 1918 as Nitto Electric Industrial Co. Ltd. 

Formed Nitto Denko America Inc. (1969) 

Formed Nitto Europe N.V. (1974) 

Formed Nitoms Inc. (1975) 

Acquired Acquires Hydranautics (1987) 

Acquired Permacel (1988) 

Acquired Graphic Technology Inc. (1989) 

Formed Jinsec Corp. (1990) 

Formed Nitto Medical Corp. and Nitto Lifetec Corp. (1996) 

Formed Nitto Shinko Corp., Nitto Denko Material (Thailand) Co. Ltd. and 

P.T. Nitto Materials Indonesia (1997) 

Formed Nitto Denko Packaging System Corp., Nitto Denko Vietnam Co. Ltd. 

and Korea Nitto Optical Co. Ltd. (1999) 

Formed Nitto Americas Inc., Mie Nitto Denko Corp., Nitto Denko Himawari 

Corp., Korea Nitto Denko, Nitto Denko Matex Corp. and Nitto Denko 

Technical Corp. (2000) 

Formed Nitto Denko Tape Materials (Vietnam) Co. Ltd., Nitto Denko 

Philippines Corp. and Nitto Denko (Suzhou) Co. Ltd. (2001) 

Formed Nitto Electronics kyusyu Corp. and Aichi Nitto Denko Corp. (2002) 

Acquired Elan Transdermal Technologies Inc. (2003) 

Formed Kinovate Life Siences Inc. and Nitto Denko Fine Circuit Technology 

Co. Ltd. (2004) 

Formed Optmate Corp., Nitto Denko (Tianjin) Co. Ltd. and Shanghai Nitto 

Optical Co. Ltd. (2005) 

FACILITIES: Plants in Tohoku, Kanto, Toyohashi, Kameyama, Shiga and Onomichi 

STOCK-FINANCIAL HISTORY: Traded on the Tokyo and Osaka stock exchanges 

IPO--1962 




05) 


SUBSIDIARIES/DIVISIONS: Japan: 

Nitto Shinko Co. Ltd. 

Nitto Denko CS System Corp. 

Nitoms Inc. 

Kyoshin Co. Ltd. 

Nissho Corp. 

Nitto Denko Matex Co. Ltd. 

East Asia: 

Nitto Denko (China) Investment Co. Ltd. 

Nitto Denko (Shanghai Songjiang) Co. Ltd. 

Nitto Denko (Shanghai Pu Dong New Area) Co. Ltd. 

Nitto Denko (Suzhou) Co. Ltd. 

Nitto Denko Xiamen Co. Ltd. 

Nitto Denko (HK) Co. Ltd. 

Nitto Denko Materials (Shenzhen) Co. Ltd. 

Shanghai Nitto Optical Co. Ltd. 

Nitto Denko (Taiwan) Corp. 

Taiwan Nitto Optical Co. Ltd. 

KoreaNitto Denko Co. Ltd. 

Korea Nitto Optical Co. Ltd. 

South Asia: 

Nitto Denko (Singapore) Pte. Ltd. 

Nitto Denko Electronics (Malaysia)Sdn. Bhd. 

Nitto Denko Materials (Malaysia) Sdn. Bhd. 

Nitto Denko Material (Thailand) Co. Ltd. 



Nitto Denko Vietnam Co. Ltd. 

Nitto Denko Tape Materials (Vietnam) Co. Ltd. 

Nitto Denko Philippines Corp. 

PT Nitto Materials Indonesia 

Nitto Denko (Australia) Pty. Ltd. 

Europe: 

Nitto Europe NV 

Nitto U.K. Ltd. 

Nitto France Sarl 

Nitto Deutschland GmbH 

Nitto Scandinavia AB 

Nitto Italia SRL 

Nitto Polska SP Zoo 

U.S. 

Nitto Americas Inc. 

Nitto Denko America Inc. 

Permacel 

Permacel Automotive Inc. 

Hydranautics 

Aveva Drug Delivery Systems Inc. 

Nitto Denko Technical Corp. 


Eisai Corp. transdermal adhesive joint develop 5/06 

preparation of Aricept agreement 

PRODUCTS ON MARKET: Industrial products: Double-coated adhesive tapes, surface-protection films, 

advanced sealing materials 

Electronics products: Polarizing films, retardation films, polarization 

conversion films, semiconductor encapsulating resins, thin metal core 

boards for MR heads, protection sheet and laminating device applicator for 

semiconductor wafer processing 

Functional products: Transdermal therapeutic patches, surgical tapes, 

tissue-cultured ginseng, high-polymer separation membrane modules, 

fluoroplastic porous films, fluoroplastic adhesive tapes 


Edmonton Research Park, 9110-23 Avenue 

Edmonton T6N 1H9, Canada 

Phone: (403) 414-9595; Fax: (403) 450-1016 

Web: www.noractech.com 

E-mail: norac@noractech.com 

KEY PERSONNEL: Dr. D. A. Evans; President 

Jaime Calderon; Head, R&D 



FACILITIES: Supercritical Fluid Extraction Plant--20,000 sq. ft. facility 


SUBSIDIARY OF: Newly Weds Foods Co. 

BUSINESS STRATEGY: Develop and manufacture natural botanicals and biological extractives with 

companies from the food, beverage, cosmetic, and pharmaceutical 

industries, commercial extraction available 

RESEARCH & DEVELOPMENT: Supercritical extraction/fractionation of natural materials; separations; 

flavors; antioxidants; biologicals; and process development, design, and 




PRODUCTS ON MARKET: Fractionated spice oleoresins SC, broad spectrum essential oils SC, food 

colorants SC, natural rosemary antioxidants SC, natural vanilla extracts SC, 

fractionated cereal oils, de-fatted cereal germs, brans and flours, lowfat/low-cholesterol 

egg powders, nutriceutical oils, botanical gums and betaglucans, 

de-caffeinated tea and coffee, hops resins and oils 


Services: Proprietary product manufacturing, toll processing, SFE product 

and process development, system design and scale-up, laboratory analytical 

services, biomass recoveries, cryogenic grinding, drying (vacuum and 

freeze), homogenization, product formulating and packaging, economic 

modeling and costings, marketing of SFE products 

P.O. Box 13547, 15 T.W. Alexander Drive 

Research Triangle Park NC 27709-3547, US 

Phone: (919) 541-9366; Fax: (919) 990-9544 

Web: www.ncbiotech.org 

E-mail: info@ncbiotech.org 

KEY PERSONNEL: Leslie M. Alexandre, Ph.D.; President and CEO 

Ken Tindall, Ph.D.; Sr. VP, Science and Business Development 

John Richert; VP, Business and Technology Development 

William O. Bullock; Bioscience Industrial Development Director 

Cynthia J. Sollod, Ph.D.; Bioscience Industrial Development Specialist 

John Richert; VP, Business and Technology Development 

Rob Lindberg, Ph.D.; Technology Development Director 

Steven Casey; Business Development Director 

Steven Burke; Sr. VP, Corporate Affairs 

Lori Greenstein; Sr. VP, Corporate Administration and CFO 


HISTORY: Established as a non-profit organization in 1984 by State of North Carolina 

as the United States' first statewide initiative in biotechnology 


FACILITIES: Located in Research Triangle Park, N.C. 

47,000 sq. ft., $6M headquarters, including 22,000 sq. ft. program 

management center, 2,000 sq. ft. library, and 19,000 sq. ft. conference and 

education facility, on 120-acre campus 

Regional offices in Asheville, Winston-Salem, Greenville, and Wilmington, 

N.C. 



The North Carolina Biotechnology Center provides long-term economic and 

societal benefits to North Carolina by supporting biotechnology research, 

business and education statewide 

Goals: 

1. Strengthen North Carolina's academic and industrial biotechnology 

research capabilities 

2. Foster North Carolina's biotechnology industrial development 

3. Work with business, government and academia to move biotechnology 

from research to commercialization in North Carolina 

4. Inform North Carolinians about the science, applications, benefits and 

issues of biotechnology 

5. Enhance the teaching and workforce-training capabilities of North 

Carolina's educational institutions 

6. Establish North Carolina as a preeminent international location for the 

biotechnology industry 



RESEARCH & DEVELOPMENT: The center does not conduct laboratory research, but supports and funds 

biotechnology R&D at the state's universities, institutions, and biotechnology 

companies through grants programs and low-interest loan programs. 


1000 Seventh Avenue S.W., P.O. Box 2518 

Calgary T2P 5C6, Canada 

Phone: (403) 750-3600 

Web: www.novachem.com 

E-mail: public@novachem.com 

KEY PERSONNEL: J.E. (Ted) Newell; Chairman 

Jeffrey M. Lipton; CEO and President 

Larry A. MacDonald; Sr. VP and CFO 

Christopher D. Pappas; Sr. VP and President, Styrenics 

Dale H. Spiess; Sr. VP and President, Olefins/Polyolefins 

John L. Wheeler; Sr. VP and CIO 

Albert Terrence Poole; Exec. VP, Corporate Strategy and Development 


HISTORY: NOVA Corp. of Alberta was incorporated in 1954 

Acquired Polysar Energy & Chemical Corp. (9/88) 

Acquired the styrenics business of ARCO Chemical Co. (9/96) 

Merged with TransCanada PipeLines Ltd. (7/98) 

Acquired the majority of Huntsman Corp.’s U.S. and European styrenics 

businesses (12/98) 

Changed name to NOVA Chemicals Corp. (1/99) 

Acquired the European polystyrene and EPS assets, Chilean EPS 

production and molding assets and associated worldwide sales and 

marketing operations of The Shell Petroleum Co. Ltd. (1/00) 

Sold its interest in the Alberta Ethane Gathering System to Fort Chicago 

Energy Partners LP (12/04) 

Formed Novidesa SA de CV, a 50:50 joint venture in Mexico Grupo Idesa 

(10/05) 

Merged its European styrenic polymers business into a 50:50 joint venture 

(called NOVA Innovene) with Innovene (the commodity chemicals business 

of BP plc) (10/05) 

FACILITIES: NOVA Chemicals Research & Technology Center--Calgary, Alberta, 

Canada 

NOVA Chemicals Technical Center--Calgary, Alberta, Canada 

Demonstration plant for Advanced SCLAIRTECH technology--Corunna, 

Ontario, Canada 

STOCK-FINANCIAL HISTORY: NYSE/TSX--NCX 


Net income (YE 05) compared to $252M (YE 04) 

Earnings per share (YE 05) compared to $2.91/share 

(YE 04) 

Average shares outstnading 82.4M (YE 05) compared to 84.8M (YE 04) 


PRIVATE PLACEMENTS: Raised $400M in private placement of senior floating rate notes due in 2013 

(10/05) 

SUBSIDIARIES/DIVISIONS: Two plastics and chemicals businesses: Olefins/polyolefins, which produces 

ethylene, polyethylene and a variety of chemical and energy products 

(commonly known as co-products), and styrenics, which produces styrene 

monomer, polystyrene and expandable polystyrene (EPS) 



Subsidiaries: 

NOVA Chemicals (Canada) Ltd./NOVA Chimie (Canada) Lt´ee--Canada 

NOVA Chemicals Inc.--Delaware, U.S. 

NOVA Chemicals (International) SA--Switzerland 

Novacor Chemicals Investments BV--The Netherlands 

NOVA Chemicals Quimica Holdings SL-Spain 

NOVA Investments (U.S.) Inc.--Delaware, U.S. 

NOVA Petrochemicals Ltd.--Alberta, Canada 

BUSINESS STRATEGY: Produce plastics and chemicals that are essential to everyday life, with a 

focus on two product chains: ethylene and polyethylene, and styrene and 

polystyrene 

RESEARCH & DEVELOPMENT: Two internally developed technologies for the production of polyethylene— 

Sclairtech technology and Advanced Sclairtech technology. NOVA 

Chemicals also conducts R&D on other polyethylene technologies including 

gas-phase and high pressure technology 

In 2005, the company focused on the development and commercialization of 

Performance Products using Advanced Sclairtech technology 

NOVA Chemicals has developed three proprietary families of catalyst 

technology: A family of single-site catalysts for Advanced Sclairtech and 

other polymer technologies including 

gas-phase polyethylene; A family of catalysts including Z-N catalysts used 

for Sclairtech technology and Advanced Sclairtech technologies; and the 

Novacat family of catalysts for use in gas-phase polyethylene 

The company owns or has the rights to a portfolio of styrenics technology, in 

the fields of polymer production and styrenics polymer applications 

PRODUCTS ON MARKET: Arcel®: High-performance, moldable foam resin 

Dylark®: Automotive engineering resins 

Dylark® FG: High-heat styrenic copolymer 

Surpass®: Performance film, rotational molding & thin-wall injection molding 

resins 

Zylar® EX: Low-temperature, clear acrylic copolymer 

Sclair®, Novapol® and high-performance Surpass® resins 

Solid polystyrene (SPS) 

Expandable polystyrene (EPS) 

NovaSep Process 

KEY PERSONNEL: Thierry Faureau; CEO 

Jean Blehaut; President 


Site Eiffel Boulevard de la Moselle, B.P. 50 

Pompey F- 54340, France 

Phone: +33 3 83 49 70 00; Fax: +33 3 83 49 70 02 

Web: www.novasep.com 

E-mail: novasep-process@novasep.com 


Changed name from Separex (1995) 

Changed name from Separex Chromatographie (1996) 

Acquired Prochrom S.A. (2000) 

Acquired Seripharm (2003) 

Acquired Applexion and Orelis (2004) 

FACILITIES: 7,280 sq. m. headquarters and industrial plant 


SUBSIDIARIES/DIVISIONS: NovaSep Inc.--Boothwyn, Pa. 

NovaSep Japan KK--Tokyo, Japan 

NovaSep Asia--Shanghai, China 



SUBSIDIARY OF: Groupe Novasep 

PRINCIPAL INVESTORS: Rockwood 

BUSINESS STRATEGY: We are a specialist in solving purification and separation needs for the life 

science industry, from laboratory to large industrial production. 

Our fields of activities include: Process and product development, systems 

and APIs. 

RESEARCH & DEVELOPMENT: Process modelling and optimisation (chromatography, crystallization, 

membranes, adsorption, ion exchange, etc.) 

Process development 

Process integration (chromatography / adsorption / crystallization / 

distillation-evaporation / membranes, etc.) 

Custom purification of APIs and intermediates in clinical phase 

Custom synthesis (gram to kilogram) 

Purification of intermediates and APIs 

Production of intermediates and APIs 

Cytotoxic expertise 

PRODUCTS ON MARKET: High, medium and low pressure Batch preparative chromatography in liquid 

and supercritical phase 

High, medium and low continuous chromatography 

Adsorption and ion exchange 

Membranes (micro, nano and ultrafiltration) 

Evaporation and crystallization 

november AG 

KEY PERSONNEL: Dr. Wolf M. Bertling; CEO 

Alexander G. Offer; CFO 

Astrid Dickert; CFO 


Ulrich-Schalk-Str. 3 

Erlangen 91056, Germany 

Phone: +49 (0) 9131 750 88 0; Fax: +49 (0) 9131 750 88 99 

Web: www.november.de 

E-mail: info@november.de 



Holding since the end of 2003 


1,300 sq. m. R&D facility (offices of R&D included) 

500 sq. m. administration facility 

STOCK-FINANCIAL HISTORY: Traded on the Frankfurt Stock Exchange--NBX 

IPO--(4/00) 

Traded in segment Prime Standard (since 03/03) 




(YE 03) 



SUBSIDIARIES/DIVISIONS: identif GmbH 

directif GmbH 

responsif GmbH 

PEQLAB Biotechnologie GmbH--51% 

PRINCIPAL INVESTORS: Dr. Wolf M. Bertling--8.03% 

Jupiter Technologie GmbH&Co. KGaA--10.31% 



BUSINESS STRATEGY: Continue to build on our technological lead in the area of biotechnology and 

nanotechnology and in the long term to become market leader in the areas 

of our core competencies. Alone or with competent partners and strategic 

alliances, we will occupy market niches and develop new markets. The 

products of november AG are needed worldwide. 

RESEARCH & DEVELOPMENT: Labeling/tracing 

Product authentication 

DNA diagnostics 

Product security and brand protection 

PRODUCTS ON MARKET: Molecular fingerprint (DNA codes) and nano-optical seal (cluster codes)= 

novel marking systems for brand protection & product security 


Biological eartag: bioactive labeling of 

livestock 


System for fully automated, rapid and 

laboratory-independent nucleic acid testing 


Immune therapies for a variety of medical 

indications 

in clinicals 


11960 S.W. 144th Street 

Miami FL 33186, US 

Phone: (305) 253-5099; Fax: (305) 251-1887 

Web: www.noven.com 

KEY PERSONNEL: Robert C. Strauss; Chairman, President and CEO 

Diane M. Barrett; VP and CFO 

Jeffrey Eisenberg; Sr. VP, Strategic Alliances 

Juan Mantelle; VP and CTO 

W. Neil Jones; VP, Sales and Marketing 


HISTORY: Incorporated in 1987 

FACILITIES: 15-acre facility in Miami-Dade County consisting of multiple buildings 

totaling 150,000 sq. ft. 

STOCK-FINANCIAL HISTORY: NASDAQ--NOVN; Trading halted--12/05 

IPO--2.25M shares of common stock (1988) 

Secondary public offering--2.749M shares of common stock at $7/share 

(4/92) 





04) 


PRIVATE PLACEMENTS: Raised $800K in private sale of 589K shares of common stock (7/91) 

SUBSIDIARIES/DIVISIONS: Novogyne Pharmaceuticals--a women’s health products company jointly 

owned by Noven and Novartis Pharmaceuticals Corp. 

BUSINESS STRATEGY: Maintain a position as a leader in the development of advanced drug 

delivery technologies, while concurrently striving to become the world’s 

premier transdermal drug delivery company, through development of a 

series of groundbreaking products 




Aventis S.A. transdermal 

worldwide 

10/99 

combination 

licensing 

estrogen/progestogen agreement (except 

system 

Canada, US and 

Japan) 

Endo Fentanyl transdermal licensing 

2/04 

delivery system 

agreement 

Novartis AG first-generation 

co-promotion joint 5/98 

transdermal estrogen venture with 


Novogyne 

Novartis AG second-generation co-promotion joint 5/99 

transdermal estrogen venture with 


Novogyne 

P&G 

transdermal delivery development 4/03 


Inc. 

system for HSDD agreement 

Shire plc Daytrana (transdermal worldwide 

6/02 

methylphenidate licensing 

delivery system) for 

ADHD 

agreement 

RESEARCH & DEVELOPMENT: Transdermal and transoral drug delivery systems in development for wide 

array of drugs 

PRODUCTS ON MARKET: Vivelle-Dot (second-generation estradiol transdermal system) for 

postmenopausal women. World’s smallest estrogen patch. 

DentiPatch lidocaine transoral delivery system, on market in U.S. 

Vivelle® Menorest® (first-generation estradiol transdermal system) 

Menorest® advanced transdermal estrogen patch (Europe and elsewhere) 

CombiPatch® (estradiol/norethindrone acetate) combination 

estrogen/progestogen patch 

Estradot® (estradiol transdermal system) world's smallest transdermal 

estrogen patch (Europe & elsewhere) 

Estalis® 

Novozymes A/S 

Krogshoejvej 36 

Bagsvaerd 2880, Denmark 

Phone: +45 88-249999 

Web: www.novozymes.com 

KEY PERSONNEL: Steen Riisgaard; President and CEO 

Per Falholt; Exec. VP and CSO 

Per Mansson; Exec. VP and CFO 

Peder Holk Nielsen; Exec. VP, Business Operations 

Arne W. Schmidt; Exec. VP, Development, Production and Quality 

Anna Lise Mortensen Grandjean; VP, Stakeholder Communications and 

Sustainability Development 

Mette Vestergaard; VP, People and Organisation 


HISTORY: Spun off from Novo Nordisk A/S in November 2000 

Acquired Delta Biotechnology Ltd. from Sanofi-Aventis (7/06) 

To acquire GroPep Ltd. (as of 8/06) 

FACILITIES: Production facilities in Denmark, Sweden, China, North America and South 

America 

R&D, production and administration facility in Denmark 

Research facilities in North America, China and Japan 



STOCK-FINANCIAL HISTORY: Listed on the Copenhagen Stock Exchange 

Sales DKK6.281b (YE 05) compared to DKK5.988b (YE 04) 

Net profit DKK861M (YE 05) compared DKK775M (YE 04) 

Earnings per share DKK13.11/share (YE 05) compared to DKK11.19/share 

(YE 04) 

Total assets DKK7.309M (YE 05) compared to DKK7.076b (YE 04) 

SUBSIDIARIES/DIVISIONS: Austria: Novozymes Austria GmbH 

Australia: Novozymes Australia Pty. Ltd. 

Belgium: Novozymes Belgium BV 

Brasil: Novozymes Latin America Ltda. 

Denmark: Novozymes Bioindustrial China A/S, Novozymes Bioindustrial 

Russia A/S, Novozymes Bioindustrial A/S 

France: Novozymes France SA, Novozymes Biologicals France SA 

The Netherlands: Novozymes Netherlands BV 

India: Novozymes South Asia Pvt. Ltd. 

Italy: Novozymes Italia Srl. 

Japan: Novozymes Japan Ltd., Novozymes Biologicals Japan Ltd., 

Novozymes Property Ltd. 

China: Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) 

Investment Co. Ltd., Novozymes (Shenyang) Bioprocessing Co. Ltd., 

Suzhou Hongda Enzyme Co. Ltd. (joint venture) 

Malaysia: Novozymes Malaysia Sdn. Bhd. 

Mexico: Novozymes Mexicana SA de CV, Novozymes Mexico SA de CV 

Sweden: Novozymes Biopharma AB 

Switzerland: Novozymes Switzerland AG, Novozymes Switzerland Finance 

AG, Novozymes Switzerland Holding AG 

Singapore: Novozymes Singapore Pte. Ltd. 

Spain: Novozymes Spain SA 

Great Britain: Novozymes UK Ltd. 

South Africa: Enzymes SA (Pty) Ltd. 

South Korea: Novozymes Korea Ltd. 

Turkey: Novozymes Enzim Dis Ticaret Limited Sirketi 

Germany: Novozymes Deutschland GmbH 

U.S.: Novozymes North America Inc., Novozymes Biologicals Inc., 

Novozymes Biotech, Inc., Novozymes US Inc. 

BUSINESS STRATEGY: Expand the existing enzyme markets through more focused R&D efforts for 

new products and applications 

Target new geographical markets with enzymatic solutions 

Explore new business opportunities based on the company's core 

technologies, fermentation and production of proteins 


Celliance Corp. Recombinant Human commercialization 7/06 

Albumin for use in cell 

culture media 

formulations 

agreement 

China Resources research into processes three-year 

8/06 

Alcohol Corp. for producing cellulose- cooperation 

based biomass for 

biofuel in China 

agreement 

Neugenesis development of a new joint research 10/02 

method for the 

production of antibodies 

project 

RESEARCH & DEVELOPMENT: Novozymes' core competencies: 

1. Genetic and biochemical diversity: Culture collection, strain screening, 

genome sequencing, expression cloning 

2. Protein design: Protein engineering, gene shuffling, molecular modelling, 

molecular dynamics, directed evolution, high-throughput screening, epitope 

mapping 

3. Protein chemistry: Protein purification, protein sequencing, protein 

analysis, protein stability, assay development 



4. Pathway engineering: Selection of hosts , genetic engineering, metabolic 

pathway engineering, homogeneous morphology 

5. Strain development and improvement: Promoter selection, manipulation 

of operons, yield improvement 

6. Large-scale production: Process development, lab fermentation, scale-up, 

recovery, formulation 

PRODUCTS ON MARKET: Enzymes for industrial use (technical enzymes, comprising detergent 

enzymes, those sold to the ethanol industry, and and other technical 

enzymes; food enzymes; and feed enzymes) 

Microorganisms for industrial use, such as cleaning, wastewater treatment, 

aquaculture and biological plant care 

Biopolymers and pharmaceutical proteins 

More than 700 different products total 


1445 Drew Avenue 

Davis CA 95616, US 

Phone: (530) 757-8100; Fax: (530) 758-0317 

Web: www.novozymesbiotech.com 

E-mail: info@novozymes.com 

KEY PERSONNEL: Glenn E. Nedwin, Ph.D.; President 

Randy M. Berka, Ph.D.; Research Fellow, Core Technologies 

Debbie Yaver, Ph.D.; Senior Research Manager 

Joel Cherry, Ph.D.; Director, Bioenergy 

Alan Sloma, Ph.D.; Director, Molecular Biology 

Stephen H. Brown, Ph.D.; Research Manager, Microbial Physiology 

Rasmus Thaisen; Finance Manager 

Marta L. Hillesheim; Director, People and Organization 




Changed name from Novo Nordisk Biotech Inc. (11/00) 

Changed name from Novozymes Biotech Inc. 



Parent company, Novozymes A/S, traded on Copenhagen stock market 

SUBSIDIARY OF: Novozymes A/S 

BUSINESS STRATEGY: Focus is on industrial biotechnology R&D and biosolutions: pharma, agribiotech 

and biochemical 

Operates as the U.S. research arm of Novozymes A/S 

Pursue endeavors and collaborations involving novel enzymes, novel 

enzyme applications and novel production technology 

RESEARCH & DEVELOPMENT: Cloning, expression, mutagenesis, and characterization of industrial 

enzymes 

Develop novel high-level expression systems 

Functional genomics 

Detergents, textiles, starch, food, baking, wine, juice, beer, pulp & paper, 

fats, feed and personal care 

Low-allergenic protein technology 

Anti-microbial compounds 

Biopolymers, e.g., hyaluronic acid 




Estuary Road, Riverside Industrial Estate 

Kings Lynn PE30 2HH, UK 

Phone: +44 (0)1553 692380; Fax: +44 (0)1553 770684 

Web: www.omex.co.uk 

E-mail: environmental@omex.com, deicers@omex.com 

KEY PERSONNEL: Alistair Marsh; Head, Sales, U.K. 

Gerry Spoors; Head, Sales, Magmex U.K. 

Adrian Gebbett; Head, Sales, Europe 

Gavin Inglis; Head, Sales, Scotland 

Philip Sheppardson; Head, Sales, Anomex U.K. 



FACILITIES: Three fully equipped laboratories in the U.K. 


SUBSIDIARIES/DIVISIONS: Two divisions: 

Wastewater Control 

Deicers 

SUBSIDIARY OF: Omex Group 

BUSINESS STRATEGY: Offer in-depth analysis and treatment of all the potential problems 

surrounding modern effluent and septicity treatment systems, from on all 

aspects of industrial wastewater treatment, from pre-treatment to sludge 

disposal 

PRODUCTS ON MARKET: Anti bulking chemicals 

Nutrients 

pH control 

Coagulates 

Products for septicity control 

Ice control products 

OmniChem 

Industrial Research Park Fleming 

Louvain-la-Neuve B-1348, Belgium 

Phone: +32 (10) 48-31-11; Fax: +32 (10) 45-06-93 

Web: www.omnichem.be 

E-mail: sales@omnichem.be 

KEY PERSONNEL: Jean-Claude Bourmanne; Managing Director 


HISTORY: Incorporated as Omnium Chimique in 1980 

Changed name to OmniChem (1980) 

Acquired by Ajinomoto Co. Inc. (1989) 

FACILITIES: cGMP chemical facilities 


SUBSIDIARY OF: Ajinomoto Co. Inc. (see separate entry) 


Under secrecy 

agreements 



RESEARCH & DEVELOPMENT: Industrial expertise in the handling of: Aluminium and hydrides, azide 

reagent, boranes, boron trifluoride, butyllithium, carbon disulphide, chlorine, 

dimethyl sulfate, epichlorohydrin, ethylene oxide, hydrazine sodium azide, 

hydrogen peroxide, lithium diisopropylamide, methyl bromide, nitric acid, 

oxalyl chloride, peracids, phosgene, phosphorus oxychloride, phosphorus 

pentachloride, sodium amide, sodium cyanide, sulfonitric acid 

In-house manufacture or in situ generation of: Azido alkyl acetate, bocchloride, 

diazo ethyl acetate, diphenylphosphorylazide (DPPA), N-vinyl-Oalkyl 

carbamate, ruppert reagent: CF3-Si (CH3) 3, trimethylsilylazide (TMS- 

N3) 

Reaction portfolio: Aldol condensation, Baeyer-Villiger oxidation, Claisen 

condensation, Chloromethylation, Diazo coupling, Diels-Alder reaction, 

Friedel-Crafts reaction, Hydroxyethylation, Knoevenagel condensation, 

Mannich reaction, Methylation, Reimer-Tiemann reaction, Vilsmeier 

formylation, Wittig reaction 

PRODUCTS ON MARKET: Generic drugs: Synthetic and botanical 

Synthetic intermediates: Tetrazoles, nitro compounds, phosgene derivatives 

Services: API supply, custom manufacturing, project manufacturing 


Under secrecy agreements 


763-D Concord Avenue 


Phone: (617) 576-1966; Fax: (617) 547-9256 

Web: www.omnigenebioproducts.com 

E-mail: info@omnigenebioproducts.com 

KEY PERSONNEL: Janice G. Pero, Ph.D.; Chairman and President 

Dr. R. Rogers Yocum; Sr. Program Director 



Began biotech R&D in October 1995 

Formerly a division of OmniGene Inc. and BioTechnica International Inc.; 

acquired bioproducts division from OmniGene Inc. 




BUSINESS STRATEGY: Contract research and licensing 

Expand bioproducts R&D 


BASF AG specialty chemicals licensing agreement 1/99 

F. Hoffmann-La 

Roche AG 

specialty chemicals licensing agreement 1/88 

Genencor 


industrial enzymes licensing agreement 1/99 

RESEARCH & DEVELOPMENT: Genetic engineering of microorganisms to produce specialty products, such 

as vitamins, amino acids, enzymes, other proteins and fine chemicals 




750 Lexington Avenue, 6th Floor 


Phone: (212) 905-0189 Toll-free phone: (866) OPTIGNX 

Web: www.ac-11.com 

E-mail: info@optigenex.com 

KEY PERSONNEL: William Walters; Chairman 

Richard Serbin; CEO 

Anthony Bonelli; President and COO 

Joseph McSherry; CFO 


HISTORY: Founded in July 2002 as Idunna Inc. 

Changed name to Kronogen Sciences Inc. (11/02) 

Changed name to Optigenex Inc. (7/03) 

Acquired some assets of CampaMed LLC (11/03) 

FACILITIES: 6,125 sq. ft. of leased space in New York, N.Y. 

STOCK-FINANCIAL HISTORY: OTC BB--OPGX 

Net sales $277.831K (YE 05) compared to $339.065K (YE 04) 



Average shares outstanding $10.128M (YE 05) compared to $8.071M (YE 

04) 


PRIVATE PLACEMENTS: Raised $4M from private placement of 625M shares (9/05) 

INVESTMENTS: Formed a joint venture called PMO Products Inc. to develop and market 

professional hair care products that contain AC-11 (11/04) 

Formed a joint venture company with Prometheon Holding LLC to develop 

and market a new line of nutraceutical products containing Optigenex's AC- 

11® as its core ingredient (8/05) 

BUSINESS STRATEGY: develops and markets proprietary products that are designed to counter 

the negative effects of aging by supporting the body's natural ability to repair 

and maintain its DNA 

RESEARCH & DEVELOPMENT: AC-11 is a compound derived from the plant Uncaria tomentosa, which is 

native to the Amazon rainforest as well as tropical areas in South and 

Central America. AC-11 has demonstrated activity in DNA repair, 

autoimmune enhancement, anti-inflammatory and anti-tumor areas. 

PRODUCTS ON MARKET: Activar AC-11 

Activar Age Manager (AC-11, with vitamins and minerals) 

Optronics 

175 Cremona Drive 

Goleta CA 93117, US 

Phone: (805) 968-3568; Fax: (805) 968-0933 


Web: www.optronics.com 

E-mail: oeinfo@optronics.com 

KEY PERSONNEL: Doug Merker; General Manager 



FACILITIES: 18,000 sq. ft. headquarters, R&D and manufacturing facility 




SUBSIDIARY OF: Karl Storz Imaging 

BUSINESS STRATEGY: Manufacture scientific grade digital cameras and software for research 

microscopy 

PRODUCTS ON MARKET: Digital microscope cameras: MicroFire color & Monochrome, MacroFire 

Color & Momochrom, QuantiFire 

Microscope video cameras 

PictureFrame 

Digital Video Medical Recorders (DVMR) 

Cables and accessories 

Organo Corp. 

2-8, Shinsuna 1-chome, Koto-ku 

Tokyo 136, Japan 

Phone: +81 3-5635-5100; Fax: +81 3-3699-7030 


Web: www.organo.co.jp; E-mail: post-org@organo.co.jp 

KEY PERSONNEL: Masahiko Denda; Chairman 

Kiyoshi Hashimoto; President, CEO and COO 


HISTORY: Founded in 1946 as a pioneer in water and wastewater treatment 


Formerly named Japan Organo Co. Ltd. 

FACILITIES: Factories in Satte, Tukuba, Nagasaki and Iwaki 

Offices in Shanghai and Hongo 

Branch offices in Sappro, Sendai, Nagoya, Osaka, Hiroshima, Fukuoka and 

Taiwan 

STOCK-FINANCIAL HISTORY: Traded on the Tokyo Stock Exchange 


Net profit ¥2.090b (YE 05) compared to ¥1.803b (YE 04) 

SUBSIDIARIES/DIVISIONS: Hokkaido Organo Shoji Co. Ltd. 

Tohoku Organo Shoji Co. Ltd. 

Tokyo Organo Shoji Co. Ltd. 

Chubu Organo Shoji Co. Ltd. 

Kansai Organo Shoji Co. Ltd. 

Kyushu Organo Shoji Co. Ltd. 

Organo Plant Service Corp. 

Organo Acty Co. Ltd. 

Organo High Tech Co. Ltd. 

Danisco Organo Food Tech Co. Ltd. 

Eco-Techno Corp. 

Organo (Asia) Sdn. Bhd. 

Organo (Asia) Sdn. Bhd. (Penang branch) 

Organo (Asia) Sdn. Bhd. (Kulim branch) 

Organo (Singapore) Pte. Ltd. 

Organo (Thailand) Co. Ltd. 

Ortech Chemical Co. Ltd. 

Organo (UK) Ltd. 

PT.Organo Indonesia 

PT.Organo Indonesia (Surabaya office) 

Organo (Philippines) Inc. 

Organo (Shanghai) Water Treatment Co. Ltd. 

Organo (Shanghai) Water Treatment Co. Ltd. (Guangzhou office) 

Organo (Suzhou) Water Treatment Co. Ltd. 



PRINCIPAL INVESTORS: Tosoh Corp.--$16M 


Bioremediation 

Technology 

R&D agreement 

Biosensor R&D agreement 

PRODUCTS ON MARKET: Water treatment equipment: Water softeners, water deionizers, Uultrapure 

water systems, condensate filters and demineralizers, multi-functional water 

systems, sterile purified water systems, distilled water production 

equipment, sea water desalination systems and high-speed filtration 

equipment 

Municipal water works and sewage water treatment: 

Coagulation/sedimentation equipment, high-rate filters, activated carbon 

filters, membrane-type water purifiers, advanced water treatment, sewage 

treatment facilities, deodorizing systems, pumping facilities, sludge treating 

facilities, sewage waste water reclamation 

Environment-related equipment: Industrial wastewater treatment equipment, 

treatment systems for power station wastewater, recovery and recycling 

equipment for industrial wastewater, dual piping water facilities, domestic 

wastewater treatment equipment, denitrification and dephosphorization 

systems, Closed systems for semiconductor factories, wastewater treatment 

equipment for cleaning facility, treatment facility for drainage, agricultural 

chemicals removal equipment for golf links 

Soil remediation systems: Ground water treatment facilities, off-gas 

treatment equipment, soil contamination survey system, soil vapor 

purification system, bioremediation system 

Separation and refining equipment: Decolorization and refining system for 

sugars solution, refining and concentration equipment, chromatographic 

separation system 

Small-scale standard equipment: Water deionizer series, water softener 

series, filter series, ultrapure water production equipment, sub-systems, 

small-sized supercritical water oxidation equipment, various types of filters, 

homogenizers, distillation stills, various types of water quality analyzers 

Water treatment chemicals: Boiler water treatment chemicals, cooling water 

treatment chemicals, cleaning and rinsing chemicals, wastewater treatment 

chemicals, drinking water treatment chemicals, chemicals feeding 

equipment, sanitation chemicals, HACCP-related equipment 

Analysis business: Ultra-microanalysis of ultrapure water and evaluation, 

analysis of harmful substances in water, soil, and waste materials, general 

analysis 

Waste disposal facilities and equipment 

Food processing materials and food additives 




40 Hobron Avenue 

Kahului HI 96732, US 

Phone: (808) 877-3144; Fax: (808) 877-5030 

Web: www.biodiesel.com 

E-mail: info@biodiesel.com 

KEY PERSONNEL: Robert King; President 

Kelly Takaya King; VP, Communications and Marketing 

William Smith; Production Technology 

Amanda Stewart; Production Technology 


FACILITIES: Two Hawaii biodiesel processing plants; Oregon plant; Texas plant 


SUBSIDIARIES/DIVISIONS: Maui Plant 

Central Maui Sanitary Landfill 

Pulehu Road 

Kahului, Hawaii 

Contact Maui Office: (808) 877-3144 

Oahu Biofuels Facility 

Honolulu, Hawaii 

George Aiwohi, Hawaii Operations Manager 

BUSINESS STRATEGY: Maintain a position as a leader in the production of biodiesel fuel that is 

derived from waste oils and grease as well as virgin crop oil, in order to 

minimize the environmental impact of such waste materials and optimize the 

conservation of traditonal fuel sources; promote community-based biodiesel 

production that utilizes local resources and distributes product locally 

RESEARCH & DEVELOPMENT: Conversion of discarded cooking oil and grease trap oil into biofuels; 

processing of virgin crop oil into biodiesel; minimizing wastestream; ongoing 

improvements in process technology and quality control protocol 

PRODUCTS ON MARKET: Biodiesel - renewable fuel produced in Hawaii, made from recycled cooking 

oil and used in commercial diesel fleets, private vehicles, farm equipment, 

generators and marine vessels 

Biofuel--vegetable oil burner fuel, made from waste grease trap oil 

Biodiesel processing plants (technology, process and construction) 


P.O. Box 999 

Richland WA 99352, US 

Phone: (509) 375-2121 

Toll-free phone: (888) 375-PNNL 

Web: www.pnl.gov 

E-mail: inquiry@pnl.gov 

KEY PERSONNEL: Dr. Leonard K. Peters; Director 

Dr. David W. Koppenaal; Chief Research Officer (interim) 

Dr. Donald M. Boyd; Deputy Laboratory Director for Operations 

EMPLOYEES: 4,200 employees, 892 Ph.D.s 




FACILITIES: 495,623 sq. ft. of active laboratory space 


SUBSIDIARIES/DIVISIONS: Environmental Molecular Sciences Laboratory 

Marine Sciences Laboratory 

BUSINESS STRATEGY: VISION: To be recognized worldwide and valued regionally for leadership in 

rapidly translating discoveries into solutions. . . for challenges in energy, 

national security and the environment. . .by integrating the chemical, 

physical and biological sciences 

MISSION: Perform basic and applied research to deliver energy, 

environmental and national security for the nation 


Micell 

Technologies 

use of supercritical 

fluids for the creation of 

medical device surface 

modifications 

RESEARCH & DEVELOPMENT: More than 100 ongoing R&D projects annually 

Pall Corp. 

2200 Northern Boulevard 

East Hills NY 11548-1248, US 

Phone: (516) 484-5400; Fax: (516) 484-5228 


Web: www.pall.com; E-mail: info@pall.com 

research and 

licensing 


expanded 8/06 

KEY PERSONNEL: Eric Krasnoff; Chairman and CEO 

Marc Wilson; President 

Lisa McDermott; CFO 

Donald Stevens; COO and President, Pall Industrial 

Steven Chisholm; Sr. VP and President, Microelectronics Group 

Roberto Perez; Sr. VP and President, Pall Life Sciences 

Jim Western; Sr. VP and President, Aerospace Group 



Acquired Gelman Sciences (2/97) 

Acquired Rochem Environmental (1/98) 

Acquired the Filtration and Separations Group (2002) 

Acquired BioSerpa process chromatography business from Ciphergen 

Biosystems Inc. (11/04) 

FACILITIES: Offices and plants throughout the world 

STOCK-FINANCIAL HISTORY: NYSE—Pll 


Net income $140.8M (YE 05) compared to $1.121/share (YE 04) 

Total assets $2.265b (YE 05) compared to $2.183 (YE 04) 

SUBSIDIARIES/DIVISIONS: Life Sciences business—Medical, Biopharmaceuticals, Laboratory 

Industrial business—General Industrial, Aerospace and Microelectronics, 

Food & Beverage 

BUSINESS STRATEGY: Pursue Growth through aggressive R&D approach that advances company’s 

products and creates niche applications across many markets, industries 

and geographies 

PRODUCTS ON MARKET: Filtration, separation and purification systems for total fluid management in 

the industrial and life sciences markets 


Paprican 


570 Boulevard St. Jean 

Pointe-Claire H9R 3J9, Canada 

Phone: (514) 630-4101; Fax: (514) 630-4134 

Toll-free phone: (888) PAPRICAN 

Web: www.paprican.ca 

E-mail: info@paprican.ca 

KEY PERSONNEL: Frank Dottori; Chairman 

Joseph Wright; President and CEO 

Dave McDonald; VP, Research and Education 

Lucie Lapointe; VP, Administration 

Richard Berry; Program Manager, Chemical Pulping 

Brian O'Connor; Program Manager, Environment 

Tom Browne; Program Manager, Mechanical Pulping and Sustainability 

Ivan Pikulik; Program Manager, Papermaking 

Maurice Douek; Program Manager, Analytical Services and Standards 

Christian Thompson; Program Manager, Engineering Development 

Jean Hamel; Program Manager, Product Performance 

Paul Watson; Program Manager, Fibre Supply and Quality 




FACILITIES: Headquarters in Pointe-Claire, PQ, Canada 

Laboratories in Quebec and British Columbia 

STOCK-FINANCIAL HISTORY: Non-profit agency 

SUBSIDIARIES/DIVISIONS: Vancouver: 

3800 Wesbrook Mall 

Vancouver BC, V6S 2L9 

Canada 

Phone: (604) 222-3201 

Fax: (604) 222-3207 

Paprican Prince George: 

P.O. Box 21018 

Pulp Mill Road 

Prince George, BC V2N 7A5 

Canada 

Phone: (250) 561-3991 

Fax: (250) 561-4412 

BUSINESS STRATEGY: Paprican, the Pulp and Paper Research Institute of Canada, provides 

valuable technology transfer and cost-competitive research addressing both 

the short-term and strategic needs of its members 


University 

collaborations with 

McGill University, 

the University of 

British Columbia 

and Ecole 

Polytechnique de 

Montreal 

RESEARCH & DEVELOPMENT: Consortium research: 

-Fibre Supply and Quality: Capturing more value from fibre resources and 

enhancing performance of market pulps 

-Chemical Pulping: Producing superior kraft pulps and the next generation of 

bleaching technologies 




-Mechanical Pulping: Developing the next generation of superiorperformance 

thermomechanical pulps 

-Papermaking: Improving wet-end chemistry, designing and developing 

highly-filled printing papers 

-Product Performance: Delivering state-of-the-art end use properties from 

advances in surfaces, coatings and web structures 

-Sustainability and Environment: Minimizing environmental impact, reducing 

total emissions,optimizing energy efficiencies in response to climate change 

and economic drivers 

Multiclient projects: Minimizing linting in mechanical printing grades, 

optimization of the use of hardwood pulp, recycling, chemimechanical pulps, 

mechanical pulp bleaching, sulphite pulping and packaging 

9960 - 67 Ave., N.W. 

Edmonton T6E OP5, Canada 

Phone: (780) 450-3957; Fax: (780) 450-3960 


Web: www.pbr.ca 

E-mail: pbr@pbr.ca 

KEY PERSONNEL: Dr. Ram D. Mehta; Chairman, President, and CEO 

Dr. Ram K. Bishnoi; Director, Lab Operations 




FACILITIES: 6,000 sq. ft. laboratory and office space 


BUSINESS STRATEGY: Become a leading provider of contract research and bioanalytical services to 

environmental, chemical, and human health industries, and to develop 

innovative technologies and products 

RESEARCH & DEVELOPMENT: Focus is on the development of diagnostic kits and test methods for rapid 

detection of environmental toxins and pathogenic bacteria and fungi 

PRODUCTS ON MARKET: Genetic and cellular toxicology testing services, environmental toxicology 

testing, food and water microbiological analysis, product safety and efficacy 

evaluation, and microbial strains for biodegradation 

Fast assays for freshwater algal toxins and shellfish toxins 

Indoor air quality monitor for mold and bacterial (including endotoxin) 

contamination 

PCI Membranes 

Jays Close, Viables Estate 

Basingstoke RG22 4BA, UK 

Phone: +44 1256 303800; Fax: +44 1256 303801 

Web: www.pcimem.com 

E-mail: aquious@itt.com 

KEY PERSONNEL: Mike Hughes; General Manager 

Alan Merry; Technical Director 

Martin Peer; Sr. Scientist 

John Hughes; Purchasing Manager 




FACILITIES: R&D, system building and tubular membrane manufacturing facility 


SUBSIDIARIES/DIVISIONS: PCI Membrane Systems Inc. 

1615 State Route 131 

Milford, OH 45150 

Phone: (513) 575-3500 

Fax: (513) 575-7393 

www.pcims.com 

SUBSIDIARY OF: ITT Corporation Inc. 

RESEARCH & DEVELOPMENT: Specific application separation studies 

PRODUCTS ON MARKET: Membrane separation products and systems 


Engelgasse 109 


Phone: +41 61 7064848; Fax: +41 61 3199619 

Web: www.pentapharm.com 

E-mail: pentapharm@pentapharm.com 

KEY PERSONNEL: Caspar V. Sturm; CEO 

Thomas Grieder; CFO 

Dr. Eric J.M. Meier; Head, Quality Management 

Markus K. Luthy; Director, Sales and Marketing 

Christian Witzig; Head, Production 

Dr. Thomas Schreier; Head, R&D 



FACILITIES: Headquarters in Basel, Switzerland 

Snake venom facilities in Brazil and Bolivia 


SUBSIDIARIES/DIVISIONS: Pentapharm do Brasil Ltda. 

Pentapharm en Bolivia 

RESEARCH & DEVELOPMENT: Extraction of active ingredients from natural sources 

Purification and characterization of snake venom enzymes 

Synthesis of small peptides and peptide like substances 

Biotechnological manufacturing of active ingredients 

PRODUCTS ON MARKET: Pefakit® 

Defibrase® 

Pefachrome® 

Pefabloc® 

Protac® 

Botrocetin® 

Prionex® 




Princeton Business Park, 5 Crescent Ave., P.O. Box 275 

Rocky Hill NJ 08553-0275, US 

Phone: (609) 497-0253; Fax: (609) 497-0321 


Web: www.peprotech.com; E-mail: info@peprotech.com 

KEY PERSONNEL: Irwin Libeskind; VP, Worldwide Marketing 




SUBSIDIARIES/DIVISIONS: PeproTech EC Ltd. 

PeproTech House 

29 Margravine Road 

London W6 8LL UK 

Phone: (0)20 7610 3055; Fax: (0)20 7610 3430 

E-mail: info@peprotech.co.uk; Web site: www.peprotechec.com 

CytoLab Ltd. 

12 Hamada Street Biet Tamar 

Entrance A, 2nd floor 

Rehovot, Israel 

Phone: +972 (0) 8 946 0948 

Fax: +972 (0) 8 946 0861 

E-mail: info@cytolab.com 

Web site: www.cytolab.com 

Peprotech Mexico SA dec V 

Montecito 38, Piso 30 Oficina 27 

Colonia Napoles CP 03810 

Mexico 

Phone: +52-55-9000-35-62 

Fax: +52-55-9000-35-64 

E-mail: pepromex@prodigy.net.mx 

PeproTech Brazil FUNPEC 

Av. Presidente Vargas 2627 

14020-260 Ribeirao Preto 

Brazil 

Phone: +55 (16) 620 1251 

Fax: +55 (16) 621 1991 

E-mail: funpecrp@uol.com.br 

Web site: www.funpecrp.com.br 

BUSINESS STRATEGY: Develop and manufacture cytokines, chemokines, neurotrophic factors, 

growth factors, and paired monoclonal and polyclonal antibodies 

RESEARCH & DEVELOPMENT: The company has developed high yield, low cost methods for the 

commercial production of over 300 recombinant cytokines and related 

antibodies 

PRODUCTS ON MARKET: Human growth factors and cytokines 

Human, murine and rat chemokines 

Murine and rat growth factors and cytokines 

Human and rat neurotrophins 

Additional recombinant proteins 

Monoclonal antibodies 

Antigen-affinity purified polyclonal antibodies 

Biotinylated polyclonal antibodies 

ELISA development kits 





11621 Electron Drive 

Louisville KY 40299, US 

Phone: (502) 266-8787; Fax: (502) 267-1329 


Web: www.pepnet.com 

E-mail: peptides@pepnet.com 

Jackie B. Spatola; Chair 

Dr. Bryce V. Johnson; CEO and President 

Krzysztof Darlak, Ph.D.; Director, Research 

DeAnna Wiegandt Long, Ph.D.; Director, Sales and Marketing 

Miroslawa Darlak; Quality Control Manager 



FACILITIES: R&D, manufacturing and distribution facilities 


BUSINESS STRATEGY: Focus on proprietary products 

Expand upon success in high quality/purity custom synthesis market 

Develop strategic joint ventures 


University of Cyclic peptide libraries exclusive licensing 2004 

Louisville 

agreement 

University of Clear resin solid exclusive licensing 1997 

Minnesota supports 

agreement 

RESEARCH & DEVELOPMENT: Novel amino acids 

Peptide backbone modifications 

Peptide mimetics 

Peptide and pseudopeptide libraries 

New resins for solid phase synthesis 

Solid supports for solid phase synthesis 

PRODUCTS ON MARKET: Resins: Clear and Clear-OX; mini-Peg Linkers; TAPI inhibitors, 

Urantide and other various biologically active peptides, enzyme inhibitors, 

substrates and peptide-related products for research purposes, 

combinatorial chemistry reagents and supplies 


2-4 Cromwell Business Centre, Howard Way, Interchange Park 

NewPort MK16 9QS, UK 

Phone: +44 1908 500600; Fax: +44 1908 500601 

Web: www.pfeiffer-vacuum.co.uk 

E-mail: info@pfeiffer-vacuum.de 

KEY PERSONNEL: Wolfgang Dondorf; CEO 

Manfred Bender; CFO 

Peter Knight; GM 

Rob Vaughan; Manager, IT and QA 

Jackie Williamson; Accounts Administrator 

Susan Dixon; Company Secretary 



Changed name from Balzers Pfeiffer (1/96) 



STOCK-FINANCIAL HISTORY: Parent company: NYSE--PV 

SUBSIDIARY OF: Pfeiffer Vacuum Technology AG 

PRODUCTS ON MARKET: Prisma 

Omnistar 

Thermostar 

Mass spectrometers 

Vacuum pumps and gauges 

Pfizer Inc. 

235 East 42nd Street 

New York NY 10017-5755, US 

Phone: (212) 573-2323; Fax: (212) 573-7851 

Web: www.pfizer.com 

E-mail: info@pfizer.com 

KEY PERSONNEL: Henry (Hank) A. McKinnell, Ph.D.; Chairman 

Jeffrey B. Kindler; CEO 

John LaMattina, Ph.D.; President, Pfizer Global Research and Development 

Ian Read; President, Worldwide Pharmaceuticals Operations 

Joe Feczko, M.D.; CMO 

Sylvia Montero; Head, Worldwide Talent Development and Human 

Resources 

Allen Waxman; General Counsel 

Rich Bagger; Head, Worldwide Public Affairs and Policy 




Signed letter of intent to sell food science group to Cultor Ltd. (11/95) 

Acquired Warner-Lambert Co. (6/00) 

Acquired Agouron Pharmaceuticals Inc. (2000) 

Merged with Pharmacia Corp. (4/03) 

Acquired Esperion Therapeutics (2/04) 

Acquired Meridica Ltd. (11/04) 

Acquired Angiosyn Inc. (4/05) 

Acquired Idun Pharmaceuticals Inc. (4/05) 

Acquired Bioren Inc. (8/05) 

Acquired Vicuron Pharmaceuticals Inc. (9/05) 

Acquired worldwide rights to Exubera from Sanofi-Aventis (3/06) 

Acquired Rinat Neuroscience Corp. (6/06) 

Acquire exclusive worldwide rights to fesoterodine from Schwarz Pharma 

AG (6/06) 

To sell its Pfizer Consumer Healthcare (PCH) business to Johnson & 

Johnson (as of 6/06) 

FACILITIES: Corporate headquarters: New York, N.Y. 

Research & Development: Groton and New London, Conn.; Sandwich, 

England; Ann Arbor and Kalamazoo, Mich.; St. Louis, Mo.; La Jolla, Calif.; 

Cambridge, Mass,; and Nagoya and Tokyo, Japan 

Veterinary medicine research and development operations in Henrietta and 

Richland Township, Mich.; Lincoln, Neb.; Sandwich, England; and 

Melbourne, Australia 

Consumer Health Care: Morris Plains, N.J. 



STOCK-FINANCIAL HISTORY: NYSE--PFE / London--PFZ 

Also listed on Euronext and Swiss stock exchanges 






Average shares outstanding 7.361b (YE 05) compared to 7.531b (YE 04) 

SUBSIDIARIES/DIVISIONS: Three business segments: Human Health, Consumer Healthcare and 

Animal Health 

Other businesses: Manufacture of empty soft-gelatin capsules, contract 

manufacturing and bulk pharmaceutical chemicals 

Subsidiaries: 

412357 Ontario Inc--Canada 

A S Ruffel (Mozambique) Limitada 

A.S. Ruffel (Private) Ltd.--Zimbabwe 

A/O Pfizer--Russia 

ACO AB--Sweden 

Adenylchemie GmbH--Germany 

Agouron Pharmaceuticals Inc.--California 

Alginate Industries (Ireland) Ltd. 

American Food Industries Inc.--Delaware 

Amicore Inc.--Delaware 

Andean Services SA--Colombia 

Angiosyn Inc.--Delaware 

Backsvalan 6 Handelsbolag--Sweden 

Balverda SRL--Italy 

Bharti Healthcare Ltd.--India 

BINESA 2002 SL--Spain 

Biocor Animal Health Inc.--Delaware 

Bioindustria Farmaceutici SRL--Italy 

Bioptics SARL--France 

Bioren Inc.--Delaware 

Biosearch Manufacturing Srl--Italy 

C.P. Pharmaceuticals International CV--Netherlands 

Capsugel (Thailand) Co. Ltd.--Thailand 

Capsugel AG--Switzerland 

Capsugel Belgium BVBA--Belgium 

Capsugel France 

Capsugel Japan Inc. (KK) 

Capsugel Ploermel--France 

CARDEL--France 

Carlo Erba OTC SpA--Italy 

Centrofarma, Sociedad Anonima--Guatemala 

Ceuticlab Laboratorios de Produtos Farmaceuticos Lda.--Portugal 

Charlie Papa Operations LLC--New Jersey 

CHC Direct LLC--Delaware 

Compania Farmaceutica Upjohn SA--Guatemala 

Consumer Health Products (Minority Interests) Co.--U.K. 

Continental Farmaceutica SL--Spain 

Continental Pharma Inc.--Delaware 

Corporacion Pharmacia de Mexico S de RL de CV--Mexico 

CPPI/CV Six (Gibraltar) Ltd. 

Davis Medica, Sociedad Limitada, Sociedad Unipersonal--Spain 

Diabel GmbH & Co. KG--Germany 

Distribuidora Mercantil Centro Americana SA--Delaware 

Duchem Laboratories Ltd.--India 

Esperion AB--Sweden 

Esperion LUV Development Inc.--Delaware 

Esperion Therapeutics Inc.--Delaware 

Euronett Inc.--Delaware 

Eversharp Canada Inc.--Canada 

Exchic CA Ltd.--Bermuda 



Farminova Produtos Farmaceuticos de Inovacao Lda.--Portugal 

Farmitalia Carlo Erba Ltd.--U.K. 

Farmogene Productos Farmaceuticos Lda.--Portugal 

Fyrcia HB--Sweden 

G. D. Searle & Co. Ltd.--U.K. 

G. D. Searle (Philippines) Inc. 

G. D. Searle (Thailand) Ltd.--Thailand 

G. D. Searle International Capital LLC--Delaware 

G. D. Searle Land Corp.--Philippines 

G. D. Searle LLC--Delaware 

G. D. Searle South Africa Pty. Ltd.--South Africa 

Godecke GmbH--Germany 

Godecke OTC Beteiligungs GmbH--Germany 

Greenstone Ltd.--Delaware 

Heinrich Mack Nachf. GmbH. & Co. KG--Germany 

Heumann Beteiligungs GmbH--Germany 

Heumann PCS GmbH--Germany 

Idun Pharmaceuticals Inc.--Delaware 

International Affiliated Corp. LLC--Delaware 

Inter-World Insurance Co. Ltd.--Bermuda 

Invicta Farma SA--Spain 

Island Pharmaceuticals Ltd.--Ireland 

J B Tillott Ltd.--U.K. 

Jouveinal Holland BV--Netherlands 

Kenfarma SA--Spain 

Keystone Chemurgic Corp.--Delaware 

Kiinteisto Oy Helsingin Tietokuja--Finland 

Kommanditbolaget Hus Gron--Sweden 

Korea Pharma Holding Co. Ltd.--Hong Kong 

Laboratoires Pfizer SA--Morocco 

Laboratorios Laprofa, Sociedad Anonima--Guatemala 

Laboratorios Parke Davis SL--Spain 

Laboratorios Pfizer de Chile 

Laboratorios Pfizer Ltda.--Brazil 

Laboratórios Pfizer Lda.--Portugal 

Laboratorios Visine SL--Spain 

Lambert Chemical Co. Ltd.--U.K. 

Losbanos Ltd.--Ireland 

Lothian Developments V SPRL--Belgium 

MED Urological Inc.--Minnesota 

Meridica Ltd.--U.K. 

Monterey Kelp Corp.--California 

MTG Divestitures Handels GmbH--Austria 

MTG Divestitures Ltd.--U.K. 

MTG Divestitures LLC--Delaware 

Nefox Farma SA--Spain 

Nostrum Farma SA--Spain 

NPF YK--Japan 

O.C.T. (Thailand) Ltd. 

Omni Laboratories Inc.--Canada 

Orsim--France 

P&UFSC Inc.--Virgin Islands 

PanServ Personalberatungs- und Anzeigenservice GmbH--Germany 

Paris Montrouge II BV--Netherlands 

Paris Montrouge II SARL--France 

Parke Davis & Co. Ltd.--Isle of Jersey 

Parke Davis Del Ecuador CA--Ecuador 

Parke Davis European Distributors Ltd.--Ireland 

Parke Davis International Ltd.--Bahamas 

Parke Davis Productos Farmaceuticos Lda.--Portugal 

Parke Davis Pty. Ltd.--Australia 

Parke, Davis & Co. Ltd.--Pakistan 

Parke, Davis & Co. LLC--Michigan 

Parke-Davis GmbH--Germany 

Parke-Davis Manufacturing Corp.--Delaware 



Parke-Davis Sales Corp.--Virgin Islands 

P-D Co. Inc.--Delaware 

Pfidev3 SAS--France 

Pfidev4 SAS--France 

Pfizer (China) Research and Development Co. Ltd. 

Pfizer (Malaysia) Sdn Bhd--Malaysia 

Pfizer (Perth) Pty. Ltd.--Australia 

Pfizer SAS--France 

Pfizer (Thailand) Ltd. 

Pfizer AG--Switzerland 

Pfizer A/S--Norway 

Pfizer AB--Sweden 

Pfizer Africa & Middle East for Pharmaceuticals, Animal Health & Chemicals 

SAE--Egypt 

Pfizer Afrique de L'Ouest--Senegal 

Pfizer Algerie Sante et Nutrition Animale spa--Algeria 

Pfizer Animal Health BV--Netherlands 

Pfizer Animal Health Korea Ltd.--South Korea 

Pfizer Animal Health SA--Belgium 

Pfizer Antilles Holdings NV--Netherlands Antilles 

Pfizer ApS--Denmark 

Pfizer Asia Holdings BV--Netherlands 

Pfizer Asia Pacific Pte. Ltd.--Singapore 

Pfizer Australia Holdings Pty. Ltd.--Australia 

Pfizer Australia Pty. Ltd.--Australia 

Pfizer Australia Superannuation Pty. Ltd.--Australia 

Pfizer BV--Netherlands 

Pfizer Beteiligungs GmbH--Germany 

Pfizer Canada Inc.--Canada 

Pfizer Caribe Ltd.--Guernsey 

Pfizer Century Holdings--Ireland 

Pfizer CHC GmbH--Germany 

Pfizer Chile SA--Chile 

Pfizer Cia. Ltda.--Ecuador 

Pfizer Consumer Health Care Mexico S de RL de CV--Mexico 

Pfizer Consumer Health Products Co.--U.K. 

Pfizer Consumer Healthcare--U.K. 

Pfizer Consumer Healthcare BV--Netherlands 

Pfizer Consumer Healthcare Comm.VA--Belgium 

Pfizer Consumer Healthcare GmbH--Germany 

Pfizer Consumer Healthcare Ireland 

Pfizer Consumer Healthcare S.Com.p.A--Spain 

Pfizer Consumer Healthcare Srl--Italy 

Pfizer Consumer Inc.--Japan 

Pfizer Convention III LLC--Delaware 

Pfizer Convention IV LLC--Delaware 

Pfizer Co-Promotions Ltd.--Isle of Jersey 

Pfizer Cork Ltd.--Ireland 

Pfizer Corp.--Panama 

Pfizer Corp. Austria Gesellschaft mbH--Austria 

Pfizer Corp. Hong Kong Ltd.--Hong Kong 

Pfizer Croatia d.o.o.--Croatia 

Pfizer Deutschland GmbH 

Pfizer Distribution Co.--Ireland 

Pfizer Distribution Services--Belgium 

Pfizer Domestic Ventures Ltd.--Isle of Jersey 

Pfizer Dominicana SA--Dominican Republic 

Pfizer Dublin Ltd.--Ireland 

Pfizer Egypt SAE--Egypt 

Pfizer Enterprises Inc.--Delaware 

Pfizer Enterprises SARL--Luxembourg 

Pfizer Esbjerg A/S--Denmark 

Pfizer ESP Pty. Ltd.--Australia 

Pfizer Europe MA EEIG--U.K. 

Pfizer European Service Center BVBA--Belgium 



Pfizer Export AB--Sweden 

Pfizer Export Co.--Ireland 

Pfizer Finance GmbH & Co. KG--Germany 

Pfizer Finance International Ltd.--Ireland 

Pfizer Finance Verwaltungs GmbH--Germany 

Pfizer Financial Services NV/SA--Belgium 

Pfizer Fundings International--Ireland 

Pfizer Global Holdings BV--Netherlands 

Pfizer Global Supply--Ireland 

Pfizer Global Trading--Ireland 

Pfizer GmbH--Germany 

Pfizer Group Ltd.--U.K. 

Pfizer H.C.P. Corp.--New York 

Pfizer Health AB--Sweden 

Pfizer Health Solutions Inc.--Delaware 

Pfizer Healthcare Ireland 

Pfizer Hellas AE--Greece 

Pfizer HK Service Co. Ltd.--Hong Kong 

Pfizer Holding France SCA--France 

Pfizer Holding Italy SpA 

Pfizer Holding und Verwaltungs GmbH--Germany 

Pfizer Holding Ventures--Ireland 

Pfizer Holdings BV--Netherlands 

Pfizer Holdings Europe--Ireland 

Pfizer Holdings International Luxembourg (PHIL) Sarl 

Pfizer Holdings Ireland 

Pfizer Holdings Mexico S de RL de CV 

Pfizer Holdings Netherlands BV 

Pfizer Holdings Turkey Ltd.--Isle of Jersey 

Pfizer Holland Pharmaceuticals BV--Netherlands 

Pfizer Hungary Asset Management LLC 

Pfizer Ilaclari Ltd. Sirketi--Turkey 

Pfizer International Bank Europe--Ireland 

Pfizer International Corp.--Panama 

Pfizer International Holdings Ltd.--Ireland 

Pfizer International LLC--New York 

Pfizer International Luxembourg SA 

Pfizer International Portfolio Investments--Ireland 

Pfizer Inventory Co.--Delaware 

Pfizer Investment Capital--Ireland 

Pfizer Investment Co. Ltd.--China 

Pfizer Ireland Pharmaceuticals 

Pfizer Ireland Ventures 

Pfizer Italia Srl--Italy 

Pfizer Japan Inc. 

Pfizer Jersey Capital Ltd.--Isle of Jersey 

Pfizer Jersey Co. Ltd.--Isle of Jersey 

Pfizer Jersey Finance Ltd.--Isle of Jersey 

Pfizer Laboratories (Pty.) Ltd.--South Africa 

Pfizer Laboratories Ltd.--Kenya 

Pfizer Laboratories Ltd.--Pakistan 

Pfizer Ltda.--Angola 

Pfizer Ltd.--Tanzania 

Pfizer Ltd.--Thailand 

Pfizer Ltd.--Uganda 

Pfizer Ltd.--U.K. 

Pfizer Ltd. (Taiwan) 

Pfizer Luxco Holdings Sarl--Luxembourg 

Pfizer Luxco Production SARL--Luxembourg 

Pfizer Luxembourg SARL 

Pfizer Manufacturing Belgium NV 

Pfizer Manufacturing LLC--Delaware 

Pfizer Manufacturing Services--Ireland 

Pfizer Medical Technology Group (Belgium) NV 

Pfizer Medical Technology Group (Netherlands) BV 



Pfizer Medical Technology Group Ltd.--U.K. 

Pfizer Middle East--Egypt 

Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals SAE-- 

Egypt 

Pfizer Namibia (Proprietary) Ltd. 

Pfizer New Zealand Ltd. 

Pfizer Overseas Pharmaceuticals--Ireland 

Pfizer Overseas Inc.--Delaware 

Pfizer Oy--Finland 

Pfizer Participations SARL--Luxembourg 

Pfizer Pension Trustees (Ireland) Ltd. 

Pfizer Pension Trustees Ltd.--U.K. 

Pfizer PGM SAS--France 

Pfizer PGRD SAS--France 

Pfizer Pharm Algerie 

Pfizer Pharma GmbH--Germany 

Pfizer Pharma Trade LLC--Egypt 

Pfizer Pharmaceutical (Wuxi) Co. Ltd.--China 

Pfizer Pharmaceutical India Pvt. Ltd. 

Pfizer Pharmaceutical Trading Ltd. Liability Co. (Pfizer Kft. or Pfizer LLC)-- 

Hungary 

Pfizer Pharmaceuticals BV--Netherlands 

Pfizer Pharmaceuticals Israel Ltd. 

Pfizer Pharmaceuticals Jersey Ltd.--Isle of Jersey 

Pfizer Pharmaceuticals Korea Ltd.--South Korea 

Pfizer Pharmaceuticals Ltd.--Cayman Island 

Pfizer Pharmaceuticals LLC--Delaware 

Pfizer Pharmaceuticals Ltd.--China 

Pfizer Pharmaceuticals Tunisie Sarl 

Pfizer Pharmaceuticals Inc.--Delaware 

Pfizer Pigments Inc.--Delaware 

Pfizer Polska Sp. z.o.o.--Poland 

Pfizer Precision Holdings SARL--Luxembourg 

Pfizer Pvt. Ltd.--Malaysia 

Pfizer Pvt. Ltd.--Singapore 

Pfizer Production LLC--Delaware 

Pfizer Products Inc.--Connecticut 

Pfizer Products India Pvt. Ltd.--India 

Pfizer Romania SRL 

Pfizer SA--Colombia 

Pfizer SA--Peru 

Pfizer SGPS Lda.--Portugal 

Pfizer SRL--Argentina 

Pfizer SA (Belgium) 

Pfizer Saidal Manufacturing--Algeria 

Pfizer Sante Grand Public (SCA)--France 

Pfizer Science and Technology Ireland Ltd. 

Pfizer Service Company BVBA--Belgium 

Pfizer Service Co. Ireland 

Pfizer Services 1 (SNC)--France 

Pfizer Services 2 (SNC)--France 

Pfizer Services LLC--Delaware 

Pfizer Servicios de Mexico SA de CV 

Pfizer Shared Services--Ireland 

Pfizer Shareholdings Intermediate SARL--Luxembourg 

Pfizer Singapore Trading Pte. Ltd. 

Pfizer Specialties Ltd.--Nigeria 

Pfizer SPOL s.r.o.--Czech Republic 

Pfizer Sterling Investments Ltd.--Isle of Jersey 

Pfizer Suzhou Animal Health Products Co. Ltd.--China 

Pfizer Technologies Ltd.--U.K. 

Pfizer Trading Polska sp.z.o.o.--Poland 

Pfizer Tunisie SA 

Pfizer UK Group Ltd.--U.K. 

Pfizer Venezuela SA--Venezuela 



Pfizer Ventures Ltd.--Isle of Jersey 

Pfizer Warner Lambert Luxembourg SARL 

Pfizer Zona Franca SA--Costa Rica 

Pfizer Inc.--Philippines 

Pfizer SA--Costa Rica 

Pfizer SA (Pfizer Pharmaceutical)--Spain 

Pfizer SA de CV--Mexico 

Pharmacia & Upjohn AG--Switzerland 

Pharmacia & Upjohn Cambridge Ltd.--U.K. 

Pharmacia & Upjohn Co. LLC--Delaware 

Pharmacia & Upjohn Holding Co.--Delaware 

Pharmacia & Upjohn LLC--Delaware 

Pharmacia & Upjohn Management Co. Ltd--U.K. 

Pharmacia & Upjohn SpA--Italy 

Pharmacia & Upjohn Trading Corp.--Michigan 

Pharmacia & Upjohn SA de CV--Mexico 

Pharmacia (South Africa) (Pty.) Ltd. 

Pharmacia Africa Ltd.--U.K. 

Pharmacia Animal Health AB--Sweden 

Pharmacia Animal Health Ltd.--U.K. 

Pharmacia Asia Ltd.--Hong Kong 

Pharmacia Australia Pty. Ltd. 

Pharmacia BV--Netherlands 

Pharmacia Brasil Ltda. 

Pharmacia Corp.--Delaware 

Pharmacia de Centroamerica SA--Panama 

Pharmacia de Centroamerica Sociedad Anonima--Guatemala 

Pharmacia de Mexico SA de CV--Mexico 

Pharmacia Diagnostics Verwaltungs GmbH--Germany 

Pharmacia Enterprises Sarl--Switzerland 

Pharmacia Europe EEIG--U.K. 

Pharmacia GmbH--Germany 

Pharmacia Grupo Pfizer SL--Spain 

Pharmacia Hepar Inc.--Delaware 

Pharmacia Holding AB--Sweden 

Pharmacia Ilac Sanayi ve Ticaret Ltd.--Turkey 

Pharmacia Industrifastigheter AB--Sweden 

Pharmacia Inter-American LLC--Michigan 

Pharmacia International BV--Netherlands 

Pharmacia International Inc.--South Dakota 

Pharmacia International SARL--Switzerland 

Pharmacia International Trading (Shanghai) Ltd. 

Pharmacia Ireland Ltd. 

Pharmacia Korea Ltd.--South Korea 

Pharmacia Laboratories Ltd.--U.K. 

Pharmacia Learning Center Corp.--Delaware 

Pharmacia Ltd.--U.K. 

Pharmacia Ltd. Co.--Michigan 

Pharmacia Malaysia Sdn Bhd 

Pharmacia Pakistan (Pvt.) Ltd. 

Pharmacia-Pfizer EEIG--U.K. 

Pharmacia Pharmatrade LLC--Hungary 

Pharmacia Polska Sp.z.o.o.--Poland 

Pharmacia SpA--Italy 

Pharmacia Searle Ltd.--U.K. 

Pharmacia Singapore Pte. Ltd. 

Pharmacia UK Holding Co. 

Pharmacia UK Ltd. 

Pharmacia United Inc.--Philippines 

Plaistow Ltd.--Ireland 

Promotora IPSA SA--Mexico 

ProRe SA--Luxembourg 

Prosec (Ireland) Ltd. 

Prosec Forsakrings AB (Prosec Insurance Co. Ltd.)--Sweden 

PT Capsugel Indonesia 



PT Pfidex Pharma--Indonesia 

PT Pfizer Indonesia 

PUCN Ltd. Partnership--Nevada 

PUCN LLC--Nevada 

Quigley Co. Inc.--New York 

Reactine SRL--Italy 

Renrall LLC--Wyoming 

Rivepar--France 

Roerig AB--Sweden 

Roerig BV--Netherlands 

Roerig Produtos Farmaceuticos Lda.--Portugal 

Roerig SA--Chile 

Roerig Inc.--Philippines 

Roerig SA--Venezuela 

Searle & Co.--Delaware 

Searle Argentina SRL 

Searle Belgium BVBA--Belgium 

Searle Chemicals Inc.--Delaware 

Searle de Mexico SA de CV--Mexico 

Searle GmbH--Germany 

Searle Holdings BV--Netherlands 

Searle Invest BV--Netherlands 

Searle Laboratorios Lda.--Portugal 

Searle LLC--Nevada 

Searle Ltd.--Bermuda 

Searle Pharma LLC--Russia 

Sefarma Srl--Italy 

Sensus Drug Development Corp.--Delaware 

Shiley International--California 

Shiley LLC--California 

Sinergis Farma-Produtos Farmaceuticos Lda.--Portugal 

Site Realty Inc.--Delaware 

Smith Brothers Cough Drops Canada Ltd. 

SmithKline Beecham Animal Health (SWA) (Pty.) Ltd.--Namibia 

Solinor LLC--Delaware 

Sopaco SRL--Italy 

Substantia SAS--France 

Sugen Inc.--Delaware 

Suzhou Capsugel Ltd.--China 

Swordfish Heimtierbedarf Verwaltungsgesellschaft mbH--Germany 

Swordfish Holding GmbH--Germany 

Tabor Corp.--Delaware 

The Kodiak Co. Ltd.--Bermuda 

The Upjohn Holding Co. M LLC--Delaware 

The Upjohn Manufacturing Co. LLC--Delaware 

Thorney Co.--Ireland 

Unicliffe Ltd.--U.K. 

Upjohn International Holding Co.--Delaware 

Upjohn International Inc.--Michigan 

Upjohn Laboratorios Lda.--Portugal 

Upjohn Pharmaceuticals Ltd.--Delaware 

Upjohn Suzhou Pharmaceutical Co. Ltd.--China 

Viagra Ltd.--U.K. 

Vicuron Pharmaceuticals Inc.--Delaware 

Vicuron Pharmaceuticals Italy Srl--Italy 

Vinci Farma SA--Spain 

Warner Lambert (UK) Ltd. 

Warner Lambert Bolivia SA 

Warner Lambert Co. (M) Sdn Bhd--Malaysia 

Warner Lambert Consumer Healthcare Pty. Ltd.--Australia 

Warner Lambert del Uruguay SA 

Warner Lambert Ilac Sanayi ve Ticaret Ltd.--Turkey 

Warner Lambert Poland Sp.z.o.o 

Warner Lambert Pty. Ltd.--Australia 

Warner Lambert Zimbabwe (Pvt.) Ltd. 



Warner-Lambert (East Africa) Ltd.--Kenya 

Warner-Lambert (Nigeria) Ltd. 

Warner-Lambert (Singapore) Pvt. Ltd. 

Warner-Lambert (Tanzania) Ltd. 

Warner-Lambert (Thailand) Ltd. 

Warner-Lambert (West Indies) Ltd.--Jamaica 

Warner-Lambert Co. AG--Switzerland 

Warner-Lambert Co. LLC--Delaware 

Warner-Lambert de Costa Rica SA 

Warner-Lambert de El Salvador SA de CV 

Warner-Lambert de Honduras, Sociedad Anonima 

Warner-Lambert de Panama, Sociedad Anonima 

Warner-Lambert de Puerto Rico Inc. 

Warner-Lambert GmbH--Germany 

Warner-Lambert Guatemala, Sociedad Anonima 

Warner-Lambert Hungary KFT--Hungary 

Warner-Lambert International NV--Netherlands Antilles 

Warner-Lambert Ireland 

Warner-Lambert Kenya Ltd. 

Warner-Lambert Manufacturing (Ireland) Ltd.--Cayman Islands 

Warner-Lambert Pottery Road Ltd.--Ireland 

Warner-Lambert SA (Pty.) Ltd.--South Africa 

Warner-Lambert SA--Delaware 

Wilcox Sweets (Pty.) Ltd.--South Africa 

W-L (Europe)--U.K. 

W-L (Portugal)--U.K. 

W-L (Spain)--U.K. 

WL de Guatemala, Sociedad Anonima 

W-L Holding SCA--France 

W-L LLC--Delaware 

Yusafarm D.O.O.--Serbia and Montenegro 

INVESTMENTS: Anaderm Research Corp.--joint venture with OSI Pharmaceuticals Inc. 

Gensia Inc.--$5M equity investment 

OSI Pharmaceuticals Inc.--587.5K shares, $2.9M 

Perlegen Sciences Inc.--$50M (12/05) 

BUSINESS STRATEGY: Discover, develop, manufacture and market leading prescription medicines 

for humans and animals 


250+ 

collaborations, 

including the 

following: 

Abgenix Inc. Abgenix's XenoMouse 

to make antibodies 

against undisclosed 

antigen targets 

AccuMed 


ActivX 

Biosciences Inc. 

Advanced 

Polymer Systems 

Inc. 

development 

agreement--Pfizer 

will make equity 

investment as part 

of up-front payment, 

Pfizer will pay 

milestones, 

research costs, 

license fees and 

provide royalties 

from sales of any 

products 


12/97 

antifungal susceptibility R&D agreement 10/92 

discovery to 

developmental stage 

projects 

APS's microsponge 

technology 

strategic 

collaborative 

agreement 

marketing 

agreement 

3/06 

4/90


AEA Technology drug discovery based 

on genomics research 


Affymetrix Inc. Affymetrix GeneChip 

expression technology 

supply agreement 7/97 

ALZA Corp. Glucotrol XL joint promotion 

agreement 

10/94 

Astex 

Therapeutics 

Cytochrome P450 licensing agreement 1/06 

Atrix Laboratories Atrix's delivery 

feasibility study 3/97 

Inc. (QLT USA technology and Pfizer's 

Inc.) 

veterinary drug 

Bayer AG nifedipine GITS exclusive marketing 

rights for Bayer 

overseas 

7/88 

Bayer 


Corp. 

Bayer's DGAT-1 

inhibitors 

BIOSTAR Inc. genetically engineered 

vaccines for animals 

Calgene Inc. genetically engineered 

plants 

Cambridge 

Antibody 

Technology Ltd. 

Cantab 


plc 

phage antibody display 

and selection 

technologies 

veterinary vaccines 

developed with 

Cantab's proprietary 

Disc-Virus technology 

ChemTrak Inc. disposable quantitative 

finger stick whole blood 

test for one of Pfizer's 

drugs in development 

using ChemTrak's 

ChondroGene 

Limited 

Chromos 

Molecular 

Systems Inc. 

Chromos 

Molecular 

Systems Inc. 

Chrysalis 

International Corp. 

AccuMeter technology 

access to 

ChondroGene's 

database of 

osteoarthritis tissuespecific 

clinical and 

gene expression 

information 

development of cell 

lines using the ACE 

system for production of 

Pfizer recombinant 

proteins 

exclusive worldwide 


licensing, research, 

and supply 

agreements through 

Pfizer Animal 

Health 

cooperative 


through Pfizer Food 

Science Group 

nonexclusive 




Pfizer's Animal 

Health Group 

development 

agreement 

two-year research 

collaboration 

collaborative 

agreement 

ACE System non-exclusive 

commercial 

genomics research for 

two major disease 

targets 

Codexis Inc. pharmaceutical life 

cycle management--use 

of Codexis' 

MolecularBreeding 

technology 


two-year R&D 

agreement 


6/06 

12/91 

2/95 

2/96 

1995 

6/98 

12/04 

12/04 

5/05 

1/98 

R&D agreement 7/04


Coley 


Group 

Collaborative 

Research, The 

Dow Chemical Co. 

Corvas 


development, 



Coley's ProMune (CPG 


7909) 

rennin for making 

cheese by genetic 

manipulation of yeast 

neutrophil inhibitory 

factor (NIF) for acute 

ischemic stroke 

exclusive global 


research, licensing, 

and worldwide 

marketing 

agreement--Dow 

assigned marketing 

rights to Pfizer 

R&D agreement 

with license option 

(10/95), Pfizer 

agreed to pay $1M 

plus $29M in 

development 

funding and 

milestones, Pfizer 

receives worldwide 

license to develop, 

manufacture and 

market NIFR&D 


license option, 

Pfizer paid $1M 

milestone after 

starting Phase I 

clinical trial (2/98) 


3/05 

1/88 

2/97 

Crucell NV Crucell's West Nile virus 

1/04 

vaccine for horses agreement 

Cubist 

antibacterial agents R&D collaboration 7/97 


(12/95), licensing 

Inc. 

agreement 

extended 

Deprenyl Animal Anipryl for canine worldwide licensing, 11/97 

Health, Inc. Cushing's disease and marketing and 

(Draxis Health canine cognitive distribution 

Inc.) 

dysfunction 

agreement--Draxis 

received $15M upfront 

payment 

(12/97), Draxis to 

receive $10M upon 

FDA approval of 

cognitive 

dysfunction 

supplementary 

claim and up to 

$16M contingent 

upon regulatory 

approval for 

Anipryl® in specific 

markets 

Eyetech 

Macugen pegaptanib development and 12/02 

Pharmaceuticals VEGF-binding aptamer marketing 

to treat age-related 

macular degeneration 

(AMD) and diabetic 

macular edema (DME) 

agreement 

G. D. Searle & Co. Searle's celecoxib and copromotion and 2/98 

its second-generation development 

compound 

agreement--Searle 

will receive $85M 

up-front payment


Immunicon Corp. reagents for the 

detection of undisclosed 

antigens on circulating 

tumor cells (CTCs) 

R&D agreement; 

amended 4/04, 

expanded 12/04, 

extended 3/06 

Immusol Inc. target validation 

collaboration 

Incyte Corp. Incyte's LifeSeq database 

genomics database, subscription (6/94), 

expanded to include extended three 

LifeSeq FL database years and 

and LifeSeq 

GeneAlbum DNA clone 

set 

expandedexpanded 

Incyte Corp. development, 


marketing of novel oral 

Inhale Therapeutic 

Systems 

CCR2 antagonists 

pulmonary delivery 

system for insulin 

Inpharmatica Ltd. identification, 

prioritization and 

validation of the 

suitability of drug 

Isis 


targets 

identification of secondgeneration 

antisense 

drugs for the treatment 

of ophthalmic disease 

LifeSpan 

LifeSpan's DrugTarget 

BioSciences Inc. Database 

Medarex Inc. up to 50 antibody 

products over 10 years 

Metabasis adenosine regulating 

Therapeutics Inc. agents (ARA) as broad- 

(Gensia Sicor Inc.) spectrum analgesic 

drugs for treating pain 

Microcide 


Inc. 

Microcide 


Inc. 

antibiotic for animal 

health applications 

drugs to treat resistant 

bacterial infections 

research and 


development 

agreement, 

completed Phase I 

clinicals 

subscription 

agreement 

multi-year drug 

discovery 

collaboration--Isis 

will receive a $1M 

technology access 

fee, research 

funding, milestone 

payments and 

royalties 

multiyear 

agreement 



research 

collaboration (5/96), 

extended through 

May 1999, 

Metabasis gets 

additional research 

funding plus 

milestones and 

royalties if Pfizer 

selects product for 

clinical 

development 

research 

collaboration 

five-year 


Microcide received 

$1M milestone 

payment related to 

identification, 

validation and 

sequencing of 

genes 


2/03 

3/98 

2/98 

11/05 

1/95 

2/01 

5/05 

12/05 

9/04 

3/98 

1/99 

2/97


Microvascular 

Systems, MPS 

(IGI) 

Millennium 


Inc. 

liposome formulations 

for injectable animal 

vaccines 

Mitokor Inc. target and drug 

discovery in certain 

neurodegenerative 

development 

agreement 

fungal diseases research, licensing, 

and product 

development 


expanded-- 

Millennium to add 

research personnel 

to focus on 

application of 

transcript profiling 

and ultra-highthroughput 

screening 

diseases 

Moleculon Poroplastic controlledrelease 

disc used in 

Paratect antiparasitic 

Monogram 

Biosciences Inc. 

bolus system 

Monogram's HIV Co- 

Receptor Tropism 

Assay to be made 

available globally 

drug discovery based 

Myco 

Pharmaceuticals on genomics technology 

NAEJA 


Inc. 

Neogen Corp. immunoassay 

diagnostic kits for the 

poultry industry 

Neurogen Corp. drugs to treat obesity 

and eating disorders 


9/87 

12/97 

technologies 

R&D agreement 1998 

manufacturing 

agreement 

nonexclusive 

collaboration 

agreement 

5/06 


anti-infectives contract research 

agreement 


supply agreements 

three- to five-year 

joint R&D 


to receive 

worldwide exclusive 

license to market 

any drugs 

developed through 

the collaboration 

and to fund 

Neurogen's R&D 

program. Neurogen 

will retain option to 

manufacture the 

products for NAFTA 

countries. 

Neurogen will retain 

a profit-sharing 

option for NAFTA 

countries (11/95). 

funded research 

portion extended for 

one year beginning 

in 11/98 

3/01 

8/92 

5/98


Neurogen Corp. drugs to treat sleep 

disorders 

Neurogen Corp. drugs to treat anxiety 

and enhance cognition 

Neurosearch A/S Neurosearch's 

automated patch clamp 

technology 

NicOx SA NicOx nitric oxidedonating 

compounds 

NicOx SA NicOx's nitric oxide- 

Noxxon Pharma 

AG 

Odyssey Thera 

Inc. 

OSI 


Inc. 

OSI 


Inc. 

donating technology 

discovery and 

development of 

Spiegelmer products 

use of Odyssey Thera's 

Protein-fragment 

Complementation 

Assay (PCA) 

technology to evaluate 

selectivity of Pfizer 

compounds 

compounds to treat 

baldness, wrinkles and 

pigmentation disorders 

cancer therapeutics that 

target oncogenes and 

tumor suppressor genes 

three-year R&D 


to fund Neurogen's 

R&D program in 

exchange for 

worldwide 



any sleep drugs 

developed through 

the collaboration 


for two years 

five-year joint R&D 


to fund Neurogen's 

R&D program in 

exchange for 

worldwide 



anxiolytic or 

cognition enhancing 

drugs developed 

through the 


extended for 

additional year 


for two years 

non-exclusive 



12/96 

12/96 

12/97 

R&D and licensing 

agreement 

8/04 


multi-year global 

collaboration 

multi-year 

collaboration 

agreement 

three-party 

collaboration 


New York 

University and 

Anaderm Research 

Corp. 

five-year R&D 


extended for five 

years (12/90), 

extended for 

additional five years 

3/06 

9/06 

4/96 

3/96


Oxford Asymmetry drug discovery based 

on genomics research 

Oxford 

Glycosciences plc. 

Peptide 

Therapeutics 

Group plc. 

Perlegen 

Sciences Inc. 

Perlegen 

Sciences Inc. 

Phyton Inc. (now 

Phyton Biotech 

Inc.) 

OGS' proteomics 

technology to identify 

disease-specific 

proteins as potential 

diagnostics, clinical 

markers and drug 

targets in Alzheimer's 

disease 

Peptide's broad 

spectrum allergy 

vaccine for veterinary 

market 

identification of genes 

associated with major 

diseases 

discovery of genes 

using Perlegen's DNA 

sample preparation 

R&D agreement 

(3/95), extended for 

one year, Pfizer will 

pay £5.4M over 

three years 

$50M research 

collaboration--Pfizer 

invested in OGS' 

IPO and will fund 

research for two 

years 

development 


will have exclusive 

option to worldwide 

license and will pay 

costs of research 

and clinical 

development for 

evaluating the 

vaccine 

four-year research 

agreement 

research 

collaboration 

collaborative 

development 

agreement 


4/97 

4/98 

1/98 

12/05 

12/02 

1996 

Phytopharm plc. obesity drug collaboration and 

licence agreement 

8/98 

Renovis Inc. research, development worldwide 

5/05 

and commercialization collaboration and 

of small molecules that 

target VR1 


Repligen Corp. growth factor inhibitors research 


Repligen received 

milestone payment 

(12/97) 

12/95 

Repligen Corp. small molecule 

research 

1/97 

compounds that 

stimulate immune 

system responses 

collaboration 

Rigel 

development of inhaled research and 1/05 

Pharmaceuticals products for allergic licensing agreement 

Inc. 

asthma and other 

respiratory diseases 

Sangamo 

Sangamo's zinc finger research agreement 1/05 

BioSciences Inc. DNA binding protein 

technology for use in 

Pfizer's mammalian 

cell- based protein 


production 

Schering AG Schering's ADP 

receptor antagonist 

program 


Schwarz Pharma fesoterodine licensing agreement 6/06


The Liposome Co. 

Inc. 

TLC D-99 licensing 


to have worldwide 


TheraTech Inc. drug delivery systems R&D agreement 

(8/92), extended for 

two years 

RESEARCH & DEVELOPMENT: Pharmaceuticals: antibiotics, antifungals, nonsteroidal anti-inflammatory 

agents for arthritis and autoimmune disease, cardiovascular agents, CNS 

agents, diabetes agents, respiratory diseases 

Improved microorganisms for production of fermentation products 

Broad range of fermentation-derived products, enzymes (rennet, proteases), 

EOR, specialty chemicals, rDNA rennin 

Interferons, antibiotics, renin inhibitors 

Animal health, including antibiotic and vitamin feed supplements 

Antiviral R&D, including AIDS research (Pfizer U.K.) 

PRODUCTS ON MARKET: KEY PHARMACEUTICAL PRODUCTS: Aricept® (donepezil hydrochloride 

tablets), Celebrex® (celecoxib), Diflucan® (fluconazole), Lipitor® 

(atorvastatin calcium) tablets, Neurontin® (gabapentin), Norvasc® 

(amlodipine besylate), Viagra® (sildenafil citrate) tablets, Xalatan® 

(latanoprost ophthalmic solution), Zithromax® (azithromycin), Zoloft® 

(sertraline HCI), Macugen® (pegaptanib sodium injection), Chantix 

(varenicline) 

KEY CONSUMER HEALTH CARE PRODUCTS: Benadryl®, Cortizone®, 

Desitin®, e.p.t.®, Listerine®, Lubriderm®, Neosporin®, Rolaids®, 

Sudafed®, Visine® 

KEY ANIMAL HEALTH PRODUCTS: Clavamox®, Synulox®, Equimax®, 

Naxcel®/Excenel®, Rimadyl®, Dectomax®, Respisure®/Stellamune®, 

Revolution®/Stronghold® 


235 projects in development, including 152 

new molecular entities and 83 product-line 

extensions. More than 400 projects in 

discovery research. 


Ferdinand-Porsche-Str. 5/1 

Denzlingen D-79211, Germany 

Phone: +49 7666-2025; Fax: +49 7666-7255 

Web: www.pharmbiodyn.com 

E-mail: info@pharmbiodyn.de 

KEY PERSONNEL: Dr. G. Friedrich; President 





RESEARCH & DEVELOPMENT: Development of products for automation of liquid chromatography 

biotechnology, cell and tissue culture 

PRODUCTS ON MARKET: Products: 

Customer designed fully automated HPLC / LC-MS 

Robo-Caesar-Set 


11/90 

8/94


Pioneer Hi-Bred International Inc. 

Consulting services: 

Automation in analytical and preparative chromatography 

Development and adapting of methods for full automation of procedures in 

liquid chromatography 

Services: Installation service, services for own products, services for clients 

in collaboration with partners, including in vitro and in vivo preclinical and 

clinical studies (analytics, drug efficacy, metabolism, pharmacokinetics); free 

radicals in vitro and in vivo (preclinical, clinical studies); and cell therapy, 

stem cells, their products in different stages of differenciation 

7100 NW 62nd Avenue, PO Box 1014 

Johnston IA 50131-1014, US 

Phone: (515) 248-4800; Fax: (515) 270-3581 

Web: www.pioneer.com; E-mail: web.editor@pioneer.com 

KEY PERSONNEL: Dean Oestreich; Pioneer President 

Diane C. Bridgewater; VP CFO 

Dennis Byron; VP, Crop Development 

Bill Fleet; VP, North America Sales 

Ian Grant; VP, Maize Development 

Mike Gumina; VP, Supply Management 

Bob Iwig; VP, Strategic Marketing 

Daniel Jacobi; VP and General Counsel 

Michael Lassner; VP, Trait Discovery 

Giuseppe Manara; VP, Global Sales Strategy 

Barbara Mazur; VP, Trait Technologies 

William Niebur; VP, DuPont Crop Genetics R&D 

Franci Phelan; VP, Human Resources 

Frank Ross; VP and Business Director, North America Operations 

Paul Schickler; VP and Business Director, International Operations 

Steve Waite; VP, Information Management and CIO 

Thomas G. West; VP, Biotech Affairs and Business Support 




Purchased the assets of Allelix Crop Technologies (12/90) 

Purchased Plant Cell Research Institute's RFLP program (3/91) 

Purchased Native Plants, Inc.'s RFLP program (4/91) 

FACILITIES: Research at more than 140 locations in 30 countries worldwide 


SUBSIDIARIES/DIVISIONS: Pioneer Argentina SA 

Pioneer Hi-Bred Australia Pty. Ltd. 

Pioneer Hi-Bred Services GmbH--Austria 

Carter's General Stores--Barbados 

Pioneer Hi-Bred Northern Europe Sales Division GmbH--Belgium 

Midwest Steel & Agro Supplies Co. Ltd.--Belize 

Semillas Villacruz SRL--Bolivia 

Du Pont do Brasil SA (Divisao Pioneer Sementes) 

Pioneer Semena Bulgaria 

Pioneer Hi-Bred Ltd.--Canada 

Semillas Pioneer Chile Ltda. 

Shandong Denghai-Pioneer Seeds Co.--China 

DuPont de Colombia SA 

Agricola Piscis SA--Costa Rica 

Pioneer Sjeme DOO--Croatia 

Pioneer Hi-Bred Services GmbH--Czech Republic 

Productora de Semillas Dominicanas--Dominican Republic 



SUBSIDIARY OF: 

Misr Pioneer Seed Co.--Egypt 

Duwest--El Salvador 

Pioneer Hi-Bred Seeds (Ethiopia) plc 

Pioneer Semences SAS--France 

Pioneer Hi-Bred Northern Europe Sales Division GmbH--Germany 

Pioneer Hi-Bred Hellas SA--Greece 

Duwest--Guatemala 

Duwest--Honduras 

Pioneer Hi-Bred Magyarorszag Kft.--Hungary 

PHI Seeds Ltd.--India 

PT DuPont Indonesia 

Pioneer Hi-Bred Italia Srl 

Pioneer Hi-Bred Japan Co. Ltd. 

Farmchem Seedlinks Ltd.--Kenya 

Chemicals & Marketing Co. Ltd.--Malawi 

PHI Mexico SA de CV--Mexico 

Pioneer Hi-Bred Northern Europe Sales Division GmbH--The Netherlands 

Genetic Technologies Ltd.--New Zealand 

Duwest--Nicargua 

Pioneer Pakistan Seed Ltd.--Pakistan 

Grupo Melo--Panama 

Representaciones Agricolas de Miguel Villanueva EIR Ltda.--Peru 

Pioneer Hi-Bred Philippines Inc. 

Pioneer Hi-Bred Services GmbH--Poland 

Pioneer Hi-Bred Sementes de Portugal SA 

Pioneer Hi-Bred Puerto Rico Inc. 

Pioneer Hi-Bred Seeds Agro SRL--Romania 

Pioneer Semena Holding GmbH--Russia 

Pioneer Hi-Bred Services GmbH--Serbia and Montenegro 

Pioneer Hi-Bred Slovensko SRO--Slovakia 

Pioneer Semena Holding GmbH--Slovenia 

Pioneer Hi-Bred RSA (Pty.) Ltd.--South Africa 

O.M.C.--South Korea 

Pioneer Hi-Bred Spain SL 

Pioneer Hi-Bred Switzerland SA 

Bytrade Tanzania Ltd. 

Pioneer Hi-Bred (Thailand) Co. Ltd. 

Sheppard Enterprises Ltd.--Trinidad and Tobago 

Pioneer Tohumculuk AS--Turkey 

Pioneer Nasinnya Ukraine LLC 

Pioneer Hi-Bred Northern Europe Service Division GmbH--U.K. 

Agar Cross Uruguaya SA 

Semillas Pioneer de Venezuela 

Farmchem Services Ltd.--Zambia 

Pioneer Hi-Bred Zimbabwe (Pvt.) Ltd. 

DuPont 

BUSINESS STRATEGY: Produce, market and sell hybrid seed corn in nearly 70 countries worldwide 

Market and sell hybrids or improved varieties of sorghum, sunflower, 

soybean, alfalfa, canola, wheat, forage and grain additives 


Affymetrix Inc. agricultural research feasibility 

collaboration 

4/97 

CuraGen Corp. seed and agricultural $25M research 4/98 

products 

collaboration-- 

Pioneer made 

$7.5M equity 

investment and 

commitment to fund 

research for 5 years 


Devgen NV develop superior crop research 

5/06 

varieties with resistance 

to plant pests 

collaboration 



DFS Inc. measure levels of 

digestible energy in 

corn grain for animal 

feed 

Dow 

joint research 

collaboration 


10/05 

Herculex joint development 

AgroSciences LLC 

agreement 

E. I. Du Pont genomics and enabling research alliance, 8/97 

technologies 

joint venture and 

equity stake 

Ecogen Inc. seed corn containing 

Ecogen's Bt genes 


Human Genome corn genome collaboration 1/96 

Sciences Inc. 

agreement 

InsectiGen InsectiGen's BtBooster 

technology 


Kimeragen Inc. agricultural applications 

of Kimeragen's gene 

enhancement 

technology 


Monsanto Co. YieldGard insectprotected 

Bt corn 


Mycogen Corp. agricultural seeds for joint development 12/95 

(now Mycogen corn, soybean, 

agreement 

Seeds) 

sunflower, canola, 

sorghum, and other 

crops with Bt-based 

insect resistance 

Plant Genetics genetically engineered licensing agreement 

Systems NV vegetable seeds 

Zeneca Mogen fungal resistance collaborative 2/94 

(now 

technology 

research and 

AstraZeneca) 


OGS (Oxford, Proteomics research 

9/98 

Glyco Sciences) 


proteomics 

technology, for 

improving 

agricultural seed 

products 

RESEARCH & DEVELOPMENT: Hybrids of corn, sorghum, sunflower and canola, and varieties of soybean, 

alfalfa, wheat and canola 

Plant tissue culture, bioengineering of agricultural crops 

Gene transfer by DNA-coated tungsten particles (microprojectile 

bombardment) and other methods 

Specialty hybrids and varieties for end users 

PRODUCTS ON MARKET: Hybrid corn, canola, sorghum and sunflower seeds, and seeds of soybeans, 

alfalfa and wheat varieties 

Silage, hay and high-moisture corn inoculants 

Software programs for farm production information 

Pioneer Information Network--project to link farmers and agribusiness with 

agriculture information


PLANTON GmbH 

Am Kiel-Kanal 44 

Kiel D-24106, Germany 

Phone: +49 431 380 15-0; Fax: +49 431 380 15-11 

Web: www.planton.de 

E-mail: info@planton.de 

KEY PERSONNEL: Dr. Michael Kleine; CEO 

Prof. Dr. Florian Grundler; Director, R&D 



FACILITIES: 440 sq. m. total 


BUSINESS STRATEGY: Develop and produce protein-based biopharmaceuticals 


2155 Stonington Ave., Suite 119 

Hoffman Estates IL 60195, US 

Phone: (847) 310-8725; Fax: (847) 310-8725 

Web: www.polium.com 

E-mail: info@polium.com 

KEY PERSONNEL: Michael Gololobov, Ph.D.; President 


HISTORY: Founded and began R&D in 2000 


BUSINESS STRATEGY: Use its proprietary technology and products to accelerate drug discovery 

and pharmaceutical development 

RESEARCH & DEVELOPMENT: Patented technology for the immobilization and recovery of enzymes and 

small molecule catalysts 

PRODUCTS ON MARKET: Finezyme systems 

Free enzymes 

Free ligands 

Rexalyst systems 

Beta amino acids 

Chiral intermediates 

SoluScav systems 


Custom R&D services 




421 Comstock Road 

Toronto M1L 2H5, Canada 

Phone: (416) 755-2231; Fax: (416) 755-0334 

Web: www.polydex.com 

E-mail: info@polydex.com 

KEY PERSONNEL: George G. Usher; Chairman, President and CEO 

Sharon Wardlaw; Exec. VP 




Acquired Vet Labs of Lenexa, Kan. 

Sold Vet Labs in early 2004 

FACILITIES: 28,000 sq. ft. Toronto production facility 

STOCK-FINANCIAL HISTORY: NASDAQ--POLXF / Boston Stock Exchange--PXL 

Sales $5.265M (YE 06) compared to $6.372M (YE 05) 


Earnings per share (YE 06) compared to $0.38/share 

(YE 05) 


PRIVATE PLACEMENTS: American Heritage Fund--1M shares at $1.75/share (12/94) 

SUBSIDIARIES/DIVISIONS: Dextran Products Ltd.--Scarboro, ON (see separate entry) 

Corporate office: 


Sandringham House 

83 Shirley Street 

Nassau, Bahamas 

Phone: (242) 322-8571 

Fax: (242) 328-6919 

PRINCIPAL INVESTORS: American Heritage Fund--$2.25M 

Continental Grain Co.--$3.6M 

BUSINESS STRATEGY: Conduct research related to dextran 


Canadian 

Bacterial Disease 

Network 

RESEARCH & DEVELOPMENT: Cystic fibrosis therapeutics 

Contraceptive gel (cellulose sulfate) 

PRODUCTS ON MARKET: Iron dextran (veterinary and human) 

Dextran sulfate for hybridoma 

Veterinary generics 

Dextran research and 

licensing 

agreements 


Dextran for cystic fibrosis in clinicals 

Ushercell - contraceptive prophylactic in Phase II/III clinicals 




400 Valley Road 

Warrington PA 18976, US 

Phone: (215) 343-6484; Fax: (215) 343-0214 


Web: www.polysciences.com 

E-mail: info@polysciences.com 

KEY PERSONNEL: Michael H. Ott; President 

Walter Baker; VP, Operations 

Dr. D. Templer; VP, Technology and Business Development 

Dr. Mark DeGrandpre; Director, Technology and Business Development 

Joe Dudenbostel; Purchasing Manager 



FACILITIES: More than 150,000 sq. ft. at four U.S. locations 

5,000 sq. ft. facility in Eppelheim, Germany 


SUBSIDIARIES/DIVISIONS: Polysciences Europe GmbH 

Handelsstr. 3 

Eppelheim D-69214, Germany 

Phone: +49 6221-765767 

Fax: +49 6221-764620 

E-mail: info@polysciences.de 

PRODUCTS ON MARKET: Diagnostic reagents, electrophoresis and chromatography supplies, electron 

and light microscopy supplies, dyes and stains, polymeric biomaterials for 

medicine and dentistry, custom packaging and formulations 

Sponsored research on confidential basis (FDA facility) 

Latex microparticles for antibody coupling and precision size standards 

Tetrazolium salts, embedding waxes, and plastic embedding media 

Custom reagent synthesis and custom packaging 

Magnetic particles and flow cytometry particles 


118 Veterinary Road 

Saskatoon S7N 2R4, Canada 

Phone: (306) 978-2800; Fax: (306) 975-3766 


Web: www.pos.ca; E-mail: pos@pos.ca 

KEY PERSONNEL: Robert E. Morgan, President and CEO 

Colin Luciuk; CFO 

Paul Fedec; VP, Scientific and Regulatory Affairs 

Karen Connell; Director, Finance 


HISTORY: Founded in July 1977 as an applied research facility for grains and oilseeds 

processing 

FACILITIES: 54,000 sq. ft. facility, including five pilot plant processing areas and 11 

laboratories 


BUSINESS STRATEGY: Provide contract R&D and custom processing services that facilitate the 

development of value added processing of agri-products for industries such 

as agbiotech, food, nutrachemicals, feed and fine chemicals. 



PRODUCTS ON MARKET: Services include: 

Process/Product development 

Laboratory services 

Analytical services 

Mini-scale product development 

Toll processing 

Quality assurance 

Chromatography 

Consulting services 

Support services 


11 Deer Park Drive, Suite 205 

Monmouth Junction NJ 08852, US 

Phone: (732) 274-0660; Fax: (732) 274-0907 

Toll-free phone: (877) Prime-03 

Web: www.primesyn.com 

E-mail: info@primesyn.com 

KEY PERSONNEL: Surendra Chaturvedi, Ph.D.; CEO 

Barry Lynn; Exec. VP 



FACILITIES: Headquarters, R&D and manufacturing facilities in Monmouth Junction, N.J. 


BUSINESS STRATEGY: Provide products and services for contract research, product development 

and assay development within the bio-pharmaceutical industry 


Biosearch 

Quasar, CAL Fluor and licensing agreement 5/05 

Technologies Black Hole Quencher 

products 

Premier Biosoft Array Designer, Beacon marketing and 4/05 

International Designer, Primer distribution 

Premier, SimVector and 

Xpression Primer 

software 

agreement 

RESEARCH & DEVELOPMENT: Expertise is in organic synthesis and analysis to method development 

PRODUCTS ON MARKET: PrimeSyn Lab Inc. is a recognized leader in the area of custom DNA/RNAi 

synthesis and purification within the U.S. PrimeSyn Lab specializes in 

ULTRA PURE Oligonucleotides and ASRs for: Cloning, mutagenesis, 

fluorescent sequencing, microarrays, diagnostics and therapeutics. 

PrimeSyn Lab also provides analytical lab services: protein analysis, mass 

spectral analysis, protein purification / characterization, analytical methods 

development, small molecule synthesis and analysis. 


Primm S.R.L. 


Via Olgettina 58 

Milan 20132, Italy 

Phone: +39 02 2104031; Fax: +39 02 2640355 

Web: www.primm.it 

E-mail: info@primm.it 

KEY PERSONNEL: Paolo Sarmientos; CEO 



FACILITIES: Laboratories, manufacturing facilities and commercial offices in Italy, 

Switzerland and the U.S. 

Animal facility located in the area of Treviso, Italy 


SUBSIDIARIES/DIVISIONS: Animal Care Unit 

Via dell'Artigianato 2 

Dosson di Casier, Treviso, Italy 

Phone: +39 0422 490200; Fax: +39 0422 490445 

Primm GmbH 

Hochbordstrasse 9 

Dubendorf, Zuerich CH-8600 

Phone: +41 1 9423848; Fax: +41 1 9423986 

E-mail: info@primm.ch 

PrimmBiotech Inc. 

Box 425695 Kendall Square 

Cambridge, MA 02142, USA 


Fax: (617) 325-2703 

E-mail: info@primmbiotech.com 

Web: www.primmbiotech.com 

Naples Facility: 

Via P. Castellino 111 

80131 Naples, Italy 

Phone: +39 081 6132295 

Fax: +39 081 19571728 

BUSINESS STRATEGY: Provide biotechnology products (DNA, peptides, antibodies), R&D and 

contract R&D for an international market 


Axxam aim is to set up an technological 6/02 

automated high 

throughput sequencing 

platform 

collaboration 

RESEARCH & DEVELOPMENT: -Design, synthesis and pharmaceutical development of novel bioactive 

peptides for various therapeutical applications 

-Use of peptides to investigate problems such as the ligand-receptor 

interactions or to study the tridimensional structure of specific protein 

domains 

-Development of recombinant strains and technologies for the industrial 

production of biopharmaceuticals. In the last few years, Primm has 

developed technologies for the manufacturing of selected recombinant 

proteins in heterologous systems 

PRODUCTS ON MARKET: Service and product divisions: 

DNA and RNA synthesis 

Peptide synthesis 




Peptide nucleic acids 

Gene cloning and expression 

Analysis of proteins and peptides 

Monoclonal and polyclonal antibodies custom service 

Animal services 

1 Procter and Gamble Plaza 

Cincinnati OH 45202, US 

Phone: (513) 983-1100; Fax: (513) 562-4500 


Web: www.pg.com 

E-mail: info@pg.com 

KEY PERSONNEL: Alan G. Lafley; Chairman, President and CEO 

Clayton C. Daley Jr.; CFO 

G. Gilbert Cloyd; CTO 

Richard L. Antoine; Global Human Resources Officer 

R. Keith Harrison Jr.; Global Product Supply Officer 

James J. Johnson; Chief Legal Officer and Secretary 

Mariano Martin; Global Customer Business Development Officer 

Charlotte R. Otto; Global External Relations Officer 

Filippo Passerini; Chief Information Officer and Global Services Officer 

James R. Stengel; Global Marketing Officer 


HISTORY: Founded in 1837 by William Procter and James Gamble 


Acquired the Philippine Manufacturing Company (1935) 

Acquired Charmin Paper Mills (1957) 

Acquired Nippon Sunhome Company (1973) 

Acquired Norwich Eaton Pharmaceuticals (1982) 

Acquired Noxell (1989) 

Acquired Shulton's Old Spice product line (1990) 

Acquired Max Factor and Betrix (1991) 

Acquired VP Schickedanz (1994) 

Acquired the Iams Company (1999) 

Acquired Recovery Engineering Inc. (1999) 

Acquired the Clairol business from Bristol-Myers Squibb Co. (2001) 

Acquired The Gillette Co. (2005) 

FACILITIES: 39 manufacturing facilities in 23 states in the U.S. 

107 manufacturing facilities in 42 other countries 

STOCK-FINANCIAL HISTORY: NYSE--PG 

Net sales $56,741M (YE 05) compared to $51,407M (YE 04) 

Net income $7,257M (YE 05) compared to $6,481M (YE 04) 


Total assets $61,527M (YE 05) compared to $57,048M (YE 04) 

SUBSIDIARIES/DIVISIONS: Modern Products Co.--Saudi Arabia 

P&G Interamericas Inc.--Buenos Aires, Argentina 

P&G Australia Pty. Ltd. 

P&G Austria GmbH 

Procter & Gamble--Minsk, Belarus 

P&G Belgium BVBA 

P&G Trgovacko Drusvo djl--Sarajevo 

P&G do Brazil 

Procter & Gamble OOD--Sofia, Bulgaria 

P&G Inc.--Toronto, Canada 

Procter & Gamble Representation Office--Kazakhstan 

P&G Guangzhou Ltd.--China 

P&G Chile Inc. Agencia--Santiago 



Procter & Gamble Interamericas--San Jose, Costa Rica 

P&G Colombia SA--Bogota 

Procter & Gamble doo--Zagreb, Croatia 

P&G Rakona AS--Prague, Czech Republic 

Procter & Gamble DK A/S--Denmark 

Distribuidora Corripio/Division P&G--Santo Domingo, Dominican Republic 

P&G Egypt--Cairo 

P&G El Salvador--San Salvador 

Procter & Gamble--Kalmistu, Estonia 

Procter & Gamble Oy--Espoo, Finland 

P&G France 

Procter & Gamble GmbH--Germany 

P&G Hellas--Athens, Greece 

P&G Interamericas Inc.--Guatemala City, Guatemala 

P&G Hong Kong Ltd. 

Procter & Gamble KTT--Budapest, Hungary 

P&G India Ltd. GO--Bombay, India 

P&G Indonesia--Jakarta 

P&G Ireland Ltd. 

P&G Israel--Tel-Aviv 

P&G Srl--Rome, Italy 

Procter & Gamble Far East Inc.--Japan 

Procter & Gamble Almaty--Kazakhstan 

P&G East Africa Ltd.--Nairobi 

P&G Korea Inc.--Seoul 

P&G Marketing Latvia Ltd. 

P&G Mfg Co. of Lebanon SAL 

P&G (M) Sdn Bhd--Malaysia 

P&G de Mexico S de RL de CV 

Industries Marocaines Modernes--Casablanca, Morocco 

Procter & Gamble Nederland BV--Rotterdam, The Netherlands 

P&G NPD Inc.--Auckland, New Zealand 

P&G Nigeria Ltd. 

Procter & Gamble Norway A/S--Oslo 

P&G Pakistan Pvt. Ltd. 

Procter & Gamble del Peru SA--Lima 

P&G Philippines Inc. 

P&G Operations Polska SA--Warsaw, Poland 

P&G Portugal SA 

P&G Commercial Co.--Puerto Rico 

P&G Marketing Romania SRL 

Procter and Gamble OOO--Russia 

P&G (S) Pte. Ltd.--Singapore 

Procter & Gamble Spol. Sro--Slovak Republic 

Procter & Gamble doo--Slovenia 

Procter and Gamble SA (Pty) Ltd.--Johannesburg, South Africa 

P&G Espana SA--Madrid, Spain 

Procter & Gamble Nordic Inc.--Stockholm, Sweden 

Procter & Gamble International Operations SA--Geneva, Switzerland 

Procter & Gamble Taiwan Ltd.--Taipei 

P&G Manufacturing (Thailand) Ltd.--Bangkok 

Procter & Gamble Tuketim Mallari Sanayi AS--Turkey 

P&G Ukraine--Kiev 

P&G Gulf FZE--Dubai 

Procter & Gamble UK--England 

The Procter & Gamble Co.--Cincinnati, Ohio 

Procter & Gamble Representative Office--Uzbekistan 

Procter & Gamble de Venezuela CA--Caracas 

Procter & Gamble Vietnam Ltd. 

P&G Yemen Ltd. 

P&G c/o Nelt--Belgrade, Yugoslavia 



BUSINESS STRATEGY: Purpose: Provide branded products and services of superior quality and 

value that improve the lives of the world's consumers. As a result, 

consumers will reward us with leadership sales, profit, and value creation, 

allowing our people, our shareholders, and the communities in which we live 

and work to prosper 


Advanced 

Microsponge systems licensing and 7/96 

Polymer Systems containing dimethicone supply agreement 

Inc. 

for use in baby wipe 

products 

Advanced Tissue human tissue system to joint development 6/91 

Sciences Inc. screen oral drugs agreement 

Advanced Tissue in vitro assay to test licensing 

9/92 

Sciences Inc. products for eye safety agreement--ATS 

combining ATS's granted exclusive 

Skin2 with P&G's worldwide rights to 

procedure for 

conducting eye irritation 

studies 

market 

Alimentary Health therapies for 

worldwide licensing 12/05 

Ltd. 

gastrointestinal 

disorders 

agreement 

Alza Corp., Ditropan (oxybutynin Alza acquired 4/98 

Hoechst Marion chloride) for treating Canadian marketing 

Roussel Inc. urge urinary 

rights and right to 

incontinence 

use Ditropan® 

trademark in 

Canada with other 

Alza products, 

Hoechst will 


package product, 

Alza will submit 

marketing 

application for 

Ditropan® XL in 

Canada 

Allelix capillary immunoassays 

for home market 

Biopulping 

Consortium 

(University of 

Wisconsin and 

USDA) 

Calgene Inc. rDNA rapeseed for 

specialty oil as food 

R&D and marketing 


Richardson-Vicks 

lignin degrading fungi collaborative 


additive 

Curis Inc. treatments for hair 

growth using Curis' 

Hedgehog agonist 

technology 

Cygnus Inc. smoking cessation 

products 

Epoch 


Inc. 

Epoch's periodontal 

diagnostic test 

development 

agreement 

research and 

development 

agreement 


marketing 

agreement 

development 

agreement--P&G 

will have first option 

to license the test 

for exclusive 

distribution in the 

U.S. and Canada 


4/87 

1985 

9/05 

2/94 

10/93


Gene Logic Inc. genetic targets for drug 

development in heart 

failure and two 

undisclosed diseases 

$75M drug 

development 

ageement 


6/97 

Geron Corp. Geron's human 

telomerase reverse 

transcriptase 

technology 


Lederle 

Ziac (bisoprolol and hct) joint marketing 12/92 

Laboratories 

Locus 


Inc. 

treatment for diabetes 

agreement 


MGI Pharma Inc. Didronel IV infusion MGI bought 

exclusive rights to 

IV form for oncology 

market (P&G to 

retain rights to oral 

Oxford Molecular 

Group plc. 

Oxford's RS3 Discovery 

and RS3 Discovery 

High-Throughput 

Screening research 

information 

management software 

in P&G's discovery 

research programs 

Quidel Corp. Quidel's QuickVue 1step 

H. pylori test and 

P&G's Helidac therapy 

Regeneron 


Inc. 

treatments for muscle 

diseases and disorders 

Sanofi-Aventis Actonel (risedronate 

sodium tablets); 

includes option for P&G 

to acquire oral health 

care brands from 

sanofi-aventis 

Synergen Inc. collagenase inhibitor for 

treatment of periodontal 

disease 

TheraTech Inc. estradiol and 

estradiol/progestin 

TheraTech Inc. transdermal 

testosterone and 

combination 

estradiol/testosterone 

hormone replacement 

patches for women 

1/90 

form) 


one-year, 

renewable 

copromotion 

agreement 

drug discovery 

collaboration 

(12/96), P&G made 

equity investment 

by purchasing 

$10M of Regeneron 

stock (3/97), 


obesity related to 

Type II diabetes 

(9/97), P&G made 

$5M milestone 

payment 

continuation of R&D 

and 


agreement 

development 

agreement 

worldwide 


distribution 

agreement 

excluding parts of 

Asia 

development 

agreement--P&G 

will fund all 

development, 

TheraTech gets 

R&D payments and 

1/97 

7/98 

10/04 

3/86 

3/95 

12/97


Trega Biosciences 

Inc. 

Trega's combinatorial 

chemistry libraries 

Zila Inc. Zila's diagnostic test for 

oral cancer 

milestones of $35M 

as well as royalties, 

TheraTech will 

manufacture 

products and 

retains certain 

copromotion rights, 

P&G gets 

worldwide rights 

(except Asia) 

screening 

agreement. P&G 

identified series of 

lead compounds 

and has exercised 

option to exclusive 

worldwide license to 

further develop 

these compounds, 

Trega received 

undisclosed 

milestone payment 


(5/98) 

exclusive marketing 

rights 

RESEARCH & DEVELOPMENT: P&G Health Sciences Institute focuses on gastrointestinal health, pain relief, 

respiratory products and safe drinking water 

Recent R&D efforts include: 

--Dryel®, a way to care for dry-clean-only clothes in the home 

--The first recombinant detergent enzymes, developed in collaboration with 

Genencor, for use in liquid laundry detergents 

--Actonel®, the first osteoporosis therapy to consistently demonstrate a 

reduction in the incidence of spinal fractures after one year of treatment 

--Physique®, a hair care line using polymers and cleaning/conditioning 

systems 

--Impress®, a new form of food wrap 

--Febreze®, a spray that uses chemistry to capture odor-causing materials 

--Iams® Hairball Care, which uses fiber technology in cats' diets to 

prevent hair ball formation 

--Crest Whitestrips, a way to whiten teeth 10 times better than the leading 

whitening toothpaste 

PRODUCTS ON MARKET: Markets more than 300 branded products in more than 160 countries, 

including: 

FABRIC AND HOME CARE: Tide, Ariel, Downy, Lenor, Dawn, Fairy, Joy, 

Gain, Ace Laundry and Bleach, Swiffer, Dash, Bold, Cascade, Mr. Clean, 

Febreze, Bounce, Cheer, Era, Bonux, Dreft, Daz, Flash, Vizir, Salvo, Viakal, 

Maestro Limpio, Rindex, Myth, Alomatik 

BEAUTY CARE: Pantene, Olay, Head & Shoulders, Clairol’s Herbal 

Essences, Nice ‘n Easy, Natural Instincts and Hydrience, Cover Girl, SK-II, 

Max Factor, Hugo Boss, Safeguard, Rejoice, Secret, Old Spice, Zest, Vidal 

Sassoon, Pert, Ivory, Lacoste, Aussie, Infusium 23, Camay, Noxzema, 

Infasil, Joy Parfum, Valentino, Sure, Wash&Go, Wella, Koleston, Wellaflex, 

Shockwaves, Rochas, Escada, Gucci, Always, Whisper, Tampax, Naturella, 

Evax, Ausonia, Orkid 

BABY AND FAMILY CARE: Pampers, Luvs, Kandoo, Dodot, Charmin, 

Bounty, Puffs, Tempo 

1/95 

2/96

Prokaria ehf 


HEALTH CARE: Crest, Iams, Eukanuba, Actonel, Vicks, Asacol, Prilosec 

OTC, Metamucil, Fixodent, PUR, Scope, Macrobid, Pepto-Bismol, Didronel, 

ThermaCare, Blend-a-med 

SNACKS AND BEVERAGES: Pringles, Folgers, Millstone 

Gylfaflot 5 

Reykjavík IS - 112, Iceland 

Phone: +354 570 7903; Fax: +354 570 7901 

Web: www.prokaria.com 

E-mail: info@prokaria.com 

KEY PERSONNEL: Prof. Jakob K. Krist; President and CEO 

Valborg Guomundsdottir; CFO 

Dr. Gudmundur Oli Hreggvidsson; VP, R&D 

Dr. Arnbor AEvarsson; Manager, Bioinformatics and Marketing 

Dr. Sigríour Hjorleifsdottir; Manager, Operations 


HISTORY: Founded in June 1998 as Islenskar hveraorverur 

Merged with Islensk natturuefni (Icelandic Natural Substances) (1/00) 


PRIVATE PLACEMENTS: Raised US$13.5M (9/00) 

BUSINESS STRATEGY: Discover, develop and produce industrial enzymes for food, feed and 

chemical applications 

Develop, produce and market thermostable molecular enzymes, such as 

DNA polymerase, ssDNA ligase and other for genetic research and 

diagnostics 

Offer DNA analytical services for fish, animals and the environment 


bitop AG screening and 

partnership 

5/03 

development program 

for novel compatible 

solutes from 

extremophilic 


agreement 

Blue Lagoon Ltd. investigations of the 

biodiversity 


deCODE genetics strategic alliance 12/98 

Marine Research fish genetics collaboration 1/04 

Institute of Iceland 

(MRI) 

agreement 

Nestle Research screening program research agreement 12/03 

Center 

program for the 

discovery of natural 

components for food 

applications 

Novartis Animal Prokaria's novel licensing agreement 5/03 

Health Inc. biomolecules for 

screening purposes 

Novozymes A/S Prokaria's industrial 

enzyme specialties 


Roquette Frere novel industrial 


enzymes 

agreement 



PRODUCTS ON MARKET: Services: 

DNA sequencing 

Genotyping 

Microbial species analysis: Species composition of unculturables, species 

identification of cultivated organisms 

Screening assay development 

Preparation of HTS extracts for small molecular screening (pharma, 

cosmetics) 

Discovery and development of extremophilic genes and enzymes 

Provision of test samples 


155 Willowbrook Boulevard, Suite 460 

Wayne NJ 07470, US 

Phone: (973) 812-9880; Fax: (973) 812-9881 


Web: www.prometic.com 

E-mail: investor@prometic.com 

KEY PERSONNEL: Pierre Laurin; Chairman, President and CEO, Prometic Life Sciences Inc. 

Steven J. Burton; CEO, Prometic BioSciences Ltd. 

Christopher L. Penney; VP and CSO, Therapeutics 




Acquired Affinity Chromatography Ltd. UK 



SUBSIDIARY OF: Prometic Life Sciences Inc. (see separate entry) 

BUSINESS STRATEGY: Discover and develop proprietary drugs in the fields of cancer and 

autoimmune diseases 

Actively looking for partners to co-develop and eventually market PBI-1402 

and PBI-1393 


American Red 

Cross 

prion removal/det collaborative R&D 1999 

American Red plasma proteins collaborative R&D 1997 

Cross 

agreement 

BioMena SA ProMetic's Enabling 

Technology 


Euroflow process columns large scale process 

data 

2003 

GlaxoSmithKline Prometic's purification development 7/04 

plc 

technology 

agreement 

Menarini purification of avidiplas R&D manufacture 

agreement 

2001 

Novo Nordisk 

University of 

Cambridge UK 

proteins collaborative R&D 1995 

Octapharma AG ProMetic's advanced development 1/05 

Mimetic Ligand affinity 


Octapharma protein 

product 

agreement 



RESEARCH & DEVELOPMENT: Specific affinity ligands for targeting therapeutic proteins 

Large scale plasma Avidiplas purification 

Therapeutic protein screening from yeast, plasma and transgenic milk 

PRODUCTS ON MARKET: Mimetic affinity adsorbents 

Bioprocess chromatography media 

mAB binding adsorbents 


PBI-1402 for peripheral arterial disease in Phase Ib/II clinicals 

PBI-1393 ready to begin clinicals 

Proteus SA 

70, allee Graham Bell, Parc Georges Besse 

Nimes 30000, France 

Phone: +33 (0)4 66 70 64 64; Fax: +33 (0)4 66 70 64 60 

Web: www.proteus.fr 

E-mail: info@proteus.fr 

KEY PERSONNEL: Daniel Dupret; Chairman, President and CEO 

Marc Vander Linden; CFO 

Gilles Ravot; CSO 

Jean-Marie Sonet; VP, Business Development and Marketing 

Jean Francois Bloch; VP; Intellectual Property and Licensing 



FACILITIES: 2,500 sq. m. R&D facility 


PRINCIPAL INVESTORS: Axa Placement Innovation 

FCJE 

Natexis Ventech 

Sofilars 

Sofimac 

Soridec 

Viveris Management 

BUSINESS STRATEGY: Contract research 

A strategic biotech R&D resource for the industry 


Aventis Animal enzymes for animal R&D agreement 1999 

Nutrition 

feed 

CEA LETI 

biochips for biodefense collaborative R&D 2000 

(Commissariat a 

l’energie 

atomique) 

agreement 

Degussa enzymes for specialty R&D agreements 1999 

chemistry 

and alliance 

2000 

2004 

ELF extremophilic micro- screening for novel 1999 

organism 

enzyme from 

extremophilic microorganism 

Girffioth 

extremophilic micro- screening for novel 2000 

University, organism 

enzyme from 

Brisbane, 

extremophilic micro- 

Australia 

organism 



Hebrew University 

of Jerusalem 

I.R.D. (Institute of 

R&D) 



Ifremer extremophilic microorganism 

Russian Academy 

of Science 


Thales systems for detection 

and identification of 

biological attack 

University of Bern chemistry for high 

throughput funcitonal 

University of 

Buenos Aires 

screening 


screening for novel 

enzyme from 


organism 


enzyme from 


organism 


enzyme from 


organism 


enzyme from 


organism 


1999 

1999 

1999 

2005 

R&D agreements 1999 

2000 

2002 

collaborative R&D 

agreements 


enzyme from 


RESEARCH & DEVELOPMENT: Novel proteins, novel industrial enzymes, new industrial chemo-biocatalytoc 

routes, biodiversity screening, protein engineering, development of gene 

based assay for the industry 

Qbiogene 

15 Morgan 

Irvine CA 92618-2005, Canada 

Phone: (440) 337-1200; Fax: (949) 421-2675 


Web: www.qbiogene.com 

E-mail: info@qbiogene.com 

KEY PERSONNEL: Milan Panic; Chairman and CEO, MP Biomedicals 

Dr. Garth Cumberlidge; President and CEO 

Steve Peronne; CFO 




Began sales in 1996 

Aquired Appligene-Oncor, Strasbourg, France 

Merged with Bio-101, Inc. and changed name from Quantum 

Biotechnologies (7/00) 

Acquired Alexis Biochemicals, Switzerland 

Acquired Bio-101, Carlsbad, California 

Acquired by MP Biomedicals 


SUBSIDIARY OF: MP Biomedicals 

BUSINESS STRATEGY: Develop and market novel and innovative products for gene delivery, gene 

therapy applications and molecular biology applications related to the study 

of the structure and function of the human genome 

2003 

2000 

2004 

2005



BTC nucleotides, enzymes, 

probes 

supply agreement 1995 

Hoffmann-La native and recombinant development, 3/98 

Roche Ltd./Perkin- Taq DNA polymerase manufacturing and 

Elmer Corp. and other thermostable marketing 

enzymes for use in 

polymerase chain 

reaction process 

agreement 

INRA CNRS baculovirus expression technology 1996 

systems 

development 

agreement 

NCI AFP expression vectors distribution license 

and CRADA 

1996 

NRC Canada adenovirus expression exclusive 

2/92 

system 

worldwide 

agreement 

NRC Canada recombinant yeast lytic exclusive 

10/91 

enzyme 

worldwide 

agreement 

NRC Canada site-directed 

exclusive 

10/91 

mutagenesis 

worldwide 

agreement 

Universite de pGATA cloning system technology 1996 

Montreal 

development 

agreement 

RESEARCH & DEVELOPMENT: Gene delivery systems 

Custom services - Adinoviral 

PRODUCTS ON MARKET: FISH kits and buffers 

DNA polymerases 

Baculovirus expression system and custom services 

Peptide coupling reagents 

Cloning vectors 

Gene delivery systems 

DNA panels 

Yeast lytic enzyme 

Adenovirus and bacterial (Alkaline Phosphatase [PhotA*} fusion)expression 

systems 

Autofluorescent proteins 

Positive selection vector 

Custom peptide synthesis 

Embyonal tissue mRNAs and cDNAs 

Custom services (Adenovirus, antibodies and peptides) 

Bio-101 systems 

Media 

Purification--DNA/RNA 

Fast Prep system 


Second-generation adenoviral vectors in development 

Transfection systems in development 

Two-hybrid systems in development 




1500 Eastlawn Avenue 

Wilmington DE 19802, US 

Phone: (302) 791-2600; Fax: (302) 761-2611 

Toll-free phone: (800) 424-CHEM (2436) 

Web: www.quiplabs.com 

E-mail: quip@quiplabs.com 

KEY PERSONNEL: Timothy B. Hidell; President 



FACILITIES: 30,000 sq. ft. building for administrative offices, R&D, quality control, and 

production and shipping facilities 


PRODUCTS ON MARKET: ACID CLEANERS: 

Acid Detergents: Acidulate, Acidulate 28, Acidulate 30HF, Acidulate 45-C, 

Acidulate 45T, Acidulate 50, Acidulate 60, Acidulate 150, Acidulate ATG, 

Acid 50-W 

Acid Neutralizers: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 1500 

Acid Neutralizers Caustics: Enviro-Kleen 500N, WWN-1 


ALKALINE CLEANERS 

Alkaline Detergents: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 700, 

Enviro-Kleen 900, Enviro-Kleen 900S, Enviro-Kleen 1100, Enviro-Kleen 

1200, Enviro-Kleen 1500, Spray Kleen LV, WWN-1 

Alkaline Neutrailizers: Acidulate, Acidulate 45C, Acidulate 50 

Hard Surface Disinfectants/Cleaners: Anlage 20, Anlage QTB, Iodex AR/18, 

MB-2000, MB-10 tablets 

Chlorine Dioxide Products: MB-10 tablets, MB DeoTrex-30 sachets 

ICS Iodine Solutions: ICS iodine blocks, ICS iodine drain gel powder, ICS 

iodine links, Iodex GS25, Iodex hand soap, Iodex AR/18 

P.O. Box 39296, 32 Haim Levanon Street 

Tel Aviv 61392, Israel 

Phone: +972 3-640-6608; Fax: +972 3-640-6675 

Web: www.ramot.org; E-mail: ramot@ramot.org 

KEY PERSONNEL: Prof. Hagit Messer-Yaron; Chairman 

Yehuda Niv, Ph.D.; CEO 

Ze'ev Weinfeld, Ph.D.; Exec. VP, Business Development 

Irit Ben Chlouch; Director, Business Development, Life Sciences 

Nissim Chen, Ph.D; Director, Business Development, Life Sciences 

Amiram Porath; Business Development European Projects Coordinator 

Tamar Raz, Ph.D.; Director, Business Development, Life Sciences 

Hanan Terkel; VP, Business Development 

Ronen Cohen; CFO 

Larissa Shniderman; Director, R&D Budget and Control 




FACILITIES: R&D facilities on Tel Aviv University campus 




SUBSIDIARY OF: Tel Aviv University Economic Corp. 

BUSINESS STRATEGY: Technology transfer company of Tel Aviv University, dedicated to promoting 

research collaboration between the university and industry, through 

licensing agreements, joint ventures, start up companies and sponsored 

research collaborations 

RESEARCH & DEVELOPMENT: The full spectrum of life sciences research 

PRODUCTS ON MARKET: Technologies available in agrotech, bioinformatics, biotechnology, computer 

science, diagnostics, engineering, medical devices and pharmaceuticals 


55 Diamond Road, Ardmore 

Crumlin BT29 4QY, UK 

Phone: +44 (0) 28 9442 2413; Fax: +44 (0) 28 9445 2912 

Web: www.randox.com 

E-mail: marketing@randox.com 

KEY PERSONNEL: Dr. S. Peter Fitzgerald; Managing Director 

Wilhelmena Fitzgerald; Director 

R. J. Fitzgerald; Facilities Director 

C. D. M. Fitzgerald; Sales Director 



FACILITIES: 200,000 sq. ft. of production, R&D and office facilities 


FINANCIAL INFORMATION: Wholly owned by Fitzgerald family 

BUSINESS STRATEGY: Reinvest all profits in company to continue a policy of extensive 

development of new products 

PRODUCTS ON MARKET: evidence® 

evidence investigator 

RX daytona 

Antioxidant tests 

Riqas (EQA scheme) 

247 software package 

Clinical chemistry products 

ELISA kits for detection of drug residues in meat, serum and urine 

Proteins 

Recombinant proteins 

Polyclonal antibodies 


Telepes UT 53. 

Budapest 1147, Hungary 

Phone: +36 (1) 46 77 533; Fax: +36 (1) 384 3102 

Web: www.reanal.hu 

E-mail: sales@reanal.hu 

KEY PERSONNEL: Dr. Istvan Nagy; President 

Gyorgy Orosz, Ph.D.; Director, Marketing and Sales 

Tamas Nagy; Head, Fine Chemicals, Agrochemicals 





Zsolt Horvath; Head, Laboratory Reagents, Diagnostics 

Andras Lengyel; Director, Production and Engineering 

Iren Huszkane Szimuj; Director, Finance 

RESEARCH & DEVELOPMENT: Protected amino acids and amino acids derivatives 

Peptide reagents 

Resins 

PRODUCTS ON MARKET: Protected amino acids and amino acids derivatives 

Peptide reagents 

Resins 

Crown ethers 

Biological buffers 

Cellulose ion exchangers 

Agrochemicals 

Other fine chemicals 


710 Hospital Street 

Richmond VA 23219, US 

Phone: (804) 644-2800; Fax: (804) 643-1335 

Web: www.recobio.com 

E-mail: info@recobio.com 

KEY PERSONNEL: Mike Schleinkofer; President and CEO 

Shane Kasper; Project Engineer 

Charles A. Firth; Sales Manager 




Reco Biotechnology is the trade name for Aqua Clean Environmental of 

Virginia LLC 


165,000 sq. ft. indoor treatment, recycling and waste management facility 


SUBSIDIARIES/DIVISIONS: Biotechnology Environmental Division 

BUSINESS STRATEGY: Operate as a comprehensive provider for non-hazardous waste 

management services 

Offer obioremediation, physical and chemical liquids treatment, fuel 

recycling, processing and disposal for a variety of industrial and 

environmental clean-up residuals 

RESEARCH & DEVELOPMENT: Remediation of environmental contaminants using xenobacteria 


Recordati SpA 


Via M. Civitali, 1 

Milan 20148, Italy 

Phone: +39 2-487871; Fax: +39 2-40073747 

Web: www.recordati.com; E-mail: inver@recordati.it 

KEY PERSONNEL: Giovanni Recordati; Chairman and CEO 

Walter Bevilacqua; VP and Director, Corporate Development 

Giorgio Oberrauch; VP and GM, Pharmaceutical Chemicals 

Abraham Sartani; VP and Director, Pharmaceutical R&D Division 

Fritz Squindo; CFO 

Franco TomasniI; VP and Director, Purchasing and Logistics 



Acquired Merckle GmbH's branded pharmaceutical business (2/05) 

To acquire Jaba Farmaceutica (as of 7/06) 

STOCK-FINANCIAL HISTORY: Italian Stock Exchange--(Reuters REC.MI) (Bloomberg REC IM) (ISIN IT 

003074447) 

IPO--1984 


Net income EUR64.5M (YE 05) compared to EUR53.1M (YE 04) 

PRIVATE PLACEMENTS: Raised $100M in private placement (10/04) 

SUBSIDIARIES/DIVISIONS: Recordati SA--Luxembourg 

Innova Pharma SpA--Italy 

Bouchara Recordati SAS--France 

Recodati Hellas Pharmaceuticals SA--Greece 

Recordati Corp.--U.S. 

Recordati SA--Switzerland 

Recordati Espana SL--Spain 

Merckle Recordati GmbH--Germany 

Recordati Ireland Ltd. 

Recordati Pharmaceuticals Ltd.--U.K. 


Allergan Imidazyl, Herbe distribution 

agreement 

1994 

Angelini prulifloxacin non-exclusive 


9/04 

ASINEX Ltd. micturition disorders drug discovery 

collaboration 

10/04 

BYK Gulden Peptazol (pantoprazole) non-exclusive 


1/02 

Dexcel Ltd. oral formulation of exclusive liensing 10/02 

cyclosporin 

agreement 

Digital Gene Digital's gene 

licensing 

4/97 

Technologies Inc. expression technology agreement--Digital 

and Recordati's calcium received $3M up 

channel blocker front and could 

(Lercanidipine) against receive milestone 

atherosclerosis 

payments and 

royalties 

Eurand 

modified-release development 9/04 

International SpA formulation of 

lercanidipine (Zanidip) 

agreement 

Grupo Uriach rupatadine licensing agreement 9/04 

InfaCare 

development and exclusive licensing 6/05 

Pharmaceutical marketing of Stanate agreement 

Corp. 

(stannsoporfin) 

Kissei 


Co. Ltd. 

silodosin licensing agreement 10/04 



Kowa pitavastatin licensing agreement 10/01 

Labopharm once-daily tramadol licensing and 11/05 

Europe 

distribution 


UK 

Lavipharm transdermal patch multi-territorial 7/05 

Laboratories Inc. containing the narcotic 

analgesic fentanyl 


LifeCycle Pharma modified-release development 4/04 

A/S 

formulation of 

Lercanidipine 

agreement 

Lundbeck escitalopram (Gaudium) marketing and 


1/02 

Mylan 

nitroglycerin 

exclusive licensing 5/01 

Technologies Inc. transdermal patch agreement 

Ono 

alprostadil alpha- licensing-in 

1989 

Pharmaceuticals ciclodextrin 

agreement 

Pharmacia Corp. treatments for 


overactive bladder agreement 

Syntex-Roche Cymevene, Gynestrel, licensing-in 

1961 

Naprosyn, Synflex, 

Syntaris, Toradol 

agreement 

Tsumurab lercanidipine licensing-out 

agreement for 

Japan 

1996 

Warner-Lambert Acequin (quinapri), licensing-in 

1988 

Co. 

Acequide (quin+HCTZ) agreement 

RESEARCH & DEVELOPMENT: Urogenital and cardiovascular therapeutic areas 

PRODUCTS ON MARKET: Fienamina® 

Proctolyn® 

Lomexin® 

Influvit® 

Tossoral 

Lacto 

Imidazyl® 

Imidazyl® Antistaminico e Eumill 

Antispasmina Colica® 

Solvobil® 

Alovex® 

Antoral® 

Dent Oral® 

Naprosyn Gel® 

Valontan® 

Transcop® transdermal patch 

Indusil® 

Alomed 


8210 Austin Avenue 

Morton Grove IL 60053, US 

Phone: (847) 967-6000; Fax: (847) 967-1214 


Web: www.registech.com 

E-mail: sales@registech.com 

KEY PERSONNEL: Louis Glunz IV.; President 

Louis Glunz III, Ph.D.; CEO 

Sean Bradley, Director, Business Development, Custom Manufacturing 

Division 





FACILITIES: Full service cGMP custom manufacturing facility 


BUSINESS STRATEGY: Develop proprietary separations technology for the life sciences industry 

Provide contract manufacturing for pharmaceuticals in a GMP facility 


Research Corp. 

Technologies 

chiral stationary phases research agreement 4/93 

RESEARCH & DEVELOPMENT: Chiral HPLC columns 

IAM column for predicting drug permeability 

Custom organic synthesis 

Analytical method development 

Process research 

PRODUCTS ON MARKET: Regisil (BSTFA) 

Whelk-O 

Pinkerton column 

Luciferin 

Renessen LLC 

520 Lake Cook Road, Suite 220 

Deerfield IL 60015, US 

Phone: (847) 236-5101; Fax: (847) 236-5146 

Web: www.renessen.com 

E-mail: info@renessen.com 

KEY PERSONNEL: Michael Stern, Ph.D.; CEO 

Neal Jakel; Ethanol Project Manager 



Joint venture between Cargill Inc. and Monsanto Co. 

FACILITIES: Building a pilot plant with higher-value ethanol production at Cargill's Iowa 

Bioprocesssing Center campus in Eddyville, Iowa (scheduled to open in 

1/07) 


SUBSIDIARIES/DIVISIONS: Argentina office: 

Panamericana 

Ramal Pilar. km 49.5 

Edificio Bureau 

Office 2.2.7 (1629) 

Pilar, Buenos Aires, Argentina 

Phone: +54 2322.473.821 

Fax: +54 2322.473.816 

E-mail: argentina@renessen.com 

SUBSIDIARY OF: Cargill Inc. and Monsanto Co. 

BUSINESS STRATEGY: Develop improved ingredients/inputs for the feed and processing industry 

Use biotechnology and breeding to produce corn and soybeans with higher 

levels of nutrients (such as oil, protein and amino acids) that are important in 

feeding animals and processing grain 



RESEARCH & DEVELOPMENT: Agricultural biotechnology: Application of plant biotechnology to improve the 

energy content, essential amino acids, protein and fiber composition of corn 

and oilseeds for animal nutrition. Use biotechnology to improve crop 

processing (for example, oil and starch processing, meal, ethanol and 

biodiesel production) 

Corn processing technology: Pilot plant under construction will test 

processing technologies that extract the trait value of the new Mavera high 

value corn. The technology is expected to make ethanol manufacturing 

more profitable and to provide the opportunity for farmers to grow net 

revenue enhancing crops on broad acres. 

PRODUCTS ON MARKET: Mavera program for growers and animal producers 


The Manchester Incubator Building, 48 Grafton Street 

Manchester M13 9XX, UK 

Phone: +44 (0) 161 606 7222; Fax: +44 (0) 161 606 7333 

Web: www.renovo.com 

E-mail: info@renovo.com 

KEY PERSONNEL: Rodger Pannone; Chairman 

Prof. Mark Ferguson; CEO 

Dr. Sharon O’Kane, Exec. Director, R&D 

Andrew Kay; Exec. Director, Commercial 

Robin Cridland; Exec. Director, Finance and Business Development 



STOCK-FINANCIAL HISTORY: LSE--RNVO 

IPO--87p/share, £50M 

PRIVATE PLACEMENTS: Raised £21M (US$33M) in financing (12/02) 

Raised £2M (US$3.2M) in over-subscription to its second round of financing 

(1/03) 

PRINCIPAL INVESTORS: Atlas Venture 

BioVeda Capital (Pte.) Ltd. 

Care Capital LLC 

HealthCap 

JPMorgan Partners 

Temasek 

BUSINESS STRATEGY: Leverage extensive scientific knowledge to develop commercial product 

candidates in scar prevention and reduction 

Be first-to-market with a pharmaceutical product to prevent and reduce 

scarring 

Continue to advance and expand the company's clinical and preclinical 

pipeline 

Extend the significant market potential for the company's lead product 

candidates to multiple body sites and fibrotic disorders 

Pursue a commercialization strategy working with partners to increase 

speed and depth of market penetration 

RESEARCH & DEVELOPMENT: Prevention and reduction of scarring throughout the body, including skin, 

vascular restenosis, eyes, nerves, adhesions and strictures, tendons and 

ligaments, fibrotic disorders 



Ongoing research focused on: 

Investigating the biology of scarring and wound healing 

Genomic microarray analysis and the ensuing inhouse databases 

Comparison of scar-free embryonic healing with scar-forming adult healing 

Hypothesis testing using in vitro and in vivo experimentation 

Keloids 

Focused proteomics 

Focused chemistry 


Juvista in Phase II clinicals 

Juvidex in Phase II clinicals 

Prevascar in Phase II clinicals 

Zesteem in Phase II clinicals 


4353 East 49th Street 

Cleveland OH 44125, US 

Phone: (216) 883-8025; Fax: (216) 883-1576 


Web: www.researchorganics.com 

E-mail: info@resorg.com 

KEY PERSONNEL: Rob Sternfeld; President and CEO 




FACILITIES: 40,650 sq. ft. production facilities, laboratories, offices, quality control 

division, shipping and receiving, and warehouses 


BUSINESS STRATEGY: Develop, manufacture, and supply highly purified biochemicals for molecular 

biology, cloning applications, diagnostic chemicals and cell culture 

RESEARCH & DEVELOPMENT: Biological buffers 

Fluorescent labels, bulk biochemicals, research biochemicals, enzyme test 

substrates 

Buffers 

PRODUCTS ON MARKET: Biological buffers, reagent biochemicals, molecular biology grade products, 

enzyme substrates, fluorescent compounds, amino acids and derivatives, 

ACS reagents, USP and FCC products, neurochemicals and plant tissue 

culture reagents 


KEY PERSONNEL: Alston Sykes; President 


8109 Ebenezer Church Road 

Raleigh NC 27612-7307, US 

Phone: (919) 510-0228; Fax: (919) 510-0141 

Toll-free phone: (800) 291-4RTP (4787) 

Web: www.rtp-labs.com; E-mail: customerservice@rtp-labs.com 



Spun off from a division of Corning Inc. in 1997 





BUSINESS STRATEGY: Support biotech and pharmaceutical industries with R&D analytical services 

RESEARCH & DEVELOPMENT: Air toxics testing for hazardous and cancer causing chemicals in products, 

pollution sources, landfill gases, ambient and indoor air, and 

pesticide/herbicide testing 

Chemical emissions testing of building materials, office equipment, printers, 

toys, microwavable food and its packaging, paper products, printing inks, 

foam insulation products, adhesives and pest control devices 

Herbal/botanical nutraceuticals and pharmaceutical industries: Testing for 

active compound purity, identification of impurities, stability, cleaning 

validations, controlled substances and special projects 

Manufacturing industries: Testing of products to support R&D and regulatory 

testing activities 


100-8900 Glenlyon Parkway 

Burnaby V5J 5J8, Canada 

Phone: (604) 456-6010; Fax: (604) 456-6066 


Web: www.responsebio.com 

E-mail: info@responsebio.com 

KEY PERSONNEL: Dr. Richard Bastiani; Chairman 

Bill Radvak; President and CEO 

Brian G. Richards; COO 

Robert G. Pilz; VP, Finance and CFO 

Joanne Stephenson; VP, Business Development 

Paul Harris, Ph.D.; VP, R&D 

Reed Simons; VP, Manufacturing 



FACILITIES: 12,000 sq. ft. leased space 

STOCK-FINANCIAL HISTORY: TSX-V--RBM / OTCBB--RPBIF 

Revenue C$3.49M (YE 05) compared to C$2.677M (YE 04) 


Loss per share (YE 05) compared to (YE 

04) 

PRIVATE PLACEMENTS: Raised $1.741M in private placement (12/03) 




SUBSIDIARIES/DIVISIONS: Response Biomedical Inc. 

Response Development Inc. 

BUSINESS STRATEGY: Develop and commercialize point-of-care (POC) diagnostic tests for use with 

its RAMP System for clinical and environmental applications, providing 

reliable information in minutes, anywhere, every time. 


3M Co. POC clinical infectious development 11/04 

disease test based on 

Response Biomedical's 

RAMP technology 

agreement 



Adapco Inc. RAMP West Nile virus 

test 

General Dynamics BiodefenseTechnology 

Canada Ltd. Integration Program 

International 

Biotech Company 

Roche 

Diagnostics 

Shionogi & Co. 

Ltd. 

Shionogi & Co. 

Ltd. 

rapid quantitative test to 

detect biotech traits in 

grain 

exclusive US 

distributor 

Military and 

Homeland Security 

Agencies 

Internationally 

development 

agreement 

NT-proBNP nonexlusive 


rapid quantitative BNP development 

test for congestive heart 

failure in Japan 

agreement 

commercialization of a marketing and 

rapid quantitative RAMP 

test in Japan for BNP 


RESEARCH & DEVELOPMENT: Diagnostic testing systems for point-of-care health, environmental and food 

quality testing 

MIniRamp - quantitative handheld analyzer 

Roal Oy 

PRODUCTS ON MARKET: RAMP® System 

RAMP® Troponin I Assay 

RAMP® Biodetection System 

RAMP® West Nile Virus (WNV) Test 

P.O.B. 57, Tykkimaentie 15 

Rajamaki 05200, Finland 

Phone: +358 (9) 290-420; Fax: +358 (9) 290 42 111 

Web: www.roal.fi 

E-mail: roal@roal.fi 

KEY PERSONNEL: Heinz-Peter Schwarte; Managing Director 

Pentti Honkamaki; Financial Manager 

Dr. Jari Vehmaanpera; Research Director 



Began biotech R&D in September 1997 


SUBSIDIARY OF: ABF Overseas Ltd. (50%), Altia Corp. (50%) 

RESEARCH & DEVELOPMENT: Gene technology for fungi and bacteria 

PRODUCTS ON MARKET: Industrial enzymes for baking, beverage, feed, textile, and pulp and paper 

applications 


12/03 

2/04 

6/04 

7/05 

10/04 

5/06



P.O. Box 12194, 3040 Cornwallis Road 

Research Triangle Park NC 27709-2194, US 

Phone: (919) 541-6000 Toll-free phone: (866) RTI-1958 

Web: www.rti.org 

E-mail: listen@rti.org 

KEY PERSONNEL: Victoria Franchetti Haynes, Ph.D.; President 

Lon E. Maggart; Sr. VP and Chief of Staff 

James J. Gibson; Exec. VP and CFO 

J. Scott Merrell; Sr. VP and CLO 


HISTORY: Founded in 1958 to conduct R&D as contractor for industry and government 

worldwide 

RTI offers innovative research and technical solutions to governments and 

businesses worldwide in the areas of health and pharmaceuticals, education 

and training, surveys and statistics, advanced technology, democratic 

governance, economic and social development, energy and the environment 

FACILITIES: 180-acre campus 

40,000 sq. ft. facilities in other locations 

STOCK-FINANCIAL HISTORY: Nonprofit corporation 

BUSINESS STRATEGY: Provides R&D services to biotech and pharmaceutical companies in drug 

discovery, clinical pharmacology, pharmaceutical R&D, preclinical 

pharmacology and safety, drug delivery, natural products, 

pharmacoeconomics, statistics, chemical engineering and biomedical 

engineering 

RESEARCH & DEVELOPMENT: Psychoactive agents, cancer drugs, hormonal agents, natural products 

PRODUCTS ON MARKET: Sudaan version 7.5--software for statistical analysis of correlated data 


5909 Sea Lion Place, Suite D 

Carlsbad CA 92008, US 

Phone: (760) 929-7744; Fax: (760) 431-7759 

Web: www.safepath.com 

E-mail: info@safepath.com 

KEY PERSONNEL: Paul Hansen; Chairman, President and CEO 

David Lambillotte; Exec. VP and Director, R&D 



Changed name from LMD Agro-Vet, LLC. (1998) 


BUSINESS STRATEGY: Continue its record of innovation in the development, manufacturing and 

marketing of high performance immunoassays 

RESEARCH & DEVELOPMENT: Diagnostics for food animials, water quality and other targeted opportunities 

Immunoassay-based diagnostics for food animals, food quality, water 

quality, and other targeted opportunities 

PRODUCTS ON MARKET: Immunoassays: 

Trichinae for swine 

Toxoplasma for swine 



E. coli O157 for meat 

Verotoxin for meat 

Salmonella 

Giardia in water 

Cryptosporidium in water 

Giardia Iamblia 

Camphylobacter 

Listeria 

Food Allergens: milk, soy, egg, peanut 


1-1-23, Ebisuno-cho-nishi, Sakai 


Phone: +81 72 223 4111; Fax: +81 72 223 8355 

Web: www.sakai-chem.co.jp 

E-mail: sales-t@sakai-chem.co.jp 

KEY PERSONNEL: Kazunobu Abe; President 



Established in February 1932 


Merged with titanium dioxide business of Tohkem Products Corp. (4/00) 

Acquired Kyodo Chemical Co. Ltd. (10/02) 

FACILITIES: Branch offices in Tokyo and Osaka 

Factories in Semboku, Nagano, Yumoto and Otsurugi 

Research center in Osaka 

STOCK-FINANCIAL HISTORY: Listed on Osaka Securities Exchange and Tokyo Stock Exchange 

IPO--3/50 (Osaka), 10/61 (Tokyo) 

SUBSIDIARIES/DIVISIONS: Sakai Division: 

5-1, Ebisujima-cho, Sakai 

Osaka 590-0985 

Phone: +81 72-223-4114 

Fax: +81 72-223-6365 

Onahama Division: 

110, Aza Tajuku, Izumi-machi Shimogawa 

Iwaki, Fukushima 971-8183 

Phone: +81 246 56 5111 

Fax: +81 246 53 5223 

BUSINESS STRATEGY: Provide a stable supply of high quality products through the development of 

advanced technologies, always striving to create new and useful value 


SR Pharma SRP-299 exclusive 


sales agreement in 

Japan 

11/99 

Bioglan ES-Gel exclusive 



Japan 

2/00 

Theratechnologies TH9507 exclusive 



Japan 

5/02 



PRODUCTS ON MARKET: Titanium dioxide 

Stabilizers and metallic soaps 

Barium and strontium products 

Zinc products 

Electronic materials 


Catalysts 

Fine organic chemicals 


11-1 Ikkyo Nomoto-cho, Higashiyama-ku 

Kyoto 605, Japan 

Phone: +81 75-541-4311; Fax: +81 75-551-2557 

Web: www.sanyo-chemical.co.jp 

E-mail: general-affairs@sanyo-chemical.com 

KEY PERSONNEL: Tetsuo Kakehi; Chairman 

Masaaki Ienaga; President 

Fusayoshi Masuda; Exec. VP 





Net sales ¥85,062M (YE 04) compared to ¥82,183M (YE 03) 

Net income ¥3,101M (YE 04) compared to ¥3,255M (YE 03) 

Earnings per share ¥27.31 (YE 04) compared to ¥27.97 (YE 03) 

Total assets ¥112,633M (YE 04) compared to ¥115,013M (YE 03) 

RESEARCH & DEVELOPMENT: Immobilized enzyme technology, enzyme immunodiagnostics, specialty 

chemicals 


Diagnostic MAbs 

Agglutination agent 

PRODUCTS ON MARKET: TOILETTRIES AND HEALTHCARE: Superabsorbent Polymers, Surfactants 

for Hair Care Products, Surfactants for Detergents, Base Materials for 

Cosmetics, Base Materials for Pharmaceuticals, Antibacterial Agents, EIA 

Diagnostic Reagents, Potting Resins for Artificial Kidneys, Pressuresensitive 

Adhesives, Hot Melt Adhesives 

MACHINES AND AUTOMOBILES: Base Materials for Polyurethane Foam, 

Polyurethane Beads for Powder Slush Molding, Lubricating Oil Additives, 

Additives for Fuel Oils, Dewaxing Aids, Base Materials for Synthetic 

Lubricants, Water-soluble Cutting Fluid, CFC-free Cleaning Agents 

PLASTICS: Pigment Dispersants, Permanent Antistatic Agents, Resin 

Modifiers, Base Materials for Polyurethane Elastomer, Epoxy Resin Curing 

Agents, Epoxy Systems, Emulsifiers for Emulsion Polymerization, Paint 

Resins 

TEXTILES: Agents for Textile Manufacturing, Scouring Agents, Dyeing 

Auxiliaries, Textile Finishing Agents, Modifiers for Polyester Fibers, Flame 

Retardants for Polyester Fibers, Polyurethane Resins for Synthetic Leather, 

Agents for Fiber Glass 

ELECTRONICS AND INFORMATION: Toner Resins, Electrolytes for 

Aluminum Electrolytic Capacitors, Electrolytes for Electric Double-layer 

Capacitors, Etching Fluids, UV/EB Curing Resins 




ENVIRONMENTAL PROTECTION AND CONSTRUCTION: Polymer 

Flocculants, Polymers for Enhanced Crude Oil Recovery, Synthetic Wood 

for Models, Water-swellable Sealants, Adhesives for Elastic Paving 

Materials, Permeable Paving Materials, Waterproofing Agents for Concrete, 

Polyurethane for Heat-insulating Materials 

Te Papa Tipu Innovation Park, Private Bag 3020, 49 Sala Street 

Rotorua, New Zealand 

Phone: +64 7 343 5899; Fax: +64 7 348 0952 

Web: www.scionresearch.com 

E-mail: enquiries@scionresearch.com 

KEY PERSONNEL: Dr. Tom Richardson; CEO 

Dr. Tim Strabala; Unit Leader, CellWall Biotechnology Centre 

Dr. Julia Charity; Sr. Scientist, CellWall Biotechnology 

Dr. Phillip Wilcox; Sr. Scientist, CellWall Biotechnology 

Dr. Christian Walter; Sr. Scientist, CellWall Biotechnology 

Dr. Armin Wagner; Sr. Scientist, CellWall Biotechnology 

Dr. Lynette Grace; Sr. Scientist, CellWall Biotechnology 



Commenced molecular biology in 1990 


BUSINESS STRATEGY: The current focus of the CellWall Biotechnology Centre is to provide 

fundamental knowledge on plant cell wall development, genetics, and 

biochemistry. The overall purpose is to spawn science discovery and 

technological innovation, which will create new products and services for 

both forestry and the emerging renewable plant materials markets. 

RESEARCH & DEVELOPMENT: Genome mapping 

DNA profiling 

Marker aided selection 

Genetic diversity surveys 

Gene transformation in conifers and model plants 

Gene isolation 

Promoter isolation and analysis 

Gene expression 

Analysis and manipulation of lignin biosynthesis 

In vitro propagation of forest trees 

Analysis and manipulation of reproductive development in conifers 

Isolation and characterisation of endogenous conifer promoters 

Engineering of insect and pathogen resistance in conifers 

Engineering of herbicide resistance in conifers 

PRODUCTS ON MARKET: DNA testing for forest trees 

Transformation protocols for conifer species 

Somatic embryogenesis technology for conifer species 

Endogenous promoters for gene expression 

Propagation systems for forest trees 




DNA markers for wood properties in development 

Transformation protocols for other conifer 

species 

in commercial evaluation 

Non-flowering radiata pine in development 

Conifers with altered lignin content and/or 

composition 


Efficient methods for mapping ESTS in commercial development 

Power of alternative experimental designs 

for QTL detection 



777 East Wisconsin Avenue 

Milwaukee WI 53202-5304, US 

Phone: (414) 271-6755; Fax: (414) 347-4795 


Web: www.sensient-tech.com 

E-mail: corporate.communications@sensient-tech.com 

KEY PERSONNEL: Kenneth P. Manning; Chairman, President and CEO 

Peter Bradley; President, Color Group 

Richard Carney; VP, Administration 

Richard F. Hobbs; VP, CFO and Treasurer 

Ralph G. Pickles; President, Flavors and Fragrances Group 

Stephen J. Rolfs; VP, Controller and Chief Accounting Officer 

Ho-Seung Yang, Ph.D.; VP, Marketing and Technology 


HISTORY: Founded as Meadow Springs Distillery in 1882 

Company's development focused on yeast through the 1950s 

In the 1960s, the company diversified into consumer foods through 

acquisitions and internal product development, including biotechnology 

Acquired 20 companies since 1997 

FACILITIES: 74 locations in 30 countries 

World headquarters in Milwaukee, Wis. 

Flavors and Fragrances Group--Indianapolis, Ind. 

Color Group--St. Louis, Mo. 

Asia Pacific Group--Singapore 

STOCK-FINANCIAL HISTORY: NYSE--SXT 





04) 

SUBSIDIARIES/DIVISIONS: Flowers and Fragrances Group 

Color Group 

Asia Pacific Group 

BUSINESS STRATEGY: Supply flavors, fragrances and colors used to make foods and beverages, 

pharmaceuticals, cosmetics, home and personal care products, printing and 

imaging products, computer imaging and industrial colors 

PRODUCTS ON MARKET: Dyes, pigments and natural colors 

Flavors and flavoring systems 

Dehydrated vegetable products 

Bioactive antioxidants 

Bioactive plant extracts 

Formulation systems for food, beverage and dietary supplement products 

Pigments and dyes for cosmetics 




Unit 2, Park Lane 

Kidderminster DY11 6TS, UK 

Phone: +44 (0)1562 825286; Fax: +44 (0)1562 825284 

Web: www.severnbiotech.com 

E-mail: info@severnbiotech.com 

KEY PERSONNEL: Andrew Smart; Managing Director/Owner 

Kate Fox; Sales Manager 




500 sq. ft. R&D facilities 



PRODUCTS ON MARKET: DNA, RNA and peptide synthesis 

General reagents 

Electrophoretic media 

Reagent buffers 

Service solutions 

Nucleotides 


13-9, Shiba-Daimon, 1-chome, Minato-ku 


Phone: +81 3-5470-3235; Fax: +81 3-3436-2625 

Web: www.sdk.co.jp 

E-mail: sdk_prir@sdk.co.jp 

KEY PERSONNEL: Mitsuo Ohashi; Chairman 

Kyohei Takahashi; CEO and President 

Hiroshi Nishimoto; Exec. Officer, Petrochemicals 

Tetsuo Tamada; Exec. Officer, Inorganics 

Norio Masubuchi; Exec. Officer, Chemicals 

Koji Kudo; Sr. Corp. Officer and CTO 

Ichiro Nomura; Director, Corp. Services, IR and Finance 

EMPLOYEES: 11,118 employees (consolidated) 

HISTORY: Founded in June 1939 through the merger of Nihon Denki Kogyo KK and 

Showa Hiryo KK 


STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and four other domestic stock exchanges 





SUBSIDIARIES/DIVISIONS: Showa Highpolymer Co. Ltd. 

Showa Denko Plastic Products Co. Ltd. 

Heisei Polymer Co. Ltd. 

Kokusai Eisei Co. Ltd. 

Nippon Polytech Corp. 

Showa Titanium Co. Ltd. 

Showa Denko Kenso Co. Ltd. 

Tohoku Metal Chemical Co. Ltd. 

Showa Aluminum Can Corp. 



Showa Denko Aluminum Trading KK 

Showa Denko Packaging Co. Ltd. 

Showa Engineering Co. Ltd. 

Showa Denko Kenzai KK 

Shoko Co. Ltd. 

Fuyo Perlite Co. Ltd. 

Union Showa KK 

PRINCIPAL INVESTORS: Japan Trustee Services Bank Ltd. 

The Master Trust Bank of Japan Ltd. 

Fukoku Life Insurance Co. 

Sompo Japan Insurance Inc. 

The Dai-ichi Mutual Life Insurance Co. 

Nippon Life Insurance Co. 

Mizuho Corporate Bank Ltd. 

Meiji Yasuda Life Insurance Co. 

Showa Denko Employee Stock Ownership 

Trust & Custody Services Bank Ltd. 

BUSINESS STRATEGY: Development of new compounds and leading-edge technologies through 

biotechnology and organic synthesis technology 

RESEARCH & DEVELOPMENT: Technology platforms: 

Oranic electronic materials 

Batteries 

Capacitors 

Magnetic/recording media materials 

Crystal growth process 

Thin film deposition process 

Precision fabricating process 

Micro-system process 

Functional gases 

Ultimate conditions process 

Heat transfer system 

Castion process 

Plasticity process 

Bonding 

Functional metallic materials 

Functional molecular design 

Controlled reaction design 

High-performance catalysts 

Specialty polymer design 

Fine particles 

Biochemistry 

Organic chemicals manufacturing process 

Surface and interface chemistry 

PRODUCTS ON MARKET: Petrochemicals: Ethylene, propylene, C4 fraction, cracked fuel oil, 

acetaldehyde, acetic acid, vinyl acetate, ethyl acetate, allyl alcohol, allyl 

ester resin 

Chemicals: Oxygen, nitrogen, argon, mixed gases, fusing ethylene, 

hydrogen, liquefied hydrogen, helium, Nitrogen/JP (laughing gas), 

AnesoxynT (inhaled painkiller), FumitoxinT (aluminum phosphide), 

AnesoxynT (system for treating excess anesthetic gas), Elaslen 

(Chlorinated polyethylene), Ecoflamer (environmentally-friendly elastomer), 

Showflamer (non-plasticizer chlorinated elastomer), Showa Denko 

Chloroprene (Chloroprene rubber), Showpalon (Chlorinated rubber), 

industrial amino acids for food additives, feed additives, cosmetic 

ingredients, amino acids for perm agents, chelating agents, biodegradable 

chelating agents, raw materials for photographic chemicals, Acrylonitrile 

(AN), High-purity FC-14, High-purity HFC-23, High-purity HFC-32, Highpurity 

FC-116, High-purity FC-C318, High-purity boron trichloride, Highpurity 

chlorine, High-purity hydrogen bromide, High-purity sulfur 

hexafluoride, High-purity nitrogen trifluoride, High-purity ammonia, Highpurity 

nitrogen monoxide, High-purity HFC-41, High-purity FC-218, High- 




purity FC-2316, High-purity tantalum pentaethoxide, High-purity nitrogen 

monoxide (for electronic materials), treatment equipment for acid gases 

discharged from the dry etching process, treatment equipment for globalwarming 

PFC emissions discharged from the dry etching process, fluorine 

generators, erosion/wear resistance surface treatment, leak detectors, 

fluorine/chlorine resistance bellows seal valves, ozone depleting gas 

scrubber, Ascorbic acid PM (APM; water-soluble, stable vitamin C 

derivative), Ascorbic acid PS (APS; water-soluble, stable vitamin C 

derivative), Apprecier (highly permeable, water-soluble vitamin C derivative), 

MaxlightT TS/F-TS (silica-coated TiO2), MaxlightT ZS (silica-coated ZnO), 

AminofectT (biosurfactant), PhospitanT C (stabilized vitamin C for food 

additive), Shodex (high-speed liquid chromatographic columns and 

instruments), Autoprep (pre-treatment for analysis), functional monomers, 

intermediates, Nanomax (UV interception zinc oxide masterbatch), 

Nanoallomer (titanium dioxide masterbatch for optical catalyst), 

Nanocoat (titanium dioxide suitable for optical catalyst coating), 

Monogermane GeH4, Xenon difluoride, Triflic acids 

(trifluoromethanesulfonic acids) CF3SO3H, Sodium borohydride NaBH4, 

CHITOSAR (chitosan -containing fertilizer), IR-photosensitive dyes, organic 

borate, DMP Metal Complex (Materials for MOCVD) 

Inorganic materials: Alumina products, aluminum hydroxide products 

(Higilite), alumina electrical filler materials, fused materials for refractory, 

fluxes, super abrasives, abrasive grains, lapping and polishing materials, 

polishing materials, lubrication and mold-release agents, plasma spraying 

materials, fine ceramics materials, shaped productions of fine ceramics 

materials, materials for photocatalyst applications, materials for heatradiation 

fillers, graphite electrodes, Carbon nanofiber (VGCF series), 

Negative-electrode material for lithium-ion batteries (SCMG), Artificial 

graphite powder (UF-G), Glassy carbon composite (SG, SR) 

Ak. Timakova Str., 2/12, 117, Academtown 

Novosibirsk 630117, Russia 

Phone: +7 383-333-4991; Fax: +7 383-333-6853 

Web: www.sibenzyme.com; E-mail: info@sibenzyme.com 

KEY PERSONNEL: Victoria Sit’ko, Ph.D.; Head, International Operations 

EMPLOYEES: 70 employees, 12 Ph.D.s, 45 M.D.s 



BUSINESS STRATEGY: Specialize in R&D, manufacture and bulk sale mostly of new enzymes. 

Product range includes enzymes of nucleic acids methabolism and related 

products for the research in molecular biology and genetic engineering 

PRODUCTS ON MARKET: 170 Restriction Enzymes, most of them (including unique) were discovered 

and characterized at SibEnzyme Ltd. 

Other enzymes for molecular biology application, DNA preparations, DNA 

Markers, Nucleotides 




12815 NE 124th Street, Suite I 

Kirkland WA 98034, US 

Phone: (425) 650-2000; Fax: (425) 650-2008 


Web: www.solomonpark.com 

E-mail: pclapshaw@solomon.org 

KEY PERSONNEL: Patric A. Clapshaw, Ph.D.; Director 

Julie Nebeker; Office Manager 

Mary Zimmer; Laboratory Manager 

Kimberly Anderson; Shipping Manager 


HISTORY: Founded in 1984 as a supplier of apolipoprotein 

FACILITIES: 2,000 sq. ft. of fully equipped biochemistry, histology and tissue culture 

facilities 


BUSINESS STRATEGY: Supply phlebotomy services, as well as human blood products for external 

quality controls, proficiency testing and calibrators 

PRODUCTS ON MARKET: Serum and plasma for custom pools for calibrators, internal controls, 

external controls, standards and proficiency testing materials 

Lipid reference controls 


P. O. Box 388 

Emmen 7800 AJ, Netherlands 

Phone: +31 591-631700; Fax: +31 591-630035 


Web: www.spark.nl; E-mail: sales@sparkholland.com 

KEY PERSONNEL: Rob Castien; President 

Marcel Jansen; Manager, Sales and Marketing 

Rob van der Knaap; Manager, R&D 

H. van Oort; Purchasing Manager 

J. Crutchfield; General Manager, USA Operations 



FACILITIES: 2,250 sq. m. facility 


SUBSIDIARIES/DIVISIONS: Spark Holland Inc.--US sales and service office 

666 Plainsboro Road, Suite 1336 

Plainsboro, NJ 08536, USA 

Phone: (609) 799-7250 

Fax: (609) 799-8250 

E-mail: usa@sparkholland.com 


Provide the analytical laboratory with innovative sample introduction, 

extraction and separation technology, enabling seamless integration of 

automated front end sample preparation into analytical systems such as 

HPLC, MS, GC and NMR. By pro-active gathering customer feedback we 

seek to understand the analytical problems in the mentioned markets. This 

knowledge will direct our R&D efforts. We aim to market our technology 



under private label as front-end system solutions and through OEM 

partnering as customized system components. 

Our organization will operate with mutual trust and respect to our customers, 

suppliers, employees, shareholders and other parties. Honesty and the right 

values will be the basis for our activities. We want to create excellent 

shareholder value and achieve sustainable growth by investing in research 

and development. We will nurture innovation and continue to look for ways 

to improve our products and services. 

RESEARCH & DEVELOPMENT: Develop and manufacture automatic sample handling and sample 

preparation systems for LC and LC MS 

PRODUCTS ON MARKET: Symbiosis system ( automated sample preparation system) 

Mistral column oven 

Triathlon Endurance autosampler 

Midas autosampler 

Reliance autosampler 

Basic Marathon autosampler 

Spherix Inc. 

12051 Indian Creek Court 

Beltsville MD 20705, US 

Phone: (301) 419-3900; Fax: (301) 210-4908 

Web: www.spherix.com 

E-mail: info@spherix.com 

KEY PERSONNEL: Dr. Gilbert V. Levin; Chairman and Exec. Officer for Science 

Richard C. Levin; CEO and President 

Roger A. Downs; VP, Operations 

Steven M. Wade; VP, Information Technology 

Jeffrey T. Lowe; VP, Corporate Communications 

Katherine M. Brailer; Corporate Secretary 



Sold Environmental & Laboratory Service Division to ManTech 

Environmental Corp. (3/96) 

FACILITIES: 95,000 sq. ft. office facility 

12,700 sq. ft. regional office located in Cumberland, Md. 

STOCK-FINANCIAL HISTORY: NASDAQ--SPEX 


Revenue $23.046M (YE 05) compared $22.348M (YE 04) 



SUBSIDIARIES/DIVISIONS: InfoSpherix Inc. (wholly-owned subsidiary) 

BioSpherix Division 

BUSINESS STRATEGY: Create value and increase the wealth of our shareholders through 

innovations that benefit our clients and the human condition 


Albert Einstein certain medicinal uses licensing agreement 11/05 

College of 

Medicine 

of Naturlose 

GleneaglesCRC Naturlose for the GleneaglesCRC to 5/06 

treatment for Type II conduct Phase IIII 

diabetes 

trials 

MD Foods 

Ingredients amba 

(Denmark) 

D-tagatose licensing agreement 1/97 



Tetra 


PhoStrip wastewater 

treatment technology 

patent rights in 

exchange for 

payments and 

continuing royalties 

on sales 

RESEARCH & DEVELOPMENT: Nonfattening sugars, antidiabetes agent, information systems, and database 

management in health and education 

PRODUCTS ON MARKET: Call center for reservations 

Telephone hotlines and information management for clinical trials applicants 

(for major pharmaceutical companies) 

PhoStrip® system for phosphorus removal from wastewater 

Tagatose nonfattening sweetner 


Naturlose for Type II diabetes to begin Phase III 


333 Ravenswood Avenue 

Menlo Park CA 94025-3493, US 

Phone: (650) 859-2000; Fax: (650) 859-2889 


Web: www.sri.com/biosciences 

E-mail: biosciences@sri.com 

KEY PERSONNEL: Samuel H. Armacost; Chairman 

Curtis R. Carlson; CEO and President 

Thomas J. Furst; Senior Vice President and CFO 

Dennis Beatrice; VP, Policy Division 

Lawrence H. Dubois; VP, Physical Sciences 

William Mark; VP, Information and Computing Sciences 

Walter Moos; VP, Biosciences Division 

John W. Prausa; VP, Engineering and Systems Division 

Leonard Polizzotto; VP, Business Development and Marketing 

Alice R. Resnick; VP, Corporate and Marketing Communications 

Norman Winarsky; VP, Ventures and Strategic Programs 


HISTORY: Founded as Stanford Research Institute in 1946 

Spun out Artificial Muscle Inc. and Bridge Pharmaceuticals (2004) 

To acquire Quality Clinical Labs (as of 4/06) 

Member--American Association for Cancer Research 

Member--American Association of Pharmaceutical Scientists 

Member--American Chemical Society 


Member--Drug Information Association 

FACILITIES: Headquarters on 63-acre campus with more than 1.4M sq. ft. in Menlo Park, 

Calif. 

Offices located in the U.S., Europe and Asia 

STOCK-FINANCIAL HISTORY: Private, nonprofit contract research organization 

SUBSIDIARIES/DIVISIONS: Sarnoff Corp.--Princeton, N.J. 

Five divisions: Engineering and Systems, Policy, Information and Computing 

Sciences, Biosciences and Physical Sciences 

BUSINESS STRATEGY: Grow by building and leveraging our assets--client relationships, our 

intellectual property and staff--in important markets 


4/91



Biosource 

oncology, infectious joint R&D 

1/96 

Technologies disease, and 

inflammation treatments 

agreement 

Dura 

SRI's jet milling process licensing agreement 7/97 

Pharmaceuticals for protein and peptide 

formulations of dry 

powder drugs for use 

with Dura's Spiros 

pulmonary drug delivery 

technology 

MDS Panlabs, combinatorial chemistry technology access 3/98 

Tripos Inc., libraries for designing agreement--Tripos 

Genelabs 


will design 

Technologies Inc. compounds that bind compounds via 

double-stranded DNA molecular modeling, 

MDS Panlabs will 

synthesize 

compounds, SRI 

(working 

independently) will 

use solid-phase 

combinatorial 

synthesis to make 

molecules to 

Genelabs 

specifications 

Taiho 

endocrine approach for research agreement 10/96 

Pharmaceutical chemotherapy in 

Co. Ltd. 

estrogen-dependent 

breast cancer 

RESEARCH & DEVELOPMENT: Pharmaceutical Discovery and Screening: custom drug design, synthesis 

and efficacy screens for drug development of: antibacterials; antivirals; 

anticancer agents; lipid-lowering agents; neurobiological therapeutics; 

women's health therapeutics; steroids (anti-inflammation, hormone analogs, 

vitamin analogs, neuroprotection); and other synthetic drugs (anticancer, 

anti-inflammation, anti-angiogenesis, nootropics, cardiovascular, CNS, 

neuroprotection), combinatorial chemistry; radiolabeled synthesis; process 

development; scale-up 

Biopharmaceutical Development: pharmacology, mammalian toxicology; 

molecular and genetic toxicology; microbiology, pharmacokinetic and 

metabolism studies; in vitro comparative metabolism; immunology and 

immunotoxicology; cGMP manufacturing; formulation design; 

preformulation; stability monitoring; analytical chemistry 

Drug Delivery: transdermal; topical; controlled release; standard 

formulations (oral, injectable, topical); alternative drug delivery (aerosols, 

nasal, controlled release, microencapsulation, taste masking, bioerodable 

polymers, protein peptide delivery) 


Edatrexate (with Memorial Sloan Kettering) in Phase I clinicals 

Tirapazamine (with Sanofi) in Phase III clinicals 

SR 4980 in preclinicals 




SR 4554 (with CRCT) in preclinicals 

SR 16234 (TAS-108) (with Taiho) in preclinicals 

*pipeline as of 10/05 




P.O. Box 509 

Macon MO 63552, US 

Phone: (660) 762-4240; Fax: (660) 762-4295 

Web: www.stewartag.com 

E-mail: stewart1@marktwain.net 

KEY PERSONNEL: Ellsworth R. Stewart; President and Treasurer 

David R. Johnson, Ph.D.; VP 

Patricia A. Stewart; Secretary 

EMPLOYEES: 25 employees, 6 Ph.D.s, 6 M.D.s. 

HISTORY: Independent company which has been providing services to the life science 

and chemical industries since 1975 

FACILITIES: 832 acre research farm in north central Missouri 

Offices in Arlington, Va. and Columbia, Mo. 

Facilities and headquarters in Macon, Mo. 


BUSINESS STRATEGY: Provide a broad spectrum of services to its clients that enable them to 

identify, register, develop, and commercialize successful products 

PRODUCTS ON MARKET: Services include: screening, efficacy testing, study monitoring, regulatory 

project coordination, efficacy project coordination, market assessment, 

marketing agreements, new product technology, product development, QA 

monitoring, registration, reregistration, organizational development, 

technology management, licensing agreements, data package development, 

strategic planning, training, seminars, diagnostics 


11011 N. Torrey Pines Road 

La Jolla CA 92037, US 

Phone: (858) 373-6300; Fax: (858) 535-0034 


Web: www.stratagene.com; E-mail: info@stratagene.com 

KEY PERSONNEL: Joseph A. Sorge, M.D.; Chairman and CEO 

Steve R. Martin; VP and CFO 

Ronni L. Sherman; Exec. VP and General Counsel 

John R. Pouk; Sr. VP, Global Sales and International Operations 

Nelson F. Thune; Sr. VP, Operations and GM, Hycor Biomedical Inc. 



Name changed from Stratagene Cloning Systems (1990) 

Merged with Hycor Biomedical Inc. (6/04) 

FACILITIES: Headquarters and R&D facilities in La Jolla, Calif. 

Manufacturing facility in Austin, Texas, includes Reagent and Instrument 

Manufacturing/Production Planning facilities 

Additional offices in Amsterdam, the Netherlands and Tokyo, Japan 

STOCK-FINANCIAL HISTORY: NASDAQ--STGN 





04) 




SUBSIDIARIES/DIVISIONS: Hycor Biomedical Inc.--Garden Grove, Calif. (see separate entry) 


Affymetrix Inc. Stratagene to provide nonexclusive 2/05 

software for GeneChip 

data analysis and 

develop ArrayAssist Life 

software 

alliance 

Jingmei Biotech 

Co. Ltd. 

Layton BioScience 

Inc. 

Rosetta 

Inpharmatics LLC 

Strand Life 

Sciences 

all products exclusive 

distribution 

agreement for 

Layton's hNT human 

neuronal cell kits, cDNA 

libraries derived from 

LNT neuron cells 

creation of an 

automated solution for 

the isolation of nucleic 

acids from clinical 

samples 

suite of next-generation 

bioinformatics software 


China 

marketing and 

distribution 


U.S., Canada, 

Europe, and the Far 

East 



development 

partnership 

RESEARCH & DEVELOPMENT: Research reagents 

Transgenic technology for modeling and assaying human diseases 

Enzymes 

Human genome mapping technology 

Genetic diseases 

PRODUCTS ON MARKET: More than 1,000 molecular biotechnology products for the research market, 

including antibodies, bioinformatics software, Quantos Cell Proliferation 

Assay Kit, cloning vectors, DNA extraction and microextraction kits, 

fluorescent proteins, benchtop coolers, microcentrifuges, Parafilm® 

dispensers, PCR labware, radioactivity shields, real-time instruments, 

temperature cyclers, tips and tubes, library construction products, library 

packaging extracts and host strains, markers and restriction enzymes, mass 

spectrometry, microarray reagents, modifying enzymes, mutagenesis, 

cloning kits, PCR instruments, PCR reagents, premade libraries, protein 

expression systems, QPCR & QRT-PCR reagents, real-time instruments, 

reference RNA, Absolutely RNA® nanoprep, miniprep and micorprep kits, 

RT-PCR reagents, RNA, DNA, two-hybrid products and viral gene delivery 

systems 


111 Pencader Drive 

Newark DE 19702, US 

Phone: (302) 456-6789; Fax: (302) 456-6770 


Web: www.sdix.com 

E-mail: sales@sdix.com 

KEY PERSONNEL: Grover Wrenn; Chairman 

Matthew H. Knight; President and CEO 

Tony Simonetta; CFO 

James W. Stave, Ph.D.; VP, R&D 

Jim Byron; National Sales Manager 

David Schlecker; Director, Human Resources 


8/94 

8/06 

12/05



Acquired Ohmicron (6/96) 

Acquired TSD BioServices Inc. (6/96) 

Acquired EnSys Environmental Products Inc. (12/96) 

Acquired HTI Bio-Products Inc. (1998) 

Acquired AZUR Environmental (2001) 

FACILITIES: 28,655 sq. ft. headquarters in Newark, Del. 

25,600 sq. ft. R&D and technical facility in Newark, Del. 

STOCK-FINANCIAL HISTORY: NASDAQ--SDIX 


Net income $584K (YE 05) compared to $1.379M (YE 04) 



04) 


SUBSIDIARIES/DIVISIONS: Strategic BioSolutions (www.strategicbiosolutions.com) 

SDI Europe 

BUSINESS STRATEGY: Strategic Diagnostics is a custom antibody production and services 

company and a leader in using immunoassay and bio-response technology 

to assure safety and quality in food, water and other environmental matrices. 


US Biosystems SDI's environmental exclusive distribution 4/05 

(USB) 

test kits when sold 

through an analytical, 

laboratory channel 

agreement 

RESEARCH & DEVELOPMENT: Rapid quantitative lateral flow assays 

Genetic modified crop test kits 

PRODUCTS ON MARKET: GeneChek® 

RaPID Assay® 

EnviroGard® 

DTECH® 

RapidChek® 

TraitChek® 

SeedChek® 


27-1 Shinkawa, 2-chome, Chuo-ku 


Phone: +81 3-5543-5500; Fax: +81 3-5543-5901 

Web: www.sumitomo-chem.co.jp 

E-mail: info@sumitomo-chem.co.jp 

KEY PERSONNEL: Hiromasa Yonekura; President 

Masami Nakamoto; Exec. VP 

Satoshi Kawachi; Exec. VP 

Shigehiro Oba; Sr. Managing Exec. Officer, Agricultural Chemicals Sector 

Ichiro Miyawaki; Sr. Managing Exec. Officer, Petrochemicals and Plastics 

Sector 

Hideaki Watababe; Sr. Managing Exec. Officer, Basic Chemicals Sector 

Masashi Araki; Managing Exec. Officer, Fine Chemicals Sector 

Naoya Kanda; Sr. Managing Exec. Officer 

Osamu Ishitobi; Sr. Managing Exec. Officer 


HISTORY: Founded in Sepember 1913 



FACILITIES: Headquarters in Osaka and Tokyo, Japan 

Laboratories and research facilities in Takarazuka, Ehime, Chiba, Osaka, 

Takatsuki, and Tsukuba 

Manufacturing facilities in Ehime, Oita, Osaka, Chiba, Aomori and Singapore 





04) 


SUBSIDIARIES/DIVISIONS: 104 subsidiaries and affiliates, including: 

Sumitomo Pharmaceuticals Co. Ltd. (see separate entry) 

Koei Chemical Co. Ltd. 

Taoka Chemical Co. Ltd. 

The Polyolefin Company (Singapore) Pte. Ltd. 

Sumitomo Chemical America Inc. 

Valent U.S.A. Corp. 

Nihon Medi-Physics Co. Ltd. 

Sumika Fine Chemicals Co. Ltd. 

BUSINESS STRATEGY: Create new and useful technologies and products in order to improve living 

standards and alleviate the problems of society 

PRODUCTS ON MARKET: Basic chemicals 

Petrochemicals and plastics 


IT-related chemicals 

Agricultural chemicals 


SunOpta Inc. 

2838 Bovaird Drive West 

Brampton L7A 0H2, Canada 

Phone: (905) 455-2528; Fax: (905) 455-2529 

Web: www.sunopta.com 

E-mail: susan.wiekenkamp@sunopta.com 

KEY PERSONNEL: Jeremy N. Kendall; Chairman and CEO 

Steven R. Bromley; President and COO 

John H. Dietrich; VP and CFO 

Benjamin Chhiba; VP and General Counsel 

Roger Eacock; VP, Supply Chain 

Debra A. Boyle; Corp. VP, Public Relations 

Allan G. Routh; President, SunOpta Grains and Foods Group 

Arthur J. McEvily; President, SunOpta Ingredients Group 

Sergio A. Varela; President, SunOpta Fruit Group 

Joseph J. Stern; President, Organic Ingredients and Exec. VP, SunOpta 

Fruit Group 

Stephen B. Easterbrook; President, SunOpta Canadian Food Distribution 

Group 

David J. Kruse; President and COO, Opta Minerals Inc. 

Murray Burke; VP and GM, SunOpta BioProcess Group 


HISTORY: Founded in 1973 as Stake Technology 

Acquired Barnes Environmental International (1995) 

Created the SunOpta Food Group (1999) 

SunOpta Food Group acquired Sunrich Inc. (8/99) 

Opta Minerals acquired eorge F. Pettinos (Canada) Ltd. (PECAL) (3/00) 

SunOpta Food Group acquired Northern Food and Dairy Inc. (9/00) 



Opta Minerals acquired Temisca Inc. (11/00) 

SunOpta Food Group acquired First Light Foods Inc. (3/01) 

Opta Minerals acquired Virginia Materials and Supplies Inc. (10/01) 

Opta Minerals acquired a 51% interest in International Materials & Supplies 

Inc. (10/01) 

SunOpta Food Group acquired Wild West Organic Harvest Co-operative 

Association (11/02) 

SunOpta Food Group acquired Simply Organic Co. Ltd. (12/02) 

SunOpta Food Group acquired Opta Food Ingredients Inc. (12/02) 

SunOpta Food Group acquired Kettle Valley Dried Fruit Ltd. (5/03) 

SunOpta Food Group acquired Pro Organics Marketing Inc. (10/03) 

Changed name to SunOpta Inc. (10/03) 

SunOpta Food Group acquired SIGCO Sun Products Inc. (11/03) 

Opta Minerals acquired the remaining 49% of International Materials (11/03) 

SunOpta Food Group acquired Sonne Labs Inc. (12/03) 

SunOpta Food Group acquired Distribue-Vie Fruits & Legumes Biologiques 

Inc. (3/04) 

SunOpta Food Group acquired Supreme Foods Ltd. (5/04) 

SunOpta Food Group acquired the assets of Snapdragon Natural Foods Inc. 

(5/04) 

SunOpta Food Group acquired Kofman-Barenholtz Foods Ltd. (9/04) 

SunOpta Food Group acquired 51% of the outstanding shares of Organic 

Ingredients Inc. (9/04) 

SunOpta Food Group acquired remaining 49.9% of Organic Ingredients 

(4/05) 

Opta Minerals acquired Distribution A&L (4/04) 

SunOpta Food Group acquired Earthwise Processors LLC (6/05) 

SunOpta Food Group acquired Cleugh’s Frozen Foods Inc. (6/05) 

SunOpta Food Group acquired Pacific Fruit Processors Inc. (7/05) 

Opta Minerals acquired certain assets of the abrasives production division of 

Hillcrest Industries Inc. (10/05) 

SunOpta Food Group acquiredLes Importations Cacheres Hahamovitch Inc. 

(12/05) 

Opta Minerals acquired Magnesium Technologies Corp. (2/06) 

STOCK-FINANCIAL HISTORY: NASDAQ--STKL / TSX--SOY 


Net earnings $13.558M (YE 05) compared to $11.016M (YE 04) 



SUBSIDIARIES/DIVISIONS: SunOpta Food Group: Natural, organic and specialty foods markets. 

Comprised of four operating groups: 

SunOpta Grains and Foods Group: Bringing identity preserved, non-GMO 

and organic soybeans, sunflower and corn products to market utilizing 

vertically integrated business models, and markets value-added soymilk 

concentrates, powders and ingredients, aseptic and ESL soy and rice 

beverages and grain snacks 

SunOpta Ingredients Group: Technical processing and contract 

manufacturing of value-added food ingredients such as oat fibers, stabilized 

brans, germs and natural preservatives 

SunOpta Fruit Group: Global sourcing and processing of organic and natural 

fruits, fruit ingredients and packaged products for industrial, food service and 

private label retail customers 

SunOpta Canadian Food Distribution Group: Distributor of organic, natural, 

kosher and specialty foods 

Opta Minerals Inc. (TSX--OPM, 70.6% owned): Processing and recycling 

silica free abrasives and a wide range of industrial minerals 

SunOpta BioProcess Group: Processing of biomass for the production of 

cellulosic ethanol and other bio-products 


Symbio 



Rapidly grow revenues, profits and shareholder value through an effective 

balance of internal growth and acquisition, with a focus on integrated 

business models in the natural, organic and specialty food markets 


Mikro-Technik sales, marketing and exclusive licensing 6/06 

GmbH & Co. KG distribution of Mikro- 

Technik's wheat and 

bamboo fibers and 

powdered cellulose 

products in North 

America 

arrangement with 

Royal Nedalco Nedalco's pentose 

fermenting yeast for the 

production of cellulosic 

ethanol in North 

America 


38 Bookham Industrial Park, Church Road 

Great Bookham KT23 3EU, UK 

Phone: +44 (0) 1372 456101; Fax: +44 (0) 1372 456099 

Web: www.symbio.co.uk 

E-mail: info@symbio.co.uk 

KEY PERSONNEL: Martin Ward; President 

David Ward, B.Sc.; Sr. Scientist 

Polly Gearing; Head, Administration 

Judy Moffat; Head, Accounts and Credit Control 



Commenced sales in 1991 

Began international distribution in 1995 





BUSINESS STRATEGY: Develop and market biotech solutions for industry and the environment, 

specifically: waste water and industrial effluent; sports turf and horticulture; 

forestry and arboriculture; industrial and commercial cleaning; lake and river 

restoration and management; and soil decontamination 

RESEARCH & DEVELOPMENT: Biological plant growth enhancement 

Wastewater and industrial effluent treatment 


Sports turf fungal control in field trials 



Syngenta International AG 

P.O. Box 


Phone: +41 61 323 11 11 

Web: www.syngenta.com 

KEY PERSONNEL: Martin Taylor; Chairman 

Michael Pragnell; CEO 

John Atkin; COO, Crop Protection 

Bruce Bissell; Head, Global Operations and Human Resources 

David Jones; Head, Business Development 

David Lawrence; Head, R&D 

Michael Mack; COO, Seeds 

Christoph Mader; Head, Legal and Taxes 

Domenico Scala; CFO 


HISTORY: Formed in November 2000 from the merger of Novartis and AstraZeneca’s 

agribusinesses 

Acquired all outstanding shares of Dia-Engei (2/04) 

To acquire Emergent Genetics Vegetable A/S (as of 6/06) 

To acquire Conrad Fafard, Inc. (as of 7/06) 

FACILITIES: Four major research sites--Located in Switzerland, the U.K. and the U.S. 

Two molecular marker laboratories--Located in Stanton Minn., and 

Toulouse, France 

STOCK-FINANCIAL HISTORY: Swiss stock exchange--SYNN / NYSE--SYT 

Sales $8.104b (YE 05) compared to $7.269b (YE 04) 




SUBSIDIARIES/DIVISIONS: Syngenta Agro SA--Argentina 

Syngenta Crop Protection Pty. Ltd.--Sydney, Australia 

Syngenta Seeds Pty Ltd.--Australia 

Syngenta Crop Protection NV--Brussels, Belgium 

Syngenta Seeds NV--Brussels, Belgium 

Syngenta Protecao de Cultivos Ltda.--Sao Paulo, Brazil 

Syngenta Crop Protection Canada Inc.--Guelph, Ontario 

Syngenta Seeds Canada Inc.--Arva, Ontario 

Syngenta Agribusiness SA--Santiago, Chile 

Syngenta (China) Investment Co. Ltd.--Shanghai, China 

Syngenta Crop Protection Ltd.--Hong Kong 

Syngenta Seeds (Beijing) Co. Ltd.--Beijing, China 

Syngenta SA--Bogota, Columbia 

Syngenta Czech s.r.o.--Czech Republic 

Syngenta Seeds A/S--Skaelskor, Denmark 

Syngenta Crop Protection A/S--Copenhagen, Denmark 

Syngenta Agro SAE--Giza, Egypt 

Syngenta Agro SAS--France 

Syngenta Seeds SAS--France 

Syngenta Agro GmbH--Germany 

Syngenta Seeds GmbH--Germany 

Syngenta Hellas AEBE--Athens, Greece 

Syngenta LAN SA--Guatemala 

Syngenta Kft--Budapest, Hungary 

Syngenta India Ltd.--Mumbai, India 

Syngenta Crop Protection SpA--Milan, Italy 

Syngenta Japan KK--Tokyo, Japan 

Syngenta Seeds KK--Japan 

Syngenta Crop Protection Sdn. Bhd.--Malaysia 

Syngenta Maroc SA--Casablanca, Morocco 



Syngenta Seeds BV--The Netherlands 

Syngenta Crop Protection BV--The Netherlands 

Syngenta Pakistan Ltd.--Pakistan 

Syngenta Crop Protection Lda.--Lisbon, Portugal 

O.O.O. Syngenta--Moscow, Russia 

Syngenta Asia Pacific Pte. Ltd.--Singapore 

Syngenta South Africa (Pty.) Ltd.--Johannesburg, South Africa 

Syngenta Korea Ltd.--Seoul, South Korea 

Syngenta Agro SA--Madrid, Spain 

Syngenta Seeds SA--Barcelona, Spain 

Syngenta Seeds AB--Sweden 

Syngenta Crop Protection AG--Basel, Switzerland 

Syngenta Seeds--Basel, Switzerland 

Syngenta Crop Protection Schweizerhalle AG--Pratteln, Switzerland 

Syngenta Crop Protection Munchwilen AG--Switzerland 

Syngenta Agro AG--Dielsdorf, Switzerland 

Syngenta Crop Protection Monthey SA--Monthey, Switzerland 

Syngenta Crop Protection Ltd.--Bangkok, Thailand 

Syngenta Seeds Ltd.--Bangkok, Thailand 

Syngenta Tarim Sanayi ve Ticaret AS--Turkey 

Syngenta Crop Protection UK Ltd.--U.K. 

Syngenta Seeds Ltd.--U.K. 

TOV Syngenta--Kiev, Ukraine 

Syngenta Crop Protection Inc.--Greensboro, N.C. 

Syngenta Seeds Inc.--Golden Valley, Minn. 

Syngenta Corp.--Wilmington, Dela. 

Syngenta Vietnam Ltd. 


COMPO development and 

marketing of a 

comprehensive range of 

plant protection and 

pest control products 


Delta and Pine biotechnology products development and 8/04 

Land Co. 

for cotton 


agreement 

Diversa establishment of shared 

biotechnology research 

platform and discovery 

Sumitomo 

Chemical 

of products 

research and 

product 

development 

collaboration 

SYN 523 herbicide development and 

marketing 

Tanimura & Antle joint venture, Dulcinea 

Farms LLC, to market 

Dulcinea brand produce 

items 


12/02 

2/05 

agreement 


RESEARCH & DEVELOPMENT: Chemical innovation to discover new active ingredients: Plans to launch one 

active ingredient per year 

Product innovation using existing active ingredients 

New products through plant breeding (vegetables and flowers): Input traits-- 

Full suite of stacked traits in corn, glyphosate tolerance and resistance to 

leaf and soil insects, Output traits--Corn for animal feed and ethanol 

production 

PRODUCTS ON MARKET: Actara®, Amistar®, Callisto®, Cruiser®, Dual Gold®, Gramoxone®, 

Karate®, Ridomil Gold®, Score®, Topik®, Touchdown®, Garst®, Golden 

Harvest®, NK®, Rogers®, S&G®



Active ingredients: 

Mandipropamid in late development 

Insecticide in late development 

Fungicides in early development 

Herbicide 1 in early development 

Herbicide 2 in early development 

Corn traits: 

Corn Root Worm (CRW) in elite breeding, planned 

launch in 2007 

GT / CRW in elite breeding, planned 


CRW / ECB in elite breeding, planned 


GT / CRW / ECB in elite breeding, planned 


Corn amylase (biofuels) in late development 

Corn phytase in early development 


1290 Industrial Way 

Albany OR 97322, US 

Phone: (541) 967-6575; Fax: (541) 967-9424 

Web: www.synthetech.com 

E-mail: customer@synthetech.com 

KEY PERSONNEL: Daniel T. Fagan; Chairman 

Dr. Gregory Hahn; President and COO 

Gary Weber; CFO and VP, Finance and Administration 

Dr. Mike Standen; Director, Technology 

Brett Reynolds; Director, Sales and Marketing 


HISTORY: Founded in 1981 by Paul Ahrens 

Acquired fine chemicals manufacturing facilities in Albany, Ore. (1987) 

Acquired technology assets and customer lists of Colorado Biotechnology 

Associates Inc. (1/06) 

FACILITIES: 25,000 sq. ft. manufacturing plant, research labs, warehouse and 

administrative offices 

20,000 sq. ft. pilot manufacturing plant 

STOCK-FINANCIAL HISTORY: NASDAQ--NZYM 

IPO--3M shares at $1/share, $3M (1984) 




PRIVATE PLACEMENTS: $1M private placement of stock and warrants (8/91) 

$1M exercise of above warrants (3/96) 

BUSINESS STRATEGY: Develop and market amino acid derivatives 

Develop and scale-up bio-organic processes for chiral fine chemicals and 

pharmaceutical intermediates, especially specialty amino acids and 

derivatives 


Biomeasure Inc. specialty amino acids supply and 

technology 

agreement 

5/89 

Miwon Korea aspartame licensing agreement 12/89 



RESEARCH & DEVELOPMENT: Focus is on nonnatural amino acids, amino acid derivatives, and small 

peptides for pharmaceutical applications (peptides, peptidomimetics, small 

molecules, etc.) 

PRODUCTS ON MARKET: Peptide building blocks--more than 400 products on market in 22 countries 

Wide range of amino acid derivatives, amino alcohols, and specialty amino 

acids--capacity from kilos to tons 


9601 Blackwell Road, Ste. 200 

Rockville MD 20850, US 

Phone: (240) 238-0800; Fax: (240) 238-0888 

Web: www.syntheticgenomics.com 

E-mail: info@syntheticgenomics.com 

KEY PERSONNEL: J. Craig Venter, Ph.D.; Chairman, CEO and Co-CSO 

Aristides Patrinos, Ph.D.; President 

Hamilton O. Smith, M.D.; Exec. VP and Co-CSO 

David Kiernan, M.D.; Exec. VP and General Counsel 




BUSINESS STRATEGY: Develop and commercialize recently discovered and potentially worldchanging 

genomic synthesis technologies 

RESEARCH & DEVELOPMENT: Initial focus is on ethanol and hydrogen production 


1-1, Doshomachi 4-chome, Chuo-ku 


Phone: +81 6-6204-2111; Fax: +81 6-6204-2880 

Web: www.takeda.co.jp 

KEY PERSONNEL: Kunio Takeda; Chairman 

Yasuchika Hasegawa; President 

Hiroshi Akimoto, Ph.D.; Managing Director 

Makoto Yamaoka; Sr. Managing Director and GM, Pharmaceutical 

Marketing Division 

Kiyoshi Kitazawa, Ph.D.; Managing Director and GM, Strategic Product 

Planning 

Hiroshi Shinha; GM, Legal 

Toyoji Yoshida; GM, Corp. Communications 

Hiroshi Takahara; GM, Finance and Accounting 

Hiroaki Ogata; GM, Business Development and Global Licensing 

EMPLOYEES: 14,510 employees; 7,345 in parent company 


Incorporated in January 1925 

FACILITIES: ¥53M Tsukuba Research Laboratories, a biotechnology research center in 

Tsukuba Science City 

Branches in Sapporo, Tohoku, Kitakanto-Koshinetsu, Tokyo, Yokohama, 

Chiba-Saitama, Nagoya, Kyoto, Osaka, Kobe, Shikoku, Chugoku, Fukuoka 

Plants in Osaka, Shonan, Hikari, Takasago, Kashima, Shimizu and 

Tokuyama 



Research laboratories in Osaka and Tsukuba 

Farm and herbal garden in Fukuchiyama and Kyoto 

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock 

exchanges 




04) 


SUBSIDIARIES/DIVISIONS: Takeda America Holdings Inc.--New York, N.Y. 

Takeda Research Investment Inc.--Palo Alto, Calif. 

Takeda San Diego Inc.--San Diego, Calif. 

Takeda Pharmaceuticals North America Inc.--Lincolnshire, Ill. 

Takeda Global Research and Development Center Inc.--Lincolnshire, Ill. 

TAP Pharmaceutical Products Inc.--Lake Forest, Ill. 

Takeda Global Research & Development Centre (Europe) Ltd.--London 

Laboratoires Takeda--France 

Takeda UK Ltd. 

Takeda Italia Farmaceutici SpA--Rome, Italy 

Takeda Pharma GmbH--Germany 

Takeda Pharma Ges. mbH--Vienna, Austria 

Takeda Pharma AG--Lachen, Switzerland 

Takeda Ireland Ltd.--Wicklow, Ireland 

Takeda Pharma Ireland Ltd.--Dublin, Ireland 

Tianjin Takeda Pharmaceuticals Co. Ltd.--China 

Takeda Chemical Industries (Taiwan) Ltd.--Taipei, Taiwan 

Boie-Takeda Chemicals Inc.--The Phillipines 

Takeda (Thailand) Ltd.--Bangkok, Thailand 

P.T. Takeda Indonesia--Indonesia 

INVESTMENTS: Wyeth-Lederle (Japan) Ltd.--30% 

TAP Pharmaceutical Products Inc.--50% (joint venture with Abbott 

Laboratories) 

Laboratoires Takeda--100% 

Takeda Italia Farmaceutici SpA--76.92% (with Finfarma SpA) 

Tianjin Takeda Pharmaceuticals Co. Ltd.--75% (with Tainjin Lisheng 

Pharmaceutical Factory) 


3M 

topical treatment for exclusive co- 2/05 

Pharmaceuticals cervical high-risk HPV development and 

infection and cervical joint marketing 

dysplasia 

agreement 

Abbott 

drug for prostate cancer joint venture called 8/77 

Laboratories and ulcer 

TAP Holdings to 

market drug 

developed by 

Takeda 

Affymax Inc. Affymax's Hematide in development and 2/06 

Japan 


agreement 

Affymax Inc. Affymax's Hematide in development and 6/06 

the U.S. 


agreement 

Ajinomoto risedronate for 

codevelopment 1992 

osteoporosis 

agreement for 

Japan and South 

Korea 

Alizyme plc development, 


marketing of ATL-962 in 

Japan 




Arius Research 

Inc. 

BioNumerik 


Inc. 

Arius' FunctionFIRST 

Platform to discover 

treatments for human 

disease 

three-year, multiproduct 

collaboration 

Tavocept (dimesna) marketing 

agreement (USA 

and Canada) 

Galaxy Biotech monoclonal antibody development, 


sales agreement 

Human Genome gene sequence 

collaboration 

Sciences Inc. 

database 

Lexicon Genetics Takeda can select and 

purchase targets for 

anti-hypertension 

medicine discovered in 

Lexicon's Genome5000 

McNeil Consumer 

Products Co. 

(Johnson & 

Johnson) 

program 


4/06 

10/04 

7/06 

6/95 

agreement 


McNeil's OTC products marketing 

agreement for 

Japan 

Merck KGaA Matuzumab co-development 

and co- 


Pharmacia & 

Upjohn (now part 

of Pfizer) 

PPD Inc. development and 


Santhera 


AG 

For all recent 

agreements, 

please visit: 

takeda.co.jp/englis 

h/press/press.htm 

agreement 

smoking cessation joint marketing 

agreement--Takeda 

to sell P&U smoking 

cessation products 

PPd's DPP4 inhibitors 

1997 

9/05 

1996 

in Japan 


Idebenone (SNT-MC17) development and 


agreement 

RESEARCH & DEVELOPMENT: Lifestyle-related diseases 

Cancer and urological diseases, gynecological disorders 

Central nervous system disorders and bone and joint disorders 

Life-cycle management of drugs for digestive system disorders 

PRODUCTS ON MARKET: Diabetes: ACTOS®, BASEN® 

Cardiovascular: BLOPRESS®, CALSLOT®, ADECUT® 

Gastrointestinal: PREVACID® 

Urology and Gynecology: LUPRON DEPOT® 

Osteoporosis: OSTEN®, BENET® 

Infection: PANSPORIN®, FIRSTCIN®, BESTCALL®, TAKESULIN®, 

LILACILLIN®, AMASULIN®, PANSPORIN T® 

Interferon and Interleukin: CANFERON A®, CELEUK® 

Central Nervous System: NICHOLIN®, HIRTONIN®, EURODIN® 

Inflammation: DASEN® 

Vitamin: ALINAMIN F®, VITANEURIN®, HICEE®, PANVITAN® 

Allergy: BRONICA®, SOLFA® 

Vaccine: Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine, 

Dried Live Attenuated Measles Vaccine, Dried Live Attenuated Mumps 

Vaccine, Dried Live Attenuated Rubella Vaccine, Japanese Encephalitis 

Vaccine 

8/05

Teledyne Isco 


Cold Remedies: Benza® Block IP 

Preparations for Rhinitis: Benza® AL, Benza® AL Spray 

Gastrointestinal Drugs: That's®, That's® 21, That's® Block 

Vitamin Products: Alinamin® A25, New Alinamin® A, Alinamin® EX, 

Hicee®-L, Hicee® 1000, Hicee® white2, Hicee® B Mate2, Hicee® E-class, 

Vitamin C ‘TAKEDA,’ Vitamin E ‘TAKEDA,’ Panvitan HI 

Vitamin-containing Tonics (Quasi-drugs): Alinamin® V, Alinamin® V&V, 

Alinamin® 7, Hicee® CEtime 

Vitamin-containing Tonics: Alinamin® e 

Athlete's Foot Treatments: Scorba® LX, Scorba® 

Laxatives: TAKEDA KANPO BENPIYAKU, Clear® 

4700 Superior Street 

Lincoln NE 68504, US 

Phone: (402) 464-0231; Fax: (402) 465-3022 


Web: www.isco.com 

E-mail: iscoinfo@teledyne.com 

KEY PERSONNEL: David Kennedy, Ph.D.; General Manager 

EMPLOYEES: 467 employees worldwide 

HISTORY: Founded by Robert W. Allington in 1958 

Signed agreement to acquire Suprex Corp. of Pittsburgh, PA (8/96) 

Signed agreement to acquire Geomation Inc. of Golden, CO (9/97) 

Acquired STIP Siepmann und Teutscher GmbH (1/98) 

Merged with subsidiary of Teledyne Technologies Inc. (2004) 

Changed name from Isco Inc. (2004) 

Acquired MGD Technologies Inc. (12/05) 

Teledyne MGD Inc. subsidiary merged into Teledyne Isco (5/06) 

FACILITIES: Sales offices in Belgium, Germany, China and Lincoln, Neb. 

200,000 sq. ft. plant 


Formerly listed on NASDAQ--ISKO: 

IPO--$7.43/share (1985) 

SUBSIDIARY OF: Teledyne Technologies Inc. 

INVESTMENTS: Geomation, Inc. 

Advanced Flow Technology Co. (AFTCO)--joint venture with AMJ 

Equipment Corp. 

BUSINESS STRATEGY: Growth by internal product development in closely related lines 

supplemented by product acquisition 

PRODUCTS ON MARKET: Instrumentation--LC and HPLC products, optical detectors, fraction 

collectors, pumps, electrophoresis apparatus, supercritical fluid extraction 

systems, and syringe pumps 

Environmental products--wastewater samplers, parameter monitoring 

products, and process monitoring products 




2030 Willard H. Dow Center 

Midland MI 48674, US 

Phone: (989) 636-1000; Fax: (989) 636-1830 

Web: www.dow.com 

KEY PERSONNEL: Andrew N. Liveris; President, CEO and Chairman 

Geoffery E. Merszei; Exec. VP and CFO 

William F. Banholzer; Corp. VP and CTO 

Bill Weideman; VP and Controller 

Frank H. Brod; Corp. VP 

Heinz Haller; Corp. VP, Strategic Development and New Ventures 

Michael R. Gambrell; Exec. VP, Basic Plastics and Chemicals Portfolio 

Charles J. Kalil; Corp. VP, General Counsel and Corp. Secretary 

David E. Kepler; Sr. VP, Shared Services and Environment, Health and 

Safety and CIO 

Romeo Kreinberg; Exec. VP, Performance Plastics and Chemicals Portfolio 

Julie Fasone Holder; Corp.VP, Human Resources, Diversity and Inclusion 

and Public Affairs 

Luciano Respini; Corp. VP, Geography 

Fernando Ruiz; Corp. VP and Treasurer 

Gary R. Veurink; Corp. VP, Manufacturing and Engineering 




Acquired United AgriSeeds Inc. (crop biotechnology) for $45M (1987) 

Formed joint venture (Dow Elanco & Co.) with Eli Lilly and Co. by combining 

their plant-sciences businesses and Dow's industrial pest-control business 

(10/89) 

Completed $38/share cash tender offer for 58.5M shares of Marion 

Laboratories, and acquired 67% of outstanding shares, which finalized 

merger to create new company, Marion Merrell Dow (12/89) 

Sold the assets from the Biotech Project of CD Medical Inc. to UniSyn 

Technologies, a wholly owned subsidiary of Synbiotics Corp. (6/90) 

Finalized agreement for Hoechst AG to acquire all outstanding shares of 

Marion Merrell Dow (2Q95) 

Member--Biotechnology Research and Development Corp (BRDC) 

Member--Midwest Plant Biotechnology/Consortium 


FACILITIES: 165 manufacturing sites in 37 countries 

STOCK-FINANCIAL HISTORY: NYSE--DOW 






SUBSIDIARIES/DIVISIONS: Divisions: 

Perfornace Plastics 

Performance Chemicals 

Plastics 

Chemicals 

Agricultural Science 

Hydrocarbon & Engergy 

INVESTMENTS: Collaborative Research, Inc.--$5M, 5% equity 

Dow Corning Corp.--joint venture with Corning Inc. 

Millipore Corp.--9.5% (1984) 

Haeger & Kaessner GmbH--acquired (1986) 

United AgriSeeds, Inc.--acquired for $45M (12/87) 

Montedison SpA--less than 5% 



Lamaur, Inc.--acquired (1987) 

FilmTec Corp. (membrane manufacturer for water purification and 

separation processes), acquired capital stock for $75M (1987) 

Essex Chemical Corp.--acquired for $366.1M, $36/share (9/88) 

Neoprobe Corp.--minority equity 

Sumitomo Chemical Co.--joint venture to manufacture polycarbonates in 

Japan (12/89) 

BOC Group plc--joint venture to develop and market membrane-based airseparation 

systems (12/89) 

BUSINESS STRATEGY: Provide innovative chemical, plastic and agricultural products and services 

to many essential consumer markets 


Access 

Access' bioresponsive collaboration 8/97 

Pharmaceuticals polymer systems and agreement--Access 

Inc. 

Dow's chelation 

gets rights to 

technology to develop chelation 

MRI contrast agents, technology. Dow 

radiopharmaceutical has equity position, 

diagnostics and 

manufacturing 

therapeutics 

rights and future 

royalties 

Caliper 

Dow's polymer 

R&D collaboration 3/97 

Technologies technology to the 

Corp. 


manufacturing of 

disposable LabChips 

Cytogen Corp. radiopharmaceutical to exclusive U.S. 5/93 

alleviate the bone pain marketing rights to 

associated with 

metastatic cancer 

Cytogen 

Diversa Corp. enzymatic method that 

modifies a chemical 

process used by Dow 


Ecogen Inc. microbial biopesticide collaborative 

development 

agreement (through 

joint venture, Dow 

Elanco & Co.) 

11/89 

Kereos Inc. patent portfolios for 



imaging agents for 

diagnosis of cancer and 

cardiovascular disease 


Neoprobe Corp. Dow's licensed MAbs R&D, supply, and 3/89, 

and radiolabeling 

technology 


OSI 

more than 140,000 of exclusive worldwide 3/97 

Pharmaceuticals Dow's compounds for licensing 

Inc. 

screening and potential agreement--Dow 

development of small received 350K 

molecule drugs 

shares of OSI 

common stock 

Sumitomo 

polycarbonates joint venture to 12/89 

Chemical Co. Ltd. 

manufacture in 

Japan 

RESEARCH & DEVELOPMENT: Agricultural products, industrial catalysts, cancer therapy and detection 

rDNA techniques, human health care 



PRODUCTS ON MARKET: PLASTICS: automotive products, electronics, engineering plastics, epoxy 

products, polyolefin products, polystyrene, polyurethane, polyurethane 

systems, synthetic rubber 


CHEMICALS: calcium chloride, caustic soda, emulsion polymers, biocides, 

coolants, heat transfer fluids, polypropylene glycols and copolymers, 

surfactants, UCAR aircraft deicing fluids, UCAR emulsion systems, acrylate 

monomers, oxygenated solvents, alkyl alkanolamines, ethanolamines, 

ethyleneamines, isopropanolamines, glycol ethers and acetates, propylene 

oxide and propylene glycols, specialty polymers, water soluble polymers 

AGRICULTURE: fungicides, herbicides, insecticides, soil fumigants, films, 

seeds, fumigants 

334 Hecla Street 

Lake Linden MI 49945, US 

Phone: (906) 296-1115; Fax: (906) 296-8003 

Toll-free phone: (888) NITRATE (648-7283) 

Web: www.nitrate.com 

E-mail: ellenr@nitrate.com 

KEY PERSONNEL: Dr. Wilbur H. 'Bill' Campbell, Ph.D.; President 

Ellen R. Campbell; VP and COO 

Troy P. Kinnunen-Skidmore; Sr. Lab Technician for Enzyme Production 

Michael J. Brodeur-Campbell; Lab Technician and Marketing Assistant 

Thomas A. Rodeheffer; Instrument Technician 




FACILITIES: 2,500 sq. ft. R&D facilities and biochemistry lab 



BUSINESS STRATEGY: As an environmental biotechnology company, develop and commercialize 

enzyme-based products for water testing and water treatment, with R&D 

funding derived from competitive grant awards and collaborative 

agreements 

Provide contract protein expression and purification services for nonmedical 

enzymes, and environmental and industrial enzyme discovery research 


EPA enzymatic nitrate Phase I & II SBIR 9/95, 

elimination technology contract 

9/97. 

NIH Phase I/II expression of nitrate Phase I/II SBIR 8/98reductase 

in Pichia grants 

12/03 

NIH SBIR nitrate biosensor R&D Phase I SBIR grant (9/99 

- 

9/00) 

NIST 

biosensors two-year CRADA 7/96 

Biotechnology 


Division 

extended three 

years 

Sigma, Assay stabilized nitrate supply agreements 2/95 

Designs, Oxford 

Biomedical 

Research 

reductase 

U.S. Army Corps enzymes involved in contract R&D 2/98, 

of Engineers degradation of 

12/00 

Research Lab nitroaromatic explosives 



USDA nitrate test kit for 

consumers 

Phase II SBIR grant 7/96 

USDA Phase I/II rapid nitrate test kits for SBIR awards 3/02grants 

agricultural samples 

9/05 

USDA SBIR enzyme-based reagent Phase I/II awards 3/02packages 

for automated 

equipment 

9/05 

YSI, Inc. enzymes contract production 

for YSI proprietary 

products 

6/99 

RESEARCH & DEVELOPMENT: Enzyme-based biosensors 

Expression of complex enzymes 

Immobilized enzyme systems for water treatment and other processes 

'Battery powered' enzyme processes 

Most recent R&D: 

Enhancement of Nitrate Reductase production, which resulted in the 

production of a new form of commercial Nitrate Reductase, called New NECi 

NaR 

Ag-Nitrate test kits to assist Ag consultants and farmers to easy evaluate the 

nitrate content of feed, soil and water 

Discrete analyzer reagent kits (D-ARK) 

The Nitrate Reductase-linked Nitrate Biosensor: Nitrate Biosensor 

Enzymatic Nitrate Elimination Technology: EzNET® 

PRODUCTS ON MARKET: Nitrate reductase, NADH forms, native and recombinant 

Nitrate kit for biomedical (NO) research 

Nitrate test kit for consumers 

Nitrate test kits for education, research, ag diagnostics, environmental 

diagnostics, water quality 

Reagent packs for water analysis equipment 


Nitrate biosensor prototype 

Enzymatic process for removal of nitrate 

from water 

prototype 

Additional enzymes for analytical 

applications 



Utrechtseweg 48, P.O.Box 360 

Zeist 3700 AJ, Netherlands 

Phone: +31 (0)30 694 41 44; Fax: +31 (0)30 695 72 24 

Web: www.tno.nl/voeding; E-mail: infofood@voeding.tno.nl 

KEY PERSONNEL: Dr. C.L Ekkers; Director 

Dr. N.J. Snoeij; Director, Marketing and Sales 

EMPLOYEES: 750 employees, 80% scientific personnel 

HISTORY: Founded in 1940 at Utrecht 

FACILITIES: Facilities in Zeist, Leiden and Groningen, Netherlands 


SUBSIDIARY OF: TNO, the Netherlands Organization for Applied Scientific Research 

BUSINESS STRATEGY: As a contract organization in the field of life sciences, TNO seeks to provide 

a link of knowledge between fundamental research and its applications to 

foods, drugs and (agro)chemicals in relation to health, safety and quality as 

well as product and process innovation 




Dyadic 

Dyadic's fungal high- profit-sharing and 8/03 

International Inc. throughput screening royalty rights 

system 

agreement, 

restructured 12/05 

University of carbohydrate 

collaborative 

Groningen bioengineering in the 

TNO-RUG Centre for 

Carbohydrate 

Bioengineering 

agreement 

University of plant biotechnology in collaborative 

Leiden 

the TNO-RUL Centre 

for Biotechnology 

agreement 

University of microbiology in the collaborative 

Utrecht 

TNO-UU Centre for 

Veterinary Health 

agreement 

University of protein technology in collaborative 

Wageningen the TNO-LUW Centre 

for Protein Technology 

agreement 

RESEARCH & DEVELOPMENT: Food and feed research 

Nutrition 

Toxicology 

TQM 

Biochemistry 

Biopharmaceutical R&D 

PRODUCTS ON MARKET: Contract research 

TNO's 23 core technologies: 

Analytical and Molecular Pharmacology 

Animal Food Technology 

Applied Plant Sciences 

Carbohydrate Technology 

Damage Assessment and Consultancy 

Environmental Toxicology 

Explanatory Toxicology 

Food and Food Supplement Analysis 

Food Science and Technology 

General Toxicology 

Microbial Physiology and Gene Technology 

Microbiology and Quality Management 

Nutritional Epidemiology 

Nutritional Physiology 

Packaging Research 

Protein and Meat Technology 

Residue Analysis 

Sensor Technology 

Target Organ Toxicology 

Toxicological Risk Assessment 




Nihonbashi Mitsui Tower 

1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku 


Phone: +81 3-3245-5111; Fax: +81 3-3245-5555 

Web: www.toray.com; E-mail: webmaster@toray.com 

KEY PERSONNEL: Sadayuki Sakakibara; President, CEO and COO 

Kazuo Tomiita; Exec. VP 

Kiyoshi Fukuchi; GM, Personnel and Industrial Relations Division 

Osamu Nakatani; GM, Manufacturing Division 

Kazuhiro Maruyama; GM, General Administration Division 

Norihiko Saitou; Chief Investor Relations Officer 

Hiroaki Kobayashi; GM, Technology Center 

Munehiro Se; GM, Purchasing and Logistics Division 




STOCK-FINANCIAL HISTORY: Common stock listed on Tokyo, Osaka, Nagoya, Fukuoka, Sapporo, London 

and Luxemburg stock exchanges 





SUBSIDIARIES/DIVISIONS: 237 subsidiaries and affiliates, including: 

DuPont-Toray Co. Ltd. 

Opelontex Co. Ltd. 

Ogaki Fuso Spinning Co. Ltd. 

Toray Textiles Inc. 

Inami Textiles Inc. 

Matsumoto Textiles Co. Ltd. 

Toray Coatex Co. Ltd. 

Towa Orimono Co. Ltd. 

Toray Monofilament Co. Ltd. 

Toyo Tire Cord Co. Ltd. 

Toyo Flocking Co. Ltd. 

Maruichi Fiber Co. Ltd. 

Sowa Textile Co. Ltd. 

Toyo Plastic Seiko Co. Ltd. 

Toray PEF Products Inc. 

Toray Advanced Film Co. Ltd. 

Dow Corning Toray Silicone Co. Ltd. 

Toray Fine Chemicals Co. Ltd. 

Soda Aromatic Co. Ltd. 

Toray ACE Co. Ltd. 

Toray Engineering Co. Ltd. 

Toray Precision Co. Ltd. 

Toray Medical Co. Ltd. 

Toray Research Center Inc. 

Toyo Jitsugyo Co. Ltd. 

Toray Plastics (America) Inc. 

Toray Resin Co. 

Toray Carbon Fibers America Inc. 

Toray Composites (America) Inc. 

Toray Textiles Europe Ltd. 

Alcantara SpA 

Toray Textiles Central Europe s.r.o. 

Toray Plastics Europe SA 

Société des Fibres de Carbone SA 

P.T. Acryl Textile Mills 

P.T. Century Textile Industry Tbk 



P.T. Easterntex 

P.T. Indonesia Synthetic Textile Mills 

P.T. Indonesia Toray Synthetics 

Luckytex (Thailand) Public Co. Ltd. 

Thai Toray Textile Mills Public Co. Ltd. 

Thai Toray Synthetics Co. Ltd. 

Penfabric Sdn. Berhad 

Penfibre Sdn. Berhad 

Toray Plastics (Malaysia) Sdn. Berhad 

Toray Fibers (Nantong) Co. Ltd. 

Toray Sakai Weaving & Dyeing (Nantong) Co. Ltd. 

Taltex (Zhuhai) Ltd. 

Toray Plastics (Shenzhen) Ltd. 

Toray Film Products (Zhongshan) Ltd. 

Toray Sanko Precision (Zhongshan) Ltd. 

INVESTMENTS: Fujirebio 

Toray-Fuji Bionics--joint venture of Toray and Fujirebio 


Acologix Inc. development and collaboration and 6/05 

commercialization of licensing 

Toray's TRK-820 in 

North America and codevelopment 

in Europe 

agreement 

Acologix Inc. Acologix's AC-200 development and 6/06 

program in Japan licensing 

agreement 

Biotech Australia 

Pty. Ltd. 

animal vaccines R&D agreement 1994 

Daiichi Seiyaku Feron natural beta-IFN development and 

for hepatitis B and C, marketing 

brain tumors, malignant 

melanoma 

agreement 

Daiichi Seiyaku, gamma-IFN development and 

Genentech Inc. 

marketing 

agreement for 

Japan, clinical 

studies shared 

with Daiichi 

Digene Corp. DNA diagnostic probes distribution 12/90 

for disease detection agreement for 

Japan 

DNA Chip 

high-performance DNA joint development 12/05 

Research Inc. microarrays 

agreement 

Japan Tobacco TRK-820 development and 3/05 

Inc. and Torii 

marketing 


Co. Ltd. 

agreement 

Maruho Co. Ltd. development and 

marketing 

agreement 

3/05 

Takeda 

compound for urinary development and 4/05 

Pharmaceutical incontinence 

marketing 

Co. Ltd. 

agreement 

Uniqlo Co. Ltd. development of 

strategic 

6/06 

breakthrough material 

for new product 

creation, creation of 

product development 

system 

partnership 



PRODUCTS ON MARKET: Fibers and Textiles: Nylon, Tetoron (polyester), Toraylon (acrylic), Ecsaine, 

sillook 


Water Treatment Membranes and Systems: Romenbra, High recovery 

seawater desalination system, Torayfil, Torayvino (household water purifier) 

Plastics: Amilan (nylon), Toyolac (ABS), Toraycon (PBT), Torelina (PPS), 

Toraypef (polyolefin foam) 

Fine Chemicals: Torayblan (synthetic gypsam), aromatic fine chemicals, 

high-functional catalysts, specialty chemicals, Intercat (Interferon for cats 

and dogs) 

Carbon Fibers and Composite Materials: Torayca, Torayca Prepreg, 

Torayca composites 

Pharmaceuticals and Medical Products: Feron (natural interferon 

preparation), Dorner (oral prostacyclin (PGI2) derivative) and Filtryzer 

artificial kidneys for dialysis 

2 Brisbane Road 

North York M3J 2J8, Canada 

Phone: (416) 665-9696; Fax: (416) 665-4439 


Web: www.trc-canada.com 

E-mail: info@trc-canada.com 

KEY PERSONNEL: Dr. David S. Dime; President 

Charles E. Dime; Exec. VP 



FACILITIES: 42,000 sq. ft. of state-of-the-art laboratory space 


BUSINESS STRATEGY: Develop, manufacture and supply fine chemicals for biomedical research 

Seek pharmaceutical partnerships for joint development of novel 

therapeutics and contract research opportunities 

RESEARCH & DEVELOPMENT: Novel therapeutics as anticancer, anti-AIDS and cardiac active compounds 

Contract R&D 

Custom synthesis and process development 

PRODUCTS ON MARKET: Biomedical research chemicals including enzyme inhibitors, 

oligosaccharides, nitric oxide synthase reagents, phosphoramidites, 

carbohydrates, detergents, fluorescent probes and crosslinkers 

Tyrosine kinase inhibitors, signal transduction, protein/ion channel reagents 




321, Sec. 2, Kuang Fu Road, Kuang Fu Compound, Taiwan 

Hsinchu 30042, China 

Phone: (+86) 886-35-732-616; Fax: (+86) 886-35-732-359 

Web: www.ucl.itri.org.tw/eng/ 

E-mail: 620257@itri.org.tw 

KEY PERSONNEL: Dr. Wu-Hsun Cheng; General Director 

EMPLOYEES: 500+ employees, 230+ Ph.D.s/masters degrees 

HISTORY: Officially organized in 1946 as Union Industrial Research Laboratories 

(UIRL) 

Merged with the Industrial Technology Research Institute (ITRI) (1973) 

UIRL changed name to Union Chemical Laboratories (UCL) (1983) 

STOCK-FINANCIAL HISTORY: Nonprofit government-sponsored agency 

SUBSIDIARY OF: Industrial Technology Research Institute (ITRI) 

BUSINESS STRATEGY: Develop technologies in packaging and electronic materials, specialty 

polymers and resins, metallocene-based catalysts/polymers, nanopolymers, 

nanochemistry, nanobiochemistry, functional and high-tech fibers 

and combinatorial chemistry 


Commonwealth Development of cooperative R&D 6/02 

Scientific and advanced 

project 

Industrial 

polymerization catalyst 

Research 

Organization 

(CSIRO) 

technology 

RESEARCH & DEVELOPMENT: Precision polymers 

Hi-tech polymers 

Functional and high-tech fibers 

Nanobio-chemistry 

Nanochemistry 

Combinatorial chemistry 


Advanced chemical engineering 

Optoelectronic/electronic chemicals 

PRODUCTS ON MARKET: Services include: 

R&D in new product/process/application 

Collaboration in new product/process/application 

Process modification/optimization 

Chemical analysis/product testing 

Technical assistance/consultation/training 


Level 2, Cumbrae-Stewart Building, Research Road 

The University of Queensland 

Brisbane Q1D 4072, Australia 

Phone: +61 7 3365-4037; Fax: +61 7 3365-4433 

Web: www.uniquest.com.au 

E-mail: enquiries@uniquest.com.au 

KEY PERSONNEL: Norbury Rogers; Chairman 

David Henderson; Managing Director 

Richard Symons; CFO 

David Henderson; Managing Director 




Gary Heyden; GM, Consulting and Research 

Harleigh Luscombe; GM, International Projects 

Dean Moss; Manager, Technology Commercialization 

Andrew Davis; Manager, Technology Commercialization 

Julia Renaud; Manager, Corp. Development 


Incorporated in July 1984 


SUBSIDIARY OF: The University of Queensland 

BUSINESS STRATEGY: Tech transfer company for The University of Queensland 

RESEARCH & DEVELOPMENT: Commercialization of innovations via licenses, patents and establishing 

start-ups 

Assembling multi-disciplinary consulting teams for international development 

projects 

Providing government, industry, and the wider community with a wide range 

of consulting, testing, expert opinion and advisory services as well as 

research and development projects 

University of Nebraska-Lincoln, 

Center for Biotechnology 

P.O. Box 880665, N300 Beadle Center 

Lincoln NE 68588-0665, US 

Phone: (402) 472-2635; Fax: (402) 472-3139 

Web: www.biotech.unl.edu; E-mail: mfromm@unlnotes.unl.edu 

KEY PERSONNEL: Dr. Michael Fromm; Director 

Rik Barrera; Manager, Business Office 

Dr. Yuannan Xia; Manager, Genomics and Flow Cytometry 

Dr. Tom Clemente; Manager, Plant Transformation 

Dr. Ron Cerny; Manager, Mass Spectrometry and Proteomic Analysis 

Dr. Y. (Joe) Zhou; Manager, Microscopy 

Dr. Jean-Jack M. Riethoven; Manager, Bioinformatics 

Dr. Hideaki Moriyama; Manager, Structual Biology 

EMPLOYEES: 5 employees, 165 faculty associates 



Affiliated with the University of Nebraska at Lincoln 

FACILITIES: Protein sequencing and proteomics, bioinformatics, genomics and DNA 

sequencing, flow cytometry analysis, plant transformation, mass 

spectrometry, and microscopy research facilities 


BUSINESS STRATEGY: Foster research and development in high priority areas of biotechnology 

RESEARCH & DEVELOPMENT: All aspects of molecular life sciences research, leading to improvements in 

agriculture, health care and the environment 


UVP Inc. 


2066 W. 11th Street 

Upland CA 91786, US 

Phone: (909) 946-3197; Fax: (909) 946-3597 


Web: www.uvp.com 

E-mail: info@uvp.com 

KEY PERSONNEL: Paul Warren; Chairman 

Leighton Smith; President 

Alex Waluszko; Exec. VP 





SUBSIDIARIES/DIVISIONS: Ultra-Violet Products Ltd. 

BioImaging Systems Group 

Laboratory Products Group 

Ultra-Violet Products Group 

PRODUCTS ON MARKET: BioImaging Systems, CCD-based, for fluorescent, chemiluminescent, 

chemifluorescent and visible light imaging of gels, blots, membranes, plates, 

slides, microarrays, film and live specimens 


analysis software in development 

imaging systems in development 


Valeant Plaza, 3300 Hyland Avenue 

Costa Mesa CA 92626, US 

Phone: (714) 545-0100; Fax: (714) 556-0131 


Web: www.valeant.com 

E-mail: info@valeant.com 

KEY PERSONNEL: Timothy C. Tyson; President and CEO 

Bary G. Bailey; CFO and Exec. VP 

Eileen C. Pruette; Exec. VP and General Counsel 

Martin N. Mercer; Exec. VP, Latin America Operations 

Wesley P. Wheeler; President, Global Marketing and Business Development 

Charles J. Bramlage; President, Europe 

David W. Kwo; Exec. VP, Asia, Africa and Australia 

John I. Cooper; Exec. VP, Global Manufacturing and Supply 

Geoffrey M. Glass; Sr. VP and CIO 


HISTORY: Founded in 1960 by Milan Panic 

Eastern European venture company ICN Galenika (75% owned by ICN, 

25% owned by Galenika) formed in May 1991 (based in Belgrade, former 

Yugoslavia) 

Former subsidiaries SPI Pharmaceuticals Inc., Viratek Inc., ICN Biomedicals 

Inc., and ICN Pharmaceuticals Inc. combined into new corporation named 

ICN Pharmaceuticals Inc. (11/94) 

Signed letter of intent to acquire 75% of Tuobin Chemicals and 

Pharmaceuticals General Corp. (China) (7/95) 

Acquired 40% of SeaLite Sciences Inc. (11/95) 



Acquired Gly Derm Inc., skin care company (2/96) 

Won bid to purchase 49% of Alkaloida Chemical Co. Ltd. (6/96) 

Acquired Dosimetry Service from Siemens Medical System Inc. (6/96) 

Acquired Leksredstva, Russian pharmaceutical company (7/96) 

Signed letter of intent to manufacture and distribute pharmaceutical products 

in Bosnia (8/96) 

Acquired Vuab, manufacturing and research facility in the Czech Republic 

(6/98) 

Changed name from ICN Pharmaceuticals (11/03) 

Sold raw materials and manufacturing operations in Czech Republic to 

Chemoprojekt, a.s. (8/04) 

Acquired Xcel Pharmaceuticals (2/05) 

To purchase Infergen® from InterMune Inc. (as of 11/05) 

FACILITIES: Headquarters in Costa Mesa, Calif., and Moscow, Russia 

Research Products facilities in Aurora, Ohio; Irvine, Calif.; Costa Mesa, 

Calif.; Sydney, Australia; Tokyo, Japan; Eschwege, Germany; Opera, Italy; 

Orsay, France; Brussels, Belgium; High Wycombe, UK; and Thame, U.K. 

Pharmaceuticals facilities in Bryan, OH; Costa Mesa, CA; Bueno Aires, 

Argentina; Montreal, Canada; Wuxi, China; Mexico City, Mexico; 

Chelyabinsk, Russia; Moscow, Russia; Kursk, Russia; St. Petersburg, 

Russia; Tomsk, Russia; Yoshkar-Ola, Russia; Rseczow, Poland; Belgrade, 

Yugoslavia; Zoetermeer, Holland; and High Wycombe, U.K. 

Diagnostics facility in Orangeburg, N.Y. 

STOCK-FINANCIAL HISTORY: NYSE--VRX 

Public offering--2.1M shares at $17.50/share (7/86) 

Public offering--$20M Swiss franc exchangeable certificates, 5.5% (2/87) 

Public offering--$37M subordinated double convertible bonds, 3.25% (3/87) 

Public offering--3M shares, $21M (6/96) 

Public offering--7.2M shares of common stock at $24/share (2/05) 





04) 

SUBSIDIARIES/DIVISIONS: ICN Canada Ltd.--Canada 

ICN Pharmaceutica SA--Mexico 

Laboratorios Grossman SA--Mexico 

ICN Pharmaceuticals Holland BV--Netherlands 

ICN Biomedicals Inc.--Delaware 

ICN Yugoslavia--Yugoslavia 

ICN Biomedicals GmbH--Germany 

ICN Pharmaceuticals Australasia Pty. Ltd.--Australia 

ICN Pharmacueticals Japan KK--Japan 

ICN Iberica--Spain 

Labsystems Benelux BV--Netherlands 

Labsystems Benelux NV--Belgium 

ICN Biomedicals Ltd.--U.K. 

ICN France SARL--France 

ICN Biomedicals SRL--Italy 

ICN Biomedicals NV/SA--Belgium 

ICN Oktybr--Russia 

ICN Polypharm--Russia 

ICN Leksredstva--Russia 

Wuxi ICN Pharmaceuticals--China 

ICN Tomsk--Russia 

ICN Yoshkar-Ola--Russia 

INVESTMENTS: SeaLite Sciences Inc. 

Biomedpreparat (Russia)--joint venture with Allen & Associates International 

Ltd. 

Alkaloida Chemical Co. Ltd. (Hungary)--won competitve bid to acquire up to 

59% of the company 



BUSINESS STRATEGY: Transform from an entrepreneurially focused corporation into an improved, 

research-based and integrated specialty pharmaceutical company, focused 

on marketing and distributing pharmaceuticals in the areas of infectious 

disease, neurology and dermatology 


Alliance 

Valeant's Mestinon and co-promotion 11/04 

Pharmaceuticals Alliance's Symmetrel agreement 

Biocode SA radioimmunoassay kits production 

agreement 

12/02 

Fujisawa U.S.A. compounds related to licensing agreement 11/01 

Inc. (now part of 

Astellas Pharma 

Inc.) 

hGH 

Metabasis pradefovir (formerly development 10/01 

Therapeutics Inc. called remofovir) agreement 

Schering-Plough ICN's oral ribavirin for licensing agreement 7/98 

Corp. 

hepatitis C 

for Europe--ICN 

retains rights to all 

other forms of 

ribavarin and 

indications 

Schering-Plough Virazole in combination licensing agreement 7/99 

Corp. 

with Schering's Intron A 

SeaLite Sciences AquaLite TSH test for distribution 

11/98 

Inc. 

thyroid disorders agreement 

Senetek plc Zeatin exclusive worldwide 


5/04 

VWR Scientific biomedical research marketing and 5/99 

Products Corp. products 

distribution 

agreement for U.S., 

Canada and Puerto 

Rico 

RESEARCH & DEVELOPMENT: Drugs for the treatment of hepatitis C and hepatitis B and in the areas of 

neurology and infectious disease 

PRODUCTS ON MARKET: More than 575 branded products, including: 

8-MOP (8 methoxypsoralen) 10 mg capsule for treatment of cutaneous T 

cell lymphoma by extracorporeal photochemotherapy 

Virazole (ribavirin) for treatment of viral diseases including hepatitis, 

herpes, and childhood diseases such as chickenpox, approved in 43 

countries 

Virazole for respiratory syncytial virus (RSV), on market in the U.S., 

Canada, the U.K., Spain, Australia, Hungary, New Zealand, and 13 other 

countries 

Immunodiagnostic reagents and instruments 

Neonatal thyroxine and thyroid-stimulating hormone diagnostic kits 

Test for galactosemia in newborns 

Dermatologicals and myasthenia product lines in U.S. 

Multiple product lines abroad including antivirals, antibiotics, 

dermatologicals, cardiovasculars, analgesics, antirheumatics, central 

nervous systems compounds and vision care lines 

Tasmar® (tolcapone) (EU)--acquired from Roche (9/04) 




905 South Carolina Avenue 

Mason City IA 50401, US 

Phone: (641) 423-1460; Fax: (515) 423-0832 


Web: www.vi-cor.com, www.milktothemax.com 

E-mail: vi-cor@vi-cor.com 

KEY PERSONNEL: Mark Holt; President 

Michael Lunning; Controller/Purchasing 

John Oppy; Technical Services Specialist 

Jodi Ames; Director, Marketing 



Pioneer in the organic foods industry 


SUBSIDIARIES/DIVISIONS: Fermented Products 

SUBSIDIARY OF: Vi-COR 

BUSINESS STRATEGY: Develop products for the production of naturally grown foodstuffs 

RESEARCH & DEVELOPMENT: Biotechnical applications 

Production of naturally grown foodstuffs 

Fermented products 

Plant extracts 

Enzymes and microbial products 

PRODUCTS ON MARKET: Lactic acid fermentation products 

Desert plant extracts 

Enzymes and microbial products 



SRC VB Vector, Novosibirsk Region 

Koltsovo 630559, Russia 

Phone: +7 3832-36-60-10; Fax: +7 3832-36-74-09 

Web: www.vector.nsc.ru; E-mail: lev@vector.nsc.ru 

KEY PERSONNEL: Prof. Lev. S. Sandakhchiev; Director General 

Jury I. Klimov; Exec. VP 

Prof. Sergey V. Netesov; Scientific Director 

Raisa A. Martynyuk; Director, R&D 

EMPLOYEES: 1,056 employees, 143 Ph.D.s, 14 M.D.s, 1 D.V.M. 




Level 3 and 4 biosafety laboratory 

Full cycle biotech production facility 


SUBSIDIARIES/DIVISIONS: Subsidiaries: 

Vector-Pharm--production and sales company 

Vector-Best--joint stock company 

Vector-BiAlgam--production and sales company 



Divisions: 

Research Institute of Molecular Biology 

Research Institute of Cell Cultures 

Research Institute of Bioengineering 

Research Institute of Aerobiology 

Research and Design Institute of Biologically Active Substances 

Institute of Collection of Cultures of Microorganisms 

WHO Collaborating Center for Orthopoxvirus Diagnosis and Repository for 

Variola Virus Strains and DNA 

BUSINESS STRATEGY: Acknowledge structure function of virus genomes 

Create highly sensitive diagnostic kits for viruses, prophylactics, and antiviral 

and anticancer treatments 

RESEARCH & DEVELOPMENT: Diagnostics kits 

Antivirals 

Vaccines 

PRODUCTS ON MARKET: Diagnostic kit for HIV 

Diagnostic kits for hepatitis A, B and C 

Recolin--recombinant interferon 

Profezyme 

Reaferon ridostin 

Hepatitis A vaccine 

Measles vaccine 

Nutrient media, sera 

Enzymes 

Biochemical reagents for laboratory studies 


Alpha-interferon analogues in preclinicals 

Subalin in preclinicals 

Erythropoietin in preclinicals 

TNF-beta analogue in preclinicals 

Alnorin in Phase II clinicals 

Virinova GbR 

Luisenstrasse. 23 a 

Burscheid 51399, Germany 

Phone: +49 (0) 2174 671 9990; Fax: +49 (0) 2174 894501 

Web: www.virinova.de; E-mail: contact@virinova.de 

KEY PERSONNEL: Prof. H.J. Duerr; Managing Director 




BUSINESS STRATEGY: Provide diagnostic technology enables the detection and quantification of 

viruses without the use of PCR or antibodies 

RESEARCH & DEVELOPMENT: Virus diagnostics for AIDS/HIV, hepatitis C (HCV), hepatitis B (HBV), herpes 

simplex (HSV-1 and HSV-2), parvo B19, paramyxo virus, adeno virus, rhino 

viruses, cytomegalo virus (CMV), parapox virus, foot and mouth disease 

virus, several plant viruses 

PRODUCTS ON MARKET: Novel virus diagnostic technology for process control and diagnostic 

monitoring of viral infections 


Vitrolife AB 


Faktorvagen 13 

Kungsbacka SE-434 37, Sweden 

Phone: +46 31-721 80 00; Fax: +46 31-721 80 90 

Web: www.vitrolife.com 

E-mail: info@vitrolife.com 

KEY PERSONNEL: Patrik Tigerschiold; Chairman 

Dr. Magnus Nilsson; CEO 

Christer de Flon; Director, Global Sales and Marketing and VP 

Anna Ahlberg; CFO 

Stefan Blomsterberg; Director, Logistics 

Hans Lehmann; Director, Development 

Goran Mellbin; Director, Quality Assurance and Quality Control 

Neil Murphy; Director, Production 

Emma Sjoqvist; Deputy Production Director 

Tony Winslof; Director, Marketing 

Nils Sellbom; President, Vitrolife Inc. 



Vitrolife AB founded in 1997 as the group holding company 

STOCK-FINANCIAL HISTORY: Listed on the Stockholm Stock Exchange since 2001 

SUBSIDIARIES/DIVISIONS: Vitrolife Sweden AB 

Faktorvagen 13 

SE-434 37 Kungsbacka 

Sweden 

Vitrolife Inc. 

3601 South Inca Street 

Englewood, CO 80110 

Swemed Lab International AB 

Billdalsvagen 2 

SE-427 36 Billdal 

Sweden 

BUSINESS STRATEGY: Provide innovative enabling technologies and products 

Develop and market complex but convenient ready-to-use/ready-to-choose 

solutions 

Target and work with opinion leaders in marketing/sales and R&D 

Position Company to benefit from regulatory environment 

Control in-house manufacturing 

RESEARCH & DEVELOPMENT: Cell Therapy: 

Media to enable the use of stem cells for therapeutic purposes 

PRODUCTS ON MARKET: EmbryoGlue® 

Culture media 

Media for micro-manipulation 

Media for sperm preparation 

Freeze-Kit1 (for embryos) 

Thaw-Kit1 (for embryos) 

Transplantation: 

Solutions and systems to maintain tissue in optimal condition outside the 

body for the required time while waiting for transplantation. New product 

CE-marked January 2006: Steen Solution 

Fertility: 

Nutrient solutions (media) and advanced one-time instruments such as 

needles and pipettes, for the treatment of human infertility 




VitroHES 

Perfadex® 

Steen Solution 

ClearVision ETC 

Needles 

Pipettes 


BC Research Complex, 3650 Wesbrook Mall 

Vancouver V6S 2L2, Canada 

Phone: (604) 224-4331; Fax: (604) 224-0540 

Web: www.vizonscitec.com 

E-mail: info@vizonscitec.com 

Brian Nixon; President and CEO 




Purchased the assets of the British Columbia Research Corp. from 

bankruptcy (1993) 

Acquired Silvagen Inc. 

Acquired Lockhart Risk Management 

Formerly operated as BC Research Inc. 

Acquired by Cantest Ltd. (8/06) 

FACILITIES: 185,000 sq. ft.research complex on 10 acres 


PRIVATE PLACEMENTS: Initial investment in new corporation (6/93) 

BUSINESS STRATEGY: Contract R&D and joint ventures, product development 

Commercialize environmental and biotech technologies 


Silvagen Inc. tissue culture spruce exclusive 

licensing/partnership 

agreement 

4/91 

Various 

clean fuel engine licensing 

companies system 

agreements 

Various 

process chemistry licensing 

companies 

agreements 

RESEARCH & DEVELOPMENT: Forest and agriculture biotechnology, environmental toxicity and chemical 

analysis, biological and chemical treatment, ocean engineering, clean fuels, 

automotive structures, ergonomics systems 

PRODUCTS ON MARKET: Chemical services: Analytical chemistry, methods development, chemical 

GLP services, environmental processes, thermochemical processes, 

electrochemical processes, chemical product development, chemical 

product evaluation, material and surface science investigation, chemical 

engineering 

Biotechnology services: Custom genetic analysis, (DNA fingerprinting, 

sequencing, cloning, PCR analysis and primer design), seed orchard 

monitoring, plant bioassays for phytotoxicity assessment, in vitro efficacy 

testing of antimicrobial compounds, bacterial diversity assessments, applied 

plant pathology research 

Toxicology: Aquatic toxicology, evaluation and monitoring of chemicals, 

contaminants, industrial effluents, and environmental effects 




Technology assessment and development: Bench-scale proof-of-concept, 

pilot plant development and scale up, market assessment, intellectual 

property management, literature searches and patent assessments 

Mining: Acid mine drainage, acid rock drainage and metal leaching services 

(geochemical characterisation, mineralogical analysis, static testing, kinetic 

testing); mineral processing and hydrometallurgy testing services (project 

design and management, mineral processing, hydrometallurgy, pilot 

studies); water and waste water treatment services (laboratory testing and 

characterisation, pilot scale testing) 

Energy and environment: Evaluation of technologies designed to improve air 

quality, reduce greenhouse gas and other emissions and improve energy 

efficiency; provision of energy market insight to assist customers with 

technology purchases or other business decisions; assistance with energy 

management initiatives; third party review of environmental and energy 

usage implications of business investments; assistance with energy utilities' 

integrated resource planning activities; verification and monitoring of 

greenhouse gas offsets, both from the purchaser's and vendor's 

perspectives 

Environment, Health and Safety: Safety management, occupational hygiene, 

risk assessment and management, indoor air quality, industrial training 

1600 Bellwood Road 

Richmond VA 23237-1326, US 

Phone: (804) 271-7677; Fax: (804) 271-7791 

Web: www.wakousa.com 

E-mail: information@wakousa.com 

KEY PERSONNEL: Hiroshi Shima; President 



Acquired the LAL business of Haemachem Inc. (2/02) 


SUBSIDIARY OF: Wako Pure Chemical Industries Ltd. 


Assure customers' and vendors' success through: 

-Integrating our international cultural attributes 

-Supplying unique and innovative quality products 

-Committing to safety, employee effectiveness, the highest level of integrity 

and a strong sense of public responsibility 

PRODUCTS ON MARKET: Hemoglobin - Hemoglobin B, UIBC - L-Type UIBC, Ketones, 

Hydroxybutyrate - Autokit 3-HB, Fatty Acids, Free - NEFA C, Total Ketone - 

Autokit Total Ketone Bodies, Albumin - Albumin HR2, Direct Bilirubin - Direct 

Bilirubin Vanadate, Bile Acids, Total - Total Bile Acids Kit, Total Bilirubin - 

Total Bilirubin Vanadate, Total Protein - Total Protein 2HA, (CH50) 

Complement, Total Activity - Autokit CH50, Apolipoprotein A1 - Autokit Apo 

A1, Apolipoprotein A2 - Autokit Apo A2, Apolipoprotein B - Autokit Apo B, 

Apolipoprotein C2 - Autokit Apo C2, Apolipoprotein C3 - Autokit Apo C3, 

Apolipoprotein E - Autokit Apo E, Cholesterol Ester Transfer Protein - CETP 

Test, HDL-Cholesterol - HDL-Cholesterol E, Triglycerides - L-Type TG H, 

Creatinine, Lp(a) - Autokit Lp(a), Urine Total Protein - Autokit Micro TP 




302 Grote Street 

Buffalo NY 14207-2442, US 

Phone: (716) 876-5290; Fax: (716) 876-2412 

Web: www.sevenson.com/analytical, www.wastestream.com 

E-mail: mbarnhart@sevenson.com 

KEY PERSONNEL: Joseph V. Giacomazza; Project Manager 

Dr. James Hyzy; Director of R&D/Operations Manager 

Dr. Brian Schepart; Laboratory Director 

Daniel Vollmer; QA/QC Officer 

Maria Bradley; Radiochemistry Manager 

Amy J. Toth; R&D Manager 

Sidney Tyrrell; Assistant Laboratory Director 



STOCK-FINANCIAL HISTORY: Parent company financials: 

NASDAQ--SEVN 

PRIVATE PLACEMENTS: $1M in start-up financing (1986-1987) 

SUBSIDIARY OF: Sevenson Environmental Services Inc. 

PRODUCTS ON MARKET: Analysis for organics by gas chromatography (GC) and GC/mass 

spectrometry (GC/MS), analysis for metals by inductively coupled argon 

plasma (ICAP) and flame/graphite furnace atomic absorption (FAA/GFAA), 

and wet chemistry 

Webs Ltd. 

Ashbourne House, Waterperry Court, Middleton Road 

Banbury OX16 4QG, UK 

Phone: +44 (1295) 277272; Fax: +44 (1295) 264070 

Web: www.websint.com 

E-mail: info@websint.com 

KEY PERSONNEL: Francis Saunders; Chairman and Managing Director 

Stephen Pickin; Technical Director 





BUSINESS STRATEGY: Provide toxicity monitor sales, laboratory analysis (water testing) and 

effluent treatment consulting 

RESEARCH & DEVELOPMENT: Toxicity monitors 

PRODUCTS ON MARKET: Amtox nitrification inhibition monitor 




4123 E. La Palma Avenue, Suite 200 

Anaheim CA 92807, US 

Phone: (714) 577-5600; Fax: (714) 577-5688 


Web: www.wedgewoodanalytical.com 

E-mail: info@wedgewoodanalytical.com 

KEY PERSONNEL: Dr. Wolfgang Babel; President and CEO 

Dr. Ian Tribick; VP, Operations 



Began biotech R&D in June 1979 

Merged Innovative Sensors and Wedgewood Technology (2004) 

Purchased Stip (2005) 

Purchased Entech (2005) 

FACILITIES: 31,000 sq. ft. manufacturing facility 

STOCK-FINANCIAL HISTORY: Privately held by Endress +Hauser AG 

BUSINESS STRATEGY: Balance growth through new product development as a liquid analytical 

'specialist.' Offer the most complete line of liquid analytical instrumentation, 

including optical (UV, absorbance, color, cell grwoth), pH, conductivity, 

chlorine, dissolved oxygen, TSS, turbidity, TOC, BOD, COD, liquid interface 

monitoring 

RESEARCH & DEVELOPMENT: Multi-ion and optical sensors and transmitters 

PRODUCTS ON MARKET: Optical: absorbance, ultraviolet, color, suspended solids, turbidity, NIR 

Electrochemical: pH / ORP, conductivity, dissolved oxygen, chlorine, ISE 


1150 Joshua Way 

Vista CA 92083, US 

Phone: (760) 599-8855; Fax: (760) 599-6965 


Web: www.westbridge.com 

E-mail: wrg@westbrige.com 

KEY PERSONNEL: Tina Koenemann; President 

Dr. Lawrence W. Parker; Director, R&D 

Javier Lopez; Production Manager 

Nancy Tami; Manager, Quality Control 



STOCK-FINANCIAL HISTORY: Publicly held, trading restricted 

$4.5M initial capital from limited partnership (4/82) 


Net


SUBSIDIARIES/DIVISIONS: Westbridge Agricultural Products 

BUSINESS STRATEGY: Develop and manufacture environmentally safe products for agriculture, turf, 

lawn and garden, odor control and bioremediation products for agriculture, 

industrial and municipal wastes 

PRODUCTS ON MARKET: Soil Triggrr® plant growth regulator 

Foliar Triggrr® plant growth regulator 

Sunburst® fertilizers 

ST-12 odor control 

BNB 931 bioremediation nutrient blend 

BNB Micro 

BNB Micro+ 

Suppress® odor control 

Biolink® organic farm inputs 


33663 Weyerhaeuser Way South 

Federal Way WA 98003, US 

Phone: (253) 924-2345; Fax: (253) 924-2685 


Web: www.weyerhaeuser.com 

E-mail: info@weyerhaeuser.com 

KEY PERSONNEL: Steven R. Rogel; Chairman, President and CEO 

Richard E. Hanson; Exec. VP and COO 

Susan M. Mersereau; Sr. VP, Information Technology and CIO 

Richard J. Taggart; Exec. VP and CFO 

George H. Weyerhaeuser Jr.; Sr. VP, Technology 



Divested aquaculture and hydroponics business divisions (1988) 

Divested Personal Care Products and GNA Insurance (1993) 

STOCK-FINANCIAL HISTORY: NYSE--WY 

Three-for-two stock split (6/88) 

Board authorized issue of 400M shares of common stock (6/88), 202M 

shares outstanding 


Net income $733M (YE 05) compared to $1.283b (YE 04) 


SUBSIDIARIES/DIVISIONS: Five major business segments: 

Timberlands--Grows and harvests trees in renewable cycles 

Wood Products--Manufactures and distributes building materials for homes 

and other structures 

Pulp and Paper--Produces a variety of papers, and the pulp to produce 

papers, absorbent products for specialty uses such as photographic film 

Containerboard Packaging and Recycling--Produces paper, boxes and bags 

to move products from factory to store to consumer. Collects and recycles 

wastepaper, boxes and newsprint to make new products 

Real Estate--Builds single- and multi-family homes and develops land 


Biopulping 

Consortium 

(University of 

Wisconsin and 

USDA) 

Chiron Corp. cellulose and other 

projects 

lignin degrading fungi collaborative 






Inc. 


Inc. 

embryogenesis and 

artificial seed 

Gel-Coat technology for 

specific woody plants 

and ornamentals 

R&D agreement 



RESEARCH & DEVELOPMENT: Tree cell and tissue culture 

Economic mass propagation of high-value forest trees 

Genetic transformation 

Selection of high-value genotypes and varieties of forest trees 

Forest establishment and management technologies 

New biological products, wood-based products 

Wood processing technologies 

Environmental research: wildlife, hydrology, fisheries, waste management 

Pulp, paper, and packaging technologies 

PRODUCTS ON MARKET: Forestry products 

Genetically improved seeds, including loblolly and ponderosa pines and 

Douglas fir 

Nursery and garden supply products, chemicals 


1185 Avenue of the Americas, 20th Floor 


Phone: (646) 723-4000; Fax: (646) 723-4001 

Web: www.xethanol.com; E-mail: inquiries@xethanol.com 

KEY PERSONNEL: Christopher d’Arnaud-Taylor; Chairman, President and CEO 

Larry Bellone; CFO 

Franz A. Skryanz; VP, Secretary and Treasurer 

Robin Buller; VP, Operations 

Jim Stewart; VP, Plant Operations and GM, Xethanol BioFuels 

David Kreitzer; VP, Business Development 

Mark Austin; Chief Technology Strategist 


HISTORY: Founded in January 2000 as Freereal-Timequote.com Inc. 

Acquired Permeate Refining Inc. (8/03) 

Merged with Zen Acquisition Corp. (2/05) 

Acquired Advanced Biomass Gasification Technologies Inc. from UTEK 

Corp. (6/06) 

FACILITIES: Two 25,000 sq. ft. ethanol production facilities in Iowa 

STOCK-FINANCIAL HISTORY: AMEX--XNL 

Formerly listed on the OTC BB--XTHN (through 6/06) 

Net sales $4.343M (YE 05) compared to $465K (YE 04) 




04) 


PRIVATE PLACEMENTS: Raised $34M in equity capital (4/06) 

SUBSIDIARIES/DIVISIONS: Xethanol BioFuels LLC--Blairstown, Iowa 

PRINCIPAL INVESTORS: Fusion Capital Fund II LLC 



BUSINESS STRATEGY: Increase production capacity at Iowa facilities through physical expansion 

using cutting-edge engineering design and integrating processing 

technologies 

Employ a regional approach to new ethanol production by focusing on port 

sites and coastal urban areas on the Atlantic and Gulf coasts 

Employ a sector strategy to expansion by focusing on the forests products 

industry 


Aventine Xethanol products distribution 

Forest Products 

Laboratory 

National 

Renewable 

Energy Laboratory 

engineering of 

genetically modified 

yeasts to decrease 

fermentation time of 

feedstocks in the 

production of ethanol 

and/or xylitol 

Clean Fractionation 

technology 

Queens University development of a 

process to reduce the 

time required to ferment 

feedstock in the 

Virginia 

Polytechnic 

Institute 

production of ethanol 

investigation of the 

effect of newly 

developed enzymes on 

feedstocks 

agreement 

CRADA 



research alliance 

RESEARCH & DEVELOPMENT: Production of ethanol and related products using locally available biomass 

rather than corn as the primary raw material 


Weizmann Institute of Science, P.O. Box 95 

Rehovot 76100, Israel 

Phone: +972 8-947-0617; Fax: +972 8-947-0739 

Web: www.yedarnd.com; E-mail: info.yeda@weizmann.ac.il 

KEY PERSONNEL: Prof. Haim Garty; Chairman 

Amir Naiberg.; CEO 

Einat Zisman, Ph.D.; CBO 

Ziv Hermon, Ph.D.; Sr. Licensing Officer 

Noa Shelach, Ph.D.; Sr. Licensing Officer 

Gil Granot-Mayer, Adv; General Counsel 

Cohen Yaacov; CFO 

Ruth Granoth, Ph.D.; Chief Intellectual Property Officer 




FACILITIES: Offices located at the Weizmann Institute of Science 

STOCK-FINANCIAL HISTORY: Technology transfer entity 

BUSINESS STRATEGY: Serve as a patent and licensing organization that acts as an intermediary 

with industry and investors interested in licensing technologies from the 

Weizmann Institute in return for commitment to develop the technologies 

into products & payment of financial considerations to the Institute. 



RESEARCH & DEVELOPMENT: Biochemistry, genetics, immunology, virology, cancer, , neurobiology, 

industrial and specialty chemicals, nanotechnologies membranes, plant 

genetics, bioinformatics and proteomics, diagnostics 

PRODUCTS ON MARKET: Copaxone® synthetic copolymer for treatment of multiple sclerosis (licensed 

to Teva Pharmaceuticals) 

Rebif® (recombinant interferon beta) for multiple sclerosis and several viral 

diseases (licensed to InterPharm Laboratories Ltd. 

Dunaliella (beta carotene) health food product with potential anticancer 

properties (licensed to Nikken Sohosha) 

GeneCards® bionformatics database 

Improved crop varieties and hybrid cultivars of cucumbers and melons 

(licensed to Isreali seed companies) 


P.O. Box 39135 

Jerusalem 91390, Israel 

Phone: +972 2-658-6688; Fax: +972 2-658-6689 

Web: www.yissum.co.il; E-mail: tamir@yissum.co.il 

KEY PERSONNEL: Dr. Giora Yaron; Chairman 

Nava Swersky Sofer; CEO 

Tamir Huberman; Director, IT 

Zvika Weiss; CFO 

Renee Ben-Israel; VP, Intellectual Property 

Gustavo Fuchs; Technology Officer 

Ken Shaked; VP, Portfolio Companies 

Ziv Shomroni; VP, Nature Science and Agriculture 

Elena Canetti; VP, Marketing, Scientific Services 

Yehuda Yarmut; Exec. VP 

Tami Kfir; VP, Marketing, Healthcare 


HISTORY: Founded in 1964 to commercialize R&D developed at the Hebrew University 

of Jerusalem 

FACILITIES: Multipurpose chemical pilot plant 

Environmental R&D laboratories 

Pharmacokinetic and biopharmaceutic research laboratory 


SUBSIDIARY OF: Hebrew University of Jerusalem 

BUSINESS STRATEGY: Establish R&D, licensing, and joint venture agreements with numerous 

companies worldwide in all areas 


BioLineRx Ltd. BL-3020 licensing agreement 7/06 

RESEARCH & DEVELOPMENT: Applied research in biotechnology, agriculture, chemistry, medical sciences 

and pharmaceuticals using organisms and products of organisms in 

biological processes, genetic engineering, food sciences, physical sciences 

and environmental sciences 

PRODUCTS ON MARKET: Diagnostic kits for screening of urinary tract infections and detection of 

antibiotics in milk 

Cherry tomatoes--cocktail hybrids 

New Drugs: 

Doxil--an approved and clinically used anticancer drug 

Exelon--a new treatment for Alzheimer's disease 


YMC Co. Ltd. 


YMC Karasuma Gojo Building, 284 Daigo-cho 

Karasuma Nishiiru, Gojo-dori, Shimogyo-ku 

Kyoto 600-8106, Japan 

Phone: +81 75-342-4510; Fax: +81 75-342-4511 

Web: www.ymc.co.jp; E-mail: sales@ymc.co.jp 

KEY PERSONNEL: Ryuji Yamamura; CEO 

Masaru Wakeshima; Exec. VP 

Takamaru Komatsu; Exec. Director 

Naohiro Kuriyama; Director, R&D 

EMPLOYEES: 112 employees, 2 Ph.D.s, 27 M.D.s 



Established YMC Europe GmbH in 1993 

FACILITIES: R&D labs, technology development center and S&S (separation and 

synthesis) center and production facilities (YSP-2, YSP-3, YSP-4) 


SUBSIDIARIES/DIVISIONS: YMC Europe GmbH 

Seika Corp. of America 

Kyoto Chromato Co. Ltd. 

Synthesis and separation division 

Chromatography division 

Sales and marketing division 

BUSINESS STRATEGY: Meet a greater diversity of markets by offering a wide variety of products 

RESEARCH & DEVELOPMENT: Chromatography and purification technology 

Fine chemicals synthesis 

PRODUCTS ON MARKET: Packed columns and packing materials for HPLC 

Preparative HPLC instruments 

Synthensis and separation technology 


Various peptides in development 

Glucose and oligosaccharide separation in development 

Separation and purification system in development 

Various packing materials for 

chromatography 


Zeltia SA 

Jose Abascal St. 2 

Madrid 28003, Spain 

Phone: +34 91 444 4500; Fax: +34 91 593 2954 

Web: www.zeltia.com 

E-mail: zeltia@zeltia.com 

KEY PERSONNEL: Jose Maria Fernandez Sousa-Faro; Chairman and CEO 

Maria Luisa Francia; CFO 

Teresa Garcia Buey; Director, Corporate Communications 

Isabel Lozano; Managing Director, PharmaMar 

Rosario Cospedal; Managing Director, Genomica 

Gonzalo Duran; Managing Director, Zelnova 

Jose Benito Mallo; XylaZel 





STOCK-FINANCIAL HISTORY: Mercado Continuo--ZEL 

Net sales EUR471K (YE 05) compared to EUR669K (YE 04) 

Operating loss (YE 05) compared to (YE 04) 


PRIVATE PLACEMENTS: Raised EUR65M through private placement of 10.75M shares at 

EUR6.05/share (6/05) 

SUBSIDIARIES/DIVISIONS: Zeltia Group: 

PharmaMar SA 

Genomica SAU 

Neuropharma SA 

Xylazel SA 

Promax SA 

Zelnova SA 

Branch offices in France, Germany, Britain and Italy 

BUSINESS STRATEGY: Operate as a biopharmaceutical leader in oncology-advancing cancer care 

through the discovery and development of innovative marine-derived 

medicines 

PRODUCTS ON MARKET: Various products through the Zeltia Group 

Zeon Corp. 

Shin Marunouchi Center Building, 1-6-2 Marunouchi, Chiyoda-ku 


Phone: +81 3-3216-1772; Fax: +81 3-3216-0501 

Web: www.zeon.co.jp 

E-mail: saitoh@lab.zeon.co.jp 

KEY PERSONNEL: Katsuhiko Nakano; Chairman 

Naozumi Furukawa; President and CEO 

Masahiro Yamazaki; Exec. Managing Director 

Tadao Natsuume; GM, R&D Center 


HISTORY: Established in April 1950 by three Japanese companies in the Furukawa 

Group--Furukawa Electric 

Co. Ltd., Yokohama Rubber Co. Ltd. and Nippon Light Metal Co. Ltd. 


Formed Syntro Zeon LC, a joint venture between Nippon Zeon of America 

Inc. and Syntro Venture Corp., to commercialize poultry vaccines resulting 

from existing development program of parent companies (2/93) 

Changed name from Nippon Zeon Co. Ltd. (7/00) 

FACILITIES: Headquarter facilities in Tokyo 

Plants in Kawasaki, Tokuyama, Mizushima and Takaoka 

Offices in Nagoya and Osaka 

STOCK-FINANCIAL HISTORY: Tokyo Stock Exchange--ZEON 

Listed on Osaka Stock Exchange 




SUBSIDIARIES/DIVISIONS: Rubber Division 

Latex Division 

Chemicals Division 

Specialty Plastics Division 

Specialty Chemicals Division 

Specialty Materials Division 

53 subsidiaries 



BUSINESS STRATEGY: Continually focus on creating new businesses, taking full advantage of 

steady revenue generated by existing businesses 


Delaware 

fowlpox vectored cooperative R&D 1994 

University 

vaccine for infectious 

laryngotracheitis 

vaccine 

agreement 

Syntro Corp., 

Hoechst-Roussel 

Agri-Vet Corp. 

recombinant viral 

vaccines for poultry 

USDA/ARS fowlpox vectored 

vaccines for coccidiosis 

USDA/ARS fowlpox vectored 

vaccines for Marek's 

disease and other 

poultry diseases 

development 

agreement--Nippon 

Zeon to fund Syntro 

development, 

testing, and ultimate 

registration of 

poultry vaccines-- 

Syntro to get U.S. 

manufacturing 

rights, Syntro Zeon 

to receive domestic 



agreement 


agreement 

RESEARCH & DEVELOPMENT: C5 chemicals technology: Organic synthesis technology and monomer 

extraction technology 

Polymer technology: Elastomer technology and cyclo-olefinpolymer 

technology 

Precision modeling technology: Film molding and ultra-fine molding 

technology 

Bio-technology: Recombinant DNA technology 

PRODUCTS ON MARKET: Synthetic rubbers 

Imaging and electronics materials 

Specialty plastics 

Environmental materials 

Synthetic latices 

Toner 

RIM 

Medical products: Cardiovascular, nutritional and gastrointestinal products 

(from ZEON Medical Inc.) 

Chemicals: Quintone 100 series (aliphatic hydrocarbon resin), Quintone 

1000 series (alicyclic hydrocarbon resin), Quinhard series (acid anhydride 

type epoxy resin hardening agent), Quinflow series (polycarboxilic acid 

sodium or ammonium salt, water type dispersant), Quintac series (styrene 

isoprene block polymer) 

Specialty chemicals: Aroma chemicals include cis-3-Hexenol (leaf alcohol) 

and leaf esters, Claigeon® (methyl dihydrojasmonate), Cepionate® (methyl 

epi-dihydrojasmonate), Jasmoneige® (methyl jasmonate), Zeppin® (methyl 

epi-jasmonate), delta-lactones, Triflaige®, alkyl cyclopentanones, 

hydrocarbons, alcohols, 5-membered ketones, hero compounds, 

heterocyclic compounds, Zorora®H fluoride compound, Zeorola®-H, 

Zeonsolve® HP (cyclopentane) 


9/90 

1992 

1990



Reitherstrasse 21-23 

Tulln A-3430, Austria 

Phone: +43 2272-602-11402; Fax: +43 2272-602-11420 

Web: www.zuckerforschung.at 

E-mail: info@zuckerforschung.at 

KEY PERSONNEL: Mag. Gerhard Robl; Commercial Manager 

Dr. Dietmar Grüll; Technical Manager 

Dr. Herbert Wesner; Technical Manager 



Changed name from Raiffeisen-Bioforschung GmbH (1994) 

FACILITIES: 2,000 sq. m. of laboratory space 

Pilot plant with fermentors, chamber filter press, separators, spray-dryer, 

autoclaves, chemical pilot plant and extruder 


PRINCIPAL INVESTORS: Agrana Zucker GesmbH 

Agrana Starke GesmbH 

Bioethanol GmbH 

BUSINESS STRATEGY: Provide R&D for Austrian sugar, starch & Bioethanol industry 

Render essential services to agriculture and industry by developing products 

and technology that promote the use of renewable resources in the 

manufacturing industry 

RESEARCH & DEVELOPMENT: Sugar technology, modified starches for food and non-food, feedstuff, 

cereals, baby food, modified proteins, wastewater treatment and improved 

crops 

Biotechnology 

Bioethanol 

PRODUCTS ON MARKET: Culture collection (catalog available) 



BioWorld ® 

INDUSTRIAL 

BIOTECHNOLOGY 

STATREPORT 

SUBJECT INDEX 



SUBJECT INDEX 

Biopreservation 


Agrium Inc. 


Biologos Inc. 


BioTime Inc. 



CryoLife Inc. 


Encelle Inc. 





ICPbio 


Lake States 







Snamprogetti Services SpA 



Zeltia SA 

Bioremediation 

Agrium Inc. 




Aluline Ltd. 

ARC Geobac Group Inc. 


astre Corp. 

Bayer Corp. 

Bioclear BV 


Biogenie Inc. 

Biolog Inc. 

Biopraxis Inc. 





Biotehnos SA 


CABI 



Cornell Institute for Biotechnology and Life 

Science Technologies 



Diversa Corp. 















Technology 
















Novozymes A/S 



Organo Corp. 



Pall Corp. 








Symbio 



University of Nebraska-Lincoln, Center for 

Biotechnology 







Biosensors 








AMDL Inc. 




astre Corp. 



BioGenes GmbH 

Bionas GmbH 









Eurogentec SA 









MoBiTec GmbH 






november AG 

Organo Corp. 

Pall Corp. 








Biotechnology 


Webs Ltd. 


Cosmetics 

3DM Inc. 



AGI Dermatics 






Bionas GmbH 




Biotehnos SA 

BRAIN (Biotechnology Research and 

Information Network AG) 


Ceapro Inc. 


Chemeq Ltd. 





Diversa Corp. 


DSM 



FibroGen Inc. 

Galderma SA 






Isolagen Inc. 

Kanebo Ltd. 


Lavipharm SA 



MedPharm Ltd. 

Merck KGaA 







Novozymes A/S 




PLANTON GmbH 



Prokaria ehf 

Proteus SA 






Energy/Biomass 

Abengoa SA 


Agrium Inc. 






Athenix Corp. 

BASF AG 

Bioclear BV 



Biotehnos SA 







Ceres Inc. 






Diversa Corp. 









Iogen Corp. 

Itochu Corp. 


Lake States 

Mascoma Corp. 




Novozymes A/S 


Pennzoil Co. 

Pfizer Inc. 

Recordati SpA 

Renessen LLC 




SunOpta Inc. 



Biotechnology 


Environmental Analysis 

Agrium Inc. 



ANU Enterprise Pty. Ltd. 

Applera Corp. 




astre Corp. 

BASF AG 

Bayer Corp. 



Bioclear BV 

BioGenes GmbH 

Biolog Inc. 



BioMerieux SA 






CABI 

Cantest Ltd. 











Hammen Corp. 


Hidex Oy 






Technology 

Itochu Corp. 






Merck KGaA 




M-Scan Ltd. 


Nanogen Inc. 




Neogen Corp. 



Optronics 

Organo Corp. 










Spherix Inc. 




Symbio 

Teledyne Isco 




Biotechnology 

UVP Inc. 




Virinova GbR 




Webs Ltd. 



Fine Chemicals 


Agrium Inc. 




Athenix Corp. 


BACHEM AG 

BASF AG 

Be-Long Group 

Biologos Inc. 

Biomol GmbH 





Cambrex Corp. 

Ceapro Inc. 

Cuno Inc. 






Diversa Corp. 



DuPont 





Genzyme Corp. 





Itochu Corp. 


Kaneka Corp. 

Kirin Brewery Co. Ltd. 



Lake States 

LG Chem Ltd. 





Mercian Corp. 

Merck KGaA 

Microbia Inc. 







OmniChem 


Optronics 

PCI Membranes 






Primm S.R.L. 

Prokaria ehf 

Proteus SA 













Biotechnology 


Xinchem Corp. 


YMC Co. Ltd. 

Zeltia SA 

Zeon Corp. 

Industrial/Laboratory 

Enzymes 

AB Enzymes Oy 

Agrium Inc. 







astre Corp. 

Athenix Corp. 

Bayou Biolabs 


Biologos Inc. 

Biomeda Corp. 

BioMerieux SA 

Biomol GmbH 


Biotal Ltd. 

Biotehnos SA 


Cambio Ltd. 



Cargill Inc. 






Chunghwa Chemical Synthesis & Biotech Co. 

Ltd. 






Digene Corp. 

Diversa Corp. 







EvoGenix Ltd. 







Hercules Inc. 





Iogen Corp. 

Itochu Corp. 


Kirin Brewery Co. Ltd. 

KRKA d.d. 



Lake States 





Merck KGaA 


Microbia Inc. 







Novozymes A/S 


Optronics 

Pall Corp. 

Paprican 


PCI Membranes 

Pfizer Inc. 

PLANTON GmbH 


Prokaria ehf 

Proteus SA 

Qbiogene 

Recordati SpA 

Roal Oy 







Symbio 







Biotechnology 






Zeltia SA 

Mining Biotechnology 

Agrium Inc. 

astre Corp. 

Be-Long Group 

Bioclear BV 




Diversa Corp. 

Hammen Corp. 






UVP Inc. 


Oil Recovery 

Biotehnos SA 




Diversa Corp. 







Novozymes A/S 







Specialty Chemicals 


Agrium Inc. 


Akzo Nobel NV 




Aluline Ltd. 









Athenix Corp. 




BACHEM AG 



BASF AG 

Be-Long Group 



Bio-Lab Ltd. 

Biologos Inc. 


Biomol GmbH 





BioVectra dcl 



Cambrex Corp. 

Ceapro Inc. 










Diversa Corp. 








Evolva SA 










Itochu Corp. 


Kaneka Corp. 



LANXESS AG 

LG Chem Ltd. 




Matreya LLC 


Merck KGaA 

Microbia Inc. 


Monsanto Co. 







OmniChem 



PCI Membranes 

Pennzoil Co. 



Pfizer Inc. 






Proteus SA 


Recordati SpA 










Symbio 








Biotechnology 


Vitrolife AB 



Xinchem Corp. 


Zeltia SA 

Zeon Corp. 

Waste Treatment 

Abengoa SA 







Alltech Inc. 

Aluline Ltd. 





astre Corp. 

Be-Long Group 


Bioclear BV 


Biogenie Inc. 

Biolog Inc. 




BioSure Inc. 



Biotehnos SA 




















Hammen Corp. 




Itochu Corp. 

KRKA d.d. 








Novozymes A/S 



Organo Corp. 


Pall Corp. 

Paprican 

PCI Membranes 

Proteus SA 




Spherix Inc. 





UVP Inc. 




Webs Ltd. 





Zeon Corp.

BioWorld® - Medical Device Daily

Create successful ePaper yourself

Delete template?

Save as template?